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DIRECTOR'S
REPORT
The understanding of cancer as an aberration of the normal processes of cell
growth and division has long stood out as a prime, if not ultimate, goal of the
world's biomedical research community. When Everest was conquered, we saw
the challenge of cancer in terms of that long-sought-after "Himalayan" goal. Now,
with time, we see that we are assaulting a more-K2-like peak, where the ice falls
ahead pose complexities that even the resolute and strong know may be close to
the limits of human endurance.
When I was a boy growing up in Chicago, cancer was only talked about in
whispers, a scourge that struck at random and against which we had no medical
means of fighting back, particularly if it had spread beyond its point of origin. The
only hope had to be the new facts that science would one day discover. After I
became a student at the University of Chicago in 1943, I became aware of the re-
monies given to its Medical School by Albert and Mary Lasker. They
wanted the world to have the scientific knowledge that would reveal the real faces
of the enemy. Blindly thrashing against a foe that we knew only by name and not
by form or substance could only perpetuate our fears. So, the Laskers put real life
into the body known as the American Society for Cancer Control, then an assem-
bly of doctors, many of whom were habituated to keeping the truth from their pa-
tients. Their efforts transformed this ineffective organization into the American Can-
cer Society, a national body founded in 1944 that would work for the public good
by using the scientific mind, as opposed to the surgeon's scalpel, as the means ul-
timately to banish cancer from the human vocabulary.
It was in this same year that Avery, MacLeod, and McCarty published their
historic paper showing that DNA molecules, not proteins, were the hereditary mol-
ecules of bacteria. At that time, very few scientists worked on or were excited by
DNA or with RNA, its equally mysterious companion nucleic acid. So the Avery re-
sult did not immediately galvanize a then-unfocused biological community into a
DNA-dominated mentality. I heard first of Avery's experiments through Sewell
Wright's course on physiological genetics that I attended in the spring of 1947, my
senior year in college. DNA's potential significance, however, only hit me with a
vengeance when I moved on in the fall to Indiana University as a graduate stu-
dent. There, my first-term courses brought me into the center of the gene replica-
tion dilemma: How could genetic molecules with their very great specificities be
exactly copied?
Salvador Luria in his virus course excited me about these still very mysterious
disease-causing agents, while Hermann J. Muller in his advanced genetics course
recounted his lifelong odyssey in search of the secrets of the gene. The simplicity
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of Luria's bacterial viruses (phages)
immediately fascinated me, and in the spring
of 1949, I started my Ph.D. thesis
research in his lab. A year earlier, Luria had be-
come one of the first recipients
of the American Cancer Society's (ACS) new re-
search grants. These were very
important monies for the fledgling scientific area
that later was to be known as
molecular biology. The National Science Foundation
(NSF) had not yet come into existence and the National Institutes of Health (NIH),
much less its National Cancer
Institute (NCI) component, had only a minuscule
i
budget for scientific investigators outside
its own Bethesda walls. At that time, the
ACS did not have its own staff for
evaluating grant proposals, a task then given to
the Committee on Growth of the
National Research Council.
Support of Luria's research by the
ACS was not at all surprising. Several types of
viruses were known to cause cancer
in a variety of animals, and it was natural to
think that some human cancers
might also have viral etiologies. But in those early
post-war years, no one really knew what a
virus was, and directly attacking how
the cancer-inducing viruses acted was
not a realistic objective. Many viruses, in-
cluding Luria's little phages, contained
DNA, and we often speculated that DNA
was their genetic component. But there were
other viruses that totally lacked DNA
and instead had RNA components.
Conceivably, both forms of nucleic acid car-
ried genetic information, but there still existed many
scientists who suspected that
maybe neither DNA nor RNA was a truly genetic molecule. Perhaps there was a
fatal flaw to the Avery experiment that no one had yet caught.
General acceptance of the primary genetic role of DNA only came when
Francis Crick and I found the double helix. The fact that it had a structure that
was so perfect for its self-replication could
not be a matter of chance. When I first
publicly presented the double helix at the 1953 Cold Spring Harbor Symposium,
there was virtually immediate and universal acceptance of its implications. At long
last, we had the reference molecule on which to base our thinking about how liv-
ing cells operate at the molecular level. And the DNA viruses immediately could
be viewed in a more approachable fashion. The DNA molecules within them were
clearly their chromosomes and, within a year, Seymour Benzer produced a
detailed genetic map of the r11 gene of phage T4 in which the mutant sites along
a gene were correctly postulated to be the successive base pairs along the dou-
ble helix.
Less obvious was whether RNA also could be a genetic molecule. By then, we
believed that RNA functioned as an informational intermediate in the transfer of
genetic information from the base pair sequences of DNA to the amino acid se-
quences in proteins (DNA--.RNA--.protein). As such, RNA did not need to be
capable of self-replication, it only needed to be made on DNA templates. Vigorous
proof that RNA also could be genetic molecules came from Alfred Gierer's 1956
demonstration in TObingen that RNA purified from tobacco mosaic virus was
infectious.
Viruses by then had become perceived as tiny pieces of genetic material sur-
rounded by protective coats made up of protein (and sometimes lipid) molecules
that ensured their successful passage from one cell to another. At first, we be-
lieved that the proteins used to construct their outer coats were the only proteins
coded by the viral chromosomes. The enzymes used to replicate their DNA were
believed initially to be those of their host cells. This assumption, however, created
the dilemma of how the RNA of RNA viruses was replicated if the RNA within their
host cells was made entirely on DNA templates. One way out of the dilemma was
to postulate that some types of DNA-made RNA were later selectively amplified by
RNA-templated RNA synthesis catalyzed by host cell enzymes. By 1959, however,
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Seymour Cohen's and Arthur Kornberg's labs began to show that phage chromo-
somes coded for many of the enzymes needed to replicate their DNA. This
opened up the possibility that animal viruses also coded for the enzymes that
duplicate their DNA. If true, I thought we might have the first real clue as to how
viruses cause cancer.
Dissolving the deep enigma surrounding viral carcinogenesis first became a
goal of mine when I learned of tumor viruses in Luria's 1947 virus course. A young
uncle of mine was then dying of cancer, and it was that fall when I first acutely
sensed the need for science to fight back. This desire was rekindled in the spring
of 1958 when I was visiting Luria's lab, by then in Urbana. There I heard Van Pot-
ter from the University of Wisconsin, Madison, give a lecture on the biochemistry
of cancer. From him I first realized that the cells of higher organisms, unlike those
of bacteria, needed specific signals to divide. In fact, the majority of cells in our
bodies are not dividing but are in an apparent resting state where DNA synthesis
is not occurring. A DNA virus infecting such cells would be unable to multiply un-
less it coded for one or more enzymes that specifically functioned to move their
quiescent host cells into the "S" phase of DNA synthesis. Conceivably, insertion of
animal viral genomes into the chromosomes of resting host cells would convert
them into dividing cells with the signal for DNA synthesis always turned on.
This idea came to me when I was preparing a lecture on cancer to beginning
Harvard students whom I was trying to excite with the new triumphs of molecular
biology. It was they who first learned of my hypothesis. That viral carcinogenesis
might have such a simple answer dominated my thoughts all that spring of 1959.
In May, I presented it as my prize lecture for that year's Warren Award of the Mas-
sachusetts General Hospital. Francis Crick and I shared the award and my pre-
sentation came after he told an overflow audience how transfer RNA was the
"adaptor" molecule he had earlier postulated for reading the messages of RNA
templates. Thanks to Mahlon Hoagland and Paul Zamecnik's new experiments,
there were no doubts as to whether Francis' ideas were on track. His talk had the
virtue of being not only elegant, but also right. On the other hand, my talk had to
seem more hot air than future truth. I left the Museum of Science Lecture Hall
depressed at the thought that I had appeared at least an order of magnitude less
intellectually powerful than Francis. Clearly, I might have given a more convincing
talk if I had a plausible hypothesis as to why RNA viruses also sometimes induce
cancer. For, as opposed to the situation with DNA, resting animal cells are con-
stantly making RNA. Conceivably, there were two very different mechanisms
through which the DNA and RNA viruses caused cancer. The other possibility was
that my idea, although pretty, was just wrong.
During that spring, I started some experiments with John Littlefield, who had
been purifying the Shope papilloma virus from rabbit warts. At that time, it was the
smallest known DNA tumor virus and we expected its DNA to have a molecular
weight of about four million. Surprisingly, using sedimentation analysis, we mea-
sured an apparent molecular weight of some seven million, with some molecules
of seemingly twice that size that we thought might be end-to-end dimers. Unfortu-
nately, we never looked at them in the electron microscope. If we had, we would
have discovered that the Shope papilloma DNA is circular and that the faster-
sedimenting molecules were not dimers, but a supercoiled form of the uncoiled
simple circle that has a molecular weight of five million. In retrospect, I felt stupid,
since earlier I had spent much time arranging for Harvard's Biological Laboratories
to get an electron microscope. But, circles were not yet in the air and I never ex-
pected to see anything interesting.
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pi Noma virus
Then the only, and not always
dependable, source of the Shope pa
was the Kansas trapper Earl
Johnson. So, the discovery of a more accessible and
even smaller mouse virus
was beginning to
revolutionize tumor virology. In 1958,
Sarah Stewart and Bernice
Eddy, working at the National Cancer Institute, opened
up the DNA tumor virus
field to modern virological methods
through being able to
propagate Ludwig Gross' "paratoid"
virus in mouse cells growing in cell culture.
They renamed this virus
"polyoma," after its unexpected property of inducing a
broad spectrum of tumors following
inoculation into immunologically immature
newborn mice. Quickly, several
molecularly oriented virologists, including Renato
Dulbecco at Caltech, Leo
Sachs in Israel, and Michael Stoker in Glasgow, took up
the polyoma virus system,
moving on several years later to the newly discovered,
similarly sized monkey tumor
virus SV40. Easily workable cell culture systems to
study the multiplication of
these viruses as well as their cancer-inducing (transform-
ing) properties were in place by
the early 1960s. The time had thus come to ask
whether these DNA viruses
contained one or more specific cancer-inducing
genes. So, there was an aura
of real excitement permeating our 1962 Sym posium
on "Animal Viruses." I came
down from Harvard and listened to Dulbecco give the
closing summary at which the
then-young Howard Temin and David Baltimore
were much in evidence.
I did not, however, then join in the
cancer gene quest. My earlier experiments
on papilloma DNA were
diversions from a ribosome-dominated lab that unfortu-
nately was still in the dark as to
where to go next. But when we found the first firm
evidence for messenger RNA in March of
1960, the course of my Harvard lab for
the next decade was firmly set. We
wanted to understand how messenger RNA
was made and then functioned to order the
amino acids on ribosomes during pro-
tein synthesis. But I continued to
emphasize tumor viruses in my Harvard lectures,
which eventually formed the basis for my
book The Molecular Biology of the
Gene (1965). Its last chapter, "A Geneticist's View of Cancer," discussed the DNA
and RNA tumor viruses, concluding with the
statement that through study of the
simple DNA and RNA tumor viruses, we
have our best chance of understanding
cancer.
My taking on the Directorship here early
in 1968 at last gave me the opportunity
to get into the DNA tumor virus field. The great era of phage and bacterial
genetics research at Cold Spring Harbor was coming to an end and we needed a
new intellectual focus as a reason for our existence. Fortunately, that summer, our
animal virus course brought to us several individuals who were just starting re-
search with tumor viruses. The lecturer to excite me most was Joe Sambrook,
then a postdoc in Dulbecco's Salk Institute lab where he worked with Henry West-
phal on the integration of SV40 DNA into the chromosomal DNA of cells made
cancerous by SV40. Soon after meeting Joe, I asked him to move here and start a
DNA tumor virus lab. He quickly accepted, wrote a successful grant application,
and arrived here the following June.
Within several years, Joe was leading a very high powered group in James lab
consisting of Henry Westphal, Carel Mulder, Phil Sharp, Walter Keller, and Mike
Botchan whose main purpose was to identify the SV40 gene(s?) that leads to can-
cer. By then, George Todaro and Robert Huebner, members of the NIH Special
Cancer Virus Program, proposed using the name "oncogene" for a cancer-causing
gene and this designation rapidly caught on. Through work here and at several
other key sites, including the Salk Institute, NIH, and the Weizmann Institute, the
SV40 oncogene(s?) was shown to be identical to the so-called "early gene(s)" that
functions at the start of the SV40 replication cycle. This was a most gratifying re-
sult, compatible with my brainstorm of a decade earlier that the DNA viral on-
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cogenes function to convert host cells into states capable of supporting DNA
synthesis.
Key tools in everyone's analysis were the newly discovered restriction enzymes
that cut DNA molecules at precise nucleotide sequences. A given restriction en-
zyme was used to cut up a viral genome into discrete pieces that could then be
isolated from each other by a powerful new ethidium bromide agarose gel proce-
dure developed here by Phil Sharp, Bill Sugden, and Joe Sambrook. Restriction
enzymes came to the laboratory when Carel Mulder brought Herb Boyer's EcoRl
into the James lab and later went on to isolate the Smal enzyme. Soon afterward,
Joe Sambrook and Phil Sharp began to use Hpal and Hpall enzymes, whose use
was pioneered by Ham Smith and Dan Nathans at Johns Hopkins. More and
more restriction enzymes came on line through the efforts of Rich Roberts, who
arrived here in late 1972. About 50% of the world's commonly used restriction en-
zymes were discovered over the next decade in the Roberts laboratory.
By then, James lab was also working with a second DNA tumor virus, a human
adenovirus that Ulf Pettersson had brought from Uppsala in 1971. Its life cycle also
was divided into an early phase and a late phase, with the genes carrying its on-
cogenic potential also being "early" genes. A clear next objective was to find and
identify the messenger RNAs for proteins encoded by the early and late adenovi-
rus genes. Ray Geste land's and Rich Roberts' groups in Demerec lab took on this
task, which soon began to generate mystifying results. All of the late mRNAs
seemed to possess a common terminal segment even though they were encoded
by widely separated sequences of DNA. Resolution of the paradox occurred in
late March of 1977, when Rich Roberts orchestrated a team consisting of Tom
Broker, Louise Chow, Rich Gelinas, and Dan Klessig to their monumental discovery
of RNA splicing. Independently, Phil Sharp and Susan Berget, then at MIT, made
the same great discovery after initially observing with the electron microscope that
the 5' end of a late adenovirus messenger RNA did not behave as expected.
The discovery of RNA splicing was a once-in-a-lifetime event that completely
transformed all of eukaryotic biology, and our 1977 Symposium, where the discov-
ery was first publicly announced, was an occasion of intense intellectual ferment.
Afterwards, new implications arose virtually weekly. Among the first was under-
standing that the T(umor)-antigen-coding SV40 early gene specified two different
cancer-causing proteins. They are derived by two different ways of splicing the
early SV40 messenger RNA. The once thought single SV40 T(umor) antigen in fact
consists of large (T) and small (t) components, with the main cancer-causing activ-
ity due to the large T antigen. Splicing also occurs with the early adenovirus
mRNAs, with two of the resulting protein products of the E1A and E1B genes play-
ing essential roles in early viral replication as well as having oncogenic activity.
Now we realize that the subsequent working out of how these tumor virus on-
cogenes actually induce cancer would have been virtually impossible if the proce-
dures of recombinant DNA had not been discovered in 1973. They have allowed
us to study the action of individual oncogenes as well as to prepare the large
amounts of highly purified oncogenic proteins needed to study their molecular
functioning. We had, however, to wait six long years after Herb Boyer and Stanley
Cohen gave us the first generally applicable recombinant DNA procedures until
the stringent NIH prohibitions against using recombinant DNA to clone viral on-
cogenes were dropped. Only in early 1979 could the recombinant DNA era of tu-
mor virology take off.
Not only were the DNA tumor viruses ripe for analysis, but how to think about
the RNA tumor viruses was also known. Through work in the 1960s by Harry
Rubin, Peter Vogt, and Howard Temin, the defective nature of most RNA tumor
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viruses had been firmly established.
Their replication requires the simultaneous
presence of a normal helper virus. In
acquiring their cancerous potentials, the
RNA tumor viruses had somehow
lost part of their own genomes. The way such
RNA genomes, be they normal or
defective, are replicated was first correctly
hypothesized by Howard Temin.
In 1964, he suggested that the infecting RNA mol-
ecules served as templates to
make DNA genomes, which, in turn, integrated as
i
proviruses into host cell chromosomes.
Proof came in 1970 when Howard Temin
working with Satoshi Mizutani, and
independently David Baltimore, discovered
within mature RNA tumor virus
particles the enzyme reverse transcriptase. Soon
the name "retroviruses" became
used to encompass all those RNA viruses that
replicate their RNA through a DNA intermediate.
Studies on the Rous sarcoma virus
(RSV) provided the first deep insights on
how the RNA tumor viruses cause cancer.
RSV mutants that were unable to trans-
form cells were found by Peter
Duesberg and his collaborators frequently to lose
part of a specific region of the genome
that they called sarc. Its true nature be-
came known from Mike Bishop's
and Harold Varmus' 1976 seminal experiments
showing that the sarc sequences within
RSV are highly homologous to those of a
normal cellular sarc equivalent. This
finding immediately suggested that the
cancer-causing signals of retroviral genomes
have nothing to do with the replica-
tion processes of retroviruses. Instead,
they originated from illegitimate recom-
binant events that replaced normal
retroviral base pairs with DNA segments bear-
ing cellular genes. A year later, the
protein product of sarc itself was isolated and
found independently by Ray Erickson
and Art Levinson to be a protein kinase, an
enzyme capable of adding phosphate
groups to preexisting proteins.
Over the next decade, more than 30 additional oncogenes were isolated from
RNA tumor viruses. In each case, they closely
resemble a normal cellular gene.
The proteins these oncogenes encode have seemingly very diverse roles; some
are growth factors, others are receptors, many
are kinases, and still others code
for proteins that bind to DNA and control transcription. Unifying the roles of all
these oncogenes, as well as of their normal cellular equivalents, is their involve-
ment in the signal transduction processes that control whether a cell divides, re-
mains quiescent, or becomes terminally differentiated. In normal cells, the func-
tioning of these signal transduction genes is tightly regulated, so that they function
only when cell division is needed. In contrast, the functioning of their oncogene
derivatives is unregulated and leads to overexpression of their respective protein
products. Proto-oncogene is the term now used to designate normal genes that
can be converted into oncogenes by mutations or abnormal recombinational
events.
We thus see that the oncogenes of DNA and RNA tumor viruses work in fun-
damentally different fashions. Those of DNA tumor viruses play essential roles in
the replication of the viral genomes, with their cancer-causing attributes related to
the tricks by which they turn their normal quiescent host cells into factories primed
for DNA synthesis. In contrast, the oncogenes of retroviruses play no role in their
replication, having arisen by genetic accidents that dissociate growth-promoting
genes from their normal regulatory signals.
When they were first found, the question had to be faced whether the on-
cogenes of retroviruses were essentially laboratory artifacts and not related to hu-
man cancer. One way to settle the matter was to devise procedures that directly
looked for human oncogenes by asking whether DNA isolated from human can-
cer cells could convert a normal cell into a cancerous cell. At MIT, Bob Weinberg
first convincingly showed that this could be done using the DNA infection (trans-
fection) procedures that Mike Wig ler helped to develop while he was a graduate
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student at Columbia University. By that time, Mike had joined our staff and was
focusing on ways to clone the genes that his transfection procedures had function-
ally introduced into cells. In 1981, Wig ler and Weinberg, working with the same
cancer cell line, used different cloning procedures to isolate the first known human
oncogene. More importantly, this bladder cell oncogene turned out to be virtually
identical to the viral RAS oncogene isolated several years before by Ed Scolnick
when he was at NCI. RAS was just the first of several retroviral oncogenes shown
to be a cause of human cancer. Now no one doubts that the study of retroviral on-
cogenes bears directly on the understanding of human cancer.
The NIH-3T3 cultured mouse cells that Wig ler and Weinberg made cancerous
by the addition of the RAS oncogenes were later found to be more predisposed to
cancer than cells obtained from the organs of living animals. Now we realize that
Weinberg's and Wigler's classic experiments would have failed if they had used
cells whose growth regulation was more normal. Two years later in 1983, Earl
Ruley, here at James lab, showed that the RAS oncogene only transforms normal
rat kidney cells to a cancerous state when a second oncogene is simultaneously
added. In his experiments, either the adenovirus E1A oncogene or the retroviral
myc oncogene could complement the activity of RAS. At the same time, Helmut
Land and Luis Parada working at MIT in Weinberg's lab independently came to
the same conclusion: Normal cells do not become fully cancerous through acquir-
ing a single oncogene, but instead they become cancerous progressively, as other
oncogenes successively come into action.
When the rush to use recombinant DNA procedures to study oncogenes be-
gan, we had to worry whether the research expertise and facilities at Cold Spring
Harbor were up to the task. So we brought to James lab in 1980 John Fiddes
from the University of California at San Francisco, where he was one of the first
serious gene cloners. At the same time, we persuaded Tom Maniatis, who, before
moving on to Caltech, had helped develop cDNA cloning as a member of our
staff, to introduce a summer molecular cloning course. Started in 1980, this course
gave rise in 1982 to the extraordinarily successful cloning techniques book Molec-
ular Cloning: A Laboratory Manual by Maniatis, Fritsch, and Sambrook, which
sold over 60,000 copies in its first edition. We also planned and constructed in
1983 a major south addition to Demerec Laboratory aimed at strengthening our
facilities for protein chemistry and mutagenesis analysis. Equally important, we
realized that we could not successfully exploit the monoclonal antibody proce-
dures discovered in Cambridge, England, by George Kohler and Cesar Milstein in
1975 until we built a further addition to James lab. We had already constructed, in
1970, a south addition for offices and a seminar room and, in 1972, a west addi-
tion for virus culture. We needed to use monoclonal antibodies first to purify and
then to better define the surfaces of oncogenic proteins. Planning for the north
(Sambrook) addition allowed us to get Ed Harlow straight from his Ph.D. at the Im-
perial Cancer Research Fund (ICRF) Laboratories in London. There he had made
monoclonal antibodies against both the SV40 T antigen and the still very mysteri-
ous p53 protein, a cellular constituent that David Lane and Lionel Crawford at
ICRF had found to bind to the SV40 T antigen.
Upon arriving here, Ed focused on the key adenovirus oncogenic protein E1A to
see which proteins it bound. He hoped that by identifying the cellular components
with which it interacted, clues would emerge as to how E1A caused cancer. To
spot these cellular proteins, he used a monoclonal antibody against E1A to
precipitate it from extracts of adenovirus-infected cells. Then, he displayed the
resulting precipitate on a gel to see whether proteins in addition to E1A could be
detected. In this way, several unknown cellular proteins were found to bind to E1A.
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What any of them did remained a mystery
until Nature in the fall of 1987 pub-
lished a paper by Wen-Hwa Lee on the properties of
Rb, a newly identified DNA
binding protein that helps to prevent
cancer. When Rb is absent in a human due
to mutations in both of his two Rb genes,
retinoblastoma (cancer of the retina) de-
velops. Those individuals who inherit a
bad Rb gene from one of their parents are
at risk for this cancer, frequently developing
retinoblastoma at an early age when
a cancer-causing mutation occurs
in the remaining good Rb gene. Harlow's lab
noticed that the Rb protein had been
assigned a size very similar to one of the
proteins (105K) that binds tightly to the
E1A protein. Hoping that they might be the
same, Harlow's lab began a
collaboration with Bob Weinberg's lab, one of the
three groups that had just cloned the Rb gene. Happily,
the two proteins (Rb and
105K) proved to be identical, suggesting that E1A's oncogene potential lies par-
tially in its ability to neutralize the anti-cancer
activity of the Rb protein. I say par-
tially because besides binding to Rb, E1A
binds also to several other, still to be
functionally identified, molecules, each of
which also may be a cancer-preventing
(anti-oncogene) protein.
The implication of Harlow's discovery
widened with the subsequent finding that
the T antigens of SV40 and polyoma
also tightly bind Rb, as does an oncogenic
protein coded by a papilloma-virus that causes
warts. Moreover, the once mysteri-
ous p53 protein that binds to the
SV40 (polyoma) T antigen was shown last year
by Arnold Levine and Bert Vogelstein also
to be an anti-oncogenic protein. Al-
though p53 does not bind to E1A, it does bind to E1B, a second "early" adenovi-
rus protein that potentiates the oncogenic
transformation potential of the E1A
protein.
The study of tumor viruses has thus advanced fundamental cancer research
more than anyone could have predicted when serious research on them began
some decades ago. The RNA tumor viruses have revealed almost all of the
oncogenes known today. Without them, we would largely be in the dark as to the
molecular players in the signaling processes that lead to cell division. Equally im-
portant have been the insights gained from learning how the oncogenes of the
DNA tumor viruses work. The knowledge that they prevent anti-oncogenes from
functioning gives us a new way to identify anti-oncogenes and will materially ad-
vance our understanding of hereditary predispositions to cancer.
We must remember, however, that the small hyperplastic tumors that result from
gain of oncogenes that promote cell growth and division are generally benign.
These usually tiny tumors generally only grow to life-threatening size when they
become infiltrated (vascularized) by newly growing blood vessels that bring to
them the oxygen and nutrients needed for their growth. Douglas Hanahan ele-
gantly showed this through experiments done in collaboration with Judah Folk-
man. In our Harris laboratory, Doug introduced oncogenes into the germ cells of
mice to produce transgenic mice in which these cell-division-signaling genes are
expressed in early development as well as throughout adult life. His targeting of
the SV40 T antigen to function in the pancreas resulted in large numbers of be-
nign hyperplasmic growths in the insulin-producing islets. Only a small percentage
of these benign growths, however, turned into rapidly growing tumors with infiltrat-
ing blood vessels. They did so by acquiring the ability to send out angiogenic
(blood-vessel-forming) signals that induced neighboring endothelial cells to form
new blood vessels. Finding out which molecules carry these signals will soon be-
come a major objective for the coming decade of cancer research. If we could
find inhibitors of these angiogenic growth factors, we might have in hand a power-
ful new way to stop cancers from growing. Most importantly, the endothelial cells
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that line our blood vessels effectively do not divide in adult life. So, as Judah Folk-
man has long dreamed, inhibitors of tumor angiogenesis would not necessarily af-
fect the healthy functioning of our preexisting blood vessels.
The truly cancerous cells of solid tumors (as opposed to those of the circulating
cells of the blood) also show failure of their normal cellular affinities and spread
(metastasize) to many unwanted tissue sites. Our first molecular clue as to the on-
cogenic changes that create cells capable of metastasis came this past January
from the cloning of an oncogene on human chromosome 18 that leads to a final
step in the progression of normal colon cells into their highly malignant equiva-
lents. Through a very difficult feat of gene cloning, Bert Vogelstein found that this
oncogene codes for a cell membrane protein involved in cell-cell recognition. Over
the next few years, the losses of many additional cell-recognition proteins are likely
to be implicated in the unwanted spread of tumor cells from their original sites of
origin
At long last, we may thus have the proper intellectual framework to understand
most of the more common life-threatening cancers. At their essence are three
types of genetic changes: (1) those that make cells divide when they should not,
(2) those that lead to the formation of blood vessels that infiltrate into and so nour-
ish the growing tumors, and (3) those that modify cell-recognizing molecules in
ways leading to losses of their respective cell's ability to recognize their normal cel-
lular partners. We have indeed come a very long way, but there remain myriad fur-
ther details to unravel about both currently known oncogenes and the many more
oncogenes yet to be discovered. Many of these new observations will initially un-
settle us and momentarily make us despair of ever being able to have a fair fight
against an enemy that so constantly changes the face it presents. But now is most
certainly not the moment to lose faith in our ability to triumph over the inherent
complexity that underlies the existence of the living state.
Given enough time, and the financial and moral resources that will let those
born optimistic stay that way, the odds for eventual success in beating down can
cer are on our side.
HIGHLIGHTS OF THE YEAR
Our Complex of Super Cabins Is Dedicated
For many scientists around the world, Cold Spring Harbor Laboratory is a tem-
porary home away from home during the various meetings and courses, which
brought more than 5400 scientists here last year. For many of these visitors, the
unheated Page Motel and its four austere companion cabins were all a seemingly
inadequate feature of the hill above James lab. We were thus relieved to complete
the six heated guest cabins on the upper campus last spring. Each has four
bedrooms and very comfortably houses eight visitors. On August 26, we dedi-
cated them to six old friends of the Laboratory. The ceremony took place during
the annual phage meeting, paying tribute to the earlier days of the Laboratory
when several of the honorees spent summers here as part of the "Phage Group':
The six cabins are now named for Herbert W. Boyer, Bentley Glass, Harry Eagle,
Salvador E. Luria, Franklin W. Stahl, and Gunther S. Stent. In his remarks, GOnther
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B. Glass, H. Eagle, M. Meselson, G. Stent, F Stahl, and J.D. Watson at Cabin Dedication Ceremony
echoed sentiments that I believe many of the "first-generation" molecular biologists
share about those early days: "From the professional point of view, I discovered
the pleasures of research . . . I was reborn as a biologist and launched into the
as-yet-unnamed molecular biology': I was disappointed that Salva could not attend
the ceremony because of his health and that Herb could not fit the cross-country
trip into his schedule. Matt Meselson gave a cleverly amusing speech on the pros
and cons of sexual reproduction, graciously replacing Herb with little notice.
I note with much pleasure the pleasing appearance of the cabins, which were
most tastefully decorated by our trustee Wendy Hatch, along with my wife Liz and
Laura Hyman. Outside, the cabins are most skillfully interconnected with wooden
walkways that next year will directly connect to the Neuroscience Center.
Neuroscience Center
progress
Neuroscience Center Progresses
The landscape of our upper campus is changing rapidly as construction on the
Neuroscience Center has been moving ahead on schedule. Since the parking ga-
rage was completed and the cornerstones were dedicated in late spring, the con-
tractors have already completed the outer shell of the Beckman Neuroscience
Laboratory. Work is in progress on Hazen Tower and the shell of Dolan Hall has al-
ready reached the second floor. Seeing these structures rise makes the day seem
just around the corner when our research staff will reach 225, up from today's 150.
This size staff will allow just the right mix of researchers from several fields and will
not need major expansion in the foreseeable future. Walking by the construction
when I get the chance, I can already see that the buildings fit comfortably into the
hillside. The upcoming 55th Symposium on "The Brain" should help give the Neu-
roscience Center the visibility it needs to attract the high-caliber researchers we
expect.
Major Gifts Received
Thankfully, there are several major gifts to report this year. A recent grant from the
Samuel S. Freeman Charitable Trust of $1 million will support our cancer research.
After Lita Annenberg Hazen's generous gift last year for construction of the Hazen
Tower, I was pleasantly surprised to receive another similar gift late in the year for
the Unrestricted Fund. This gift will allow me to say "yes" to more of the immediate
and ever-changing needs of the Laboratory. The Kresge Foundation gave us a
generous challenge grant of $500,000 for Dolan Hall, provided we raise the almost
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$2 million remaining for full funding. The Fannie E. Rippel Foundation also gave a
challenge grant of $250,000 for equipping the Neuroscience Center, after we raise
an additional $500,000. These two endorsements will be powerful tools for our de-
velopment office. Challenge grants also emphasize the importance of every dollar
contributed, since we must raise the additional funds before we receive anything
from the foundations. The Neuroscience Center received boosts of $300,000 and
$100,000 from the Pew Charitable Trusts and the Booth Ferris Foundation, respec-
tively. Within the Neuroscience Center, three rooms have already been named
(benefactors are in parentheses): The Oakes Ames Seminar Room (Mrs. Pauline A.
Plimpton and Mr. Amyas Ames), the Gardner Neuroscience Library (Mr. and Mrs.
Robert B. Gardner, Jr.), and the Lucy and Edward Pulling Seminar Room (Mr. and
Mrs. George W. Cutting, Jr.). Our AIDS research program has received $100,000
from the Mellam Family Foundation.
State of the Second Century Campaign
Through the diligent efforts of a corps of staff members and volunteers over the
last year, the campaign has, to date, exceeded everyone's expectations. Since the
public phase of the campaign started in April, we have raised almost $9.3 million.
The tireless efforts of David L. Luke III as chairman of the campaign and chairman
of the Corporate Committee of the campaign have certainly been the major factor
in the campaign's success and the Laboratory is deeply indebted to him. To reach
our goal, we must raise at least another $7 million, and hopefully more. These
monies are required for some of the most important items for our continued finan-
cial health, such as the need for endowed chairs to offer our best scientists steady
support, $2 million to renovate McClintock lab, and $2 million of the $3 million to-
tal needed to completely overhaul and expand the sorely inadequate kitchen and
dining facilities in Blackford Hall.
The Blackford renovations and the planning for six more super cabins are part
of a broader program to upgrade many of our infrastructure facilities. This is es-
sential in view of the expanding staff and growing meetings and course atten-
dance. The Corporate Committee of the campaign has undertaken to raise the
needed funds from pharmaceutical and biotechnology-oriented companies in the
U.S. and abroad that have sent their scientists here for meetings and courses.
Headed by David L. Luke III, the committee already has commitments from
Bristol-Myers Squibb Co., Burroughs Wellcome Co., Merck & Co., Pall Corp., and
Westvaco Corp. Our goals for this Infrastructure Fund also include enlarged waste-
treatment facilities, better fire protection, energy management, new data process-
ing and office equipment, upgraded maintenance facilities, road construction/re-
pair, and expanded research support facilities.
David Beach, a Hughes Investigator, Co-organizes New
Yeast Course
Late in the year, we received the good news that David Beach had been named a
Howard Hughes Medical Institute Investigator. David thus becomes the first
Hughes Investigator in the Laboratory's history and joins a very select group of
about 175 top researchers throughout the country. With this high distinction comes
research support for seven years plus funds to expand and renovate McClintock
laboratory for new lab space for David and his team. HHMI recognized David's
work on cell cycle control and the cdc2 gene that has helped bring the fission
yeast S. pombe to the forefront of cancer research. Recent observations of a pos-
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David Beach
Ed Harlow
J. Salk, J.D. Watson
sible connection between
cdc2 and the src proto-oncogene have stirred interest
throughout the scientific
community. His evidence shows that either the src protein
or a tyrosine kinase with
similar activity regulates cdc2. cdc2 has already been
shown to be a component of
the maturation promoting factor (MPF).
Continuing our expansion to a
year-round teaching institution, the fourth and
last of our new set of spring
and fall advanced courses was taught in October on
"The Molecular Genetics of
Fission Yeast."This course grew out of the prominenc
e
fission yeast has had in recent
years, again partly due to co-organizer David
Beach's research. As with the
other three new courses, this yeast course was more
than successful and has been
scheduled again for fall 1990.
Harlow Wins Milken Award
The Laboratory and the scientific
community quickly realized the importance of Ed
Harlow's discovery concerning the
retinoblastoma anti-oncogene-DA protein inter-
action. More public bodies are now
recognizing this great breakthrough, and the
Milken Family Medical Foundation
honored Ed in December with a cancer re-
search award for his research. The
award from the foundation, located in Sherman
Oaks, California, includes $50,000. This
is only the second year that the Milken
Foundation has given this cancer award,
and Ed was one of just three recipients
in basic science this year, sharing the
honor with Bert Vogelstein of Johns Hop-
kins Medical School and Charles Scher of
St. Jude's Medical Center in Memphis.
Molecular Cloning II Arrives
The long-awaited second edition of Molecular Cloning: A Laboratory Manual ar-
rived in November, bringing to an end the four years of hard work by Joe Sam-
brook, Ed Fritsch, Tom Maniatis, Nina Irwin, Nancy Ford and her staff, and the
numerous scientific advisers. Their long hours of testing and retesting methods,
going over manuscripts, and even adding the latest techniques in the middle of
editing have created a new standard, filling a void left by the outdated first edition.
The manual now spans three volumes and over 1600 pages. With 25,000 advance
orders and another 10,000 within the first few months after publication, I am confi-
dent that this book will become the leader of a now-crowded field of similar texts.
Also to be noted is the enormous success of "Antibodies': the splendid lab man-
ual by Ed Harlow and David Lane published in late 1988. By now over 16,000
copies have been sold, and already it is the second most popular book we have
ever published.
Jonas Salk Visits Laboratory
After his early 1950s discovery eradicated polio in this and other countries and
made it possible for parents to relax in the summertime, Jonas Salk has turned his
attentions to another publicly terrifying disease-AIDS. On December 7, Jonas dis-
cussed his strategy for controlling HIV infection and the disease using a vaccine.
He presented his work at a Banbury conference on AIDS and afterward spoke to
a more general audience at Grace Auditorium. He reported that his "whole-virus"
vaccine method, similar to the one he used in the 1950s against polio, has
showed evidence of halting or slowing the progression of the infection. Having
celebrated his 75th birthday recently, it is heartening to see that Jonas is still work-
ing at full force.
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Undergraduate Research Program
The Undergraduate Research Program returned to full financial health in 1989
with the return of funding from the National Science Foundation, which unexpect-
edly had been lost in 1988. From a pool of 106 well-qualified applicants (43 male,
63 female), program director Winship Herr put together a fine group of 16 under-
graduates. The group was split equally male/female and students came from as
far as Great Britain (3) and Yugoslavia (1). In addition to the NSF funds, contribu-
tions to cover the costs of the program were received from the Burroughs Well-
come Fund, Baring Brothers Ltd., the Robert P. Olney Fund, and Miles, Inc./Bayer
AG. Attesting to the intensity and interest the program sparks, one student, Steven
Palmer, temporarily interrupted his studies to spend a year continuing his research
at Cold Spring Harbor.
Robertson Research Fund
Thanks to the careful administration of the Robertson Research Fund, our largest
endowment, the unstable market of the last two years has had a negligible impact
on the income from the fund. This has allowed us to continue support for younger
scientists who have not yet established themselves and secured their own grant
support. Last year, the Outstanding Junior Fellow Awards went to Carol Greider,
who came to us from the University of California, Berkeley, and Eric Richards, who
moved here after finishing his Ph.D. at Massachusetts General Hospital of Harvard
Medical School. Carol, who works on the biochemistry of the enzyme telomerase,
has also made the observation that there may be a link between age and telo-
mere length. Eric is studying the regulation of telomere length in the small-genome
plant Arabidopsis as well as trying to clone its centromere. Our still growing plant
program and the labs of Robert Franza and John Anderson received interim sup-
port in anticipation of grant funds. Other Robertson funds went for most needed
salaries and stipends for postdoctoral fellows and visiting scientists.
54th Symposium Focuses on Immunological
Recognition
After a 13-year hiatus, immunology returned to the Symposium with 446 attendees
hearing 94 speakers over 14 sessions. Remembering the 41st Symposium, when
DNA manipulation was in its infancy, crystallography lacked the powerful imaging
computers, and transgenics were not yet reality, this meeting showed how far our
understanding of the development and functioning of the immune system has
come. As in past years, the meeting was fully registered months in advance,
thanks largely to co-organizer John Inglis. With his extensive background in immu-
nology, he and I managed to bring together the many very high caliber speakers,
including Lee Hood, Susumu Tonegawa, Philippa Marrack, Hugh McDevitt, Iry
Weissman, and Walter Bodmer. A traditional break from the grueling lecture
schedule, the Dorcas Cummings Memorial lecture was given by Gustav Nossal,
Australia's best-known scientist. His overview of the use of colony-stimulating fac-
tors in medicine and the autoimmune nature of diabetes was one of our best lec-
tures ever for a public audience. From what I saw and heard about the 19 dinner
parties that followed the lecture (a 35-year-old tradition), "a good time was had by
all':
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J. Greenberg, G. Cutting
S. Klimasauskas, V. Shick, E.
and M. Ustav, G. and N. Yenikolpov, and K. Galactionov
Iron Curtain around Science
Drops, Too
The events of the last year in Eastern Europe
have reshaped not only the political
and economic climates of the
planet, but also the scientific atmosphere. I have
been fortunate to be involved in
forging new ties with the scientific community in
the Soviet Union, since I was
recently elected to the Soviet Academy of Sciences.
Due to the removal of what visiting
scientist Grigory Yenikolopov called "a hostage
mentality': Soviets have been able to leave
the country with their families to pursue
research in other countries temporarily.
As a result, after having had only one So-
viet researcher here in our first 99 years,
we now have five visiting scientists from
the Soviet Union and one from Poland.
They are Konstantin Galactionov from
Leningrad, Grigori Yenikolopov and Valentin
Shick from Moscow, Saulius
Klimasauskas from Lithuania, and Mart Ustav from Estonia.
LIBA and Associates Membership Up
Last year, under the guidance of Chairman George W. Cutting, Jr., and with con-
siderable help from Jane Greenberg, LIBA membership soared to 781 members,
an increase of 47% over 1988. Annual giving also increased, allowing LIBA to sup-
port fellowships for Ashok Dubey, Anindya Dutta, Jeffrey Kazazz, and Erich
Grotewold. The New Investigator Start-Up Fund awarded grants to Carol Greider
and Arne Stenlund.
The Associates Program, only three years old, also had a very good year in
1989. Over $205,000 was donated by 135 associates, a membership increase of
22%. At the annual meeting in January, John Reese, a LIBA Director and new
Laboratory trustee, was put in charge of the newly formed Associates Committee
to continue expansion of the program. This annual giving, added to LIBA funds, is
an important source of dependable unrestricted funds that enables the Laboratory
to react quickly to promising research projects.
Baring Brothers & Co., Inc., Hosts Second Executive Conference
For top executives in the biotechnology industry, trying to combine the daily oper-
ation of their organizations with the need to keep up with rapidly changing tech-
nology is often an impossible task. For the second year straight, we were fortunate
to have the leading investment banking firm Baring Brothers & Co., Inc., co-
sponsor a two-day conference for executives on an important and practical field of
biology. The conference, organized by Douglas E. Rogers (a director at Baring
Brothers), gave chairmen, presidents, CEOs, and other top executives an intensive
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Baring Brothers executives at the DNA Learning Center lab
lesson on this year's topic: "Growth Factors in Development-Clues for New Thera-
pies:' Eight top scientists attended, including Stanley Cohen of Vanderbilt Univer-
sity, who won a Nobel Prize for the first purification of a growth factor. They dis-
cussed the use of growth factors to study and possibly treat a variety of diseases,
including bone disorders and diseases of aging. A highlight of the conference was
a laboratory experiment in the Bio2000 teaching laboratory at the DNA Learning
Center. There, the executives assumed the role of geneticist as they diagnosed a
case of sickle cell anemia using the latest recombinant DNA techniques, including
the polymerase chain reaction. Increasing their relationship with the Laboratory,
Baring Brothers also gave us a grant that last summer sponsored two students
from England in our Undergraduate Research Program.
Banbury Meetings Target Human Diseases
Continuing a shift in focus from an initial exclusive emphasis on risk assessment at
our Banbury Center conferences, Director Jan Witkowski held several meetings
pertaining directly to human diseases. In the fall, there were two meetings on
AIDS-one on HIV gene expression, the other on the pathogenesis of HIV infec-
tion. An early fall meeting on the genetics of alcoholism, sponsored by the
Christopher D. Smithers Foundation, forged important links among geneticists,
physiologists, and psychiatrists as they try to coordinate their differing viewpoints.
Various aspects of addiction in general were also addressed at a workshop for
congressional aides in January 1990. Topics ranged from the biology of addiction
to the potential impact on society of legalizing drugs. Jan's ambitious schedule of
pertinent events at the Banbury meeting house would greatly please its donor
Charles S. Robertson were he still alive to see the leading role of the Banbury
Center in focusing on the public aspects of today's biological revolutions.
Changes in Scientific Staff
Early this year, we said farewell to Senior Staff Scientist Doug Hanahan whose af-
filiation with us began in 1978. Doug worked in Matt Meselson's lab at Harvard as
a graduate student before earning his doctorate in 1983. Dividing his time be-
tween Harvard and Cold Spring Harbor, he became one of Harvard's prestigious
Junior Fellows before joining our staff full time in 1985 as Staff Investigator. He set-
tled into James lab, at first doing recombinant DNA experiments on the collagen
gene, and quickly advanced to Senior Scientist in recognition of his acclaimed
studies using transgenic mice. Our loss is the West Coast's gain; Doug now con-
tinues his work in San Francisco as an associate professor at the Hormone Re-
search Institute, Department of Biochemistry, University of California.
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Senior Staff Investigator Steven
Briggs has returned to Pioneer Hi-Bred Interna-
tional, Inc., in Johnston, Iowa.
Steve, who completed his Ph.D. at Michigan State in
1982, shared a joint appointment with Pioneer
and the Laboratory and first came
here in 1986 as a visiting scientist.
Assuming a pivotal role in the rebuilding of a
major plant genetics program at Cold Spring
Harbor, he was promoted to Senior
Staff Investigator in 1987. During
his stay here, his efforts were focused on the
genetic and molecular analyses of disease
resistance in plants, isolatin g genes
that confer resistance to corn pathogens,
for example, rust.
Early in the year, Carmen Birchmeier
accepted a position at the Max DelbrOck
Laboratory, Max Planck Institute,
Cologne, West Germany. Prior to her arrival at
the Laboratory, she worked on
her doctorate with M.L. Birnsteil at the University of
Zurich, followed by a postdoc period at
the Max Planck Institute in Tubingen, Ger-
many. Before being promoted to Staff Investigator,
she trained in Mike Wigler's lab
as a postdoc exploring new assays
for the detection of human oncogenes.
Staff Associate Maureen McLeod,
who worked in David Beach's lab, departed
after having worked with us for five years.
She received her Ph.D. from SUNY
Stony Brook in 1984 and worked on cell cycle regulation
during her time here.
She is now assistant professor at the
SUNY Health Science Center, Department of
Microbiology and Immunology, in Brooklyn.
New Staff Members
Joining the Laboratory as Senior Staff Investigator
is Thomas Marr. Tom comes to
us from the Los Alamos National
Laboratory where he was a staff member and
principal investigator in the theoretical biology and biophysics group. He col-
laborates in Hershey lab with Rich Roberts, pursuing his interest in computational
molecular biology and the algorithms for the physical mapping of DNA.
Robert Martienssen has accepted a position as Staff Investigator and presently
is working in DelbrOck lab. He received his Ph.D. in plant molecular genetics from
Cambridge University in 1986 and completed his postdoc at the University of
California, Berkeley, where he worked with Michael Free ling. Rob is researching
nuclear genes that regulate plastid development in maize.
New Visiting Scientists
In addition to our visitors from the Soviet Union, this year four visiting scientists
representing a diverse number of countries are continuing their respective areas of
research at Cold Spring Harbor. From Scotland we have Robin Allshire, who, after
completion of his doctoral dissertation in Edinburgh in 1985, focused his efforts on
chromosome structure and function at the Medical Research Council Cytogenics
Unit. Now he works here in DelbrOck lab. Doing experiments in Demerec lab is
Clement Echetebu, a native of Nigeria, who is on leave from the University of Ni-
geria in Nsukka. Clement did his postgrad work in molecular biology at Moscow
State and completed his doctorate at Odense University in Denmark.
Janos Posfai, who also is with Rich Roberts, is here for a second visit to con-
tinue the exploration of biological sequence analysis utilizing mathematical
methods. Janos, on leave from the Institute of Biophysics Biological Research in
Szeged, Hungary, first worked at the Laboratory in 1987. Yan Wang is here from
Beijing, China, working in Demerec. He received his M.D. in 1968 and continued
his postdoctoral work in the Department of Biochemistry at SUNY, Stony Brook,
before coming to the Laboratory.
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Staff Promotions
Loren Field and Dafna Bar-Sagi were both promoted to the position of Senior Staff
Investigator from Staff Investigator. Loren, whose field of study is the molecular bi-
ology of the cardiovascular system, completed his postdoc with K.W. Gross at
Roswell Memorial Park Institute in Buffalo. Arriving at the Laboratory in 1986 as a
visiting scientist, he has utilized the powerful methods of germ-line DNA transfor-
mation to create transgenic mice that model diseases affecting the coronary
system.
Ever since her arrival in 1984, Dafna's research has centered on the molecular
mechanisms of growth control and oncogenic transformation, particularly the role
of RAS proteins. She completed her early education in Israel and received her
Ph.D. from SUNY, Stony Brook, in 1984 before joining the cell biology group in
McClintock lab in September 1984 as a postdoc.
In 1987, Adrian Krainer was one of the first two young scientists appointed to the
position of Cold Spring Harbor Fellow. This program encourages independent re-
search by outstanding young scientists who, during their graduate studies, display
exceptional promise of becoming leading scientists in the future. Adrian, who
joined the Laboratory after working with Tom Maniatis at Harvard, continues to re-
search RNA splicing in mammalian cells and now has accepted a position as Staff
Investigator.
Visiting scientist Jacek Skowronski was also promoted to Staff Investigator. His
work is focused on transgenic mouse models of HIV-induced diseases. Jacek, a
native of Lodz, Poland, joined the Lab in 1986 after spending three years at the
National Institutes of Health in Bethesda as a visiting fellow.
Gil Morris, Karl Riabowol, Masafumi Tanaka, and Toshiki Tsurimoto, formerly
postdocs, accepted positions as Staff Associates. Gil Morris works with Mike
Mathews' protein synthesis group in Demerec lab investigating the control of gene
expression. Karl Riabowol is with Mike Gilman's group in James studying the
mechanisms of signal transductions that result in changes in nuclear transcription.
Masafumi Tanaka works with Winship Herr studying the regulation of transcription
in mammalian cells. Toshiki Tsurimoto works in Bruce Stillman's lab looking for an
understanding of the mechanism and regulation of DNA replication in eukaryotic
cells.
Postdoctoral Fellows
Postdoctoral research fellows leaving the Laboratory this year were Dennis Carroll
to the State Department, Washington, D.C.; Wai-Kit Chan to Columbia University
Law School; Susan Erster to the Biomedical Sciences Research Center, North
Shore University Hospital in Manhasset; Joanne Figuerido, East Norwich; Leslie
Goodwin to the NYU Medical Center in New York City; Seth Grant to the Howard
Hughes Medical Institute, Center for Neurobiology and Behavior, New York City;
Gurmukh Johal to Pioneer Hi-Bred International in Johnston, Iowa; Janise Meyer-
tons to Abbott Laboratories in North Chicago; Judith Potashkin to Chicago Medi-
cal School, Department of Pharmacology and Molecular Biology in North
Chicago; and Richard Sturm to the Center for Molecular Biology and Biotechnol-
ogy, University of Queensland, Australia.
Graduate students who completed their doctorates included Leonard Brizuela,
who returned to his home in Caracas, Venezuela; Lonny Levin, who is at the
Howard Hughes Medical Institute, Johns Hopkins Medical School in Baltimore,
Maryland; Ian Mohr who is at the Department of Molecular Biology at the Univer-
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sity of California at Berkeley; and Brian
Ondek who is in the Department of Biol-
ogy at the University of California at
San Diego, La Jolla. Robert Booher is contin-
uing his studies at the University of California
School of Medicine in San
Francisco.
Employees Recognized for More Than 15 Years of Service
Several new names have been added to the growing list of dedicated Laboratory
employees who have worked here for so many years. Fifteen-year awards were
presented to Deon Baker, purchasing secretary (now retired); Bob Borruso, equip-
ment maintenance technician; Annette Kirk, Assistant Managing Director of Publi-
cations; Michael Mathews, Senior Staff Scientist, and Lane Smith, plumbing
supervisor.
M. Mathews, B. Borruso, D. Baker, L. Smith
Making the Business Connection
To create a more tangible bond with the Long Island business community, we
have created the Centennial Committee. Co-chaired by Robert R. McMillan of Riv-
kin, Radler Bayh, Hart & Kremer and Thomas A. Doherty, Chairman and CEO of
Norstar Bank, the committee's main goals are to increase the Laboratory's visibility
on Long Island and to sponsor a centennial book. The book will feature a section
titled "Partners for the Future," highlighting some of the larger companies on Long
Island. It is hoped that this presentation of the strength and depth of research and
industry on Long Island will be used by local development agencies to attract new
businesses from the U.S. and abroad to the region.
:old Sprirkz Harhor I_ahorator\
Centennial Committee
Doherty, J.D. Watson, R. McMillan
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Laboratory Is Number One among Independent Labs
A recent article in the newspaper The Scientist confirmed what we have liked to
dream-the Laboratory is number one among the 74 members of the Association
of Independent Research Institutes (AIRI). The article based this on "citation im-
pact': a measure of how many times other researchers cite papers from our scien-
tists. Between 1973 and 1987, our scientists' papers were cited an average of 58.7
times, which is more than five times the average impact and 15 more citations
than number two on the AIRI list. My thanks and congratulations to all the re-
searchers here over the last two decades who made this possible.
Strong Board of Trustees
For an institution such as ours that is not tied financially to any outside university
or foundation, long-term strength is often directly related to the expertise of its
governing body. In our case, the sound financial and scientific position we have so
far reached heading into our centennial owes very much to the diligent and caring
work of all the members of our board of trustees, who encompass a broad spec-
trum of outstanding achievements. Unfortunately, after their two consecutive three-
year terms on the board, we had to bid a partial farewell to Eric R. Kandel and
John Klingensteinpartial" because they are both remaining as advisers on the
neurobiology committee. Eric's unmatched experience and wisdom have been,
and will continue to be, a guiding force behind the Neuroscience Center and the
neurobiology course program. Last year, he helped to organize our lecture course
on behavior and this year will organize our October Aplysia meeting. John has
long been a champion of the neurobiology program and his expertise in invest-
ment banking, gained from his many years with Wertheim & Co., has been vital as
our operating budget grows and we increase our endowments.
As biotechnology begins to have a real impact on the pharmaceutical industry,
we were very fortunate when William R. Miller, Vice Chairman of the Board of
Directors of Bristol-Myers Squibb Company, joined our board this past year. He
has over a quarter-century of experience under his belt at Bristol-Myers Squibb
and is well-known throughout the international pharmaceutical industry. After a
one-year hiatus following his past two terms on the board, we welcomed back an
old friend, Townsend J. Knight, whose dedication to the Laboratory equals that of
his Jones family ancestors. Filling Eric Kandel's position as representative from
Columbia University is Thomas M. Jessell, already a familiar face at the Labora-
tory. Since 1983, he has been a lecturer at summer neurobiology courses, and
now, as a member of the neurobiology committee, he will help us to shape the fu-
ture of the entire program. With so many good scientists and projects here, our
concerns often turn from where the next discoveries are to how we will pay for
them. John R. Reese of Lazard Freres & Co. has joined the board to help us ad-
dress these concerns with his knowledge of investment banking. A resident of
Cold Spring Harbor and already a LIBA Director, John needs no lessons on how
to be a Laboratory supporter. Having not really lost two members and gaining
three, our board may indeed be stronger than ever.
More Responsibilities Come with My Directorship of the National Center
for Human Genome Research
In October 1988 when I first went down to NIH to help in the build up of its Hu-
man Genome Program, I was then the Associate Director for Human Genome Re-
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search working under its Director, Jim
Wyngaarden. At first, my office did not have
the formal powers to give out grants; that
role remained the responsibility of the
National Institutes for General Medical
Sciences. On October 1, 1989, however, my
responsibilities became much more operational.
A new grant-awarding division
within NIH was created to manage NIH's
role in our nation's effort to map and se-
quence the human genome of some three
billion base pairs.
I am now the Director of the National
Center for Human Genome Research
(NCHGR), whose offices are located on the sixth floor of the Lister Hill Building,
with fine views over the NIH Bethesda Campus.
We have a staff of almost 30
scientists and administrative aides who will function over
the more than 100 million
dollars that we hope to distribute each year
in grants or contracts to scientists
working at a large number of universities, medical schools, research institutions,
and our biotechnology-oriented
companies. Companion to our NIH effort is a
Department of Energy Program that plans to distribute roughly half this sum, in
large part to those of its National Laboratories such as Los Alamos, Lawrence
Berkeley, and Livermore that have initiated major human genome mapping and
sequencing efforts.
As the NCHGR Director, I am constantly on the shuttle that flies from LaGuardia
Airport to Washington National as well as traveling for talks that explain our ge-
nome program to influential university and industrial bodies. I must also attend
many of the increasingly large number of highly technical small meetings that
bring together key scientists in our program. I'm also spending more time working
for NIH here at my Cold Spring Harbor desk than I initially planned, in large part
due to the ease with which documents can be transmitted to me from Bethesda
over the fax. By now, I suspect that half of my efforts are devoted to NIH, leaving
me badly stretched to find the time and energy for my responsibilities here.
Fortunately, ever since my appointment 22 years ago, this institution has run
very well without my constant day-to-day interventions. This was most certainly the
case prior to 1976 when I simultaneously taught at Harvard, and it is even more
true today. This only has been possible because of the high competence of our
key scientists and administrative staff. Today, Morgan Browne, our Administrative
Director, Richard Roberts, our Assistant Director for Research, and Terri Grod-
zicker, our Assistant Director for Academic Affairs, know they have to run their own
shows and do so well. My functioning in two jobs is also immeasurably aided by
Susan Cooper in her capacity as Director of our Public Affairs Department. Partic-
ularly important have been her interactions with the many journalists who want to
learn more about my job in Washington. My secretary here, Andrea Stephenson,
also has been of immeasurable help in presiding over travel plans that often must
change at the last moment.
Even with all this help and encouragement, I am just making do and worry what
will happen if my genome duties present an even greater call on my time. I do not
have the answer and try to keep this potential crisis from affecting my current day-
to-day existence.
Our Objectives Must Remain Heroic
I constantly surprise visitors who ask to see my lab by replying that I have never
had one since I came here 22 years ago. Initially, that situation reflected the fact
that I had an active research lab at Harvard and running two groups was far be-
yond my capabilities. Later, when we made Cold Spring Harbor our sole resi-
dence, I was by then never tempted to strike out again as an experimentalist. In
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trying to keep this Laboratory growing in an exciting way, I was never bored and
had more than enough anxieties to keep me from either growing complacent or
worrying whether my peers viewed me as past my prime and lacking the
strengths that led me toward the double helix. The science around me in the labs
of our staff was much better than I could have then pulled off through a personal
group. By merely walking out of my office, I moved into a scene where the aim
was to find the future not follow the past. So I could feel quietly satisfied that my
move away from Harvard had not led me into a derivative world lacking the in-
tellectual power of the American Cambridge.
The unique quality of Cold Spring Harbor was allowing us to strive for research
objectives that most scientists even at Harvard or MIT inherently shy away from
because the odds for success look too low. It has been these heroic purposes
that has led to our high relative ranking as measured by the "citation index:' That
we are judged so well by the outside scientific world obviously reflects the intelli-
gence and high motivation of the so many excellent scientists who have worked
here over the past two decades. But these talents would have been lost in the
crowd of excellence elsewhere if we had strived for more obviously attainable
goals.
Looking Forward to the Next Decade
At least until this century ends, we must remain deeply committed to the pursuit of
oncogenes and anti-oncogenes. We have come too far to turn back now before
we have our quarry. The cancer research facilities in James, Sambrook, Demerec,
and McClintock labs should remain so committed until victory. We furthermore
must be constantly improving these labs, with the next major upgrade needed be-
ing a major refurbishment of our hallowed McClintock lab. So renovated, it will be
an ideal site for bringing oncogenes and anti-oncogenes into the world of those
who study how normal cells progress through the cell cycle.
We must also set our sights very high as we move seriously into neurobiology.
In finally understanding how our brains perceive, memorize, and learn, enormous
challenges must be faced and we should have no illusions that anyone soon will
find a double helical type of simplicity within the brain that will provide a simple in-
tellectual framework on which to base our ideas and experiments. So, we must be
realistic over the short term, while keeping very clear that cognition, not selective
neural gene functioning, is what makes the human brain the ultimate gem of all
science. Thus, although developmental neurobiology is likely to be the main initial
focus of our new Beckman lab, we must have in residence experimentalists who
pursue the essences of perception and memory, as well as their more theoretical
colleagues who make models for how we may learn. If somehow we can integrate
these several worlds together, our ever-growing commitment to neurobiology will
make our next century even more exciting than our first one.
This will indeed be a hard challenge. But in so striving, we shall try hard to
maintain the traditions of our past that are so satisfying to look back upon, tradi-
tions of scientific honesty, abhorrence of pomposity, and devotion to the teaching
that rapidly disseminates the new facts of science to the best of our youths.
April 4, 1990 James D. Watson
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ADMINISTRATION
We were pleased with the Laboratory's financial results for 1989. Revenues
exceeded expenditures, and there was a surplus after fully funding depreciation
and providing some moderate reserves for future contingencies. These results em-
phasize the financial health of the Laboratory as it enters its second century and
are a reflection of the basic strength of its programs.
This is most clearly demonstrated by the research program. Now is a particu-
larly difficult time for federal funding of basic research, with only about 15% of ap-
proved new grant submissions to the NIH being funded nationwide. Yet, scientists
here continue to be awarded a good share of available funding, and their extraor-
dinary research is attracting increasing support from private foundations, corpora-
tions, and individuals.
Federal funding for meetings and courses is no less difficult to obtain. But
again the quality of the education program attracts support from a wide variety of
government and private sources, and in 1989, this funding was sufficient to make
the year a financial as well as an intellectual success. A record 5417 visiting scien-
tists from academia and private industry attended the meetings, courses, and
seminars held on the main campus and at Banbury Center.
The Cold Spring Harbor Laboratory Press achieved record revenues of nearly
$4.5 million during 1989. The enormous success of the second edition of the Mo-
lecular Cloning manual and of Ed Harlow's Antibodies manual helped support the
publication of a number of less popular but no less worthy books. Moreover, the
Journal Department, with substantially reduced investment now needed for Genes
& Development, found it possible to invest the funds required to launch Cancer
Cells, our second journal.
Banbury Center and the DNA Learning Center also had a good year. Banbury
meetings focus on scientific subjects that have particular social or environmental
relevance or are designed to appeal to corporate scientific interests. One result
was a record number (31) of Corporate Sponsors who contributed over $500,000
in support of the Laboratory-wide meetings program. Programs of the DNA Learn-
ing Center continued to have increasing national impact on high school science
education, and the Center made further progress toward financial self-sufficiency
after overhead and depreciation.
The financial strength of the Laboratory benefited from another good invest-
ment performance of the endowment, consisting primarily of the Robertson and
Cold Spring Harbor Funds. As of December 31, 1989, these funds totaled $45 mil-
lion, a gain of more than 22% over the prior year. Once again, we were able to
reinvest sufficient income from the Funds to compensate for inflation and to pro-
vide for the future growth of Laboratory programs.
A year as rewarding as 1989 is made possible by the contributions of many in-
dividuals and departments. Some, such as Buildings and Grounds, Development,
and Public Affairs/Library, are described elsewhere in this report. The Meetings
and Food Service Departments continue to astound us with their gracious and ef-
ficient registration, housing, and feeding of our many visitors. Other departments,
particularly in Nichols Building, should not be overlooked.
Our Controller, Bill Keen, has built an organization that handles the Laboratory's
finances with great effectiveness. The operating and capital budgets are managed
professionally with a minimum of surprises, and these are most generally of a
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positive nature. The addition
of Barbara Wang and
Alison McDermott to our staff
within the past two years has made
it possible to provide greater financial as-
sistance to the Cold Spring
Harbor Laboratory Press, Banbury Center, and the
DNA Learning Center and to
maintain the necessary close supervision of now
some $75 million of endowment,
capital, and operating funds.
Susan Schultz and the Grants
Management Department fulfill a particularly vital
function. Grants are the lifeblood
of the Laboratory. The task of assisting the staff
in obtaining and properly
managing these grants grows in direct proportion to the
number of scientists here. That
number increased by some 25% during 1989 and
will increase again by at least
that amount as the Neuroscience Center is fully
staffed.
Such growth also impacts our
Purchasing and Human Resources Departments
One of the most important services
provided to the scientific staff is fast and effi-
cient response to equipment, supply,
and personnel needs. At the beginning of
1990 when Chuck Haibel was
promoted to the new position of Contracts and
Equipment Manager Buildings and
Grounds, Sandy Chem lev was promoted to
Manager of Purchasing and already it is
clear that our confidence in her is well
placed. In November, Cheryl Sinclair joined
the Laboratory as Manager of Human
Resources after Tony Napoli accepted a
position as Vice President of Human Re-
sources at Tarkett, Inc., part of STORA
Group, a large Swedish conglomerate.
Cheryl comes to the Lab from Kollmorgan
Corporation, where she was Personnel
Director of the PCK Technology Division.
We are delighted to have her with us
.John Maroney, now successfully beyond the
ordeal of the New York State Bar
Exam, has been an enormous help in sharing administrative tasks and in manag-
ing commercial relations. Licensing of inventions is a
small but increasing source
of income for the Lab and the scientific staff. John's aim is to familiarize the staff
with the procedures and benefits of patenting their discoveries, and he acts as an
interface with patent attorneys and private industry.
The Board of Trustees, with its unique mix of prominent scientific and lay mem-
bers, takes an active role in the affairs of the Laboratory. Roberta Salant responds
to their needs with an efficiency and grace that is much appreciated by all.
We look to 1990 and beyond with much anticipation. By this time next year,
there will be research and courses under way in Beckman Laboratory; Dolan Hall,
along with six additional guest houses, will be providing 108 more overnight ac-
commodations for visiting scientists, bringing the total above 200. A major renova-
tion and expansion of kitchen and dining facilities in Blackford Hall will be under
way. It is hoped that Jack Richards and Jim Hope will have figured out how to
feed our employees and visitors while Blackford lies in pieces. Refurbishment and
expansion of McClintock Laboratory will also be imminent.
During this centennial year, it is good to reflect on the first 100 years of extraor-
dinary achievement at Cold Spring Harbor Laboratory--clearly, the next 100 years
will be no less eventful.
G. Morgan Browne
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BUILDINGS AND GROUNDS
As I write this report for 1989, I have to think back 20 years ago when I started
this job. I had been concerned that we would run out of work in three to four
years when all the old buildings were rebuilt. Twenty years later, I could fill volumes
for the next few years. So let's go back and see what we did in 1989.
Telephone Service Upgrade
In 1989, we completed a major upgrade to the telephone system, specifically the
PBX switch. This switch handles all of the Laboratory telephone traffic and is the
heart of the telecommunications system. The original PBX switch was ten years old
and operating at full capacity. Because the Laboratory is continually expanding, it
was decided to upgrade to a larger, state-of-the-art PBX switch. On Saturday, July
19, the new switch was installed, with a loss of service of only 15 minutes. It was a
smooth transition, with minimal disruption to the working Laboratory. Credit for a
job well done goes to my assistant, Peter Stahl, who is now keeping all of our
phones and switch gear on line with very few problems.
Conversion to Natural Gas Burners
New York State regulations regarding in-ground oil tanks have made it impossible
for us to continue to use this form of heating. We have therefore been removing
the oil tanks and converting to natural gas burners. Our Plumbing Department
worked long and arduous hours designing and installing gas burners in the larger
buildings, and a new gas main was installed by LILCO. We expect to complete all
conversions to gas within the next two years.
Landscaping and Paving
The Grounds Department had a very busy 1989 as well. We landscaped the area
around the new cabins. This required working on a hillside with only picks,
shovels, and rakes. We also paved the parking areas north of Nichols and at
Waterside next to the Buildings and Grounds Department. Also, we built a pond
next to Nichols' parking lot. All of these jobs were held up because of inclement
weather-rain, rain, and more rain. Yet we kept the grounds looking great thanks
to Buck Trede, our Grounds Foreman, and his crew.
New Construction
Our Carpentry Department had its hands full also. To start the year, we built a
mock-up of one of the neurobiology labs scheduled for construction and set it up
in the Bush Lecture Hall. It remained there through January for all to see and
comment upon. We then went to work on the six new cabins. Off to a slow start
due to very cold weather in January and a very wet spring, we were concerned
that the cabins would not be completed by the first meeting. A number of other
misfortunes also complicated our spring work. Carl Fabrizi, one of our carpenters,
fell off the scaffold and could not work for several days; and Jeff Goldblum, our
lead carpenter, had a personal emergency and was not his usual energetic self for
a time. Lou Jagoda, our electrician, broke his ankle and was also slowed down a
bit. And of course there was the rain! In spite of the problems, the cabins were
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completed and wood decks and walks were installed,
all before the first spring
meeting!
Alterations and Renovations
Demerec: After many years of talk about a north
addition to Demerec, in 1989 we
constructed a small extension to house a seminar room, a secretarial area, and a
post-doc office. The extension also provides a new entrance to Demerec and has
a landscaped patio area. We completed the work on time and the extension was
occupied on November 15.
Harris: Completed in 1982, the Harris Building needed updating and new paint
throughout. We rebuilt the cage-washing area, installed a new tunnel washer, put
up a new ceiling, and painted the interior of the building from top to bottom.
Wawepex: We gutted the lower floor of Wawepex in preparation for a new develop-
ment office. We installed new windows and added a new porch, air conditioning,
and built-in furniture. We also added a new walk and stairs to Blackford lawn.
DNA Learning Center: A great deal of our time was spent in the DNA Learning
Center. In 1989, our last project, the designing and building of two laboratories in
the basement area, was completed.
Thanks to a Great Staff
I want to thank my staff for a job well done. We have a crew of workers who do an
excellent job despite all the obstacles and they are great mechanics. They are the
best, and their efforts are appreciated.
Jack Richards
DEVELOPMENT
In its first complete year as an administrative entity, the Development Department
was fully engaged in directing the $44 million Second Century Campaign, the first
public capital campaign in the 100-year history of Cold Spring Harbor Laboratory,
and expanding the annual giving base both in number of donors and in number
of dollars.
Unrestricted annual giving to the Cold Spring Harbor Laboratory Associates
Program and to the Long Island Biological Association (LIBA) provides strong
underpinning for the fiscal health of the Laboratory. These programs are soundly
and enthusiastically guided by Chairman George W. Cutting, Jr, and 28 directors.
(A complete report of their 1989 activities may be found in Financial Support of
the Laboratory, later in this Annual Report.) The increase in the numbers of these
annual supporters and the success of the Second Century Campaign give
testimony to the fact that Cold Spring Harbor Laboratory is no longer "Long
Island's best kept secret':
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The official announcement of the public phase of the Second Century
Campaign occurred in Grace Auditorium on April 22nd at a dinner for more than
100 campaign volunteers and guests. Campaign Chairman and Trustee Treasurer,
David L. Luke III, assigned the task of raising the remaining $16 million to the six
campaign committees; $28 million had already been raised through the outstand-
ing efforts of Dr. Watson, Dr. Clarkson, Mr. Luke, Morgan Browne, and the trustees.
By year's end, another $8.9 million had been raised, making the total of campaign
gifts and pledges, $36.8, with $7.2 million left to raise to meet our $44 million goal
by December 1991.
Several important areas in the Neuroscience Center have been named as a
result of significant campaign gifts: The Hazen Tower (Mrs. Lita A. Hazen), The
Oakes Ames Seminar Room (Mrs. Pauline A. Plimpton and Mr. Amyas Ames),
The Gardner Neuroscience Library (Mr. and Mrs. Robert B. Gardner, Jr.), and The
Lucy and Edward Pulling Seminar Room (Mr. and Mrs. George W. Cutting, Jr.).
A request from someone who believes in, works for, and has given to an institu-
tion is far more effective than any other type of request. Thanks to the practical
labors of our campaign volunteers, most of whom have made their contributions,
the Second Century Campaign is progressing well. We are most fortunate to have
the assistance of these dedicated people.
Another important element responsible for the progress we have been able to
make this year is the Development Department staff. Joan Pesek is a most
effective liaison to LIBA and a cordial cultivator of new members; she manages
the CSHL Associates Program and is a very knowledgeable tour leader. Debra
Mullen has given order to our fledgling department, keeps accurate track of the
complexities of our ever-increasing number of gifts (annual and campaign), and
manages to satisfy the demanding secretarial needs of the Department. During
the year, an important addition made in the person of Claire
provides considerable expertise and artistry in the coordination of our campaign
committees and the identification and cultivation of new campaign prospects. But,
perhaps the Department's greatest asset is George Cutting, a trustee of the
Laboratory who, each day, volunteers long development hours, is the Chairman of
LIBA, and is one of the co-chairmen of the campaign's Special Gifts Committee.
He is a creative and genial campaign leader and we could not function nearly as
efficiently without him.
This entire Annual Report attests to the continuing remarkable work being done
at the Laboratory and is a great source of pride not only for those who work "on
grounds': but also for those who work "off grounds': We are most grateful to those
who have helped make such progress toward our development goals. (Campaign
contributions are listed under Financial Support of the Laboratory.) Only vital and
growing institutions need capital campaigns and as we enter the second year of
the public phase of the Second Century Campaign, we invite those who have not
yet participated to do so. (Methods of contributing, either outright, in trust, or by
will, are outlined under Financial Support of the Laboratory.) Come celebrate
our past 100 years and make secure our next 100 years!
Konrad Matthaei
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LIBRARY SERVICES
Archives
The Laboratory archives, formerly the library attic, is now a
comfortable and active
facility, housing the Carnegie collection of historic
books and journals, as well as a
number of newer books about Long Island and of
interest to the Laboratory. In
addition, there are files of original papers from the early Carnegie years.
Laboratory information and material are continually
kept current to ensure accurate
records for future generations. Researchers from the media as
well as staff
members are making use of this facility. Lynn Kasso ably handles organization of
archival materials and fulfills outside requests from both publishers and the press.
In connection with the dedication of the new cabins in August, 24 photographs
of historic buildings from the archives were selected by Laura Hyman and
Elizabeth Watson to be enlarged to 16 x 20", sepia-toned, and framed. These
photographs were hung in each cabin bedroom. The archives also played a major
role in the preparation and planning of the Laboratory's first major exhibit of
paintings and prints by Jane Davenport Harris De Tomasi, which will take place
early in 1990 as part of the Centennial celebration.
Reference Services
The library began its plans to automate several of its reference services. A
workstation consisting of a PC and a printer was installed for use by Laboratory
patrons. Weekly issues of Current Contents on diskette are available for current
awareness access by author, journal title, and key word. Users may either print
references or download them to floppy disk. In December, a compact disk version
of the National Library of Medicine's Index Medicus Med line database was set up
on a trial basis. It provided scientists with unlimited access to this database at no
cost to the individual user. This type of end-user search capacity proved so pop-
ular that the library will continue this service in 1990 and add other databases on
CDs such as Biological Abstracts as they become available. Genemary Falvey,
the Head of Library Service, is currently investigating other applications of technol-
ogy to extend user participation further.
Our computerized search service continues to be Genemary Falvey's first
priority. She conducts three times as many searches today as she did five years
ago. Wanda Stolen capably handles our computerized interlibrary loan service,
which provides faster access to articles requested by staff scientists. Photocopies
of the tables of contents of 60 journals are sent as received to 32 scientists.
Storage Facility
The storage facility at West Side School continues to house our older and less-
used bound journals. We monitor the requests each year and withdraw unused
titles to make room for others and consequently free up space in the main library
for newer materials.
Staff Changes
Helena M. (Leigh) Johnson joined the library staff in November, replacing
Jeannette Romano-we welcome her aboard.
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Space Needs
Library materials and personnel have been rearranged to allow for maximum
capacity in the space allotted to us in the Library building. To provide for the
future needs of the Laboratory's growing personnel, it will be necessary to plan
future expansion in the present building by retrieving our space from the Publica-
tions Department, by adding to the present building, or by moving to larger
quarters.
Susan Cooper
PUBLIC AFFAIRS
From New Staff to Seasoned Staff
For the first time in its six-year history, the Public Affairs Department has no staff
changes to report. This continuity in personnel has contributed to the vast number
of materials and events produced by the department in 1989. Margot Bennett,
Emily Eryou, Herb Parsons, and Dan Schechter are a dedicated team of
professionals whose willingness to work long hours very often is the only reason
so much is accomplished in so little space.
For more than ten years, Herb Parsons has served the Laboratory, first as
audiovisual technician and now as Audiovisual Director. When he began, Herb
handled 9 summer meetings, 5 Banbury meetings, and 12 courses. Today the
program has grown to 13 summer meetings, 23 Banbury meetings, and 19
courses. I want to take this opportunity on behalf of the Laboratory to thank Herb
for his enthusiasm, dedication, and hard work.
Good Local Press Coverage
The Department issued a dozen press releases and talked to countless reporters
and anchor people, eliciting 12 television segments and 145 magazine and
newspaper articles mentioning Cold Spring Harbor Laboratory and its scientists.
Local coverage has been particularly satisfying this year, laying the foundation for
better local support from Long Island communities and businesses. Cablevision's
News 12 Long Island featured the Laboratory in its new health segment and the
Long Island Association's magazine, Long Island, featured the Laboratory in its
cover story, "Harbor of Discovery: Several items were reported in Long Island
Business News as well. On the national front, the Laboratory and its DNA
Learning Center found themselves touted on ABC, CBS, and PBS and discussed
in the New York Times, Washington Post, and Christian Science Monitor, to
mention just a few. Newsday published a profile on the "Dean of DNA': featuring
Dr. Watson's dual role at the Laboratory and at the Office of Human Genome
Research in Washington, D.C. Equally compelling was the extensive and personal
profile of Dr. Watson in the Washington Post=The Man Behind the Double Helix':
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An Array of Available Materials
At a time when information reaches our TV screens
and front pages concurrent
with discovery, it behooves scientific institutions to describe their research in an
accountable and unambiguous manner. It is our obligation to present tools that will
nurture, not mystify, our constituency. To this end, The Good Fight: Cancer
Research at Cold Spring Harbor Laboratory was completed in 1989. Designed for
the lay reader, this piece explains the research tools employed by the laboratory
scientist to pursue the complexities of the cancer puzzle. A Vision of Hope, a new
10-minute video, presents a concise view of the Laboratory from research to
education and is used to cultivate new audiences.
Four regular issues of the Laboratory's newsletter, Harbor Transcript, were
completed, along with one special campaign issue highlighting the kick-off dinner
for the public phase of the Second Century Campaign. In its seventh year, the
Harbor Transcript is now mailed to nearly 6000 neighbors and friends. In addition
to its regular features, the newsletter highlighted research in the areas of electron
microscopy, cancer and AIDS, and the cell cycle.
Equally important to the Laboratory's public face are its promotional pieces. In
1989, the staff supported the work of other departments by writing, designing,
and organizing numerous cultivation tools, publicity pieces, and events. The
McClintock Renovation and Infrastructure brochures were created to marshal
funds for the physical plant. A variety of other fund-raising pieces were rewritten,
updated, or restructured for use in the Second Century Campaign. Meetings and
courses posters, a Nature Study brochure, a LIBA Associates plaque, and a
multipurpose Centennial notecard round out the materials available.
The Memorial Program
In 1989, I was approached by a young man whose father was dying of cancer.
The older man, Walter Sturm, who had survived Kristallnacht during World War II,
waged a heroic battle against the disease for 20 years. Through his son, Robert,
the family was searching for a substantive way to honor their father. Over the
years, Bob had searched scientific literature for solutions to his father's advancing
disease, discovering in the process that papers from the Laboratory were cited
most often. The family decided that only quality research would provide the better
diagnosis and treatment they had sought unsuccessfully for their father. Before his
death on March 24, 1989, Mr. Sturm agreed that any memorial funds resulting
from his death should be contributed to the Laboratory. Fittingly, the Sturm Fund
has generated over $3500.
In dealing with a mechanism for handling the numerous small contributions
from the Sturm Fund, Public Affairs designed a memorial program. Envelopes and
pledge cards are now available to anyone through our department.
Special Events
During the final year of our first century, the Public Affairs Department planned
and hosted a variety of events. On May 12, marking the completion of the first
phase of the Neuroscience Center, we extolled the donors with the placement of
the cornerstones, followed by a festive dinner. On August 26, the new cabins were
dedicated and named for six of our most esteemed alumni: Bentley Glass, Harry
Eagle, Salvador Luria, Gunther Stent, Franklin Stahl, and Herbert Boyer. A
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dedication booklet commemorating this event included a history of visitor housing
and profiles of the honorees.
Centennial
Peter Orth, one of the most consistently acclaimed pianists of his generation,
performed a wonderful concert in honor of our Centennial. LIBA member Mary
Lenore Blair was the "angel" who coupled Orth with the Laboratory. Mrs. Blair
recruited sponsors who, in addition to making financial contributions, hosted
dinners for friends, who in turn purchased tickets to the concert. On August 13,
Orth performed to a full house and received the most resounding standing ovation
ever experienced here.
To commemorate the Centennial, in December, each member of the staff was
presented a lapel pin and FA.C.E.S. '89, a book of photographs of all Laboratory
personnel. In addition to snapshots, this rogue's gallery lists date of employment,
job title, and resident town for each entry, providing an ever-growing population
with the ability to identify co-workers.
Each event adds momentum to, and sets the stage for, our 100th birthday party
in July 1990. To ensure its success and mark the day in grand style, Judith
Carlson has been retained to create a Centennial book. The book will include a
record of Centennial events, historical highlights of Laboratory activities, pho-
tographs, and appropriate salutations from the Laboratory's community. A section
called 'Partners for the Future" will be congratulatory messages from the Long
Island business community. A committee of prominent business figures is being
organized by Robert McMillan, Publisher, Economic Times of Long Island, and
Thomas Doherty, Chairman of the Board, Norstar Bank, for the purpose of
producing this wonderful tribute.
Susan Cooper
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RESEARCH

TUMOR VIRUSES
The Tumor Virus Section presently comprises nine groups, united historically
through their use of the DNA tumor viruses to probe cellular functions. The
research conducted in this section covers an extraordinarily broad range of topics,
and its scope has expanded in recent years as the exploration penetrates more
deeply into the molecular machinery of the cell. Although the principal goal
remains to develop an understanding of malignancy, a great deal of current effort
is concentrated on exposing the mechanisms of macromolecular synthesis that
operate in the normal state. Some of the most dramatic advances have illuminated
regulatory processes that govern cellular functions in both the normal and
transformed states and determine the transition between them. Common
regulatory themes that have emerged repeatedly involve the modulation of enzyme
function by interaction with other macromolecules or by covalent modification,
especially phosphorylation; examples of these two fundamental strategies are
described in a number of the reports that follow. In addition to studies of the two
traditional workhorses, adenovirus and SV40, several groups have also begun to
dissect the control processes exploited by the AIDS virus, HIV-1, and last year also
saw the initiation of bovine papillomavirus studies in Dr. Arne Stenlund's laboratory.
The year's end sadly brought to a formal close Dr. Yasha Gluzman's long,
productive, and ever lively connection with Cold Spring Harbor Laboratory.
Related work on SV40 T antigen will continue, however, in Dr. Bruce Stillman's lab,
and we hope that Yasha will maintain a vigorous interest, if less frequent presence,
in the project in the future.
DNA SYNTHESIS
B. Stillman E. White A. Dutta R. Cipriani
T. Tsurimoto T. Melendy N. Kessler
G. Bauer F. Bunz S. Longinotti
S. Brill K. Fien L. Mellon
J.F.X. Diffley Y. Marahrens S. Penzi
S.-U. Din S. Smith P Sabbatini
The replication of DNA is a central step in cell
growth and division and is necessarily a precise and
highly regulated process. Our goal is to understand
the mechanism and regulation of cell chromosomal
DNA replication. To achieve this goal, we use as ex-
perimental systems, the DNA tumor virus, SV40, and
the yeast, Saccharomyces cerevisiae. It is therefore
satisfying that in the past year, these two avenues
of approach have crossed many times, emphasizing
the fundamental nature of DNA replication and, at
the same time, reinforcing our initial belief that the
DNA tumor viruses offer valuable insights into the
intricate workings of their host cell.
SV40 DNA Replication
S. Brill, F. Bunz, S.-U. Din, A. Dutta, K. Fien, T. Melendy,
T Tsurimoto, N. Kessler S. Longinotti, B. Stillman
The DNA tumor virus, SV40, contains a small cir-
cular chromosome that replicates in the cell nucleus
during the S phase of the cell cycle. The virus en-
codes a protein, the SV40 T antigen, that plays a cen-
tral role in the replication of the viral genome. There-
fore, the majority of proteins that replicate SV40
DNA are encoded by the host cell. Moreover, the
mechanism of SV40 DNA replication reflects the
mechanism of DNA synthesis from a single chro-
mosomal origin of replication. Thus, SV40 is an ex-
cellent system to study cellular DNA replication.
Our primary goal over the past five years has been
to identify and characterize the cellular proteins re-
quired for DNA replication and chromatin assem-
bly, ultimately to use them to study the regulation
of DNA replication. A cell-free extract prepared
from human cells supports the complete replication
of SV40 DNA when purified T antigen is supplied.
The mechanism of DNA replication in the cell ex-
tract reflects the process that occurs in SV40-infected
cells. To identify the cellular components of the repli-
cation machinery, we have fractionated the extract
into multiple components and have identified a num-
ber of novel replication factors. A brief summary
of the functions of the known human cellular DNA
replication factors follows.
REPLICATION FACTORS
Replication Factor A. In 1988, we reported the
purification of a novel replication factor from hu-
man cells called replication factor A (hRF-A) and
demonstrated that it was a single-stranded DNA-
binding protein required for initiation of DNA repli-
cation. The human protein contains three protein
subunits with molecular weights of 70K, 34K, and
11K. In last year's Annual Report, we noted that hRF-
A functions during the presynthesis stage of DNA
replication to aid in unwinding of the SV40 replica-
tion origin; however, it also functions to stimulate
the activity of both DNA polymerase a and DNA
polymerase 8.
As a first step toward characterizing the function
of RF-A in cellular DNA replication, we identified
a homolog of hRF-A in the yeast S. cerevisiae. This
protein was purified using an origin unwinding as-
say in which the yeast protein, like its human coun-
terpart, would cooperate with SV40 T antigen to pro-
mote extensive unwinding of SV40 origin containing
plasmid DNAs. The yeast protein (yRF-A), also a
single-strand-specific DNA-binding protein, has a
subunit structure similar to hRF-A, containing pro-
teins with molecular weights of 69K, 36K, and 13K.
In both cases, the largest subunit was responsible for
the DNA-binding activity. The yeast protein, how-
ever, would not support complete SV40 DNA repli-
cation when it was substituted for the human factor
in vitro. This was due to a specific interaction be-
tween RF-A and DNA polymerase a. We have also
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studied the potential role of
RF-A in regulation of
DNA replication (see below).
Replication Factor C. This year, we reported the
purification of a new DNA replication factor , called
RF-C, that is required for SV40 DNA replication in
vitro. RF-C, which is involved in the elongation stage
of DNA replication, is a multisubunit factor con-
taining protein subunits with molecular weights of
approximately 140K, 41K, and 37K. T
subunit binds to DNA, whereas the 41K subunit
binds to ATP. RF-C functions as a DNA
stimulatory factor; it stimulates DNA polymer-
ase a activity by itself but cooperates with prolifer-
ating cell nuclear antigen (PCNA) (see below) and
RF-A to greatly stimulate DNA polymerase 8. Sub-
sequent biochemical analysis of RF-C revealed two
interesting functions: It binds specifically to single-
stranded DNAs containing an annealed primer with
a free 3'-OH end and it is a DNA-dependent ATPase.
Indeed, analogs of ATP that cannot be hydrolyzed
by RF-C (e.g., ATPyS) inhibit the RF-C-dependent
activity of DNA polymerase 8.
These results suggest that RF-C plays a critical
role in the initiation of DNA synthesis by DNA poly-
merase 8, the enzyme we have implicated as the
leading-strand DNA polymerase. This can now be
tested directly with purified DNA polymerase 8 (see
below).
Proliferating Cell Nuclear Antigen. The first
replication factor to be identified using the SV40 sys-
tem was PCNA, a protein we have described in previ-
ous reports. PCNA was shown to be required for syn-
thesis of the leading strand at a DNA replication fork
during the elongation stage of SV40 DNA replica-
tion in vitro and to be a processivity (stimulatory)
factor for DNA polymerase 8. Recent studies have
demonstrated that PCNA also stimulates the DNA-
dependent ATPase activity of RF-C, suggesting that
RF-C, PCNA, and DNA polymerase 8 form a mul-
tiprotein complex at the replication fork.
Human PCNA has been cloned into an Esche-
richia coli expression plasmid, and large amounts
of the protein can be easily purified. In collabora-
tion with P. Fisher's laboratory at SUNY, Stony
Brook, we have purified PCNA from Drosophila and
demonstrated that it can substitute for the human
protein. This underscores the extraordinary conser-
vation of the DNA replication apparatus. Antibod-
ies to Drosophila PCNA immunostain cells in Dro-
sophila tissue that are proliferating, but not those
that are terminally differentiated. Therefore, these
antibodies should be useful for investigating the re-
lationship between cell proliferation and terminal
differentiation in lineages of cells throughout
development.
DNA Polymerase S. Continued fractionation of
the human cell extract has revealed several new repli-
cation activities that are required for SV40 DNA
replication in vitro. Apart from the DNA polymer-
ase a/DNA primase complex, which has long been
known to be required for SV40 DNA replication, our
studies with PCNA suggested that DNA polymer-
ase 8 is required for complete DNA replication. In-
deed, genetic evidence from other laboratories, using
the yeast S. cerevisiae, has demonstrated that DNA
polymerase 8 (DNA polymerase III in S. cerevisiae)
is essential during the S phase of the cell cycle. We
have now purified to homogeneity another replica-
tion factor that is a DNA polymerase that can be
stimulated by PCNA. We are now in a good posi-
tion to test our previous model for coordinated syn-
thesis of both strands at a replication fork.
Conserved Functions in DNA Replication. The
elucidation of the functions of the human replica-
tion factors RF-A, RF-C, and PCNA has enabled
us to compare these activities with the functions of
replication factors that operate in replication of the
bacterial (E. coli) chromosome and replication of
bacteriophage T4 DNA. Table 1 summarizes a com-
parison of some of the known replication proteins
from human cells, bacteria, and its phage, T4. Al-
though this list is not complete (e.g., DNA helicase
activities and origin recognition proteins are not
listed), it emphasizes the highly conserved activities
that function in the process of DNA replication.
Of particular interest is that the bacteriophage T4
DNA polymerase is structurally related to the hu-
man and yeast polymerase a enzymes and to the yeast
polymerase 8 enzyme (the gene encoding the human
polymerase 8 has not been cloned), but the E. coli
polymerase III is not structurally related. We have
also noted sequence similarities between the human
PCNA and the phage T4 gene 45 protein, but the
13 subunit of E. coli DNA polymerase III is not struc-
turally related. It therefore appears that the func-
tions have been conserved, but E. coli probably has
diverged further away from the ancestral form. This
may suggest that bacteria have a higher capability
TABLE 1 Conserved Functions of DNA Replication
Proteins
Human Phage T4 E. coli Functions
RF-A
RF-C
gene 32 SSB single-stranded DNA bind-
ing; stimulates DNA
polymerase; promotes
origin unwinding
gene 44/62 y8.8't DNA-dependent ATPase;
primer-template binding;
stimulates DNA poly-
merase
PCNA gene 45 (dnaN) stimulates DNA poly-
merase; stimulates DNA-
dependent ATPase
gene 43 DNA pol III DNA polymeraseDNA pol as
DNA pol 6
DNA primase a gene 61 dnaG primase
a The human DNA pol a and primase activities function as a multiprotein
complex.
for evolutionary change than either eukaryotes or
the E. coli phages.
Regulation of DNA Replication. The studies de-
scribed above on DNA replication using the SV40
system have provided valuable insight into the mech-
anism of DNA replication. Having isolated these hu-
man cell proteins, we are now in a strong position
to investigate the regulation of DNA replication, ei-
ther directly in human cells or indirectly by identify-
ing homologs in yeast and using the power of yeast
cell cycle genetics. During the past year, this effort
has proven to be productive, and we foresee it as a
major part of future experimentation.
The first protein we have studied is RF-A, primar-
ily because it is involved in both the initiation and
elongation of DNA replication. A panel of mono-
clonal antibodies directed against the p70 and p34
subunits of hRF-A was obtained, and polyclonal an-
tisera were raised against the subunits of hRF-A and
yRF-A. These antibodies were used to determine that
the p34 subunit of hRF-A and the p36 subunit of
yRF-A are phosphorylated in a cell-cycle-dependent
manner. The protein is not phosphorylated in the
GI phase of the cell cycle, but it is phosphorylated
at the G1 to S phase transition and throughout the
S and possibly G2 phases. Dephosphorylation oc-
curs late in G2 or during mitosis, thereby resetting
the cycle (see Fig. 1). Because the levels of RF-A do
not vary during cell cycle progression and the pro-
teins are stable, the phosphorylation of RF-A at the
start of S phase raises the possibility that the phos-
phorylation may be one mechanism to regulate DNA
39
G
I
S G 2/M
1
r
i
cdc 19 280<F 4 7 21 HU 9 13 17 N 23 20 14
15 30 5 18
p34 [
FIGURE 1 Immunoblot analysis of yRF-A p36 from
cell-cycle-arrested cultures. Extracts of cdc
strains arrested at 38°C for 5 hr orwild-type cells treated with
a-factor (aF), hydroxyurea (HU),
or nocodazole (N) for 3.5 hr were blotted and probed with affinity-purified anti-p36 antibody.
The phosphorylated form of yRF-A p36 is shown as an upper band of
the doublet and is present
only in the S phase.
replication. Attempts to determine if the phosphory-
lation of hRF-A may influence its function in the
SV40 cell-free replication system have been thwarted
by the identification of a potent RF-A kinase activ-
ity that is present in the replication reactions. Cur-
rent efforts are aimed at further characterizing this
potentially interesting protein kinase. Finally, a
genetic approach to the regulation of RF-A function
will be possible with the cloning of the genes encod-
ing the yRFA subunits.
Chromatin Assembly
S. Smith, G. Bauer, B. Stillman
In addition to our studies on DNA replication, we
have developed a cell-free system for replication-
dependent chromatin assembly and have reported
last year the purification of a human cell chromatin
assembly factor, CAF-1. The addition of purified
CAF-1 to the crude replication extract allows the as-
sembly of the replicating DNA into a chromatin
structure containing regularly spaced nucleosomes.
Therefore, the mechanism of chromosome assem-
bly in this cell-free system should reflect similar
events that occur during replication of cellular chro-
mosomes. To investigate the role of CAF-1 in the
replication-dependent chromatin assembly process
and to determine if it plays a regulatory role during
S phase, we have used the purified protein to raise
a panel of monoclonal antibodies that recognize dif-
ferent subunits of the multisubunit CAF-1 complex.
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Immunoprecipitation analysis demonstrated that
CAF-1 exists as a multiprotein complex in vivo and
that the subunits are phosphorylated. Immunostain-
ing of human cells demonstrated that CAF-1 is local-
ized in the nucleus of human cells, but the levels seem
to vary from cell to cell. In addition, some antibod-
ies stained a perinuclear structure as well as the nu-
cleus; however, the significance of these observations
is not clear and is under investigation. The mono-
clonal antibodies directed against CAF-1 also im-
munodeplete the chromatin assembly activity from
crude nuclear extracts, confirming that CAF-1 is re-
quired for chromosome assembly.
Finally, recent studies have demonstrated that
chromosome assembly can be reconstituted in vitro
with purified CAF-1, histones, and a partially frac-
tionated replication extract. The purified replication
proteins could not support chromatin assembly in
the presence of CAF-1 and histones, suggesting the
existence of other CAF activities.
Eukaryotic Origins o
DNA Replication
J.F.X. Diffley, N. Kessler Y. Marahrens, B. Stillman
Eukaryotic chromosomal DNA replication initiates
from multiple origins during S phase. Little is cur-
rently known about either the DNA sequences that
function as replication origins or the proteins that
interact with these sequences. Seminal experiments
by Laskey and co-workers demonstrated that virtu-
ally any DNA tested would replicate in a cell-cycle-
dependent fashion when microinjected into Xeno-
pus oocytes. This result suggested that specific se-
quences may not be required for the initiation of
DNA replication, at least in early Xenopus devel-
opment when DNA replication proceeds extremely
rapidly and presumably from a very large number
of origins. Experiments in the yeast S. cerevisiae,
however, demonstrated an absolute requirement for
specific ARSs (autonomously replicating sequences),
indicating that DNA replication cannot initiate from
any sequence. The number of ARSs in the yeast ge-
nome, in fact, is roughly the same as the number of
origins of replication, as estimated from fiber auto-
radiography. Taken with the fact that ARSs have re-
cently been shown directly by two-dimensional gel
techniques to function as origins of DNA replica-
tion both in plasmids and in the chromosome, this
result demonstrates that only very specific sequences
can function as origins of DNA replication in yeast.
A resolution of this paradox may come from anal-
ysis of ARS sequence requirements and the cellular
proteins that bind to these sequences. A number of
laboratories including our own have been interested
in elucidating the sequences involved in ARS func-
tion. Although the picture is not complete, two im-
portant generalizations can be made. First, all ARSs
contain an 11-bp consensus sequence essential for
ARS function. Second, this consensus sequence by
itself is insufficient for efficient ARS function. In
virtually all cases tested, a flanking sequence is re-
quired for ARS function, and we showed several
years ago that this sequence is dependent on both
its spacing and its orientation relative to the con-
sensus sequence. Although the mechanism by which
these auxiliary sequences function is not known and
there is little similarity among these sequences, they
have been correlated with the presence of degener-
ate matches (9/11 and 10/11) to the ARS consensus
sequence, with nuclear matrix attachment sites, and
with structural features such as static DNA bending
and ease of unwinding. None of these features, how-
ever, correlates completely with flanking sequence
function. Thus, all near matches to the ARS con-
sensus sequence can be specifically eliminated from
the histone H4 ARS with virtually no effect on ARS
function. The C2G1 ARS does not contain bent
DNA, and bent DNA can be removed from ARS1
with little effect. Deletions of the H4 ARS exist that
are not easily unwound but do function as efficient
ARSs; others exist that are efficiently unwound but
do not function as ARSs. Flanking sequences at
different ARSs may fulfill their replication enhance-
ment functions by different mechanisms, or, alter-
natively, some unifying mechanism for the function
of these sequences may exist.
We continue to characterize two proteins, ABF1
and ABF2, which were identified in our laboratory
and interact specifically with the ARS1 sequence in
anticipation that such an analysis will lead to an un-
derstanding of ARS function. Last year, we described
the cloning and sequence analysis of one of these
proteins, ABF1. ABF1 binds to a single site within
ARS1 and several other ARSs tested. The binding
site for ABF1 is important but not essential for the
ARS1 flanking sequence function, leading to the pro-
posal that the ARS1 flanking sequence (also known
as domain B) can be subdivided into at least two sub-
domains. In addition to binding to several ARSs,
ABF1 is also an important transcription factor in
yeast. ABF1-binding sites have been identified as
functional elements in controlling the expression of
genes encoding ribosomal and mitochondrial pro-
teins, subunits of RNA polymerase C, and glycolytic
enzymes. Thus, it is not surprising that the ABF1
gene is essential for viability and suggests that ABF1
may have an important role in coordinating various
essential cellular processes - perhaps including DNA
replication - during cell growth. We have recently
shown that ABF1 is a phosphoprotein and are cur-
rently in the process of investigating the possibility
that this phosphorylation is regulated during the cell
cycle or, perhaps, under different growth conditions.
In addition, we have recently begun characteriza-
tion of the ABF1 gene product. We showed last year
that ABF1 contains an unusually elongated zinc fin-
ger DNA-binding motif and that the cysteines in
and/or adjacent to this finger are required for
sequence-specific DNA binding. Remarkably, muta-
tional analysis has revealed that a second region of
the ABF1 protein, located more than 200 amino acids
from the zinc finger, is also required for sequence-
specific DNA binding and that the spacing between
these two domains is not critical for binding. We are
currently investigating whether each domain can
contact DNA independently with reduced affinity
or whether each requires the presence of the other.
Furthermore, we are in the process of combining our
in-vitro-generated ABF1 mutants with an in vivo ap-
proach to map essential domains in the protein.
We have recently succeeded in cloning the gene
encoding the second ARS-binding factor, ABF2.
ABF2 is a protein with an unusual combination of
DNA-binding activities. Most striking is the fact that
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ABF2 binds to multiple discrete sites within all ARSs
tested and induces a complex series of structural al-
terations similar to or identical with DNA bends
within at least one of these ARSs, ARS1. Although
the ABF2 gene is not essential for yeast viability,
strains in which the ABF2 gene have been deleted
show a marked growth defect that is greatly accen-
tuated at elevated temperatures. The predicted se-
quence of the ABF2 protein reveals a high level of
sequence similarity with the vertebrate high-mobility
group proteins HMG1 and HMG2 and the Schi-
zosaccharomyces pombe developmental regulator
matl-Mc. The ABF2 sequence is also similar to the
human RNA polymerase I transcription factor, UBF
(identified in R. Tjian's laboratory). Interestingly,
UBF and ABF2 also exhibit great similarities in their
mode of DNA binding. Both proteins can bind to
many apparently unrelated DNA sequences and in-
duce DNase I hypersensitive sites. The ability of
ABF2 to bind to specific sites within the different
unrelated flanking sequences of many ARSs may
serve to explain how these sequences function and
provide some resolution to the paradox concerning
the requirement of specific DNA sequences in the
initiation of DNA replication. In this regard, we have
made a series of linker scan mutations across ARS1
and are in the process of testing for
ABF2 binding and ARS function both on plasmids
and in the chromosome using two-dimensional gel
technology.
Function of the Adenovirus
E1B Oncogene
E. White, R. Cipriani, P Sabbatini
The adenovirus E1B gene is required for regulation
of viral gene expression in productively infected cells
and for oncogenic transformation. Last year, we
made some interesting discoveries that have greatly
enhanced our understanding of E1B protein func-
tion. The E1B gene of adenovirus encodes two ma-
jor tumor antigens, the 19K and 55K proteins. The
coding regions for these proteins have been placed
under the control of heterologous promoters to
ascertain the role of individual E1B proteins in trans-
formation and their primary biological function.
These E1B plasmid expression vectors have led to two
significant findings. First, both E1B proteins pos-
sess transforming activity when cotransfected with
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a plasmid encoding E1A, but it is the 19K protein
that confers anchorage-independent growth. Second,
the E1B 19K protein has the unique and unusual abil-
ity to associate with and disrupt the organization of
two distinct classes of intermediate filaments, cyto-
plasmic vimentin filaments and nuclear lamin fila-
ments. We propose and are preparing to test that the
biological function of the 19K protein in transfor-
mation and productive infection is a direct conse-
quence of the perturbation of intermediate filaments.
This year, we have been expanding upon these
results in three areas. First, we are preparing to iden-
tify those cellular proteins, most likely intermediate
filament proteins, that directly interact with the 19K
protein. Second, we are expanding our investigation
of the role of E1B proteins in transformation and
establishing whether or not E1B gene products are
capable of cooperating with oncogenes other than
E1A. Third, we are performing a mutational analy-
sis of the 19K-coding region to determine whether
intermediate filament disruption and the transfor-
mation function of the 19K protein are genetically
linked and therefore functionally related.
As a first step toward identification of the cellu-
lar proteins, which are targets for functional modifi-
cation by the 19K protein, the 19K protein has been
expressed in bacteria and purified. This will provide
a source of 19K protein for in vitro binding experi-
ments that will be necessary to demonstrate direct
binding of the 19K protein to intermediate filament
proteins.
The ability of E1B proteins to cooperate with the
products of other viral oncogenes is also well under
way. In a collaborative effort with P. Howley at the
National Cancer Institute, we have discovered that
the E1B 19K protein can enhance the transforming
activity of the human papillomavirus type-16 E6 and
E7 transforming genes. This is important because
it establishes that the transforming activity of the
E1B 19K protein is not restricted to cooperation with
the adenovirus E1A gene and may represent a more
universal function related to the development of hu-
man cancer.
Finally, mutational analysis has so far identified
an important region of the 19K protein required for
both transforming activity and intermediate filament
disruption. A single substitution of an acidic glu-
tamic acid residue for the basic lysine at position 44
of the 19K-coding region results in simultaneous loss
of transforming activity and the ability to associate
with and disrupt intermediate filaments. This is read-
ily apparent in double-label indirect immunofluo-
rescence of transfected cells transiently expressing
either the wild-type 19K protein or the mutant pro-
tein. Where the wild-type protein localizes to the nu-
clear envelope and cytoplasm and disrupts intermedi-
ate filaments, the mutant protein is defective for
nuclear localization and the organization of inter-
mediate filaments is completely unaffected (Fig. 2).
Closer inspection of the sequence surrounding this
mutation identified a possible homology with nu-
clear localization signals in polyomavirus large T an-
tigen and a Drosophila lamin protein:
Control I9K
Polyomavirus large T antigen
E1B 19K protein
Lamin DM0
SV40 T antigen
P K K A R E D
CR I K ED
K R L R A V
P K K K R K V
Those amino acids known to be absolutely
required for nuclear localization are indicated in bold
type and are usually basic (R or K) amino acids.
Whether this sequence of the 19K protein is a bona
fide nuclear localization signal is being explored.
Control Vim
CMVI9K I9K CMVI9K Vim
pm44 I9K pm44 Vim
FIGURE 2 Double-label indirect immunofluorescence with anti-vimentin and E1B 19K
antisera of He La cells transfected with expression vectors producing wild-type 19K pro-
tein or the K to E substitution at amino acid 44.
In summary, the E1B 19K protein represents a
transforming protein with a novel function that will
be useful both for understanding the unique mech-
anism of oncogenic transformation and for deter-
mining the function of those cellular structures with
which it interacts, intermediate filaments.
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The large T antigen encoded by SV40 is a multifunc-
tional protein that possesses numerous posttransla-
tional modifications. Current work is aimed at un-
derstanding the role that this protein plays in SV40
DNA replication by evaluating the effects of post-
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binding domain of large T antigen localized the
amino- and carboxy-terminal boundaries of this do-
main between amino acids 132 and 246, respectively.
In addition, these studies revealed differences in
binding specificity and affinity between proteins iso-
lated from bacteria or mammalian sources. Specifi-
cally, we found the following:
1. The amino-terminal 259 amino acids of SV40 T
antigen purified from Escherichia coli bound in-
efficiently to the wild-type origin and very ineffi-
ciently to DNA bearing only isolated site I and
site II recognition sequences. However, the same
protein isolated from He La cells bound to the ori-
gin much more efficiently, particularly to site II.
2. The amino-terminal 246 amino acids of T anti-
gen contained the highest origin-specific DNA-
binding activity of all truncated proteins tested,
thus defining the carboxy-terminal boundary of
the origin binding domain to between amino acids
246 and 249. The 246-amino-acid protein bound
to single-stranded DNA, demonstrating that the
single- and double-stranded DNA-binding do-
mains reside in the same or overlapping amino
acid sequences. The DNA-binding properties of
the 246-amino-acid protein were also affected by
the cellular source of the material: T antigen from
mammalian sources bound more efficiently to site
II than protein isolated from E. coli.
3. Analysis of full-size SV40 T antigen isolated from
E. coli showed that the protein was indistinguish-
able from its mammalian counterpart in its abil-
ity to function as an ATPase and helicase and to
bind DNA fragments bearing site I or the wild-
type origin. However, it did not bind to site II,
an essential cis-acting element within the SV40
origin of replication. This observation explains
its inability to unwind origin-containing plasmids
and to replicate SV40 DNA efficiently in vitro.
Our data, combined with those from other labora-
tories analyzing T-antigen phosphorylation and its
biochemical effects, led us to speculate that phos-
phorylation of Thr-124 is a critical step in the acti-
vation of SV40 T antigen to a replication-competent
state. To prove this point, it was necessary to purify
a kinase that would phosphorylate Thr-124. The
properties of the 259-amino-acid T antigen from E.
coli presented us with a simple screen for such a ki-
nase. It was anticipated that phosphorylation of Thr-
124 would dramatically stimulate binding to the
SV40 origin, particularly to site II. Initial experi-
ments employing casein-kinase II and cAMP-de-
pendent kinase, provided by Dr. Marshak (Protein
Chemistry, this section), demonstrated that both of
these kinases could phosphorylate the 259-amino-
acid T antigen. However, the binding activity of the
phosphorylated protein was not stimulated, but in-
stead appeared to be inhibited. In contrast, treatment
of the 259-amino-acid T antigen with cdc2 kinase,
provided by Drs. D. Beach and L. Brizuela (Genetics
Section), resulted in an efficiently phosphorylated
protein with a substantially increased ability to bind
to site II. Amino acid analysis of this material re-
vealed phosphothreonine as the sole phosphoamino
acid present, and direct amino acid sequencing of
the phosphorylated protein located the phospho-
threonine in a peptide comprising amino acids 112-
131. To prove that phosphorylation was occurring
on Thr-124, we changed residue 124 to alanine by
site-directed mutagenesis. The resulting Ala-124-259
T antigen was not phosphorylated by cdc2 kinase,
and the binding properties of Ala-124-259 T anti-
gen were not affected by exposure to cdc2 kinase.
Treatment of full-size SV40 T antigen purified
from E. coli with cdc2 kinase produced a protein that
bound to site II actively and initiated SV40 DNA
replication in vivo very efficiently. These data prove
that phosphorylation of Thr-124 is a critical step in
activation of SV40 T antigen into a competent com-
ponent of the DNA replication machinery and im-
plicates a cdc2 kinase as a potential modulator of
this activity.
Current studies pursue two directions. First, in col-
laboration with Dr. Beach, we are trying to prove
directly the involvement of cdc2 kinase in phosphory-
lation of Thr-124 in vivo by expressing the truncated
or wild-type T antigen in Schizosaccharomyces
pombe (cdc2 mutant or wild-type parental strain).
Second, using a refined DNA footprint analysis, we
are exploring the nature of the interactions between
the carboxyl terminus of T antigen and its DNA-
binding domain and the effect of phosphorylation
on this interaction.
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MOLECULAR BIOLOGY OF BOVINE PAPILLOMAVIRUS
A. Stenlund M. Ustav J. Alexander
P Szymanski
The papillomaviruses are a group of small DNA
viruses that are characterized by their ability to cause
benign tumors (warts) in a variety of animal hosts.
In humans, certain types have proven to be clinically
important because they have been implicated as a
potential causative agent of cervical carcinomas.
Over the years, bovine papillomavirus type 1 (BPV-
1) has emerged as the prototype for this virus group
by virtue of its ability to transform and replicate the
viral genome in certain rodent cells in culture. These
properties have made it possible to study at least
some aspects of the viral life cycle in a tissue-culture
system. From the molecular biologist's point of view,
two properties of this virus are of particular interest.
First, it has recently been demonstrated that the vi-
ral genome carries coding information for a group
of site-specific DNA-binding proteins, which appear
to be key regulators of viral gene expression. One
of these is encoded in its entirety from the E2 open
reading frame (ORF) and is an activator of viral gene
expression that functionally resembles a mammalian
transcription factor. This resemblance extends also
to the structural level; the carboxy-terminal part of
P1
I E6
E7
the protein contains a domain that is responsible for
dimerization and DNA binding, whereas the amino-
terminal part of the protein contains an acidic acti-
vation domain. The other members of the E2 fam-
ily are two polypeptides that share the DNA-binding
domain with the activator and therefore have the
same DNA-binding specificity. These polypeptides
lack the domain responsible for activation and have
been described as repressors of transcription. Both
the activator and repressor forms exert their various
functions through specific binding sites dispersed
throughout the viral genome (see Fig. 1). The bind-
ing sites that are not clustered in the E2 responsive
enhancer are exclusively located close to known
promoters, where the specific effect of binding of
an E2 molecule appears to be dependent partly on
the position of the site.
The second interesting feature of the virus life cy-
cle is the replication properties of the viral genome.
It appears that the virus is capable of at least two
different modes of DNA replication. In a stably
transformed cell, which is the best-studied stage in
terms of both DNA replication and gene expression,
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FIGURE 1 Schematic figure showing the organization of the early region of the BPV genome. Open bars
represent the early open reading frames E1-E8. Arrows labeled P1-P5 represent the five known promoters
that transcribe the early region. Filled boxes show the location of mapped binding sites for the gene prod-ucts from the E2 open reading frame.
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the viral genome replicates as an episome that is sta-
bly maintained at an approximate copy number of
100 molecules per cell. Density-labeling experiments
have shown that viral DNA replication is regulated
at the level of copy number control and that, in a
manner reminiscent of cellular DNA replication,
each molecule is replicated only once per cell cycle.
In the earlier stages (about which little is known),
before the viral DNA becomes established as a sta-
bly replicating episome, viral DNA replication takes
place through a different pathway, which involves
amplification to the 100 copies per cell that are then
maintained.
We are interested in studying the transition be-
tween the two different types of replication in terms
of both the direct changes in the mode of replica-
tion and the differences in viral gene expression that
presumably accompany and cause these changes.
Due to the multistep nature of the establishment of
stable replication, a genetic analysis is complicated
by the fact that mutations that affect an early step
in establishment cannot be assayed for their effect
on later stages in the absence of conditional mutants.
To circumvent this problem, we are trying to dissect
the viral genome and its replication machinery into
its components for subsequent reconstitution of sim-
plified systems that can execute specific parts of the
viral replication cycle in vivo. An important part of
this approach has been to develop systems for study
of early gene expression and replication, which is
something we accomplished this first year. This was
possible mainly through development of a highly ef-
ficient electroporation procedure that makes it pos-
sible to deliver the viral genome at high frequency
into the host cell, which is difficult to transfect using
conventional methods.
Analysis of Immediate-Early
Gene Expression in BPV-1
R Szymanski, A. Stenlund
For mostly technical reasons, analysis of gene ex-
pression and viral gene regulation has so far been
performed with subgenomic fragments of viral DNA
almost exclusively either in BPV-transformed cells
or, for transient expression assays, in a variety of cell
types where BPV does not replicate. This means that
even though viral gene expression in transformed
cells has been extensively studied, virtually nothing
is known about immediate-early gene expression or
about regulation of viral genes in the context of the
whole viral genome. We have begun to study early
viral gene expression under replication conditions
as well as the response of viral transcription units
to the viral trans-activator E2. In these experiments,
the viral genome has been introduced into recipient
mouse C127 cells through electroporation under con-
ditions where replication takes place, followed by
RNA extraction at various later timepoints. The as-
say for expression that we have used is an RNase pro-
tection assay with specific probes for the five differ-
ent promoters in the early region of BPV. So far, we
have not been able to detect any activity using repli-
cation conditions, which indicates either that the lev-
els of expression are very low (less than 1 molecule
of RNA per transfected cell) or that transcription
is initiated from start sites other than the five
promoters that have been mapped in BPV-trans-
formed cells. In the presence of the cotransfected E2
trans-activator, at least two of the five promoters,
P2 and P4, are substantially activated in a manner
that is dependent on the presence of the E2-inducible
enhancer located immediately upstream of P2. It is
interesting to note that the level of activation is very
similar for the two promoters, even though in the
case of P2, the promoter is immediately adjacent to
the E2 enhancer, and in the case of P4, a distance
of approximately 2.5 kb separates the enhancer and
the promoter.
Analysis of Viral Functions Involved
in Transient Amplification and Stable
Maintenance of BPV Episomes
M. Ustav, A. Stenlund
Replication of the BPV genome in permissive rodent
cells appears to take place in two different stages.
Initially, amplification occurs where the viral DNA
replicates faster than the cellular DNA, resulting in
an increase in copy number of the viral DNA on a
per cell basis. After this initial stage, replication of
the viral DNA proceeds at a constant rate, resulting
in maintenance of a constant copy number that is
stable over many cell generations. The requirement
for viral genes for stable replication has been stud-
ied through conventional transfection assays; how-
ever, the amplification stage is less well character-
ized. We have therefore developed a transient
replication assay that relies on a highly efficient elec-
troporation procedure to deliver the DNA to a suf-
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ficiently large fraction of the cells to allow detection
of DNA replication at early times after infection.
Low-molecular-weight DNA is then isolated at vari-
ous times after transfection. The samples are digested
with the restriction endonuclease Dpnl, which cuts
only methylated (unreplicated) DNA. The products
are then analyzed by gel electrophoresis and South-
ern transfer. Using this procedure, we have estab-
lished a tentative time course for early replication,
where newly synthesized DNA is first detected be-
tween 24 and 48 hours after transfection, after which
time, the amount of replicated DNA increases ex-
ponentially. Initial results from this type of experi-
ment indicate that genes like E5, which are required
for stable replication, are dispensable for this type
of transient replication. This is consistent with the
idea that the requirements are different for the differ-
ent modes of replication. On the other hand, func-
tions like the trans-activator E2, which has been
shown to be required for stable replication, are also
ADENOVIRUS GENETICS
T. Grodzicker P Yaciuk
E. Moran M. Corrigan
For the past several years of this project, we have
been engaged in a genetic analysis of E1A- transform-
ing functions. Genetic analysis has revealed a close
biological relationship between the adenoviruses and
other classes of DNA tumor viruses, specifically, the
papovaviruses, including SV40, and the human
papillomaviruses. Each of these viruses contains a
transforming gene that encodes a protein contain-
ing a highly conserved stretch of about 20-amino-
acid residues, designated conserved domain 2 in the
El A products, which is involved in binding the prod-
uct of the cellular retinoblastoma (RB) tumor sup-
pressor gene (see also Protein Immunochemistry
Section). Mutations in these highly conserved re-
gions, with concomitant loss of RB-binding activ-
ity, severely impair the transforming activity of the
affected genes. The basic structure of the E1A pro-
teins and their relationship with SV40 T antigen are
described in Figure 1.
Although domain 2 of E1A is required for E1A-
transforming functions, it is not sufficient for these
functions. A second region, amino-terminally dis-
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absolutely required for transient replication; this
shows that some viral functions may be required
throughout the viral life cycle. We are now in the pro-
cess of analyzing a battery of mutants for the in-
volvement of various viral gene products in the early
events of replication.
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tal to domain 2, is likewise absolutely required for
E1A-transforming function. With the loss of either
of these regions, the E1A products lose the ability
to induce cell proliferation, establish an extended
growth potential in primary cells, or cooperate with
a second oncogene such as an activated ras gene to
induce full morphological transformation. During
the past year, we have made a close study of the
amino-terminal transforming region. We have ap-
proached this (1) by analyzing the biological conse-
quences of loss of E1A amino-terminal functions
and (2) by continuing to compare the transforming
sequences of adenovirus-2 (Ad2) E1A and SV40 T
antigen.
BIOLOGICAL ACTIVITIES ASSOCIATED WITH THE
E1A AMINO-TERMINAL FUNCTION
Several lines of evidence indicate that the amino-
terminal transforming function is completely inde-
pendent of domain-2 function and RB-binding ac-
tivity. Loss of domain 2 does not result in loss of
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FIGURE 1 E1A and T-antigen protein structure. Several differ-
ent splice products are made from the E1A gene. The major early
products are the 12S and 13S mRNAs. The 12S and 13S protein
products are identical except for the presence of an internal re-
gion of 46-amino-acid residues unique to the 13S product. The
E1A proteins are composed of alternating regions of relatively
high or low amino acid sequence identity. There are three highly
conserved regions, two of which are common to the 12S and
13S products, and the third comprises the 13S-unique region.
The 13S-unique region plays an important role in trans-activation
of other early virus genes, but E1A-transforming functions do not
depend on the 13S-unique trans-activation function. The amino-
terminal 140 residues of common sequence, containing the two
common conserved domains, are sufficient to induce DNA syn-
thesis and rapid proliferation in BRK cells. The numbers above
the bars indicate the endpoints of various E1A deletion mutants.
The blackened areas represent the regions deleted. All deletions
retain the original frame of translation. A representation of the
T-antigen product is shown at the top of the figure, with the domain-
2 homologous region aligned with E1A domain 2.
all E1A-mediated cell-cycle-regulating activity. Mu-
tants completely deleted for domain 2, and without
detectable ability to bind the RB product, retain sub-
stantial ability to induce DNA synthesis in quiescent
primary baby rat kidney (BRK) cells. An amino-
terminal deletion peptide is able to cooperate in trans
with a domain-2 deletion peptide in a ras cotrans-
formation assay, indicating that loss of amino-
terminal function can occur without tertiary disrup-
tion of domain-2 structure or function. This evidence
implies that each biologically active region is func-
tioning autonomously during transformation. If so,
then conserved domain 2 and the amino-terminal
region may mediate distinctly different biological ac-
tivities required in transformation.
It is reasonable to assume that the E1A products
mediate their cell-growth-regulating effects by
directly or indirectly influencing the expression of
cellular growth-related genes. Yet, the well-char-
acterized E1A gene trans-activation function is
unique to the 13S E1A product and is not required
for cell-growth-regulating activity. An independent,
and negative, gene-regulating function intrinsic to
the E1A products has been identified, however, that
is more closely linked with E1A-transforming activ-
ity, in that it too is independent of the 13S unique
region. This is the ability of the E1A products to re-
press the effects of enhancer-stimulated transcription.
To investigate whether the amino-terminal trans-
forming region of the E1A products mediates bio-
logical events distinct from those associated with
conserved domain 2, we analyzed amino-terminal
mutants for their ability to transform primary BRK
cells, induce DNA synthesis, repress insulin-enhancer-
stimulated transcription, and bind to E1A-associated
cellular proteins. The endpoints of the deletions are
indicated in Figure 1.
The mutant plasmids were first assayed for bio-
logical activity in a ras cotransformation assay. De-
letions near the extreme amino terminus, extending
from residue 2 to 36, or 15 to 35, showed no activity
at all, although they encode stable proteins. Both of
these mutants remove only sequences outside of con-
served domain 1, whereas a deletion extending from
residue 51 to residue 116, described last year, retains
substantial transforming activity, suggesting that the
strictly essential upstream sequences lie toward the
extreme amino terminus of the EIA products, rather
than across the whole region of conserved domain
1. To exclude the possibility that loss of function in
the amino-terminal mutants is merely a consequence
of tertiary effects resulting in impairment of domain-
2 function, we determined the activity of the mu-
tant constructs in a trans-cooperation assay. The
E1A.2-36 and E1A.15-35 mutants can cooperate ef-
ficiently with the domain-2 deletion mutant,
ElA.CXd/, increasing the likelihood that these de-
letions are affecting a specific active site, rather than
broadly disrupting required tertiary structure
throughout the E1A protein products.
E1A proteins have the ability to bind a number
of cellular proteins, including the p105-RB product
and an unidentified 300-kD product. The E1A.2-36
and E1A.15-35 deletions bind the RB gene product
efficiently but do not coprecipitate the 300-kD prod-
uct detectably. These results confirm that binding
RB is insufficient for E1A transformation activity.
E1A.2-36 (and E1A.15-35) deletion products bind RB
both physically and functionally, as determined by
their ability to complement a domain-2 deletion mu-
tant; however, these mutants have no transforming
activity by themselves. These results support the hy-
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pothesis that E1A-mediated
transformation is a con-
sequence of the activity of two independently func-
tioning regions within the protein: the amino-terminal
region and conserved domain 2. To address
this pos-
sibility more directly, we compared mutants
in these
regions for their ability to induce DNA
synthesis and
repress insulin-enhancer-stimulated transcriptional
activity.
We assayed the ability of E1A.2-36 to
induce DNA
synthesis and virus replication in BRK
cells, and we
compared its activity with that of two domain-2 mu-
tants, E1A.928 and ElA.CXd/. The 928 mutation is
a point mutant in residue 124 that affects only
domain-2 activity. The CXd1 mutant (residues 121-
150) deletes all of domain 2 and part of domain 3.
The transformation defect in the 928 point mutant
is as severe as that of the complete deletion mutant.
We previously showed that these domain-2 mutants
retain an appreciable ability to induce DNA synthe-
sis in BRK cells despite their severe transforming de-
fect. The levels of [31-1]thymidine incorporated in-
to viral DNA during infection with Ad 5d1309 (an
E1A.WT virus), E1A.928, and the amino-terminal
mutant, E1A.2-36 were compared. The results (Fig.
2A) indicate that the 2-36 deletion significantly im-
pairs the ability of the E1A products to induce DNA
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replication. Replication of viral DNA in infected
quiescent cells requires two E1A functions: the abil-
ity to induce cellular DNA synthesis and the ability
to trans-activate other viral proteins. The latter ac-
tivity is a function of domain 3. To demonstrate that
the impairment in the E1A.2-36 deletion is actually
a defect in the ability to induce cellular DNA syn..
thesis, we coinfected E1A.2-36 with a dornain.3
defective mutant, E1A.hr3. E1A.hr3 fails to trans.
activate viral products and therefore fails to repli-
cate viral DNA (Fig. 2B), but it retains the ability
to induce cellular DNA synthesis sufficient to sup-
port rapid and extensive proliferation of BRK cells.
Coinfection of the E1A.2-36 and ElA.hr3 viruses
results in near wild-type levels of viral DNA synthe-
sis (Fig. 2B). If the induction of cellular DNA syn.
thesis is indeed independent of both domain-2 and
domain-3 activities, we would also expect that E1A.2-
36 could be complemented for virus replication by
the E1A.CXd1 mutant that inactivates both domains
2 and 3. Such complementation does indeed occur
(Fig. 2B), indicating that induction of DNA synthe-
sis correlates closely with the amino-terminal trans-
forming function and not with the domain-2 trans-
forming function.
Both the 13S and 12S E1A products repress insu-
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FIGURE 2 Analysis of virus DNA production in infected quiescent cells. Primary BRK cells were in-
fected in the presence of [31-ljthymidine at a multiplicity of 10 pfu/cell. Coinfection experiments were
done at a total multiplicity of 10, i.e., 5 pfu/cell of each virus. Viral DNA was extracted and counted at30 hr postinfection.
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lin enhancer-stimulated transcription in pancreatic
13 cells. To identify more precisely the regions in E1A
that are required for repression, we cotransfected the
deletion mutants into an insulin -producing (3 cell line,
along with p-700 CAT, a plasmid that contains the
coding region of the bacterial chloramphenicol
acetyltransferase (CAT) gene linked to the rat insu-
lin II gene enhancer promoter. These experiments
were done in collaboration with R. Stein at Vander-
bilt University. The 2-36 and 15-35 mutants were
greatly impaired in their ability to repress -700 CAT
expression, whereas the domain-2 deletion mutant,
E1A.121-150 (CXdI), repressed CAT enzyme levels
as efficiently as wild type. These results suggest that
enhancer repression, like the ability to induce DNA
synthesis, correlates closely with the amino-terminal
transforming function and not with the domain-2
transforming function. Enhancer repression and in-
duction of DNA synthesis therefore correlate closely
with 300-kD binding and not with Rb binding.
There appears to be a striking corrrelation be-
tween binding of the 300-kD product and the spe-
cific biological activities of E1A that mediate in-
duction of DNA synthesis and the repression of
enhancer-stimulated transcription, both of which are
essentially independent of domain-2 function and
RB binding. These results are exciting because they
reveal possible new steps in the mechanism of cell
growth control and point to the 300-kD product and
the repression function as playing major roles in this
process. Characterization of the 300-kD product and
identification of cellular targets of E1A-mediated
repression will be a major focus of our work in the
upcoming years.
RELATIONSHIPS BETWEEN TRANSFORMING
SEQUENCES OF AD2 E1A AND SV40 T ANTIGEN
By last year, we had shown that conserved domain
2 of E1A represents a structural and genetic unit com-
mon to the transforming proteins of both adenovi-
rus and SV40. During the past year, we attempted
to determine whether SV40 T antigen encodes a
function analogous to that encoded in the amino-
terminal E1A sequences. We now know more pre-
cisely which sequences in the amino terminus are re-
quired for E1A-transforming function, but we still
cannot recognize any sequences in T antigen that
show a close relationship to the required E1A amino-
terminal sequences. Nevertheless, given the degree
of independence between the two transforming func-
tions in the E1A products, a T-antigen functional
homolog need not necessarily be a structural homo-
log. We have obtained preliminary results this year
indicating that T antigen does, indeed, carry a trans-
forming function able to substitute for the amino-
terminal function in the E1A products.
We first determined that most sequences in T an-
tigen downstream from the domain-2 homologous
region (residues 101-118 in T antigen) and the T-an-
tigen nuclear localization sequence (residues 127-
133) are not required for cooperation with ras in the
cotransformation assay in primary BRK cells. A con-
struct expressing only residues 1-148 is competent
for transforming function in this assay. These results
suggested that if a function analogous to that en-
coded in the E1A amino-terminal sequences also ex-
ists in T antigen, it will lie within the first 148
residues, probably upstream of residue 100. The
amino-terminal and domain-2 E1A functions can
complement each other in trans. To learn whether
sequences in T antigen outside the domain-2 homol-
ogous region can substitute for the E1A amino ter-
minus in the trans-cooperation assay, we made a T-
antigen construct lacking all of conserved domain
2 and tested its transforming function. This construct
is negative in the ras cooperation assay but can
cooperate in trans with an E1A construct lacking
amino-terminal sequences. We have isolated cell lines
stably transformed as a result of cotransfection with
ras, the E1A deletion peptide, and the T-antigen de-
letion peptide and have shown that they express the
expected mutant products. Although these results are
preliminary, and the level of complementing activ-
ity is very low, they support the hypothesis that T
antigen carries a function analogous to the E1A
amino-terminal function. We are currently charac-
terizing a series of chimeric proteins that replace
amino-terminal E1A amino acid sequences with se-
quences from T antigen in order to identify the T-
antigen sequences responsible for the complement-
ing activity. Our goals now are to determine the pre-
cise required sequences of the active sites and to dis-
tinguish whether the active sites encode the same
specific biochemical function (perhaps involved with
300-kD binding) or different specific functions that
ultimately have a similar effect on cell growth.
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The Protein Immunochemistry Group is composed
of two sections. The Monoclonal Antibody Facility
provides a central site for the production of mono-
clonal antibodies for Cold Spring Harbor Labora-
tory scientists. This facility is managed by Carmel-
ita Bautista and is staffed by Margaret Falkowski and
Susan Allan. During 1989, this facility produced a
total of 873 hybridoma cell lines for the CSHL staff.
The other section of the Protein Immunochem-
istry Group is a research unit that has been studying
the molecular mechanisms used by the adenovirus
E1A proteins to transform cells. These studies have
concentrated on the physical interactions between
the E1A proteins and various cellular polypeptides.
There are at least ten cellular proteins that are spe-
cifically associated with E1A in virus-transformed
or infected cells. These proteins were originally
known by their relative molecular weights of 300K,
130K, 107K, 105K, 90K, 80K, 60K, 50K, 40K, and
28K. Recently, several of these proteins have been
identified. Probably the most startling was the find-
ing that the 105K protein was the product of the
retinoblastoma (RB) tumor suppressor gene. This
protein, now known as pRB, is thought to act as a
negative regulator of cell proliferation. This inter-
action, its potential significance, and the other pro-
tein/protein complexes are discussed in detail below.
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Retinoblastoma Protein and p107 Are
Targeted by the Early Proteins of
Several Small DNA Tumor Viruses
N. Dyson, K. Buchkovich-Sass, E. Harlow [in collaboration
with K. Munger, B. Werness, P Howley, National Cancer
Institute, Bethesda, Maryland; and P. Whyte, Fred Hutchinson
Cancer Research Center, Seattle, Washington]
The E1A proteins of adenovirus 5 (Ad5), the E7 pro-
teins of human papillomavirus 16, and the large T
antigens of SV40 have several features in common.
All are multifunctional proteins that are synthesized
by small DNA tumor viruses early in viral infection.
All three proteins are believed to play an important
role in the ability of these viruses to drive infected
cells through the cell cycle to S phase, where effi-
cient replication of viral DNA occurs. A feature of
these viral proteins, which is probably closely related
to this mitogenic activity, is that each will immor-
talize primary rodent cells in culture and either
transform cells directly (SV40 large T antigen) or
cooperate with other oncogenes to produce fully
transformed cells (E1A or E7).
Analysis of recombinant adenoviruses contain-
ing mutated E1A genes has previously shown that
the ability of E1A to associate with three cellular pro-
teins of 105K, 107K, and 300K correlates with the
ability of E1A to function as an oncogene in a co-
transformation activity (Whyte et al., Cell 56: 67
[1989]). Recently, the 105K protein, now known as
pRB, has been identified as the product of the RB
susceptibility gene (Whyte et al., Nature 334: 124
[1988]). Loss of the RB gene has been associated with
the generation of tumors of the developing retina
as well as in other tissues. Similar to E1A, the SV40
large T antigen has also been shown to associate with
pRB, and genetic analysis shows that mutations of
large T antigen, which disrupt binding to pRB, in-
activate transformation by the viral protein (DeCaprio
et al., Cell 54: 263 [1988]). It is hypothesized that
these viral proteins bind to and inactivate pRB in
order to overcome a negative control of cell prolifer-
ation, thus mimicking the loss of the RB gene seen
in several types of tumor cells.
Two regions of E1A have been shown to be im-
portant for binding to pRB, and amino acid se-
quences homologous to these regions are found in
the large T antigens of SV40 and many other
polyoma-type viruses. In collaboration with R. Ber-
nardo and S. Friend (Massachusetts General Hospi-
tal), L. Gooding (Emery University), J. Hassel
(McMaster University), E. Major (National Insti-
tutes of Health), J. Pipas (University of Pittsburgh),
and T. VanDyke (University of Pittsburgh), we have
used a coimmunoprecipitation assay to show that
the large T antigens of commonly used isolates of
mouse, monkey, baboon, or human polyoma-type
viruses can all bind to mouse or human pRB. This
conservation of function between viral proteins sug-
gests that binding to pRB is an important feature
in early viral infection and that pRB binding may
be a common component in transformation by these
viral oncoproteins.
Although adenoviruses and polyoma-type viruses
can cause tumors in rodents, neither class of virus
is frequently associated with human cancer. In col-
laboration with Peter Howley's laboratory at the Na-
tional Cancer Institute, we have used in vitro assays
to demonstrate that the E7 proteins of several types
of human papillomaviruses (HPVs) also bind to pRB.
HPVs are associated with and are believed to be
causative agents for a wide variety of anogenital le-
sions. More than 60 types of HPVs have been iden-
tified, but only certain types are commonly found
associated with anogenital lesions. In addition, le-
sions with certain HPV types (such as HPV-16 and
HPV-18) are associated with a high risk of progres-
sion to malignancy, whereas other HPVs are almost
entirely found in benign lesions (e.g., HPV-6b and
HPV-11). E7 proteins from HPV types 6b, 11,16, and
18 were all shown to be able to bind to pRB in vitro,
although the E7 proteins of HPV types 6b and 11
formed complexes with lower affinities. The levels
and control of synthesis of the E7 proteins are differ-
ent with the respective HPV types, and the biologi-
cal significance of the differences in E7-pRB affini-
ties is unclear. However, these results implicate pRB
binding as a potential step in HPV-associated car-
cinogenesis.
Where known, mutations in Ad5 E1A, HPV-16
E7, or SV40 large T antigen that prevent associa-
tion with pRB also abolish transformation activity,
suggesting a role for pRB binding in the transfor-
mation process. The interpretation of the analysis
of E1A mutants, however, is complicated by the ob-
servation that the regions involved in binding to pRB
are also essential for the association of E1A with
other cellular proteins. Recently, we have shown that
the E1A-associated cellular p107 protein also forms
stable protein/protein complexes with the large T an-
tigens of SV40 and JC virus in virus-transformed
human cells. Since p107 and pRB share overlapping
binding sites on both E1A and SV40 large T anti-
gen, the relative contributions of binding to each pro-
tein for transformation have been difficult to assess.
However, since binding to both pRB and p107 is con-
served by these unrelated viruses, it seems likely that
both are cellular targets in a common mechanism
for transformation by the viral proteins.
Synthetic Peptides That Bind to
the Retinoblastoma Protein
N. Dyson, C. McCall, L. Duffy, E. Harlow
We have used synthetic peptides containing ElA
amino acids 37-54 (from conserved region 1) and
115-132 (from conserved region 2) to show that se-
quences in both of these regions of E1A make phys-
ical contact with the RB protein. Peptides from each
region alone are able to block the interaction between
E1A and pRB, but most effective blocking is seen
with peptides containing sequences from both
regions. Similarly, when region-1 or region-2 pep-
tides are coupled to Sepharose beads, they are able
to form stable complexes with RB polypeptides. As
in the blocking experiments, peptides containing
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both region-1 and region-2 sequences provide the
highest affinity interaction. In cross-blocking experi-
ments, region-1 peptides are unable to block the in-
teraction between region-2 peptide beads and pRB,
and the converse is also true, suggesting that the two
regions of E1A make distinct and independent con-
tacts with pRB.
Peptides containing regions 1 and 2 were used to
raise monoclonal antibodies to the pRB-binding sites
on E1A. Approximately 60 hybridomas were produced
from two fusions that recognize ElA in immuno-
precipitations. Regardless of whether they recognize
epitopes in region 1 or region 2, these antibodies have
a common characteristic in that they fail to recog-
nize E1A when it is associated with p130, p107, or
pRB, and they do not coprecipitate these cellular pro-
teins. Preliminary data suggest that these antibod-
ies inhibit E1A /pRB association in vitro. Several of
these antibodies also directly recognize cellular pro-
teins that may be candidates for cellular pRB-binding
proteins.
Five of the monoclonal antibodies that were raised
against E1A cross-react with the HPV-16 E7 protein.
These antibodies all recognize epitopes in region 1
of El A, confirming that the homologous sequences
in E7 contain similar structures. Currently, we are
using similar methods to determine whether these
regions of E7 also make direct contact with pRB.
Regions of the Retinoblastoma
Protein Needed for Binding to
Adenovirus E1A or SV40 Large
T Antigen Are Common Sites
for Mutations
Q. Hu, N. Dyson, E. Harlow
The protein product of the RB gene is thought to
function in a pathway that restricts cell proliferation.
As described above, the transforming proteins from
three different classes of DNA tumor viruses have
been shown to form complexes with the pRB. Genetic
studies suggest that with all three classes of viruses,
these interactions with the RB protein are important
steps in transformation. To understand the function
of the pRB/viral oncoprotein complexes better, we
have mapped the regions of pRB that are necessary
for these associations. Mutations were introduced
into the pRB-coding region using a polymerase chain
reaction strategy. Mutant RB polypeptides were ex-
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pressed in vitro by translation in rabbit reticulocyte
lysates programmed with cRNA prepared from in
vitro transcription systems. The resultant RB poly-
peptides were then mixed with either adenovirus E1A
or SV40 large T antigen. If complexes formed, they
were detected following immunoprecipitation with
monoclonal antibodies specific for the viral proteins.
Two noncontiguous regions of RB were found to
be essential for complex formation with adenovirus
E1A or SV40 large T antigen. These two regions are
located between amino acids 393-572 and 646-772.
Interestingly, these binding sites on RB overlap with
the positions of naturally occurring, inactivating mu-
tations of the RB gene. These results strongly sug-
gest that these viral oncoproteins are targeting apro-
tein domain that plays an important role in the
normal function of the RB protein.
To study further this domain of pRB, we have
raised monoclonal antibodies to the ElA/T-binding
regions of pRB. A panel of monoclonal antibodies
has been isolated that will immunoprecipitate na-
tive pRB from mammalian cells. Several of these an-
tibodies recognize subsets of pRB that can be dis-
tinguished by their relative levels of phosphorylation.
These antibodies are currently being tested to see if
they block the interaction of pRB with ElA or T
antigen.
Cell Cycle Regulation of
the Retinoblastoma Protein
K. Buchkovich-Sass
All RB tumor cells have lost the ability to synthe-
size pRB, the product of the RB tumor suppressor
gene. The correlation between loss of the RB pro-
tein and tumor formation has led to the hypothesis
that pRB functions as an inhibitor of cellular
proliferation, yet pRB is synthesized in most actively
proliferating cells. A resolution of this paradox could
be the phase-specific control of pRB activity during
the cell cycle.
We have shown that pRB is synthesized through-
out the cell cycle and that the steady-state level does
not change dramatically (within twofold) during the
cycle. However, the phosphorylation state of the pro-
tein does vary in a phase-dependent manner. In the
Go/GI phase of the cell cycle, an unphosphorylated
species of the protein is the only detectable form,
whereas in the S, G2, and M phases, multiple phos-
phorylated species of pRB are detected. The earliest
phosphorylation events occur late in the G1 phase,
as determined by hydroxyurea treatment of syn-
chronized cells. Hydroxyurea inhibits DNA synthe-
sis but does not block the phosphorylation of pRB.
The removal of phosphates from pRB is not com-
plete until after metaphase mitosis, as determined
by nocodazole treatment of cells.
A candidate for the kinase(s) controlling pRB
phosphorylation is the human homolog of the
Schizosaccharomyces pombe cdc2 product. Partially
purified human cdc2 will phosphorylate pRB in
vitro, and a subset of the pRB tryptic phosphopep-
tides generated after labeling the protein in vivo are
the same peptides phosphorylated by cdc2 in vitro.
cdc2 is known to be a cell-cycle-regulated kinase, with
peaks of activity in the S and M phases of the cell
cycle. The yeast cdc2 p34 is required for entry into
these phases of the cycle.
There are two clues as to which form of pRB, the
phosphorylated or the unphosphorylated, is active
in controllng cellular proliferation. First, in their nat-
ural hosts, DNA tumor viruses infect cells that are
often arrested in a Go- or G1-like phase. The early
proteins of these viruses are responsible for induc-
ing infected cells to enter S phase, and several of these
proteins bind to pRB. These two activities of the early
viral proteins may be directly related, suggesting a
Go or G1 activity for pRB. Second, Ludlow and col-
leagues (Cell 56: 57 [19891) have shown that SV40 T
antigen binds only to the unphosphorylated form
of pRB. If SV40 antigen regulates pRB function via
physical association, as has been proposed, then it
must be the unphosphorylated form of pRB that is
the target of T antigen. Since the unphosphorylated
form of pRB is found predominantly in the Go /G1
phase of the cell cycle, T antigen must target a
Go /G1 activity of pRB. Together, these findings pro-
vide the first indication that pRB may have an im-
portant role in controlling some elements of cell cy-
cle progression.
Is the E1A-associated p107
Protein Related to pRB?
L.-K. Su, C. Herrmann
p107 is a cellular protein that has been found to form
complexes with oncoproteins of certain DNA tumor
viruses. This protein has several properties similar
to those of pRB, the product of the retinoblastoma
susceptibility gene (RB-1). Similar to the pRB pro-
tein, p107 is a nuclear phosphoprotein. The regions
on two viral oncoproteins, the adenovirus E1A and
SV40 T antigen, that are required for their interac-
tion with pRB and the p107 have been characterized.
The regions of these oncoproteins that are required
for their association with p107 overlap with the
regions required for binding to pRB. In other experi-
ments, these regions have been shown to be impor-
tant for the transformation activity of these onco-
proteins. In addition, large T antigen will only bind
to the unphosphorylated form of either pRB or p107,
whereas E1A binds both phosphorylated and un-
phosphorylated forms.
Although p107 has many properties similar to
those of the pRB proteins, it is not an alternative
form of pRB. Evidence for this includes the existence
of p107 in a cell line that does not have a functional
RB-1 gene, different proteolytic patterns of these two
proteins, and failure of several antibodies against
pRB to recognize p107. The facts that both p107 and
pRB share the same binding regions of E1A and that
both of them bind to SV40 large T antigen suggest
that they may function in a simliar way or in an an-
tagonistic way. In either case, it is interesting to spec-
ulate that p107 is involved in the regulation of the
cell proliferation as pRB has been suggested to be.
These questions can only be answered by exten-
sive study of p107. To study p107, we are purifying
the p107 protein and cloning its complementary
DNA. Since p107 can be easily detected by and pu-
rified through its association with adenovirus E1A,
a cell line that expresses E1A constitutively has been
used as the source of p107. Immunoprecipitation and
SDS-PAGE have been used to purify the p107. The
purified protein has been used for immunization of
animals and for amino acid sequencing. To date, the
sera of immunized aminals have not shown a re-
sponse. However, the amino acid sequence of one
peptide from p107 has been obtained in collabora-
tion with Dan Marshak (Protein Chemistry, this sec-
tion). We are in the process of obtaining a cDNA
probe by polymerase chain reaction using the syn-
thesized oligonucleotide deduced from the amino
acid sequence.
In addition to the studies of the p107 gene, we have
also been studying its phosphorylation. Phosphory-
lation is a common mechanism to alter the activity
of a protein. Several years ago, we observed that im-
mune complexes containing E1A and associated cel-
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lular proteins possess a protein kinase activity. Re-
cently, we have begun to identify and characterize
this kinase. The major endogenous substrates of this
kinase are the p107 and p130 proteins; the kinase also
phosphorylates exogenous histone. Using E1A mu-
tant viruses or E1A antibodies that coimmunoPre-
cipitate a subset of the complex proteins, we have
been able to eliminate the E1A-associated 300K pro-
teins as a potential source of the kinase activity. Ly-
sates precleared of the pRB protein retain the kinase
activity, suggesting that the pRB protein is also not
required for the kinase activity. It seems unlikely that
p107 itself is the kinase, since in several cases, we are
able to immunoprecipitate p107 from 35S-labeled
cell lysates, and it does not become phosphorylated
in a kinase reaction. Therefore, we believe that an-
other associated protein is the kinase. We have be-
gun to purify this activity and are examining its prop-
erties during various stages of the cell cycle. We are
also measuring the activity of the kinase in a num-
ber of tumor cell lines in which the level of p107 is
believed to be altered.
p60 E1A-associated Protein
also Binds to the Human
cdc2 Protein
A. Giordano, B. Faha [in collaboration with
J. Lee, R. Franza, G. Draetta, and D. Beach,
Cold Spring Harbor Laboratory]
The adenovirus E1A proteins associate with a group
of cellular proteins in virus-transformed or infected
cells. Our results show that the cellular p60 protein
forms a complex not only with the adenovirus E1A
proteins, but also with the product of the cdc2 gene.
The cdc2 gene encodes a p34 protein that forms the
catalytic subunit of a kinase known as MPF (for
mitosis-promoting factor). This kinase is involved
in regulation of the cell cycle in a wide range of eu-
karyotes. The p60/cdc2 complex occurs in both
virus-infected cells and uninfected cells. We have
shown that the p60/cdc2 complex has histone H1 ki-
nase activity and that the kinase activity is cell-cycle-
regulated, the highest activity being seen in inter-
phase. The time of activation of this complex differs
from that seen with MPF, which is most active in
mitosis. Differential timing of activation of these two
complexes, p60/cdc2 and MPF, suggests that each
might play a distinct role in cell cycle regulation.
We have also investigated the interaction of E1A
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with p60. An extensive series of E1A deletion mu-
tants have been used to map the binding sites of p60
on E1A. E1A residues between 30-60 and 121-127
form the needed structures for interaction with p60.
These same residues are also required, either in to-
tal or in part, for the interactions with pRB and p107.
Interestingly, mutations in this region destroy the
ability of E1A to function as an oncogene.
PUBLICATIONS
Buchkovich, K., L. Duffy, and E. Harlow. 1989. The retinoblastoma
protein is phosphorylated during specific phases of the cell
cycle. Cell 58: 1097-1105.
Buchkovich, K., N. Dyson, P Whyte, and E. Harlow. 1989. Cellu-
lar proteins implicated in transformation by adenovirus and
other DNA tumor viruses. In Common mechanisms of trans-
formation by small DNA tumor viruses (ed. L. Villereal), pp.
51-63. American Society for Microbiology Press, Washing-
ton, D.C.
Dyson, N., K. Buchkovich, P Whyte, and E. Harlow. 1989. The
107K cellular protein that binds to adenovirus E1A also binds
to the large T antigens of SV40 and JC virus. Cell 58: 249-255.
Dyson, N., K. Buchkovich, P Whyte, and E. Harlow. 1989. Pro-
teins that are cellular targets for transformation by DNA tu-
mor viruses. In Current communications in molecular biol-
ogy: Recessive oncogenes and tumor suppression (ed. E.
Stanbridge et al.), pp. 133-140. Cold Spring Harbor Labora-
tory Press, Cold Spring Harbor, New York.
Dyson, N., P Howley, K. Munger, and E. Harlow. 1989. hu-
man papillomavirus-16 E7 oncoprotein is able to bind to the
retinoblastoma gene product. Science 243: 934-937
Giordano, A., P Whyte, E. Harlow, B.R. Franza, D. Beach, and
G. Draetta. 1989. A 60 kd cdc2-associated polypeptide com-
plexes with the E1A proteins in adenovirus-infected cells. Cell
58: 981-990.
Horowitz, J., D. Yandell, S. Park, P Whyte, K. Buchkovich,
E. Harlow, R. Weinberg, and T. Dryja. 1989. Point mutational
inactivation of the RB anti-oncogene. Science 243: 937-940.
Winger, K., B. Werness, N. Dyson, W. Phelps, E. Harlow, and
P Howley. 1989. Complex formation of the papillomavirus E7
proteins with the retinoblastoma tumor suppressor gene prod-
uct. EMBO J. 8: 4099-4105.
Whyte, P, N. Williamson, and E. Harlow. 1989. Cellular targets
for transformation by the adenovirus E1A proteins. Cell
56: 67-75.
In Press, Submitted, and In Preparation
Buchkovich, K., N. Dyson, Q. Hu, P Whyte, and E. Harlow. 1990.
Cellular proteins that are targets for transformation by DNA
tumor viruses. In Proto-oncogenes in cell development. Ciba
Foundation Symposium No. 150 (ed. T. Hunter). (In press.)
Dyson, N., K. Buchkovich, Q. Hu, P Whyte, and E. Harlow. 1990.
Cellular targets for transformation by DNA tumor viruses. In
Genetic basis for carcinogenesis, 20th International Sym-
posium of the Princess Takamatsu Cancer Research Fund
(ed. A. Knudson et al.). (In press.)
Dyson, N., R. Bernards, S. Friend, L. Gooding, J. Hassel, E. Ma-
jor, J. Pipas, T. VanDyke, and E. Harlow. 1990. The large T
antigens of many polyomaviruses can bind to the product
of the retinoblastoma gene. J. Virol. 64: 1353-1356.
Hu, Q., N. Dyson, and E. Harlow. 1990. The regions of the retino-
blastoma protein needed for binding to adenovirus E1A or
SV40 large T antigen are common sites of mutation. EMBO
J. (in press).
PROTEIN CHEMISTRY
D.R. Marshak G.E. Binns M. Di Donato
R. Breckenridge G.L. Russo
D. Carroll M.T. Vandenberg
The Protein Chemistry Laboratory is engaged in re-
search pertaining to the structure and function of
proteins involved in fundamental mechanisms of
normal and abnormal growth of cells. We use ad-
vanced instrumentation such as protein sequencers,
mass spectrometers, and peptide synthesizers to take
a biochemical approach to the analysis of proteins
and particularly in the analysis of modifications on
proteins. It is these modifications, such as phos-
phorylation, and the enzymes that catalyze them,
that appear to modulate many of the regulatory
mechanisms in cellular growth.
Mapping Phosphorylation Sites
on Nuclear Oncoproteins
D. Carroll, M.T. Vandenberg, D.R. Marshak
During the past year, our work on mapping phos-
phorylation sites has concentrated on SV40 large T
antigen (LTag) and the Myc protein. We have also
assembled a spectrum of protein kinases to use for
in vitro phosphorylation of the overexpressed pro-
teins. These kinases include casein kinases I and II
(CK-I and CK-II); protein kinase C (PK-C); cAMP-
dependent protein kinase (PK-A); myosin-light-chain
kinase (MLCK); calcium-calmodulin kinase II (CaM
K-II); raf kinase (raf); p34cdc2 (p34); glycogen syn-
thase kinase 3 (GSK-3); and phosphorylase b kinase.
Studies of p34 phosphorylation of LTag were con-
ducted in collaboration with Y. Gluzman (Molecu-
lar Biology of SV40 Section) and D. Beach (Genetics
Lee, C., W. Craigen, D. Munzy, E. Harlow, and T. Caskey. 1990.
Cloning and expression of a mammalian peptide chain re-
lease factor: Conserved structure to tryptophanyl-tRNA syn-
thetase. Science (Submitted.)
A. Vongs
I.J. Yu
Section). The cell-cycle-regulated protein kinase, p34,
phosphorylates LTag specifically at Thr-124. This
modification affects the specificity of binding of
LTag to the origin of replication on SV40. We demon-
strated the site of phosphorylation biochemically by
isolating and characterizing the phosphorylated pep-
tide from a proteolytic digest of LTag labeled in vitro
with [y- 32P]ATP and purified p34. The protein was
digested sequentially with trypsin, followed by staph-
ylococcal V8 protease, and subjected to electropho-
resis on polyacrylamide gels containing SDS and urea
using a Tris-tricine buffer system. Sequence analy-
sis of this peptide gave the amino acid sequence cor-
responding to residues 102-126, and the phosphory-
lation site was determined by an increase of 32P
radioactivity appearing at the cycle corresponding
to Thr-124. These results were confirmed by analy-
sis of a mutant LTag with a threonine-alanine sub-
stitution at position 124 (Y. Gluzman, Molecular
Biology of SV40 Section).
Further studies on LTag phosphorylation by CK-
II have resulted in an interesting phenomenon. First,
phosphorylation of LTag by CK-II shows nonlinear
kinetics, with a concave upward curvature, indicat-
ing that at higher substrate concentrations, the rate
of the reaction increases. This is not true for other
substrates for CK-II that we have tested. Adding cata-
lytic amounts of LTag to CK-II reactions with other
substrate proteins indicates that LTag will acceler-
ate the phosphorylation. The activating domain on
LTag has been identified using synthetic peptides,
and it appears to consist of residues 116-138. This
peptide contains the polybasic nuclear localization
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site as well as the p34 phosphorylation site.
This do-
main is adjacent to the CK-II phosphorylation sites
at residues 106, 111, and 112. We are
currently trying
to evaluate the affects of p34
phosphorylation on
CK-II phosphorylation in vitro. The
effect of LTag
on CK-II appears to act in vivo, since extracts
of COS
cells that have LTag overexpressed have
approxi-
mately eightfold higher CK-II activity than
the par-
ent strain, CV-1. These studies have
prompted us to
evaluate further the roles of activators and poten-
tial inhibitors of CK-II activity in vivo.
Phosphorylation sites on Myc have been deter-
mined by in vivo and in vitro labeling experiments.
Phosphorylated peptides have been analyzed by elec-
trophoresis on high-resolution, Tris-tricine/urea gels
as described above for LTag. The in vivo experiments
were done with COLO 320 cells, which are a human
colon-carcinoma-derived cell line that overexpresses
Myc. The in vitro phosphorylation experiments are
performed with Myc protein expressed in and puri-
fied from Escherichia coli. The patterns of Myc
phosphorylation in the cells can be partially ac-
counted for by phosphorylation of the purified pro-
tein by PK-A, CK-II, and p34. The sites of phos-
phorylation were determined by sequence analysis
and mass spectral analysis of the purified, phos-
phorylated peptides. Mass spectrometry allows us
to determine the exact stoichiometry and residues
that are modified. There appears to be a domain in
the protein of approximately 7 kD in the middle of
the protein that contains the bulk of the phosphory-
lation sites. This hyperphosphorylated domain regu-
lates the DNA binding of Myc, since CK-II phos-
phorylation in this domain abolishes the activity.
Phosphorylation of Transcription
Factors
D.R. Marshak, G.L. Russo, I.J. Yu
[in collaboration with E. Chang and M. Gilman,
Cold Spring Harbor Laboratory]
Transcription factors refer to a large family of pro-
teins that either bind to regulatory elements of genes
or interact with protein complexes that, in turn, pro-
mote gene transcription. Many of these transcrip-
tion factors appear to be phosphorylated, mainly by
attachment of phosphate to serine and threonine
residues, catalyzed by several candidate nuclear pro-
tein kinases. Of these, we have studied casein kinase
58
p34,dc2, glycogen synthase kinase, protein kinase
C, and cAMP-dependent protein kinase. Using this
panel of enzymes, our strategy
i
has been to phos-
phorylate transcription factors n vitro and to test
how individual phosphorylation events might alter
the ability to bind to the appropriate DNA element
or to direct transcription.
i
To this end, we require pu-
rified proteins produced in relatively large amounts,
unlike the natural products that are in vanishingly
small quantities. E. Chang has expressed several fac-
tors in E. coli, and these are purified to milligram
quantities through classical procedures.
We have begun to study two regulatory proteins
involved in the control of transcription of the c-fos
gene. Two regulatory elements have been defined by
M. Gilman and his colleagues (Molecular Genetics
of Eukaryotic Cells Section) as the serum response
element and the cAMP responsive element, and the
corresponding proteins that bind to these elements
have been termed the serum response factor (SRF)
and the cAMP-responsive-element-binding protein
(CREB). Both of these proteins have been expressed
in E. coli and purified to apparent homogeneity.
Using our panel of protein kinases, we have begun
to examine the phosphorylation sites on the proteins
as well as the effects of these phosphorylations on
DNA binding. Preliminary evidence suggests that
phosphorylation plays a major role in modulating
the transcriptional activator functions of these pro-
teins. Further studies will take advantage of our mass
spectrometry and protein chemistry expertise to de-
termine the stoichiometry and location of the phos-
phorylation sites.
Role of Casein Kinase II in
Cell Growth
I.J. Yu, D. Carroll, D.R. Marshak
We are continuing our studies of CK-II in cell growth
and viral transformation. To this end, we continue
to develop reagents that will allow us to investigate
changes in enzyme activity, protein levels, and
mRNA levels inside cells. Antibodies have been pre-
pared in rabbits against purified bovine liver CK-II.
These sera react with the enzyme on nitrocellulose
and by immunoprecipitation. Recently, several ad-
ditional antisera have been prepared by using syn-
thetic peptide antigens raised to various regions of
the a and 13 subunits of the enzyme. We are using
these antibodies to investigate the subcellular local-
ization of CK-II during serum stimulation or virus
infection, as well as in cell division cycle experiments.
We hope that these antibodies will allow us to dis-
tinguish between the catalytic (a) and putative
regulatory (13) subunits of the enzyme. We are cur-
rently isolating the cDNA clone for the human a
subunit using the polymerase chain reaction (PCR).
We have constructed oligonucleotide probes based
on the published sequence with specific restriction
sites. Using total RNA from He La cells, we are using
reverse transcriptase followed by the PCR reaction
to isolate a full-length clone (1.2 kb). If successful,
this will allow us to use our cDNA to probe the lev-
els of mRNA in stimulated versus unstimulated cells
and in the cell cycle.
Initial studies on cell cycle control of CK-II as
compared with p34 have demonstrated a reciprocal
relationship between these enzyme activities. CK-II
appears to be maximally stimulated in G1 phase of
the He La cell cycle, consistent with our previous ob-
servations of CK-II stimulation early in serum acti-
vation of fibroblasts. The mitotic form of p34, how-
ever, is maximally active during the G2/M phase of
the cell division cycle. One interesting region to ex-
amine will be S phase, when both enzymes are par-
tially activated and the cell is undergoing profound
changes in nuclear activity to replicate DNA. The
initiation and control of the DNA synthesis phase
of the cell cycle are of particular excitement for con-
tinued effort in protein kinase activity measurements.
Synthetic Peptide Substrates
for Protein Kinases
D.R. Marshak, M.T. Vandenberg, R. Breckenridge,
G.E. Binns, M. Di Donato, D. Carroll
We have been actively involved in the design and syn-
thesis of peptides that are phosphate acceptors on
serine or threonine residues. Peptides are synthesized
by chemical methods based on the original Mer-
rifield approach using Na-t-Boc-protected amino
acids and solid supports. Synthesis is done using au-
tomated techniques on an Applied Biosystems 430A
instrument. The peptides are cleaved from the sup-
port in liquid hydrogen fluoride, precipitated with
ethyl ether, and purified by reverse-phase high-
performance liquid chromatography. The peptides
are extensively characterized by mass spectrometry,
sequence analysis, and amino acid analysis to en-
sure that we have generated a pure product. Peptides
are analyzed as kinase substrates by carrying out a
phosphorylation reaction with radiolabeled ATP and
then separating the radioactivity incorporated into
the peptide either by immobilization on phosphocel-
lulose paper or by thin-layer chromatography. Both
methods have been very successful in quantitative
analysis of the products.
Two classes of peptide substrates for protein ki-
nases have been characterized: CK-II substrates and
p34cdc2 substrates. The CK-II substrates are modeled
on the sites of phosphorylation of the nuclear on-
coproteins, such as Myc, Fos, adenovirus E1A, and
SV40 T antigen. These peptides contain serine or
threonine residues followed by a cluster of acidic
amino acid residues. The presence of a I3-turn gener-
ated by proline residues is common but apparently
not essential for activity. Substrate peptides for
p34cdc2 generally contain a serine or threonine resi-
due followed by a proline residue and several basic
amino acids. The exact structural features of these
substrates and their specificities as substrates is un-
der intense investigation.
Structural Analysis of a Human
IGF-II Variant
D.R. Marshak [in collaboration with J. Perdue
and W. Burgess, American Red Cross
Research Center, Maryland]
During the year, we have been fortunate to be in-
volved in the analysis of several proteins related to
growth in human physiology. In collaboration with
a group at the American Red Cross Research Cen-
ter in Maryland, we characterized a new form of the
insulin-like growth factor II (GF-II) from human
plasma. This protein turned out to be a variant of
the more common form, containing a tetrapeptide
replacement (Arg-Leu-Pro-Gly) of a serine residue
near the amino-terminal end of the protein. The mass
of the protein (measured by plasma desorption mass
spectrometry) was 7809.4, less than 0.0507o from the
calculated mass based on classical sequencing tech-
niques. These studies indicate that the mass spec-
trometer is an invaluable tool in structural analysis
of proteins. This variant of IGF-II represents approx-
imately 2 5 Wo of the plasma IGF-II activity.
Sequence Analysis of Peptides
by Mass Spectrometry
D.R. Marshak, G.E. Binns
Sequence analysis of peptides by plasma desorption
mass spectrometry (PDMS) has been accomplished
for an assortment of peptides. Peptides ranging in
molecular weight from 1100 to 3600 amu displayed
useful sequence ions under PDMS. Acidic, basic, and
neutral peptides all showed sequence fragment ions,
and carboxy-terminal sequence information was
readily obtained on all peptides (A, B, or C" ions).
The A ion series was most abundant for the basic
peptides, and the C" ion series was most abundant
for the acidic peptides. Sequence-specific fragment
ion patterns appear to occur. For example, peptide
CSH084 showed dehydration ( -18 amu) of all the
Y" ions in the internal basic region (residues 10-16).
Subsequent examples of peptides containing aro-
matic side chains indicate that loss of the indole moi-
ety from the side chain is common under PDMS.
A similar generation of these w' ions from histidine
residues through loss of imidazole has also been de-
tected. We suggest that PDMS is generally useful for
sequence analysis of peptides of various composi-
tions. In particular, PDMS is useful as a complemen-
tary tool to classical methods of protein chemistry,
and PDMS should be considered an important part
of a multidisciplinary approach to the structural
analysis of peptides and proteins.
At low sample loads (10 pmoles), the B, C", and
Y" ions remained detectable, whereas the A and Z
ions were not detected. Therefore, sequence analy-
sis of peptides at the low pmole level is possible by
PDMS. At higher sample loads, the A ion series was
abundant and gave nearly complete sequence infor-
mation. Because the amino-terminal sequence ion
array (A, B, C" ions) yields carboxy-terminal se-
quence information, PDMS is quite useful in con-
junction with amino-terminal sequence analysis
using chemical methods. Sequence fragment ions are
more abundant with smaller amounts of nitrocellu-
lose electrosprayed on the targets. Optimal nitrocel-
lulose loading for 1.0 nmole (Val-5) angiotensin I was
10-25 lig. In contrast, the [M + H]+ was more abun-
dant at high loading of nitrocellulose (100 lig). Data
acquisition for 4 hours yielded significant abundance
of sequence ions for all the peptides studied. Longer
acquisition times increased the signal-to-noise ratio
for the fragment ions and permitted the assignment
of more sequence. These studies demonstrate that
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PDMS analysis of peptides can provide rapid and
accurate sequence information as a supplement to
chemical analyses.
Peptide Synthesis
G.E. Binns, M. DiDonato, D.R. Marshak
As part of the core protein chemistry support facil-
ity, peptide synthesis is performed to assist research-
ers in their work throughout the programs at Cold
Spring Harbor Laboratory. In general, there are three
uses of peptides: (1) as antigens for antibody produc-
tion; (2) as enzyme substrates; and (3) for biological
studies. Approximately half the peptides synthesized
are used as antigens by coupling to carrier proteins
or by direct injection into animals. The antibodies
produced in this way allow an investigator to pre-
pare a reagent that reacts very specifically with a site
on the protein of interest. Such "site-directed" anti-
bodies are of tremendous value in structure-function
studies of proteins. To facilitate the rapid synthesis
of these peptides, we have employed small-scale (0.1
mmole) rapid-cycle chemistry using an automated
synthesis instrument. To optimize these procedures,
we developed new cycles that double couple 10 of
the 20 common amino acids first in dimethylforma-
mide and then in dichloromethane. This procedure
generates very high-yield and high-quality products.
We have performed the synthesis of larger pep-
tides and small proteins using other methods. For
larger scale and longer syntheses, we have employed
a new solvent system consisting of N-methylpyrro-
lidone and dimethylsulfoxide. This permits the swell-
ing of the resin to increase and boosts coupling
yields, although reaction times are increased. Using
this technique, we synthesized the full-length pro-
tein 510013, consisting of 91 residues, as well as a piece
of the protein containing 48 residues. These proteins
have been purified by high-performance liquid chro-
matography and are currently being studied as struc-
tural analogs of the native proteins. Many other syn-
theses have been performed, several resulting in
peptides that have high biological activity. This in-
dicates that the amount of racemization and the
structural changes in the synthetic species compared
to that of the native peptide are minimal. The col-
lection of methods now employed produce peptides
of the highest quality and activity available any-
where.
During the last 4 years, the growth of the protein
chemistry core services has increased dramatically.
Since Dr. Marshak's arrival in 1986, sequence anal-
ysis has doubled every year, and peptide synthesis
has increased at an even faster pace. We are now see-
ing the number of procedures performed per year
begin to plateau as we reach the physical capacity
of the instruments and the limited personnel. At
present, scientists have to wait weeks to months for
their analyses because of these limitations in re-
sources. In addition, we have instituted several new
methods, such as mass spectrometry, high-perfor-
TABLE 1 Growth of Protein Chemistry
Procedure 1986 1987 1988 1989
Protein sequences
Peptide synthesis
Amino acid analysis
Chromatography
47
6
87
18
357
61
162
46
389
68
215
64
197
35
mance electrophoresis, and quantitative chemical
analyses to maintain the facility on the leading edge of
new technology. However, this further limits the time
available for each procedure. The growth of the use
of protein chemistry is illustrated in Table 1. We hope
that statistics such as these will help to justify in-
creased resources for protein chemistry.
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PROTEIN SYNTHESIS
M.B. Mathews
A.P. Rice
G.F. Morris
C. Echetebu
S. Gunnery
C. Kannabiran
M. Kessler
M. Laspia G. Bennett
T Pe'ery R. Galasso
C. Herrmann L. Manche
Y Ma R. Packer
K.H. Mellits M. Sullivan
We have continued to study the regulation of gene
expression at both the transcriptional and transla-
tional levels. Our work uses systems drawn from
adenovirus and the human immunodeficiency vi-
ruses (HIV), as well as cellular genes. During the past
year, Gil Morris was promoted to a staff associate
position and the group expanded in numbers. We
were joined by Odi Echetebu, a visiting scientist,
Chitra Kannabiran and Shobha Gunnery, both post-
doctoral fellows, and Frank Ma, a graduate student,
while Chris Herrmann received her doctorate and
moved to Ed Harlow's laboratory in the James
building.
Adenovirus VA RNA and
Translational Control
K.H. Mellits, T. Pe'ery, Y. Ma, L. Manche,
M. Stoddart, M.B. Mathews
In the mid-1960s, an "unusual" RNA component was
discovered in human cells infected with adenovirus
type 2 (Ad2) and was termed virus-associated (VA)
RNA. Ten years later, it was realized that there are
in fact two such RNAs, VA RNA, and VA RNA'',
both about 160 nucleotides in length. These RNA
polymerase III transcripts were mapped to two
closely spaced genes at approximately map unit 30
on the adenovirus genome. The RNAs accumulate
to high concentrations in the cytoplasm of adeno-
virus-infected cells, and their sequences suggested
that they can adopt stable secondary structures. Since
then, much has been learned about the role of these
RNAs in adenovirus infection. Their participation
in translational control was discovered through the
study of mutants that contain disruptions of the tran-
scriptional control regions located within the 5' half
of the VA RNA genes. Protein synthesis was de-
pressed in cells infected with an adenovirus mutant
62
that cannot make VA RNA,. Mutant viruses unable
to transcribe VA RNA', showed no such defect, but
the defect was exacerbated when both VA RNAs were
missing, indicating that VA RNA can also partic-
ipate in the translational function. Subsequent work
showed that VA RNA, antagonizes a cellular an-
tiviral defense mechanism by preventing the activa-
tion of a cellular protein kinase known as DAI, the
double-stranded RNA (dsRNA)-dependent protein
kinase. When activated by dsRNA, a process involv-
ing autophosphorylation, this enzyme inhibits pro-
tein synthesis by phosphorylating the initiation fac-
tor eIF-2 and thereby trapping a second initiation
factor, GEF (also known as eIF-2B). VA RNA pre-
vents the dsRNA-mediated activation of DAI.
Present work is addressing the nature of the in-
teractions of DAI with RNAs that activate it
(dsRNA) or block its activation (VA RNA). On the
basis of partial nuclease digestion data, we recently
proposed a secondary structure model for Ad2 VA
RNA, that contains two duplex regions, each about
20 base pairs long (believed to be too short to acti-
vate the kinase) together with several loop structures
(Fig. 1). To assess the validity of this model, we have
begun to compare the structures of a variety of VA
RNAs. These include the VA RNA, species of the
closely related Ad5 serotype, of two more distantly
related human viruses (Ad7 and Ad12), and of mon-
key and chicken adenoviruses (SA7 and CELO), as
well as the VA RNA,' species of Ad2 and Ad7. The
5' halves of these RNAs share pol.III transcription
sequences but are otherwise divergent in primary se-
quence. Computer-assisted structural analysis sug-
gests that they may all possess a region similar to
the functionally important central domain of Ad2
VA RNA, (stippled area in Fig. 1), and direct ex-
amination of the structures of Ad7 VA RNA, and
of the CELO and Ad12 VA RNAs confirms that their
secondary structures are similar to, but not identi-
cal with, that of Ad2 VA RNA,.
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FIGURE 1 Structure of VA RNA. The approximate limits of the
central domain (stippled area) are superimposed on the second-
ary structure model for Ad2 VA RNAi. (Redrawn from Mellits and
Mathews, EMBO J. 7: 2849 [1988].)
We have continued to pursue the mutagenic ap-
proach described in previous Annual Reports to de-
termine which VA RNA sequences or structures are
necessary to prevent the activation of DAI. As a first
step, we made a series of deletion and substitution
mutations throughout the 3' half of the VA RNA,
gene and tested the resulting mutant RNAs for their
ability to rescue protein synthesis in vivo. The results,
coupled with structural information based on par-
tial ribonuclease digestion, defined a small region
of duplex RNA (nucleotides 73-84, Fig. 1) that is
dispensable for VA RNA, function and a complex
stem-loop structure (the central domain, Fig. 1) that
is important for function. Further genetic analysis
suggests that secondary structure is more important
than primary sequence per se in the regions that flank
the central domain. More recently, we have used a
vector containing the bacteriophage T7 promoter to
make mutant RNAs in the quantities necessary to
assay their ability to function in vitro. Thus far, with
a single puzzling exception, the wild-type and mu-
tant VA RNAs tested all function in vitro as would
be expected from their behavior in vivo. We have
gone on to make new mutations in this vector, most
notably to elucidate features of the central domain
that are important for function. Small deletion and
substitution mutations were introduced by oligo-
nucleotide-directed mutagenesis and were tested for
their ability to block DAI activation by dsRNA. De-
letion or substitution of most of the nucleotides in
the loop was tolerated, but a substitution in the
neighboring short stem severely impaired the abil-
ity of the mutant RNAs to function. Thus, neither
the size nor the sequence of the loop is critical; on
the other hand, the structure and/or sequence of the
short stem is important for function, as are some
sequences immediately adjacent to the central do-
main. We presume that the deleterious mutations
perturb the conformation of the central domain, and
we are currently probing the secondary structure of
these mutants to determine the structural ramifica-
tions of the mutations.
Because of its extensive secondary structure, it was
proposed that VA RNA, might block activation of
DAI by imitating short duplex RNA and thereby
preventing the interaction between dsRNA and DAI.
Consistent with this hypothesis, DAI has a single
binding site for dsRNA, and this site can be blocked
by VA RNA,. Moreover, VA RNA, binds to DAI
both in vivo and in vitro and can be cross-linked to
the enzyme. However, the mutational analysis sum-
marized above ascribes a dominant functional role
to the central domain of the molecule rather than
to its duplex axis. To explore the relationship between
DAI binding and the structure and function of VA
RNA,, we assessed the ability of mutant RNAs to
bind to the kinase. In many cases, a mutant's bind-
ing efficiency correlated with its function as mea-
sured in vivo, but there were several exceptions: A
number of mutants that do not function in vivo
bound well, and one that functions in vivo did not
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bind efficiently. These results
indicate that efficient
binding is neither necessary nor
sufficient for func-
tion. Consideration of RNA
structures suggested
that efficient binding requires
a short stem formed
at the apex of the molecule
rather than the central
domain, a deduction that was
confirmed by deter-
mining the structures of the shortest
fragments that
retain the ability to bind to DAI. The short
duplex
structure that promotes efficient
binding to DAI is
not essential for function,
implying that the domains
that control these activities are separate
and distinct.
We postulate that the interaction
of DAI with the
apical stem occurs at the enzyme's dsRNA-binding
site, but does not prevent activation,
and that this
binding facilitates apposition of the
central domain
to a sensitive region of the DAI
active site, leading
to inhibition of DAI autophosphorylation. To
flesh
out these ideas, we are currently examining the in-
teraction of DAI with RNA duplexes of various
lengths and the ability of VA RNA, to bind to the
kinase in the presence of dsRNA.
Regulation of Gene
Expression by E1B
C. Herrmann, M.B. Mathews
The adenovirus E1B 19,000-dalton (19K) tumor an-
tigen is essential for the complete transformation of
primary rodent cells and is required for the normal
infection of permissive human cells. We have used
a plasmid cotransfection assay or cell lines that sta-
bly express the 19K protein to examine the effect of
the 19K protein on expression of a reporter gene
product. The results showed that the 19K polypep-
tide stimulates expression from all promoters intro-
duced into cells by transfection, including a variety
of viral promoters and one cellular promoter. In ad-
dition, the 19K protein increases expression from an
RNA polymerase III-transcribed gene but does not
affect the level of expression of an endogenous cel-
lular gene. The effect of the 19K protein appears to
be independent of promoter sequence but is strongly
influenced by the time course of the experiment, with
the greatest stimulation observed at late times.
We have recently shown that the 19K protein
stimulates the rate of transcription from transfected
promoters, as measured by nuclear run-on assay. Ex-
amination of plasmid DNA levels by dot-blot anal-
ysis of Hirt extract DNA revealed that the 19K pro-
tein increases the stability of plasmid DNA. This
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stabilization of DNA accounts for the incre ased trap_
scription from transfected promoters, indicating that
the primary role of the 19K protein in increasing ex-
pression from transfected promoters is to increase
the level of plasmid DNA retained in the cells.
The role of the 19K protein in regulating viral gene
expression during infection was also examined.
Whereas it has a negative effect on viral gene expres-
sion in the presence of the E1A 13S or 12S products
(see DNA Synthesis, this section), the 19K protein
stimulates viral gene expression in the absence
of
ElA gene products. The enhanced transcription of
viral genes results from increased viral DNA levels.
These results demonstrate that in infected cells, as
in transfected cells, the 19K protein produces a
general and indirect increase in transcription rates
by elevating viral and plasmid DNA levels. The
stabilization of template DNA is consistent with the
role of the 19K protein in preventing the degrada-
tion of viral and chromosomal DNAs during infec-
tion. Thus, the 19K protein may represent the first
example of a viral oncogene product that modulates
gene expression by controlling DNA levels.
Regulation of PCNA
G.F. Morris, C. Kannabiran, M.B. Mathews
The proliferating cell nuclear antigen (PCNA), also
known as cyclin, is a highly conserved protein that
functions in DNA replication by stimulating the
processivity of DNA polymerase 8. Sequence homo-
logs for PCNA have been found in animals, plants,
insects, insect viruses, and yeast, and a functional
analog has been identified in T4 bacteriophage (see
DNA Synthesis). The relevance of PCNA to DNA
metabolism and the correlation of PCNA expres-
sion with cell proliferation prompted us to examine
its expression during periods of cell growth in de-
tail. To present, we have focused on the transcrip-
tional response of the PCNA gene to the transform-
ing genes of adenovirus, located in the El region.
In the long term, we will employ this growth-respon-
sive target gene as a prototype to work toward the
mechanism(s) by which other stimuli trigger cells to
grow and divide.
We have cloned the promoter for PCNA from hu-
man placental DNA and have begun to define se-
quences within the promoter that are important for
its activity. The region from nucleotide -1269 to
+ 60 was excised from a 1.5-kb genomic clone and
fused to the chloramphenicol acetyltransferase
(CAT) reporter gene to determine if this DNA frag-
ment can function in transient expression assays. Af-
ter transfection into He La cells, this PCNA promoter
was found to drive the synthesis of CAT, albeit 20-40
times less efficiently than the SV40 early promoter.
In contrast, in 293 cells (which express El products),
the PCNA promoter was as active as the SV40 early
promoter in transient expression assays. To locate
functionally important elements of the PCNA pro-
moter, we prepared a series of upstream deletion mu-
tants of the promoter and fused them at + 60 to the
CAT reporter gene (Fig. 2). Removal of more than
1000 nucleotides of upstream sequence (nucleotides
-1269 to - 248) had little effect on the expression
of CAT activity in HeLa or 293 cells. Further dele-
tion, removing the region between -1269 and -172,
had little impact in 293 cells but reduced activity in
HeLa cells by approximately 30-4007o. Removal of
sequences from -1269 to - 88 or - 47 reduced the
activity of the promoter in both cell lines to levels
only slightly higher than the basal levels observed with
the parent clone lacking any inserted promoter se-
quences (pBACAT).
Within this last segment, -172 to - 88, lie two
potential SP1 sites and two CCAAT motifs. Such
elements are found in a number of genes that are
-1269 -4 +60
-559 +60
- 248 -> +60
-172 -- +60
-88 -+60
-47 -) +60
pBACAT
- 559 -) -2
constitutively expressed, but it is interesting to note
that the organization of these sequences in the
PCNA promoter resembles that seen in the human
thymidine kinase promoter, possibly reflecting simi-
lar regulatory patterns for these two replication-
related proteins. The functions of these elements are
only conjectural at the moment, but it is possible
that the CCAAT motif plays a regulatory role in de-
velopment and in response to serum stimulation, and
the repeated arrangement of SP1 sites may allow for
the rapid transcription of these genes during periods
of accelerated growth. Although the PCNA pro-
moter lacks an identifiable TATA box upstream of
the transcription site, there is some homology near
the cap site to the published initiator sequence and
to sequences near the transcription initiation site of
the thymidine kinase promoter. To assess the possi-
bility that this region specifies the site of transcrip-
tion initiation in the PCNA promoter, as proposed
for the initiator element, we deleted nucleotides -1
to + 60 from the promoter-CAT construct contain-
ing nucleotides - 559 to - 60. This deletion reduced
the strength of the PCNA promoter in HeLa cells
only slightly, but in 293 cells, it reduced expression
by about half. Whether this signifies a role for the
-1 to + 60 region in the El response, or some other
difference between the two cell types, is not yet clear.
UPSTREAM
PROMOTER
SEQUENCE
TRANSCRIBED
PCNA
CAT CODING
REGION
FIGURE 2 PCNA promoter activity in HeLa and 293 cells. A human genomic DNA fragment containing nucleotides
-1269 to +60 (relative to the PCNA transcription initiation site at +1) fused to the CAT reporter gene contained
in the promoter-less plasmid pBACAT. Each construct was assayed by transfection into HeLa and 293 cells, and rela-
tive activities were determined by normalizing the experimentally determined CAT activities to that of the full-length clone.
1--C-1.77:77.7.77.71
NT +1-> +60
CAT ACTIVITY
HELA 293
1.0 1.0
1.1 0.9
1.0 1.2
0.6 0.9
0.2 0.3
0.2 0.1
0.2 0.1
0.7 0.3
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Prompted by these results, as well l asCNA after
by earlier
data showing increased expression
o P
infection with E1A-containing
adenoviruses, we
asked whether the PCNA promoter
could be trans-
activated by El products of adenovirus
expressed
from a plasmid. Cotransfection of
He La cells with
the adenovirus El region
(encoding both E1A and
E1B products) increased the activity of
all .the
promoter-CAT fusion constructs, with
the possible
exception of the -47 to + 60 construct,
whose basal
activity was so low that it is difficult to be
certain
that El was ineffective. These data imply that
at least
one El responsive element resides
between - 88 and
-47, or possibly between -88 and -2. Within the
region from - 88 to - 2, there are two sequence ele-
ments that have homology with known
targets for
trans-activation by the E1A 13S product. All of the
adenovirus early gene promoters apart from E1B
contain at least one E1A-responsive ATF site, and
a sequence that has perfect homology with a
CREB/ATF site is located in the PCNA promoter
surrounding nucleotide - 50. There is also limited
homology with E1A-responsive E2F sites at about
- 20 and -40. Current experiments are designed to
determine if these candidates are in fact El-
responsive elements and, if so, whether they are the
sole El-responsive elements in the PCNA promoter.
The El region of adenovirus produces several pro-
teins that influence gene expression: One of our goals
is to determine which of these proteins affect PCNA
and to delineate their roles. To this end, we first tested
the E1A and El B genes separately to discover if ei-
ther alone could recapitulate the trans-activation ob-
served by cotransfection with El. When cotrans-
fected singly with the PCNA-CAT reporter, neither
E1A nor El B trans-activated as well as the intact El
region, although in combination they were nearly as
effective as the El plasmid. To analyze matters fur-
ther, the two major E1A transcripts were placed un-
der the control of the strong cytomegalovirus pro-
moter, and the two major E1B gene products cloned
in a similar fashion were obtained from Dr. E. White
(DNA Synthesis, this section). These plasmids al-
low the four major E1A products to be synthesized
efficiently and independently.
Preliminary experiments with these clones indi-
cate that the E1A 13S and 12S gene products and
the EIB 19K gene product increase the levels of de-
tectable CAT activity upon cotransfection into HeLa
cells, whereas the EIB 55K gene product is without
effect. Stimulation by E1A 13S and E1B 19K was ex-
pected on the basis of the general trans-activation
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and DNA stabilization properties of these two prod-
ucts, but the E1A 12S gene product is best known
as a transcriptional repressor. However, its ability
to trans-activate the PCNA promoter is fully con-
sistent with observations, made previously in this lab-
oratory by Dr. E. Moran, that PCNA synthesis is
induced in baby rat kidney cells by infection with
an adenovirus expressing the 12S E1A gene product.
Experiments are under way to discover whether the
same promoter sequences are required for response
to each of these three El products and to more phys-iological stimuli such as serum.
Mechanism of trans-Activation
by HIV-1 Tat Protein
M.F. Laspia, M. Kessler, S. Gunnery,
A.R Rice, M.B. Mathews
The human immunodeficiency viruses, HIV-1 and
HIV-2, have been implicated in the pathogenesis
of acquired immunodeficiency syndrome (AIDS).
HIV-1 is prevalent in isolates from patients with
AIDS. It infects helper T cells, monocytes, and ner-
vous system cells, and following a prolonged latency,
it a period of active viral growth character-
ized by severe depletion of the helper T-cell popula-
tion. This renders the host immunocompromised and
susceptible to infection by opportunistic pathogens
as well as to neurological disorders.
In addition to the structural genes gag, pol, and
env, common to all nondefective retroviruses, HIV-1
encodes several novel regulatory genes. One of these,
tat, is an essential gene that greatly stimulates the
expression of genes directed by the long terminal re-
peat (LTR) of the virus. Tat acts via the TAR se-
quences located in the LTR downstream from the
site of transcription. The 5'-untranslated leader tran-
scribed from TAR is capable of forming a stem-loop
structure, and mutations that disrupt this structure
greatly reduce trans-activation by Tat. The mecha-
nism of Tat action remains controversial, as regula-
tion has been proposed to occur at several levels, but
in our hands, Tat appears to act principally at the
transcriptional level.
To explore the molecular mechanism of Tat ac-
tion, we employed a recombinant adenovirus con-
taining an HIV-1 LTR-CAT gene fusion in place of
the El region. This virus provides an efficient means
to deliver an HIV-1 LTR-driven reporter gene into
Tat-expressing or control cells. As described last year,
analysis of HIV-1-promoted cytoplasmic RNA re-
vealed two classes of correctly initiated transcripts
in He La cells. One class contains long, predomi-
nantly polyadenylated RNA and corresponds to full-
length transcripts; the other class contains short,
exclusively poly(A)- RNA, approximately 55-59
nucleotides in length, corresponding to terminated
or processed RNAs. Tat increases the accumulation
of full-length RNA at least 100-fold but does not
affect the accumulation of short transcripts. The
general trans-activator encoded in the adenovirus
ElA gene, on the other hand, increases the accumu-
lation of both full-length and short transcripts. These
results are consistent with Tat, as well as E1A, act-
ing to increase HIV-1-promoted transcription. This
is unlikely to be the only effect, however, since Tat
increases the level of full-length RNA without in-
creasing the short transcripts, whereas E1A increases
accumulation of both transcript classes.
To establish these conclusions more firmly, we
performed direct measurements of RNA synthesis
using nuclear run-on assays. The products were hy-
bridized to short single-stranded DNA probes cor-
responding to various regions of the gene, provid-
ing an estimate of transcription rates and RNA
polymerase distribution along the gene. In the ab-
sence of Tat, transcription in the promoter proximal
region is low and decreases sharply in the CAT gene:
This polarity suggests that the density of RNA poly-
merases on the template declines with increasing dis-
tance from the promoter. Tat produces a large in-
crease (over 15-fold) in transcription rate in the HIV-1
leader and also increases transcription of CAT se-
quences. Transcriptional polarity also occurs in the
presence of Tat, although to a lesser degree: About
30010 of the RNA polymerases in the leader region
transcribe into the CAT gene in the presence of Tat,
and only 1007o do so in its absence. ElA also produces
a large increase in promoter proximal transcription
and it increases transcription in the CAT gene se-
quences as well, but the sharp polar effect on tran-
scription is quantitatively similar to that seen with-
out trans-activators. The increase in transcription
rates brought about by Tat or E1A can be observed
within the first 24 nucleotides of the leader, suggest-
ing strongly an increase in transcriptional initiation.
Thus, as depicted in Figure 3, we conclude that Tat
and ElA both stimulate initiation and that Tat ad-
ditionally suppresses transcriptional polarity.
Studies with deletion mutants demonstrate that
TAR is required for the stimulation of HIV-1 tran-
scription by Tat but not by E1A, confirming that
TAR is not indispensable for a high level of HIV-1
transcription. Since the basal level of transcription
is neither increased nor decreased by the deletions,
TAR is neither a negative element (e.g., a termina-
tor) nor a positive element required for basal levels
of transcription. Although we do not fully under-
stand the nature of the interaction between Tat and
TAR, our findings are most readily consistent with
the hypothesis that Tat interacts with TAR at the
DNA level to promote the efficient formation of an
initiation complex capable of stable elongation. In
light of genetic evidence suggesting that the effect
of Tat is mediated by TAR RNA, it is also possible
that one or both of Tat's activities result from a novel
regulatory interaction (direct or indirect) with an
RNA structure formed immediately downstream
from the site of transcription initiation.
To explore further the mechanism of trans-acti-
vation by Tat, we are currently studying the combined
effects of Tat and E1A on HIV-1 LTR-directed gene
expression. At the level of CAT enzyme and mRNA
accumulation, these two trans-activators produce a
much greater than additive effect on reporter gene
expression. Synergy between Tat and other trans-
activators has been observed before, and the inter-
action between Tat and E1A may serve as paradigm
for such interactions. Consistent with the model pro-
posed above (Fig. 3), the effect of Tat on E1A-stim-
ulated RNA accumulation is similar to its effect on
basal transcription in that accumulation of full-
length RNA is increased but short transcripts are un-
affected. Interestingly, preliminary results from run-
on transcription assays suggest that the combined
effect of Tat and E1A produces no more than an ad-
ditive increase in promoter proximal transcription.
This observation implies that the synergistic trans-
activation is due primarily to stabilization of tran-
scriptional elongation rather than to an additional
stimulation of initiation, possibly because the latter
process is operating at maximal efficiency. We are
currently examining the effect of Tat and E1A to-
gether on transcription rates in the 3' end of the gene
to assess the role of stabilization of transcription
elongation in the synergy produced by these two
trans-activators. These studies will be extended to
an analysis of the basis of the synergy between Tat
and other transcriptional activators, such as phor-
bol esters.
An earlier study from Peterlin's laboratory (Kao
et al., Nature 330: 489 [1987]) reported that Tat in-
creases the efficiency of transcription elongation
without any effect on the level of transcription ini-
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FIGURE 3 A model for transcriptional activation of
HIV-1 gene expression by Tat. A schematic of the HIV-1 pro-
moter fused to the CAT reporter gene is shown on
the top line. In the absence of trans-activators (the second
line), very few RNA polymerases (depicted as half ellipses)
initiate transcription, and those that do disengage
from the template after transcribing a short distance. On
the third line, the HIV-1 trans-activator Tat interacts with
the TAR element to promote the formation of a modified RNA
polymerase complex (shaded ellipses) which ini-
tiates transcription efficiently and elongatesstably, resulting in a large increase
in expression of the reporter gene.
In the presence of a general trans-activator, the adenovirus El A protein (the fourth line), RNA polymerases initiate
efficiently but undergo transcription termination, resulting in a small
stimulation of CAT expression. (Reproduced,
with permission, from Laspia et al., Cell 59: 283 [19891.)
tiation. This study differed from ours in several nota-
ble respects, any or all of which could account for
the discrepant conclusions. First, whereas we used
a recombinant adenovirus to deliver HIV -1 LTR-CAT
template into human cells via viral infection, Kao
and co-workers introduced plasmids containing the
LTR-CAT sequences into monkey COS cells by trans-
fection techniques. Second, the transfected plasmid
contained an SV40 origin and replicated to high copy
number in the COS cells, whereas the recombinant
adenovirus experiments were conducted under non-
replicating conditions. Third, the plasmid construct
and the adenovirus recombinant were derived from
different sources (ARV2 and pU3RIII, respectively):
They exhibit sequence differences in the promoter
region and encode different lengths of HIV leader
(186 and 83 nucleotides, respectively). Finally, there
were of course variations in procedural details.
To assess the significance of these differences in
a systematic fashion, we are conducting run-on tran-
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scription assays using nuclei isolated from COS cells
transfected with replication-competent plasmids fol-
lowing the protocol of Kao et al. Preliminary data
suggest that cotransfection of a Tat-expressing plas-
mid with the pU3RIII-based construct results in a
substantial increase in transcription initiation and
a detectable, but lesser, increase in elongation. This
finding resembles that obtained with the recom-
binant adenovirus/HeLa cell system, although the
basal level of HIV-directed transcription (observed
in the absence of Tat) is higher in COS cells. How-
ever, a different result was obtained with the ARV2 -
based construct, where Tat functions primarily by
increasing the efficiency of transcription elongation.
Removal of the additional 3' leader sequences (cor-
responding to parts of the R and U5 segments of
the viral LTR) present in the ARV2-based construct
but not in the pU3RIII construct did not change the
result. This suggests that the source of the dis-
crepancy resides in the promoter or the TAR region,
and current work is aimed at pinpointing the se-
quences responsible. Bearing in mind the results ob-
tained in the adenovirus system, it is possible that
the ARV2 promoter can reach its maximal initiation
rate in the absence of Tat and the pU3RIII promoter
cannot.
Structural Analysis of HIV
Tat Proteins
A.P Rice, C.O. Echetebu, F. Carlotti,
M. Sullivan, R. Packer
We are interested in gaining an understanding of the
structural features of the Tat protein that are
important for its function. Such an understanding
is crucial for the rational design of inhibitors of the
protein that could be used in treating AIDS. Tat is
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essential for HIV replication, and the molecular
mechanisms involved in Tat trans-activation appear
to be unique to HIV-1, HIV-2, and some closely
related lentiviruses. Inhibitors of Tat function may
therefore specifically block HIV replication. The Tat
protein from HIV-1 isolate HXB2 consists of 86
amino acids and has three regions with notable
sequence features (Fig. 4A). The amino terminus is
proline-rich, containing five prolines within the first
18 residues. This region is followed by a cysteine-rich
region, with seven cysteines from residue 22-37. The
cysteine-rich region is capable of binding metal ions,
either Zn" or Cd"; Tat expressed and purified from
Escherichia coli exists as a homodimer with four
metal ions bound per dimer. The cysteine-rich region
is followed by a basic region, with eight lysines or
arginines between residues 49 and 57. The basic
region serves as a nuclear localization signal, similar
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FIGURE 4 HIV-1 Tat protein. (A) The Tat protein from HIV-1 isolate HXB2 is shown. The initiator methionine and seven cys-
teine residues are indicated by closed circles; the basic region, a nuclear localization signal, is indicated by the box. Predicted
sites of cleavage by trypsin are indicted by arrows: Note that the basic region contains eight cleavage sites. The trypsin
cleavage site at residue 78 is indicated by an asterisk; a single cleavage of wild-type Tat at this site results in a molecule
that is relatively resistant to subsequent cleavage. (B) The trans-activation activities of Tat proteins possessing single muta-
tions between residues 18 and 47 are summarized. Those mutants indicated by circles are equivalent to wild type in activity,
those indicated by asterisks possess 10-30% wild-type activity, and those indicated by triangles possess less than 10%
wild-type activity. The cysteine mutants, analyzed by ourselves and other groups, contain substitutions of glycine or serine
for cysteine. The noncysteine mutants contain substitution of alanine for the wild-type residue.
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to that first observed and
characterized in SV40 large
T antigen.
Last year, we reported the construction and
tial characterization of a collection
of 24 mutant Tat
proteins. Because of the small size
of the Tat pro-
tein, the collection represents mutations
throughout
the entire molecule. In most cases,
the mutant pro-
teins contain substitutions of a single wild-type
amino acid. The mutant proteins were constructed
by site-directed mutagenesis, and their trans-acti-
vation activities were measured by plasmid DNA
transfection experiments. Results of this analysis
are
summarized in Figure 4B. To investigate the struc-
ture-function relationships of the Tat protein, we
expressed wild-type and mutant Tat in analytical
amounts in a wheat germ cell-free translation sys-
tem. Wild-type and 15 selected mutant cDNAs were
cloned into a riboprobe vector, allowing the produc-
tion of pure mRNAs by in vitro transcription. These
mRNAs were translated in the wheat germ system,
giving a single radiolabeled protein for structural
analysis.
We initially employed trypsin as a probe for the
structure of Tat protein, based on the rationale that,
under limiting conditions, proteases digest proteins
preferentially in unstructured regions. Trypsin first
cleaves wild-type Tat near its carboxyl terminus, most
likely at residue 78, and the singly cleaved Tat is then
relatively resistant to further digestion. Some mu-
tant Tat proteins with low trans-activation activities
do not display this relative resistance to trypsin, be-
ing up to 100-fold more sensitive than wild-type Tat.
Therefore, these mutant Tat proteins are significantly
less structured than the wild-type protein when ex-
pressed in the wheat germ system. Their altered struc-
ture probably explains these mutants' low trans-
activation activities in human cells. A second class
of mutant Tat proteins also exhibit low trans-activa-
tion activity but display trypsin sensitivity identical
to that of wild-type Tat. The mutations in this class
may identify regions, or even individual amino acids,
that are directly involved in protein-protein or pro-
tein-nucleic acid interactions that are important in
the trans-activation process. Interestingly, to date,
all the members of this second class of mutations,
low in trans-activation activity but wild-type in over-
all structure, are located between residues 18 and 29.
Metal ions can be manipulated in the wheat germ
system, and the effects on Tat structure can be ana-
lyzed. Pretreatment of wheat germ-expressed Tat
with EDTA results in a more than tenfold increase
in sensitivity to trypsin. Presumably, EDTA removes
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endogenous Zn" or Cd" bound to Tat and causes
destructuring of the molecule. Addition of excess
Cd" after EDTA treatment results in partial resto-
ration of Tat to its trypsin-resistant state. Initial ex-
periments demonstrate that some mutant proteins
are deficient in these apparent interactions with metal
ions. We are currently assaying our collection of mu-
tants to correlate trans-activation activity with the
ability to interact with metal ions. Future work will
also use wheat germ-expressed Tat to investigate di-
rect binding of the Tat protein with TAR RNA.
We have initiated similar studies with the Tat pro-
tein of HIV-2, a human immunodeficiency virus iso-
lated from western Africa. HIV-2 is closely related
to HIV-1 both in genetic organization and in nucleo-
tide sequence, but displays significant biological
differences. It appears that a much lower percent-
age of individuals infected with HIV-2 develop
AIDS. The HIV-1 and HIV-2 Tat TAR systems share
interesting cross-trans-activation properties: The
HIV-1 Tat protein can fully trans-activate both the
HIV-1 and HIV-2 LTRs; however, the HIV-2 Tat pro-
tein can fully trans-activate its cognate HIV-2 LTR
but can only partially trans-activate the HIV-1 LTR.
To gain insight into structural features of Tat pro-
teins important for the trans-activation process, we
are analyzing similarities as well as differences be-
tween the HIV-1 and HIV-2 Tat proteins. As with Tat-
1, the first coding exon of Tat-2 is fully competent
for trans-activation activity. The first coding exon
of Tat-2 encodes 99 amino acids, and the first cod-
ing exon of Tat-1 encodes 72 amino acids. The se-
quences of the two proteins are highly conserved in
the center of the molecules, including the cysteine-
rich and basic regions (residues 22-57 of Tat-1 and
residues 49-84 of Tat-2), but their termini show con-
siderable divergence. To define structural features of
the Tat-2 protein that are important for activity, we
are using site-directed mutagenesis to construct a col-
lection of mutant proteins that will be assayed for
trans-activation activity following the procedure de-
scribed in last year's Annual Report for analysis of
the HIV-1 Tat protein. We have inserted the first cod-
ing exon of the HIV-2 Tat gene into an expression
vector, pSVL, that has three important features: (1)
Tat is under control of the SV40 late promoter; (2)
the plasmid contains the SV40 origin of replication,
allowing high-level expression in COS cells; (3) the
plasmid contains the bacteriophage fl origin, allow-
ing production of single-stranded DNA for muta-
genesis and DNA sequence analysis. Preliminary as-
says have shown that the pSVL/Tat-2 expression
vector trans-activates the HIV-2 LTR by more than
20-fold and that the pSVL/Tat-1 and pSVL/Tat-2
expression vectors fully trans-activate the HIV-2
LTR, whereas only the pSVL/Tat-1 vector fully trans-
activates the HIV-1 LTR.
We will use the pSVL/Tat-2 vector to construct
and analyze mutant Tat-2 proteins. We will construct
proteins truncated at the carboxyl terminus to de-
termine the maximum deletion that retains activity.
We expect, if Tat-1 can be used as a paradigm, that
the Tat-2 protein truncated after residue 84 will re-
tain partial activity, but further truncations will abol-
ish activity. In addition, the amino terminus of Tat-
2 is relatively acidic, containing 9 acidic residues
within the first 49 amino acids, and is predicted to
exist in an a-helical structure. The amino terminus
of Tat-2 is therefore reminiscent of the activating do-
mains of transcription factors that are sequence-
specific DNA-binding proteins. To determine if the
acidic residues in the amino terminus of Tat-2 are
important for activity, we will substitute alanine for
the wild-type residues in individual proteins. We will
also construct chimeras between the Tat-1 and Tat-2
proteins in an attempt to define regions of the pro-
teins involved in full trans-activation of the HIV-1
and HIV-2 LTRs.
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romolecular complex called the spliceosome. Al-
though density gradient sedimentation and native
gel analysis can be used to identify this stable com-
plex, these techniques fail to purify the complex suf-
ficiently to allow the identification of its protein con-
stituents; in addition, after these techniques are used,
the complex is not amenable to ultrastructural anal-
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ysis. In an effort to isolate native
spliceosomes, we
have developed a new isolation technique.
Splicing extracts contain endogenous
complexes
that copurify with spliceosomes
formed on ex-
ogenously added pre-mRNA substrates.
Unlike sev-
eral purification schemes previously
used by others,
our purification method involves
the removal of
these contaminating particles from extracts
prior to
the addition of exogenous RNA substrate.
Splicing
extracts are first incubated under splicing conditions
without the addition of exogenous RNA substrate.
We have found that during this preincubation, sev-
eral splicing factors, including the small
nuclear ri-
bonucleoprotein particles (snRNPs), are released
from large complexes. This pretreated extract
is then
subjected to sucrose gradient fractionation, and ma-
terial less than 30S is collected. These upper gradient
fractions contain all of the factors necessary for in
vitro pre-mRNA splicing. If this extract is then used
for in vitro splicing with the addition of the exoge-
nous pre-mRNA substrate and fractionated by su-
crose gradient sedimentation, the spliceosomes
formed on the exogenous substrate sediment as a 45S
complex into a clean portion of the gradient.
Using these pre-cleared extracts, we have inves-
tigated the kinetics of spliceosome formation using
native gel With the pre-cleared extract,
complex formation is accelerated, perhaps due to the
prior release of splicing factors from endogenous
complexes. Cleared extracts have also allowed us to
analyze the snRNA composition of the spliceosome,
and, as noted by others, we find that the abundant
nucleoplasmic snRNAs Ul through U6 are present
in the spliceosome. In agreement with other investi-
gators, we have found that the U4 snRNA is under-
represented in the spliceosome, consistent with the
model that U4 snRNP leaves the spliceosome prior
to the first step of splicing. We are presently con-
ducting ultrastructural studies of splicing complexes
in collaboration with David Spector (Molecular
Genetics of Eukaryotic Cells Section). Our approach
is to use biotinylated pre-mRNA substrates in splic-
ing reactions with the pre-cleared extracts. Purified
splicing complexes are being tagged using 1-nm strep-
tavidin gold particles. It is hoped that the substan-
tial purification which we achieve using cleared ex-
tracts coupled with gold particle tagging will allow
us to identify splicing complexes unambiguously.
This should open the door to more-detailed ultra-
structural characterizations such as epitope mapping
using monoclonal antibody probes.
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Biochemistry of Mammalian
Pre-mRNA Splicing
A.R. Krainer, D. Kozak, N. Pecina
The long-term aim of our research is to obtain a
detailed understanding of the mechanism of pre-
mRNA splicing in mammalian cells. In particular,
we are interested in determining how the RNA
cleavage-ligation reactions are catalyzed and how the
specificity of splice-site selection is achieved. As part
of this effort, we are purifying several of the nucleo-
protein and protein factors that are necessary for
cleavage of the pre-mRNA at the 5' splice site and
for lariat formation. Our general strategy is to de-
velop complementation assays for individual activi-
ties, such that one or both cleavage-ligation reactions
are strictly dependent on the presence of the active
component in question. The factors responsible for
these activities are purified and then characterized
to determine their mode of action. The identifica-
tion and detailed characterization of splicing factors
should provide crucial insights into the mechanism
of pre-mRNA splicing, the specificity of splice-site
selection, and the origin and evolution of the splic-
ing machinery and of pre-mRNA introns.
Purification and Characterization
of Splicing Factors
A.R. Krainer, D. Kozak [in collaboration with G. Conway,
Cold Spring Harbor Laboratory]
SF2 PURIFICATION
Our previous work demonstrated that the cytoplas-
mic S100 fraction obtained during the preparation
of nuclear extracts contains active small nuclear ri-
bonucleoproteins (snRNPs) and other splicing fac-
tors, but it is usually deficient in at least one protein
activity, termed SF2, which is necessary for the first
cleavage-ligation of pre-mRNA splicing. The reason
for the selective retention of SF2 in the nuclear frac-
tion in a hypotonic buffer is not known. It may be
that the polypeptides responsible for SF2 activity are
tightly bound to the nuclear membrane or to a sub-
nuclear structure. Alternatively, SF2 is part of large
RNP complexes, which cannot traverse the nuclear
pores in their intact form. In fact, sedimentation
analysis showed that SF2 and other splicing factors
are associated with large endogenous RNP coin-
plexes in nuclear extracts. To facilitate the purifica-
tion of SF2, we developed a different extract prepa-
ration procedure, which maximizes the recovery of
SF2, as judged from titrating the extracts against a
constant amount of complementing S100 fraction.
From this extract, SF2 has been purified to appar-
ent homogeneity by conventional chromatography
and FPLC, using complementation of the S100 ex-
tract as a functional assay.
The polypeptide composition of the fractions
from the last column, Phenyl Superose, was analyzed
by SDS-PAGE to try to identify the polypeptide(s)
responsible for SF2 activity (Fig. 1). In the first ac-
tive fraction (Fig. 1A, lane 3), only a doublet of 33
kD is detectable by Coomassie blue (Fig. 1B, lane
3) or silver staining. Complementing activity peaks
in the adjacent fraction (lane 4), which also corre-
sponds to the 33-kD doublet peak. This fraction con-
tains additional polypeptides. Complementing ac-
tivity was also detectable in the next three fractions,
although it did not correlate well with the presence
of the 33-kD doublet. A second peak of activity was
detected in fraction 16, which contains, among other
bands, a polypeptide that comigrates with the top
band of the 33-kD doublet. On the basis of these
data, in particular the presence of complementing
activity in fraction 3, we conclude that SF2 activity
is most likely encoded by one or both of the 33-kD
polypeptides, although there may also be other poly-
peptides with SF2 activity. At this stage, we cannot
rule out the existence of very minor polypeptides that
are responsible for activity. We have shown that the
33-kD polypeptides are distinct from the heteroge-
neous nuclear RNP (hnRNP) Al and Ul snRNP A
polypeptides, which are similar in size. A small
amount of endogenous hnRNA copurifies with the
SF2 polypeptides, but SF2 activity does not appear
to require an essential RNA component, as judged
from its resistance to micrococcal nuclease treament.
RNA-BINDING PROPERTIES OF SF2
To determine whether purified SF2 binds RNA, sev-
eral types of analyses were carried out. Ultraviolet
cross-linking demonstrated binding to pre-mRNA
and to mRNA. In this type of analysis, when the
cross-linked material is extensively digested with
ribonuclease A, the protein-oligoribonucleotide ad-
ducts usually comigrate or migrate slightly behind
the untreated polypeptides on SDS-PAGE. In the
case of SF2, the labeled adducts comigrate with the
33-kD doublet, as expected if both polypeptides bind
RNA. No RNA binding was detected by North-
western blotting, but this could be due to poor
renaturation after SDS-PAGE. We have not been
able to separate the two polypeptides by nondenatur-
ing techniques, and thus we cannot presently deter-
mine whether only one or both are responsible for
the observed activities. However, amino acid analy-
sis of the individual electrophoretically separated
polypeptides suggests that they are highly related.
The above experiments showed more efficient cross-
linking to mRNA than to pre-mRNA, which may
reflect the higher-order structure of these RNAs or
perhaps efficient binding or cross-linking to the
spliced exon borders.
Footprinting experiments were carried out by par-
tial modification of globin pre-mRNA with di-
methylsulfate, followed by primer extension, and by
partial digestion of end-labeled pre-mRNA with
ribonucleases. No specific footprint was observed,
suggesting that at least in the absence of other com-
ponents, SF2 does not bind pre-mRNA in a se-
quence-specific manner. However, since we do not
know what fraction of the SF2 molecules was active
in these experiments, and since detection of a foot-
print requires efficient binding, sequence-specific
RNA binding by SF2 cannot be completely ruled out.
SF2 IS REQUIRED FOR SPLICEOSOME FORMATION
The complementation assay employed for the purifi-
cation of SF2 indicates that this activity is required
for cleavage of the pre-mRNA at the 5' splice site
and lariat formation. This reaction is normally
preceded by the assembly of specific pre-spliceosome
and spliceosome complexes, in which pre-mRNA in-
teracts in a stable manner with multiple components
of the splicing apparatus, such as the U snRNPs. To
determine the requirement for SF2 in this assembly
pathway, RNP complexes were analyzed by a gel-
retardation assay. Under the electrophoretic condi-
tions employed, three specific complexes are nor-
mally detected. When pre-mRNA is incubated with
the S100 extract under splicing conditions, no spe-
cific complexes are detected. Incubation of pre-
mRNA with purified SF2 also fails to generate spe-
cific complexes of discrete mobility. A smear is
detected under these conditions, which is consistent
with nonspecific RNA binding by SF2, as detected
with the assays described above. In contrast, when
pre-mRNA is incubated with purified SF2 and S100,
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FIGURE 1 Phenyl Superose column profile. (A) SF2 complementation assay. Splicing reactions
were carried out with the S100 extract plus the indicated chromatographic fractions. Roman numerals
indicate fractions from preceding chromatographic steps. Numbers 1 through 28 correspond to
the Phenyl Superose fractions. The pre-mRNA, intermediates, and products of splicing are indi-
cated at the left of the autoradiogram. (B) Polypeptide composition. The proteins in the indicated
fractions were analyzed by SDS-PAGE, followed by Coomassie blue staining.
three discrete complexes are detected, which have the
same mobility as the specific complexes obtained
with the nuclear extract. We conclude that SF2 is re-
quired for the assembly or the stabilization of the
earliest specific complex in the spliceosome assem-
bly pathway, which is thought to be the A complex.
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SF2 HAS AN RNA ANNEALING ACTIVITY
We have tested purified SF2 for possible RNA heli-
case and/or annealing activities (Fig. 2). Com-
plementary 32P-labeled RNAs were incubated with
purified SF2 in splicing buffer in the presence or ab-
sence of ATP. After incubation, digestion with
TI - -
ATP - -
SF2 - -
ANTI-SENSE -
SENSE -
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+ + + + + + + + TI
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FIGURE 2 RNA annealing and helicase assays. Individual or
pre-annealed complementary RNAs were incubated as described
in the text and figure diagram and digested with ribonuclease
Ti. The digestion products were analyzed by denaturing PAGE
and autoradiography.
ribonuclease Ti was carried out, and nuclease-
resistant double-stranded RNAs were detected by de-
naturing PAGE. In the absence of protein, com-
plementary RNAs do not anneal under these buffer
conditions at 30°C, due to the higher-order struc-
tures of the individual strands (Fig. 2, lanes 3 and
5). Annealing requires an initial incubation at high
temperature to eliminate these intramolecular helices.
However, in the presence of SF2, rapid annealing can
take place at 30°C, with or without ATP (Fig. 2, lanes
4 and 6). When the complementary strands are pre-
annealed, SF2 does not melt them, even when ATP
is present (Fig. 2, lanes 8 and 10). In summary, SF2
lowers the activation energy for intermolecular RNA
duplex formation, and thus behaves as an RNA an-
nealing activity. The 35-kD hnRNP Al protein has
been shown to have helix destabilizing properties on
double-stranded RNA. Under some conditions, this
lowering of the melting temperature by hnRNP Al
can promote RNA annealing (S. Munroe, pers.
comm.). We therefore tested purified Al (kindly
provided by S. Wilson, National Institutes of Health)
to see if it could substitute for SF2 in the splicing
complementation, exon skipping (see below), and
RNA annealing assays. Concentrations of Al that
were active in RNA annealing did not substitute for
SF2 in the other assays. These observations suggest
that if RNA annealing activity is integral to SF2 and
necessary for splicing, it is not sufficient, implying
that specific protein-protein or protein-RNA inter-
actions are involved in mediating the role of SF2 in
splicing and splice-site selection.
Further experiments are necessary to elucidate the
precise substrate specificity, if any, of the SF2 RNA
annealing activity. However, we can envisage three
types of complementary RNA targets upon which
the SF2 RNA annealing activity could act to medi-
ate its effects on splicing and splice-site selection.
First, at least two snRNA-pre-mRNA helices are
known to be formed during splicing and to contrib-
ute to splice-site selection; these involve base-pairing
interactions between the 5' terminus of Ul snRNA
and pre-mRNA 5' splice sites and between an inter-
nal region of U2 snRNA and pre-mRNA branch-
point sequences. Second, U4 and U6 snRNAs coex-
ist in a single snRNP particle held together by
intermolecular base pairs, and there is some evidence
that the U4 subunit may be released from the spliceo-
some during the course of splicing, possibly to be
recycled. Third, pre-mRNA may be recognized as a
proper splicing substrate when it adopts a defined
secondary and tertiary structure. Some of the in-
tramolecular RNA helices may preferentially expose
the splice sites and branchpoint.
SF2 INFLUENCES 5' SPLICE SITE SELECTION
Ul and U2 snRNAs play important roles in splice-
site selection, by virtue of their ability to interact by
intermolecular RNA-RNA base pairing with 5' splice
sites and branchpoint sequences, respectively. How-
ever, these interactions are not sufficient to account
for the specificity of splice-site selection. Splice sites
are often surrounded by cryptic splice sites that are
only activated upon mutation of the natural splice
sites. It is not known whether the same set of fac-
tors that recognize natural splice sites are also capa-
ble of recognizing the cryptic sites when the natural
sites are mutated. Furthermore, although 5' and 3'
splice sites from different introns are usually com-
patible, the splicing machinery normally avoids exon
skipping, by an unknown mechanism. Many genes
are capable of expressing multiple protein isoforms
by using alternative 5' and/or 3' splice sites, often
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in a regulated manner. Again, it is not known how
this type of mechanism is controlled. Finally, it ap-
pears that in addition to the conserved 5', 3', and
branchpoint sequence elements, additional, poorly
defined sequences in exons and introns can also in-
fluence splice-site selection and splicing efficiency.
It is not known how these context elements exert their
effects. We have investigated whether SF2 plays a role
in splice-site selection, in addition to its more general
role in the splicing reaction.
The in vitro splicing system derived from He La
nuclear extracts generally follows the same hierar-
chy rules that are followed in the cell, with respect
to the recognition of bona fide versus cryptic splice
sites. For example, a 13-thalassemic allele of human
13-globin that contains a G--.A transition at position
1 of the first intron cannot express normally spliced
mRNA in detectable quantities, either in vivo or in
vitro. Instead, three cryptic 5' splice sites are acti-
vated (Fig. 3, top). The predominant spliced mRNA
detected in vitro corresponds to use of the first up-
stream cryptic 5' splice site, whereas the second up-
stream cryptic 5' splice site and thedownstream cryp-
tic 5' splice site are used only in a small proportion
of the pre-mRNA molecules (Fig. 3, bottom, lane
11). It is noteworthy that these cryptic sites are com-
pletely silent in the context of the wild-type allele.
When wild-type 13-globin pre-mRNA is spliced in
the reconstituted in vitro system consisting of crude
S100 extract and pure SF2, the intermediates and
products are virtually indistinguishable from those
obtained with the nuclear extract (Fig. 3, lanes 2 and
4). When pre-mRNA derived from the thalassemic
allele is spliced in the same system, no wild-type
mRNA is generated, and two of the three cryptic sites
are activated (Fig. 3, lane 13). Surprisingly, the down-
stream cryptic 5' splice site is now the preferred site,
whereas the first upstream cryptic is used at a low
level, and the second upstream cryptic is not used
at a detectable level (compare lanes 13 and 11). To
determine whether this unique pattern reflects differ-
ences in the concentration of SF2 and/or other
differences between the two extracts, we carried out
titrations of SF2 while holding the amount of S100
extract constant. The extent of utilization of the
downstream cryptic site was directly proportional to
the concentration of SF2 (Fig. 3, lanes 12-16). In the
absence of SF2, the S100 alone was unable to sup-
port any splicing reaction with either the wild-type
or the mutant pre-mRNA (not shown). With the mu-
tant substrate, the first upstream cryptic site was used
at a roughly constant low level over a broad range
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of SF2 concentration. Remarkably, the highest con-
centration of SF2 inhibited all splicing with the mu-
tant but not with the wild-type pre-mRNA (Fig. 3,
lanes 3 and 12).
We next tested whether addition of excess puri-
fied SF2 to the nuclear extract would affect splice-
site selection. No effect was observed with the wild-
type pre-mRNA (Fig. 3, lanes 9 and 10); in contrast,
with the thalassemic pre-mRNA, addition of SF2
again activated the downstream cryptic 5' splice site
(Fig. 3, lanes 18 and 19). The first upstream cryptic
site was still used at a high level, but the second up-
stream cryptic site was inactive. These results indi-
cate that the concentration of SF2 can affect the use
of cryptic 5' splice sites. In particular, the internal
cryptic site is favored. We also infer that there are
other differences between the nuclear extract system
and the S100 plus SF2 system. The nuclear extract
already contains some SF2, which is an essential
splicing factor. Even when further supplemented
with purified SF2, the nuclear extract still efficiently
used the first upstream cryptic splice site, whereas
under all conditions employed, the S100 system could
only use this site inefficiently.
Previous studies have shown that the sequence
context surrounding splice sites could influence their
use by the splicing apparatus. cis-competition studies
employing duplicated splice sites have demonstrated
this context effect and have also suggested that when
comparable splice sites are present in cis, the splic-
ing machinery favors the use of the internal sites.
However, if the internal sites are weaker, due, for ex-
ample, to an unfavorable sequence context, then the
external sites are preferred. We have employed sev-
eral pre-mRNAs containing duplicated 5' or 3' splice
sites (kindly provided by R. Reed, Harvard Medical
School) to analyze the mode of action of SF2 (Fig.
4). Substrate 2 contains a short duplication of the
13-globin first intron 5' splice site and surrounding
sequences. Substrate 3 contains a longer duplication
of this site. As shown previously, the external 5' splice
site is used when substrate 2 is spliced in nuclear ex-
tracts (Fig. 4, lane 2, NE), due to an insufficient se-
quence context surrounding the internal duplicated
site. In the case of substrate 3, which contains a larger
duplication, the internal 5' splice site is used exclu-
sively (Fig. 4, lane 3, NE). When the same substrates
are spliced by S100 extract plus purified SF2, the in-
ternal splice site is used exclusively, even in the case
of substrate 2, which contains the short duplication
(Fig. 4, lanes 2 and 3, S100 + SF2). When the nu-
clear extract is supplemented with SF2, there is a par-
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FIGURE 3 Effect of SF2 on cryptic 5' splice-site utilization. (Top) The structure of humanI3-globin
pre-mRNA is shown at the bottom of the diagram, with all potential splices indicated. The nucleotide
sequence of the region surrounding the first intron 5' splice-site is shown at the top. Thenatural
and cryptic 5' splice-site sequence elements are indicated in boldface, with the invariant GU
dinucleotides underlined. The single-base (3-thalassemia mutation that results in cryptic 5' splice-site
activation is shown. The exon-intron boundary is shown schematically below the sequence. (Bot-
tom) Splicing reactions (25 pi) were carried out with the indicated microliter amounts of nuclear
extract (NE), S100 fraction, and purified SF2. The substrates were truncated pre-mRNAs con-
taining the first two exons and first intron of wild-type (lanes 1-10) or thalassemic (lanes 11-20)
humanI3-globin alleles. The electrophoretic mobilities of wild-type pre-mRNA, intermediates, and
splicing products are indicated schematically at the left of the autoradiogram. Wild-type mRNA
is 367 nucleotides; mRNA spliced via cryptic splice site 1 is 329 nucleotides; mRNA spliced
via cryptic splice site 2 is 351 nucleotides; and mRNA spliced via cryptic splice site 3 is 379
nucleotides.
tial switch to the internal duplicated 5' splice site in
the case of substrate 2 (Fig. 4, lane 2, NE + SF2).
Thus, high concentrations of SF2 can compensate
for the poor context surrounding the internal dupli-
cated 5' splice site.
Two additional substrates containing different size
duplications of the human (3-globin first intron 3'
splice site were also tested in the different extracts.
In nuclear extract, substrate 4 is spliced exclusively
via utilization of the external duplicated site. In con-
trast, substrate 5, which contains a larger duplica-
tion, uses predominantly the internal site, although,
in a minor proportion of the pre-mRNA molecules,
the external 3' splice site is chosen. Identical splic-
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FIGURE 4 Effect of SF2 on artificial alternative 5' splicing substrates. The
six pre-mRNA substrates are shown sche-
matically at the right of the autoradiogram. Shaded areas represent the
duplicated exon and intron sequences. Sub-
strate 1 is a wild -type 3- globin truncated pre-mRNA. Substrates
2 and 3 contain duplications of the first intron 5' splice
site and surrounding exon and intron sequences. Although not
shown in the diagram, pre-mRNA 2 is longer than
pre-mRNA 3 due to the presence of non-13-globin sequences at the
duplication junction. Substrates 4 and 5 contain
duplications of the first intron 3' splice site and surrounding exon and intron sequences.
Substrate 6 contains duplica-
tions of both the 5' and 3' splice sites and their respective surrounding sequences.
The angled lines represent all
the possible splicing events. The bold angled lines represent splicing events that are promoted by high concentra-
tions of SF2. Splicing reactions were carried out with nuclear extract, nuclear extract
supplemented with additional
purified SF2, and S100 extract plus purified SF2, as indicated at the top of the autoradiogram.
ing patterns were obtained with the S100 extract sup-
plemented with SF2. With nuclear extract sup-
plemented with SF2, there was slightly less efficient
use of the external 3' splice site. These results indi-
cate that SF2 does not strongly influence the selec-
tion of competing 3' splice sites. Finally, a construct
containing duplications at both 5' and 3' splice sites
was processed in the different in vitro systems (sub-
strate 6). In nuclear extract, the external 5' and 3'
splice sites were recognized, as expected from previ-
ous studies. However, in the S100 + SF2 system, or,
to some extent, in SF2-supplemented nuclear extract,
the internal 5' splice site and the external 3' splice
site were selected.
In summary, SF2 promotes the utilization of prox-
imal 5' splice sites and has no effect on 3' splice-site
selection. The molecular mechanism responsible for
this effect remains unknown, but its elucidation
should help clarify our understanding of splice-site
selection. Since the observed effect is targeted at 5'
splice sites, it is tempting to speculate that it relates
to the Ul snRNA-5' splice-site interaction, perhaps
involving the intermolecular RNA-RNA annealing
activity described above. On the other hand, the U2
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snRNA-branchpoint interaction could also have an
indirect effect on 5' splice-site selection, since the
branchpoint A and the 5' terminus of the intron are
joined to form a lariat. It is unclear, however, and
of great importance why high concentrations of SF2
promote selection of the proximal 5' splice sites. We
plan to examine more substrates to determine
whether this is simply a coincidence and thus
whether in some cases, distal sites are favored.
The striking effect of SF2 on in vitro 5' splice-site
selection in mutant and artificial constructs suggests
a plausible mechanism for the in vivo regulation of
alternative splicing in at least some cases. A variety
of transcription units are alternatively spliced in a
tissue-specific or developmentally controlled man-
ner. In those cases involving alternative 5' splice-site
utilization, regulation might be accomplished by
controlling the levels of activity of SF2 or a similar
factor. Regulation of SF2 activity could be achieved
by posttranslational modification. Analogous mech-
anisms could operate to regulate 3' splice-site selec-
tion. Our observations show that the concentration
of an essential splicing factor can affect splice-site
selection. It seems likely that this also applies in the
case of other splicing factors as well. In collabora-
tion with D. Helfman (Molecular Genetics of Eu-
karyotic Cells Section), we are currently analyzing
whether SF2 can influence alternative splicing of rat
tropomyosin pre-mRNAs in vitro.
CLONING OF SF2 AND OTHER BIOCHEMICAL STUDIES
We are presently trying to elucidate the structural
relationships between the two SF2 polypeptides. This
task has proved difficult due to our inability so far
to obtain antibodies that react by a Western blot as-
say. Antibodies generated against native SF2 immu-
noprecipitate a doublet of 33K polypeptides and a
55K polypeptide from 35S-labeled He La cells. We
do not know at present if the 55K band represents
a subunit of SF2 or a cross-reacting polypeptide. The
purified 33K polypeptides have been isolated elec-
trophoretically, and their amino acid composition
was determined by the Protein Chemistry Facility.
By this criterion, the polypeptides appear to be
related. The SF2 polypeptides also yielded a single,
limited amino-terminal amino acid sequence. This
sequence is identical to that of a slightly smaller poly-
peptide, which is inactive, and may arise by partial
proteolysis. On the basis of the latter amino acid se-
quence, we used the polymerase chain reaction
(PCR) to generate a specific probe from first-strand
He La cell cDNA. This unique probe was used to iso-
late a cDNA clone. We are currently determining the
nucleotide sequence of this cDNA, as well as gener-
ating antibodies against a fusion protein expressed
in Escherichia coli. These experiments should help
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Regulation of transcription in mammalian cells is
best characterized as combinatorial and modular.
Unlike the more streamlined and highly evolved bac-
terial regulatory networks, eukaryotic transcription,
particularly in multicellular organisms, is controlled
clarify the structural relationships among the vari-
ous polypeptides and allow a more precise defini-
tion of the structure and function of SF2.
Another project is being done in collaboration
with G. Conway (Tumor Viruses Section), to con-
tinue the purification of SF4B, another polypeptide
factor necessary for 5' splice-site cleavage and lariat
formation. When the purification is completed,
SF4B will be used together with SF2 and our puri-
fied snRNPs to attempt to reconstruct the pre-
spliceosome and spliceosome assembly pathway and
to determine whether these factors are sufficient to
catalyze the first cleavage-ligation reaction.
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by baroque arrays of cis-acting binding sites for
trans-acting factors. This complexity is increased by
the propensity of proteins that activate transcription
to bind to grossly divergent DNA sequences and for
multiple different transcription factors to bind to the
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same site. These transcription factors are frequently
modular, consisting of separate domains for DNA
binding (e.g., homeodomains and zinc fingers) and
transcriptional activation (e.g., acidic and glutamine-
rich domains). To probe transcriptional regulation
in mammalian cells, we study the bidirectional
SV40
transcriptional regulatory region. In past years,
we
analyzed the arrangement of cis-acting elements;
more recently, we have characterized trans-acting fac-
tors that regulate transcription.
Our analysis of transcription factors has been con-
centrated on understanding differential transcrip-
tional activation by the ubiquitous and lymphoid-
specific octamer motif-binding proteins Oct-1 and
Oct-2. The recent discovery that these two activa-
tors are homeodomain proteins and therefore related
to proteins that direct development of the fruit fly
Drosophila melanogaster has integrated our tran-
scriptional studies with studies of development. One
of the challenges in the field of Drosophila devel-
opment is to understand how homeodomain proteins
that bind to very similar DNA sequences can have
very different effects on development. Because Oct-
1 and Oct-2 bind to the same DNA sequence but are
known to activate transcription differentially, they
serve as examples of how developmental regulation
may occur in Drosophila. Last year, we discovered
that protein modification and protein:protein inter-
actions involving Oct-1 and Oct-2 can be used to dis-
tinguish between homeodomain proteins that bind
to the same sequence.
Transcriptional Activation by
SV40 Enhancer Elements
B. Ondek
During past years, much of our effort was devoted
to understanding the underlying structure of the
SV40 enhancer. These studies, together with studies
by R Chambon and colleagues (Strasbourg), showed
that the SV40 enhancer is composed of many differ-
ent individual units or cis-acting elements that come
together in different ways to create an enhancer. The
individual units, which we refer to as enhansons, rep-
resent protein-binding sites and can be classified into
different groups by their intrinsic ability to enhance
transcription. Thus, certain enhansons (class A) can
cooperate with copies of themselves or other enhan-
sons to activate transcription, but only when ap-
propriately juxtaposed in pairs. The appropriately
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juxtaposed binding sites are referred to as protoen-
hancers because duplication of these elements, with-
out strict spacing requirements, can create a potent
enhancer. Enhansons of the second class, class 13,
cannot enhance transcription alone or as duplicates
of themselves but instead must cooperate with a
class-A enhanson to be active. The third class of en..
hansons (class C) does not require precise juxtapo-
sition with a second enhanson for activit y, and thus
these enhansons individually display protoenhancer
activity. The octamer motif (ATGCAAAT) found
within the SV40 enhancer is an example of a class-
C enhanson. The large number and multiple activi-
ties of SV40 enhansons help explain the complex
structure of this enhancer.
We have now compared the activity of enhansons
and protoenhancers both near and far from the tran-
scriptional start site and in the context of either an
extended upstream promoter region or a truncated
promoter containing only a TATA box. The first se-
ries of studies were designed to test whether in-
dividual class-A enhansons, which are inactive as en-
hancers when positioned at a distance, can activate
transcription when positioned near the start site.
Analysis of individual or inappropriately duplicated
coreA enhansons revealed, however, that they can-
not activate transcription even when positioned near
the transcriptional start site. Thus, a functional pro-
toenhancer is required for transcriptional activation
even when distance is not an issue.
The second series of studies were directed at the
question of how the transcriptional activation poten-
tial of an enhancer is targeted to a specific transcrip-
tional start site. There must be considerable DNA
sequence information required to target enhancer
function effectively, because enhancers can be posi-
tioned at large distances from the transcriptional
start site without activating many closer cryptic
promoters. Use of two truncated 13-globin promoters,
one containing CCAAT and CACCC proximal pro-
moter elements (pf3A'27) and the other truncated to
the TATA box (pf3A36) showed that only the ex-
tended promoter could respond effectively to a dis-
tal enhancer. The TATA-box-only promoter was very
sensitive to the distance between the enhancer and
the TATA box. Thus, an enhancer with two copies
of a highly active coreA/coreA protoenhancer, al-
though virtually inactive at a distance, was a potent
activator close to the TATA box. A single coreA pro-
toenhancer, however, was relatively inactive in a prox-
imal position. Although the single protoenhancer
element is a weak activator positioned near the TATA
box, it confers on the TATA box the ability to re-
spond effectively to a distal enhancer. Thus, the re-
quirements for autonomous activation (two protoen-
hancers) and for targeting enhancer activity (one
protoenhancer) apparently differ. By testing the abil-
ity of a series of truncation mutants of the herpes
simplex virus trans-activator VP16 to activate tran-
scription and target enhancer function, we have
shown that mutants that do not effectively activate
transcription alone because they lack an acidic acti-
vation domain can still target enhancer activity.
Thus, these results suggest that targeting enhancer
activation and direct activation itself are different,
albeit perhaps overlapping, properties of trans-acting
factors.
Structure and Function of Oct-1
R. Aurora, G. Das, J.S. Lai, V Shick,
R. Sturm, K. Zito
We have been using the mammalian octamer motif
(ATGCAAT)-binding proteins Oct-1 and Oct-2 as
models to understand how two proteins can bind to
the same DNA sequence and differentially activate
transcription. Oct-1 and Oct-2 are members of a new
class of homeodomain proteins called POU (for Pit,
Oct, Unc). The founding members of the POU class
of homeodomain proteins include the mammalian
pituitary-specific factor Pit-1 /GHF-1 and the nema-
tode developmental gene product unc-86. This new
class of homeodomain proteins is distinguished by
the presence of an extended region of sequence
similarity approximately 160 amino acids long. The
carboxy-terminal portion contains the 60-amino-
acid-long homeodomain, and the amino-terminal re-
gion contains a POU-specific sequence of about 75
amino acids. A nonconserved region of 15-27 amino
acids separates these two conserved domains. Dele-
tion analysis and point mutagenesis showed that both
of the POU subdomains (POU-specific and POU-
homeo) are involved in sequence-specific DNA bind-
ing, whereas the exact structure of the nonconserved
region is not critical for binding.
We are now examining the contribution of the
POU-specific and POU-homeodomain regions in
sequence-specific DNA binding. By using large
amounts of the entire Oct-1 POU domain and the
homeodomain alone isolated from genetically en-
gineered Escherichia coli, we have shown that the
homeodomain retains sequence-specific DNA-
binding activity but at greatly reduced affinity com-
pared to the POU domain.
The two POU proteins Oct-1 and Pit-1 share
related but distinct DNA recognition properties. To
understand the contribution of the POU-specific and
POU-homeodomain regions for recognition of the
different DNA-binding sites by Oct-1 and Pit-1, we
have constructed a series of chimeric Oct-1/Pit-1
POU domains in which the two different segments
of the POU-specific region (A and B boxes), the
linker, and the homeodomain of Oct-1 are exchanged
for Pit-1 sequences. The chimeric proteins reveal that
both the POU-specific and POU-homeodomain
regions contribute to sequence-specific DNA recog-
nition. Curiously, however, the relative contribution
of each region differs among different binding sites.
We are now examining whether the POU-specific re-
gion contributes to sequence-specific DNA binding
by making contact with the DNA or instead by
modulating the conformation of the homeodomain
bound to DNA.
Following the initial isolation of a cDNA clone
encoding Oct-1, we have continued our analysis of
the oct-/ gene by isolating multiple cDNA and
genomic clones and performing an expression anal-
ysis in different adult mouse tissues. Analysis of the
oct-/ expression pattern in adult mice showed that
as is the case in cell culture, Oct-1 is ubiquitously
expressed. Analysis of 16 different human Oct-1
cDNAs revealed one cDNA encoding an alternatively
spliced form of oct-/ mRNA that can encode an Oct-
1 protein in which the carboxyl terminus of the pro-
tein is truncated and replaced by a short 12-amino-
acid sequence. This alternatively spliced form, called
oct-1B, is expressed at 5- to 20-fold lower levels than
the original oct-/ mRNA in all human cell lines
tested. We continue efforts to detect the truncated
Oct-1 protein, but it is apparently present in low
amounts or modified. Nevertheless, when translated
in vitro, the truncated Oct-1 protein, which retains
the DNA-binding domain, can bind to the octamer
motif and may therefore be able to alter the activa-
tion patterns of the larger Oct-1A protein in vivo.
Analysis of human genomic clones reveals that
the oct-1 gene is very large. To date, we have isolated
over 70 kb of genomic DNA but have not yet iso-
lated the entire gene. The large size of the gene is
reminiscent of some Drosophila homeobox genes
such as Ultrabithorax and Antennapedia (which are
very large) and distinguishes this homeobox gene
from that of many of the vertebrate homeobox genes
analyzed to date, which are considerably smaller in
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size. Chromosome mapping of the
oct-/ gene by
C.-L. Hsieh and U. Francke (Stanford University)
shows that this gene is located on
human and mouse
chromosomes 1. These are regions
of synteny be-
tween the human and mouse genomes.
The region
in which the oct-/ gene maps contains
a number of
genes that are related to genes that lie on
human
chromosome 19, where the oct-2 gene
is located (Ko
et al., Cell 55: 135 [1988]). This relationship between
multiple genes near the oct-/ and oct-2 chromosomal
loci suggests that the oct-/ and oct-2 genes
may have
arisen by an ancient chromosome duplication. The
similarities between the region surrounding oct-/ in
mouse chromosome 1 and a region of mouse chro-
mosome 7 suggest that the oct-2 gene will lie on
mouse chromosome 7.
Oct-1 and Oct-2: Protein Modification
and Protein:Protein Interactions
in Transcriptional Activation by
POU Homeodomain Proteins
M. Cleary, W. Herr, L. Leo, S. Stern,
M. Tanaka, W. Thomann
The DNA recognition sequence of the Oct proteins,
the octamer motif (ATGCAAAT), is found in the
promoters of both ubiquitously expressed genes and
lymphoid-specific genes. In the SV40 enhancer, the
octamer motif confers lymphoid-specific activation
of transcription. The different activities of the oc-
tamer motif correlate with the ubiquitous and
lymphoid-specific expression patterns of the Oct-1
and Oct-2 proteins, respectively. Separate studies,
done last year in collaboration with N. Hernandez
(Genetics Section), indicated that the ability of the
Oct proteins to activate transcription is promoter-
context-dependent. Thus, the Oct-1 protein is dedi-
cated to activation of transcription of the ubiqui-
tously expressed small nuclear RNA and histone
H2B genes, whereas Oct-2 can activate the more typ-
ical mRNA genes such as immunoglobulin genes.
We have used the cloned cDNA copies of the
genes for Oct-1 and Oct-2 (the latter obtained from
P. Sharp and D. Baltimore, MIT) to study their
differential activation functions. We find that to ac-
tivate transcription, Oct-2 relies on two interdepen-
dent domains, an amino-terminal glutamine-rich re-
gion and a carboxy-terminal serine-, threonine-, and
proline-rich region. Neither of these sequences is
acidic and therefore do not conform to the acidic
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activation domains found in the yeast activators
GAL4 or GCN4. Analysis of Oct-1/Oct-2 chimeras
reveals that Oct-1 also contains a functional gluta-
mine-rich region but fails to activate transcription
of an mRNA promoter because the Oct-1 carboxyl
terminus is inactive, indicating that differential ac-
tivation by Oct-1 and Oct-21s determined by the corm
bination of multiple activation domains.
To show that wild-type, mutant, and chimeric pro-
teins were expressed appropriately during the ac-
tivation assays, we showed that in each case these
octamer motif binding proteins can interfere with
the activity of the SV40 enhancer Sph motifs that
overlap the SV40 enhancer octamer motif. We also
assayed expression of the Oct proteins directly by
fusing an epitope from the influenza virus hemag-
glutinin protein to the amino terminus of selected
proteins. Using a monoclonal antibody directed at
the fused epitope, we could specifically immunopre-
cipitate the ectopically expressed Oct proteins. Fig-
ure 1 shows the results of such an analysis of tran-
siently expressed wild-type, chimeric, and mutant Oct
proteins. The results reveal that Oct-2 and transcrip-
tionally active Oct-1/Oct-2 chimeras produce a het-
erogeneous set of proteins. The heterogeneity is due
to phosphorylation, which induces a shift in elec-
trophoretic mobility. phosphorylation-induced
shift in electrophoretic mobility is largely or entirely
absent from molecules lacking one or the other ac-
tivation domain and inactive Oct-1/Oct-2 chimeras.
Thus, in Oct-2, nonacidic activation domains may
stimulate transcription by inducing protein phos-
phorylation, which could activate transcription by
causing a conformational change or perhaps by
creating an acidic domain.
Although Oct-1 does not normally activate an
mRNA promoter, it can activate such a promoter
in the presence of the herpes simplex virus (HSV)
trans-activator VP16. VP16 is an HSV late gene prod-
uct that is incorporated into the virion tegument and,
upon infection, activates expression of the HSV im-
mediate early genes. VP16 does not bind to DNA
directly but instead binds to its target sites by form-
ing a multiprotein-DNA complex with Oct-1. We
have shown that the Oct-1 homeodomain is respon-
sible for directing formation of the complex with
VP16. Oct-2 fails to direct formation of a similar
complex, and this is because the Oct-2 homeodo-
main differs from Oct-1 at 7 out of 60 possible
positions.
Sequence comparisons and a structural analysis
indicate that homeodomains contain a tri-a-helical
Oct-
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FIGURE 1 Immunoprecipitation of recombinant Oct proteins.
HeLa cells were transfected with the Oct expression vector indi-
cated above each lane, and the cells were metabolically labeled
with [35S]methionine for 4 hr. The cells were lysed and subjected
to immunoprecipitation with a monoclonal antibody directed at
the amino-terminally fused epitope from the influenza virus hemag-
glutinin protein. The immunoprecipitates were analyzed by 8%
SDS-PAGE and fluorographed. The Oct-2 deletions span the
amino-terminal glutamine-rich domain (Oct-2AN2) or the car-
boxyl terminus (Oct-2AC1 and C2). The chimeric Oct proteins
are divided into three regions, amino terminus, POU domain, and
carboxyl terminus, and the origin of each region is indicated by
1 (Oct-1), 2 (Oct-2), or A (deleted). Thus, Oct-2.1.1 contains the
amino terminus of Oct-2 fused to the Oct-1 POU domain and car-
boxyl terminus. The +/- designation under each lane indicates
the potential of each Oct protein to activate the r3-globin promoter
in our assay. (Reprinted, with permission, from Tanaka and Herr,
Cell 60: 375[1990].)
structure (helices 1-3) similar to the DNA-binding
domains of the bacteriophage X and 434 repressors.
Figure 2 shows a diagram of the DNA-binding do-
main of X repressor. In the tri-a-helical structure,
helices 1 and 2 lie over helix 3; this latter helix makes
the major contacts with the DNA and thus has been
coined the "DNA recognition" helix. In contrast, the
external surfaces of helices 1 and 2 face away from
the DNA. When the Oct-1 and Oct-2 homeodomains
are modeled into the structure of the X repressor
DNA-binding domain, the positions of the seven
residues differing between Oct-1 and Oct-2 lie in (or
in one case adjacent to) helices 1 and 2 on the sur-
face of the homeodomain facing away from the
DNA. Three of the differences lie in helix 2, where
positive control mutations in X repressor lie.
The X positive-control (pc) mutations affect the
ability of the X repressor to activate transcription but
do not affect DNA-binding activity. In X repressor,
pc mutations lie in or adjacent to helix 2 in a region
that probably contacts promoter-bound RNA poly-
merase directly. Changing in Oct-1 the three residues
in helix 2 that differ between Oct-1 and Oct-2 into
the Oct-2 amino acids is sufficient to disrupt for-
mation of the complex with VP16 without obviously
affecting the DNA-binding activity of the protein
(see Fig. 2). These results suggest that the tri-a-helical
DNA-binding motif is an ancient target for protein-
protein interactions mediating transcriptional con-
trol. We now plan to extend these studies by perform-
ing detailed structural analyses of the VP16/Oct-1
interactions.
Regulatory Elements of
the HIV Promoter
W. Phares, B. Whelan [in collaboration with B.R. Franza,
Cold Spring Harbor Laboratory]
In 1988, we initiated a study of the human immuno-
deficiency virus (HIV) promoter as a part of a new
program project at the Laboratory to study activa-
tion of HIV in infected cells. There are a number
of striking similarities between the SV40 early pro-
moter and the HIV promoter: They both contain
TATA box motifs, multiple binding sites for the tran-
scription factor Spl, and two copies of the 10-bp KB
motif in inverse orientation, GGGACTTTCC (called
the enhancer cores ECI and ECII) in HIV or
GGAAAGTCCC in SV40. In SV40, the x13 motif
lies within the SV40 C protoenhancer element, which
was identified in our studies of the SV40 enhancer
and is active in many different cell types.
To dissect the HIV promoter, we are focusing our
attention on the sequences upstream of the Spl-
binding sites, which by analogy to the SV40 early
promoter probably contain multiple enhancer ele-
ments. We showed last year that the 03 motifs of
HIV could functionally replace the SV40 enhancer
to allow growth of SV40 in CV-1 cells. To extend this
finding further, we have compared the activities of
reiterated copies of the HIV ECI and ECII elements
and the SV40 C element in transient expression as-
says of transfected DNA. The results show that mul-
tiple copies of both the HIV-derived and SV40-
derived elements can independently enhance tran-
scription to similar levels in CV-1 cells, human H9
T cells, and HeLa cells, whereas single (spm5) and
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FIGURE 2 X. repressor DNA-binding domain model with the positions
of differences between the Oct-1
and Oct-2 homeodomains indicated and VP16-induced complex
formation by Oct proteins with exchanged
helix 2. (Left) Diagram of the tri-a-helical DNA-binding motif of X repressor
and DNA (behind) as a model
for the POU homeodomain (S. Harrison, pers. comm.). The three a helices are drawn as cylinders, with
the a-carbon backbone indicated by solid (facing viewer) and dashed (hidden from viewer) lines. The seven
amino acid positions that differ between Oct-1 and Oct-2 are circled or
boxed, with the Oct-1 residues
shown inside and an arrow pointing to the Oct-2 residue. Boxed positions were
exchanged in the helix-
swap experiment, and asterisks indicate those positions in the homeodomain
that are analogous to X repressor
pc-2 and pc-3 mutations. (Right) Gel-retardation assay for VP16-induced complex formation by wild-type
Oct-1 (lanes 3,4), Oct-1 carrying Oct-2/helix-2 (Oct-1/He2-2; lanes 5,6), wild-type Oct-2 (lanes 7,8), and Oct-2
carrying the Oct-1/helix-2 (Oct-2/He2-1; lanes 9,10). Each protein was assayed without (lanes 1,3,5,7,9) and
with (lanes 2,4,6,8,10) VP16 protein. The positions of Oct-1 and Oct-2 complexes and VP16-induced com-
plexes (VIC) are shown at the left. (Bottom) Longer exposure of the Oct complexes and VICs. (Reprinted,
with permission, from Nature 341: 624[1989].)
double (dpm10) point mutations that mutate either
one or the other of the terminal nucleotides of the
KB motif GGGACTTTCC abolish or drastically re-
duce activity in these cell lines. In Jurkat T cells, these
elements are all relatively inactive in unstimulated
cells, but the activity of the wild-type constructs is
strongly stimulated by treatment of the cells with
PMA and PHA. Taken together with the SV40 rever-
tant analysis, these results indicate that the enhancer
core elements of HIV are functionally equivalent to
the SV40 C element. Thus, if NF-KB is responsible
for the activity of the KB motif, its activity is un-
likely to be lymphoid-specific but may instead be a
general target for activation by mitogenic signals.
In collaboration with B. Robert Franza (Molecu-
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lar Genetics of Eukaryotic Cells Section), we have
examined the proteins that bind to the multimerized
wild-type and mutant HIV and SV40 KB motifs. The
multimerized enhancer constructs used in vivo pro-
vide a matched set of active and inactive elements
that only differ by one or a few point mutations. The
multimerized copies of each element were used in
DNA affinity precipitation assays after biotinylation.
Analysis of the precipitated proteins from stimulated
Jurkat T cells shows that several families of proteins
coprecipitate with each of the wild-type ECI, ECII,
and SV40 C element sites. Curiously, although in a
triple point mutation, these proteins fail to precipi-
tate, in the inactive single point mutant spm5, these
proteins still bind and instead a new series of pro-
teins appear. An interesting possibility is that this
mutation is inactive because it promotes the bind-
ing of an inappropriate set of proteins instead of
merely preventing the activators from binding.
We are now expanding our studies of HIV regula-
tory elements by examining the promoter sequences
in different isolates of HIV from AIDS patients.
These studies will involve the use of the polymerase
chain reaction (PCR) to amplify directly the regula-
tory region from HIV isolates from single individu-
als at different times of infection and in different
cell types (i.e., T cells and macrophages) without pas-
sage of the virus in cell culture. We have already ob-
served a large degree of heterogeneity within the long
terminal repeat of different HIV isolates. This het-
erogeneity is likely to uncover rearrangements of
enhancer elements that are important for HIV patho-
genesis and that may display different cell type-
specific activities.
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MOLECULAR GENETICS OF EUKARYOTIC CELLS
Research in this section touches on broad problems in eukaryotic biology, from
the control of cell proliferation to the regulation of gene expression; from the
simple eukaryotic organism, the yeast Saccharomyces cerevisiae, to the mouse.
Our approaches are equally eclectic: genetic, biochemical, and ultrastructural. Two
unifying themes are the mechanism of action of oncogenes and the process of
signal transduction. Dr. Franza's laboratory studies early changes in transcription
patterns, particularly in human T cells. Dr. Field's laboratory utilizes transgenic
approaches to study problems in cardiovascular physiology, development, and
neoplasia. Dr. Skowronski's laboratory studies pathogenesis of HIV-1, the human
immunodeficiency virus that causes AIDS, and the transforming potential of
papillomavirus oncogenes using transgenic mouse models. Dr. Bar-Sagi's
laboratory studies the involvement of the ras proteins and phospholipase A2 in
signal transduction and ligand-stimulated exocytosis. Dr. Spector's laboratory
studies the functional compartmentalization of the nucleus using immunoelectron
microscopy. Dr. Helfman's group studies the family of tropomyosin genes and the
alteration of expression of these genes seen upon cellular transformation and
development. Dr. Garrel's group continues to improve protein database collection.
Dr. Gilman's laboratory studies nuclear events that result in changes in
transcription. Dr. Wigler's laboratory continues studies on ras and other
oncogenes, and the control of cell growth and proliferation.
TRANSGENIC MICE
L. Field P Yenikolopov S. Teplin
J. Skowronski K. Cochrane L. Usher
M. Steinhelper P Weinberg
The advent of transgenic mouse technology has
provided new and exciting experimental inroads
toward the analysis of complex biological systems.
Using this technology, it is possible to introduce
chimeric genes directly into the mouse germ line.
Once integrated, the foreign DNA is retained and
transmitted to subsequent generations in a Mende-
lian fashion. This method of mammalian gene trans-
fer provides an ideal model system with which to
study complex biological problems at the organis-
mal level in that the consequences of a single, defined
genetic trait can be studied in intact animals. The
Mouse Genetics Group at Cold Spring Harbor Lab-
oratory has developed several model systems that
have been designed to address a broad range of
biologically relevant issues. These studies include
characterization of selected genetic elements of the
human immunodeficiency virus long terminal repeat
(LTR), characterization of the transforming activity
of the bovine papillomavirus E2 protein, identifica-
tion of genes that regulate myocardiocyte prolifera-
tion, and transgenic models of hypertension. Our
models illustrate the potential utility of the transgenic
approach, especially with regard to the ability to
study complex disease processes.
Transgenic Models of
Viral Pathogenesis
L. Usher, G. Yenikolopov, J. Skowronski
Transgenic mice provide a system whereby various
aspects of viral host range and pathogenicity can be
studied in the absence of viral infection. Direct
introduction of viral DNA into mouse embryos and
its subsequent germ-line transmission result in its
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presence in every cell of the body. This circumvents
the limitations of host range and tissue tropism
associated with the infection process itself. Our effort
has been concentrated on two viruses, the human
immunodeficiency virus type 1 (HIV-1) and bovine
papillomavirus type 1 (BPV-1). Both viruses, upon
introduction of their complete genetic information
into the mouse germ line, induce lesions resembling
those arising in natural hosts. Thus, different aspects
of pathogenicity of these two viruses can be ad-
dressed in transgenic mice.
In Vivo Specificity
of the HIV-1 LTR
J. Skowronski
The disease spectrum displayed by viral pathogens
is restricted, among other factors, by tropism of vi-
ral infection and specificity of viral transcriptional
control elements. HIV-1 preferentially infects cells
expressing the CD4 surface antigen, which is a re-
ceptor for the virus mediating its entry through spe-
cific interaction with the HIV-1 env gene product.
The major cellular targets in HIV-1 infections are
helper/inducer T lymphocytes. CD4 antigen is also
expressed at variable, although reduced, levels on
subsets of glial cells, cells of the monocyte/macro-
phage lineage, and B lymphocytes, all of which are
infectable by HIV-1. Surprisingly, however, some
CD4- cells (e.g., fibroblasts) can also be infected in
vitro by HIV-1. It is possible that in addition to CD4 -
mediated viral entry, other mechanisms may be
operational.
As one approach to define the in vivo tissue spec-
ificity of the HIV-1 transcription control infor-
mation, hybrid reporter genes composed of the
HIV-1 LTR positioned to direct expression of the
SV40 early region were introduced into the germ line
of inbred mice. Three lines of transgenic mice result-
ing from three independent integration events of the
HIV-1 T-antigen gene were generated. Although in-
tegration of foreign DNA microinjected into mouse
embryos and integration of proviral DNA in infected
cells are not mediated by the same mechanisms, a
common feature of both is that integrations can tar-
get many different chromosomal locations. The tran-
scriptional activities of the HIV-1 T-antigen trans-
genes residing in three independent chromosomal
sites of the HIV-1 T-antigen transgenic lines were
studied in detail.
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The HIV-1 promoter preferentially targets expres-
sion of the SV40 reporter gene to the lymphoid tis-
sue, as transgenic transcripts are consistently ob-
served in thymuses, lymph nodes, and spleens of mice
of all three transgenic lines. Skin is another organ
reproducibly targeted by the HIV-1 T-antigen con-
struct. In addition to expression of the HIV-1 T-an-
tigen transgenes in lymphoid tissue and skin, which
is consistently observed in mice of all the three lines,
each transgenic line reproducibly shows a character-
istic, but unique, pattern of additional sites of trans-
gene expression. Levels of expression in these addi-
tional sites vary greatly between different transgenic
lines. Patterns of these additional sites of transgene
expression are heritable within lines of transgenic
mice and thus reflect a dominant transcriptional ef-
fect of the particular chromosomal locus where
transgenes become integrated. There are many well-
characterized examples of activation of cellular tran-
scription units by murine retroviruses integrating in
their vicinity. It also appears that retroviral promoters
may be targets of similar interference and that some
chromosomal loci can confer high constitutive lev-
els of expression on resident proviruses.
HIV-1 LTR reproducibly targets expression of
reporter genes into lymphoid organs, all of which
contain major populations T lymphocytes, a
major target of HIV-1. However, analysis of cell-type
specificity revealed that transgene expression in T
cells is relatively low. This is reminiscent of the
inactivity of the viral promoter and virus itself in
resting human T cells and in T-cell lines. The striking
observation is that cell types other than T cells are
permissive for the HIV-1 promoter and contribute
the majority of expression detectable in thymuses
and spleens. Permissive cell types, which appear to
provide a better environment for expression of the
HIV-1 LTR than resting T cells, include splenic B
lymphocytes and an unidentified stromal element in
the thymus. These data, at least with regard to B cells,
are in agreement with results of experiments per-
formed by other investigators with human cells
isolated directly from infected individuals or with
permanent cell lines. Human B lymphocytes, under
some conditions, are infectable with HIV-1 and do
support expression of the HIV-1 LTR more effi-
ciently than cultured T cells. It is intriguing that B
lymphocytes, macrophages, and thymic epithelial
cells, all of which support transcription directed by
the HIV-1 LTR in vivo, are by the virtue of performed
functions involved in direct interactions with CD4 -
positive T cells. Such direct interactions may provide
a microenvironment that facilitates otherwise infre-
quent events of infection of these cell types. Given
transcriptional inactivity of HIV-1 in latently infected
T cells, such events of infection of constitutively
permissive cell types, although possibly infrequent
and thus not necessarily obvious, may contribute to
increased virus replication in natural infections.
Benign Fibroepitheliomas
in BPV-1 E2 Transgenic Mice
G. Yenikolopov, J. Skowronski [in collaboration with
I. Seidman, New York University]
BPV-1, a circular double-stranded DNA tumor virus,
induces benign fibropapillomas, composed of pro-
liferative epidermal cells and fibroblasts. BPV-1, or
a subgenomic fragment comprising the viral early
region open reading frames (ORFs El through E8),
can also transform selected murine cell lines in vitro.
Results of experiments with mutant viruses have
implicated three of the early ORFs, E2, E5, and E6,
as necessary for the transforming activity of the
virus. Overexpression of the E5 or E6 ORF alone,
but not the E2 ORF, results in transformation of
permissive cell lines, which indicates that the former
two encode proteins with the oncogenic activity. E2
ORF encodes a set of transcription factors that
interact directly with the BPV-1 enhancer to regulate
expression of the BPV-1 early genes. Although in
vitro experiments failed to prove a direct involvment
of E2 in BPV-1 transformation of cultured cells, E2
proteins, as transcription factors, have a potential
to perturb expression of cellular genes and may act
synergistically with the E5 and E6 oncogenes to
effect cellular transformation or tumorigenesis.
As one way of addressing this issue, we have
constructed transgenic mice expressing the BPV-1 E2
gene in a variety of tissues. To achieve a broad pattern
of expression, the E2 ORF, followed by the SV40
splicing and polyadenylation signals, was placed
under the transcriptional control of the chicken
13-actin promoter (pCBAE2). Eight founder mice
harboring the pCBAE2 construct were generated and
used to establish seven independent lines of pCBAE2
transgenic mice. Of mice from each of four trans-
genic lines (pCBAE2 5, 6, 7 and 8), 10-2007o develop
overt kidney lesions at 6-15 months of age. These
lesions are characterized by abnormal retention of
urine in the renal pelvis and, as a consequence,
atrophy of the kidney tissue (hydronephrosis). Such
lesions usually result from obstruction of urinary
tracts, which can be caused by tumors of the urogeni-
tal organs (or those located in immediate vicinity).
Histological analyses of the urinary tracts collected
from several affected animals revealed focal hyper-
plastic growth in the upper portions of urethras.
Polypoidal projections into the lumen of urethras
were caused by abnormal proliferation of both the
stromal (fibroblastic) and epithelial (transitional
epithelium of the urethra) components of the urethra
wall. These hyperplastic changes were histologically
benign in most cases examined. Interestingly, in one
case, a histologically malignant focal growth of
epithelial cells (transitional cell carcinoma) was iden-
tified within the polypoid structures. This spectrum
of lesions arising in pCBAE2 transgenics has never
been observed in nontransgenic mice or mice of
various transgenic lines that were maintained and
autopsied in a CSHL colony (>100 mice at 1-2 years
of age).
Expression of the pCBAE2 transgene was assessed
at the RNA level. pCBAE2 transcripts, correctly ini-
tiated at the 13-actin cap site, are detectable in several
tissues, including kidney, urethra, bladder, testis,
vagina, intestine, and skin. The highest levels of
expression were consistently detected in the urinary
tract, specifically bladders and urethras prior to
development of overt macro- or microscopical le-
sions. These observations suggest that E2 gene pro-
ducts can, under certain conditions, induce abnormal
proliferation of fibroblasts and epithelial cells.
However, the identity of E2-expressing cells, and thus
the mechanism of concomitantly induced prolifera-
tion of both fibroblastic and epithelial components
of affected urethras, is at the present time unknown.
Sporadic occurrence of transitional cell carcinomas
in polypoid proliferations suggests that transitional
epithelium may be a primary target of E2 in pCBAE2
transgenic mice. The localization of lesions in
pCBAE2 transgenic mice is different both from that
observed in natural infections with BPV-1 in cattle
and from what is seen in transgenic mice harboring
the complete BPV-1 genetic information. Interest-
ingly, experimental infection of cattle and laboratory
rodents with BPV-1 induces lesions in the urinary
tracts that very closely resemble those of E2 trans-
genic mice. This particular location of stromal/
epithelial hyperplasia in E2 mice may be due to
unusually high susceptibility of the target tissue,
transgene expression pattern, or other features of
these particular transgenic models.
The BPV-1 E2 gene encodes a family of transcrip-
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tion factors, which have a common DNA-binding
specificity and the properties of both positive and
negative regulators of transcription. At the present
time, we do not know which forms of E2 are ex-
pressed in the target tissues of transgenic mice, and
therefore phenotypes observed in pCBAE2
mice may
result from either of these activities. E2 proteins
and
their DNA-binding specificities are conserved
among
different members of papillomavirus family, which
includes several viruses implicated in human skin and
genital premalignant and malignant lesions.
The
ability of E2 to induce hyperplastic growth in trans-
genic mice suggests that this conservation of E2 may
be important not only in the context of viral func-
tions, but also in the context of the virus-host interac-
tions resulting in deregulation of growth control in
target cells.
Cardiac Tumors in Transgenic Mice
M. Steinhelper, P Weinberg, S. Teplin, L. Field
Mammalian adult cardiac muscle is incapable of
growth by proliferation of existing muscle cells. This
inability to proliferate has important implications
for individuals who suffer from myocardial infarcts
and related trauma. The failure of adult cardiomyo-
cytes to divide results in the replacement of electro-
mechanically functional muscle with electrically
inactive fibrous (scar) tissue that is unable to con-
tract. Such electrical and mechanical dysfunction
places individuals suffering heart attacks at risk for
further cardiac disease. A resource of proliferating
adult heart muscle cells may provide insight into the
mechanisms by which myocardiocyte growth is reg-
ulated during development and disease states. In
addition, the ability to induce controlled myocardial
growth in vivo would have therapeutic implications
for the treatment of heart disease. As a first step
toward these goals, we have generated several lineages
of transgenic mice whose hearts express the SV40
T-antigen oncogene. Expression of this transform-
ing gene in myocardiocytes induces cell division,
leading to the formation of heart tumors. We have
analyzed the structural and functional properties of
the cells constituting the tumors and have investi-
gated whether cardiac muscle cells derived from the
heart tumors can divide in culture, with the goal of
isolating a stable cardiac heart muscle cell line. In
separate experiments, we have identified a genetic
locus that regulates both the temporal pattern and
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morphology of cardiac tumorigenesis. This locus,
when identified and cloned, may provide insight into
the molecular events that regulate myocardiocyte
proliferation. Descriptions of these studies are con-
sidered separately below.
PROPAGATION OF SUBCUTANEOUS TUMOR
TRANSPLANTS DERIVED FROM ANF-TAG ATRIA
This work was carried out in collaboration with N.
Lanson, J. DelCarpio, and W. Claycomb (LSU
Medical Center, New Orleans). A transgenic model
was developed in which expression of T antigen was
targeted to the cardiac atria using the atrial natri-
uretic factor (ANF) promoter. Transgenic mice car-
rying this fusion gene (designated ANF-TAG) express
T antigen in both atria. However, these animals
exhibit unilateral right atrial hyperplasia. The
differential capacity of right and left atrial cardio-
myocytes to respond to T antigen with right unilateral
hyperplasia is most likely a result of differential
asymmetrical expression of genes in cardiac tissue.
This hypothesis is founded on the observation that
when prehyperplastic neonatal transgenic atria were
transplanted to a physiologically neutral environment
(i.e., subcutaneously in nude mice), only transgenic
right atria proliferated. This observation suggests
that the unilateral right atrial hyperplasia observed
in the ANF-TAG mice is unlikely due to a trivial
consequence related to environmental cues that differ
between the atria.
The tumorigenic capacity of hyperplastic right
atria was also demonstrated in histocompatible
syngeneic animals. Injection of minced transgenic
atria subcutaneously into numerous mice yielded
tumors composed of well-differentiated cardiomyo-
cytes. Subsequent passage of these tumors yielded
tumors with enhanced growth properties as assessed
in vivo and in tissue culture. Analysis of tumors by
electron microscopy indicates that the majority of
tumor cells retain several differentiated characteris-
tics, such as well-formed sarcomeres, abundant
transverse tubules, atrial-specific electron-dense
granules (which contain ANF immunoreactivity),
and intercalated discs. Virtually all tumor cells, with
the exception of vascular tissue (presumably arising
from the host), contain both sarcomeric myosin and
T antigen. The tumor cells proliferate rapidly as
documented by the observation that 20-30% of cells
incorporate [31-l]thymidine within an 18-hour peri-
od. Somewhat surprisingly, our analysis of the ex-
pression of additional cardiac determinants at either
the protein level or the RNA level revealed few dif-
ferences between normal cardiac tissue, the primary
atrial tumors, and the subcutaneous transplant
tumors.
Studies of cardiac cells are hindered presently by
the absence of a cell line that displays any signifi-
cant degree of differentiation. The well-differentiated
cardiac phenotype displayed by the cells constitut-
ing our tumors, coupled with their rapid prolifera-
tion in vivo, suggested that these cells might be an
ideal resource for cell-culture experiments. Thus, cells
dissociated enzymatically from either primary atrial
tumors or the subcutaneous syngeneic transplants
were tested for their ability to proliferate in culture.
Cells isolated from several primary atrial tumors
essentially do not divide in culture; however, cells
isolated from the transplant tumors grew quite
rapidly. Cells from both tumor types were well
differentiated and contracted spontaneously in cul-
ture. Intact cell-cell communication was evident from
the synchronous contraction of neighboring cells
observed under light microscopy. Structural analysis
by electron microscopy has revealed that the trans-
plant tumor cells are highly differentiated. Further-
more, the contracting cells retained a high degree of
cardiac-specific electrophysiological activity. For
example, the resting membrane potentials and the
action potentials are similar to those of normal atrial
cells. Cultures of spontaneously contracting tumor
cells can be obtained following passaging or recovery
from frozen stocks. The characteristics displayed by
these cells suggest that they are a unique and renew-
able resource of proliferating and highly differen-
tiated cardiomyocytes.
GENETIC LOCI AFFECTING ATRIAL HYPERPLASIA
IN ANF-TAG MICE
ANF-TAG transgenic mice were produced in (C57BL/
6J x DBA/2J)/F2 embryos, abbreviated (B6 x
D2)/F2. Consequently, subsequent breeding of the
transgenic animals must result in segregation of
alleles arising from one or the other progenitor
strains (namely, B6 alleles or D2 alleles). Given this
segregation, there is a distinct possibility that poly-
morphic alleles which differentially affect atrial
tumorigenesis in ANF-TAG mice may be identified.
To address this issue systematically, we have gen-
erated sublines by repeatedly backcrossing ANF-TAG
mice to either the B6 or D2 progenitor animals. Over
the past year, we have monitored the survival of these
two populations of ANF-TAG mice.
We observe that backcrossing to B6 yields an
apparent homogeneous population of mice that die
from atrial tumorigenesis at 46.5 ± 1.6 weeks
(n = 30). In contrast, mice of the D2 subline appear
to consist of two statistically distinct populations;
approximately one half of the animals in the D2
subline die at 6.6 ± 0.7 weeks (n = 17 ) , whereas the
other half die at 24.6 ± 0.8 weeks (n =14). Unfortu-
nately, the mice from the 6.6-week group die around
the time of sexual maturity and are unproductive
breeders. Thus, the D2 subline must be propagated
from the slower dying population. Such crosses yield
transgenic offspring that fall into each of the two
populations (i.e., a 6.6-week group and a 24.6-week
group). The simplest interpretation of these results
is that a single genetic locus (designated X) differs
between the two progenitor inbred strains. Mice with
an XD/XD genotype would die rapidly and mice
with an XB/XB genotype would live longer. Heter-
ozygous mice (XD/XB) would die at an intermedi-
ate rate, assuming codominance. The strongest evi-
dence in favor of this working hypothesis is that
presumptive XD/XB heterozygotes (slower D2 pop-
ulation) when crossed to D2 (XD/XD) yield two
populations, fast and intermediate, in roughly equal
proportions. We are presently generating informa-
tive backcross populations to confirm that the
transition from the slow to intermediate population
is determined by a single locus.
Associated with the differences in the rate of
tumorigenesis is an intriguing morphological differ-
ence between atrial tumors in the two sublines. Mice
from the D2 subline show a gross hyperplasia involv-
ing essentially all right atrial myocytes. Moreover,
unilateral left atrial involvement has never been
observed. In contrast, atrial tumors in the B6 subline
appear to arise from a focal event involving the
proliferation of only a portion of the right atrial cells.
The delayed onset and focal nature of the atrial
tumors arising in the B6 subline suggest that addi-
tional genetic events are required for T-antigen-
induced proliferation. Were this the case, one might
expect that this putative cooperative event could
occur at finite frequency in the left atrium and
consequently give rise to left atrial tumors. Indeed,
such events do occur as illustrated by three mice (all
animals from the B6 subline) that had left atrial
tumors in the absence of right atrial involvement.
Finally, our observations regarding genetic back-
ground have been observed in two ANF-TAG lineages
in which the chromosomal location of the transgene
differs. This observation effectively rules out triv-
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ial explanations related to the site of transgene
integration.
In conclusion, these traditional genetic backcross
experiments have revealed at least one and at most
two genetic loci that regulate both the temporal
pattern and eventual end-stage morphology of T-an-
tigen-induced cardiac pathology. We hope to identify
genetically these loci by utilizing traditional linkage
studies as well as recombinant inbred lines of mice.
TRANSGENIC MODELS OF VENTRICULAR
CARDIOMYOCYTE PROLIFERATION
The initial microinjections of the ANF-TAG con-
struct yielded several transgenic animals that died
at very early ages. At necroscopy, these animals
exhibited gross right atrial hyperplasia similar to that
seen in the established ANF-TAG lineages. Further
histological analyses revealed that these mice also
developed ventricular pathology; the left wall and
the septum of the ventricles were grossly hyperplas-
tic, whereas the right ventricular wall and left atrium
are relatively normal in appearance. Immunohisto-
logical analyses indicated that T-antigen expression
is seen throughout the hyperplastic septum and left
ventricle. As the endogenous ANF gene is expressed
in ventricles during late embryological development,
those ANF-TAG mice exhibiting ventricular onco-
protein expression presumably carried transgenes
that integrated in a chromosomal site compatible
with normal developmental expression of ANF.
These observations demonstrate that T antigen can
induce embryonic or neonatal ventricular cardio-
myocytes to divide.
To extend these observations to adult ventricular
tissue, we have generated transgenic mice that express
T antigen when fused to different cardiac-specific
promoters. Our initial results are from mice express-
ing a rat a-myosin heavy-chain-T-antigen (MHC-
TAG) fusion gene. We have obtained three founder
mice that contain the MHC-TAG fusion gene. Two
of the mice died prematurely of cardiac tumorigen-
esis without transmitting the fusion gene to progeny.
The third founder mouse has transmitted the fusion
gene successfully and has a fractionated ECG typical
of that seen in ANF-TAG mice with atrial hyperpla-
sia. Transgenic progeny of this MHC-TAG founder
inherit similar electrical abnormalities and heart
pathology. Preliminary immunohistochemical anal-
ysis indicates that in this lineage, both atria and
ventricles contain the oncoprotein and exhibit hy-
perplasia. This pattern of T-antigen expression ob-
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tained from the rat a-myosin heavy-chain gene pro-
moter is consistent with the cell-type specificity for
the endogenous MHC gene. In summary, our pre-
liminary observations in the MHC-TAG lineages
indicate that adult ventricular myocytes can prolifer-
ate in response to T antigen. These animals will
provide a useful resource to assess the pathophysio-
logical consequences of ventricular tumorigenesis
and may also provide the basis for the generation
of a ventricular myocyte cell line.
Transgenic Models of Hypertension
Research
K. Cochrane, M. Steinhelper, S. Teplin,
P. Weinberg, L. Field
Blood pressure and electrolyte homeostasis is largely
dependent on an integrated, multi-organ response
to numerous hormonal signals. The inappropriate
regulation of these hormones often has overt patho-
physiological consequences, as exemplified by the
malignant hypertension that can accompany adrenal
medullary tumors and reninomas. The ability to
generate animal model systems with specific, known
alterations in this hormonal regulatory cascade
would be of considerable utility. During the last three
years, our laboratory has been using the transgenic
approach to study the molecular biology and physi-
ology of ANF, a peptide hormone that is synthesized
and stored in the cardiac atria. The circulating form
of the hormone is a 28-amino-acid peptide derived
from the carboxyl terminus of a 152-amino-acid
preprohormone precursor by proteolytic cleavage.
ANF is secreted into the circulation in response to
volume overload, presumably as a consequence of
atrial wall stretch. ANF exhibits profound effects on
the cardiovascular and renal systems upon acute ad-
ministration. These include a prompt and pro-.
nounced natriuresis and diuresis, an increase in
glomerular filtration rate, inhibition of angiotensin-
II-stimulated proximal tubular sodium and water
reabsorption, inhibition of the renin-aldosterone
axis, as well as potent vasodilatory and smooth mus-
cle relaxant properties. Although the physiological
consequences of acute ANF administration are well
known, the role of the hormone in the chronic regu-
lation of blood pressure and electrolyte homeostasis
has remained elusive. In an effort to address this issue
directly, we have generated a transgenic model that
exhibits chronically elevated levels of ANF in the
systemic circulation. These transgenic animals are
hypotensive, i.e., they have lower blood pressure,
as compared to the nontransgenic littermates. Our
molecular and physiological analyses of this model
are described below.
GENERATION OF A TRANSGENIC MODEL WITH
ELEVATED ANF LEVELS
To generate transgenic animals that would exhibit
elevated levels of ANF in the systemic circulation,
we constructed a fusion gene composed of the
transthyretin (or TTR) promoter fused to the mouse
ANF structural gene. The transthyretin-ANF fusion
gene (abbreviated TTR-ANF) was designed such that
the TTR promoter would target expression of ANF
to the liver. The mouse TTR gene was isolated from
a BALB/cCr bacteriophage genomic library, and
the promoter (localized on a 3-kb restriction frag-
ment of the 5'-flanking region) was subcloned into
Bluescribe vector. The mouse ANF sequences were
also isolated from a BALB/cCr genomic library. The
promoter and a region of the 5'-untranslated leader
of the ANF gene were removed by BAL-31 exonucle-
ase, and a Sall restriction site was introduced. This
fragment was ligated into the clone carrying the TTR
sequences such that transcripts arising from the TTR
promoter would encode pre-pro-ANF. The TTR-ANF
fusion gene was linearized at a unique Ndel site and
microinjected into one-cell embryos obtained from
C3HeB/Fe inbred mice using standard methodolo-
gies. Ten independent TTR-ANF transgenic mice
were obtained from our initial series of microinjec-
tions. Of these, four animals were genetically mosaic
and did not transmit their fusion genes, and two
animals were sterile. However, the remaining four
animals have successfully transmitted their fusion
genes, and transgenic lineages have been established.
These lineages have been designated TTR-ANF 2,
4, 5, and 6, respectively.
To characterize expression of the TTR-ANF trans-
gene, RNA was isolated from transgenic animals
from the four TTR-ANF lineages and subjected to
both Northern blot and RNase protection analyses.
Our experiments indicate that the TTR-ANF 2 and
4 lineages express the fusion gene in the liver and
the TTR-ANF 5 and 6 lineages do not. Developmen-
tal studies in the TTR-ANF 4 lineage indicate that
the transgene is active at day 15 of development and
is essentially at adult levels by birth. RNase protec-
tion tissue surveys for TTR-ANF fusion gene expres-
sion in the TTR-ANF 2 and 4 lineages have revealed
that the fusion gene is expressed only in transgenic
liver. To characterize the effect of transgene expres-
sion on hormone levels in the systemic circulation
in the TTR-ANF 2 and 4 lineages, an ANF-specif-
ic radioimmunoassay (RIA) was performed. These
studies revealed that the transgenic animals have
approximately eightfold elevated plasma levels of
immunoreactive ANF as compared to their nontrans-
genic littermates. This difference is observed at every
age assayed (3-25 weeks), and no differences in
expression are seen between male and female trans-
genic animals. Several studies have indicated that
plasma polypeptides can nonspecifically interfere
with the ANF RIA. For this reason, we also per-
formed the RIA on plasma that had been extracted.
Given the small blood volume of a mouse, it was
necessary to pool plasma from three animals for each
assay. Analysis of the extracted pooled plasma sam-
ples revealed that the transgenic animals have approx-
imately 20-fold elevated levels of immunoreactive
ANF as compared to their nontransgenic littermates.
Sephadex G-75 column chromatography was em-
ployed to assess the molecular form of the immuno-
reactive ANF present in the plasma of transgenic
animals. The study showed that approximately 6507o
of the immunoreactive plasma ANF in the transgenic
animals comigrates with pro-ANF, and 3507o comi-
grates with the processed hormone.
CHRONIC CARDIOVASCULAR REGULATION IN
TRANSGENIC ANIMALS THAT OVEREXPRESS ANF
The molecular and biochemical data described above
attest that mice expressing a TTR-ANF fusion gene
in their liver have elevated concentrations of immu-
noreactive ANF in the systemic circulation. Our ini-
tial assessment of the physiological consequences of
chronically elevated ANF levels has relied on blood
pressure determination. Direct measurements pro-
vide the most reliable assessment of blood pressure.
Although direct pressure is easily measured by can-
nulation of femoral arteries in anesthetized mice,
ideal recordings would be obtained from conscious
animals with indwelling catheters. To this end, we
have implanted indwelling cannulas into the aorta
of nontransgenic and TTR-ANF mice. These analy-
ses revealed that TTR-ANF 4 transgenic mice have
a MAP (mean arterial blood pressure) of 75.5 +
0.9 mm Hg (n=9) and age-matched nontransgenic
littermates have a MAP of 103.9 ± 2.0 mm Hg (n = 9).
Similarly, the TTR-ANF 2 transgenic mice are also
hypotensive (78.9 ±1.4 mm Hg). The observation that
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two independent TTR-ANF transgenic
lineages are
hypotensive provides compelling proof that
the de-
crease in blood pressure arises as a consequence
of
transgene expression. Examination of water balance,
plasma and urinary electrolytes (sodium and potas-
sium), and heart rates revealed no significant dif-
ferences between the TTR-ANF 4 mice and their
nontransgenic littermates.
We have characterized several tissues in the TTR-
ANF transgenic lineages to determine whether ANF
overexpression elicits any histopathological changes.
The initial experiments simply entailed harvesting
tissue and processing for standard hematoxylin and
eosin histological analyses. We have observed a
reactive hyperplasia in the zona glomerulosa of the
adrenal gland of the TTR-ANF 4 transgenic mice.
The zona glomerulosa in the transgenic animal is
markedly hyperplastic, as evidenced by its increased
thickness and by an increase in the ratio of nuclear
density to cytoplasm density. That this pathology
involved cell division was confirmed in [3H]thymi-
dine incorporation studies. The hyperplastic re-
sponse in the adrenal zona glomerulosa is somewhat
surprising as several studies have shown that ANF
effectively inhibits aldosterone production. Thus,
one would not expect zona glomerulosa hyperpla-
sia (which has previously been observed in animals
maintained low-salt diets). However, it is possible
that the signals to retain salt (i.e., aldosterone pro-
duction) circumvent the inhibitory effect of ANF on
zona glomerulosa cells. Alternatively, the zona glom-
erulosa hyperplasia may arise as a consequence of
ACTH stimulation. These issues will be resolved
when we determine the levels of aldosterone, ADH,
and ACTH in the transgenic mice.
The ability to generate transgenic mice that carry
defined modifications of the ANF structural gene
provides a unique opportunity to correlate specific
genetic alterations with their pathophysiological
consequences in intact animals. Our initial study
conclusively demonstrates that chronically elevated
levels of ANF can exert a sustained hypotensive
effect. In addition, the study attests to the potential
utility of the transgenic mouse model for the study
of cardiovascular physiology. Whether the lower
MAP observed in transgenic mice results from direct
actions of ANF on the heart and vasculature or from
indirect actions on other cardiovascular regulatory
systems, such as the renin-angiotensin-aldosterone
system or the sympathetic nervous system, is cur-
rently under study. Undoubtedly, the TTR-ANF
transgenic mice will facilitate investigations of such
regulatory mechanisms.
ACUTE CARDIOVASCULAR REGULATION IN
TRANSGENIC MICE THAT OVEREXPRESS ANF
These studies were carried out in collaboration with
A. Veress and H. Sonnenberg (University of Toron-
to). The studies described above indicate that chron-
ically elevated levels of ANF can induce a sustained
hypotensive response. However, the observation that
other physiologicalparameters remain normal indi-
cates that the animals are at physiological homeosta-
sis. In an effort to characterize cardiovascular
homeostasis in the TTR-ANF mice further, we have
initiated experiments to assess the capacity of these
animals to respond to acute physiological stress. As
indicated above, ANF is a major effecter of the renal
response to intravascular or extracellular fluid vol-
ume expansion. In rats, plasma levels increase about
fivefold after a 25% increase of circulating volume,
and volume natriuresis is markedly impaired or pre-
vented either by atrial appendectomy or by prior
ANF antibody injection. To determine whether
chronically elevated ANF concentration would affect
the renal volume response, kidney function was
studied in TTR-ANF transgenic mice and their non-
transgenic littermates before and during acute
intravascular expansion. Animals were anesthetized
and prepared for clearance measurements. After a
1-hour control period, 4.5% albumin in Ringers was
infused intravenously over the next 20 minutes to
raise calculated blood volume by 25%. A further 40
minutes was allowed before taking a blood sample
for determination of immunoreactive ANF. Plasma
ANF averaged 5185 ± 514 pg/ml in the transgenic
group, compared to 577 ± 83 in controls, confirm-
ing earlier results. Similarly, average blood pressure
was about 20 mm Hg lower in transgenics. Despite
this relative hypotension, baseline urine volumes and
sodium excretions were not different from those of
nontransgenic controls. After blood volume expan-
sion, both diuresis and natriuresis were markedly
elevated compared to control, even though blood
pressure remained relatively depressed. Glomerular
filtration rates were not statistically different between
groups, either before or after volume expansion.
Since baseline hematocrits also were not different,
these data suggest that the ANF-induced decrease
in arterial and therefore renal perfusion pressure
counteracts the direct natriuretic effects of the pep-
tide, thus allowing maintenance of salt balance.
However, when volume is expanded acutely, the
relatively elevated ANF levels in the transgenic group
exaggerate the renal response, even to the point of
volume depletion. It will be instructive to determine
volume responses on different sodium diets, as well
as the nephron segments affected by the primary
lesion and compensatory mechanisms.
Transgenic Mice with Cardiac
Arrhythmias
M. Steinhelper, L. Field [in collaboration with K. Dresdner
and A. Wit, Columbia University]
A progressive increase in both the frequency and
severity of cardiac conduction abnormalities accom-
panies the formation of cardiac tumors in both ANF-
TAG and MHC-TAG mice. These pathological per-
turbations in cardiac conduction should have a basis
at the cellular and molecular levels. In an effort to
identify such mechanisms, we have examined certain
electrophysiological properties, such as the resting
membrane potential, action potential waveform, and
automaticity, as atrial hyperplasia proceeds. In
addition, application of multiple electrode recording
techniques has allowed us to map the three-dimen-
sional changes in intercellular electrical coupling
during atrial hyperplasia. Evidence acquired to date
indicates that atrial hyperplasia is accompanied by
the formation of multifocal pacemakers. In humans,
such multifocal pacemakers are responsible for a
significant portion of cardiac dysrhythmias. Addi-
tional characterization of the electrophysiological
perturbations during the development of atrial hy-
perplasia should enhance our understanding of the
molecular mechanisms by which cardiac arrhythmias
arise and develop.
The consistent observation of arrhythmias in
transgenic mice expressing the T-antigen oncoprotein
in cardiac tissue has led us to consider alternative
approaches for producing a heritable model of car-
diac arrhythmia in the absence of cardiac hyperpla-
sia. Although a molecular basis for the initiation and
maintenance of cardiac arrhythmias is not known,
it is highly likely that inappropriate intercellular
propagation of electrical depolarizations is involved.
In cardiac tissue, conduction of the electrical current
from cell to cell is facilitated by structures within the
cell membrane called intercalated disks. The disks
have low resistance compared with the surrounding
lipid bilayer, and it is thought that the velocity and
pattern of electrical propagation may reflect the
number and distribution of the disks in the cardiac
membrane, respectively. The cardiac intercalated
disks are related to the gap junctions present in
electrically inactive tissues such as the liver. Gap
junctions comprise a single protein (called a con-
nexin) that is arrayed as a homohexamer within the
plasma membrane. Recently, cDNA clones for the
liver and cardiac connexins were obtained from a rat
heart cDNA library. Analysis of the predicted protein
sequences revealed that connexin 43 (heart) and
connexin 32 (liver) are highly conserved, with the
notable exception that the cardiac connexin has a
11-kD carboxy-terminal extension.
Several groups have assessed the ability of the con-
nexins to induce cell-cell coupling by injecting RNA
encoding these proteins into frog oocytes. Expres-
sion of both the liver and cardiac connexins induced
large voltage-insensitive conductance between pairs
of oocytes. However, expression of both connexins
within the same cell type yielded gap junctions com-
posed of nonfunctional heterohexamers. These ob-
servations provide formal proof that connexins can
mediate intercellular electrical communication. Fur-
thermore, these observations suggest that expression
of the liver gene in the heart would lead to the for-
mation of nonfunctional intercalated disks. To de-
termine whether inappropriate intercellular commu-
nication can induce cardiac arrhythmias, we have
created two fusion genes that should facilitate and
inhibit electrical coupling between cardiac muscle
cells. Our initial fusion gene constructs have ex-
ploited the ANF promoter so as to limit fusion gene
expression to the atria. In the past few months, we
have obtained several independent lineages of ANF-
C43 and ANF-C32 transgenic mice and will initiate
transgene expression analysis shortly.
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GENETICS OF CELL PROLIFERATION
M. Wigler J. Field
D. Young
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I. Wieland M. Riggs
H. -P. Xu L. Rodgers
C. Nicolette J. Brodsky
G. Asouline J. Douglas
Our laboratory focuses on two general areas: signal
transduction and growth control. Much of our work
centers about the RAS proteins, small guanine-
nucleotide-binding proteins, which reside on the in-
ner surface of the plasma membrane, that have been
highly conserved in evolution and play a critical role
in mediating signals that control cellular growth and
other cellular events. We study the RAS proteins in
the yeasts Saccharomyces cerevisiae and Schizosac-
charomyces pombe and in mammalian cells. In
addition to RAS, we also study the families of
mammalian cAMP phosphodiesterases, which play
important roles in modulating the response of cells
to cAMP. We plan to continue our studies of ROS,
an oncogene that is expressed specifically in glio-
96
blastomas. Finally, we are developing a method for
genomic difference cloning, which should enable
scientists to discover new genetic abnormalities in
cancer cells and search more effectively for new
pathogenic organisms.
RAS in Saccharomyces cerevisiae
J. Field, R. Ballester, E. Chang, K. Ferguson, C. Nicolette,
A. Vojtek, J. Colicelli, J. Gerst, T Michaeli,
M. Riggs, L. Rodgers, H.-P Xu
There are two RAS proteins in S. cerevisiae, encoded
by the RAS] and RAS2 genes. They are highly ho-
mologous to the mammalian RAS genes. These yeast
proteins are essential for growth and control the ac-
tivity of adenylyl cyclase, the product of the CYRI
gene. Activation of RAS2 by point mutation (e.g.,
RAS2va119) leads to activation of the cAMP signal-
ing pathway and a consequent cluster of cellular
phenotypes, including loss of tolerance to heat shock
and sensitivity to nitrogen starvation. We have pre-
viously described the cloning of many genes that
function along the RAS pathway, including CDC25,
which encodes a factor that probably functions to
regulate RAS by controlling guanine nucleotide ex-
change; CYR1; BCY1, which encodes the regulatory
subunit of the cAMP-dependent protein kinase
(cAPK); TPK1, TPK2, and TPK3, which each en-
code catalytic components of the cAPK; and PDEI
and PDE2, which encode the low- and high-affinity
cAMP phosphodiesterases, respectively. Using these
genes, we have demonstrated a powerful feedback
inhibition that maintains this system in homeosta-
sis. We have demonstrated that the mammalian RAS
proteins have been sufficiently conserved in evolu-
tion that they can function in yeast and stimulate
yeast adenylyl cyclase in in vitro biochemical reac-
tions. We have further demonstrated that RAS pro-
teins must bind guanosine triphosphate in order to
stimulate adenylyl cyclase. Finally, we have demon-
strated through genetic analysis that it is highly likely
that RAS proteins have additional functions in yeast
(Wig ler et al., Cold Spring Harbor Symp. Quant.
Biol. 53 649 [1988]).
Many of the most essential questions about RAS
in yeast remain unsettled: How is RAS itself con-
trolled? How does RAS control adenylyl cyclase? Are
there intermediate proteins required for this func-
tion? What are the other functions of RAS in yeast?
We have made progress on these questions.
RAS in S. cerevisiae:
How Is It controlled?
R. Ballester, E. Chang, K. Ferguson,
C. Nicolette, A. Vojtek
We have previously shown that RAS can stimulate
its yeast effector only when bound to GTP. Thus,
RAS may be controlled by factors that influence
nucleotide binding. Two genes have been discovered
in S. cerevisiae that are likely to encode proteins in-
volved in this type of control of RAS. The first is
CDC25, which encodes a product that probably cata-
lyzes guanine nucleotide exchange on RAS. The sec-
ond is IRA1, which encodes a protein that probably
catalyzes GTP hydrolysis by RAS (Tanaka et al., MoL
Cell. Biol. 9: 757 [1989]). IRAI has slight homology
with a mammalian gene called GAP (Trahey et al.,
Science 242: 1697 [1988]). GAP has been shown to
induce GTP hydrolysis by RAS (Trahey and McCor-
mick, Science 238: 542 [1987]). It has been proposed
by other investigators that GAP is the effector for
RAS (Adari et al., Science 240: 518 [1988]). In con-
trast, genetic analysis strongly suggests that IRA1
protein is involved with the down regulation of RAS
(Tanaka et al., Mol. Cell. Biol. 9: 757 [1989]), and
more specifically with its feedback control (Wig ler
et al., Cold Spring Harbor Symp. Quant. Biol.
53: 649 [1988]; Ballester et al., Cell 59: 681 [1989];
Tanaka et al., MoL Cell. Biol. 9: 757 [1989]). We have
found that mammalian GAP, when expressed in
yeast, does indeed down-regulate RAS (Ballester et
al., Cell 59: 681 [1989]). It down-regulates both wild-
type RAS2 and mammalian Ha-ras, when expressed
in yeast, but not the activated RAS2va" protein,
and can genetically complement iral- yeast. These
results suggest to us that mammalian GAP may be
involved in the feedback inhibition of RAS in mam-
malian cells.
cAMP levels in yeast are regulated by glucose
(Thevelein and Beullens, J. Gen. MicrobioL 131: 3199
[1985]). Other nutrient effects may be mediated
through the cAMP effector pathway. We do not
know the chain of events by which these signaling
events occur. Other gene products besides those of
CDC25 and IRA] may be involved. To explore this
area, we have begun searching for genes that, when
overexpressed in yeast, can suppress the loss of IRA]
or can suppress the loss of CDC25. Several new can-
didate yeast genes have been identified, and they will
be characterized by sequence, genetic, and biochem-
ical analyses. To perform biochemical analysis, we
must first find conditions under which some com-
ponent can affect the nucleotide bound to RAS. We
are in the process of purifying CDC25 protein from
yeast to determine under what conditions it can cata-
lyze nucleotide exchange. We have shown that dom-
inant interfering mutants of RAS can block func-
tion of wild-type RAS (Powers et al., MoL Cell. Biol.
9: 390 [1989]). Interference is suppressed by overex-
pression of CDC25. We therefore proposed that these
interfering RAS mutants form stable complexes with
CDC25. We are in the process of testing this hypoth-
esis by biochemical studies.
Our focus on the control of RAS is CDC25. For
97
reasons stated below, we believe it is likely
that
CDC25 has a mammalian homolog. Our
studies in
yeast thus will help guide experiments
in mammalian
cells. The fundamental question, both in yeast and
in mammals, is the nature of the ultimate initiating
signal for the pathway. In yeast, this
initiating sig-
nal may originate from within the cell,
perhaps a con-
sequence of the metabolic state of the cell. There may
be a similar initiating signal in mammalian
cells.
RAS in S. cerevisiae: Its
Interactions with Adenylyl
Cyclase
R. Ballester, J. Colicelli, K. Ferguson, J. Field, J. Gerst,
T. Michaeli, M. Riggs, L. Rodgers, A. Vojtek
We showed several years ago that the major effects
of RAS proteins in yeast were explainable by their
stimulation of adenylyl cyclase and that RAS pro-
teins do indeed stimulate adenylyl cyclase in vitro.
It has remained an open question whether this in-
teraction is direct or whether it requires the presence
of intermediary proteins. To help resolve this ques-
tion, we are using extensive genetic and biochemical
approaches. S. cerevisiae adenylyl cyclase made in
Escherichia coli is neither full length nor RAS-
responsive (unpublished results). To purify the
adenylyl cyclase complex from yeast, we developed
a method of epitope fusion and utilized immunoaf-
finity chromatography. This epitope fusion method
is widely applicable for studying stable protein com-
plexes. The adenylyl cyclase purified by this method
copurifies with a tightly associated subunit with an
apparent molecular weight of 70K (Field et al., Mol.
Cell. Biol. 8: 2159 [1988]). We call this protein CAP
for cyclase-associated protein. We have raised poly-
clonal antisera to CAP and identified the cDNA en-
coding CAP (Field et al., Cell [1990] in press) by
screening an S. cerevisiae cDNA expression library
(a generous gift from J. Kuret, Structure Section)
with this antisera.
We have found that CAP is identical to a gene
we had previously isolated, called SUPC. supC was
a mutation that suppressed the phenotypes of acti-
vated RAS. In fact, cells that have disruptions of
CAP do not respond to activated RAS2va119, and the
adenylyl cyclase purified from such yeast does not
respond to RAS proteins in vitro.
We are currently testing if the coexpression of
CAP and adenylyl cyclase in E. coli is sufficient to
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generate a RAS-responsive complex. At present, we
know that these two proteins do form a complex
when coexpressed in E. coli, but we do not yet know
if other factors are required to form a RAS respon-
sive complex. We are continuing the search for such
factors by both biochemical and genetic means.
CAP is itself an interesting protein. Preliminary
data suggest that it is conserved in evolution (see sec-
tion on S. pombe, below). Disruptions of CAP lead
to a severe phenotype that, at present, can best be
explained by a failure to manage amino acid metab-
olism. We are in the process of testing this hypothe-
sis and are looking at the interaction of CAP with
GCN4, a protein involved in general amino acid me-
tabolism (Hinnebusch, Mol. Cell. Biol. 5: 9 [1985]).
The primary structure of CAP indicates that it con-
tains two domains, separable by a stretch of prolines.
Work in progress suggests that each domain has a
distinct function: The amino-terminal domain is re-
quired for RAS responsiveness and the carboxy-
terminal domain is required for amino acid response.
We will continue to explore the function of CAP in
an attempt to understand its role in mediating RAS
effects, its role in mediating other signal transduc-
tion pathways in yeast, and its role in the evolution
of signal transduction pathways.
We have also investigated the domains of adenylyl
cyclase that appear to be required for interactions
with RAS by assaying the RAS responsiveness of mu-
tant adenylyl cyclase molecules in vitro. Figuring
prominently in this work is a domain of cyclase that
we call the leucine-rich repeat. The leucine-rich re-
peat occurs in the middle third of the adenylyl cy-
clase molecule and is composed of about 25 units
of a consensus motif 23 amino acids in length. This
motif is punctuated by proline and asparagine and
contains leucine or an aliphatic amino acid every two
to three residues. Similarly organized repeats have
now been noted in a number of mammalian and in-
sect proteins that form stable complexes with other
proteins (Field et al., Science 247: 464 [1990]). Our
work has shown that an adenylyl cyclase molecule
with an amino-terminal deletion within 100 amino
acids of the leucine-rich repeat is still fully RAS-
responsive (Colicelli et al., Mol. Cell. Biol. [1990] in
press). Deletions within the remaining molecule de-
stroy RAS responsiveness. Small inframe insertion
mutations reveal a different picture. Such mutations
are generally without effect, except within the
leucine-rich repeat. These data indicate that large-
scale spacing of the adenylyl cyclase molecule is crit-
ical to its ability to respond to RAS, and the struc-
tural requirements within the leucine-rich repeat are
especially rigorous.
We have discovered a second approach to study-
ing RAS/target interactions. Mutant forms of
adenylyl cyclase can actually interfere with the func-
tion of RAS, as evidenced by their ability to restore
heat-shock resistance to strains carrying the
RAS2va1l9 mutation (Field et al., Science 247: 464
[1989]). This observation led us to map the minimum
region of the adenylyl cyclase molecule capable of
interfering with RAS to the leucine-rich repeat it-
self. These studies also led to the design of genetic
screens for the mammalian effectors of RAS (see
below).
RAS in S. cerevisiae:
Its Other Functions
T. Michaeli, A. Vojtek, H.-P. Xu
Although most of the functions of RAS in S. cere-
visiae can be explained by effects on the cAMP sig-
naling pathway, not all of its functions can be so
readily explained (Wig ler et al., Cold Spring Har-
bor Symp. Quant. Biol. 53: 649 [1988]). First, rasl-
ras2- spores are not viable, whereas cyrl- spores are.
Second, cells that are rasl- ras2- and suppressed by
high-copy kinase genes, such as TPK1 and SCH9,
are temperature sensitive, whereas cells that are cyrl-
and suppressed by these kinase genes are not tem-
perature sensitive.
There is a third effect of RAS that is not readily
explained by its effects on adenylyl cyclase. We have
found that high levels of expression of an Ha-ras pro-
tein that has lost its carboxy-terminal processing site
(e.g., Ha-raster/86) can suppress the phenotype of the
RAS2va119 gene in yeast (Michaeli et al., EMBO J.
8: 3039 [1989]). Our biochemical and genetic analy-
ses suggest that these types of Ha-ras mutants do
not interfere with the processing of RAS2va1l9 or its
interaction with adenylyl cyclase. Moreover, the mu-
tant Ha-ras proteins must be bound with GTP to
interfere. Our results are most readily explained if
the mutants of Ha-ras bind to a second RAS effec-
tor, effectively competing for its binding with
membrane-bound RAS. We think that this function
has been conserved in evolution, since similar inter-
fering effects of defective Ha-ras proteins are seen
in Xenopus oocytes (Gibbs et al., Proc. Natl. Aad.
Sci. 86: 6630 [1989]). Several candidate yeast suppres-
sor genes of these mutant Ha-ras genes have been
found and are being analyzed. These studies may
lead to the discovery of RAS effector pathways that
are truly conserved in eukaryotes.
RAS in S. pombe
M. Kawamukai, M. Riggs, L. Rodgers, Y. Wang,
H.-P Xu, D. Young
We have initiated the study of RAS in S. pombe, a
fission yeast that is very diverged from S. cerevisiae.
At the nucleotide level, S. pombe appears as diverged
from S. cerevisiae as it is from mammals. In this or-
ganism, there is a single known homolog of RAS,
called rasl (Fukui and Kaziro, EMBO J. 4: 687
[1985]). rasl- cells are viable, round, sporulation-
defective, and mating-deficient (Fukui et al., Cell
44: 329 [1986]). rasl does not appear to operate
through adenylyl cyclase. These differences between
S. pombe and S. cerevisiae make the study of rasl
in S. pombe particularly attractive.
We have focused on the function of rasl and have
utilized two approaches. First, we are in the process
of analyzing the adenylyl cyclase system of S. pombe.
Knowledge of this system will allow us to compare
and contrast S. pombe and S. cerevisiae RAS-re-
sponsive systems. We will be able to test S. cerevisiae
components in S. pombe to learn more about their
function. In particular, we will be able to learn if
these components are RAS-specific or adenylyl-cy-
clase-specific. Second, we are in the process of a
genetic analysis of suppressors of rasl- deficient cells,
in the expectation that some suppressors will encode
proteins in the rasl effector pathway. Progress has
been made in both of these approaches. We have
identified the S. pombe gene encoding adenylyl cy-
clase (Young et al., Proc. Natl. Acad. Sci. 86: 7989
[1989]). This gene encodes a protein that is highly
similar to S. cerevisiae CYR1, including the carboxy-
terminal catalytic domain and the leucine-rich re-
peats. Amino-terminal to the repeats is complete
divergence. Overexpression of S. pombe CYR] leads
to sterility in that organism. We have begun to look
for suppressors of this phenotype. It is our expecta-
tion that S. pombe contains another RAS-like pro-
tein that controls its adenylyl cyclase activity.
The availability of the S. pombe system will en-
able us to examine the functions of S. cerevisiae genes
more clearly. For example, we have already found
that antibodies to S. cerevisiae CAP can be used to
precipitate S. pombe adenylyl cyclase activity. A
homolog to CAP must exist in this organism, and
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we have begun searching for it in S. pombe expres-
sion libraries. By isolating this homolog, we will learn
about the evolution of the domains of CAP, and this
knowledge will help us to search for CAP homologs
in higher organisms.
Our genetic analysis of the RAS pathway in
S. pombe has centered around the search for genes
that, when overexpressed, can suppress the pheno-
type resulting from ras] deficiency. To do this, we
have created S. pombe strains lacking rasl or con-
taining dominant interfering mutants in rasl, of the
type that we found in S. cerevisiae which block
CDC25 function (Powers et al., Mol. Cell. Biol.
9 390 [1989]). Such cells are defective in sporulation.
One gene was isolated from a high-copy chromo-
somal library that could suppress the interfering rasl,
and we called it sirl. The nucleotide sequence of sirl
indicates that it encodes a serine/threonine kinase.
Genetic analysis indicates that the sirl product acts
downstream from Rasl protein and perhaps up-
stream of the product of byrl, another gene encod-
ing a protein kinase that is capable of suppressing
ras] deficiency (Nadin-Davis and Nasim, EMBO J.
7: 985 [1988]). Thus, it is likely that the sirl kinase
is closer to the root of the S. pombe rasl pathway
than is the byrl kinase. We are testing if sirl copuri-
fies as part of a rasl responsive complex. In yeast,
Sirl protein appears to be exclusively membrane
bound. We have succeeded in expressing Sirl pro-
tein in E. coli.
Mammalian RAS
R. Ballester, E. Chang, J. Colicelli, K. Ferguson,
J. Field, C. Nicolette, M. Riggs, L. Rodgers,
A. Vojtek, H. -P. Xu
The parallels between the mammalian and yeast RAS
pathways are striking. First, mammalian RAS can
function in a yeast host and can stimulate yeast
adenylyl cyclase in vivo and in vitro. Second, yeast
RAS can function in mammalian cells to induce
transformation (DeFeo-Jones et al., Science 228: 179
[1985]). Third, mammalian GAP can complement
yeast deficient in IRA]. Fourth, we and other inves-
tigators have shown that Ha-ras mutants that are
dominant interfering in yeast are dominant interfer-
ing in mammalian cells (Powers et al., Cell 36: 607
[1984]; Feig and Cooper, Mol. Cell. Biol. 8 3235
[1988]). Most recently, we have shown that the yeast
SCD25 gene, a homolog of CDC25 (Boy-Marcotte
et al., Gene 77: 21 [1989]), can transform animal cells.
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Despite these similarities, the targets of RAS action
appear to be different in yeast and vertebrates.
We have applied a genetic approach to identify..
ing mammalian components that interact with RAS.
We constructed mammalian cDNA libraries in yeast
expression vectors and have searched these libraries
for genes that can suppress mutations in the RAS
pathway in yeast (Colicelli et al., Proc. Natl. Acad.
Sci. 86: 3599 [1989]). We have utilized three types of
screens, using both S. cerevisiae and S. pombe as
hosts.
The first cDNA screen has been for genes that
can suppress the heat-shock phenotype of cells with
the RAS2vall9 mutation. The rationale for this screen
is that, like the defective adenylyl cyclase gene, the
mammalian effector of RAS might well interfere
with activated RAS. Several candidates have emerged
from this screen. One set encodes cAMP phos-
phodiesterases (see below). The second set is under
evaluation. Genes from the second set do not ap-
pear to encode cAMP phosphodiesterases and bear
no homology with previously identified nucleotide
sequences in the data banks. At least one member
of this set encodes a product that interferes with ac-
tivated rasl in S. pombe. We expect that genes from
this set either encode true inhibitors of RAS func-
tion (e.g., by blocking nucleotide exchange) or, more
likely, are effectors of RAS that are not functional
in yeast hosts.
In the second cDNA screen, we have sought
cDNA genes that can suppress the loss of rasl in
S. pombe. Several mammalian cDNAs have been iso-
lated this way, and they are still under investigation.
Among the genes so isolated have been Ha-ras,
RAPT, and RAMA. The latter two genes are mem-
bers of the RAS superfamily (Pizon et al., Oncogene
3: 201 [1988]). RAP] was also isolated as Ki-rev-1,
a gene capable of suppressing Ki-ras function in
mammalian cells (Kitayama et al., Ce1156: 77 [1989]).
Our results demonstrate that RAP genes and RAS
genes can share effectors.
The third cDNA screen is designed to search for
genes that can suppress S. cerevisiae with tempera-
ture-sensitive alleles of CDC25. We hope that this
screen uncovers mammalian homologs of CDC25.
The ROS Oncogene
C. Birchmeier, K. O'Neill, M. Riggs, S. Sharma
The ROS oncogene was first discovered as the trans-
forming principle of the avian retrovirus UR-2 (Neck-
ameyer and Wang, J. Virol. 53: 879 [1985]). We first
encountered it as MCF3, an oncogene arising by rear-
rangement following a DNA transfer experiment.
Subsequent studies revealed ROS to be expressed in
a high proportion of human glioblastomas, but in
very few other kinds of tumors, and not at all in nor-
mal glial cells. In glioblastomas, the predominant
mRNA is about 8.0 kb. We have cloned cDNA to
this mRNA from SW1088 and have completed the
nucleotide sequence (Birchmeier et al., Cell 43: 615
[1985]). We have also cloned a cDNA to a 4.0-kb ROS
mRNA found in another cell line, U118 (Sharma et
al., Oncogene Res. 5: 91 [1989]). ROS can encode a
transmembrane tyrosine kinase that shares homol-
ogy with the product of the Drosophila melanogas-
ter sevenless gene, both in the intracellular kinase
domain and in the extracellular domain. Studies of
ROS have shown that in two out of two glioblas-
tomas, it has undergone mutation, consistent with
the idea that the aberrant expression of ROS con-
tributes to the malignancy of tumors of glial origins.
We plan to continue these studies, examining the ex-
pression of ROS in primary brain tumors, using an-
tisera to a ROS protein that we have developed. It
is our hope that ROS protein will prove to be a use-
ful cell surface marker for the diagnosis and treat-
ment of tumors of glial origin.
lammalian cAMP Phosphodiesterase
Genes
G. Bolger, J. Colicelli, T Michaeli, M. Riggs, L. Rodgers
In the course of analysis of mammalian cDNAs that
can suppress the effects of activated RAS in yeast,
we discovered several cDNAs encoding high-affinity
cAMP phosphodiesterases (Colicelli et al., Proc.
Natl. Acad. Sci. 86: 3599 [1989]). These phos-
phodiesterases are of the class inhibited specifically
by rolipram, and they comprise a family of enzymes
similar in structure to the product of the dunce lo-
cus in D. melanogaster (Chen et al., Proc. Natl. Acad.
Sci. 83: 9313 [1986]). We have begun identifying and
enumerating the species of phosphodiesterases ex-
pressed in human brain. The number of such genes
expressed is surprisingly high. We are pursuing this
project in the expectation that the characterization
of the phosphodiesterases may be of medical value
and in the hope that an understanding of the pat-
tern of gene expression may lead to insights into
the organization and evolution of neuronal cell
populations.
A New Method for Genomic
Difference Cloning
I Wieland, G. Bolger, K. O'Neill, G. Asouline
One common and fundamental problem of molec-
ular biology confronts us when two similar genomes
differ and we desire to understand the difference. One
simple form of this problem can occur when a ge-
nome becomes deleted for sequences present in an-
other due to germ line mutation, as can happen in
genetic disease, or due to somatic mutation, as can
happen during the development of cancer. Differ-
ences can also be acquired by infection with a DNA-
based pathogen. Methods for identifying and isolat-
ing sequences present in one DNA population that
are absent or reduced in another are called "differ-
ence cloning." Methods for difference cloning of
cDNA populations have been widely described. Only
one method for the difference cloning of genomic
DNA is reported in the literature. This method was
first described by Lamar and Palmer (Cell 37: 171
[1984]), who used it to clone sequences from the Y
chromosome. Kunkel and co-workers used a varia-
tion of this method to clone fragments of the
Duchenne's muscular dystrophy locus (Kunkel et al.,
Proc. Natl. Acad. Sci. 82: 4778 [1985]), which be-
comes deleted in some afflicted individuals. We have
developed a different method for genomic difference
cloning that is potentially more powerful (Wieland
et al., Proc. Natl. Acad. Sci. [1990] in press). Al-
though our method is not yet sufficient to isolate
and define the small differences in genomes that
would make it enormously useful as a tool for the
study of neoplasia or infectious disease of viral ori-
gin, improvements are under way that will bring our
method into that range. In its present state, our
method is useful for the analysis of some genetic dis-
eases and infectious diseases of unknown origin.
In our procedure for genomic difference cloning,
sequences present in one genomic DNA population
("tester") are isolated that are absent in another
("driver"). By subtractive hybridization, a large ex-
cess of driver is used to remove sequences common
to a biotinylated tester, enriching the "target" se-
quences that are unique to the tester. After repeated
subtractive hybridization cycles, tester is separated
from driver by avidin/biotin affinity chromatogra-
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phy, and single-stranded target is amplified
by the
polymerase chain reaction, rendering it double-
stranded and clonable. We have successfully modeled
two situations: the gain of sequences that result from
infection with a pathogen and the loss of sequences
that result from a large hemizygous deletion. We ob-
tain 100-700-fold enrichment of target sequences.
We are in the process of improving the method by
exploiting the second-order kinetics of self annealing.
We are hopeful that we can soon begin to identify very
small sequence differences between chromosomes.
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RAS ONCOGENES AND SIGNAL TRANSDUCTION
D. Bar-Sagi N. Gale
L. Graziadei
S. Kaplan
S. Palmer
A. Samatar
Y. Ye h
During the past year, our research has continued to
focus on two areas: (1) the cellular function of ras
proteins and (2) the molecular properties of
phospholipase A2 (PLA2). Both ras proteins and
PLA2 have been implicated in the transduction of
signals across the plasma membrane, and earlier
studies from our laboratory indicate a possible
functional link between PLA2 activation and ras-
induced cell transformation. Our goal is to under-
stand the role that these proteins play in the control
of cell proliferation.
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Molecular Cloning of
Phospholipase A2
N. Gale, S. Palmer, A. Samatar, D. Bar-Sagi
During the past several years, evidence has been
accumulating in support of a role for membrane
PLA2 (mPLA2) in the transduction of mitogenic
signals. A major aim in our laboratory has been the
cloning of mPLA2. As an initial approach, we have
carried out immunological screening of rat pan-
creatic and rat brain Xgtl 1 libraries using rabbit
polyclonal anti-PLA2 antibodies. These antibodies
recognize mPLA2 in rat cells, as determined by
immunocytochemical and functional assays, and
therefore constitute a potentially powerful tool for
use in screening cDNA expression systems. However,
exhaustive screening of a Xgtl 1 cDNA expression
library from rat brain tissue has not yielded positive
clones. Presumably, the low abundance of PLA2
message within cells and/or the toxic effects of its
overexpression in the Escherichia coli system has
made the cloning of PLA2 refractory to this meth-
od. In an attempt to circumvent these difficulties,
we are utilizing the polymerase chain reaction (PCR).
Alignment of the peptide sequences of all the known
mammalian PLA2s reveals a significant sequence
divergence among these enzymes. However, several
regions of high conservation can be identified,
including the calcium-binding loop and regions
comprising the enzyme's active site. Using the
information generated by these alignments, we have
designed several slightly degenerate pairs of synthetic
oligonucleotide primers to be used to amplify the
rare PLA2 sequence from rat brain cDNA. Although
this research is still in progress, pilot studies suggest
that this method will yield success in the cloning of
intracellular PLA2.
To learn more about the structure, function, and
evolution of PLA2, we have also sought to clone
the genes for other members of the PLA2 family
from Drosophila melanogaster and Saccharomyces
cerevisiae. Toward this end, we are using a full-length
cDNA clone of the secreted pancreatic form of the
enzyme that was isolated in our laboratory. South-
ern analysis reveals several hybridizing bands when
using the pancreatic cDNA probe at low stringency.
To date, a Drosophila genomic DNA library has been
screened, and several positive phages have been iso-
lated. Characterization of these clones from Drosoph-
ila and the pursuit of similar clones from yeast will
be the focus of continuing effort in the laboratory.
Role of Phospholipase A2
in Exocytosis
L. Graziadei, D. Bar-Sagi
Last year, we demonstrated that microinjection of
the ras oncogene induces exocytotic degranulation
in rat peritoneal mast cells. This exocytotic response
involves the translocation of histamine-containing
granules to the plasma membrane, fusion of the gran-
ule and plasma membranes, and subsequent release
of the granule contents to the extracellular space. Cel-
lular PLA2 is a candidate for a mediator of this re-
sponse as the enzyme's activity results in the release
of lysophospholipids, which are potent membrane
fusogens.
We have used our polyclonal anti-PLA2 serum to
analyze the participation of PLA2 in ligand-induced
exocytotic degranulation. Affinity-purified prepara-
tions of these anti-PLA2 antibodies recognized a
16-kD band on immunoblots of total cellular pro-
teins from mast cells. Furthermore, incubation of
mast-cell membranes with the anti-PLA2 antibod-
ies resulted in a significant inhibition of PLA2 ac-
tivity, as assayed by thin-layer chromatography.
These results indicate that the anti-PLA2 antibod-
ies recognize a population of the mast-cell mem-
brane-associated PLA2. Compound 48/80 and the
calcium ionophore A23187 are each capable of in-
ducing mast-cell degranulation. Compound 48/80
acts via a cell surface receptor, whereas A23187
bypasses the receptor and activates the exocytotic re-
sponse by postreceptor signals. Microinjection of
affinity-purified anti-PLA2 antibodies inhibited de-
granulation induced by compound 48/80, and that
induced by calcium ionophore was unaffected. These
observations suggest a regulatory role for PLA2 in
ligand-induced exocytosis.
The anti-PLA2 antibodies were employed in an
immunocytochemical localization study utilizing in-
direct immunoperoxidase and immunogold tech-
niques. Resting mast cells show a low level of im-
munoperoxidase staining primarily on the cell
membrane and, infrequently, on intracellular mem-
branes, including those of the histamine-containing
granules. Enhanced staining was detected on mem-
brane ruffles. Stimulation of cells with compound
48/80 or calcium ionophore induced a dramatic
redistribution of staining. Heavy, discrete patches of
staining were evident over the points of apposition
between the plasma membrane and granule mem-
brane that appear prior to membrane fusion. Sur-
rounding areas of membrane were depleted of stain-
ing. To refine the localization of immunoreactive
material, immunogold labeling was performed. A
sporadic gold labeling of the granule matrix was ob-
served in resting and stimulated cells. Granule mem-
branes showed little labeling, whereas most of the
gold particles were localized to the plasma membrane.
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Taken together, our observations indicate that
catalytic activity of PLA2 is required for some types
of ligand-induced exocytosis in rat peritoneal mast
cells. The spatial redistribution of this enzyme dur-
ing exocytosis is consistent with a role for PLA2 as
a catalytic membrane fusogen. Our future studies
will focus on the functional interrelation between
PLA2 and ras proteins in the exocytotic response.
Role of ras Proteins in
Transmembrane Signaling
in B Lymphocytes
L. Graziadei, D. Bar-Sagi [in collaboration with K. Riabowol,
Cold Spring Harbor Laboratory]
Signal transduction in B lymphocytes is marked by
a well-characterized set of morphological changes:
surface immunoglobulin (Ig) receptors cross-linked
by antibody or appropriate multivalent antigens
form aggregates called patches that then collect, via
interaction with the cytoskeleton, into a single cap-
like assembly at one pole of the cell. Receptor aggre-
gation constitutes the initial signal for a process
known as B-cell activation, which includes growth
factor receptor expression, clonal proliferation, and
Ig class switching. The movement of cross-linked sur-
face Ig provides a useful experimental system for the
identification of other cell membrane components
that may be involved in B-cell activation. In partic-
ular, using double-labeling techniques, it is possible
to monitor the movement of surface Ig induced by
a specific labeled ligand while visualizing any as-
sociated changes in the localization of a second, spe-
cifically labeled membrane component.
We have used double immunofluorescence stain-
ing to monitor the distribution of ras proteins in
mouse splenic B cells during various stages of patch-
ing and capping. Surface Ig was stained with fluo-
rescein-conjugated goat anti-mouse IgG. ras proteins
were stained using affinity-purified rabbit anti-ras
antibodies, followed by rhodamine-conjugated goat
anti-rabbit IgG. The specificity of the anti-ras anti-
bodies was established by immunoprecipitation and
immunofluorescence staining. Resting cells displayed
a uniform membrane staining of IgG and ras. How-
ever, stimulation of B cells with anti-mouse Ig was
accompanied by the redistribution of ras proteins.
At each stage of patching and capping, ras redistri-
bution paralleled that of surface IgG, with ras be-
coming directly localized under each patch and cap
(Fig. 1). The kinetics of redistribution of each pro-
tein were identical.
We have initiated studies aimed at understand-
ing the mechanisms underlying the redistribution of
ras proteins and the functional significance of this
redistribution event. Treatment of B cells with meta-
b
FIGURE 1 Redistribution of surface IgG and p21's in mouse splenic B lymphocytes treated with anti-
mouse IgG. Induction of patching and capping was carried out using fluorescein-conjugated goat anti-
mouse IgG or fluorescein-conjugated Con A. Upper panels show the fluorescence staining pattern of surface(a,c,e,g) and Con A receptors (i), and lower panels show the fluorescence staining pattern of p21'.(a, b) Uniform distribution prior to stimulation with goat anti-mouse IgG or Con A; (c,d) patching after 5
min of stimulation; (e,f) capping after 15 min of stimulation: (g) IgG caps at 15 min of stimulation; (h) same
cells as in panel h stained with secondary antibody
alone; (i) Con A cap after 30 min of stimulation. Magnifi-
cation, 3312x.
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bolic inhibitors or with cytoskeletal disrupting agents
prevents surface Ig capping. Under these conditions,
IgG is arrested in patches and ras remains in a cor-
responding patchy distribution. Furthermore, we
have demonstrated the specificity of ras capping by
using concanavalin A (Con A), a nonmitogenic lec-
tin, to induce the capping of Con-A receptors. Al-
though Con-A-induced caps are morphologically in-
distinguishable from those induced by IgG, ras
displays a resting, uniform membrane distribution
in these cells (Fig. 1). Thus, the redistribution of ras
proteins appears to be a signal-specific event. Over-
all, these findings illustrate for the first time the dy-
namic aspects of the association of ras with the
plasma membrane and provide evidence that the dis-
tribution of ras proteins can be controlled by recep-
tor-ligand interaction. We are now investigating the
functional significance of this redistribution event.
Two possibilities are being specifically examined: (1)
ras protein as a component of the mechanism for
the ligand-induced capping process or (2) ras pro-
tein as a component of the signaling pathway trig-
gered by the aggregation of ligand-receptor complexes.
Association of ras Proteins with
Cellular Polypeptides
S. Kaplan, D. Bar-Sagi
We are using polyclonal anti-ras antibodies to iden-
tify cellular proteins that interact with p2lras. In ad-
dition to p2lras proteins, the anti-ras antibodies
precipitate from A431 cell lysates several polypep-
tides with relative molecular weights of approxi-
mately 150K, 120K, 105K, and 50K. Two-dimensional
gel electrophoresis of the immunoprecipitates reveals
two additional, although less prominent, "coprecipi-
tates" with relative molecular weights of 50K and
60K. Several lines of evidence suggest that these pro-
teins are cellular polypeptides that interact with ras:
(1) These polypeptides are not precipitated from cells
when the antibody is preincubated with an excess
of purified ras protein. (2) After denaturation, the
p2lras proteins, but not the other polypeptides, are
specifically recognized by the antibodies. (3) In im-
munoblots of A431 cells, the anti-ras antibodies did
not detect the ras-associated polypeptides. Thus, it
is unlikely that the 150K, 120K, 105K, and 50K poly-
peptides are recognized directly by the anti-ras anti-
bodies due to epitopes shared with p2lras proteins.
Cellular fractionation reveals that the 150K polypep-
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FIGURE 2 Immunoprecipitation of native or denatured proteins
from A431 cells. A431 cells were labeled with [35S]methionine,
and cell lysates were prepared in RIPA buffer with or without 1%
SDS. The SDS-treated lysates were boiled for 5 min and then
diluted tenfold with RIPA buffer. Aliquots from the native and the
denatured samples were immunoprecipitated with the anti-ras
(a-ras) antibodies or with the anti-ras antibodies preincubated
with 1µg of purified Ha-ras protein (T24). The immune complexes
were collected on protein ASepharose, washed, and separated
on a 12.5% SDS-polyacrylamide gel.
tide is found exclusively in the membrane (P-100)
fraction, whereas the 120K and 105K polypeptides
are found in both the membrane and soluble (S-100)
fraction. The 120K and 105K are phosphorylated on
serine and threonine residues. We are currently char-
acterizing the association of these proteins with
p21ras in normal and ras-transformed cells. Our aim
is to establish whether the cellular proteins consti-
tute functional targets for ras proteins.
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NUCLEAR ONCOGENES AND SIGNAL TRANSDUCTION
M. Gilman R. Attar
L. Berkowitz
D. Girgenti
R. Graham
K. Riabowol
W. Ryan
Our major interest is how extracellular signals are
communicated to the nucleus. Our focus is the proto-
oncogene c-fos, which is a critical crossroads for in-
formation flow to the nucleus. The c-fos gene is rap-
idly activated at the transcriptional level by trigger-
ing of any one of several intracellular signal
transduction pathways. Sequences within the c-fos
gene thus constitute physical targets for these incom-
ing signals. Several projects in our laboratory are
concerned with identifying these target sites and trac-
ing the signaling chains back toward the cell surface.
The product of the c-fos gene is a nuclear protein
that participates in the formation of a heterogeneous
set of sequence-specific DNA-binding proteins that
are presumed to act on the next set of genes acti-
vated in the transcriptional cascades triggered by
growth and differentiation factors. Thus, the c-fos
gene is itself part of the cell's signal transduction ma-
chinery, acting to convert short-term signaling in-
formation (on the order of minutes) to long-term
cellular responses (on the order of hours and days).
Other projects in the laboratory are aimed at under-
standing the role of Fos in this process and especially
how the biological specificity of growth factors might
be reflected in the make-up of Fos protein complexes.
Functional Analysis of the
Serum Response Element
M. Gilman, R. Graham
A major DNA target in the c-fos gene for incoming
signals is the serum response element (SRE). The
SRE was first identified as a sequence required for
induction of c-fos transcription by whole serum.
Subsequently, the SRE was shown to consist of a 20-
bp dyad symmetry element that is necessary and suf-
ficient for the response of c-fos to serum, many pu-
rified growth factors, and at least two distinct intra-
cellular signal transduction pathways. More recently,
the SRE has also been shown to be the target for
repression of c-fos transcription in unstimulated cells
and for the rapid repression that follows induction
by serum. In the latter case, the Fos protein itself
is believed to play a role. Thus, the SRE is a mul-
tifunctional element. As described below, the SRE
is a binding site for at least three cellular DNA-
binding proteins. At least one of these proteins is
required for activation of c-fos transcription in re-
sponse to serum, because microinjection of an SRE
oligonucleotide into quiescent cells blocks subse-
quent induction of c-fos expression by serum. Other
proteins may be required for repression.
To attempt to assign specific functional roles to
each of the DNA-binding proteins that interact with
the SRE, we performed saturation mutagenesis on
a portion of the SRE that is contacted by all three
proteins. Our goal was to generate a collection of
mutant sites that bound distinct combinations of the
three proteins. Of particular interest, we isolated sev-
eral single-nucleotide substitutions in the SRE that
bound one protein, SRF, at wild-type levels but failed
to form a ternary complex with a second protein
(p62-rcF) that specifically recognizes the SRE-SRF
complex (Fig. 1). This ternary complex has been
reported to be required for serum activation of c-fos
transcription. However, each of these mutants was
found to be inducible by serum at at least wild-type
levels. Our current hypothesis is that the SRF-p62TcF
is required for activation by some but not all signal-
ing pathways.
Structural and Functional Studies
of SRE-binding Proteins
W.A. Ryan, Jr., M. Gilman [in collaboration with
D. Marshak and E. Chang, Cold Spring
Harbor Laboratory]
The c-fos SRE is a control element that mediates
c-fos activation by several distinct intracellular sig-
nal transduction pathways and c-fos repression by
one or more distinct pathways. To understand how
these different activities are regulated, we are study-
ing the cellular DNA-binding proteins that interact
at the SRE. Until recently, only a single SRE-binding
protein was known. This protein is SRF, a 67-kD pro-
tein that binds symmetrically to the SRE. Mutations
that interfere with SRF binding abolish both induc-
tion and repression of c-fos transcription. However,
it has not been possible to demonstrate any biochem-
ical changes in SRF activity or structure that accom-
pany c-fos induction or repression, so the specific
function of SRF has remained obscure. To identify
additional DNA-binding proteins that might partic-
ipate in the complex regulatory events at the SRE,
we fractionated human cell nuclear extracts and used
two different DNA-binding assays to look for novel
SRE-binding proteins. We found two. One protein
binds directly to the SRE in asymmetric fashion dis-
tinguishable from SRF. Its apparentmolecular mass
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FIGURE 1 DNA-binding assay of mutant serum response ele-
ment derivatives. Nine SRE probes, each containing a single
nucleotide substitution, were used as substrates in a mobility-
shift assay. Each probe was assayed with partially purified nu-
clear fractions enriched for SRF and p62TCF. Arrow points to the
ternary complex containing SRE DNA and both proteins. The
lower band contains only SRF.
is 62 kD, as determined by DNA-affinity precipita-
tion and by UV cross-linking, and it is chromato-
graphically separable from SRF. We call this protein
p62DBF (direct binding factor). A second protein,
chromatographically distinct from the other two pro-
teins, does not bind directly to the SRE, but rather
specifically recognizes and binds the SRF-SRE com-
plex, forming a biochemically distinguishable ter-
nary DNA-protein complex. This protein complex
makes additional contacts with SRE DNA on the
5' side of the dyad not obtained with SRF alone. By
UV cross-linking, we have determined the size of this
protein to be 62 kD, and we call it p62TcF (ternary
complex factor). The two 62-kD proteins are bio-
chemically and chromatographically distinct, but the
possibility remains that they are related forms of the
same polypeptide.
The specific roles played by each of these proteins
in the c-fos transcription cycle remain to be estab-
lished. At present, we have been unable to demon-
strate any biochemical modifications to these pro-
teins associated with induction or repression of c-fos
transcription. The DNA-binding activities of the pro-
107
teins do not appear to change, and although these
are phosphoproteins in vivo, we have detected no
changes in the phosphorylation state of the proteins.
More sensitive assays are being used to examine these
proteins in vivo.
To carry out structural and functional studies of
SRF, we have obtained an SRF cDNA from Richard
Treisman (ICRF) and expressed the protein at high
levels in Escherichia coli. E. coli SRF has an appar-
ent molecular mass of 62 kD. It binds specifically
to the SRE in vitro, but its specific activity in these
assays is substantially lower than SRF purified from
human cells. In addition, it is inefficient at forming
a ternary complex with p62TcF. Preliminary results
suggest that E. coli SRF is efficiently phosphorylated
in vitro by casein kinase II (CK-II) and that phos-
phorylation significantly augments its DNA-binding
activity. Ongoing experiments are aimed at under-
standing the role of CK-II phosphorylation in SRF
function.
Cloning of a Novel
SRE-binding Protein
R. Attar, M. Gilman
As described above, the SRE is a target for multiple
signals that activate and repress c-fos transcription.
The SRE is a binding site for at least three cellular
DNA-binding proteins. One of these proteins,
p62DBF, binds directly to the SRE in a manner dis-
tinguishable from that of SRF. To determine the
structure and function of this protein and its possi-
ble relationship to the other 62-kD SRE-binding pro-
tein, p62TcF, we have purified this protein by DNA-
affinity chromatography and have attempted to iso-
late cDNA clones encoding it.
We screened a He La cell cDNA expression library
for phage expressing proteins that specifically bound
an SRE oligonucleotide. For this study, we used a
variant SRE sequence that binds p62DBF with high
affinity and binds SRF with low affinity. We isolated
a phage that encoded a lacZ fusion protein that spe-
cifically bound this SRE oligonucleotide, but not a
mutant site that does not bind the human protein
in vitro. The fusion protein binds specifically to the
SRE in both a Southwestern blot and a mobility-shift
assay (Fig. 2).
Analysis of the partial DNA sequence of this
clone revealed that it was a previously unidentified
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gene that belongs to the family of zinc-finger-
containing proteins related to the Drosophila Krup-
pel gene. The clone contains seven tandem repeats
in the carboxyl terminus that match the zinc finger
consensus for this gene family. In the zinc finger re-
gion, the clone shares 6507o sequence identity with
several human and mouse Kruppe/-related genes.
The presence of zinc fingers in this clone strongly
suggests that it is a DNA-binding protein and prob-
ably a transcription factor. Experiments currently
under way are aimed at determining whether this
clone indeed encodes p62DBF and what its effector
function is.
Regulation of c-fos
Transcription by cAMP
L. Berkowitz, M. Gilman
Among the signal transduction pathways that acti-
vate c-fos transcription is the well-characterized
cAMP pathway. We had found previously that in-
duction of c-fos transcription by cAMP was inde-
pendent of the SRE. To locate the sequences in the
c-fos promoter responsive to cAMP, we tested a se-
ries of promoter deletions and point mutants for
their ability to respond to cAMP in a transient ex-
pression assay. We found that the c-fos promoter car-
ries multiple elements that contribute the cAMP re-
sponsiveness of the promoter. The relative strengths
of these sites as CREs correlated with their affinity
for CRE-binding factors in vitro. Thus, their
strengths reflect their intrinsic activities and not their
relative positions in the promoter.
The elements we mapped in the transient expres-
sion assay are functional as CREs in the endogenous
c-fos gene. This was demonstrated by microinjection
competition assays. We microinjected into quiescent
fibroblasts double-stranded oligonucleotides corre-
sponding to the major CRE at -65 and to the SRE
and stimulated the cells with cAMP or serum. Treat-
ment with cAMP failed to induce c-fos expression
in cells injected with the CRE oligonucleotide but
induced c-fos normally in cells injected with SRE
DNA. Conversely, induction of c-fos expression by
serum was blocked by the SRE oligonucleotide but
not by the CRE. We therefore concluded that bind-
ing of proteins to elements related to the CREs
mapped in the transient expression assays is also re-
quired for activation of the endogenous c-fos gene
A. COOMASSIE
1.1-1 cnX X X 2
-200--
40.
- 92 -
- 69 -
- 46 -
I 2 3 4
B. SOUTHWESTERN BLOT C. MOBILITY SHIFT
+GUANIDINE HCI GUANIDINE HCI
PM34 PROBE PM)2 PROBE
=
1.11X X X
N ,E= N
11-1 c <IX X X
rM34 PROBE PM PROBEP
LLI iEnW <
(\j
X X X X X
I 2 3 4 5 6 7 8 9 10 II 12
Xgt 11 XA2 XE2
I I
N r0 NM NMN re)22- 22-22-
ac _3 a_ a_ 3 a_ o_ 3
I 2 3 4 5 6 7 8 9
FIGURE 2 DNA-binding assays of novel SRE-binding protein. Cultures of E. coli were infected with phage vector or two insert-containing
recombinants. A2 is the clone described in the text; E2 is an independently isolated clone carrying a different insert. Portions of
the infected cells were lysed and loaded onto an SDS/polyacrylamide gel. (A) Portion of the gel stained with Coomassie blue; (B)
identical gel lanes were blotted to nitrocellulose. In lanes 1-6, proteins on the filters were denatured in guanidine HCI and renatured
by dilution; lanes 7-12 were not treated in this way. The filters were incubated in solution containing radiolabeled oligonucleotide
encoding an SRE derivative (PM34) that binds p62DBF or a derivative that does not bind (PM12). (C) Mobility-shift assay of solubilized
fusion proteins with the same probes as in panel B and with a true wild-type SRE probe.
in its natural chromatin configuration. Moreover, un-
related elements such as the SRE do not play a sig-
nificant role in regulating c-fos expression in re-
sponse to cAMP in these cells.
Microinjection experiments carried out previously
in the lab demonstrated that activation of c-fos ex-
pression by cAMP was due to the catalytic activity
of cAMP-dependent protein kinase (pkA) and that
the action of pkA also required CRE-binding pro-
teins. These observations suggested a model in which
activation of gene expression by cAMP occurs via
phosphorylation of cellular proteins by pkA that
eventually act on CREs. The simplest form of this
model is that this interaction is direct, i.e., that pkA
directly phosphorylates and activates CRE-binding
transcription factors. A candidate for such a factor
has recently been described by M. Montminy and
colleagues. This protein, termed CREB, is a high-
affinity CRE-binding protein that is phosphorylated
in vitro by pkA. To determine whether direct phos-
phorylation of CREB by pkA could account for
regulation of gene expression by cAMP, we isolated
cDNA clones encoding human CREB. We recovered
two distinct clones that differed by a 14-amino-acid
peptide. Both CREB mRNAs are widely expressed
in many tissues. Both encode proteins that bind as
dimers to the c-fos CRE in vitro (Fig. 3). Both func-
tion as cAMP-regulated transcription factors in vivo.
When the site of phosphorylation by pkA was mu-
tated, cAMP-regulation of CREB activity was lost.
This observation is consistent with direct phosphory-
lation of CREB by pkA. The two forms of CREB
differ in their transcriptional activities when the pkA
phosphorylation site is destroyed. This observation
suggests a regulatory role for the inserted peptide
in the larger form of CREB.
Current experiments are directed at learning
whether CREB or other CRE-binding proteins par-
ticipate directly in the regulation of c-fos expression
in vivo. A second issue we would like to address is
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FIGURE 3 DNA-binding assay of in-vitro-translated CREB pro-
teins. CREB cDNAs were transcribed into mRNA in vitro using
T7 RNA polymerase, and the resulting RNA was translated in
a reticulocyte lysate. Shown is a mobility-shift assay of the reticulo-
cyte lysates programmed by CREB-A RNA (lanes 2 -4, 11), CREB-
B RNA (lanes 5-7, 12), brome mosaic virus RNA (lanes 8-10).
probes were c-fos promoter fragments containing either a
wild-type CRE (located at -65 in the promoter) (lanes 1-10), or
a similar probe carrying mutations that inactivate the CRE (lanes
11-13).
where in the cell phosphorylation of CREB by pkA
takes place and how nuclear translocation of either
the kinase or phosphorylated CREB is regulated.
Generation of Antibodies
against Fos-associated
and Fos-related Proteins
K. Riabowol, D. Girgenti, M. Gilman
The Fos protein associates with a subset of proteins
in the nucleus, which includes the protein product
of the c-jun proto-oncogene. Like Fos, Jun is a nu-
clear transforming protein and both are members of
a set of DNA-binding proteins collectively termed
AP-1, which specifically bind activator protein-1 (AP-
I) sites. These sites are also referred to as TPA-
response elements (TREs). The Fos protein is able
to bind DNA by itself, but both specificity and
avidity of binding are conferred when Fos is com-
plexed with Jun. For example, in one set of experi-
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FIGURE 4 Immunoprecipitation of T-cell lysates with antisera
raised against Fos and Fos-associated proteins. [35S]Methionine-
labeled H9 cell lysates were prepared from ionomycin-stimulated
(+) or unstimulated (-) H9 cells under denaturing (D) or non-
denaturing (ND) conditions. Lysates were immunoprecipitated
with antiserum from rabbits immunized with TrpE-Fos fusion pro-
tein (R1, R2) or with total proteins from preparative Fos im-
munoprecipitations. Immunoprecipitations from stimulated cells
were also done in the presence of unlabeled Fos fusion protein
(P) to determine if antisera from these rabbits directly recognized
the proteins they precipitated under nondenaturing conditions.
ments in which c-Jun homodimers were observed to
bind a THE sequence, Fos:Jun heterodimers bound
30-fold more efficiently, whereas c-fos failed to bind
at detectable levels.
Fos, Jun, and the protein products of several other
genes including FosB, FRA1, JunB, and JunD con-
tain a highly conserved basic motif believed to bind
DNA, and a structure termed the leucine zipper. The
leucine zipper consists of a heptad repeat of leucine
residues that are oriented toward one "face" of an
a-helical polypetide. Leucine residues on an a-helical
region of one protein are proposed to interdigitate
with those of a second protein, resulting in dimer
formation through strong hydrophobic interactions.
Recent evidence suggests that the sequences of the
leucine zipper regions control the stability and there-
fore the composition of protein complexes that form
in vivo. This, in turn, would determine which com-
plexes could subsequently associate with subsets of
specific DNA regulatory regions, thereby regulating
gene expression through more amino-terminal acti-
vation domains. These observations suggest that the
diverse effects upon cellular physiology seen when
various cell types are treated with different extracel-
lular stimuli might be due to the expression of de-
fined subsets of the Fos/AP-1 complex proteins.
To determine if such cell-type-specific or stimulus-
specific expression of Fos complex proteins occurs
in vivo, we have taken a two-step immunological ap-
proach. The first step involves identification of cell-
type-specific or stimulus-specific proteins of the Fos
complex. As shown in Figure 4, antisera from two
rabbits immunized with TrpE-Fos fusion proteins (R1
and R2) directly recognize [35S]methionine- labeled
Fos protein from stimulated T cells under both de-
naturing (D) and nondenaturing (ND) conditions.
However, when antisera were preincubated with
excess Fos fusion protein, no Fos protein was re-
covered (lanes marked P). Antisera from these two
rabbits also independently recognize two other prom-
inent proteins, but only under nondenaturing con-
ditions. This suggests that these proteins associate
with the Fos/AP-1 complex by binding to discreet
regions of the Fos protein. One of these proteins mi-
grates on one- and two-dimensional gels similarly
to the previously characterized Fos-associated on-
coprotein Jun (antiserum from R1). The other pro-
tein called p35 in Figure 4 migrates with an Mr of
35 kD, has an isoelectric point similar to that of the
characterized Jun proteins, and, like the putative
form of Jun recovered by R1 antiserum, is synthe-
sized in the absence of stimulation in T cells. Since
CELL BIOLOGY OF THE NUCLEUS
D.L. Spector S. Huang G. Lark
R. Derby
Our research program has continued to focus on the
structural-functional organization of the mam-
malian cell nucleus. During the past year, we have
we have been unable to detect the presence of p35
in a wide variety of human and rodent cell lines, p35
likely represents a T-cell-specific member of the Fos
protein complex. As a first step toward cloning p35
and other uncharacterized members of the Fos pro-
tein complex, large amounts of Fos complex proteins
were isolated using affinity-purified Fos antibodies
that had been cross-linked to protein A-Sepharose
beads. A rabbit was inoculated several times to gener-
ate antibodies that directly recognize proteins which
associate with Fos. Reactivity against several proteins
including Jun and p35 was obtained after three in-
jections. Unlike the case for antisera raised against
the Fos fusion protein, preincubation of the antise-
rum from rabbit 3 (R3) with Fos fusion protein failed
to prevent the immunoprecipitation of p35, Jun, or
the majority of other proteins recognized by this an-
tiserum (Fig. 4, compare R3 lanes ND+ and Pl. This
antiserum and monoclonal antibodies also generated
by boosting animals with proteins of the Fos com-
plex will be used to screen protein expression libraries
to isolate cDNA clones of these proteins.
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had several changes in personnel. Dr. Wai-Kit Chan
left the laboratory to attend Columbia University
Law School. Michael Delannoy, a technician in the
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laboratory, has left to assume a new position at Johns
Hopkins University, where he is responsible for the
operation of the electron microscopy laboratory; Joe
Suhan has left for an electron microscopy position
at Carnegie-Mellon University.
Dr. Sui Huang joined the laboratory as a post-
doctoral fellow, and she will be working on mRNA
transport. Gayle Lark joined the laboratory as an
electron microscopy technician, and she is concen-
trating on projects relating to nuclear localization
of proteins involved in pre-mRNA processing. The
use of the electron microscopy core facility has con-
tinued to expand, and a large number of collabora-
tions are under way with the excellent technical ex-
pertise of Robert Derby, who has also recently joined
the laboratory.
Reorganization of snRNP-enriched
Nuclear Regions upon Alterations
in the Level of Transcription
D.L. Spector M. Sovak [Undergraduate Research Program]
In a series of previous studies, we have shown that
small nuclear ribonucleoprotein particles (snRNPs)
are distributed in a nuclear network that extends be-
tween the nucleolar surface and the nuclear envelope-
lamina. In addition, we have shown that the bulk
of nuclear DNA is not contained within this nuclear
region. In the present study, we are interested in de-
termining the effects of alterations in the level of
transcription on the distribution of snRNPs. Cells
treated with 0.04 pg/m1 of actinomycin D (for 2 hr),
a drug concentration that inhibits RNA polymerase
I activity, showed no alteration in the distribution
pattern of snRNPs (Fig. 1d) as compared to control
cells (Fig. lb). Cells treated with 0.04 pig/m1 ac-
tinomycin D showed little to no autoradiographic
grains over the nucleoli, since this dose of drug spe-
cifically inhibits RNA polymerase I. However, cells
incubated with a higher dose of actinomycin D (10
µg /m1 for 2 hr) known to inhibit all RNA polymer-
ase activity exhibited a marked alteration in the dis-
tribution pattern of snRNPs (Fig. 10. snRNPs were
diffusely distributed throughout the nucleoplasm,
excluding the nucleoli. Cells treated with this higher
dose of actinomycin D, which inhibits all RNA poly-
merases, showed no autoradiographic grains in the
nucleoplasm. The alteration in the snRNP distribu-
tion pattern upon incubation of cells with concen-
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trations of actinomycin D that inhibit all RNA poly-
merases is similar to what we have previously shown
to occur to the distribution of snRNPs after heat
shock, which inhibits transcription of most genes
and processing of their transcripts.
Since RNA polymerase II, which is involved in
the synthesis of pre-mRNA, is highly sensitive to
a-amanitin, whereas RNA polymerase I is insensi-
tive and RNA polymerase III is sensitive only to high
concentrations, we were interested in the effect of
this drug on the snRNP distribution pattern. Cells
were treated with a concentration of a-amanitin that
would specifically inhibit RNA polymerase II (5
µg /ml) for 5, 9, 11, 18, and 24 hours. Cells were ex-
amined by immunofluorescence microscopy to de-
termine the effect on the snRNP distribution pat-
tern and by in situ autoradiography to determine the
effect on transcription. Cells incubated in drug from
5 hours (Fig. 2d) to 9 hours (Fig. 2f) exhibited snRNP
clusters that were more rounded in appearance than
those observed in control cells (Fig. 2b). At 9 hours
of drug incubation, the level of transcription by RNA
polymerase II was decreased as determined by sig-
nificantly fewer autoradiographic grains within the
nucleoplasm due to [3H]uridine incorporation. Af-
ter 11 hours of incubation with the drug, the snRNPs
appear larger clusters (Fig. which are fewer
in number as compared to control cells (Fig. 2b). By
18-24 hours, each cell contains one large im-
munoreactive region plus several rounded snRNP
clusters (Fig. 2j,1). These data show that the snRNP
network, characteristic of actively growing mam-
malian cells, reorganizes upon inhibition of tran-
scription by RNA polymerase II and is therefore sen-
sitive to the transcriptional level of genes transcribed
by RNA polymerase II.
Localization of Single Copy
Genes in the Interphase
Cell Nucleus
D.L. Spector
Recent developments that enhance the efficiency of
hybridization and the sensitivity of hybrid detection
have made it possible to identify and localize spe-
cific cellular or viral DNA and RNA sequences even
when present in low copy number. Although the
genes transcribed by RNA polymerase I are highly
organized within a nuclear region known as the
eFIGURE 1 CHOC 400 cells immunostained with anti-Sm antibodies exhibit a speckled
staining pattern throughout the nucleoplasm excluding the nucleoli (b). Cells incubated
with 0.04 vig/mlactinomycin D for 2 hr show no change in the distribution of snRNPs
(d). Cells incubated with 101.1g/mlactinomycin D for 2 hr exhibit a diffuse distribution
of snRNPS (f). Magnification, 830x.
nucleolus, little information is available with regard
to the nuclear organization of genes transcribed by
RNA polymerases II or III. We have begun to study
the distribution of several genes that have different
transcription units to evaluate their intranuclear spa-
tial organization. This study represents the begin-
ning of a long-term goal to determine whether there
is an underlying spatial organization to the inter-
phase genome. These initial studies, which evaluate
the distribution of interphase genes based on the type
of transcription unit, will lay the groundwork for
future studies that will evaluate whether cell-cycle-
regulated genes, housekeeping genes, structural
genes, or developmentally regulated genes localize
in clustered patterns in the interphase nucleus. Such
studies combined with antibody localization studies
of proteins involved in such processes as transcrip-
tion and RNA processing (snRNPs) will provide im-
portant data on the organization of nuclear func-
tion. Our studies on gene localization have started
out by examining the localization of the dihydrofo-
late reductase (dhfr) gene, a housekeeping gene, in
the interphase nucleus of Chinese hamster ovary
cells. The mammalian dhfr gene is a 26-29-kb gene
that is transcribed by RNA polymerase II and whose
transcription unit contains introns and codes for a
poly(A) signal. We have obtained clones inserted into
pBR322 for several regions of the CHO dhfr gene
from Dr. Larry Chasin (Columbia University). We
have selected several of these clones, subcloned them,
and inserted them into the Gem4Z plasmid for use
in in vitro transcription reactions using SP6 and T7
polymerases. We have prepared subclones of the dhfr
gene that range in size from 1.4 kb to 2.1 kb (Fig.
3) and represent unique sequences.
Probes pMB5-EcoRI and pB13-7 represent intron-
plus exon-containing probes, whereas probe pB61H1
represents an intron-containing probe. Using T7
polymerase, we have made single-stranded bio-
tinylated RNA probes that are complementary to
the DNA sense strand and can be used for DNA lo-
calization. We have used a mixture of our probes
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FIGURE 2 Cells incubated with 5 p,g/mla-amanitin for 5 hr begin to show a round-
ing up of snRNP clusters (d) as compared to control cells (b). This change is more
apparent after 9 hr of drug incubation (f). By 11 hr of drug incubation, snRNPs
appear to accumulate in large clusters (h), which increase in size by 18 and 24
hr of drug incubation (I,!). Magnification, 800x.
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FIGURE 3 Diagram of the dhfr gene and probes used for in
situ hybridization.
pMB5-EcoRI, pB61H1, and pB13-7 (Fig. 3) to
achieve a combined hybridization length of >5 kb
(total length = 5.3 kb) to localize the dhfr gene in
nonamplified CHO cells, where it is present as two
copies per diploid genome. We have been able to
localize the two single copies of the dhfr gene in un-
amplified CHO cells by using Streptavidin-FITC.
Each cell in Figure 4 shows two spots, representing
the two copies of the gene in these diploid cells. Each
spot represents the signal from the hybridization of
biotinylated riboprobes spanning 5.3 kb of the gene.
We are now preparing probes to localize a second
gene in these cells. Double-label gene localizations
(4 spots) in the same cell will allow us to map the
three-dimensional localization of a specific gene
copy within the interphase nucleus.
Differential Distribution of Factors
Involved in Pre-mRNA Processing
in the Schizosaccharomyces pombe
Cell Nucleus
D.L. Spector, R.J. Derby [in collaboration with
J.A. Potashkin, Cold Spring Harbor Laboratory]
IMMUNOFWORESCENT LOCALIZATION OF sNRNAs
We have localized the abundant snRNAs in a wild-
type strain of the fission yeast Schizosaccharomyces
pombe by indirect immunofluorescence and immu-
noelectron microscopy using an anti -m3G antibody
(obtained from Adrian Krainer, Cold Spring Har-
bor Laboratory) that recognizes the fission yeast
homologs of Ul-U5 snRNAs. The snRNAs were
localized to the nonchromatin-containing portion of
the nucleus (Fig. 5b,e,h,k), as determined by double-
labeling with the fluorochrome DAPI, which spe-
cifically binds to DNA (Fig. 5c,f,i,l). This portion
of the S. pombe nucleus has been referred to as the
nucleolus. To confirm that the immunolabeled
snRNAs were present in the nucleolar portion of the
nucleus, a nucleolar-specific antibody was used on
another series of samples. D77 is an antibody (ob-
tained from John Aris, Rockefeller University) that
recognizes a nucleolar protein of 38 kD in Sac-
charomyces cerevisiae, and it has been shown to
cross-react with S. pombe. D77 is thought to recog-
nize the yeast homolog of fibrillarin, which is a pro-
tein found in the fibrillar region of the metazoan
nucleolus and is associated with the nucleolar-
specific U3 snRNP. Immunofluorescense micros-
copy of cells stained with the D77 antibody showed
immunoreactivity in the nonchromatin-enriched
portion of the S. pombe nucleus (Fig. 5n,q,t,w), con-
firming its nucleolar composition. To rule out the
possibility that the chromatin-enriched region of the
nucleus is inaccessible to antibodies, we used a DNA-
specific antibody, 2C10 (obtained from David Stol-
lar, Tufts University), for immunofluorescence stain-
ing. As shown in Figure 5, z, cc, ff, and ii, the DNA
antibody recognizes the same region of the nucleus
as the fluorochrome DAPI (Fig. 5aa,dd,gg,jj), which
clearly demonstrates that antibodies can penetrate
the chromatin-enriched portion of the nucleus.
IMMUNOELECTRON MICROSCOPY
When observed by electron microscopy, the S. pombe
nucleus contains a light staining region and a dark
staining region (Fig. 6a). The percentage of the to-
tal nucleus occupied by each of these regions in each
section varied depending on the plane of section
through the nucleus. The light staining region has
previously been shown to contain chromatin. The
chromatin appears to be fairly uniform in appear-
ance, with little to no condensed or heterochroma-
tin present (Fig. 6a). The dark staining region of the
nucleus contains nucleolar components. In our
preparations, there appear to be several electron lu-
cid zones (between 1 and 5) within the nucleolar re-
gion (Fig. 6a). These regions resemble fibrillar
centers of mammalian cell nucleoli and are often sur-
rounded by a region of greater electron density, which
resembles the fibrillar component of mammalian cell
nucleoli. To determine if there are any snRNAs in
the chromatin region that were not abtindant enough
to be detected by immunofluorescence, we used im-
munoelectron microscopy. To visualize the snRNAs
at the electron microscopic level, we used monoclo-
nal m3G antibody in combination with secondary
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FIGURE 4 In situ hybridization to the dihydrofolate reductase gene in interphase CHO cells. The two
single copies of the gene have been localized in each cell (A,C,E,G,I) using biotinylated riboprobes span-
ning 5.3 kb of the gene. Visualization is accomplished by FITC-labeled avidin. (/) Stained with the fluorochrome
Hoechst 33258 to show the total distribution of DNA. Magnification, 885x.
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FIGURE 5 Indirect immunofluorescence localization of snRNAs, nucleoli, and DNA in the fission yeast S. pombe. Immuno-
fluorescence was performed with spheroplasts prepared from a wild-type strain of S. pombe using a fluorescein-conjugated
anti-mouse secondary antibody. Phase-contrast views (a,d,g,j,m,p,s,v,y,bb,ee,hh), immunfluorescence micrographs of cells
labeled with anti-m3G (b,e,h,k) to localize snRNAs, D77 (n,q,t,w) to localize nucleoli or anti-DNA antibody (z,cc,ff,ii), and
counterstained with DAPI to show the distribution of chromatin (c,f,i,l,o,r,u,x,aa,dd,gg,jj).
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FIGURE 6 Transmission electron micrograph of a cell section of S. pombe (a) showing the electon-dense
and less-electron-dense portions of the cell nucleus. Within the electron-dense portion of the nucleus, ir-
regularly shaped electron lucid regions are observed (arrowheads). These regions resemble fibrillar centers
of mammalian cell nucleoli. Ultrathin sections of fission yeast were incubated with anti-m3G primary anti-
body followed by 15-nm colloidal gold-conjugated secondary antibody and poststained for electron mi-
croscopy. The control cells that were not incubated with primary antibody show no gold labeling (a). Yeast
cells stained with both primary and secondary antibody show the majority of the gold particles in the nu-
cleus (b). An enlarged view of the nucleus shows that the majority of the gold particles were present in
the electron-dense portion of the cell nucleus (c). Arrowheads in b and c point to representative gold parti-
cles. Bar 0.5 j.tm.
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antibodies coupled to colloidal gold. Control sec-
tions that were labeled only with secondary antibody
showed no gold staining (Fig. 6a). Sections of
spheroplasts labeled with both primary and second-
ary antibodies showed the majority of the gold par-
ticles in the nucleus and minimal background label-
ing in the cytoplasm (Fig. 6b). The gold particles
located in the nucleus were concentrated in the
electron-dense nucleolar region (Fig. 6c). The gold
particles were counted in 50 individual spheroplasts
to quantitate the distribution of snRNAs in yeast
cells. The results showed that 85% of the gold parti-
cles were localized in the nucleolar region, 1107o were
present in the chromatin-enriched region, and 407o
were present in the cytoplasm. To confirm further
the nucleolar origin of the electron-dense nucleolar
region, cells were immunolabeled with the nucleolar-
specific antibody D77, and 20 cells were counted to
quantitate the distribution of this protein within the
cell nucleus; 7807o of the gold particles were located
in the electron-dense nucleolar region, 1007o were
present in the chromatin-enriched region, and 1307o
were present in the cytoplasm.
The results from these experiments showed that
the majority of the snRNAs are present within the
more electron-dense portion of the nucleus, which
has been referred to in the literature as the nucleo-
lus. These findings are in contrast to the results ob-
tained with mammalian cells, where the majority of
the abundant snRNAs are present in a nonnucleo-
lar network within the nonchromatin-containing
regions of the nucleoplasm. Our data suggest that
this dark-staining region of the S. pombe nucleus
contains both nucleolar components and nuclear
particles involved in pre-mRNA processing. Clearly,
further research is needed to define which nuclear
processes are occurring in the two parts of the yeast
nucleus and the relationship between components
within each of these nuclear regions as well as be-
tween the regions themselves. Such studies will de-
pend on the availability of new nuclear-specific
probes. In addition, the yeast system provides for
powerful genetic approaches to define associations
between nuclear structure and function.
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CELLULAR TRANS-ACTIVATORS OF GENE EXPRESSION
B.R. Franza J.-H. Lee G. Mak
Y. Li J. Ross
We study cellular proteins involved in the control of
growth of mammalian cells. The mammalian cell we
study most comprehensively is the human T lym-
phoblast. When an interesting event is observed in
the T lymphoblast, we then compare other mam-
malian cells, including lymphoblasts and fibroblasts
from different species, to determine the generality
or specificity of the proteins involved in the change.
The QUEST protein database system is the tool that
permits such comparative, qualitative and quantita-
tive observations.
During the past several years, we have focused on
three processes. One is the effect expression of on-
cogenes has on the entire complement of proteins
present in a particular cell type. The second process
is the induction of protein alterations when quies-
cent cells are stimulated to proliferate. These studies
are directed at determining the molecules involved
in conveying signals to the genome and the earliest
responses of the genome to these signals. The third
process is the control of gene expression at the level
of regulation of transcription of mRNA encoding
genes.
A coalescence of several observations of each of
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the above processes led to the recognition that pro-
teins whose expression was altered within moments
of the quiescent (resting) cell receiving certain sig-
nals were among the proteins involved in modulat-
ing transcription of mRNA. Included in the resul-
tant set of proteins were the products of two cellular
genes whose abnormal expression leads to oncogen-
esis. The goal, implicit in these studies, to construct
a molecular map of the networks involved in regulat-
ing transcription as well as other genome responses
to a change in growth status is in its infancy. The
results of the initial studies appear to justify a com-
prehensive application of the strategy underlying
these early investigations.
The strategy employs several tools. Among them
are recombinant or synthetic fragments of DNA con-
taining genetically defined transcriptional control
elements; antibodies to proteins identified either to
associate with the control elements or to respond to
stimuli that activate quiescent cells; high-resolution
two-dimensional protein gels; a computer-accessible
protein database; and an in vitro assay of transcrip-
tional activation/repression to determine biological
function of identified proteins. Because of the for-
midable complexity of a living cell, the strategy is
designed to enable multiple investigators to make ob-
servations that ultimately can be linked. Several
projects, utilizing or contributing necessary compo-
nents to the strategy, were initiated or further devel-
oped during 1989. These will be discussed in indi-
vidual sections.
Further Studies of the Interaction
of Cellular Proteins with
Single-strand Transcription
Regulatory Control Sites
Franza [in collaboration with F. Rauscher,
Wistar Institute]
During the past year, we have characterized further
the interaction of the Fos and Jun proteins with
single-strand oligonucleotides that contain the AP-1
(ssAP-I) sequence element. One of the studies in-
volved the introduction of ssAP-1 or a synthetic mu-
tant (mssAP-1) into lysates of whole cells. The cells
used for these studies are the human T lymphoblast
line, Jurkat. Prior to lysing the cells, they were stimu-
lated with agents that we know induce the expres-
sion of the Fos and Jun proteins. Unstimulated cells
serve as a control for the level of induction. The
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microscale DNA affinity precipitation (DNAP) as-
say coupled with two-dimensional gels are the
methods used to study the protein-DNA interactions
for these studies and others discussed below. As seen
in Figure 1 (panel B vs. E), a significant induc-
tion of Fos and Jun occurred, and the proteins as-
sociate with ssAP-1 oligonucleotides. No detectable
Fos or Jun associated with the mutant ssAP-1 oligo-
nucleotides (see Fig. 1, panel C vs. F). We conclude
from this study that a specific single-stranded piece
of DNA is the target for a unique interaction of the
Fos/Jun complex. In this case, several thousand cel-
lular proteins were presented to the single-strand
AP-1 site, and yet only a very small number of pro-
teins apparently associated with it in a specific in-
teraction. All other proteins in the figure are nonspe-
cifically interacting with the insoluble matrix used
to recover the DNA (compare Fig. 1, panels A and
D with the others).
A different approach to the issue of a specific in-
teraction of the Fos/Jun complex with ssAP-1 in-
volved the expression of mutant forms of either the
Fos or Jun protein in vitro, followed by DNAP as-
says of their ability to interact with the ssAP-1 site
cooperatively. Several mutant forms of Fos and Jun
had already been shown to abrogate cooperative in-
teractions with the double-strand AP-1 (T. Curran
and colleagues, Roche Institute, Nutley, New Jersey).
The same proteins showed significant reductions in
interactions with single-strand AP-1 sites. These stud-
ies suggest that a possible function for the Fos/Jun
complex, localized to the AP-1 site, may involve an
alteration of DNA structure in which single-strand-
specific binding is a requisite or consequence.
Development of Antipeptide Antibodies
to Proteins That Associate with
the Transcription Control Elements
AP-1 and CRE: Two-dimensional
Protein Gel Characterization
B.R. Franza, G. Mak
Among the transcription regulatory elements we
study are the AP-1 site and the cAMP response ele-
ment (CRE) site. We demonstrated that a subset of
Fos and Jun proteins along with other cellular pro-
teins preferentially associated with either site. Since
these studies were initiated, numerous groups have
isolated several different genes whose products in-
teract with these sites and in some cases are genetic
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FIGURE 1 Single-strand AP-1 site DNAP binding assays of cellular extracts. Jurkat cells were used for these assays. Cells were
either not stimulated or stimulated with PMA plus the calcium ionophore A23187. Stimulation was for 30 min, at which point [35Syne-
thionine was added for an additional 30 min. Cells were extracted, DNAP assays were performed, and proteins were resolved on
two-dimensional gels. (A, D) Proteins from the unstimulated cells that are recovered using the single-strand probe ssDAP-1; (B, E)
proteins from stimulated cells that bind to the DAP-1 probe from cells that were stimulated; (C, F) proteins from stimulated cells that
associated with the mutant single-strand probe, mssDAP-1.
relatives of either Fos or Jun. To pursue further the
types of studies that interest us regarding these two
regulatory elements, we needed good immunologic
reagents.
To produce these reagents, we decided to choose
regions of each protein that are not conserved among
its genetic relatives. Peptides were synthesized by Dan
Marshak and colleagues at Cold Spring Harbor Lab-
oratory. We then injected the peptides, without any
modification, into the lymph nodes of rabbits. Fol-
lowing two additional lymph node injections, we de-
tected a very significant response to the first peptide
used. We are familiar with the proteins that antibod-
ies to this peptide immunoprecipitate from mammal-
ian cells. T. Curran designated it the M peptide -
amino acids 127 to 152 of the Fos protein - several
yeats ago. Anti-M-peptide sera were used in our ori-
ginal studies of the Fos complex and Fos-related an-
tigens (FRA). We used the same peptide to verify
whether immunization by lymph node injection of
unmodified peptide approach would work. It did,
and subsequently we have isolated substantial amounts
of antisera to one of the CRE-binding proteins to
FosB and Jun. Combined with more extensive DNAP
analysis, we envision using these and other antisera
to study protein-DNA interactions at each control
element as cells are activated to proliferate.
In Vitro Demonstration of
Transcriptional Activation
of the HIV-1 LTR
Y. Li, J. Ross
The strategy for elucidating the molecular network
that controls alterations in transcription in response
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to changes in cellular growth status incorporates an
in vitro assay to assist in determining the biochemi-
cal function of the participating proteins. We have
modified the traditional format for preparing ex-
tracts of cells for transcription assays. These extracts
retain the ability to transcribe mRNA in vitro. The
modifications permit the extraction of small num-
bers of cells. The time from extraction to perfor-
mance of the transcription reaction has been reduced
to 20 minutes. This approach permits the simultane-
ous analysis of multiple samples of cells exposed to
transcriptional activating agents for different inter-
vals. In addition, several different experiments can
be compared with relative ease to determine the
reproducibility of the temporal course of activation
for different agents. Represented in Figure 2 are sam-
ples derived from Jurkat cells treated for different
periods with the mitogenic lectin, phytohemagglu-
tinin (PHA). The transcripts produced in the reac-
tion are detected and quantified by using the primer
extension method. A second primer to an endoge-
nous cellular transcript for the U2 snRNA gene is
used to control for sampling and/or gel-loading er-
rors. Clearly, a significant induction of transcription
from the HIV-1 LTR template occurs in cells exposed
to PHA.
We have also determined that biotinylation of the
template does not interfere with the production of
mRNA transcripts. This will permit the isolation of
the template from the reactions and determination
of proteins associated with templates using the
DNAP procedures. Initially, this approach allows
the correlation of induction of transcription with the
proteins associated with control regions within the
HIV-1 LTR template. Biochemical fractionation of
activated extracts combined with this approach will
enable simultaneous assay of transcriptional activ-
ity and the proteins enriched by the separation proce-
dures. We may learn whether the relative abundance
of several proteins in a cell at different moments in
its growth cycle will determine the transcriptional ac-
tivity of a gene. It may be that purification of a tran-
scription factor to homogeneity and subsequent ad-
dition of it to an assay, although productive of a
response, may not mimic its activity in the cell. In
the cell, it is in context relative to all other transcrip-
tion factors. Determining abundances of the several
proteins capable of interacting at a specific control
element may therefore be essential to understand-
ing the contribution they each make to the transcrip-
tion of specific genes. Coupling the DNAP assay,
two-dimensional gels, and in vitro assay of transcrip-
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FIGURE 2 In vitro transcription of Jurkat nuclear extracts. This
figure demonstrates an analysis of the transcriptional activity of
Jurkat cells stimulated for the indicated intervals with PHA. The
HIV-1-LTR template was used in the in vitro transcription assays.
Primer extension analysis was used to demonstrate the quan-
titative change in in vitro transcription activity of each extract.
Duplicate reactions for each time point were performed. A se-
quence reaction is shown to the right of the assay products to
indicate the site of initiation of transcription.
tional activity may contribute to elucidation of these
issues.
Identification of the Large Subunits
of RNA Polymerase II
B.R. Franza
Since we study mRNA transcription and since two-
dimensional gels and the resultant protein databases
are central to the strategy, we are beginning to ac-
quire antibodies to known proteins involved in tran-
scription. Using antibody provided by Dr. M.
Dahmus (University of California, Davis), we have
successfully identified a set of proteins, including
several isoforms of the large subunit of RNA poly-
merase II, the enzyme that catalyzes the synthesis
of mRNA (see Fig. 1). Several other proteins were
specifically enriched using the rabbit antisera pro-
vided by Dahmus. It may be that one or more of
these proteins is functionally associated with the
large subunit. Studies are under way to characterize
these proteins further, to identify all the members
of the RNA polymerase II complex, and to begin
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FIGURE 3 Two-dimensional gel analysis of Jurkat cellular proteins immunoprecipitated by an anti-human RNA polymerase II anti-
body. (A) Cellular proteins immunoprecipitated by a control antibody; (8) proteins immunoprecipitated by an anti-RNA pol 11 large-
subunit antibody. Jurkat cells were labeled for 2 hr with [35S]methionine and then extracted and immunoprecipitated. Proteins were
then resolved on two-dimensional gels.
characterizing how these proteins are modulated as
the cell responds to signals that alter its growth status.
Characterization of cdc2 and
Associated Proteins in Human
T Lymphoblasts
B.R. Franza [in collaboration with G. Draetta and D. Beach
Cold Spring Harbor Laboratory]
Resting T lymphoblasts are cells capable of being
induced to synthesize DNA and then divide. Acti-
vation of these cells is accomplished by their being
exposed in vivo to antigenic challenge, cytokines
(growth factors), other cells, or combinations of the
above. The cells not only divide, but mature (differen-
tiate). The responses involve transcriptional activa-
tion (and repression) of specific cellular genes. These
events can be mimicked in tissue culture dishes by
exposing less mature cells to different growth fac-
tors, mitogenic lectins, tumor promoters, other cells,
antigens, or combinations thereof., In addition to cel-
lular genes being transcriptionally activated in re-
sponse to these signal-inducing events, viral genes
integrated in the cellular genome are also activated.
One of these viral genes is the proviral form (DNA
copy) of the AIDS virus, HIV-1.
The induction of transition from resting (Go) to
DNA synthesis and proliferation has been to some
extent genetically dissected. Mutant cells have been
identified that will arrest at different stages under
certain growth conditions. Genes have been identi-
fied to overide (suppress) the defect(s). One conse-
quence of mutation of the cell-division cycle gene,
cdc2, in Schizosaccharomyces pombe is a block of
progression of the cell through the G1 stage to the
S stage (DNA synthesis interval). It was therefore
of interest to us to identify the cdc2 products in T
lymphoblasts so that we could monitor changes in
cdc2 as resting cells are induced to exit their resting
state, activate transcription of specific genes, and
commit to DNA synthesis.
The first immunoprecipitation of a T-lymphoblast
cellular protein extract with anti-cdc2 antibody and
the resultant two-dimensional gel image contained
several bits of information (see Fig. 4). It showed
the diversity of isoforms of cdc2 in asynchronously
dividing T lymphoblasts. It also revealed several
other proteins associated specifically with cdc2. Fig-
ure 4 shows the initial two-dimensional gel image of
the cdc2 complex in the human T-lymphoblast cell
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FIGURE 4 A complex of cellular proteins is recovered from Jurkat cells using the
anti-CDC2 antibody. The same anti-cdc2
immunoprecipitated proteins were split into two equal samples and resolved on two types of two-dimensional gels. (Left)
Proteins resolved by isoelectric focusing. (IEF); (right) proteins resolved on a gel type referred to as noneqiulibrium gel (NEQ)
electrophoresis. NEQ gels are used to detect proteins that are too basic to be resolved by isoelectric focusing. Cellular pro-
teins were labeled for 2 hr with [35S]methionine.
line, Jurkat. One of these proteins subsequently has
been identified as cyclin B (antibody provided by J.
Pines and T. Hunter, Salk Institute). Another pro-
tein, p13, was also identified to be associated with
cdc2, analogous to the situation in S. pombe.
A surprise was the identification of a cellular pro-
tein known from previous two-dimensional gel im-
ages (collaborative study with E. Harlow, Tumor
Viruses Section) to be associated with the adenovi-
rus El A gene product. This protein, designated p60,
although its migration in two-dimensional gels is
faster than vimentin (known molecular size, 55,700),
was shown by P. Whyte and E. Harlow to be recog-
nized by a monoclonal antibody, C160. Use of this
antibody in immunoprecipitation assays followed by
two-dimensional gel electrophoresis showed that spe-
cific isoforms of cdc2 were complexed to p60. The
data presented in Figure 5 are the result of collabora-
tive studies involving A. Giordano, E. Harlow, D.
Beach, and G. Draetta (Cold Spring Harbor Labo-
ratory). Another human cell line, HeLa, was used
in these studies. Of note is the absence of the spots
just below cyclin B (compare Fig. 5 with Fig. 4) in
the lymphoblast lines immunoprecipitated with anti-
cdc2 antibodies. Otherwise, the components of the
cdc2 complex are (details of figure are
found in the legend).
Our interest in the p60 protein was further height-
ened by observations described in the next section.
In addition, G. Draetta established that the C160 an-
tibody immunoprecipitated a kinase activity toward
the histone H1 protein, a previously identified sub-
strate for the cdc2 kinase. The question we are most
interested in is p60, either in its H1 kinase form or
in some other form, a contributor to the activation
process when resting T lymphoblasts are stimulated?
Association of p60 with a Major,
Immediate Substrate of
Protein Kinase C
B.R. Franza, J.-H. Lee, G. Mak
Using the monoclonal anti-p60 antibody, I identifed
several other proteins, in addition to cdc2, that as-
sociate with p60. One of these proteins is now re-
ferred to as MARCKS. MARCKS was orginally iden-
tified as a substrate for protein kinase C. Agents that
activate protein kinase C induce an extremely rapid
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FIGURE 5 Two-dimensional gel of cdc2- and E1A-associated proteins. The left panel represents proteins detected in an
anti-cdc2 (G6) immunoprecipitate. A through / are regions of comparable two-dimensional gels in which p60 is resolved.
(A) Anti-cdc2; (B) anti-cdc2 precipitation performed in the presence of 100 nmoles of competing antigenic peptide; (C) anti-
p60 precipitation with the C160 monoclonal antibody; (D) mixture of proteins from immunoprecipitates shown in A and C;
(E) anti-E1A precipitation using the M73 monoclonal antibody; (F) mixture of proteins from immunoprecipitates shown in
A and E; (G) proteins recovered in a p13-Sepharose precipitation; (H) precipitation with anti-cyclin B; (I) mixture of proteins
in A and H. Open arrowheads in the p34/CDC2 box indicate isoforms that associate with p60 in C160 monoclonal antibody
precipitates. Filled arrowheads show the primary form of cdc2 in anti-cyclin B precipitates. Actin, tubulins, and the 73-kD
heat-shock protein (HSP73) are indicated for orientation purposes. p62/cyclin B, p60, and p13 isoforms are indicated in the
appropriate boxes. All samples were resolved in pH 3-10 isoelectric focusing gels (first dimension) followed by separation
in 10% polyacrylamide gels (second dimension) (Garrets 1983).
phosphorylation of this protein. Its two-dimensional
gel signature is unique. As shown in Figure 6, anti-
body to MARCKS (kindly provided by Dr. P. Green-
gard, J. Wang, and colleagues, Rockefeller Univer-
sity, New York) immunoprecipitates the same cluster
of proteins as found associated with p60. In addi-
tion to p60, several other proteins are associated with
p60 (A through D in Fig. 6). The technique for iden-
tifying these proteins is simple. Cells are lysed, the
immunoprecipitation is accomplished, the immune
complex is equilibrated in a kinase-permissive
buffered solution, and [y- 32P]ATP is added. After
10 minutes at 30°C, the immune complex is solubi-
lized and the proteins are electrophoretically sepa-
rated. The addition of 32P to proteins is nonspecific,
i.e., protein phosphorylation is apparently only a
function of the mass amount of each particular poly-
peptide present in the immune complex. Proteins
that nonspecifically associate with the insoluble ma-
trix used to capture the immune complexes are de-
tected. Therefore, many of the proteins seen in each
image are the same and are confirmed as nonspecific
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FIGURE 6 MARCKS protein kinase C substrate coprecipitates with
cdc2-associated protein p60. (A) Proteins recovered
with an anti-cdc2 antibody in the presence of the synthetic peptide
to which the antibody was raised; (B) proteins immuno-
precipitated by the anti-cdc2 antibody; (C) proteins immunoPrecipitated
by the anti-p60 antibody (C160).
by their equivalent presence in the control reaction
in which the antigenic peptide is mixed with the ex-
tract prior to addition of the anti-cdc2 antibody (Fig.
6, panel A).
It is interesting that at least one of the proteins
associated with p60, i.e., MARCKS, is an immedi-
ate target of a kinase activated at the earliest mo-
ments of cellular activation. It is also interesting that
an apparently unique p60-associated protein, not
MARCKS, is found in lymphoblasts. In fact, in the
Jurkat T-lymphoblast line, MARCKS is not detected,
but the unique p60-associated proteins are. It may
be that signals converge on the p60/cdc2 complex
via MARCKS or the other p60-associated proteins.
p60 may thereby be used to convey signals to cdc2.
It is possible that the equivalent to the "start" func-
tion of cdc2 in S. pombe involves a functional con-
nection of MARCKS and the other p60-associated
proteins with cdc2. Having the gene for p60 will be
essential to studying such questions. Dr. J.-H. Lee
is attempting to clone the gene for the cdc2-asso-
ciated p60 protein.
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MOLECULAR BIOLOGY OF THE CYTOSKELETON
D.M. Helfman K. Galactionov L. Goodwin
J. Kazzaz A. Kistler
G. Mulligan M. Pittenger
M. Leonard R. Roscigno
W. Guo
J. Lees-Miller
L. Finn
The cytoskeleton is involved in a multitude of cellu-
lar functions such as cell shape and motility, or-
ganelle movement, chromosome movement, and
cytokinesis. The cytoskeleton of all eukaryotic cells
is composed of three major filamentous systems: ac-
tin filaments, intermediate filaments, and microtu-
bules. Each of these filamentous systems contain a
number of different protein components, although
different cell types and tissues express specific pro-
tein isoforms that comprise these structures. The re-
search in our laboratory is focused on two related
problems in molecular and cell biology: (1) the mech-
anisms responsible for tissue-specific and develop-
mentally regulated patterns of gene expression and
(2) the functional significance of cell-type-specific
protein isoform expression. Our laboratory has been
interested in understanding the regulation and func-
tion of tropomyosin gene expression in muscle and
nonmuscle cells. Tropomyosins are a diverse group
of actin-binding proteins with distinct isoforms pres-
ent in striated muscle (skeletal and cardiac), smooth
muscle, and nonmuscle cells. We now know that 12
different tropomyosin isoforms are expressed from
three separate genes in rats. The a-tropomyosin (a-
TM) gene encodes nine isoforms, the I3-tropomyosin
(I3-TM) gene encodes two isoforms, and the tropo-
myosin-4 (TM-4) gene encodes only a single isoform.
We have been studying the expression of these genes
with particular attention to understanding the mech-
anisms of their regulation at the posttranscriptional
(alternative RNA splicing) and the transcriptional
levels. In addition, the expression of a diverse group
of tropomyosin isoforms in a highly tissue-specific
manner via alternative promoters and alternative
RNA processing strongly suggests that each isoform
is required to carry out specific functions in conjunc-
tion with the actin-based filaments of various mus-
cle and nonmuscle cells. The function of these differ-
ent isoforms is not known and is under study in our
laboratory. We are also interested in the relationship
between transformation and tropomyosin gene ex-
pression. Transformed cells exhibit dramatic altera-
tions in the patterns of tropomyosin isoform expres-
sion. How these changes in tropomyosin expression
are related to the transformed phenotype is currently
being investigated. Finally, we have begun to study
the role of p34 cdc2 in the process of differentia-
tion. Below is a summary of our present studies.
Alternative RNA Splicing in the
Control of Gene Expression
D.M. Helfman, R. Roscigno, G. Mulligan,
L. Finn, M. Leonard, W. Guo
An ever-growing number of cellular and viral genes
have been characterized that encode multiple pro-
tein isoforms via the use of alternatively spliced
exons. In many cases, alternative splicing contrib-
utes to developmentally regulated and tissue-specific
patterns of gene expression. At present, little is
known about the mechanisms that are responsible
for the selection of alternative splice sites in com-
plex transcription units and how the splicing signals
in alternatively spliced exons differ from those in
constitutively spliced exons. We are using the rat (3-
TM gene as a model to investigate developmental
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and tissue-specific alternative splicing. The gene
spans 10 kb with 11 exons and encodes two distinct
isoforms, namely, skeletal muscle [3 TM and fibro-
blast TM-1 (Fig. 1). Exons 1 through 5, 8, and 9 are
common to both mRNAs expressed from this gene.
Exons 6 and 11 are used in fibroblasts as well as
smooth muscle, whereas exons 7 and 10 are used ex-
clusively in skeletal muscle. In addition, during my-
ogenesis, expression of these two isoforms is sub-
ject to developmental control. From this gene,
myoblasts express exclusively the fibroblast TM-1
isoform, but upon differentiation, they express only
the skeletal muscle [3 -TM isoform. Our previous
studies of tropomyosin pre-mRNA splicing revealed
an ordered pathway of splicing in which either of
the internal alternatively spliced exons (exons 6 or
7) must first be joined to the downstream common
exon before they can be spliced to the upstream com-
mon exon (Helfman et al., Genes Dev. 2: 1627
[1988]). We subsequently characterized the branch-
points formed during the use of these alternatively
spliced exons (Helfman and Ricci 1989). These
studies revealed that the splicing of exon 5 to exon
7 (skeletal-muscle-type splice) is accompanied by the
selection of multiple branchpoints, which are located
an unusually long distance (144, 147, and 153 nucleo-
tides) from the 3' splice site of exon 7. These results
were found to be different from those of most branch-
points mapped previously, in which a single adeno-
sine residue located 18-40 nucleotides from a 3' splice
site is used during lariat formation. In addition, these
studies suggested that the use of branchpoints lo-
cated at long distances (i.e., >40 nucleotides) from
a 3' splice site may be an essential feature of some
alternatively spliced exons.
We have now investigated the functional role of
the intron sequences between the unusual branch-
points and the 3' splice site of the skeletal muscle
exon (exon 7) in splice site selection of the rat 13-TM
gene. These studies have identified two distinct ele-
ments in the intron, upstream of exon 7, involved
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in splice site selection (Helfman et al. 1990). The first
element is composed of a polypyrimidine tract lo-
cated 89-143 nucleotides upstream of the 3' splice
site, which specifies the location of the lariat branch-
points used, 144-153 nucleotides upstream of exon
7. The 3' splice site AG dinucleotide has no role in
the selection of these branchpoints. The second ele-
ment is composed of intron sequences located be-
tween the polypyrimidine tract and the 3' splice site
of exon 7. It contains an important determinant of
alternative splice site selection, because deletion of
these sequences results in the use of the skeletal-
muscle-specific exon in nonmuscle cells. We propose
that the use of lariat branchpoints located far up-
stream of a 3' splice site may be a general feature
of some alternatively excised intron, reflecting the
presence of regulatory sequences located between the
lariat branch site and the 3' splice site. The data also
indicate that alternative splicing of the rati3.-TM gene
is regulated by a somewhat different mechanism
from that described for the rat a-TM gene and the
transformer-2 gene of Drosophila melanogaster (see
below). Work is currently under way to explore fur-
ther the role of specific intron sequences in alterna-
tive splice site selection and to identify cellular fac-
tors that may interact with specific regions of the
pre-mRNA to regulate alternative RNA splicing (see
below).
Analysis of cis-Acting Elements
Involved in Alternative Splice
Site Selection of 13-TM Pre-mRNA
W. Guo, D.M. Helfman
As described above, intron sequences upstream of
exon 7 act as a negative regulatory element, prevent-
ing the use of this exon in nonmuscle cells. The mech-
anism by which these intron sequences play a role
in alternative splice site selection in not known. One
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FIGURE 1 Schematic diagram of the rat OTM gene and the two different isoforms expressed from this gene. The amino
acids encoded by each exon are indicated. The cap site and polyadenylation sites are also indicated.
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way in which these sequences could regulate splice
site selection is by binding to factors in nonmuscle
cells that inhibit the use of this 3' splice site. This
"blockage" mechanism has been proposed for a num-
ber of alternatively spliced genes, including the
transformer-2 gene and the suppressor of white
apricot gene of D. melanogaster. However, the block-
age model cannot explain the regulation of the rat
13-TM gene, because using precursors without dele-
tions in intron 6, we are able to detect splicing of
exon 5 to exon 7 both in vitro and in vivo if exon
7 is first joined to exon 8 (Helfman et al., Genes Dev.
2: 1627 [1988]). Therefore, it is unlikely that a nega-
tive factor simply binds to the 3' splice site of exon
7 and prevents its use in nonmuscle cells. On the
other hand, a factor bound to the 3' splice site of
exon 7 might function by preventing the use of the
5' splice site of this exon. Such a mechanism would
be consistent with the observation that splicing of
exon 5 to exon 7 in nonmuscle cells requires that exon
7 first be spliced to exon 8 (Helfman et al., Genes
Dev. 2: 1627 [1988]). A second way in which these
sequences may regulate splice site selection is by par-
ticipating in the formation of RNA structures that
sequester this exon and prevent its utilization in non-
muscle cells. Computer analysis of possible RNA
involving intron sequences up-
stream and downstream from the skeletal muscle
exon reveals that this exon may be sequestered in a
stable hairpin structure (Helfman et al. 1990). Al-
though the use of computer algorithms is not with-
out limitations, analysis of the same gene from
chicken reveals a similar secondary structure that
could sequester this exon. Thus, on the basis of com-
puter analysis, there is phylogenetic conservation of
these structures. Additional data consistent with this
hypothesis come from our previous studies which
demonstrated that splicing of exon 5 to exon 7 in
nonmuscle cells required that exon 7 first be spliced
to the downstream common exon. Joining exon 7
to exon 8 and thereby removing the flanking intron
may have prevented the formation of RNA second-
ary structures that interfere with the interaction of
splicing factors with the splice site of exon 7.
To determine whether intron sequences upstream
of exon 7 act either by interacting with cellular fac-
tors that block the use of this exon or through the
formation of RNA structures that sequester this
exon, we are carrying out a more a detailed analysis
of these cis-acting sequences. We are introducing a
series of point mutations in specific regions of the
pre-mRNA and analyzing their effects in vitro and
in vivo. In addition, to determine if alternative splic-
ing is the result of RNA secondary structure, we are
introducing mutations in intron sequences upstream
as well as downstream from exon 7 that should
destabilize any secondary structure. These studies
should provide important information about the
mechanism responsible for alternative splice site se-
lection of (3 TM pre-mRNA. In addition, these
studies should have broad implications for the
numerous biological systems that involve alternative
RNA processing as a mechanism to regulate the ex-
pression of cell-type-specific proteins.
Identification of Pre-mRNA
Binding Proteins
G. Mulligan, D.M. Helfman
Regulation of alternative splice site selection may be
achieved through blockage of splice sites or facilita-
tion of exon usage, perhaps via alterations in RNA
structure. We are presently defining factors that bind
to (3 TM pre-mRNAs which may act to regulate al-
ternative splicing. Using pre-mRNA uniformly la-
beled with "P-labeled nucleotides, we are determin-
ing whether muscle and nonmuscle cells express
proteins that interact with specific regions of the pre-
mRNA. These studies involve UV cross-linking, gel
shifts, and direct binding assays. In both He La and
myogenic splicing systems, we have identified a pro-
tein of 60-65 kD that binds to the long polypyrimi-
dine sequence within intron 6. This pyrimidine tract
is a cis-element critical for the use of the adjacent
upstream lariat branchpoints associated with the
splicing of exon 5 to 7 (skeletal-muscle-type splice).
Recently, a 62-kD protein was reported that binds
to extended polypyrimidine sequences thought to be
involved in pre-mRNA splicing (Garcia-Blanco et al.,
Genes Dev. 3: 1874 [1989]). It remains to be deter-
mined how these interactions contribute to the splic-
ing of tropomyosin pre-mRNAs. In addition, we are
pursuing proteins whose interactions exhibit tissue-
specific differences.
Structure and Evolution of the
Tropomyosin Genes
J. Lees-Miller, D.M. Helfman
Tropomyosin is a simple dimeric protein that forms
an a-helical coiled-coil along its entire length. Its
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structure is stabilized by a hydrophobic core formed
by nonpolar residues in the first and fourth positions
of a repeated seven-amino-acid pattern. The early
evolution of genes encoding tropomyosins and a host
of other coiled-coil proteins appears to have occurred
through duplication of seven-amino-acid units and
multiples there of. The tropomyosin genes from ex-
isting organisms frequently possess exons encoding
21 or 42 amino acids. These values correlate well with
the presence of actin-binding sites, which is one func-
tion that all tropomyosins have in common. A com-
parison of the D. melanogaster TMII gene and the
vertebrate genes indicates that the positions of the
intron-exon splice junctions relative to the final tran-
script are identical, demonstrating evolutionary con-
servation of gene structure over several hundred
million years. Another common feature of most
tropomyosin genes is alternative splicing of the pri-
mary transcript.
Our recent completion of the structure of the three
rat tropomyosin genes has allowed us to examine the
evolution of the vertebrate tropomyosins (Fig. 3). Se-
quence comparison of several vertebrate tropomyo-
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sins indicates that four genes evolved from a corn_
mon ancestor. The rat a -gene is the most complex
of these transcription units (Fig. 2). It possesses al-
ternative promoters, and alternative exons 2a and
2b, 6a and 6b, and 9a, 9b, 9c, and 9d. The rat 13_:rm
gene is less complex, with a single promoter and two
sets of alternative exons 6a and 6b and 9a and 9d
(Fig. 1). The TM-4 gene is not alternatively spliced,
unlike all the other tropomyosin genes from mul-
ticellular organisms that have been described (Fig.
3). Two exon-like sequences that are highly similar
to alternatively spliced exons 2b and 9a of the rat
a-TM gene, the rat 13TM gene, and the human TMnm
gene have been located in the appropriate region of
the gene encoding rat fibroblast TM-4. However, sev-
eral mutations in these sequences render them non-
functional as tropomyosin-coding exons. We have
termed these exon-like sequences, vestigial exons. It
appears that most vertebrates do not require all the
possible tropomyosin isoforms that could be encoded
by four complex tropomyosin genes. Many of the
alternative splices and in some cases entire genes have
therefore been selectively lost.
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FIGURE 2 Schematic diagram of the rat a-TM gene and nine different isoforms expressed
from this gene. Boxes represent exons and horizontal lines represent introns; they are
not drawn to scale. The gene contains two alternative promoters that result in expression
of two different amino-terminal coding regions (exons la and lb), two internal mutually
exclusive exon cassettes (exons 2a and 2b and 6a and 6b), and four alternatively spliced
3' exons that encode four different carboxy-terminal coding regions (exons 9a, 9b, 9c,
and 9d). The different polyadenylation signals are also indicated (A).
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FIGURE 3 Organization and evolution of the vertebrate tropomyosin genes. (A) The
intron-exon structure of the vertebrate tropomyosin genes. We have tentatively iden-
tified an exon-9c-like sequence in intron 9a of the chicken 0-TM gene. No similar
sequence is found in the 131-M gene of the rat. (B) A possible evolutionary relation-
ship between four vertebrate tropomyosin gene is presented. The sequence of 13
vertebrate tropomyosins were compared over the 176-amino-acid region encoded
by exons 3, 4, 5, 6b, 7, and 8. Gene duplications are indicated at diamonds (0).
The numbers represent a best approximation to the encoded amino acid differences
between the genes, where species-specific differences are ignored. The figure over-
estimates by three the number of amino acid substitutions between the TMnm gene
and the (TM gene. Double arrows indicate the difference. It should be noted that
exons 6a and 6b and exons 9a and 9d correspond to exons 6 and 7 and 10 and
11, respectively, presented in Fig. 1 for the rat 13-TM gene.
The Brain Tropomyosins
J. Lees-Miller, D.M. Helfman
Tropomyosins are thought to be involved in the regu-
lation of the structure and motility of cells through
their interaction with cytoskeletal actin filaments.
Within the nervous system, the cytoskeleton is es-
sential for the formation and maintenance of cell
contacts both within neural networks and between
neurons and their support cells. We have found that
a set of tropomyosins specific to brain (termed
TMBr-1, TMBr-2, and TMBr-3) is expressed through
the use of alternative promoters and alternative splic-
ing from the a-TM gene (Fig. 2). The alternative
splicing results in three brain tropomyosins with
unique carboxy-terminal sequences. This region of
tropomyosin is known to be critical for its interac-
tion with actin and with Ca"-sensitive regulatory
components such as troponin. Our goals are to de-
termine the functional significance of the brain iso-
forms and to understand the regulatory mechanisms
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involved in their expression. As a first step, we
have
developed a high-yield bacterial expression system
and a rapid purification procedure that produce
near-
gram quantities of pure protein. This protein, along
with a brain tropomyosin-specific synthetic peptide,
is being used to raise polyclonal and monoclonal an-
tibodies. We now have a polyclonal serum specific
for TMBr-1 and TMBr-3. It is being used to study
the location of brain tropomyosins in the develop-
ing rat brain and their distribution in other species.
We are also searching for a cell line that expresses
the brain isoforms. These cells will be essential for
understanding the function of the brain tropomyo-
sins and the mechanism by which their expression
is regulated.
a-TM Diversity: Microinjection
of Fluorescent ly Labeled
Tropomyosins
M. Pittenger, L. Goodwin, D.M. Helfman
The function of the various tropomyosin isoforms
in cells is, with perhaps one exception, not under-
stood. In skeletal and cardiac muscle, tropomyosin,
in association with the troponin complex, is thought
to control the interaction between actin and myosin
filaments in response to fluxes of cellular calcium
levels. However, in the rat alone, there are 12 isoforms
of tropomyosin expressed from three genes that are
expressed in a tissue-specific manner. The a-TM gene
itself encodes nine tropomyosin proteins (Fig. 2). To
begin to understand the importance of a-TM isoform
diversity and the role that these proteins play in non-
muscle cells, we have utilized the cDNA clones gener-
ated in our laboratory to produce highly purified
quantities of each isoform in a bacterial expression
system.
In using the pET-8C expression system (made
available to us by Bill Studier of Brookhaven Na-
tional Laboratory), the translational start site of the
cDNA of interest is placed adjacent to a T7 poly-
merase transcriptional initiation site. The T7 poly-
merase is coded on another plasmid present in the
bacteria, and its expression is chemically inducible
by IPTG. The induced protein may represent up to
20% of bacterial protein. The tropomyosin isoforms
are purified by classical methods from the lysed bac-
teria, with yields of 5-30 mg of protein per liter of
culture. We have analyzed these purified proteins and
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find them to be 95-99% homogeneous, with the
majority of the contaminants being fragments of
tropomyosin polypeptides and therefore difficult to
remove. These are probably not degradation prod-
ucts but are more likely due to inappropriate trans-
lation initiation. With the aid of the Protein Chem-
istry core facility, we have sequenced the amino
terminus of several of the purified tropomyosins and
found them to be correct. Moreover, certain tropo-
myosins isolated from eukaryotic cells have been
shown to lack the amino-terminal methionine coded
by the mRNA. We find that this bacterial expres-
sion system correctly removes this methionine from
isoforms where it is not normally found, while leav-
ing it on at least one isoform that retains this methi-
onine in vivo. The signals for this type of processing
are not known but probably reside in the first cod-
ing exon.
With these tropomyosins in hand, we have begun
to ask questions about the functional role of these
proteins in living cells using microinjection and flu-
orescent analog cytochemistry. We have labeled the
purified proteins with FITC, an amine-reactive com-
pound, which usually modifies lysine residues un-
der our conditions. The FITC-Tm was purified away
from excess unreactive dye and analyzed for dye/pro-
tein ratio. We have found that a dye/protein ratio
of near one is necessary to visualize localized FITC-
Tm in fibroblast cells. Ratios of about 1.5 may prove
optimal, but higher dye/protein ratios can cause pro-
tein denaturation and have been difficult to attain
experimentally. These fluorescent derivatives were
microinjected into tissue culture cells and allowed
to mix with the endogenous pool. The cells were then
fixed and viewed with the fluorescent microscope.
So far, we have found that both the 248- and 284 -
amino -acid tropomyosins are found in association
with actin filaments. We have not seen a preference
for any isoform at the leading or trailing edge of a
moving cell. The isoforms do not appear to enter
the nucleus. In preliminary experiments, we have syn-
chronized cells and tried to follow injected FITC-
Tm5A as the cell progresses through the cell cycle.
We have seen a speckled pattern around the nucleus
of cells that appear to be entering mitosis. Many
more such experiments are planned using this and
other FITC-Tms. We also will study the reorganiza-
tion of tropomyosin isoforms in cells migrating into
the wound created in a cell monolayer. Experiments
are also planned to microinject transformed rat cells
to see if the isoforms maintain the same localiza-
tion as in normal cells. Transformed cells have al-
tered Tm expression, and it will be of interest to note
how these cells respond to such injections.
Functional Significance of 13-TM
Isoform Diversity
A. Kistler, M. Pittenger, K. Galactionov, D.M. Helfman
The I3-TM gene generates two isoforms of tropomyo-
sins through alternative mRNA splicing (Fig. 1).
Both isoforms contain amino acids encoded by the
common exons 1 through 5,8, and 9. In skeletal mus-
cle cells, exons 7 and 10 are utilized to produce skele-
tal muscle13-TM, whereas in smooth muscle and non-
muscle cells exons 6 and 11 are used, generating the
TM-1 isoform. The mRNA for the skeletal muscle
13-TM is expressed in skeletal muscle but is undetect-
able in nonmuscle and smooth muscle cells. In con-
trast, mRNA for TM-1 is found in fibroblasts and
smooth muscle cells but not in skeletal muscle cells.
No mRNAs that contain exons 6 + 10 or 7 + 11 have
been detected in any tissue or cell type examined.
These mutually exclusive exons encode differences
in the amino acid sequences in two short regions of
the tropomyosin molecule. Exons 6 and 7 encode an
internal region in the protein sequence acids
189-213), and exons 10 and 11 encode the carboxyl
terminus (amino acids 258-284). The functional sig-
nificance of these differences in the two tropomyo-
sin isoforms is not understood. Similarly, why the
tissue-specific splicing prohibits incorporation of
exons 6 and 10 or 7 and 11 in the same isoform is
unclear.
Using our cDNA clones and the bacterial expres-
sion system described above, we have produced and
purified two naturally occurring 13-TM isoforms. In
addition, we have also produced two chimeric iso-
forms (TM610 and TM711) by swapping the carboxy-
terminal exons (10 and 11) from the cDNA clones
of each of the naturally occurring (3-TM isoforms.
The actin-binding capabilities of these proteins will
be assayed in vitro and compared to tropomyosin
biochemically purified from skeletal muscle tissue.
We are currently labeling these purified proteins with
various fluorescent probes. The labeled proteins will
be introduced into tissue culture cells by microin-
jection. By so doing, we hope to determine whether
the differences in each of the isoforms and chimeras
result in differential localization or incorporation
into microfilament structures during various cellu-
lar events, such as mitosis, spreading, and motility.
Why Do Transformed Cells Alter
Tropomyosin Expression?
M. Pittenger, D.M. Helfman
There are dramatic alterations in tropomyosin iso-
form expression in cells transformed by such diverse
agents as DNA and RNA tumor viruses, UV irradi-
ation, and chemical carcinogens. The underlying rea-
sons for these alterations are not understood. Mor-
phological alterations are the most obvious and
immediate characteristics of transformed cells in cul-
ture. It is not known whether these gross abnormal-
ities are directly related to transformation (e.g., by
interfering with cell-cell communication and/or sig-
nal transduction pathways) or if they occur only as
an indirect consequence. We are interested in asking
if morphological alterations are directly related to
changes in tropomyosin expression. This also re--
quires an understanding of the normal regulation
of tropomyosin expression.
We have used a pulse-chase experiment and high-
resolution gel electrophoresis and quantitative anal-
ysis to look at the half-life of tropomyosin proteins
in normal rat embryo fibroblasts. We find that all
tropomyosins have long half lives, greater than 20
hours. We will analyze some transformed rat cell lines
to see if alterations in half-life of particular isoforms
can account for the alteration in their abundance.
To analyze tropomyosin expression through the cell
cycle, we have synchronized populations of cells by
thymidine block and mitotic shake off. The newly
synthesized proteins in each population were pulse-
labeled and resolved by two-dimensional gel elec-
trophoresis. Only a modest change was detectable
in the newly synthesized tropomyosins. This alone
would not account for the changes seen in trans-
formed cells. However, it will be interesting to see
if there is any change in the degradation rate of iso-
forms through the cell cycle.
To address the question of whether morphologi-
cal alterations are directly related to changes in
tropomyosin expression, we have plated normal rat
fibroblasts on a substrate that has been treated with
polyHEMA to prevent cell attachment. This treat-
ment can be varied to allow cells to spread to differ-
ent extents. New synthesis of tropomyosins has then
been analyzed by two-dimensional gel electropho-
resis. We find that cells that cannot attach and spread
properly show synthetic patterns similar to those of
the transformed cells. Further experiments of this
type are planned.
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Transcriptional Control of
Tropomyosin Gene Expression
J. Kazzaz, D.M. Helfman
The rat 13-TM gene expresses two distinct isoforms
via an alternative splicing mechanism (Fig. 1). Al-
though the gene is expressed in muscle (skeletal,
cardiac, and smooth) and nonmuscle cells, a single
transcription initiation site is used in the various cell
types that express the gene. We now wish to deter-
mine if the same cis-acting elements are used in mus-
cle (skeletal, cardiac, and smooth) and nonmuscle
cells (e.g., fibroblasts), and if the same or different
trans-acting factors are involved in transcriptional
control of the gene in different cell types. Sequence
analysis of the 5' end of the [31-TM gene has already
revealed a number of potentially important elements
involved in transcriptional control in skeletal muscle
cells. The gene contains three copies of a skeletal-
muscle-specific enhancer element located approxi-
mately 304, 352, and 398 by upstream of the tran-
scriptional start site. The consensus sequence of this
14-nucleotide-long element (C/GNG/AG/ACAC/
GC/GTGC/TC/TNC/G) has been found in a num-
ber of genes expressed in skeletal muscle, including
the muscle creatine kinase, &subunit of the acetyl-
choline receptor, myosin light chain 1/3, desmin, and
vimentin (Buskin and Hauschka, Mol. Cell. Biol.
9: 2627 [1989]). This element is believed to be the
site of action of the myogenic regulatory factors
myoD and myogenin. Since these myogenic regula-
tory factors are expressed in skeletal muscle but not
in cardiac and smooth muscles nor nonmuscle cells,
it is likely that expression of the 13-TM gene in cells
other than skeletal muscle will require a different set
of transcriptional regulatory proteins. Work is in
progress to determine the cis-acting elements re-
quired for expression in muscle versus nonmuscle
cells and to identify the cellular factors that interact
with these elements.
Cell Cycle Regulatory Proteins and
Growth Control in Mammalian Cells
K. Galactionov, D.M. Helfman
It is assumed that somatic cells predominantly pos-
sess a control point located in the G, phase of the
cell cycle, where they can be committed to the nor-
mal cell cycle or remain in a quiescent state. This
point has been named "start" in yeasts and restric-
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tion point (R) in mammalian tissue culture cells. In
yeasts, the function of one of the key proteins in-
volved in cell cycle control, p34 cdc2 (cdc28 in Sac-
charomyces cerevisae), is dependent on other genes
that regulate its function independently at GI-S and
G2-M transition. The function of p34 cdc2 at the
G2-M transition was better understood after the dis-
covery of cyclins and their role in activation of p34
cdc2 protein kinase activity (as a catalytic subunit
of maturation promoting factor, which is probably
the same entity as growth-dependent histone HI ki-
nase). On the other hand, earlier experiments on tis-
sue culture cells suggest that some unstable protein(s)
is required to pass the restriction point. Taking into
account that cyclin homologs were identified which
affect start function of S. cerevisae, it is possible to
question the role of cyclins, their homologs, or other
cdc2-associated proteins in Go-GI transition in
mammalian cells. One can also speculate on the in-
volvement of p34 cdc2 in the control of differentia-
tion in mammalian cells.
We are using the mouse myogenic cell line BC3H1
as a model to study the possible role of p34 cdc2
in the regulation of differentiation. This cell line
responds to decreases of serum levels in the media
by cessation of proliferation and, 24-48 hours later,
induction of muscle-specific isoforms of actin, my-
osin, tropomyosin, etc. Because of the inability of
this cell line to form myotubes, the process of dif-
ferentiation can be reversed by simply changing the
serum concentration of the media. In this case, the
process of dedifferentiation was monitored by the
loss of the muscle markers and activation of the nor-
mal cell cycle. To study changes in the p34 cdc2 phos-
phorylation and associated proteins during cell cy-
cle activation from the quiescent state, we chose
Swiss-3T3 cells because the time course of the cell
cycle following serum stimulation has been previ-
ously studied in detail.
Proteins associated with p34 cdc2 during differ-
ent stages of differentiation and dedifferentiation of
BC3H1 cells and cell cycle activation of the 3T3 cells
were detected by immunoprecipitation with G6 an-
tibody (kindly provided by G. Draetta and D. Beach,
Genetics Section) directed against a peptide, repre-
senting the carboxyl terminus of human cdc2. Work
from David Beach's laboratory has shown that this
antiserum precipitates, in addition to p34 cdc2, pro-
teins with molecular masses of 62 and 60 kD from
HeLa cells (Draetta and Beach, Cell 54: 17 [1988]).
The 62-kD protein was shown to be the human cy-
clin B gene product, whereas the 60-kD protein rep-
resents a protein associated with the E1A gene prod-
uct in adenovirus-transformed human cells (Giordano
et al., Cell 58: 981 [1989]). Our data show that in
BC3H1 cells, p34 cdc2 forms stable complexes with
the 47-, 55-, 56-, and 65- and 67-kD proteins that
are different from p62 (cyclin B), which is precipi-
tated as well. Some of these proteins associate with
p34 cdc2 mostly at G1 (p56) and others at the G2-M
transition (47 and 62 kD). Isolation of complexes
containing p56 and p34 cdc2 are under way.
In the 3T3 cells, we found p34 cdc2 associated
with a previously unidentified protein with a mo-
lecular mass of approximately 56 kD (p56) in corre-
lation with passing the R point. This event precedes
phosphorylation of the p34 cdc2 at the particular
site(s) of the GI /S border. p56 is phosphorylated at
the same time point as p34 cdc2, but it is not the
substrate of the p34 cdc2 at this stage of the cell cy-
cle. S-phase-specific "isoform(s)" of p34 cdc2 was
shown to contain phosphotyrosine. No detectable
protein kinase activity toward histone HI was found
in the complexes of p56 and p34 cdc2, compared with
the high activity of the complexes between p34 cdc2
and p62/cyclin B in the same cells. We are now in
the process of searching for possible GI /S sub-
strates for the complexes between p34 cdc2 and p56,
for the G1-S transition.
Our data indicate that different proteins may as-
sociate with p34 cdc2 during differentiation of the
myogenic cells, compared to 3T3 cells entering a
quiescent phase of the cell cycle. We plan to isolate
these newly identified proteins associated with p34
cdc2 in the myogenic cell line BC3H1. The isolated
proteins will be used for preparation of antibodies
and for peptide sequence analysis, which could sub-
sequently lead us to cloning of the genes for these
proteins.
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During the past year, the QUEST Center has been
focused on the construction of two major databases,
one for mouse embryos and one for yeast cells. Both
of these are patterned after the rat REF52 database,
built by Jim Garrels and Robert Franza, which was
reported last year. At the same time, the QUEST
Center has continued to support many smaller proj-
ects of two-dimensional gel analysis, ranging from
human cells to bacterial cells to plants.
The mission of the QUEST Center is not only to
build databases derived from computer analysis of
two-dimensional gels, but also to continue to im-
prove and disseminate the technology that makes
such analysis possible. Because the QUEST facility
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is now operating smoothly from gel electrophoresis
to database analysis, Jim Garrels was
able to spend
much of 1989 on a sabbatical leave. From October
1988 through September 1989, he has
worked 2 days
per week with the Millipore company of Bedford,
Massachusetts, helping to explore improved methods
of two-dimensional gel electrophoresis. During
this
period, he has also set up a home-office in the Bos-
ton area to continue explorations of future two-
dimensional gel software.
The year 1989 was also the renewal year for the
NIH Research Resources Grant that has funded
QUEST for the past 5 years. The new directions for
the technological and scientific goals of QUEST have
been approved at an increased funding level. In the
renewal, a full-time Computer Resource Manager
was requested to manage the software upgrades and
the interaction of users with the software. Further-
more, the renewal application included a new pro-
gram for QUEST, a protein identification section to
be headed by a full-time protein chemist. Both were
approved. The new Computer Resource Manager,
Gerald Latter, will start in January, 1990, and a pro-
tein chemist at the senior staff level will be hired dur-
ing 1990.
Our staff in the Grace Building has not changed
during 1989. Cecile Chang, the Operations Super-
visor, continues to interact with service and col-
laborative users to coordinate data processing and
use of the workstations. Jim Kos has maintained the
hardware and software, adding utility programs as
needed. Phyllis Myers tirelessly performs the service
of starting the gel matches and carefully checking
the results.
In the two-dimensional gel laboratory in the
McClintock Building, Ann Rudman departed in Au-
gust, and Heidi Sacco began maternity leave in Sep-
tember. During July, Heidi recruited and trained two
new laboratory technicians, Christy Blanchford and
Shuling Fang, and they have run the gel laboratory
during Heidi's absence. When Heidi returns part-
time in 1990, she will continue to supervise the gel
laboratory, but will take on responsibilities in a new
core facility for two-dimensional gel scanning.
Yeast Database
J.I. Garrels, C. Chang, P. Myers [in collaboration with
C. McLaughlin, University of California, Irvine,
and J. Warner, Albert Einstein College of Medicine]
The yeast database has grown in the past year
through the analysis of several major experiments
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described below. Each of these experiments has been
analyzed on three different two-dimensional gel
types (pH 3.5-10, 10% slab; pH 4-8, 10% slab; and
nonequilibrium, 15% slab), and routinely 2000-3000
proteins per sample are scored. These gels are sensi-
tive enough to detect many proteins that represent
less than 0.001% of the total protein synthesis, al-
though many other proteins of such low intensity
cannot yet be resolved from the larger spots on the
gel. The proteins of lowest detectable intensity rep-
resent about 100-300 molecules per cell.
INTRONS IN YEAST
Our experiment to study proteins encoded by genes
with introns has been further analyzed. The mutant
rna2 fails to remove introns at the nonpermissive
temperature, and, after the decay of normal mRNAs,
proteins encoded by genes with introns fail to be syn-
thesized. Our studies show that for Saccharomyces
cerevisiae grown in balanced growth on glucose, only
2% of the detected proteins are coded from genes
with introns. Interestingly, most of these are ribo-
somal proteins, which were previously identified on
gels of purified ribosomes.
KINETICS OF LABELING AND MODIFICATION
A study of the kinetics of labeling, processing, and
turnover has been put into the database. The vast
majority of yeast proteins appear to be labeled with
the same relative intensity in a 30-second pulse, a
60-minute pulse, and a 5-minute pulse, followed by
a 20-minute chase. (The time to complete a polypep-
tide chain in yeast is about 30 seconds.) Thus, for
most yeast proteins, the posttranslational modifica-
tions, if any, are rapid.
Most proteins are stable as judged from the 20-
minute chase (carried out under balanced growth
conditions). Protein spots that represent posttrans-
lationally modified forms should appear with in-
creasing intensity as pulse times increase from 2 to
60 minutes (unless the modification occurs quickly
on nascent chains). There are 50 such proteins. Those
that appear with lower intensity for longer pulses ei-
ther are precursors to a modified form or are unsta-
ble. In this class, 31 proteins have been found.
N-ACETYLATION OF YEAST PROTEINS
One of the most common protein modifications is
acetylation of the amino-terminal amino acid. Three
groups following entirely different strategies have iso-
lated mutants that affect this process and define two
genes that appear to code for subunits of the trans-
acetylase. Whiteway and Szostak isolated ARD1
(Cell 43: 483 [1985]) on the basis that it was involved
in the switch between the mitotic cell cycle and al-
ternate developmental pathways. The NAT] gene was
isolated by Grunstein, Sternglanz, and co-workers,
who screened a library of temperature-sensitive mu-
tants to detect a mutant defective in histone acetyl-
transferase activity. The mutant turned out to be
defective in the acetyltransferase activity for a wider
range of proteins (Mullen et al., EMBO J. 8: 2067
[1989]), and the fact that it was functionally related
to ARD1 was noted. Smith and co-workers took the
direct approach of purifying the N-acetyltransferase,
sequencing peptides, and preparing oligonucleotide
probes (Lee et al., J. Biol. Chem. 264: 12339 [1989]).
Both Sternglanz's and Smith's laboratories conducted
a preliminary survey of the two-dimensional gel elec-
trophoresis pattern in the mutants, the former using
the QUEST laboratory and the latter using Protein
Databases Inc. Both groups noted that a number of
proteins changed position in the mutant.
We have undertaken a detailed analysis of pro-
tein synthesis in the ardl and natl mutants because
of our intrinsic interest in protein modification and
because of the possible relationship between these
mutants and a switch between the mitotic cell cycle
and alternative developmental pathways. The com-
parison of protein patterns from normal and the
acetylation mutants was challenging because so
many of the major proteins are shifted in position.
Proteins that are N-acetylated in the wild type lose
one negative charge in the mutant and migrate to
a more basic position on the isoelectric focusing gel.
Figure 1 gives an example of the wild-type, mutant,
and mixed patterns, revealing charge shifts for a large
number of spots.
In a pH 4-8 gel, 152 of the 1325 scored proteins
are normally N-acetylated by the NATI,ARD1 en-
zyme. Proteins that are clearly nonacetylated num-
ber 534. In addition, 639 low-intensity proteins do
not appear to be acetylated, but cannot be unam-
wild-type mixture mutant a r d 1
FIGURE 1 Comparison of the wild-type strain and the N-acetylation mutant (ardl) isolated by Szostak et
al. The cells were labeled with [35S]methionine for 15 min at log phase. In mutant ardl, a total of 152 pro-
teins (about 50% of the total protein mass) were shifted toward the basic side of the two-dimensional gel
(pH 4-8, 10% polyacrylamide), compared with the wild-type strain (see text). The middle graph is a mixture
of wild type and mutant; + indicates a group of four spots that correspond to the spots marked either
in the wild-type or mutant cells.
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biguously scored. The 152 acetylated proteins rep-
resent about 50% of the total protein mass in this
gel type. Thus, N-acetylation is heavily biased to-
ward the major proteins. All of the N-acetylated pro-
teins are stable, and they all are labeled in the short-
est pulse labelings. In all 152 cases, the mutant and
the wild-type proteins have the same relative abun-
dance. Therefore, for cells in balanced growth in glu-
cose, the lack of the N-acetyl group does not lead
to instability that can be detected in a 15-minute
pulse.
Mouse Embryo Database
J.I. Garrets, C. Chang [in collaboration with
K. Latham and D. Solter, Wistar Institute]
The mouse embryo database is being developed by
Drs. Davor Solter and Keith Latham as a tool to sup-
plement many studies ongoing in Dr. Solter's labo-
ratory. As a baseline study of the normal embryo,
the database will be enormously valuable for in-
terpretation of more-specialized experiments involv-
ing genetic manipulation of embryos. The mouse em-
bryo database should be useful to many researchers,
and like the yeast database, it is being developed with
the needs of the larger community in mind.
Carefully staged mouse embryos have been la-
beled at 3-hour intervals, from fertilization through
the four-cell stage, which is a 57-hour time span.
Typically, 20-30 embryos are required per time point.
Further labelings have been done to extend this study
through the blastocyst stage, but only samples
through the four-cell stage have been analyzed.
It is known that by the two-cell stage, much of
the maternal mRNA has been degraded and new pro-
teins coded by embryonic mRNA are being made.
The timing of this switchover and its impact on the
types and amounts of proteins being synthesized
have not been previously studied in detail. We find
that during any 3-hour interval of the late zygote/
early two-cell stages, more changes occur in the pat-
tern of protein synthesis than in the entire transition
of REF52 cells from proliferation to quiescence. In
contrast, cells labeled 3 hours apart in the four-cell
stage appear to be as similar as duplicate cultures
of REF52 cells.
To explore this period of rapid change further,
we followed the fate of each of 748 proteins that can
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be accurately measured during the two-cell stage. Of
these, 169 (23%) disappear during the two-cell stage
and are probably coded from maternal mRNA. An-
other set of 174 proteins (23%) appear for the first
time during the two-cell stage and are probably coded
by newly activated embryonic genes. Most of the re-
maining proteins show increases or decreases of more
than twofold between the beginning and the end of
the two-cell stage. These may represent proteins
coded by both maternal and embryonic mRNAs, but
for which the switch affects the rate of synthesis.
Only 78 proteins (10%) remain constant (within a
factor of 2) during the entire two-cell period. In con-
trast, 92% of the proteins are synthesized at a con-
stant rate throughout the four-cell stage. Figure 2
shows a portion of the gels from the two-cell stage
(four of the eight gels) with the most constant pro-
teins highlighted. The massive changes in the sur-
rounding spots are apparent.
We plan to extend the mouse embryo database
to the blastocyst stage and to supplement it with
many more identified proteins.
Signal Transduction/Nuclear
Regulatory Protein Database
B.R. Franza
Efforts to identify several cellular proteins involved
in the processes of signal transduction and/or the
control of mammalian mRNA transcription have
been fruitful. Details of each of these studies are
presented in Cellular trans-Activators of Gene Ex-
pression, in this section. We have identified the fol-
lowing proteins in the QUEST two-dimensional pro-
tein pattern: the large subunits of RNA polymerase
II as well as certain coimmunoprecipitating proteins;
mammalian cyclin B (p62); an important complex
between p60 and the "MARCKS" proteins (a known
substrate of protein kinase C); Fos B, a Fos-related
gene product; and p13, another cdc2-associated pro-
tein. The QUEST two-dimensional gel system made
possible the recognition that proteins other than cy-
clin B and p13 were associated with cdc2 and that
a major substrate of protein kinase C was associated
with an E1A-associated cellular protein. These ob-
servations have prompted much experimentation at
Cold Spring Harbor Laboratory during 1989.
FIGURE 2 Changes of protein synthesis during the two-cell stage of mouse embryos. Gel images are shown from four
time points of the two-cell stage, with constant proteins highlighted. The dramatic changes of protein synthesis are apparent,
reflecting the reprogramming of protein synthesis as embryos switch from the use of maternal mRNA to newly synthesized
embryonic mRNA.
Service Projects
C. Chang, P. Myers, J. Kos, J. Garrels
The QUEST center performs numerous small ser-
vice and collaborative projects. Some of the key
projects for 1989 are described below.
S. Shaw and Y. Shimizu (National Institutes of
Health) have used the QUEST system to investigate
naive and resting T cells, separated on the basis of
their CD45 isoforms. Differences in the proteins pat-
terns were found, and these proteins are being charac-
terized to find additional regulators in the T-cell sig-
nal transduction pathway.
C. Kumar (Schering Corp.) has used the QUEST
system to study normal and transformed human
HOS cells, using an isoform of myosin-light-chain
2 (MLC2) as a marker. So far, he finds that MLC2
expression is repressed by ras, met, src, and TPA,
but not by feline leukemia virus. He plans to expand
these studies into an entire database for HOS cells.
J. Higginbotham (Pioneer Hi-Bred and CSHL)
has used the QUEST system to study more than 1900
proteins from inbred maize lines. More than 200 sub-
stantial differences among strains were found, and
these were checked to be sure that environmental fac-
tors, such as time of imbibition, were not responsi-
ble. These studies will be useful in better understand-
ing the relationship of the inbred genotypes.
T. Holt and C. Thompson (Pasteur Institute) have
used QUEST to identify and study proteins involved
in the synthesis of the antibiotic bialaphos. More
than 20 proteins were identified, using regulatory
mutants that fail to induce the pathway, and the ex-
pression of these proteins was studied in cells pulse-
labeled from early log-phase growth to late station-
ary phase.
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New Directions in QUEST Technology
J.I. Garrels [in consultation with G. Latter]
The year 1989 was the last year of our initial 5-year
Resource Grant from the NIH Biomedical Research
Technology Program. Therefore, much of the past
year has been spent in planning the next phase of
the QUEST center. We have explored new avenues
of hardware and software technology, we have tested
ideas and developed preliminary data, and we have
presented and defended our ideas during the review
process. Throughout this period, Jerry Latter served
as a consultant to QUEST. The review was success-
ful, and Jerry has been hired to join QUEST as the
Computer Resource Manager in January 1990.
WORKSTATIONS
In reequipping the QUEST center, we have decided
to continue with the powerful Sun workstations for
the demanding task of processing hundreds of gel
images to build the master databases. We have also
decided to use the Macintosh computer more for
statistical analysis of the data and as a vehicle for
database dissemination (see below). New Sun Sparc-
station 4/330 and Sparcstation 1 workstations were
ordered by the end of the year. In addition, we are
thankful to Sun Microsystems for the gift of one Sun
4/330 and one Sun 4/60 Sparcstation as part of their
academic grant program.
STANDARDIZED USER INTERFACE
Standardized graphics is now an essential compo-
nent of modern software. X Windows give a library
of powerful subroutines for almost any type of
graphics or windowing operation, and programs that
use X can run on virtually any workstation. Con-
version of the QUEST software to X was begun by
Jim Garrels using a Sun 4/260 workstation. Displays
of gel images are now almost instantaneous. Previ-
ously, QUEST users could view only images from
one matchset at a time; now any number of match-
sets can be displayed simultaneously in overlapping
windows. It is even possible to control multiple
screens from the same program if desired.
One of the major responsibilities of Jerry Latter,
as the new Computer Resource Manager, will be the
development of a standardized user interface. Such
interfaces represent standard specifications and soft-
ware toolkits that allow implementation of menus
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and control windows with a common "look and feel."
Jerry has researched these, and he is currently lean-
ing toward the OpenWindows interface standard and
the XView toolkit developed by Sun. The implemen-
tation of a standardized user interface will greatly
improve our ability to train users of the QUEST sys-
tem, both at CSHL and elsewhere, when we begin
to disseminate the QUEST software.
New Directions in QUEST Databases
J.I. Garrels [in consultation with G. Latter]
We have also explored and tested new directions for
the QUEST databases. These databases, which are the
end result that proves the worth of all our technol-
ogy, will be enhanced (1) by making them available
to scientists everywhere who use personal computers,
(2) by making them compatible with commercial pro-
grams for statistical analysis and data presentation,
(3) by connecting them to other biological databases,
(4) by enlarging databases through core research in
key database areas, and (5) by enhancing them with
many more protein identifications.
DATABASE DISSEMINATION ON THE MACINTOSH
Jerry Latter has worked during 1989 to build a pro-
totype database interface for the Macintosh. Using
the Hypercard utility in the Macintosh, Jerry has
been able to present entire gel images that can be
scrolled and zoomed, and he has been able to con-
nect the spots as "buttons" that display annotations,
spot names, spot graphs, etc., when "pushed" by a
mouse click. Our aim is to format the spot quanti-
tation data, as well as the spot names and annota-
tions, from each database in a format compatible
with Hypercard, and to disseminate these data with
all the relevant gel images on CD-ROM disks. Such
a database would give users everywhere complete ac-
cess to the QUEST databases and would allow them
to check important results against the original im-
ages. One of the hardest tasks in developing the
QUEST system is writing the statistical analysis rou-
tines and plotting routines to cover every type of
analysis that a user might want. Fortunately, a wide
variety of commercial packages for the Macintosh
already provide for statistical analysis, for spread-
sheet analysis, and for creation of presentation qual-
ity slides and figures. Jim Garrels has explored many
of these packages during the past year, and he has
set up the interface to move data easily between the
QUEST program and the Macintosh.
THE NEW FOCUS FOR CORE DATABASES
New databases to be built by the QUEST staff are
(1) a mammalian cell proliferation database, (2) a
nuclear regulatory protein database, and (3) a yeast
protein database. The first is an outgrowth of our
REF52 database, but it has been broadened to in-
clude studies of interest from any mammalian cell
culture system that provides information about the
regulation of cell growth. The second database area
is centered on the work of Robert Franza (see his
section of this report). The third database area, yeast
cells, continues to be led by Calvin McLaughlin and
Jonathan Warner. In each of these areas, a database
can be built under the direction of one or two scien-
tists, who know both the particular field and the
fine points of using the QUEST system to build
databases.
We expect our work in each of these database
areas to be supplemented by a full-time protein
chemist, to be hired during 1990, who will special-
ize in protein identifications. The next generation
of technology should make database construction
severalfold easier and faster, and with a full-time ef-
fort at protein identification, we expect that QUEST
in the 1990s will truly become a database resource.
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GENETICS
Genetic techniques continue to be widely used at Cold Spring Harbor Laboratory,
in particular by those who work with the ascomycete fungi, Saccharomyces
cerevisiae and Schizosaccharomyces pombe. The Plant Genetics Group
continues to use both maize and increasingly the model plant, Arabidopsis, for
studies in molecular genetics. Arabidopsis is a pond weed that has a very short
life cycle and is highly tractable to genetic methods. Whereas yeast has been
viewed in recent years as the new E. coli, with the advantage that it is a
eukaryote, Arabidopsis is becoming the yeast of the plant world. This is a simple
system upon which genetic methods can readily be applied. The work of the
Genetics Group, in yeast, plant, and animal cells, is described in this section.
EUKARYOTIC CELL CYCLE CONTROL
D. Beach J. Bischoff
T. Connolly
G. Cottarel
S. Davey
S. Dembski
U. Deuschle
B. Ducommun
J. La Monica
K. Lundgren
T. Matsumoto
L. Molz
Our research has focused for the past five years on
the regulation of the eukaryotic cell cycle. Initially,
we studied the fission yeast exclusively, because of
the appealing genetic accessibility of this organism.
However, the broad conservation of the molecular
elements that regulate the cell cycle, apparently in
all eukaryotic cell types, allows us now to take an
integrated approach that initially involves identifi-
cation of regulators by the technique of yeast genetics
and subsequently elaborating their role in both yeast
and mammalian cells.
During the last year, the members of the "start-
up" Beach laboratory largely moved on to other po-
sitions. Giulio Draetta assumed a group leader po-
sition at EMBL, Heidelberg, and Maureen McLeod
became an assistant professor at Downstate Medi-
cal School, Brooklyn. Robert Booher and Leonardo
Brizuela each obtained PhD degrees (SUNY Stony
Brook) and moved on to postdoctoral positions at
the University of California at San Francisco and
Merck Sharpe and Dohme. We are joined by several
new postdoctoral fellows, including Jim Bischoff,
Uli Deuschle, Karen Lundgren, Tim Connolly, Giul-
laume Cottarel, Tomohiro Matsumoto, and Scott
Davey.
Fission Yeast Cell Cycle
T Connolly, G. Cottarel, U. Deuschle, B. Ducommun,
K. Lundgren, T. Matsumoto, L. Molz, D. Beach
We have pursued the study of the cdc2+ protein ki-
nase and continued to identify genetic elements with
which it interacts. cdc2+ plays a central role in cell
cycle regulation and is required both for the initiation
of DNA replication and for entry into mitosis. Pre-
viously, we found that the products of both sucl+
and cdc13+ act as subunits of the protein kinase.
cdc13+ is of particular interest because it is required
only at mitosis. The interaction between cdc2+ and
cdc13+ thus defines a "G2-specific" function of
cdc2+. Nucleotide sequencing of cdc13+ revealed ho-
mology with a class of proteins known as mitotic
cyclins. In fission yeast, we showed that the cdc13+
gene product behaves as a cyclin. It accumulates pro-
gressively during interphase and is abruptly degraded
at each mitosis (Fig. 1).
cdc2 and the cdc13+-encoded cyclin progressively
form a complex during interphase, but the enzyme
is not catalytically activated until the onset of mito-
sis. Activation requires the function of the cdc25+
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FIGURE 1 (A) Representation of the cell cycle oscillation of cy-
clin and the cdc25 product, in comparison with the time of acti-
vation of the cdc2-cyclin complex (M-phase promoting factor,
MPF). (8) Molecular representation of the cdc2-cyclin complex
at the G2/M transition.
gene product. Antibodies were raised against the
cdc25+ product, and immunoblotting revealed that
the protein varied in abundance during the cell cy-
cle. Thus, both the cdc13+ and cdc25+ products dis-
play cell cycle oscillation, but unlike the cyclin, cdc25
is a dose-dependent activator of mitosis (Fig. 1A).
Although the accumulation of the cyclin and
cdc25 proteins is gradual, the cdc2/cyclin complex
is activated very abruptly at the G2/M transition. In
higher eukaryotes, we found that at this stage of the
cell cycle, the cdc2 subunit of the protein kinase be-
comes dephosphorylated on tyrosine and threonine
residues. This also occurs in fission yeast, in partic-
ular in a cdc25's strain after release from the restric-
tive temperature (Fig. 2). The cdc25+ protein is prob-
ably not itself a phosphatase but may act to stimulate
the relevant phosphatase (Fig. 1B). Direct evidence
that dephosphorylation of cdc2 contributes to acti-
vation of the enzyme has been obtained by treating
cdc2/cyclin from either starfish or frog oocytes with
144
potato acid phosphatase. The enzyme dephosphory-
lates cdc2 and stimulates its histone kinase activity
(in collaboration with L. Meijer, Roscoff, France,
and C. Jessus, CNRS, Paris).
Cyclin/cdc2 Localization at
the Mitotic Centrosomes
B. Ducommun, G. Draetta, R. Booher,
L. Brizuela, D. Beach
In a study of the localization of cdc2 in mammalian
cells (in collaboration with K. Riabowol, Cold Spring
Harbor Laboratory, and D. Vandre, Southern Meth-
odist University, Texas), we found that cdc2 is pre-
dominantly a nuclear protein in interphase cells. Fur-
thermore, microinjection of anti-cdc2 antibodies
caused cells to fail to enter mitosis. This provides
the first direct evidence that cdc2 is required for cell
cycle progression in mammalian cells. During mito-
sis, cdc2 becomes widely distributed throughout the
cell as the nuclear membrane dissolves. At this time,
extensive staining of the mitotic centrosomes be-
comes apparent. This suggests that cdc2 is likely to
be involved in nucleation of the mitotic spindle.
In a further study in fission yeast (in collabora-
tion with C. Alpha and J. Hyams, UC, London),
we found that both cdc2 and its associated cyclin were
localized in the spindle pole body, which is the yeast
counterpart of the mitotic centrosome. The spindle-
pole-body-associated cyclin showed an interesting
property. Whereas the bulk of the cyclin is degraded
relatively early in mitosis, the pole-body-localized
protein is delayed in degradation. Thus, during spin-
dle elongation, cyclin is observed exclusively in the
pole bodies (Fig. 3).
cdc2 and Mammalian Oncoproteins
J. Bischoff, G. Draetta, L. Brizuela, D. Beach
During the course of studies of the cdc2 protein ki-
nase in mammalian cells, we have engaged in a se-
ries of collaborations with other laboratories at Cold
Spring Harbor to investigate interconnections be-
tween cdc2 and oncogene products.
We found that SV40 large T antigen is a particu-
larly good substrate of cdc2 (in collaboration with
D. McVey, I. Mohr, D. Marshak, and Y. Gluzman).
We took advantage of T synthesized in bacteria and
were able to show that cdc2 phosphorylates residue
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FIGURE 2 (Top) Activity of cdc2-cyclin () and level of phosphotyrosine in cdc2 (heavy
circles) in a cdc25 mutant of fission yeast after release from a restrictive temperature. (Bot-
tom) Immunoblot showing the phosphotyrosine content of cdc2.
Thr-124. This site is known to be phosphorylated in
vivo and is essential for replication of SV40. Fur-
thermore, protein that is mutant at this site is un-
able to support virus replication in cell-free lysates.
In addition, bacterially derived T, unlike that puri-
fied from mammalian cells, cannot support DNA
replication. We found that this deficit can be directly
overcome by phosphorylation at Thr-124 by cdc2.
This provides the first evidence that cdc2 can act to
control DNA replication in a higher eukaryote.
FIGURE 3 Double staining of fission yeast with anti-
tubulin (a) and anti-cyclin (b). Each mitotic spindle can
be seen to be spanned by regions of anti-cyclin stain-
ing. These are the spindle pole bodies.
In a further study (in collaboration with A. Gior-
diano, R. Franza, and E. Harlow), we found that
a 60-kD polypeptide, previously identified as an E1A-
associated protein in adenovirus-infected cells, acts
as a cdc2 subunit in uninfected cells. p60 is not the
mammalian cyclin B (cdc13 homolog), and the cdc2 -
p60 complex shows properties different from those
of cyclin B-cdc2. In particular, cdc2-p60 is most ac-
tive during interphase, whereas cyclin B-cdc2 is an
M-phase enzyme. Although the respective roles of
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these two complexes are not yet clear, these obser-
vations emphasize that cdc2 is not a single protein
kinase, but rather the catalytic subunit of a family
of cell cycle regulatory protein kinases.
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PRE-mRNA SPLICING AND sNRNA SYNTHESIS IN
SCHIZOSACCHAROMYCES POMBE
D. Frendewey D. Kim M. Gillespie
J. Potashkin I. Barta
A. Serrano
We pursue two related lines of research. Our primary
interest is the splicing of mRNA precursors (pre-
mRNAs). We have also recently begun to investigate
small nuclear RNA (snRNA) synthesis. We are study-
ing both of these processes in the fission yeast
Schizosaccharomyces pombe. These two areas of re-
search are related, in general, by the fact that the
snRNAs known as Ul, U2, U4, U5, and U6 are re-
quired for pre-mRNA splicing and are components
of the spliceosome, the large ribonucleoprotein struc-
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ture in which pre-mRNA splicing occurs. In fission
yeast, this relationship exhibits an additional pecu-
liar twist: The gene for the U6 RNA of S. pombe
is interrupted by an intron whose structure resem-
bles that of a pre-mRNA intron. Therefore, in fis-
sion yeast, it appears that U6 RNA, in addition to
being an essential component of the pre-mRNA
splicing machinery, might itself be produced from
a precursor that is a substrate of the spliceosome.
Our initial efforts to examine these phenomena
have been genetic. To identify genes that are required
for pre-mRNA splicing or snRNA synthesis, we have
isolated temperature-sensitive (ts) mutants that are
defective in these processes. Analysis of the mutants
has generated the three main projects that are cur-
rently under investigation in our laboratory.
U6 RNA Synthesis
J. Potashkin, I. Barta, M. Gillespie, D. Frendewey
In our 1987 and 1988 Annual Reports, we described
the isolation and initial characterization of three ts-
pre-mRNA splicing mutants: prpl, prp2, and prp3.
Indicative of the complete (prpl and prp2) or par-
tial (prp3) block in pre-mRNA splicing, these mu-
tants accumulate unspliced pre-mRNAs at the non-
permissive temperature (37°C). As part of our initial
analysis of the prp- mutants, we observed that after
a short period at 37°C, each had a reduced U6 RNA
content compared to the wild type. The levels of the
other snRNAs were normal. At the time, we had no
explanation for these results. However, the discov-
ery of an intron in the S. pombe U6 gene (Tani and
Ohshima, Nature 337: 87 [1989]) suggested that the
reduction in U6 RNA in the prp- mutants might re-
sult from inefficient splicing of the U6 precursor (U6
pre-RNA).
In 1989, we confirmed the lower U6 RNA con-
centration in the prp- mutants by a more sensitive
assay and went on to show that the splicing of the
U6 pre-RNA was indeed impaired in prpl, prp2, and
prp3. The severity of the U6 splicing defects exhibited
by the three mutants paralleled that seen for pre-
mRNA, suggesting that the U6 pre-RNA might be
spliced by the same mechanism and require some of
the same gene products as pre-mRNAs. We would
like to investigate these questions further in the
future.
The presence of a pre-mRNA-type intron in the
S. pombe U6 gene raises a number of interesting
questions with regard to splicing and snRNA syn-
thesis. The S. pombe U6 gene is the only example
of an interrupted U6 or other snRNA gene. How did
this intron arise and why is it maintained? The U6
RNA from all sources so far investigated is tran-
scribed by RNA polymerase III, and this is also ex-
pected to be true for S. pombe. Yet the intron in the
S. pombe U6 pre-RNA is the type found only in
RNA polymerase II transcripts (e.g., pre-mRNAs).
Is the U6 pre-RNA spliced by the pre-mRNA splic-
ing machinery or does it use its own unique mecha-
nism? It has been proposed (Brow and Guthrie, Na-
ture 337: 14 [1989]) that the S. pombe U6 intron was
inserted as the result of a mishap during the splicing
of a pre-mRNA. This hypothesis predicts that the
position of the intron reflects a functional domain
in the U6 RNA.
To begin to address these questions, we initiated
a search for intron-containing U6 genes in other
Schizosaccharomyces strains and several more dis-
tantly related species of yeast. The primary goal of
this project was to investigate the uniqueness of the
S. pombe U6 intron. In addition, if introns were
found in the other strains, their sequences might re-
veal conserved features peculiar to U6 introns. Our
approach was to use the polymerase chain reaction
(PCR) to amplify a highly conserved portion of the
U6 genes from the various yeast strains. The intron
resides in this region of the S. pombe U6 gene. The
sizes of the PCR products would be the first indica-
tions of the presence or absence of introns. Subse-
quent sequencing would define the position and
structure of any introns that were found.
The results of the amplifications showed that the
U6 genes in all of the Schizosaccharomyces strains
were interrupted by introns of approximately the
same size as that found in S. pombe. The U6 genes
from the other yeast species did not contain introns
within the fragment that was amplified. The PCR
products from the Schizosaccharomyces strains were
cloned and sequenced. The sequences of the introns
are shown in Figure 1. All the introns were found
in precisely the same position and were approxi-
mately identical in size (50-52 bp). As expected, the
positions displaying the greatest sequence conserva-
tion were at the 5' and 3' splice sites and the branch-
point consensus. However, an unexpected region of
homology was found immediately upstream of the
presumptive branchpoint. When 11 bases from the
corresponding region of the S. pombe intron were
compared with all available S. pombe sequences in
the databases, a surprising similarity was found to
the B-box promoter elements of the 7SL RNA and
several tRNAs (starred bases in Fig. 1). The B box
is the 3' half of the bipartite internal promoter re-
quired for transcription of 7SL RNA and tRNA by
RNA polymerase III.
This result was surprising by comparison with ver-
tebrate U6 genes, whose transcription by RNA poly-
merase III does not require internal sequences.
Similarity to known promoter elements is, of course,
not proof of function. However, the hypothesis that
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Alignment of the Schizosacchar omyces U6 Introns
SpU 6 TT /GTAAGTA ACAATATTTACCAAGGTTCGAGTCATACTAACTCGTTGTTTAG/AG
11 1111111 1111111111111111
1 III 11111111 111111111 11
SmU6 TT/GTAAGTA ACAATATTTACCAAGGCTTGAGCTATACTAACCTGTTGTTTAG/AG
11 1111111 I 1111111
I I
1
11111111 111111111 11
SoU6 TT/GTAAGTACACCCCAGACGACCAAGGTTCGAGTCATACTAACTCGTTGTTTAG/AG
11 11111111 1111 1 1 1
11111111 111111 II III 11
SjU6 TT/GTAAGTACCCCCCTAAGGTCGTGAGTTCGAGTTCCACTAAC
ACCCGTCTAG/AG
11 11111111 II 11 111111111111111111111
111111 III II
SvU6 TT/GTAAGTACTGCCTGGAGTAtGTGAGTTCGAGTTCCACTAAC
ACCCGTTTAG/AG
con TT/GTAAGTAc--Cc-taa-taccaagGtTcGAGttatACTAACt-gttGTtTAG/AG*******
FIGURE 1 U6 gene intron sequences. Shown are the sequences of the sense
strands, with respect to the U6 RNA, of
the introns and two bases in the flanking exons for the U6 genes of five
Schizosaccharomyces strains. The strains are indi-
cated by abbreviations to the left of the sequences: (Sp) S. pombe: (Sm) S. malidevorans; (So) S. octosporus; (Sj) S. japoni-
cus var. japonicus: (Sy) S. japonicus var. versatilis. The splice junctions are identified by slashes. Gaps were introduced
to accommodate the best alignment of all the sequences. Identities between any two adjacent sequences are denoted by
vertical bars. A consensus sequence (con) is given below the aligned sequences, with bold uppercase letters designating
positions of absolute conservation. The 5' and 3' splice site and branchpoint consensus sequences are underlined, and
the bases that match the B-box consensus are starred.
the conserved internal sequence in the Schizosac-
charomyces U6 genes is a B-box promoter element
makes several predictions. First, we would expect to
find a corresponding A box in the fission yeast U6
genes. The first exon of the S. pombe U6 gene con-
tains a stretch of 12 bases that is very similar in se-
quence and position, relative to the transcription ini-
tiation site, to those of the A box in the S. pombe
7SL RNA gene. Second, deletion of the intron from
the S. pombe U6 gene should drastically reduce or
abolish transcription of U6 RNA. Thus, the intron
may be necessary for expression of U6 RNA, which
may explain why this unusual gene structure has been
maintained in the fission yeast. Third, the conserved
sequence in the S. pombe U6 intron should bind fac-
tors that recognize the B box, and therefore the
S. pombe U6 gene should compete for the transcrip-
tion of t RNA genes in in vitro assays. We have ini-
tiated experiments to test these predictions and to
define the sequences required for U6 RNA transcrip-
tion in S. pombe.
Pre-mRNA Splicing Mutants
J. Potashkin, D. Kim, D. Frendewey
The isolation of the prpl, prp2, and prp3 mutants
identified three genes that are required for pre-
mRNA splicing. During the past year, we initiated
a project to clone the prpl+ and prp2+ genes. Since
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the prp- mutants are is -, our cloning strategy was
to transform prpl and prp2 with an S. pombe
genomic library and select transformants that can
grow at 37°C (ts+). If the ts+ phenotype is dependent
on the plasmid, then the transformant is likely to
contain the prpl+ or prp2+ genes or a gene that can
suppress the prp- mutation.
We have obtained ts+ transformants for both prpl
and prp2. Plasmid has been isolated from these
transformants and cloned in Escherichia coli. We are
now testing the plasmids from the bacterial clones
to see if they can cure the is phenotype in prpl and
prp2, thus confirming that we have cloned either the
prpl+ and prp2+ genes or prp- suppressors.
In addition to our attempts to clone one or more
prig+ genes, we have recently expanded our bank of
is mutants and have initiated a screen for new prp-
mutants. In our previous screen, we used a North-
ern assay to identify mutants that accumulate pre-
mRNA at the nonpermissive temperature. Our new
search will take advantage of our observation that
unspliced U6 pre-RNA levels are elevated in theprp-
mutants. We will again use a Northern assay, but this
time we will be looking for mutants that accumu-
late U6 pre-RNA at 37°C. This screening method
is more sensitive (because of the abundance of U6
RNA compared to mRNA), faster, and easier. Any
mutants identified will also be checked for pre-
mRNA splicing defects. An important question in
S. pombe splicing is whether the U6 pre-RNA is
spliced by the same mechanism as pre-mRNAs or
whether it requires its own specific factors. The U6
screen might allow us to answer this question by iden-
tifying mutations that affect the splicing of the U6
pre-RNA but not pre-mRNA.
snml: An snRNA Maintenance Mutant
J. Potashkin, A. Serrano, D. Frendewey
In the 1988 Annual Report, we described the char-
acterization of an unusual mutant, which at that time
we called prp4. This is mutant maintains reduced
steady-state levels of Ul, U2, U4, U5, and U6
snRNAs and K RNA, the RNA subunit of the tRNA
processing enzyme RNase P, compared to the wild
type. In addition, the mutant produces aberrantly
large U2, U4, and U6 transcripts at the nonpermis-
sive temperature. We observe a slight accumulation
of pre-mRNA and a significant reduction in pre-
tRNA processing in the mutant at 37°C. Because
these RNA processing defects are probably second-
ary effects of the reduction in snRNA content, we
have renamed the mutant snml to indicate a defect
in snRNA maintenance.
The initial analysis of the snml mutant pheno-
type has been completed in the past year. This in-
cluded experiments showing that the aberrantly large
U2 and U4 transcripts are extended at their 3' ends,
as we had earlier expected. We also established that
the larger U6 RNA that accumulates in snml is not
extended at its 3' end but is the unspliced U6 pre-
RNA. We have yet to determine if the reduction in
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U6 RNA in snml is solely the result of a splicing
defect or might be caused by a lower transcription
efficiency or instability. We are continuing our ef-
forts to better define the primary defect in snml; i.e.,
does the snml mutation manifest its effect at the level
of transcription, processing, or stability of the
snRNAs?
We have also begun a project to clone the snm1+
gene by the same strategy described above for the
prpl+ and prp2+ genes. As with prpl and prp2, we
have obtained ts+ transformants of snml, isolated
plasmid from the transformants, and cloned it in
E. coli. We are now testing the bacterial clones for
their ability to convert snml to ts+ upon transfor-
mation. Since snml is the first mutant isolated that
affects snRNA metabolism, we are confident that
its analysis and the characterization of the snm1+
gene will enhance our understanding of the synthe-
sis and maintenance of an important class of RNAs.
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Robertson's Mutator
V. Sundaresan, J. Brown, J. Colasanti,
A. Doseff, Z.Y. Zhao
Our main area of investigation has been the maize
transposable element system called Robertson's Mu-
tator (Mu). This system is characterized by an ex-
ceptionally high mutation rate due to the transposi-
tion of a family of elements called the Mu
transposons, of which a 1.4-kb element called Mul
is the best-characterized member. At present, little
is known about the protein factors that catalyze Mu
transposition or the genes encoding them. Mutator
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lines of corn carry many copies of actively transpos-
ing Mu elements, but they can switch to an inactive
state in which the Mu elements are present but not
transposing. Our studies have focused on the mech-
anism and regulation of transposition of the Mu ele-
ments. A second area of interest has been the regu-
lation of plant growth. In this context, we are
beginning to isolate genes for plant growth hor-
mones, as well as genes that regulate cell division in
plants.
Protein-binding Sites on the Mu
Terminal Inverted Repeat
Z.Y. Zhao, V Sundaresan
To identify factors that regulate Mu transposition
activity, we have been characterizing protein-binding
sites on the terminus of the Mul element. Three such
sites have been identified in mobility-shift assays
using labeled Mu] probes and nuclear protein from
Mu-active and Mu-inactive plants (see Fig. 1). The
binding activity for sites I and III is detected in nu-
clear protein from both Mu-active and Mu-inactive
lines, whereas the binding activity for site II is found
only in the Mu-active line. Thus, the protein that
binds to site II is a candidate for a Mu transposase.
The DNA sequences for sites I and II have been de-
termined more precisely by DNase I footprinting and
confirmed by mobility-shift experiments using syn-
thetic oligonucleotides. The oligonucleotide CGGG-
AACGGTAA (site I) binds to protein from both
Mu-active and Mu-inactive plants, whereas the oli-
gonucleotide CGGCGTCT (site II) binds only to pro-
tein from Mu-active plants. Furthermore, we deter-
mined that site I is in fact a duplication of a hexamer
sequence CGGG/TAA, which exhibits the same
binding activity and is the unit binding site. The iden-
II
CGGCGTCT
-175
tification of these binding sites is particularly in-
teresting in view of the discovery that there is an out-
ward promoter 16 by from the end of Mu] (R.
Martienssen, see below). When the Mu system be-
comes inactive, it results in transcription of down_
stream sequences from this promoter, and suppres-
sion of mutant phenotypes can occur. When Mu is
active, there is no detectable transcription from this
promoter. Currently, our model is that a protein
binding to site I is a positive regulator of transcrip-
tion from this promoter. When Mu is active, the pro-
tein binding to site II (the putative transposase) in-
terferes with this activation of the Mu] promoter by
the site I protein (the two sites are only 5 by apart).
We have initiated transformation experiments to
verify this model by using the particle gun system
(Klein et al., Nature 327 70 [1987]).
Changes in State of a Mul
Insertion at the bronzel Locus
A. Doseff, V Sundaresan
McClintock described a "change in state" of a mut-
able locus as a change at the locus that alters the
pattern of expression of the gene in a heritable man-
ner (Carnegie Inst. of Wash. Yearbook 66: 20 [1968]).
Examples of such changes in state have been exten-
sive in both the Spm and Ac-Ds transposon systems.
We have now found examples of changes in state in
the Mu system in our studies of a Mul insertion at
the bronze] (bz1) locus. The allele that we are study-
ing, bzMum9, was isolated by D. Robertson (Iowa
State University) and is characterized by a pattern
of small purple spots on a bronze background.
Southern blotting and DNA sequence analysis show
that a Mul element is inserted into the gene at the
intron-exon junction (J. Colasanti, Weiss, and V.
III
r\f\f\_)-->
-213
-165 -40 -16
CGGGAACGGTAA
I
FIGURE 1 Location of the protein-binding sites I, II, and Ill, and the transcript initiation
site on the 213-bp terminal inverted repeat of Mul.
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Sundaresan, unpubl.; see Fig. 2). Three heritable
changes in state of bzMum9 (csl, cs2, and cs3) have
been isolated, and their phenotypes and molecular
structure are summarized in Figure 2.
1. csl consists of an extremely high density of spots
so that the kernel appears solidly colored until
examined closely. We have found that this change
in state carries a new 1.7-kb insertion at the up-
stream end of the Mul element. The nature of
this new insertion is as yet unknown, but it does
not appear to be a Mu element. At present, we
have no model to account for the 10-100-fold in-
crease in excision frequency that is apparently due
to this insertion.
2. cs2 is a pseudorevertant, i.e., the kernel is a solid
purple color, but the Mul element is still at the
locus. Interestingly, detailed Southern analysis re-
veals a 0.65-kb deletion of the downstream seg-
ment of Mul. We propose that this deletion has
created a new splice site downstream from the
normal splice site, and the new splice site allows
the Mul element to be spliced out of the mRNA,
resulting in bz expression. We will verify this
model by analyzing the RNA from cs2.
3. cs3 exhibits a pattern in which the spots are very
dense on the crown of the kernel, and sparse
otherwise (an "Rnavajo"-type pattern). So far, we
have not found any change in the DNA of cs3
Bz
bztlum 9
bzMum 9cs 1
bzMum 9cs2
bztlum 9cs3
O
by Southern blotting, but our experiments would
not detect very small insertions or deletions.
Coordinate Regulation of Activity
of Different Mu Elements
J. Brown, V. Sundaresan
The Mu transposon system can switch from an ac-
tive state to an inactive state during propagation of
Mu stocks, and this switch has been correlated with
hypermethylation of the Mul elements (Chandler
and Walbot, Proc. Natl. Acad. Sci. 83: 1761 [1986];
Bennetzen, Mol. Gen. Genet. 208: 45 [1987]). We
have questioned whether the switch to the inactive
state affects all the Mu elements at the same time
or whether there is a progression of inactivation. For
this purpose, we utilized the bzMum9 allele described
earlier, along with a second Mu-induced mutation
at the waxy locus, wxMum5. The kernel phenotype
of wxMum5 is that of small sectors of normal starch
on a waxy background. This mutation has been
found to be due to the insertion of a Mu8 element
into an exon of the wx gene. Mu8 is a member of
the Mu family of transposons and has the same ter-
mini as Mul, but nonhomologous internal se-
quences. We crossed these two alleles together and
then outcrossed them to recessive testers; the
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FIGURE 2 Representations of the phenotypes
of different changes in state alleles of
bzMum9 and the corresponding DNA rearrangements.
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bzMum9 wxMum5 recombinants are being scored
for loss of mutability in the kernel. In the crosses
examined so far, there is an excellent correlation be-
tween loss of mutability at bz and loss of mutability
at wx, suggesting that the switch from active to in-
active Mu occurs simultaneously for the different Mu
elements.
Synthesis of Cytosine Methylated
DNAs In Vitro
J. Colasanti, V. Sundaresan
For our studies of the effects of transposon activity
on DNA methylation, it was necessary to devise a
simple method to synthesize cytosine-methylated
DNA. We have found that this can be done by poly-
merase chain reaction (PCR) in which 5-methyl-
dCTP is substituted for dCTP. The reaction condi-
tions are much the same as those for regular PCR,
except that the extension time had to be increased
to 5 minutes for a 1-kb fragment as the enzyme oper-
ates less efficiently with the methylated nucleotide,
and the yields decrease significantly for amplifica-
tion of larger fragments. Using this method, we could
demonstrate that cytosine-methylated DNA is com-
pletely resistant to the restriction enzyme Hinfl at
the concentrations normally used to cut genomic
DNA, i.e., 10-100-fold enzyme excess. This would
account for the observed resistance to Hinfl diges-
tion of the Mul elements in inactive Mu lines (Chan-
dler and Walbot, Proc. Natl. Acad. Sci. 83: 1761
[1986]). We find that Hinfl at 15,000-fold excess will
completely digest cytosine-methylated DNA, but use
of such a vast excess of enzyme is impractical in most
genomic digests.
A Suppressible Allele of
the dl Locus of Maize
J. Colasanti, V. Sundaresan
Maize plants that are homozygous for the dwarf I
(d1) mutation are 10-40% the height of wild-type
siblings, have broad dark green leaves, and undergo
aberrant floral development in which vestiges of the
Male flowers appear in the female flower. Biochem-
ical studies have shown that these pleiotropic effects
are the result of a deficiency of the active form of
the growth regulator gibberellic acid, GA1. The con-
version of the inactive form of gibberellic acid
(GA20) to the active form is catalyzed by an enzyme
encoded by the dl gene.
We have been attempting to isolate the dl gene
by transposon tagging, using the transposable ele-
ment Mu. Initially, there were two dwarf mutants
derived from the self of a Mutator line crossed with
a non-Mutator line in a screen by Michael Freeling
(University of California, Berkeley). One of the
mutants exhibited the expected ratio of dwarf to
normal plant for a recessive allele. After several
outcrosses, however, restriction-fragment-length poly-
morphism (RFLP) analysis with Mu-specific probes
showed that no particular element segregated with
the dwarf phenotype. The other dwarf mutant seg-
regated at non-Mendelian ratios upon selfing, with
mutant plants appearing less frequently with each
subsequent generation, until it finally disappeared.
Recent evidence with another Mu-induced mu-
tation provided a precedent for a form of allelic sup-
pression, governed by the Mu element, that may ex-
plain the observed frequencies and loss of the
mutation. In the case of the hcf106 mutation, the
activity of this gene is correlated with the state of
activity of the Mu element inserted within the gene
(R. Martienssen, see below). When Mu is active, the
hcf106 gene expresses the mutant phenotype, and
when Mu is inactive, the hcf106 lesion is suppressed
and the plants appear to be wild type. To determine
if a similar phenomenon was occurring with the dis-
appearing dwarf line, DNA from later generations
was analyzed, and the Mul elements were found to
be methylated, suggesting that Mu activity was lost
(Chandler and Walbot, Proc. Natl. Acad. Sci.
83: 1761 [1986]; Bennetzen, Mol. Gen. Genet. 200: 45
[1987]). Plants from this inactive line were crossed
to active Mu plants (Mu-active plants crossed with
Mu-inactive plants give Mu-active progeny), and the
resulting progeny were selfed to uncover recessive al-
leles. One line segregated dwarf plants at a ratio of
3:1, suggesting that the mutation has been rescued
by restoring Mu activity.
Because the expression of the mutation depends
on the state of Mu activity, it is likely that the dwarf
mutation is indeed caused by insertion of the Mu
element. We are now outcrossing the rescued dwarf
plants to follow the cosegregation of the Mu elements
with the mutant phenotype and to ultimately clone
the mutant gene.
Cloning of Plant
Cell-division Genes
J. Colasanti, V. Sundaresan
There are several important differences in the regu-
lation of growth and differentiation between plants
and animals. In plants, for example, the state of ter-
minal differentiation is not as clearly defined, and
in several plant species, an entire new plant can be
regenerated from a fully differentiated somatic cell.
Furthermore, plant cells in tissue culture can be in-
duced to form shoots, roots, or both, merely by vary-
ing the balance of certain plant growth hormones
(auxins and cytokinins). It is therefore of interest to
study such basic processes as regulation of cell divi-
sion, which have received much attention in animal
systems but have not yet been studied in plants. To
this end, we have begun to clone the plant homo-
logs of the cell-division-cycle genes. The first such
gene we have cloned is the gene encoding p34cdc2,
a key regulatory protein of the cell cycle in both
animals and yeasts. Using oligonucleotides to highly
conserved regions of this gene, we were able to iso-
late a partial cDNA clone from maize, and a partial
genomic clone from Arabidopsis (Fig. 3). There is
one copy of the cdc2 gene in the Arabidopsis genome
by hybridization, and possibly up to five copies in
the maize genome, although some of these copies
might be pseudogenes. In maize, we have detected
a 1.4-kb mRNA for cdc2 that is highly abundant in
the apical meristem, where the most cell division oc-
curs, and in low levels in differentiated leaf. We are
currently attempting to isolate a full-length cDNA
clone for maize cdc2. Several new cDNA clones have
been recently isolated by screening a maize seedling
cDNA library (a gift from A. Barkan, University of
California, Berkeley), and these are being charac-
terized.
Role of the hcf106 Gene Product
in Thylakoid Biogenesis
R. Martienssen, A. Jahrsdoerfer [in collaboration
with A. Barkan, University of California, Berkeley]
The nonphotosynthetic mutant of maize, hcf106,
contains a recessive nuclear mutation that prevents
the normal assembly of photosynthetic electron
transport complexes and causes aberrant thylakoid
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FIGURE 3 Comparison of partial amino acid sequence data
derived from the cloned maize and Arabidopsis cdc2 homologs
with that of human and S. pombe cdc2, showing a highly con-
served domain. The dots represent identity with the maize
sequence.
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membrane organization. Figure 4 shows electron
micrographs of mature chloroplasts from wild-type
and mutant mesophyll cells. Mutant thylakoids have
lost the lateral heterogeneity characteristic of wild-
type plastids, comprising alternating stromal (un-
stacked) and granal (stacked) lamellae. Instead, they
frequently form circular structures such as the one
shown in Figure 4. Furthermore, photosystems I and
II, and the cytochrome f/b6 complex, fail to ac-
cumulate to more than 5-1007o of wild-type levels,
whereas the ATPase and light harvesting complexes
are unaffected. Consequent reductions in chloroplast
pigment levels result in pale-green leaves. These emit
an increased fluorescence when illuminated with
ultraviolet light (thus, the designation hcf for high
chlorophyll fluorescence), as they are unable to chan-
nel harvested light energy into photosynthetic elec-
tron transport. Homozygous mutant seedlings die
approximately 3 weeks after germination, when seed
reserves are exhausted. Heterozygous plants survive
to maturity, enabling propagation of the mutation.
hcf106 arose in a Robertson's mutator line and
showed signs of somatic instability (namely, dark
green sectors), suggesting that it was caused by the
insertion of a Mu transposable element. Heterozy-
gous plants were outcrossed in successive generations
to the inbred line B73, resulting in segregation of the
20-50 Mu] elements found in these lines. A 3.7-kb
SstI fragment homologous to Mu] was found by
Southern analysis in every mutant seedling derived
from these outcrosses. This fragment was cloned into
a phage vector and was subsequently identified as
part of the hcf106 gene (Martienssen et al. 1989). A
1.2-kb transcript that hybridized to the cloned locus
was identified on Northern blots. This transcript was
regulated by mutator activity, suggesting that it en-
coded the hcf106 gene product (see below).
Thylakoid biogenesis in maize leaves occurs in a
well-defined developmental sequence. Proplastids,
which are found in younger, dividing cells at the base
of the leaf, have semicrystalline prolamellar bodies
and a poorly developed thylakoid membrane system.
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FIGURE 4 Electron micrographs of mature chloroplasts from wild-type (left)
and mutant (right)
mesophyll cells from 10-day-old seedling leaves. Magnification,
12,000 x .
More mature plastids are found in older, elongating
cells from successive leaf sections from leaf base to
leaf tip. These contain thylakoids that become pro-
gressively more elaborate, while the prolamellar bod-
ies rapidly disappear. Northern analysis has shown
that the hcf106 transcript is found primarily in the
base of the leaf, consistent with a role in the early
stages of thylakoid assembly and organization.
Lower amounts (three- to fivefold) are found at the
tip of the leaf, and still lower (but detectable) levels
are found in the root. Thylakoid elaboration can also
be induced in etioplasts of dark-grown plants by ex-
posure to the light. A three- to fivefold induction
of mRNA was observed following a 24-hour dark-
light transition, reflecting this morphological change.
The RACE protocol for the rapid amplification
of cDNA ends was used to isolate several full-length
cDNA clones, and these are being sequenced. cDNA
clones made by conventional methods were also ob-
tained from A. Barkan (University of California,
Berkeley), and these are also being sequenced in case
of polymerase chain reaction (PCR) error. These
clones include a second, distantly related sequence
that appears to be the product of a low-stringency
cognate gene of unknown function.
Somatic Excision of Mu
R. Martienssen, A. Jahrsdoerfer
The Mu/ element at the hcf106 locus is located in
the 5'-untranslated region, close to the initiation of
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transcription (see below). The first 5 by of the 9-bp
target site duplication (ATCTCCAAC) are the same
as the last 5 by of Mu] (ATCTC). DNA from two
hcf106 revertant sectors was cloned from sectored
leaves following PCR amplification using primers
flanking the site of Mu] insertion. The sequence of
the two revertant alleles and the sequence of the wild-
type allele from the inbred line B73 are compared
to the mutant sequence in Figure 5. The first exci-
sion precisely removed a single copy of the target-
site duplication. This was not a contaminating wild-
type product, since a 6-bp duplication (to the left
of the target site in Fig. 5) was present in the mutant
and revertant alleles, but absent from B73. The sec-
ond excision left 5 by of one repeat at the locus. This
is the region of the Mu] terminus homologous to
the target site. Thus, naively, both products might
have been generated by recombination between the
target site and either its duplication or the homolo-
gous sequence at the end of Mu]. Further analysis
of other sectored leaves will be required to determine
if this is a general pattern of Mu excision.
Suppression of Mu-induced
Mutations
R. Martienssen [in collaboration with A. Barkan,
University of California, Berkeley]
The hcf106 mutation is unusual in being Mu-
suppressible: When Mu activity is lost, homozygotes
adopt a wild-type phenotype. The loss of Mu activ-
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FIGURE 5 Nucleotide sequence of mutant, wild-type (from the inbred line B73), and revertant alleles of hcf106. The target
site duplication is boxed. Only the first 9 by of the 200-bp terminal inverted repeats are shown. Mu/ is 1350 by long.
ity is reversible: When Mu-off plants are crossed to
Mu-on plants, most of the progeny regain Mu ac-
tivity, but when Mu-off plants are selfed, no such
"reactivation" occurs. Suppression of the hcf106 mu-
tant phenotype is also reversible. When suppressed
hcf106 homozygotes (phenotypically wild type) were
crossed to Mu-on heterozygotes, the mutant pheno-
type segregated 1:1 in the resulting progeny. In con-
trast, when suppressed plants were selfed, no mu-
tant progeny were observed.
Mu-off plants typically have methylated Mul ele-
ments, whereas Mu-on plants have elements that are
unmethylated at the Hinfl sites in their terminal in-
verted repeats. Consistent with this observation, all
of the mutant hcf106 seedlings examined had un-
methylated elements, whereas 9507o of the suppressed
plants had methylated elements. An exceptional sup-
pressed plant had unmethylated elements (includ-
ing the one at the hcf106 locus), but appeared to be
Mu-off by other criteria (i.e., failure to detect new
Mul transpositions in the progeny). Suppression of
the mutant phenotype in the progeny of this excep-
tional plant was still reversible, as shown by reacti-
vation crosses. Suppression in this case may be due
to the segregation of a trans-acting factor (such as
transposase). Alternatively, suppression may have oc-
curred prior to the onset of DNA methylation.
Suppression of the mutant phenotype was accom-
panied by accumulation of mRNA transcripts from
the hcf106 locus, despite the insertion of a Mul ele-
ment into the untranslated leader. In contrast, mu-
tant seedlings had no detectable transcript (Martiens-
sen et al. 1989). The 5' end of the suppressed
transcript was mapped by S1 and primer extension
and was shown to be heterogeneous, with the lon-
gest transcript initiating at a site 15-16 by inside the
Mul element (Fig. 6) (A. Barkan and R. Martiens-
sen, in prep.). This suggests that loss of Mu activity
results in activation (or derepression) of a promoter
in the Mul terminal inverted repeat. This may be as-
sociated with the binding of trans-acting factors to
this region (Z.-Y. Zhao and V. Sundaresan, pers.
comm.).
In 9507o of suppressed plants, suppression of the
mutant phenotype was associated with DNA meth-
ylation of Mul elements. In these plants, DNA flank-
ing the Mul element at the hcf106 locus was also af-
fected by loss of Mu activity (Fig. 6). PvuII and Pstl
sites in the hcf106 promoter were unmethylated in
the wild-type and mutant alleles, but methylated in
the suppressed allele. A Pvul site downstream from
Mu was partially methylated in suppressed plants as
well. This may reflect a requirement for promoter
competition in the mutant phenotype. When the
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FIGURE 6 Promoter region of the hcf106 gene from mutant, wild-type, and suppressed alleles. Arrows indicate tran-
scription start sites. (0) Modified restriction sites; (0) unmodified restriction sites; (crosshatched circles) partially modified
restriction sites. The Southern blot shows DNA from wild-type (B73), homozygous mutant (On), and homozygous sup-
pressed (Off) seedlings digested with restriction enzymes and hybridized to a probe from the upstream flanking region
of the hcf106 gene. The faintly hybridizing upper band is a reduced stringency homolog unlinked to hcf106.
wild-type promoter is methylated, and inactive, the
Mu] promoter becomes active, so restoring transcript
levels. Transient expression experiments using the
particle gun will be used to test this model.
In some families, mutant plants were observed
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that had large, phenotypically wild-type sectors.
DNA isolated from these sectors contained modi-
fied Mu] elements, including the one at the hcf106
locus (Martienssen et al. 1990). The pattern of stripes
suggested that clonal switching events associated
with DNA modification had occurred in cells near
the tip of the apical meristem, so that more and larger
sectors were observed in successive leaves until, in
the upper leaves, the entire plant was phenotypically
wild type. This resulted in a gradient of transposon
inactivity (and methylation) up the plant and may
account for reciprocal effects in the transmission of
Mu activity (Brown and Sundaresan, CSHL Annual
Report, p.172 [1988]). This is because the male and
female flowers are formed from different parts of
the shoot apical meristem, and so have different
proportions of active and inactive cells.
Molecular and Genetic Analysis
of the Maize P Locus
T. Peterson, S. Allan, P Athma, E. Grotewold
The primary goal of our work is to understand how
a gene in a higher eukaryote is expressed in particu-
lar organs during development. Our model is the
maize P gene, which is required for the production
of red flavonoid pigments in certain parts of the
plant. These pigments are nonvital, and thus mu-
tants with altered amounts and distributions of pig-
ment can be isolated and studied readily. Since the
expression of P can be visualized directly without
the need for a biochemical assay, subtle changes in
the intensity and pattern of pigmentation are read-
ily recognized.
We are using molecular, genetic, and biochemi-
cal methods to determine how P is regulated during
plant development. Our first aim is to delineate the
coding and regulatory regions of P. As reported in
last year's Annual Report, we have cloned 34 kb of
DNA from the P locus and defined a region of 7
kb that is transcribed to produce several poly-
adenylated RNAs (Lechelt et al. 1989). Flanking the
transcribed region are two 5.8-kb direct repeats. Fi-
nally, a 250-bp sequence present within both direct
repeats is also repeated at a site outside the repeats.
Faced with the complex structure of P, we required
a method to define the P gene coding and regula-
tory sequences. We decided to implement a major
program toward saturating the P locus with inser-
tions of the transposable element Ac. Our starting
allele, P-ovov, carries an insertion of Ac within the
transcribed region; from this allele, we selected de-
rivatives with altered P expression. To date, we have
isolated and studied nearly 100 mutant derivatives
of P-ovov. Structural analyses revealed that the mu-
tant derivatives carry deletions (P. Athma and T.
Peterson, in prep.), intragenic transpositions, and
other rearrangements. In the most informative cases,
Ac has transposed from its original site in the P-ovov
allele to a new site. In most cases, the new site of
Ac insertion lies within the 7-kb transcribed region.
However, in a significant number of cases, Ac has
inserted at sites located 5-7 kb upstream of the puta-
tive transcription start site. These insertions 5' of the
transcribed region may identify regulatory elements,
although at present, we cannot rule out the possi-
bility of upstream coding sequences. We have also
identified four cases in which Ac has inserted into
either one or the other of the flanking 5.8-kb direct
repeats; however, in all four cases, the phenotypic
expression of P was normal. We conclude that in-
tact flanking direct repeats are not essential for P
expression.
We have continued to refine our knowledge of the
molecular structure of the P locus. In the past year,
we determined the nucleotide sequence of an addi-
tional 5.3 kb of genomic DNA, which, together with
3.3 kb previously sequenced, provides 8.6 kb of com-
pleted sequence. This region covers the 7-kb tran-
scribed region completely. The genomic sequence will
be compared to the cDNA clone sequence to deter-
mine the exon/intron boundaries, to search for
regulatory sequences in the 5' region, and to design
oligonucleotide primers for polymerase chain reac-
tions (PCR) to determine the structures of mutant
P alleles. A number of cDNA clones from P have
been isolated, but unfortunately, these have all been
too short to be useful. Since the average insert size
in our cDNA libraries is quite large, we suspect that
a region of strong secondary structure in the P
mRNA is inhibiting the progress of the reverse tran-
scriptase, resulting in short clones. To circumvent this
problem, we are currently mapping the 5' end of the
P RNA, and with this information and the genomic
sequence, we will design oligonucleotide primers for
PCR amplification of P transcripts.
Last year, we reported that the P-ovov allele, which
produces orange variegated pericarp and cob, re-
sulted from a short-range transposition of Ac to
a new site in the P locus. Biochemical analyses
showed that the orange pigment specified by P-ovov
derives not from synthesis of a new pigment, but
rather from a reduced level of the pigments speci-
fied by P-rr. P-ovov carries an insertion of the 4.5-
kb transposable element Ac within the transcribed
region; Northern analysis indicates that P-ovov
produces two transcripts that are the same size as
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those in the wild-type allele and that the Ac se-
quences must be removed from the mRNA by splic-
ing (Peterson 1990).
In the last year, we have obtained an important
clue as to the function of the P gene. We examined
the expression of RNA from two unlinked structural
genes that encode two enzymes in the pigment bio-
synthetic pathway. RNAs from both genes could be
readily detected in plants expressing a functional P
gene; however, no RNA from either gene could be
detected in plants homozygous for a deletion of P.
Thus, our current hypothesis is that P regulates the
expression of RNA from the structural genes in the
pigment biosynthetic pathway.
In the coming year, we intend to utilize the parti-
cle gun transformation method to study the expres-
sion of P in tissue explants. In this technique, tis-
sues can be transformed by bombardment with
DNA-coated particles and examined for expression
of the introduced gene. Our initial aim will be to
perform a "complementation test" by introducing
cloned segments of P into p pericarps. If a positive
result is obtained, we will then introduce deleted and
modified constructs to localize the 5' elements re-
quired for pericarp-specific expression.
We thank Christopher Brown, Patrick Nolan, and
Michael Persans for their assistance in various
aspects of this work.
Molecular Tagging of a
Disease Resistance Gene
G. Johal, S.P. Briggs
Our focus is on efforts to describe the genes and pro-
teins that control disease resistance in plants. The
primary host molecules that determine disease re-
sistance in animals were recognized long ago as an-
tibodies. The study of antibodies and the genes that
encode them has provided a detailed understanding
of host-pathogen interactions in animals. No anti-
bodies or functionally equivalent molecules have
been found in plants. Clearly, plants and animals
have evolved different mechanisms for halting in-
fections. Although it is obvious from genetic analy-
sis that plants do have genes for resistance to patho-
gens, no such genes have been isolated. The isolation
of plant resistance genes would not only open up an
important new field for investigation, but also per-
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FIGURE 7 Cosegregation of a 3.2-kb Sstl fragment with the
hm656 allele. (Lanes 1-11) DNA from plants that inherited the
mutant allele; (lanes 12-15) from siblings did not in-
herit the mutant allele. The Southern blot was probed with the
Mul internal region.
mit resistance genes to be manipulated in vitro, pos-
sibly resulting in more effective forms of resistance.
We are using genetic methods rather than bio-
chemical methods to isolate plant genes for resis-
tance. Biochemical methods are not useful because
nothing is known about the products of such genes.
Our genetic approach utilizes transposable elements
to mutate resistance genes; transposition into a gene
disrupts both its DNA sequence and its function.
Such events are detected as rare susceptible plants
within a population of resistant plants. We have iso-
lated many mutants of this type. Two of our mutants
appear to result from the insertion of a well-known
transposable element, Mul, into a corn gene for re-
sistance. Standard methods can now be used to clone
the Mul element, along with some of the flanking
DNA that it inserted into. The flanking DNA is part
of the resistance gene, and it can be used to clone
the rest of the gene. This report describes how the
two Mul insertions were identified.
Earlier reports have described how our mutants
were isolated. Once we had obtained a collection of
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FIGURE 8 Cosegregation of a 5.8-kb Sstl fragment with the
hm1062 allele. (Lanes 1-12) DNA from plants that inherited the
mutant allele; (lanes 13-15) DNA from siblings that did not in-
herit the mutant allele. The Southern blot was probed with the
Mul internal region.
mutants, the challenge was to identify which ones,
if any, were caused by the Mul element. The test we
used was simple. Progeny were separated into two
classes: those that inherited the mutant allele and
those that did not. To separate the progeny into the
two classes, we needed an unambiguous test to iden-
tify the mutant, or Hm*, allele from the standard
recessive, hm, allele. Both alleles produce the same
phenotype, a fully susceptible plant. We obtained
a set of restriction-fragment-length polymorphism
(RFLP) probes from David Grant at Pioneer Hi-
Bred International, Inc. These probes had already
been localized to the region of chromosome 1 where
Hm was known to be. By hybridizing each probe to
DNA from members of a family in which Hm was
segregating, we were able to place Hm on the RFLP
genetic map. The family members were from the
cross K61/Prl x K61, where K61 is a homozy-
gous hm inbred and Prl is a homozygous Hm in-
bred. Polymorphisms were detected with Sad and
HindIII. We scored Hm by inoculating each plant
with the fungal pathogen, Helminthosporium car-
bonum race 1, isolate SB111. Probes PI0200644 and
PI0200044 were found to map 5 cM proximal and
distal to Hm, respectively. These probes were used
to identify each Hm * allele and to determine which
family members inherited Hm*.
We then examined the same progeny for the pres-
ence of the Mul element. For a probe, we used an
internal Aval-BstNI fragment of Mul (pAB/5 ob-
tained from Loverine Taylor), which does not hybrid-
ize to the highly repetitive terminal inverted repeats.
Nevertheless, the probe detects 10-50 fragments in
DNA from Mutator plants, when an enzyme that
cuts outside of the element is used. To simplify the
restriction pattern, we crossed our mutants with non-
Mutator inbreds to inactive the Mutator system (so
that no new fragments are created) and to reduce the
number of fragments by segregation. This strategy
permitted us to observe each of several fragments
segregating in the Hm* families. In two cases, we
found that a particular size DNA fragment that con-
tained Mul was only present in progeny which in-
herited a mutant (Hm*) allele. This could be ex-
plained by an insertion of Mul into the resistance
gene (Hm), so that Mul and the mutant allele (Hm *)
are always inherited together. The Hm* alleles desig-
nated hm1-656 and hm1 -1062 are associated with a
3.2-kb and 5.8-kb Sad fragment, respectively (see
Figs. 7 and 8).
PUBLICATIONS
Colasanti, J., A.J.S. Klar, and V. Sundaresan. 1989. R locus im-
printing is tissue-specific and not positional. Maize Genet.
Newslett. 63: 53.
Lechelt, C., T Peterson, A. Laird, J. Chen, S. Dellaporta, E. Dennis,
P Starlinger, and W.J. Peacock. 1989. Isolation and molecu-
lar analysis of the maize P locus. Mo/. Gen. Genet. 219:
225-234.
Martienssen R.A., A. Barkan, M. Freeling, and W.C. Taylor 1989.
Molecular cloning of a maize gene involved in photosynthetic
membrane organisation that is regulated by Robertson's Mu-
tator. EMBO J. 8: 1633-1639
Martienssen R.A., A. Barkan, W.C. Taylor, and M. Freeling. 1989.
A Mu-suppressible hcf mutant, and non-reciprocal transmis-
sion of Mu activity. Maize Newslett. 63: 37.
Sundaresan, V 1989. Dosage of Mu. Maize Genet. Newslett.
63: 54.
In Press, Submitted, and In Preparation
Athma, P and T. Peterson. 1990. Ac transpositions reflected as
twin sectors on P-ovov ears. Maize Genet. Newslett. (in press).
Athma, P and T Peterson. 1990. Deletions at the maize P locus
are promoted by the transposable element Ac. (In preparation.)
159
Brown, J. and V. Sundaresan. 1990.
Intragenic recombination
at the maize Al locus. (Submitted.)
Colasanti, J. and V Sundaresan. 1990. Synthesis of
cytosine meth-
ylated DNAs in vitro. (Submitted.)
Colasanti, J.M. Free ling, and V. Sundaresan.
1990. A new Mu-
induced suppressible mutation. (Submitted.)
Grotewold, E. and T. Peterson. 1990. Isolation of
cDNA clones
homologous to the P-gene flanking regions. Maize
Genet.
News lett. (in press).
Johal, G. and S.P. Briggs. 1990. Placement of
hml on the Pioneer
RFLP map. Maize Genet. News lett. (in press).
Johal, G. and S.P. Briggs. 1990. Mu/-associated hml alleles, Maize
Genet. Newslett. (in press).
Peterson, T. 1990. Intragenic transposition of Ac generates a new
allele of the maize P gene. (Submitted.)
Martienssen R.A., A. Barkan, W.C. Taylor, and M. Freeling. 1990
Somatically heritable switches in the DNA modification of Mu
transposable elements monitored with a suppressible mu-
tant in maize. Genes Dev. (in press).
G1 CYCLINS OF SACCHAROMYCES CEREVISIAE:
FIRST TICK OF A TWIN CLOCK?
B. Futcher B. Elliott I. Fitch G. Tokiwa
K. Erickson R. Nash M. Tyers
Our main interest has been the WHIZ gene of Sac-
charomyces cerevisiae, which appears to be a rate-
limiting regulator of the cell cycle. Sequencing
showed that the Whil protein is a cyclin homolog.
This was surprising, because Whil regulates the
GI/S transition, whereas other known cyclins regu-
late G2/M. This suggested that there might be two
classes of cyclins, G, cyclins and mitotic cyclins,
that operate at different points in the cell cycle. That
is, we imagine that a control mechanism containing
the Cdc28 protein kinase and G, cyclins controls
the GI/S transition, and a different but homolo-
gous mechanism containing Cdc28 and mitotic cy-
clins controls the G2/M transition. In some species,
different Cdc28/Cdc2 homologs might specialize for
either Gi/S or G2/M. We call this the "Twin Clock"
hypothesis, and we are attempting to prove it by iden-
tifying "mitotic" cyclins in S. cerevisiae and "G," cy-
clins in other species.
Whil is not the only cyclin homolog working in
the G, phase. Steve Reed and co-workers have
found two other cyclin homologs in S. cerevisiae
called Clnl and Cln2. The simultaneous deletion of
all three of these cyclin homologs is lethal and pre-
vents cells from leaving the G, phase (Richardson
et al., Cell 6: 1127 [1989]). Because of the sequence
homology and functional overlap between WHI1
and CLN1 and CLN2, the WHIZ gene has been re-
named CLN3.
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Immunological and Biochemical
Characterization of the Cln3 Protein
M. Tyers, G. Tokiwa, K. Erickson, B. Futcher
Since Cln3 bears considerable homology with the
cyclins, it is expected to have some biochemical prop-
erties in common with them. Other cyclins oscillate
in abundance during the cell cycle, reaching a peak
in mitosis and being degraded at metaphase/ana-
phase. These cyclins are found in a complex with their
cognate Cdc2/Cdc28 kinase homolog and serve to
activate the kinase. The Cln3-1 mutant protein is
a dominant, hyperactive protein that pushes cells
through the G,/S transition prematurely. At the
molecular level, the CLN3-1 mutant allele has a stop
codon two thirds of the way through the open read-
ing frame. This removes the last third of the protein.
This missing third contains PEST regions (Pro-, Glu-,
Ser-, and Thr-rich regions), which are thought to be
signals for proteolysis. A hypothesis for the pheno-
type of CLN3-1 mutants is that the wild-type pro-
tein is short-lived because of its PEST signals but
that the mutant protein is long-lived because of the
absence of PEST signals. This would increase the
relative abundance of the mutant protein and so
make it appear to be hyperactive.
To see whether Cln3 and Cln3-1 behaved as pre-
dicted, we needed a good antibody against Cln3.
None of the simple approaches we tried produced
antibodies of sufficient sensitivity to detect Cln3 in
yeast. An approach that did work was based on the
epitope-tagging method developed by L. Field, R.
Lerner, M. Wig ler, and co-workers. A nine-amino-
acid epitope was tandemly triplicated and then used
to tag the Cln3 gene at its amino terminus, its car-
boxyl terminus, or at an internal site. The tagged
Cln3 genes were transcribed from the inducible yeast
GAL1 promoter, which increased steady-state mRNA
levels about 200-fold. This overexpressed, triply
tagged protein could be detected in yeast extracts by
immunoprecipitation and by Western blotting by a
high-affinity monoclonal antibody. The tagged pro-
teins seemed to have wild-type function. Triplication
of the epitope was essential - Cln3 with a single tag
was not detectable in yeast. Calculation of Cln3
abundance suggested that in a wild-type strain, the
normal protein is present at only a few copies per
cell, which explains our inability to detect it.
This system has only been working for a short
time, and so our results are still preliminary. We have
used glucose repression of the GAL promoter to
measure the half-life of Cln3 and Cln3-1. Cln3 is very
unstable, with a half-life of only a few minutes, but
Cln3-1 is stable with a half-life of more than 1 hour.
Thus, terminus of Cln3 does seem to
cause rapid turnover, and the dominant, hyperacti-
vation of Cln3-1 does seem to be caused by the lack
of proteolysis. This bodes well for the PEST hypoth-
esis. As yet, we have seen no evidence that Cln3 abun-
dance varies in the cell cycle, nor have we seen any
evidence of an effect of a factor on the protein. Both
C1n3 and Cln3-1 are phosphoproteins in vivo. When
Cln3 or Cln3-1 is immunoprecipitated, a protein ki-
nase activity is coprecipitated that phosphorylates
Cln3 and Cln3-1 in vitro. It is not yet clear if this
protein kinase is Cdc28.
These results do not necessarily reflect the nor-
mal behavior of the protein. The proteins we have
studied are tagged and overexpressed. We are work-
ing on ways of controlling against or eliminating
potential artifacts.
Cloning of a Mitotic Cyclin
from S. cerevisiae
I. Fitch, B. Futcher
A prediction of the Twin Clock Hypothesis is that
S. cerevisiae should have at least one mitotic cyclin
as well as its three G, cyclins. A pair of degenerate
polymerase chain reaction (PCR) primers was made
corresponding to two highly conserved regions of
type-B mitotic cyclins. These were used to amplify
S. cerevisiae genomic DNA. A fragment of the ap-
propriate size was obtained. The corresponding gene
was cloned and has been partially sequenced. It is
approximately 6007o identical to the Cdc13 protein
of Schizosaccharomyces pombe, a known type-B mi-
totic cyclin. The alignment is shown in Figure 1; the
fragment is referred to as CLN10.
We think that this fragment may come from a gene
for an S. cerevisiae B-type mitotic cyclin. Genetic ex-
periments will determine if loss of function of this
gene leads to a G2 or mitotic arrest.
The whi3 Mutation
R. Nash, B. Futcher
Like WHIM, whi3 is a mutation that causes cells
to divide at aberrantly small sizes. We originally ob-
CLN1 0 LQLVGTSCLFIASKYEEIYSPSIKHFAYETDGACSVEDIKEGERF
I
cdc13 LQLVGIAALFIASKYF.EVMCPSVQNFVYMADGGYDEEEILQAERYI
LEKLDFQISFANPMFLRRISKADDYDIQSRTLAKFLMEIS
CLN1 0
LRVLEFNLAYPNPMNFLRRISKADFYDIQTRTVAKYLVEIG
cdc 1 3
FIGURE 1 Alignment of the Cdc13 protein
and the CLN10 fragment.
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tained the whi3 mutation by transposon mutagene-
sis using the Ty transposon. Genetic crosses showed
that the inserted Ty element was inseparable from
whi3 (although this does not absolutely prove that
the Ty element caused the mutation). We have cloned
the inserted Ty element and flanking genomic DNA
on both sides. Some of the flanking DNA has been
subcloned and used as a probe to clone the wild-type
(uninterrupted) DNA from the same locus. This
DNA is unusual in that it undergoes recombination
and rearrangement in E. coli; partly because of this,
it is not yet clear whether the cloned DNA contains
the intact WHI3 gene.
Relationship between Heat-shock
Resistance and Stationary Phase
B. Elliott, B. Futcher
Yeasts that have exhausted their growth medium and
have stopped growing or dividing are said to be in
stationary phase. Such stationary phase cells charac-
teristically have a 1C DNA content, have stores of
glycogen and trehalose, survive very well upon stor-
age, and are resistant to heat shocks and other en-
vironmental stresses. Stationary phase has been com-
pared and equated with the Go state of mammalian
cells.
For historical reasons, it has been assumed that
only G1 phase cells are capable of taking on sta-
tionary phase characteristics, and this has led to the
idea that resistance to stress is dependent on being
in a special, G1-like cell cycle phase. We have tested
this by measuring the extent to which cells can sur-
vive heat shock under different conditions. We find
that fast-growing cells are very sensitive to heat
shock, nongrowing, stationary phase cells are very
resistant to heat shock, and cells growing at various
intermediate rates have a corresponding intermedi-
ate degree of heat-shock resistance. Within these
populations growing at different rates, we have ex-
amined individual cells at known places in the cell
cycle. We find that position in the cell cycle makes
little or no difference to the heat-shock resistance
of each cell. Rather, heat-shock resistance seems to
be correlated mainly with growth rate. Therefore, it
now seems unlikely that the resistance to stress of
stationary phase cells has anything to do with any
special cell cycle compartment. Rather, stationary
phase is probably just arrest in GI phase, and not
a good model for the Go phase of mammalian cells.
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TRANSCRIPTION AND CELL CYCLE REGULATION IN YEAST
K.T. Arndt A. Sutton
K. Tice
In almost all aspects of basic cellular processes, the
yeast Saccharomyces cerevisiae has been found to
be very similar to higher eukaryotic cells. For this
reason, and the ease of manipulation and the power-
ful genetic approaches available with yeast, we are
using yeast in our laboratory to study transcription
regulation and cell cycle control.
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Transcriptional Regulation
of the HIS4 Gene
K. Tice
Our ultimate goal is to understand completely the
regulation of the yeast HIS4 gene and use HIS4 regu-
lation as a model for the transcriptional regulation
of other systems. The HIS4 gene is under complex
transcriptional control. Two independent systems ac-
tivate HIS4 transcription: basal control and general
amino acid control. In general amino acid control,
starvation for any one or more amino acids causes
an increase in the levels of the GCN4 protein. The
GCN4 protein binds to the sequence TGACTC,
repeated five times in the HIS4 promoter, to acti-
vate HIS4 transcription. GCN4 binds one of these
HIS4 elements, repeat sequence C, much more
tightly than the others, and most (about 80%) of
the GCN4-dependent activation of HIS4 transcrip-
tion is due to repeat sequence C. We are using defec-
tive GCN4 derivatives to obtain mutations in the
general transcription machinery (see below).
The basal level control activates HIS4 transcrip-
tion in the absence of amino acid starvation. In ad-
dition, either phosphate or adenine starvation will
cause a further increase in the already high basal lev-
els of HIS4 transcription. Activation of the basal
level transcription of HIS4 requires two trans-acting
proteins, encoded by the BAST and BAS2 genes. Mu-
tations in BAS2 cause a phosphate requirement
(BAS2 is the same gene as PHO2), and mutations
in either BAST or BAS2 cause an adenine require-
ment. Thus, in yeast, the phosphate, purine, and
histidine pathways are coregulated. Analysis of the
metabolites in these pathways shows the biological
rational for the coregulation.
DNA sequence analysis indicates that BAS1 con-
tains an amino-terminal region similar to that of
Myb proteins and that BAS2 contains a centrally lo-
cated homeo box. The Myb domain is the DNA-
binding domain for BAS1, and the homeo box re-
gion is the DNA-binding domain for BAS2. The Myb
motif was first identified in the v-myb gene of avian
myeloblastosis virus. Cellular homologs of v-myb
were then found in all vertebrates. In addition, Myb-
type proteins have been found in Drosophila and
corn (Cl). The Myb motif contains three repeats of
a sequence, whose most striking feature is three reg-
ularly spaced tryptophans. Within each repeat, the
first and second tryptophans are separated by 18 or
19 amino acids, and the second and third trypto-
phans are separated by 18 amino acids. The third
tryptophan of a given repeat is separated by 12 amino
acids from the first tryptophan of the next repeat.
The regions of the HIS4 promoter to which BAS1
and BAS2 binds were determined by DNase I foot-
printing using proteins prepared from overproduc-
ing strains of Escherichia coli. The relative positions
of binding of BAS1, BAS2, and GCN4 are shown
in Figure 1. The combined BAS1+BAS2-binding re-
gion corresponds almost exactly to the cis-acting
regions of the promoter that were determined to be
required for basal level transcription of HIS4. In-
terestingly, at high BAS1 concentrations, BAS1 binds
to the GCN4-binding site. We have also determined
that (1) the amino-terminal fragment of BAS1 con-
taining the Myb motif has full DNA-binding activ-
ity, (2) BAS1 and BAS2 bind adjacently on the HIS4
promoter, (3) even though the BAS1- and BAS2 -
binding sites overlap by eight to ten bases, they can
bind simultaneously to the HIS4 promoter, (4) the
En protein (encoded by the homeo box engrailed
gene, which is the homeo box gene to which BAS2
is most closely related) binds almost identically to
the HIS4 promoter as does the BAS2 (En and BAS2
protect the same DNA sequences from DNase I and
bind at about the same affinity), and (5) BAS1 and
BAS2, from yeast or E. coli, show no evidence of
cooperative binding to the HIS4 promoter.
Basal level transcription of the HIS4 gene requires
both BAS1 and BAS2. Either protein alone, even
when overexpressed, can only poorly activate HIS4
transcription (at 1/100th the level of when both BAS1
and BAS2 are present). Since BAS1 and BAS2 do
not bind cooperatively to the HIS4 promoter, the na-
ture of the requirement for both BAS1 and BAS2
for basal level HIS4 transcription remains to be de-
termined. In addition to activation of HIS4 tran-
scription, BAS2 is required to activate the transcrip-
tion of the secreted acid phosphatases (the major
TATA
FIGURE 1 HIS4 promoter and its binding factors.
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secreted acid phosphatase is encoded by the PHO5
gene). However, BAS1 has no role in the activation
of the transcription of the secreted acid phospha-
tases. In the next year, we would like to determine
if BAS2 requires a second DNA-binding protein (to
take the place of BAS1) for activation of the secreted
acid phosphatases.
The function of BAS1 and BAS2 in yeast may
have relevance to their homologs in higher systems.
Like BAS2, the En protein of Drosophila cannot ac-
tivate transcription by itself. The question remain-
ing is whether En functions as a repressor (by com-
peting for the binding of other homeo box proteins
that are able to activate transcription by themselves)
or whether En is similar to BAS2 in that a second
DNA-binding protein is required for activation of
transcription. The avian v-Myb protein can trans-
form only myeloid cell lineages in vitro or in vivo.
One explanation of this result is that vertebrate Myb
proteins, like BAS1, require a second DNA-binding
protein for activation of transcription of genes that
lead to the transformed phenotype. The BAS1 DNA-
binding site is similar to that defined for v-Myb pro-
tein in vitro. In the near future, we would like to
determine if a Myb/En system can functionally sub-
stitute for the BAS1/BAS2 system for activation of
HIS4 transcription.
BAS1, BAS2, and GCN4 are the three activation
proteins for HIS4 transcription. In strains deleted
for all three proteins, HIS4 transcription is extremely
low and the strains are His-. However, as measured
by gel-shift assays using total yeast extracts, these
three activator proteins represent only a very small
fraction of the binding activity to the HIS4 promoter.
The major binding activity is due to a protein we
have termed YNF1 that binds to the HIS4 promoter
as shown in Figure 1. In the absence of GCN4, BAS1,
and BAS2, YNF1 is not able to activate HIS4 tran-
scription. In addition, the binding sites for YNF1
and GCN4 overlap; GCN4 binds much tighter to the
middle repeat element than to the other four repeat
elements, and most GCN4-dependent transcription
occurs through the middle repeat sequence. In vitro
DNA-binding studies show that either GCN4 or
YNF1 can bind to their respective sites. They cannot
bind simultaneously. This result argues that YNF1
might be a repressor of GCN4-dependent HIS4 tran-
scription. However, using HIS4 promoters that con-
tain point mutations in the YNF1-binding site that
completely eliminate YNF1 binding in vitro (which
are completely outside the GCN4-binding site), we
have found that the presence or absence of YNFI
binding has almost no effect on the steady-state lev-
els of GCN4-dependent transcription.
We have very recently determined that YNFI is
the same protein as RAP1. RAP1 (which is proba-
bly the same as GRF1-TUF) is a very abundant DNA-
binding protein in yeast that binds to silencers, telo-
meres, and the promoters of many of the genes
encoding ribosomal proteins and glycolytic enzymes.
In addition, most of the RAP1 protein is found as-
sociated with the nuclear matrix or scaffold. The
binding of RAP1 to the HIS4 promoter is somewhat
unexpected, since it was believed that RAP1 by it-
self is a transcriptional activation protein. In the con-
text of the HIS4 promoter, RAP1 cannot activate
transcription by itself, since a strain lacking GCN4,
BAS1, and BAS2 has extremely low levels of HIS4
transcription. Future experiments will be directed to
show if RAP1 is required for the rapid kinetics of
GCN4-dependent induction of HIS4 transcription,
such as occurs when general control is induced by
amino acid starvation. We also want to determine
if RAP binding to the HIS4 promoter correlates with
association of HIS4 with the nuclear matrix. These
experiments will allow us to determine if association
with the nuclear matrix is required for rapid kinetics
of induction. It may be that genes that are not as-
sociated with the nuclear matrix are in repressed
chromatin structures and cannot be induced until
that region of DNA undergoes DNA replication,
which then makes the promoter free to associate with
activator proteins. We already know that nucleo-
somes are phased on the HIS4 promoter and that
the nucleosomes are excluded from the RAP1-
binding site.
A Genetic Selection for General
Transcription Factors
A. Sutton
When the levels of HIS4 transcription are quanti-
tated by assaying the levels of 13-galactosidase from
a HIS4-lacZ fusion, a wild-type strain gives about
400 units of activity, whereas a strain containing de-
letions of the GCN4, BAS1, and BAS2 genes gives
less than one unit of activity. As a result, a strain
deleted for the three activators of HIS4 transcrip-
tion is His-. We have reverted this strain to His with
the assumption that mutations in genes encoding
general transcriptional factors could result in in-
creased HIS4 transcription. This reversion analysis
has identified four suppressor genes that permit
HIS4 transcription in the absence of GCN4, BAS1,
and BAS2. We have termed these suppressors sit
genes for suppressors of initiation of transcription.
These suppressor genes encode factors that affect
the transcription of many diverse genes.
Two of the suppressors, SITI and SIT2, are en-
coded by RPB1 and RPB2, the genes for the two
largest subunits of RNA polymerase II. All strains
containing suppressor mutations in RPBI and RPB2
have reduced transcription of the INOI gene and an
inositol requirement.
Mutations in SIT3 or high-copy-number SIT3 in-
crease HIS4 transcription in the absence of GCN4,
BAS1, and BAS2. SIT3 is the only suppressor that
suppresses when the wild-type gene is present in high
copy number. The increase in HIS4 transcription by
high-copy-number SIT3 or by sit3 alleles is largely
independent of the HIS4 TATA sequence. We se-
quenced the SIT3 gene and found that it is identical
to GCRI, a gene previously identified as being re-
quired for high-level transcription of almost all
glycolytic enzymes (whose combined mRNAs con-
stitute over 50070 of the mRNA in a yeast cell).
Presently, we are not sure exactly how SIT3 func-
tions. Our current model is that SIT3 is a protein
that if altered (sit3 mutants) or if overexpressed (high-
copy-number SIT3) can recognize transcriptional ac-
tivation proteins at almost any promoter to stimu-
late TATA-independent transcription.
The SIT4 protein is over 5007o identical to the cata-
lytic subunit of bovine type-2A protein phosphatase.
In the haploid, sit3 in any pairwise combination with
sitl, sit2, or sit4 is viable, consistent with the view
that SIT3 encodes a factor that functions as an ac-
cessory role to the RNA polymerase II holoenzyme.
In contrast, all pairwise combinations between sitl,
sit2, and sit4 are inviable. The inviability of sitl sit2
double mutants is easily understood as an interac-
tion between altered versions of the largest subunits
of RNA polymerase II that leads to a more severe
phenotype than either of the single mutants. One
interpretation of the gene interactions between sit4
and the sitl and sit2 RNA polymerase II mutations
is that SIT4 encodes a factor that interacts with RNA
polymerase II. This model needs to be tested directly
by Western and immunoprecipitation analyses to de-
termine the phosphorylation state of RPB1 in strains
containing wild-type SIT4, sit4 mutations, and over-
expression of SIT4.
Progression from G1 to S Phase
Requires the SIT4 Protein
Phosphatase
A. Sutton
Regulation of the cell cycle, most importantly the
decision of whether or not to initiate a new cycle,
is a major determinant of cell proliferation. For the
yeast Saccharomyces, cells that are nutritionally
starved (such as by limiting an essential nutrient in
the growth medium) or cells in a saturated culture
arrest in G1. Cells that have arrested at this point
in G1 are in a physiological state distinct from GI
cells in actively growing cultures. In general, cells ini-
tiate a new cycle only when they will be able to com-
plete the entire cycle.
Much of what is known about regulation of the
cell cycle comes from strains containing conditional
mutations that arrest in G1 at the nonpermissive
temperature. Strains containing cdc19, cdc25, or
cdc35 (adenylate cyclase) arrest in G1 at what seems
to be close to the nutritional arrest point (unbud-
ded uninucleate GI cells with no spindle pole satel-
lites). Conditional mutations in the CDC28 gene,
which encodes a protein kinase, cause arrest in Gi
unbudded uninucleate G1 cells containing spin-
dle poles with a satellite structure. This G1 arrest
point in cdc28 mutants has been operationally de-
fined as START. Supposedly, if a normal cell passes
START, it is committed to completion of the cycle.
As stated above, we originally identified the SIT4
gene as a suppressor of a HIS4 transcriptional de-
fect. All sit4 strains are temperature sensitive for
growth. We have found that at the nonpermissive
temperature, sit4 strains (and mutations in sit4
created solely with a temperature criterion) have a
cell-cycle-arrest phenotype and arrest as large non-
budded uninuclear GI cells. Reciprocal shift experi-
ments show that SIT4 is required only for progres-
sion from 01 into S phase. In the first experiment,
a sit4-102 strain was arrested in late GI by a-factor.
The cells were released from a-factor arrest by wash-
ing away the a-factor and shifted to the nonpermis-
sive temperature at various times after release. If the
released cells were shifted to the nonpermissive tem-
perature at any time before they began to initiate a
bud (which takes 30-40 min), they did not initiate
a cell cycle but arrested as large unbudded uninucle-
ate cells with a 1N DNA content. In contrast, if the
released cells were shifted to the nonpermissive tem-
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perature at any time after they initiated a bud, the
cells continued with their current cell cycle (e.g., the
bud continued to grow) and arrested as large unbud-
ded uninucleate cells in late GI. In the second ex-
periment, unsynchronized sit4-102 cells were first
arrested at the nonpermissive temperature as large
unbudded cells. When a-factor was added and the
cells shifted to the permissive temperature, the cells
initiated budding and completed a cell cycle before
arresting in late GI by a-factor. In a third set of ex-
periments, sit4-102 cells in the GI stage of the cell
cycle were isolated by centrifugal elutriation. The
synchronized cells were grown until they formed a
very small bud, at which time both a-factor was
added and the cells were shifted to the nonpermis-
sive temperature (for sit4-102). The cells continued
with their current cell cycle and arrested exclusively
at the a-factor arrest point (as "schmoos"). These
experiments, and the proper controls, show that the
execution point for the essential function of SIT4
is in very late GI (and only in late GI) and that this
essential function of SIT4 is required for progres-
sion into S phase.
The localization of the SIT4 protein was deter-
mined by indirect immunofluorescence using anti-
bodies directed against the amino terminus of SIT4.
These experiments show that SIT4 is localized pri-
marily to the cytoplasm and mostly excluded from
the nucleus. SIT4 coimmunoprecipitates with two
larger proteins that might be regulatory subunits. Al-
though SIT4 is not phosphorylated, the two larger
SIT4-associated proteins are phosphorylated. We are
currently investigating if the association of these two
proteins with SIT4 or the phosphorylation state of
these two proteins varies in the cell cycle. The steady-
state levels of SIT4 do not vary in the cell cycle.
We are also investigating the role of SIT4 in
progression from GI into S phase using two differ-
ent genetic approaches. Hopefully, these approaches
will identify substrates of SIT4 or regulators of SIT4
activity. The first approach we have taken is to iden-
tify wild-type genes that, in high copy number, sup-
press the slow-growth defect of sit4 His suppressor
strains. Using this approach, we have obtained four
different genes. None of these genes rescue the
temperature-sensitive defect of sit4 strains. One of
these genes is another protein phosphatase that we
call PPH2. DNA sequence analysis of the PPH2
gene shows that it is 86% identical to type-2A pro-
tein phosphatases and that the similarity extends to
the very carboxyl terminus. In contrast, SIT4 has no
similarity to the carboxyl terminus of type-2A or
type-1 protein phosphatases. Since overexpression of
PPH2 partially rescues only a subset of the defects
of a sit4 strain, we believe that SIT4 represents a class
of phosphatase distinct from the canonical type 1
and type 2A.
A second gene (which we call S/S/) that, in high
copy number, suppresses the slow-growth defect of
sit4 strains encodes a predicted protein that is 28%
identical overall (for an overlap of 330 amino acids)
to bacterial DnaJ proteins. The SIS1 protein has a
predicted molecular mass of 37.6 kD and is essen-
tial for viability. Immunoprecipitation experiments
show that SIS1 is phosphorylated and coimmuno-
precipitates with a protein (p40) of 40 kD that is not
phosphorylated. We are currently investigating if
SIS1 is a substrate of SIT4 and if the association of
SIS1 with p40 varies in the cell cycle. A third gene,
called SIS2, that, in high copy number, suppresses
the slow-growth defect of SIT4 strains encodes a
predicted protein of 53 kD that is not similar to any
protein in the current databases. We are investigat-
ing the function of this protein in relation to the role
of SIT4 in GI/S progression.
Our second genetic approach to SIT4 function
is to obtain second-site suppressors of the tempera-
ture-sensitive arrest phenotype of sit4-102 strains.
This analysis has identified three different comple-
mentation groups, which we call ptsl through pts3.
Interestingly, about half of the alleles of both ptsl
and pts2 cause complete failure to germinate. In ad-
dition, all ptsl strains are sensitive to nutrient limi-
tation. Hopefully, the PTS genes have identified
important GI control proteins that relate to SIT4
function.
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INITIATION AND TERMINATION OF TRANSCRIPTION INHUMAN SNRNA GENES AND HIV-1
N. Hernandez S. (fill
L. Johal
J.A. Lister
SMALL NUCLEAR RNA GENES
S. Lobo P Reinagel
R. Ratnasabapathy M. Sheldon
The human U2 and U6 small nuclear RNA (snRNA)
genes constitute a fascinating model to examine the
links between formation of a transcription complex
at a specific promoter and the ability of this tran-
scription complex to elongate and recognize (or ig-
nore) transcription termination signals. In addition,
they also provide a so far unique system to study the
mechanisms that govern RNA polymerase selection
by transcriptional promoters.
The U2 snRNA gene is transcribed by RNA poly-
merase II. The promoter contains a proximal element
located around position - 50 and functionally
equivalent to a TATA box, in that it is essential for
efficient transcription and localizes the start site of
transcription. It also contains an enhancer located
around position - 200 and consisting of an Spl-
binding site adjacent to an octamer motif. Termina-
tion of transcription just downstream from the re-
gion corresponding to the mature 3' end of the RNA
is directed by the 3' box, a short sequence conserved
among RNA polymerase II snRNA genes. This ter-
mination signal is peculiar in that it is recognized
only by transcription complexes derived from
snRNA promoters and not by transcription com-
plexes derived from mRNA promoters. Reciprocally,
the RNA polymerase II snRNA promoters are pe-
culiar in that the transcription complexes they di-
rect are not capable of transcribing through long
DNA templates, but they will terminate at sequences
even only remotely related to the 3' box.
The U6 snRNA gene belongs to a growing family
of RNA polymerase III genes that include the 7SK
and probably the RNase MRP RNA genes. In these
genes, the elements essential for initiation of tran-
scription are not contained within the coding se-
quences, but rather lie within the 5'-flanking se-
quences. Curiously, two of these promoter elements
are similar in their sequence and spatial arrangement
to the U2 promoter elements. Thus, the U6 promoter
contains an enhancer region that is characterized,
like the U2 enhancer, by the presence of an octamer
motif. It also contains a proximal element that
matches in 13 out of 17 positions the human U2 prox-
imal element. The third element of the U6 promoter
is not found in the U2 promoter and consists of an
A/T-rich region located -18 to
- 26 nucleotides
upstream of the start site of transcription and remi-
niscent of the TATA box of mRNA promoters. Its
function is, however, quite different. In the human
U6 promoter, the A/T box constitutes a dominant
element that defines the promoter as a U6 promoter.
Mutation of the A/T box converts the U6 promoter
into a predominantly RNA polymerase II promoter,
whereas insertion of the A/T box into the U2 pro-
moter converts it into an RNA polymerase III pro-
moter. We are interested in characterizing in detail
the cis-acting elements involved in transcription by
RNA polymerase II and III and in identifying the
trans-acting factors involved in transcription of the
U2 and U6 genes.
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
The human immunodeficiency virus type 1 (HIV-1)
contains, in addition to the genes normally found
in retroviruses, a set of genes encoding regulatory
proteins. One of these genes encodes the tat protein,
a potent trans-activator of viral gene expression. tat
acts through a sequence called TAR, located down-
stream from the transcriptional start site. TAR could
thus represent a DNA element, an RNA element, or
both. Indeed, the mechanism of tat trans-activation
is the subject of considerable controversy, and tat
effects at the levels of translation, initiation and elon-
gation of transcription, and other ill-defined path-
ways have all been described in the literature. We are
particularly intrigued by the proposal that TAR may
be a termination site and tat an antiterminator; in
this model, tat would increase gene expression by al-
lowing the RNA polymerases to bypass a transcrip-
tional block located close to the initiation site of tran-
scription. In support of this model, short transcripts
whose 3' ends map just downstream from TAR can
be detected in steady-state RNA from cells express-
ing the HIV-1 long terminal repeat (LTR). However,
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in contradiction to this model, deletion of TAR does
not result in increase of expression from the HIV
LTR. Thus, TAR does not seem to contain a nega-
tive element such as a premature termination site.
This paradox could be resolved if the HIV-1 promoter
directed the formation of a transcription complex
with not much processivity, comparable in this re-
spect to the transcription complex formed on the U2
promoter. Such a transcription complex might stop
at a premature termination site such as TAR if TAR
were present, and might stop randomly if the prema-
ture termination site were deleted. As an approach
to understand the mechanism of tat trans-activation,
we would like to determine how the short transcripts
are generated and what the role of HIV promoter
elements is in tat trans-activation.
cis-Acting Elements and Factors
Involved in Transcription of the
Human U6 snRNA Gene
S. Lobo, P. Reinagel, J. Lister, L. Johal,
S. 'fill, N. Hernandez
ROLE OF THE REGION AROUND THE U2 CAP SITE
IN RNA POLYMERASE SELECTION
We have continued our analysis of the cis-acting ele-
ments involved in transcription by RNA polymer-
A.
ase II and I I I in the U2 and U6 promoters. We had
shown before that insertion of the U6 A/T box into
the U2 promoter extending from position - 247 to
-7, i.e., lacking the U2 cap site, converts it into an
RNA polymerase III promoter (see Fig. IA, con-
structs pU2/-247/RA.2 and pU2/TA). This obser-
vation suggests that the U2 and U6 promoters bind
a common set of transcription factors and that RNA
polymerase specificity is determined by the absence
or presence of the factor(s) binding to the A/T box.
However, in the Xenopus U6 gene, transcription by
RNA polymerase III requires, in addition to the A/T
box, the sequences surrounding the start site of tran-
scription. This observation raises the possibility that
in the complete U2 promoter with an A/T box in-
serted, the sequences surrounding the cap site just
upstream of the potential RNA polymerase III start
site could suppress RNA polymerase III transcrip-
tion. To exclude this possibility, we modified the con-
struct pU2/TA by site-directed mutagenesis to cre-
ate pU2/TA/U2Cap (Fig. 1A). In this modified
construct, the natural U2 sequence surrounding the
U2 cap site was restored, so that the U2 promoter
sequences now extend to position + 7 downstream
from the U2 cap site. Analysis of expression from
this construct in vivo and in vitro showed that 50%
of the total transcription was directed by RNA poly-
merase III, compared to 80% with the parent con-
struct. Thus, although the U2 cap site sequences
PROXIMAL ELEMENT
1 1
pU2/-247/RA.2 CTCACCGCGACTTGAATGTGGATGAGAGTGGGACGGTGACGGCGGGCGCGAAGGCccetCgAgtACcTagaGt
pU2/U2Cap GAGCGCATCGCTTagaGt
pU2/TA t t tatat ccctCgAgtACcTagaGt
pU2/TA/U2Cap t t tatat GAGCGCATCGCTTagaGt
B.
pU2/-247
LS-34/-43
U6/Hae/RA.2
LS5/Hae
pU2/-247/RA 2
pU2/TA
pU2/TA/(LS-34/-43)
PROXIMAL ELEMENT
GGC TGGGGCTCTCACCGCGACTTGAATGTGGATGAGAGTGGGACGGTGACGGCGGGCGCGAAGGCGAGCGCATCGCT
ccctc. g
ACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCa
tctcgagaa 2
GGC TGGGGCTCTCACCGCGACTTGAATGTGGATGAGAGTGGGACGGTGACGGCGGGCGCGAAGGCccctCgAgtACcTa
tTtAtatat ccctCg.gtA.c.a
ccctc. g tTtAtatat ccctcg.gta.c.a
FIGURE 1 (A) 5'-flanking sequence in different U2 constructs. The nucleotides that differ from the wild-type U2 sequence are repre-
sented by boldface characters. Underscores indicate the different start sites of transcription; uppercase underscored characters rep-
resent RNA polymerase II start sites, and lowercase underscored characters represent RNA polymerase Ill start sites. The proximal
element homology is indicated. (8) 5'-flanking sequences in different U2 and U6 constructs. Symbols are the same as in A.
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coinfluence the relative levels of RNA polymerase
II and III transcription, the U6 A/T box is neverthe-
less the dominant element.
CHARACTERIZATION OF THE U6 A/T BOX
The U6 A/T box has the sequence TTTATATAT.
This sequence is nearly perfectly conserved in the
human 7SK gene (TTTATATAG), but quite diver-
gent in the mouse RNase MRP RNA gene (ATAAA-
TTAG). To characterize the sequence flexibility in
this region for RNA polymerase III transcription,
we replaced the U6 A/T box with TATA boxes from
different mRNA promoters. Analysis of expression
of the different constructs showed that a large num-
ber of different sequences can replace the A/T box
without suppressing RNA polymerase III transcrip-
tion. The minimal requirement seems to be a run of
at least six A and T residues. We are in the process
of refining this analysis and determining whether se-
quences flanking the A/T box also play a role. A
detailed knowledge of the sequence requirements in
this region for RNA polymerase III transcription will
be useful to discriminate between factors binding
specifically to the U6 A/T box and therefore proba-
bly involved in U6 transcription and factors bind-
ing nonspecifically to A/T-rich regions.
CHARACTERIZATION OF THE REGION IMMEDIATELY
3' OF THE PROXIMAL ELEMENT
We also examined in some detail the region immedi-
ately downstream from the proximal element homol-
ogy in the U2 and U6 promoters. We showed before
that in the U2 promoter, a linker-scanning mutation
that modifies this region and overlaps with the prox-
imal element homology itself only by 1 by (Fig. 1B,
mutant LS-34/-43) is as detrimental to transcription
as mutations that modify the central part of the prox-
imal element homology. This suggested that the re-
gion immediately downstream from the proximal ele-
ment contains some element required for RNA
polymerase II transcription, although this region is
not conserved in different RNA polymerase II
snRNA promoters. In the human U6 promoter, a
clustered point mutation that modifies essentially the
same region (LS5, see Fig. 1B) has little effect on
RNA polymerase III transcription. However, when
combined with a mutation that debilitates the A/T
box and switches the U6 promoter to a predomi-
nantly RNA polymerase II promoter, the LS5 mu-
tation has a marked deleterious effect, again sug-
gesting that this region is required for RNA
polymerase II transcription. However, because the
above mutations are different and were introduced
in the context of different promoters, the above data
cannot be rigorously interpreted.
To determine whether the region downstream
from the proximal element represents an element re-
quired mainly for RNA polymerase II transcription,
we introduced the LS-34/-43 mutation in the con-
text of the pU2/TA promoter that directs both RNA
polymerase II and RNA polymerase III transcrip-
tion, thus creating the pU2/TA/(LS-34/-43) con-
struct (Fig. 1). Analysis of expression from this con-
struct showed that introduction of the LS-34/-43
mutation suppressed RNA polymerase II transcrip-
tion but had little effect on RNA polymerase III tran-
scription. Thus, at least one element in the U2 and
U6 promoters appears to be required by RNA poly-
merase II but not by RNA polymerase III. The U2
and U6 transcription complexes thus differ by at least
one factor in addition to the A/T box binding fac-
tor, and the absence of this factor in nuclear HeLa
cell extracts might explain the apparent paradox of
active RNA polymerase III but inactive RNA poly-
merase II transcription from snRNA promoters in
vitro.
Why does the U6 gene contain a polymerase II
promoter element? This element may represent a
remnant from when the snRNA promoters may have
been transcribed by the same RNA polymerase. Al-
ternatively, there may be slightly divergent U6 gene
copies in the human genome that are transcribed by
RNA polymerase II. Little is known about the ge-
nomic organization and the copy number of the true
U6 genes in the human genome, although the total
number of U6 loci including pseudogenes has been
estimated to be 200. Finally, the U6 gene we have
analyzed may itself be transcribed by RNA polymer-
ase II under circumstances not reproduced in our
assay.
We are now interested in identifying and eventu-
ally purifying transcription factors involved in U2
and U6 transcription, and one of the intriguing ques-
tions is how the 3' box signals termination of tran-
scription by RNA polymerase II. To determine
whether the factors recognize the 3' box at the DNA
level, we performed competition experiments in vivo,
in which an excess of 3' box sequences was trans-
fected together with a reporter gene containing a 3'
box followed by a polyadenylation site. Even the
highest concentration of 3' box sequences did not
result in an increase of polyadenylated RNA rela-
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tive to RNA ending at the 3' box from the reporter
construct. This suggests either that the amount of
3' box binding factor in the nucleus is very large, or
that the 3' box does not bind a factor at the DNA
level, or that the U2 transcription complex is locked
in a stable structure such that individual factors can-
not readily exchange between different binding sites.
However, similar experiments in which an excess of
U6 proximal element sequences was cotransfected
with the U2 gene or an excess of U2 proximal ele-
ments was cotransfected with the U6 gene resulted
in a decrease of U2 and U6 transcription, respec-
tively, suggesting that the U2 and U6 transcription
complexes are not completely stable and demonstrat-
ing that the same factors can bind to the U2 and U6
proximal elements in vivo. To identify the factor(s)
that interacts with the U6 proximal element, we have
more recently begun to fractionate the U6 in vitro
transcription system. This approach should also al-
low the identification of the factor(s) interacting with
the A/T box.
Mechanism of trans-Activation of
the HIV-1 Promoter by the Viral
trans-Activator tat
R. Ratnasabapathy, M. Sheldon, S. (fill, L. Johal,
N. Hernandez
To study the mechanism of tat trans-activation, we
are following two approaches. In the first one, differ-
ent constructs are transfected into T cells or He La
cells, and tat trans-activation and formation of short
transcripts are monitored by RNase T1 protection.
In the second, formation of short transcripts is stud-
ied in an in vitro transcription system.
IN VIVO ASSAYS
Figure 2 shows the hybrid gene construct used in the
transfection experiments and from which all other
constructs are derived. It consists of HIV-1 sequences
from -147 to + 80, i.e., containing the HIV promoter
and the entire TAR sequence. The HIV sequences
are followed by a fragment from adenovirus 2 (Ad2)
containing the L3 polyadenylation site, and this en-
sures that transcripts that read through the poten-
tial premature termination sites in TAR will have dis-
crete polyadenylated 3' ends and will therefore be
stable. This artificial transcription unit is followed
by two fragments: (1) a fragment carrying the T3 pro-
moter, so that riboprobes can be generated from each
construct without additional cloning steps, and (2)
a fragment (not shown in the figure) carrying the
SV40 origin of replication, so that the plasmid can
be replicated in vivo by inclusion of an SV40 T-
antigen expression vector in the transfections. 5' to
the HIV-1 promoter are two tandem polyadenylation
sites (not shown in the figure) derived from SV40.
The presence of the tandem SV40 polyadenylation
sites reduces considerably the amount of stable RNA
extending through the HIV-1 promoter in transi-
ent transfections, presumably because RNA derived
from cryptic promoters within the vector becomes
polyadenylated at these sites.
This construct was transfected into Jurkat cells
with or without a second plasmid directing expres-
sion of the tat protein, and the transcripts generated
were characterized by RNase T1 protection mapping.
We detect bands whose sizes correspond to short
transcripts ending downstream from the TAR region
as well as transcripts extending to the Ad2 L3 poly-
adenylation site. Control experiments have con-
firmed that (1) these transcripts correspond to cor-
rectly initiated RNA, (2) the bands are not the results
of artifactual cleavage of the hybrids by RNase Ti,
and (3) the long transcripts correspond to poly-
adenylated RNA, whereas the short transcripts are
not polyadenylated. In the presence of tat, the
amount of polyadenylated RNA increases, whereas
the amount of short transcripts decreases, both in
T cells and in HeLa cells. This observation is simi-
lar to the results reported by M. Peterlin and col-
leagues for experiments in COS cells and is consistent
with tat acting as an antiterminator of transcription.
We have generated a whole series of constructs
in which the HIV-1 promoter was replaced by differ-
ent mRNA promoters or by the U2 and U6 pro-
moters. Surprisingly, all of these hybrid constructs
Sp I
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p H I V- I /TAR
FIGURE 2 Hybrid gene in HIV-1 construct. The HIV-1 promoter elements, the TAR re-
gion, the L3 polyadenylation site, and the T3 promoter are indicated.
T3
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still generated short transcripts and were trans-acti-
vated by tat. The only exception was the U6 promoter,
which when placed upstream of TAR generated short
transcripts but was not trans-activated by tat. Thus,
the HIV-1 promoter does not contain any element
required for short transcript formation or for tat
trans-activation. We have now generated more con-
structs with substitutions in the TAR region, so as
to define which regions of TAR are required for short
transcript formation.
TRANSCRIPTION IN VITRO
We have prepared nuclear extracts from He La cells
and from Jurkat cells. These extracts direct efficient
transcription initiation from the HIV-1 promoter.
Initiation is accurate, and transcription is directed
by RNA polymerase II. Interestingly, a large amount
of short transcripts is generated in vitro, which are
identical in size to the short transcripts observed in
vivo. The amounts of short transcripts vary in differ-
ent extracts, but they are always detectable. Prelimi-
nary experiments suggest that these short transcripts
are not the results of a processing reaction uncou-
pled from transcription, but rather are generated by
termination of transcription or by a processing reac-
tion coupled to transcription. Thus, in time courses,
the short transcripts appear at the same time as long
transcripts. Moreover, in experiments in which tran-
scription is allowed to proceed for 1 hour, then
blocked by addition of a-amanitin, and incubation
is continued for various periods of time, the amounts
of short transcripts do not increase during the incu-
bation period. We have yet to find a mutant that does
not generate short transcripts in vivo nor in vitro to
convince ourselves of the specificity of the in vitro
reaction. If it does accurately reflect in vivo events,
we will determine by competition or depletion ex-
periments whether specific factors are involved in
premature termination of transcription in the TAR
region.
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STRUCTURE AND COMPUTATION
This section includes five laboratories interested in the detailed structural proper-
ties of proteins and computational biology. It includes the laboratories of Jim
Pflugrath and John Anderson, who are interested in macromolecular crystallogra-
phy, and Rich Roberts, whose group has had a long-standing interest in restriction
enzymes and their associated methylases. During the last year, the program lost
one of its founding members, Dr. Mark Zoller, who has joined Genentech Corpora-
tion in San Francisco to pursue his interests in site-directed mutagenesis. For-
tunately, Dr. Jeff Kuret, a former postdoctoral fellow of Dr. Zoller, was persuaded to
stay on and has accepted the position of Staff Investigator. His laboratory studies
protein kinases, and Dr. Kuret has established a close collaboration with Dr.
Pflugrath. The program was also fortunate in enticing Dr. Tom Marr to leave Los
Alamos National Laboratory, where he has been responsible for designing the
new GENBANK database. Dr. Marr has accepted the position of Senior Staff In-
vestigator at Cold Spring Harbor Laboratory. His extensive background in biology
and computer science will considerably enhance computational biology at the
Laboratory.
NUCLEIC ACID CHEMISTRY
R.J. Roberts A. Dubey
L. Hamablet
S. Klein
S. Klimasauskas
D. Macelis
C. Marcincuk J. Posfai
J. Mart ling D. Roberts
J. Meyertons M. Wallace
S. Miceli K. Zachmann
G. Otto
Studies of the Mspl Methylase
A. Dubey
The Mspl restriction-modification system recognizes
the sequence 5'-CCGG-3'. The complete system has
been previously cloned and sequenced (Lin et al.,
Nucleic Acids Res. 17: 3001 [1989]). A subfragment,
containing the methylase gene, was cloned next to
a fragment containing the inducible pTac promoter,
and this derivative overproduces the methylase to
high levels. Dr. B. Mollet in this laboratory had pre-
viously attempted the purification of the Mspl
methylase directly from this strain and found that
it was possible to purify small amounts of the methy-
lase quite readily; however, most of the enzyme was
in the form of large aggregates of unknown specific
aciivity. This was caused by overexpression of the
Mspl methylase in Escherichia coli strain RR1, which
results in the formation of inclusion bodies. We have
now examined the formation of these inclusion bod-
ies and discovered that they are temperature-sensitive
and are not produced at temperatures below 30°C.
At normal growth temperatures of 37°C, about 50Wo
of the total Mspl methylase produced forms biolog-
ically inactive aggregates. At 30°C, greater than 9907o
of the total Mspl methylase is soluble. We are con-
tinuing to fine-tune the overexpression system to pro-
duce higher yields of soluble and enzymatically ac-
tive Mspl methylase.
In the recombinant strain overexpressing the Mspl
methylase, a shorter protein with an apparent mo-
lecular mass of 40 kD has been identified in addi-
tion to the 51-kD species. Amino-terminal sequence
analysis of these two proteins shows that the 40-kD
protein is a truncated form of the Mspl methylase,
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missing exactly 40 amino acids from the amino ter-
minus. The new amino terminus is located at the sec-
ond methionine within the open reading frame that
encodes the protein. This suggests that the two forms
are produced by alternative sites of translation ini-
tiation. However, the missing amino acids from the
amino terminus are not sufficient to account for the
differences in apparent molecular mass, and we are
continuing to analyze the lower-molecular-mass
form. We are presently trying to identify the Mspl
methylase from the original Moraxella strain so as
to discover which of the two forms of the methylase
represents the bona fide protein. We are also trying
to separate the two forms of the enzyme so as to char-
acterize them. For these studies, we have prepared
polyclonal antibodies against the Mspl methylase to
help identify the protein in cells that are not overex-
pressing it.
A new scheme for the purification of the Mspl
methylase is presently being devised using phos-
phocellulose and hydroxyapatite chromatography.
Considerable purification has been achieved, al-
though at least one further step will be necessary be-
fore homogeneous protein is available for kinetic
studies and crystallization.
The Architecture of Cytosine
Methylases
J. Meyertons, S. Klimasauskas
The primary goal of this work is to identify the pro-
tein domains of the Hhal (recognition sequence: 5'-
GmeCGC-3') and HpaII (recognition sequence: 5'-
CmeCGG-31) methylases that form part of their
respective restriction-modification systems. These
enzymes are responsible for the sequence-specific
recognition of DNA, although nothing is known
about the detailed mechanisms by which this is
achieved. A plasmid was constructed with the two
methylase genes in tandem and arranged in the same
orientation relative to transcription. Hhal and HpaII
methylase gene fusions were made by cleaving the
plasmid between the methylase genes and digesting
the plasmids with BAL-31 nuclease. This resulted in
hybrid methylases that had the amino-terminal re-
gion of the Hhal methylase fused to the carboxy-
terminal region of the HpaII methylase, and vice
versa.
An alternative scheme to generate hybrid methy-
lases is also being pursued. The polymerase chain
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reaction (PCR) is being used to construct exact de-
letions from the plasmid containing both methylase
genes such that the amino terminus of one methyl -
ase becomes joined to the corresponding carboxyl
terminus of the second methylase. These construc-
tions take advantage of the conserved sequence mo-
tifs that are present within the cytosine methylases
so that the boundaries in the hybrids are defined by
the sequence motifs. Thus, in each case, the overall
architecture of the methylase is maintained.
To detect the hybrid methylases, an assay was de-
vised that relied upon the Mcr system of E. coll. The
Mcr system is a sequence-specific, modification-
dependent restriction system that cleaves DNA at 5-
methylcytosine residues. The two Mcr systems known
are identified as A and B. The McrA system restricts
DNA methylated by the HpaII methylase, whereas
both McrA and McrB systems restrict DNA methyl-
ated by the Hhal methylase. Methylated plasmids
transformed into an E. coli strain with an active Mcr
system are cleaved and destroyed. To permit detec-
tion of active hybrid methylases, E. coli strains with
temperature-sensitive mutations in the Mcr genes
were constructed. Three E. coli strains with tempera-
ture-sensitive Mcr mutations were identified. The
Mcr temperature-sensitive mutations in E. coli will
be further characterized, because these strains could
potentially have value in studying both prokaryotic
and eukaryotic methylases.
Isolation of Mutants of Integration
Host Factor
D. Roberts
Integration host factor (IHF) is a site-specific DNA-
binding protein in E. coli that has been shown to play
a role both in regulation of gene expression and in
site-specific recombination (for review, see Friedman,
Cell 55: 545 [1988]). It is a heterodimer composed
of two homologous subunits, IHF-a and IHF-f3, each
about 100 amino acids long. IHF binds DNA by con-
tacts in the minor groove (Craig and Nash, Cell
39: 707 [1984]; Yang and Nash, Cell 57: 869 [1989]).
Binding of IHF to DNA causes the DNA to bend
(Prentki et al., EMBO J. 6: 2479 [1987]; Stenzel et
al., Cell 49: 709 [1987]; Robertson and Nash, J. Biol.
Chem. 263: 3554 [1988]). We are interested in learn-
ing more about the structure and function of IHF,
and as a first step in studying this, we have isolated
many new mutants of IHF.
IHF mutants were isolated with the genes on plas-
mids. Both genes have been cloned (Miller, Cold
Spring Harbor Symp. Quant. Biol. 49: 691 [1984];
Flamm and Weisberg, J. Mol. Biol. 183: 117 [1985]).
We subcloned small fragments containing the genes
(350-400 bp) and inserted them downstream from
the lac promoter. These plasmids were mutagenized
by growth through the mutator strain mutD and
screened for mutants using two different screens.
First, mutants were selected as survivors of heat in-
duction of a Mu lysogen. IHF is required for growth
and replication of the bacteriophage Mu (Ross et al.,
J. Bact. 187: 905 [1985]). A lysogen of a Mu phage
with a temperature-sensitive repressor was made
IHF-, transformed with the mutagenized plasmids,
and plated at 42°C. Only transformants with defec-
tive IHF genes on the plasmids should survive. The
second screen was to look for increased [3-galac-
tosidase activity from a lacZ fusion to a promoter
known to be repressed by IHF. The promoter used
was the Tn/O transposase promoter.
We isolated 80 mutants of IHF, 50 mutants of
IHF-a, and 30 mutants of IHF-[3. These mutants
were tested for IHF function in five different genetic
assays, involving five different IHF-binding sites.
About two thirds of the mutants were defective in
all assays, and sequence analysis showed that these
were either single-base insertions, single-base dele-
tions, stop codons, or introduction of a proline in
an a-helical region. The remaining mutants were all
missense mutations. Since IHF is homologous to the
bacterial histone-like protein HU, and the crystal
structure of HU has been determined (Tanaka et al.,
Nature 310: 376 [1984]; White et al., Proteins 5: 281
[1989]), the effects of the missense mutations can be
interpreted with reference to the structure of HU.
Most of these changes were in amino acids that are
conserved between IHF and HU in the region likely
to interact directly with DNA. The strongest mutant
was nonfunctional in all assays and was a glycine-
to-glutamic acid change in the DNA-binding region.
The effect of this mutation can be easily explained
by the inability of the protein to interact with DNA
due to the presence of a larger and charged amino
acid residue. The rest of the mutants appeared to be
defective in some assays but functional in others and
included changes of phenylalanine to serine, argi-
nine to cysteine, arginine to histidine, and proline to
serine. Although these changes could weaken the
protein:DNA interaction, it is not clearwhy the mu-
tant proteins function in some assays but not in
others. These mutants will be investigated further
for DNA binding and bending to determine whether
specific DNA contacts are affected.
Prediction of Protein Function
from Sequence
G. Otto
We are continuing our work on the comparative anal-
ysis of sequences with the aim of predicting protein
function. The general strategy is to compare a test
sequence of unknown function with sets of sequences
sharing known functions. Significant similarities be-
tween the test sequence and sequences of one of these
sets imply that the test sequence shares the function
of that set. One focus of this work is on the methods
of measuring sequence similarity. We define similar-
ity as a probability that an optimal alignment of two
sequences is due just to random matching of unre-
lated sequences. This definition leads to a useful ar-
ray of techniques for (1) comparing sets of sequences,
(2) deriving a sequence pattern or motif from a set
of sequences, and (3) searching for matches to a given
pattern in a set of sequences.
An important goal of this work is to develop a
database of sequence patterns that are predictive of
specific protein functions. This will be useful as a
screen to analyze newly determined sequences for
possible functions. As the Human Genome Initia-
tive begins to produce large volumes of sequence,
it will be essential that methods are available to ana-
lyze those sequences automatically. A predictive mo-
tif database would be extremely useful in this regard.
We have designed a prototype version of this data-
base and are presently implementing it. In addition
to exploring ways to find new motifs for entry into
the database, we are tackling the difficult problem
of making sure that it is completely up to date. With
each new release of the sequence databases, it is
necessary to ensure that the formal description of
each motif is still predictive.
Advanced Computer Tools for the
Analysis of Biological Sequences
J. Posfai, K. Zachmann, R.J. Roberts
FUNCTIONAL MOTIFS IN PROTEIN SEQUENCES
The sizes of sequence data libraries have increased
dramatically over the past few years. In many cases,
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sequences of functionally related proteins are now
available from different organisms. The successful
global comparisons of such related sequences often
reveal the presence of conserved elements that rep-
resent regions of the proteins that are important for
function and/or structure. This in turn can allow the
definition of amino acid sequence motifs that are
diagnostic of function or structure. A database of
such diagnostic motifs would be of great importance
in assigning function to new protein sequences. This
database cannot conveniently be built and main-
tained by manual methods, since these would be too
time consuming given the ever-increasing number of
known sequences. Therefore, we have been develop-
ing algorithms and computer tools that enable such
motifs to be generated semiautomatically.
The first step is to identify groups of function-
ally related sequences from the databases. This is
achieved by use of the key words that appear in the
annotation of database entries. For instance, these
key words in the PIR database are treated as descrip-
tors of knowledge about protein functions (e.g., bind-
ing a substrate and catalyzing a reaction), and pro-
teins that share key words are considered to be
functionally related. Such sequences are retrieved
from the database, and a filtering program eliminates
any duplicate sequences. This is necessary because
the databases frequently contain identical duplicates.
At the next step, the pairwise sequence similarity
scores are calculated by the RDF method (Lipman
and Pearson, Science 227: 1435 [1985]). A program
that provides a convenient visual representation of
similarity helps in the selection of the globally related
sequences. This program shows the sequences se-
lected and their interrelationships as dots and edges
in a graphic display. The investigator manipulates
these symbols by a high-level interface (buttons,
slides, scrollbars, pop-up menus, mouse). Exception-
ally high or exceptionally low scores of selected sub-
sets of the sequences can be displayed. The valency
of each point, defined as the number of sequences
with exceptional scores connected to it, is also dis-
played. The order in which the sequences are put on
the screen is determined by an algorithm, which
results in globally similar sequences appearing as
closely packed dots with many internal connections.
The final decision in selecting the sequences for
global alignment from all sequences on the screen
is left to the operator, since human pattern recogni-
tion is still superior to that of the best computer al-
gorithms. Additional tools for alignment, motif de-
tection and testing, incorporation into the database,
and update are either in prototype form or being
designed.
DETECTION OF ERRORS IN DNA SEQUENCES
The DNA sequence libraries have been estimated to
contain one error in every 10,000 bases. It would be
extremely useful to be able to detect the locations
of sequence errors before sequences were placed in
databases. We have designed an algorithm that would
help to detect insertion/deletion errors located in
coding regions. Since these errors shift the reading
frame of translation, any sequence similarity of the
gene product of the correct DNA sequence with
other protein sequences will be shifted from one
frame of translation to another frame near the lo-
cation of the error. A comprehensive error checking
of a new DNA sequence by this principle requires
a program that screens the protein sequence library
for local similarities with any of the six translation
frames of the DNA sequence. The other reading
frames must be checked for continued similarity
around the starts and ends of any similarities found.
Such adjoining similarities could indicate possible
sequence errors and would suggest that the primary
data be checked carefully for inconsistencies.
Because of the sizes of sequence databases, the
simple program outlined is extremely demanding in
computational resources. To get results in reason-
able times, instead of straightforward algorithms, we
have applied a special tool of computer science,
called a "finite state machine" at two critical stages
of the checking process. This imaginary machine is
created as a series of pointers, tables of states, and
vectors of outputs when the program starts. At a cost
of memory usage and computational time at the start
of the program, considerable speed is gained at ev-
ery cycle of the repeated steps when processing large
amounts of data. One machine performs the trans-
lation from DNA sequence to amino acid sequence.
This way we can actually build the translated se-
quences more quickly than we would get them from
pretranslated sequences stored in disk files. A sec-
ond machine is used to report seven out of ten (or
similar) hits between two matched segments by per-
forming a single comparison between two amino
acids instead of ten comparisons.
Using this approach, we detected two errors in a
particular DNA sequence in the EMBL database in
which we were interested. Careful examination of the
literature that appeared after the initial determina-
tion of the sequence revealed that in a subsequent
publication, the original authors had found and cor-
rected the errors, thus verifying the validity of our
approach. As our knowledge of sequences becomes
more and more complete for every new sequence, the
chances of finding similar ones in the databases in-
creases and so does the potential of our method. The
basic idea of searching for interrupted similarities
in a protein or DNA sequence can be generalized as
a technique for error detection and may also find
application in the detection of consecutive introns.
Restriction Endonucleases
L. Hamablet, S. Klein, D. Macelis, J. Mart ling,
J. Meyertons, S. Miceli, R.J. Roberts
The collection of restriction endonucleases continues
to grow, and more than 1300 enzymes have now been
characterized; 157 different specificities are known.
During the last year, 28 new enzymes have been iso-
lated and characterized as part of a collaborative pro-
gram with I. Schildkraut and D. Comb (New Eng-
land BioLabs). Among these are six valuable new
specificities. Of special interest is an enzyme that we
have found from a Frankia species that recognizes
the octanucleotide sequence GGCCGGCC. This en-
zyme has been characterized in detail; unfortunately,
it is present in extremely small quantities, and the
Frankia strain from which it is isolated grows ex-
tremely slowly. The enzyme will be extremely valu-
able for genome mapping studies, since it cleaves
DNA such as the human genome very rarely. Within
known human DNA sequences, the frequency of
Fsel sites is very similar to that of Notl sites.
In collaboration with New England Bio Labs, we
have begun experiments to clone the gene for Fsel.
Initially, we have been exploring a new general
strategy with which to clone cytosine methylase
genes, taking advantage of the sequence motifs that
we have found in cytosine methylases to design PCR
primers. Initial tests of this approach in a strain of
Staphylococcus aureus, which produces an isoschiz-
omer of Sau3AI, have proved quite successful. The
initial experiments with DNA from the Frankia spe-
cies gave rise to an amplified segment that had all
of the characteristics of a cytosine methylase, al-
though it remains to be determined whether this frag-
ment that we have cloned truly contains the coun-
terpart methylase of the Fsel restriction enzyme gene.
For many years, we have maintained a database
of information about restriction enzymes. This data-
base, REBASE, has now been fully implemented in
a relational format. We have been using the ORACLE
Database Management System for this purpose and
have written a large number of report generators so
that the contents of the database can be disseminated
to individual investigators. Presently, we send elec-
tronically either a standard generic form that may
be reformatted by the recipient or a variety of spe-
cific formats that will directly support known pack-
ages of computer programs for identification of re-
striction enzyme recognition sites. One of the most
popular of these is a file that can be used directly
by the UWGCG software package. Further software
tools are being developed that help in the acquisi-
tion and management of these data. Another major
project currently under way is a package of programs
that will aid in the identification of new restric-
tion enzymes based mainly on digestion patterns on
known DNAs and, when necessary, preliminary
mapping of a few cleavage sites. This project involves
the improved implementation of existing programs,
many of which were written at Cold Spring Harbor
Laboratory, together with new routines to digitize
the incoming data and to allow the rapid visualiza-
tion of results.
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MACROMOLECULAR CRYSTALLOGRAPHY
J.E. Anderson E. Chang J. Fu
J. W. Pflugrath C.K. Cheung T. Malone
F.-C. Chuan D. Milano
T. Sellati
D. Sterner
K. Zachmann
A primary objective of the Macromolecular Crys-
tallography Group is to determine the structures of
a number of biologically important proteins to
atomic resolution in order to better understand their
functions in cell processes such as signal transduc-
tion, growth control, and development. Our studies
are designed to benefit from and to complement the
genetic and biochemical experiments performed by
other groups at the Laboratory. Together with these
biochemical data, crystallographic models of ki-
nases, oncogene products, trans-acting factors, and
other proteins will help us to comprehend the roles
of these macromolecules in cell division, in cell trans-
formation, and, ultimately, in afflictions such as can-
cer, AIDS, and Alzheimer's disease.
Our crystallographic experiments require well-
formed crystals of the macromolecule being inves-
tigated. To grow crystals of a useful size (>0.3 mm
on a side), one must have available several milligrams
of the highly purified macromolecule. Although this
does not guarantee that crystals can be produced,
it is the minimal prerequisite before attempting to
crystallize the molecule. To this end, a major part
of our laboratory and time is devoted to producing
and purifying to crystallographic homogeneity the
proteins we are studying. When a suitable crystal is
obtained, it is placed in an intense X-ray beam
smaller than a pencil lead. The X-ray beams dif-
fracted by the crystal are measured on our area de-
tector. We must quantitate tens of thousands of these
diffracted beams from several dozen different crys-
tals. Fortunately, these experiments are computer
controlled, with much of the software written in-
house. Only after all the data are collected can we
begin to construct a three-dimensional model of the
macromolecule - all the atoms and bonds - with the
aid of computer graphic tools.
Structural Studies of Pvull
Endonuclease
J. Anderson, F.-C. Chuan [in collaboration with
I. Schildkraut, New England BioLabsj
We have two crystal forms of the restriction endo-
nuclease from Proteus vulgaris, R PvuII, that dif-
fract X-rays to 2.5 A resolution. R PvuII binds to
the DNA site CAGCTG and cleaves both strands be-
tween the internal cytosine and guanine. One of the
crystal forms is space group P422, with a=b=176.2
A, c= 50.6 A. It grows as trapezoidal prisms by va-
por diffusion in hanging drops over reservoirs con-
taining 0.13 M ammonium acetate, 0.065 M sodium
acetate, and 2007o PEG-4000 (pH 5.5). Each 4-6-p,1
drop yields 1-10 crystals in several days. Crystals of
the second crystal form, which appear much less fre-
quently under the same conditions, are orthorhom-
bic needles with unit cell dimensions of 106, 84, and
47 A. The space group has not yet been determined,
due to the scarcity of crystals large enough for dif-
fraction experiments.
We are currently collecting native data from the
P422 crystals and are preparing to make heavy atom
derivatives. We are making slight modifications of
the crystallization conditions in an effort to increase
the frequency and size of the orthorhombic needles
so that we can characterize them and collect data
from them. We are also preparing to set up cocrystal-
lizations of R PvuII with oligonucleotides carrying
its recognition site in order to determine the struc-
ture of the complex and compare it to that of the
free protein.
Structural and Functional Studies of
Fos and Jun Proteins
C.K. Cheung, E. Chang, F.-C. Chuan, J. Anderson
[in collaboration with C. Abate and
T Curran, Roche Institute]
The protein products of the proto-oncogenes c-fos
and c-jun interact to form a DNA-binding transcrip-
tion factor that is a major component of the activity
of the eukaryotic transcription factor AP-1. Fos/Jun
heterodimers bind to DNA at AP-1 sites (TGACTCA)
in the promoters of many genes, including the hu-
man immunodeficiency virus (HIV). Once bound,
they can activate or repress transcription. We intend
to crystallize these proteins and determine their struc-
tures in the presence and absence of oligonucleotides
carrying AP-1 sites. This will help us to understand
the role that these proteins play in normal cellular
regulation and in the regulation of HIV, and the role
altered versions of these proteins play in oncogenesis.
OVEREXPRESSION AND PURIFICATION OF JUN
We overexpressed Jun in Escherichia coli using a bac-
teriophage T7 expression system. Bacterial cells
freshly transformed with the expression plasmid and
induced at 37°C with isopropyl-P-D-thiogalactoside
produce about 30% of their total protein as Jun. Jun
is in the insoluble fraction of the crude cell lysate,
and after an initial centrifugation, the overexpressed
protein is already 80-90% pure. The pellet is resus-
pended in 6 M urea and loaded onto a heparin-
Sepharose column equilibrated in 6 M urea. About
4 mg of Jun eluting in 1 ml from the heparin column
at about 100 mm NaCl in a linear salt gradient is
denatured with SDS and P-mercaptoethanol (BME)
and layered as a single sample onto a 1.5-mm thick
10% SDS-polyacrylamide gel. After electrophore-
sis, the protein is located by staining a small slice
of the gel with Coomassie blue. The protein band
is sliced out of the gel, diced, and electroeluted in
50 mm ammonium bicarbonate overnight in a Bio-
Rad electroelution apparatus; at the same time, the
SDS is removed by dialysis against a large excess of
50 mm ammonium bicarbonate. About 2 mg of Jun
is recovered after electroelution. By silver-staining,
it is judged to be greater than 98% pure.
STRUCTURAL DOMAINS OF JUN
After digestion of purified Jun in phosphate-buf-
fered saline (PBS) with a variety of proteases (Staph-
ylococcus aureus V8 protease, chymotrypsin, pro-
tease K, papain, trypsin, and thermolysin), relatively
resistant fragments consistently appear. The frag-
ments have apparent molecular weights of approxi-
mately 30K from SDS-PAGE. Since sites for these
proteases exist throughout the protein, we interpret
this to mean that the 30K polypeptides are folded
in such a way that the sites are protected from cleav-
age. In other words, these fragments represent folded
structural domains. The 30K fragments from V8 and
chymotrypsin digestion were isolated by gel electro-
elution, and their amino-terminal sequences were de-
termined. The V8 fragments have rather heteroge-
neous amino termini, but they tend to begin in the
neighborhood of residues 80 and 110. The chymo-
tryptic fragment begins at residue 99. The differences
in amino termini probably reflect the availability of
protease sites in the sequence. We made a prepara-
tive digestion of Jun with chymotrypsin, and puri-
fied the 30K fragment, called Jun99, by electroelu-
tion as described above for intact Jun.
GEL SHIFT EXPERIMENTS SHOW THAT BACTERIAL
JUN PROTEINS ARE ACTIVE
Both Jun and Jun99 prepared as described above
bind to DNA carrying an AP-1 site in initial gel-shift
experiments (C. Abate). The binding of both is im-
proved in the presence of a truncated Fos protein
comprising the Fos DNA-binding domain, which
forms heterodimers with Jun and Jun99.
CRYSTALLIZATION OF FOS AND JUN PROTEINS
We are currently carrying out crystallization trials
with purified Jun. When sufficient quantities of pu-
rified Jun99 become available, we will attempt to
crystallize it as well. We are attempting to cocrystal-
lize Jun with the Fos DNA-binding domain. We will
also try to cocrystallize the proteins with oligonu-
cleotides carrying an AP-1 site. Once crystals are in
hand, we will determine their structures using X-ray
crystallography.
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Structural and Functional Analyses
of CRE-binding Proteins
E. Chang, T Sellati [in collaboration with M. Gilman and
D. Marshak, Cold Spring Harbor Laboratory]
Transcription of many cellular and viral genes is in-
duced by cAMP. This often involves the binding of
protein factor(s) to a conserved sequence called the
cAMP-responsive element (CRE; TGACGTCA) in
the promoter region of these genes. Many CRE-
binding (CREB) proteins have been cloned and iso-
lated by a number of research groups. However, the
mechanism by which these proteins stimulate tran-
scription remains unknown. We are studying the
CREB protein with the hope of learning how this
protein regulates gene expression in response to
cAMP. To facilitate our studies, we have overex-
pressed two CREB proteins, CREB2 and CREB6,
in E. coli. CREB2 and CREB6 are very similar to
each other, except that CREB6 contains 14 addi-
tional amino acid residues in its amino-terminal re-
gion. These CREB proteins are produced in the solu-
ble fraction of E. coli extracts and can be easily
purified to 9007o homogeneity.
CREB2 has been further characterized. Several
lines of evidence emerging from these studies sug-
gest that the E. coll-produced CREB2 protein is func-
tionally active and therefore has a conformation
similar to its counterpart from mammalian sources:
(1) The E. coll-produced CREB protein retains its
sequence-specific binding activity. Results from gel-
shift experiments indicate that CREB2 binds to a
DNA fragment containing the - 65 CRE sequence
from mouse c-fos promoter but fails to bind to a
similar fragment carrying mutations in the CRE. (2)
The DNase I footprint generated by E. coll-made
CREB2 protein on the c-fos CRE is similar to that
determined by other groups for CREB protein iso-
lated from mammalian cells. (3) The E. coli -made
CREB2 protein stimulates transcription in vitro from
a c-fos promoter containing the wild-type - 65 CRE
sequence but not the same promoter carrying a mu-
tant CRE. (4) The E. co/i-made CREB protein, like
the CREB proteins produced by mammalian cells,
can be phosphorylated by protein kinases.
We are currently studying several aspects of CREB
structure and function. Since proteins produced in
bacteria are largely unmodified, the recombinant
CREB proteins will be very useful for studying the
effects of phosphorylation on CREB structure and
function. We will phosphorylate the E. coil- made
CREB proteins with protein kinase(s) and determine
whether the modification affects their 1)NA-binding
and transcriptional activities. Limited proteolytic
digestion of the E. coll-produced CREB2 protein
with S. aureus V8 protease generates a 30-kD pro-
tease-resistant fragment. We will determine if phos-
phorylation will change the protease digestion pat-
tern. In addition to the full-length CREB protein,
we have overexpressed several truncated CREB pro-
teins in E. coli. We are now characterizing these pro-
teins with respect to their ability to bind to the CRE
and to stimulate CRE-dependent transcription. These
experiments initiate our efforts to identify impor-
tant structural and functional domains of CREB.
Finally, we are further purifying the E. coil -made
full-length and truncated CREB proteins. Once this
is accomplished, we will try to crystallize the pro-
teins and determine their three-dimensional struc-
tures in the presence and absence of the cognate
DNA substrate. Results from such studies will help
to reveal the structural basis for substrate specific-
ity. Furthermore, these results, together with the
results of similar studies of Jun (see above), will help
to explain how the similarities and differences be-
tween CREB and Jun affect their ability to recog-
nize and bind to similar DNA sequences.
Yeast cAMP-dependent Protein Kinase
J.W. Pflugrath, T. Malone, D. Sterner [in collaboration with
J. Kuret, Cold Spring Harbor Laboratory]
Protein kinases are key regulatory molecules that
modulate many cellular processes including cell
growth, differentiation, and proliferation. Nearly 100
protein kinases have been identified thus far, each
of which is capable of integrating input signals and
coordinating physiological responses by phosphor-
ylating a specific range of substrate proteins. A
detailed three-dimensional structure would expand
our knowledge of this class of important enzymes
to the molecular level. Toward this end, we have ini-
tiated a crystallographic study of the cAMP-depen-
dent protein kinase from Saccharomyces cerevisiae,
also known as TPK1.
From extremely pure preparations of genetically
engineered TPK1 (see J. Kuret's section), we grew
kinase crystals in the hexagonal space group P6122
(or its enantiomorph) with unit cell lengths of 61 A
by 61 A 320 A. Density measurements of these
crystals indicate the presence of 12 protein molecules
in the unit cell or one per asymmetric unit. We mea-
sured diffraction intensities on our Enraf-Nonius
FAST area detector with monochromatized X-rays
generated by a GX-21 rotating anode operated at 45
kV, 95 mA. All the data collection experiments were
controlled by the software package MADNES, de-
veloped in part by us. The reproducibility of the data
as determined by Rsyn, ranged from 407o to 807o. To
solve the crystallographic phase problem, we have
soaked numerous crystals in a stabilizing buffer con-
taining different heavy atom compounds. Although
many such treatments cracked or dissolved the crys-
tals, we collected diffraction intensities on the in-
tact crystals to find any that had incorporated the
heavy atom. Isomorphous difference Patterson maps
calculated with data from two separate crystals
treated with a gold compound and a mercury com-
pound showed significant substitution. These should
allow us to calculate an electron density map in the
coming months. Further heavy atom screening will
continue. Finally, data from several native crystals
were collected at the National Synchrotron Light
Source beamline X12-C with the generous assistance
of R. Sweet. We will continue to use this national
resource.
Area Detector Software
J. W. Pflugrath [in collaboration with the EEC Cooperative
Workshop on Position-Sensitive Detectors]
Although we continue to develop and improve the
device-independent area detector software system
MADNES, the year ended with the software in a ma-
ture state. This system is used by our group and
dozens of other crystallography laboratories world-
wide to collect and process X-ray diffraction data
from several kinds of area detectors. Our group coor-
dinates the maintenance and debugging of MADNES.
This is done through a digest distributed worldwide
to interested colleagues via a computer network. In
the past year, MADNES was adapted for use on two
new kinds of detectors, including a new experimen-
tal CCD-based detector of M. Strauss and E. West-
brook of Argonne National Laboratory for use at
synchrotrons. As more scientists use the program,
it has become clear that a new intuitive user inter-
face is required. We have begun to address this need.
PROTEIN KINASE STRUCTURE AND FUNCTION
J. Kuret A. O'Connor
K. Kopecek
Protein kinases are enzymes that catalyze the trans-
fer of the y-phosphoryl group of ATP to nucleophilic
amino acids of protein substrates, thereby modulat-
ing the substrates' biochemical function. They are
employed by cells for regulatory purposes because
of the fine control and high signal amplification
achievable by reversible protein phosphorylation;
evidence of their importance in cell biology can be
found throughout this volume. Our research com-
bines the techniques of X-ray crystallography and
molecular genetics to study these enzymes in detail.
Yeast cAMP-dependent
Protein Kinase
J. Kuret, A. O'Connor [in collaboration with
J.W. Pflugrath, Cold Spring Harbor Laboratory]
Our first aim is to elucidate the structural basis of
protein kinase activity, a goal that is crucial for un-
derstanding how these enzymes modulate a limited
subset of proteins. For years, this question has been
approached by chemical, enzymological, and genetic
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methods by many investigators, with each new tech-
nique surpassing its predecessor in elegance. Yet, in
the end, the problem can be solved only with a high-
resolution three-dimensional structure of a protein
kinase. Therefore, we initiated a crystallographic
study of the yeast cAMP-dependent protein kinase
(cAMPdPK) catalytic subunit (TPK1). We chose to
study this enzyme because (1) its gene has been
cloned (by Mike Wigler's Laboratory, see Molecu-
lar Genetics of Eukaryotic Cells Section), (2) mu-
tant proteins with altered catalytic properties can be
obtained using genetic screens in yeast, (3) it can be
overexpressed in a soluble form in yeast, and (4) it
retains the well-characterized structural and kinetic
features of the mammalian enzyme. Thus, the yeast
system allows us to study the structure and function
of a protein kinase using diverse techniques.
The first step in our structural approach to ki-
nase function was to simplify the primary structure
of TPK1 as much as possible while retaining its en-
zymatic properties. We reasoned that by reducing
main-chain flexibility and microheterogeneity, the
resolution obtainable from X-ray crystallography
could be maximized. Moreover, by minimizing the
mass of TPK1, we could employ a wide range of
heavy atom compounds for isomorphous replace-
ment and make nuclear magnetic resonance (NMR)
analysis of its active site practical. A similar strategy
proved valuable in the successful study of c-Ha-ras
p21 tertiary structure.
Examination of the primary structure of TPK1
reveals an amino terminus extending far beyond the
beginning of the canonical protein kinase domain
and bearing little similarity to any known kinase
structure, including TPK2 or TPK3 (two isozymes
of TPK1). Many Saccharomyces cerevisiae genes en-
code proteins far larger than their mammalian homo-
logs, including BCYJ (the cAMPdPK regulatory
subunit), without conferring any obvious functional
advantage on them. This strange organization of the
S. cerevisiae genome may result from reverse tran-
scription of yeast mRNA to cDNA, which, after in-
sertion into chromosomes by recombination, creates
genes deficient in introns and extended at their 5'
ends. Regardless of their origin, nonessential se-
quences can complicate structural studies. In the case
of TPK1, the amino-terminal 83 amino acids con-
tain five of the eight most flexible regions in the pro-
tein, as predicted by the algorithm of Karplus and
Schulz. Moreover, this same region contains the most
hydrophilic region of the protein, as predicted by the
method of Hopp and Woods, which is consistent
with it being highly solvated and flexible.
Considering that the structural features potentially
detrimental to crystallography were located in the
amino-terminal 83 amino acid residues of TPK I, that
the sequence similarity among TPK1, TPK2, and
TPK3 begins 14 residues from the first glycine of the
putative nucleotide binding loop, and that all pro-
tein kinases contain at least ten amino acids amino-
terminal to this glycine, we decided to eliminate
residues 1-80 of TPK1 and replace them with the syn-
thetic amino terminus Met-Pro-. We chose Met-Pro-
as the amino terminus for truncated TPK1 because
this sequence is a good substrate for the yeast meth-
ionyl aminopeptidase and is a poor substrate for
known posttranslational modifications. Thus, the
engineered sequence (termed TPK1A) eliminates
nearly 2007o of the mass ofTPK1, reduces main-chain
flexibility, retains homology with TPK2 and TPK3
at the amino terminus, and cannot be modified post-
translationally.
We overexpressed TPK1A in yeast, developed a
novel purification procedure that yielded enzyme of
very high purity, and characterized its biochemical
properties. As summarized in Table 1, TPK1A is very
similar to its parent in substrate affinity, maximum
velocity, and sensitivity to the protein kinase inhibi-
tor analog PKI5_24. We conclude that TPK1A re-
tains all the structural features necessary for protein
kinase activity and that determination of its three-
dimensional structure will help us to localize the
amino acid residues responsible for catalysis and sub-
strate recognition.
With highly purified and concentrated enzyme in
hand, we searched for suitable TPK1A crystalliza-
tion conditions using the hanging-drop vapor diffu-
TABLE 1 Properties of Catalytic Subunits: Yeast
TPK1 and TPK1A
Kinase
Physical properties
quarternary structure
amino acid residues
molecular mass
amino-terminal blocking group
Kinetic properties
Vmax (fimole /mg /min)
Km Kemptide (gm)
Km MgATP (4m)
K, PKI5.24 (nM)
casein phosphorylation
TPK1 TPK1A
monomer
396
46,000
13.2
101
33
280
no
monomer
318
37,300
none
11.1
83
45
125
no
sion technique combined with an incomplete fac-
torial search strategy. Remarkably, after consuming
just 1.5 mg of protein, we discovered hexagonal crys-
tals growing over a period of 2-4 days at 4°C. After
careful refinement of precipitant concentrations, we
were able to grow crystals of the same morphology
at room temperature as well (Fig. 1). These condi-
tions have consistently yielded crystals from several
separate preparations of the protein. Our best crys-
tals are obtained at this temperature by seeding, are
hexagonal dipyramids, and have the dimensions 0.5
x 0.5 x 1.5 mm. The close of the year found Jim
Pflugrath employing the data collection software
package MADNES to record the crystal's diffrac-
tion pattern and screening for suitable heavy atom
reagents required to solve the structure by the method
of isomorphous replacement.
Yeast Casein Kinase 1
J. Kuret, A. O'Connor
We are also using S. cerevisiae to study casein ki-
nase 1, a ubiquitous protein kinase in eukaryotes.
Our principal goals are to purify the enzyme from
yeast, to determine its primary structure by sequenc-
ing its gene, and to elucidate its biological function
by a combination of genetic and biochemical ap-
proaches. During the past year, we successfully pu-
rified casein kinase 1 from S. cerevisiae to near
homogeneity using classical purification procedures.
The enzyme is a monomer of 54,000 daltons in so-
lution, possesses a blocked amino terminus, is in-
hibited by heparin (IC50 = 80 ng/ml), has an isoelec-
tric point of 9.0, and has a turnover number of
approximately 4.3 when assayed with casein. Al-
FIGURE 1 Crystals of TPK1A
though these physical and kinetic features are very
similar to those of mammalian casein kinase 1, de-
finitive proof must be provided at the level of amino
acid sequence. We are in the process of isolating the
cDNA encoding casein kinase 1 from a yeast cDNA
expression library prepared in bacteriophage
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NEUROSCIENCE
Neuroscience at Cold Spring Harbor Laboratory has focused on the role of growth
factors in the differentiation and aging of neural cells. We have been bolstered this
year by the dramatic finding that the neurite extension factor, a form of the protein
S100[3, is elevated in certain cells surrounding the amyloid plaques in Alzheimer's
disease. We are also pursuing the role of this factor in Down's syndrome, a de-
velopmental neurological disease. As we look forward to the new Neuroscience
Center at Cold Spring Harbor, our studies continue to probe the fundamentals of
growth and differentiation of neurons, particularly as it pertains to human neuro-
logical diseases.
NEURONAL GROWTH AND DIFFERENTIATION
D.R. Marshak Y.S. Bae
N. Chester
J.C. Figueiredo
S. Pesce
A. Vongs
During the last 4 years, the work in our laboratory
related to neuroscience has centered on the out-
growth processes, or neurites, from embryonic
neurons in cell culture. This system serves as a model
for the development of neurons in vivo, by allowing
us to isolate and characterize a neurite extension fac-
tor. We have characterized the structure and func-
tion of the factors and have developed reagents to
permit analysis of brain tissue taken from patients
with several neurological diseases on autopsy. The
past year has revealed some spectacular findings
related to the neurite extension factor protein, S100(3,
and neurological diseases.
Role of S10013 in Alzheimer's Disease
D.R. Marshak, S. Pesce [in collaboration with W.S.T. Griffin,
University of Arkansas]
A significant segment of the population over 65 years
of age is afflicted with Alzheimer's disease (AD), a
neurodegenerative process that results in memory
loss and progressive dementia. The hallmarks of AD
neuropathology are prevalent in temporal lobe struc-
tures, such as the hippocampal formation, that have
been associated with learning and memory. These
neuropathological symptoms include an abnormal
number of neurons that contain neurofibrillary tan-
gles, extracellular plaques with f3-amyloid cores, and
reactive astrocytes. A puzzling feature of plaque
pathology is the presence of enlarged neurites en-
circling the 13-amyloid deposits. The presence of solu-
ble neurotrophic factors could give rise to inappropri-
ate growth of neurites. In support of this idea, we
have shown that the levels of a neurotrophic factor,
the protein S10013, and its encoding mRNA are
elevated in AD, but not control, brain temporal lobe.
Moreover, AD temporal lobe extracts had more
S10013-specific neurotrophic activity than similar ex-
tracts from age-matched controls. We have suggested
that elevated levels of 510013 contribute to the cellu-
lar neuropathology in AD.
Levels of S10013 in Down's Syndrome
D.R. Marshak, S. Pesce [in collaboration with P. Whitaker,
SUNY Stony Brook, and S. Kish, Toronto]
Down's syndrome (DS) is a developmental disorder
arising from extra copies of all or part of human
chromosome 21, by either trisomy, partial duplica-
tion, or translocation. In addition to mental retarda-
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FIGURE 1 Autoradiograph of protein immunoblots of AD and
control samples of temporal lobe. Samples extracted in hypo-
tonic buffer containing nonionic detergent were subjected to poly-
acrylamide gel electrophoresis, transferred to nitrocellulose filters,
and incubated with S10013 antibodies followed by radioiodinated
goat anti-rabbit immunoglobulin.
tion, DS patients that live to middle age invariably
develop a degenerative neurological disorder that is
indistinguishable from AD. This is further supported
by the findings that genes related to AD reside on
chromosome 21, although distinct from the DS
regions. Because the gene for S10013 is located on
chromosome 21 near the telomere of the long arm,
we tested samples of DS autopsy brain for S10013 lev-
els. It appears that immunoreactive levels of SlOOP
are elevated in DS early in life, reaching fivefold over
normal levels at 3 months and decreasing to normal
levels by 9 months. This correlation holds for both
frontal and parietal cortex in 21 normal and DS sam-
ples. We are trying to obtain autopsy tissue from DS
patients of various ages, including middle age, el-
derly, and fetal, to attempt to identify the critical
time of S10013 elevation in human brain development.
Molecular Cloning and
Expression
D.R. Marshak, S. Pesce, J. Figueiredo, N. Chester
Isolation of a cDNA clone for S10013 was done for
several reasons. First, cloning of the cDNA in an
Okayama-Berg vector allowed transfection in COS
cells and expression of the protein in mammalian
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cells. Second, subcloning the coding region into a
commercial vector (pBS+; Stratagene) allowed
production of a cRNA probe for slot-blot and North-
ern blot analyses of RNA from cells and tissues.
Third, the clone provides a vector for constructing
transgenic mice that overexpress the protein as
models of neurological disease. Oligonucleotides
corresponding to the 5' and 3' ends of the coding re-
gion were synthesized and used to screen a rat brain
cDNA library made in pcD2, a mammalian expres-
sion vector that utilizes the SV40 early promoter. Of
63 clones that were positive with the 3' probe, is
clones that were also positive for the 5' probe were
selected. Restriction enzyme maps and DNA sequence
analysis permitted the selection of a full-length clone
with a total insert of 1.6 kb. Transfection of COS
cells followed by labeling with [35S]methionine and
immunoprecipitation yielded a full-length protein
product comigrating on polyacrylamide gels with na-
tive S10013. Extracts of the transfected cells showed
neurite outgrowth activity, whereas extracts of mock-
transfected or untransfected cells showed no neurite
extension factor activity.
The coding region of the cDNA clone was iso-
lated as a 916-bp BamHI fragment and subcloned
into pBS+. Restriction maps of this construct indi-
cated that the insert was oriented with the 5' end of
the complementary strand under control of the T3
promoter. Synthesis of RNA probes using the T3
polymerase resulted in positive slot blots and North-
ern blots of brain RNA. Finally, transgenic mice are
being constructed to provide an animal model for
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FIGURE 2 Immunoprecipitation of S10013 expressed in COS
I cells. Cells were transfected with 5 4g or 20 i.g plasmid (as
indicated) or with salmon sperm DNA (Mock). The cells were
labeled and extracted as described in the text. The extracts were
subjected to polyacrylamide gel electrophoresis and autoradi-
ography. Arrow shows the position of migration of S10013.
Down's syndrome. We are also investigating trisomy
ten mice (with C. Epstein, UCSF) that have an extra
copy of the S10013 gene and severe neurological
defects. The cDNA probe has also been used in col-
laboration with K. Gardiner of the Eleanor Roosevelt
Institute in Denver to confirm the localization of the
gene and continue fine-structure mapping of chro-
mosome 21. Present experiments revolve around the
construction of expression plasmids that utilize
tissue-specific promoters for specific populations of
cells in the brain.
Role of sloop In Vivo
Marshak, S. Pesce [in collaboration with E. Azmitia,
New York University, and P. Whitaker, SUNY Stony Brook]
We have begun to examine the role of 510013 in vivo
using the rat model system. The findings of Drs.
Hippocampus
IIIIII
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Medial Raphe'
Whitaker and Azmitia indicate that serotonergic neu-
rons of the brain stem that innervate the hippocam-
pus appear to respond to S10013 as a neurotrophic
factor. Combined with our findings of increased
S10013 in temporal lobe areas including the hippo-
campus, this suggests that S10013 may play a key role
in the normal development of contacts between
serotonergic neurons of the Raphe nuclei and neu-
rons of the hippocampus. Abnormal levels of S10013
either during development (as in Down's syndrome)
or in aging (as in Alzheimer's disease) may lead
to errors or lesions in these connections. We have
demonstrated that serotonergic agonists can specif-
ically release S10013 from glial cells that surround the
neurons of the hippocampus, indicating that the neu-
rotransmitter compound itself might regulate the re-
lease of the neurotrophic factor in the developing
brain. Further studies indicate that chemical lesion
of the connections between the brain stem and the
hippocampus results in up-regulation of serotonin
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FIGURE 3 Working model of neurite factor (NEF) action in the developing nervous system. In each panel, the triangles represent
developing serotonergic neurons of the Raphe nuclei, the squares represent target neurons in the hippocampus, and circles repre-
sent astroglial cells. When astrocytes of the Raphe proliferate, they release NEF ("), which induces neurite outgrowth from the serotonergic
neurons. These cells grow axons that innervate the hippocampus and release serotonin (5-HT). The serotonin induces NEF from
hippocampal glia, which in turn promotes continued outgrowth of axonal processes. The final result is a mature serotonergic innerva-
tion of the hippocampus.
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receptors and sensitivity to S10013 release by sero-
tonergic agonists. Injection of radiolabeled 510013
into the hippocampus indicates that much of the
S10013 released is associated with hippocampal neu-
rons. Further studies are in progress to map the path-
ways and pharmacology of S10013 action in vivo,
which may reveal some of the characteristics of510013
function in normal brains and in diseased states.
Structural Analysis of Neurite
Extension Factor
D.R. Marshak [in collaboration with J. Pflugrath,
Cold Spring Harbor Laboratory]
Previously, sequence analysis and gel electrophore-
sis indicated that neurite extension factor (NEF) con-
sisted of a disulfide form of the protein slow. Sub-
sequent analysis of various preparations of NEF
suggested that the active species was a disulfide dimer
of two identical subunits. In further experiments,
monomer and dimer species have been identified on
immunoblots of brain extracts of humans and in an-
imal models, including rat, chicken, and cow, indi-
cating that the dimer is present in vivo. Separation
of monomer and dimer species has been accom-
plished by high-performance electrophoresis chro-
matography on polyacrylamide gels and by HPLC
gel-filtration chromatography in the presence of
acetonitrile at either pH 6.0 phosphate buffer or
0.1% (w/v) trifluoroacetic acid. In all cases, the di-
meric form appears to be the active species. How-
ever, concentration of the protein under acidic con-
ditions gives rise to polymers, which can be reduced
by treatment with 2-mercaptoethanol. Analysis of
the protein by plasma desorption mass spectrome-
try gave a subunit molecular weight of 10,553, con-
sistent with an acetylated amino terminus, and no
other covalent modifications. Therefore, the present
evidence points to a disulfide dimer as the active
species.
Further analyses of the three-dimensional struc-
ture of the 510013 monomer and dimer are being ac-
complished by solving the X-ray crystal structure.
In collaboration with J. Pflugrath at Cold Spring
Harbor Laboratory, we are attempting to grow crys-
tals of 510013 suitable for X-ray analysis. We have
also succeeded in synthesizing the protein chemically
using solid-phase methods on an automated instru-
ment. The protein has 91 amino acids and took ap-
proximately 4 weeks to synthesize after several ini-
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tial failures. Purification and characterization of the
product are now under way. We would like to com-
pare the three-dimensional structures of the native,
synthetic, and dimerized forms of 510013.
Regulation of Brain Protein
Kinases
Y.S. Bae, D.R. Marshak
The action of growth factors in the nervous system
has been implicated in the onset of symptoms of
neurological disease, such as Alzheimer's disease. We
have begun to study the regulation of the signal
transduction systems that are stimulated by growth
factors in the brain. In particular, we have purified
casein kinase II (CK-II) from bovine brain to ex-
amine the stimulation and repression of the activi-
ty. Brain CK-II appears to have an endogenous
inhibitor as well as compounds that can activate the
enzyme. Our current research focuses on the isola-
tion and characterization of molecules that regulate
this kinase. CK-II is important to transcriptional
control, and it is possible that alterations in CK-II
levels or activity are associated with degeneration
of neurons.
TABLE 1 Mass Spectrometric Analysis of Bovine
Pancreatic Thread Protein (PTP)
Observed Calculated Difference
Protein M/Z M/Z ( %)
Unmodified intact
PTP
[M+H]+ 15,036.11 15,035.96 0.001
[M + 2H]2+ 7,519.99 7,518.49 0.020
[M +3H]3+ 5,013.30 5,012.66 0.013
Unmodified A
chain
[M+H]+ 11,073.13 11,073.39 0.002
[M+2H]2+ 5,537.04 5,53720 0.003
Unmodified B
chain
[M+H]+ 3,973.07 3,969.63 0.087
Pyridylethylated
A chain
[M+H]+ 11,390.35 11,388.81 0.014
[M + 2H]2+ 5,694.72 5,694.91 0.003
Pyridylethylated
B chain
[M+H]+ 4,286.40 4,285.05 0.032
[M + 2H]2+ 2,144.03 2,143.03 0.047
Structural Analysis of Pancreatic
Thread Protein
D.R. Marshak [in collaboration with J. Crabb,
W. Alton Jones Cell Science Center, and J. Gross,
Massachusetts General Hospital]
The pancreatic thread protein (PTP) is a macro-
molecule that forms helical structures that can be
identified under electron microscopy and is a com-
ponent of insoluble occlusions found in the pan-
creas. Interestingly, monoclonal antibodies against
the protein identify the same protein in brain lesions
found in Alzheimer's disease. The protein was iso-
lated from bovine pancreas and was found to con-
sist of two disulfide-bonded chains. Plasma desorp-
tion mass spectrometry allowed us to measure the
molecular weight of the intact protein, as well as the
separate A and B chains. Upon reduction and alky-
lation of the protein with 4-vinylpyridine, each chain
was found to have three cysteinyl residues by mea-
suring the increase in mass due to the chemical
modification. Further analysis of proteolytic frag-
ments of the unreduced protein allowed us to as-
sign the complete disulfide bonding pattern. This
is another example of the utility of mass spectrom-
etry in conjunction with classic methods of protein
chemistry in the analysis of proteins involved in neu-
rological disease.
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CSH LABORATORY JUNIOR FELLOWS
In 1986, Cold Spring Harbor Laboratory began a new program to encourage inde-
pendent research by outstanding young scientists who, during their graduate
studies, displayed exceptional promise of becoming leading scientists of the future.
The purpose of this program is to provide an opportunity for one fellow each year
to work independently at the Laboratory for a period of up to 3 years on projects
of their choice. Each fellow is provided with a salary, research support, and techni-
cal assistance so that they can accomplish their goals free from other distractions.
The interaction among research groups at the Laboratory and the program of
courses and meetings on diverse topics in molecular biology contribute to a re-
search environment that is ideal for innovative science by these fellows.
The first Cold Spring Harbor Fellow (1987) was Adrian Krainer, a former gradu-
ate student with Tom Maniatis at Harvard University. The 1988 Fellow was Carol
Greider from Elizabeth Blackburn's laboratory at the University of California, Berke-
ley. The 1989 Fellowship was awarded to Eric Richards from Fred Ausubel's labo-
ratory at the Massachusetts General Hospital. Dr. Richards joined the Laboratory
during the summer of 1989 and is studying the molecular biology of the centro-
meres and telomeres of Arabidopsis.
C.W. Greider
E.J. Richards
Telomerase: The Long and
the Short of It
C.W. Greider, L.A. Harrington, S. Kaplan
TELOMERASE BIOCHEMISTRY AND REACTION
MECHANISM
Telomerase is an RNA-containing enzyme that synthe-
sizes repeats of the telomeric sequence d(TTGGGG),
onto the ends of chromosomes. This enzyme may
be involved with both normal telomere replication
and healing of broken chromosomes. Without a
mechanism to elongate telomeres, one would pre-
dict that chromosomes might shorten from their ends
due to the inability of DNA polymerases to repli-
cate completely both strands at the end of a DNA
molecule. Thus, telomeres, in conjunction with
telomerase, serve to replicate and protect chromo-
some ends. We are interested in both the biochemis-
try of telomerase and the biology of telomere repli-
cation in vivo.
The telomerase enzyme is a unique kind of DNA
polymerase; it contains an essential RNA compo-
nent that provides a template for the d(TTGGGG),
repeats which the enzyme synthesizes. Last year, we
cloned and sequenced the Tel telomerase
RNA component and showed that it contained the
sequence 5'-CAACCCCAA-3'. The presence of one
and a half repeats of the sequence CCCCAA sug-
gested that d(TTGGGG), sequence primers could
be stably bound, elongated, translocated, and then
further elongated in a processive manner as shown
in Figure 1A. However, an alternative is that telomer-
ase may add a single repeat, dissociate from the
primer, and then rebind for a further round of
d(TTGGGG) addition (Fig. 1B). To distinguish be-
tween the processive and distributive mechanisms,
we carried out primer challenge experiments. Telo-
merase was reacted in the presence of excess primer
under standard reaction conditions (1 I.tm [32P)-
dGTP, 100 Jim dTTP, 1 mm Mg", 10 mm Tris at pH
8.0) for 2 minutes, and the reaction was then diluted
30-fold into two different reaction mixtures. The first
mixture contained unlabeled dGTP, 100 [tm dTTP,
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FIGURE 1 (A) Processive model for elongation of telomeres by telomerase. The Tetrahymena telomere is shown containing an
overhang on the d(TTGGGG), strand. After recognition of the d(TTGGGG), strand by telomerase, the 3'-most nucleotides are hy-
bridized to the CAACCCCAA sequence in the RNA (1). The sequence TTG is then added one nucleotide at a time (2). Translocation
then repositions the 3' end of the TTGGGG strand such that the 3'-most TTG nucleotides are hybridized to the RNA component
of telomerase (3). Elongation occurs again, copying the template sequence to complete the TTGGGGTTG sequence (4). (8) Distribu-
tive model for elongation of telomeres by telomerase. This model is similar to that described in A, except that instead of the transloca-
tion step, the enzyme dissociates from the telomere (3) and must reassociate (4) for a further round of d(TTGGGG), addition.
and a large excess of primer d(TTGGGG)4 oligonu-
cleotide. The second mixture contained unlabeled
dGTP, 100 um dTTP, and no primer oligonucleo-
tide. The reactions were then allowed to proceed for
3, 4, or 10 minutes (Fig. 2). The labeled products
increased in size, even after dilution into excess
primer oligonucleotide, suggesting that the telomer-
ase reaction is processive.
Another interpretation for the results seen in Fig-
ure 2 is that the telomerase preferentially elongates
long products over short ones. To test this, we mixed
d(TTGGGG)8 with d(GGGGTT)3 and showed that
even at a molar ratio of 1:0.3, the shorter oligonu-
cleotide was the preferred substrate. Kinetic analy-
sis confirmed these results. d(TTGGGG)8 has a Km
of 22 nm, and d(TTGGGG)4 has a Km of 2 nm. From
these experiments, we conclude that d(TTGGGG)
repeat synthesis by telomerase is processive.
The telomerase reaction produces a characteris-
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tic 6-bp ladder of products (see Fig. 2). Careful ex-
amination of the pattern of these products showed
that there is a strong pause after the addition of
the second dT and the first dG in the sequence
d(TTGGGG). The pause at the first dG residue is
consistent with the model proposed in Figure 1A,
in which elongation proceeds to the end of the tem-
plate and then a translocation step occurs after the
addition of the first dG residue. These data suggest
that the entire CAACCCCAA template is used by
telomerase.
We are actively pursuing purification of the telo-
merase enzyme with the aim of identifying the (as
yet still elusive) protein components and of obtain-
ing very pure enzyme for further biochemical dis-
section of the enzyme mechanism. Theexperiments
described above were done using enzyme purified
over two columns, with a purification of about
40-60-fold. Since it's initial identification, telomer-
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FIGURE 2 The telomerase reaction is processive. Telomerase
was reacted for 2 min in the presence of 1 pm [32P]dGTP, 100
pM dTTP, and 3000 nM d(TTGGGG)4; 30 41 of this reaction was
diluted into 900 41 of either 1 pm cold dGTP, 100 pM dTTP, 2700
nM d(TTGGGG)4 (lanes labeled diluted + (T2G4)4) or 1 pm cold
dGTP, and 100 pM dTTP (lanes labeled diluted without (T2G4)4).
The reactions were then stopped after 3, 4, or 10 min total reac-
tion time and run on a sequencing gel. As controls, the undiluted
reaction was also stopped at either 2 or 10 min total reaction time.
ase has proven to be extremely labile, making purifi-
cation over more than two columns very difficult.
We are taking both conventional and affinity ap-
proaches to purification and hope to soon have
highly purified enzyme for structural and functional
analysis.
TETRAHYMENA TELOMERASE RNA EXPRESSION
IN YEAST
In addition to telomerase biochemistry, we are pur-
suing several aspects of telomere biology in vivo. One
approach is to express the Tetrahymena telomerase
RNA component in the yeast Saccharomyces cere-
visiae. Identification of the RNA component of a
yeast telomerase through direct hybridization has not
been possible. This is not unexpected since the se-
quence of the telomerase RNA from the ciliate Eu-
plotes crassus does not cross-hybridize with Tetra-
hymena RNA, although the RNA can fold into a
structure similar to that of the Tetrahymena RNA (D.
Shippen-Lentz and E.H. Blackburn, pers. comm.). To
express the Tetrahymena RNA in yeast, the gene was
cloned directly behind the bacteriophage T7 pro-
moter. This construct allows the bacteriophage T7
polymerase to produce a transcript identical in se-
quence to the RNA found in Tetrahymena. This T7
construct was transformed into a yeast strain that
contains the T7 RNA polymerase gene cloned be-
hind the yeast GAL10 promoter (a gift from Rolf
Sternglanz). When these yeast are grown on galac-
tose, the T7 RNA polymerase is induced and the
telomerase RNA is transcribed. The telomerase RNA
is stable in yeast as it can be visualized by Northern
analysis of total yeast RNA.
We are examining the chromosomal telomeres in
the yeast cells expressing the telomerase RNA. If the
Tetrahymena RNA competes with the putative yeast
telomerase RNA, telomeres might become shorter.
If the Tetrahymena RNA substitutes for the yeast
RNA, Tetrahymena telomeric d(TTGGGG), repeats
might be incorporated into the yeast telomeres. These
possibilities are being examined by Southern blots
and by cloning and sequencing yeast telomeres.
TELOMERES SHORTEN DURING MAMMALIAN AGING
As a second approach to in vivo telomere biology,
we have recently begun a collaboration with Drs. B.
Futcher and C. Harley to examine the behavior of
human telomeres with aging. This study is rooted
in the observations of Hayflick (Exp. Cell Res.
25: 585 [1961]) that primary (i.e., nontransformed)
fibroblasts can go through only a limited number
of doublings in vitro. Fibroblasts taken from a young
donor can go through about 90 doublings, whereas
those from an old donor go through many fewer dou-
blings before senescence. Similar observations were
made for other cell types and other species. The rea-
son for the limit on the number of cell divisions is
unknown.
In 1973, before the structure of telomeres was
known, Olovnikov proposed that chromosome short-
ening due to incomplete telomere replication might
limit the number of divisions a cell can go through
(J. Theor. Biol. 41: 181 [1973]). Recently, Cooke and
Smith (Cold Spring Harbor Symp. Quant. Biol. 51: 213
[1986]) observed that human sperm telomeres are
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about 15 kb long, whereas telomeres from other so-
matic tissues are only about 10 kb long. This obser-
vation, in conjunction with the proposal by Olov-
nikov, suggested that human telomeres are elongated
only in the germ line and that these telomeres are
then gradually shortened during vegetative growth.
Loss of telomeres may be a direct cause of cellular
senescence.
To examine this theory, we passaged primary fi-
broblasts from different aged donors and examined
telomere length after increasing the number of dou-
blings in vitro. We found that mean telomere length
decreases by about 30 by per generation, that the
distribution of telomere lengths becomes broader,
and that the total hybridization signal to the telo-
meric probes decreased as cells aged (Figs. 3 and 4).
We also found that telomere lengths at early passage
correlated with the age of the donor; older donors
Probe:
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had shorter telomeres. These observations are con-
sistent with sequences being lost from the chromo-
some ends with each round of replication and telo-
mere lengthening occurring in the germ line.
To follow up the observations on telomere length
and aging, we plan to look at the lengths of telo-
meres in a number of different tissues from individ-
uals of different ages, as well as from individuals who
have specific aging diseases, such as progeria and
Werner's Syndrome. Since mouse telomeres have the
same sequence as humans, we can further test the
correlation of aging with telomere length in animal
models. In addition, the recent identification of
telomerase activity in HeLa cells allows us to look
directly at whether telomerase activity is restricted
to the germ line in mammalian cells. Thus, we hope
to directly test whether telomere shortening is a cause
or an effect of aging in mammals.
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FIGURE 3 Primary fetal lung fibroblasts (HSC172) were passaged until senescence occurred (88 Mean
Population Doublings, "MPD 88"). The DNA from these cells was digested with Mspl and Rsal, run on
a 0.7% agarose gel, and blotted to Nytran. (A) The blot was probed with the human telomeric probe
d(TTAGGG)3. (8) As a control, the same blot was stripped and reprobed at low stringency with d(TTGGGG)4
to identify internal repetitive DNA bands (indicated by an l).
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FIGURE 4 Mean telomere length (A) and total telomeric DNA
(B) were determined by scanning Southern blots similar to those
shown in Fig. 3. Mean telomere length is plotted as a function
of in vitro age for three cell lines. HSC172 (El) is a fetal fibroblast
cell line, and F001 (A) and F002 (0) are two primary fibroblast
lines established from old individuals (70 and 90 years).
Characterization of Centromeric
DNA from Arabidopsis thaliana
E.J. Richards, David Fessell
Centromeres are the chromosomal regions respon-
sible for the proper partitioning of the chromosomes
during mitosis and meiosis. One component of the
centromere is the kinetochore, a complex nucleopro-
tein structure that attaches to the spindle microtu-
bules and drives chromosome movement. In addi-
tion, control of sister-chromatid separation is exerted
at the centromere, resulting in sister-chromatid sepa-
ration at anaphase in mitosis and meiosis II and
sister-chromatid nondisjunction at meiotic anaphase I.
I am interested in identifying and characterizing
the DNA sequences required for centromere func-
tion as a first step toward understanding how cen-
tromeres work. At present, functional centromeric
DNA sequences have been identified in only two sys-
tems, Saccharomyces cerevisiae and Schizosaccharo-
myces pombe. The picture that emerges from cen-
tromere studies in the yeasts is rather confusing; the
budding yeast centromeres are quite small (120 bp)
and do not resemble the large (50-100 kb) arrays of
repetitive DNAs that make up S. pombe centromere
regions. Although it is generally thought that the
S. pombe centromeres may provide a simple model
for the larger, more structurally complex centromeres
of higher eukaryotes, I have decided to begin charac-
terizing a higher eukaryotic centromere directly.
I have chosen to work on the flowering plant,
Arabidopsis thaliana, for several reasons. The
streamlined genome of this plant, with only 70
Mbp/n and a low repeated DNA content, facilitates
chromosome walking and physical mapping efforts.
In addition, A. thaliana is a good genetic system,
and this attribute has been exploited to construct
restriction-fragment-length polymorphism (RFLP)
maps, providing molecular landmarks sprinkled
throughout the genome. The availability of viable
aneuploid mutants and strains carrying chromo-
somal rearrangements is particularly useful for mo-
lecular chromosome studies.
CENTROMERE 1: CHROMOSOMAL WALKING AND
PHYSICAL MAPPING
I am presently trying to characterize and isolate an
A. thaliana centromere using a combination of phys-
ical mapping and chromosome walking techniques.
The approach is similar to that first used to isolate
yeast centromeres: begin with molecular markers that
flank a centromere and walk across the gap. The cen-
tromere of A. thaliana chromosome 1 is the best tar-
get, since it is the most precisely mapped, and sev-
eral genetic and RFLP markers are closely linked
to this centromere. Included among these RFLP
markers is an AT-rich moderately repetitive element
I previously identified as residing adjacent to an ar-
ray of highly reiterated telomere-similar repeats. The
challenge now is to put together a fine-structure
genetic and physical map of the region to delimit the
centromere. Toward this end, I am setting up crosses
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using aneuploid strains in order to isolate chromo-
somes with crossover between centromere 1 and
neighboring morphological and RFLP markers. The
results of these experiments will establish a more pre-
cise genetic map position for centromere 1 and or-
der flanking markers. These markers can then be
used to construct large-scale restriction maps of the
region, providing a location of the centromere in
physical terms.
While the mapping project is under way, I have
begun a chromosomal walk in the region. Using the
centromere-l-linked moderately repeated element as
a low-copy-number probe, I have isolated several
YAC clones from a library constructed in C. Som-
merville's laboratory (Michigan State University).
The clones are currently being analyzed to determine
if they are derived from centromere 1.
USING TELOCENTRIC CHROMOSOMES TO ISOLATE
CENTROMERIC SEQUENCES
Several A. thaliana aneuploid strains have been iso-
lated that contain telocentric chromosome deriva-
tives, in addition to the normal diploid complement
of ten metacentric chromosomes (i.e., telotrisomic
mutants). The telocentric chromosomes were recov-
ered after fracture through the centromere and con-
sequently should contain a new, "healed" telomere
close to the centromere. Using telomeric probes, it
should be possible to identify and isolate the healed
telomeres with large regions of flanking sequence
stepping into the centromere. In essence, this is an-
other version of the chromosome walk just de-
scribed, except in this case, the starting point is a
telomere, rather than flanking RFLP marker.
Because of the potentially large size of the cen-
tromere and the uncertain molecular distance be-
tween the healed telomeres and their "adjacent" cen-
tromeres, a YAC cloning system is being used to
isolate large inserts. I have recently shown that cloned
A. thaliana telomeres can serve as telomeres in S. cere-
visiae, demonstrating the feasibility of isolating large
telomeric restriction fragments directly by selection
for telomere function in yeast.
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54th COLD SPRING HARBOR SYMPOSIUM
ON QUANTITATIVE BIOLOGY
Immunological Recognition
May 31-June 7, 1989
ARRANGED BY
James D. Watson, Cold Spring Harbor Laboratory
John R. Inglis, Cold Spring Harbor Laboratory
446 participants
The stark necessity of healthy immune function has been thrust into public
consciousness in the 1980s by the tragedy of AIDS. The consequences of
immune function gone awry can also be seen in such treatable but still incurable
disorders as rheumatoid arthritis, multiple sclerosis, diabetes, and the myriad
forms of allergy. To understand immune responses, and thus their malfunction,
requires knowledge of the genetics of lymphocytes, the complexity of the signals
they deliver and respond to at the cell surface, and the extraordinary assortment
of responses they make when stimulated.
Research in the 1980s cut through to the molecular basis of these events.
Antigen receptor molecules from T cells were identified and found to be encoded
in a unique set of rearranging gene segments, separate from but evolutionarily
related to the immunoglobulin genes. The analysis of other cell-surface molecules
revealed diversity among T cells that correlated with differences in function.
Crucially, it was observed that the products of MHC loci could bind peptide
fragments of antigen and deliver them to the surface of antigen-presenting cells. A
structural basis for T-cell antigen recognition became apparent when the solution
of the crystal structure of the class I histocompatibility molecule HLA-A2 showed
L. Annenberg Hazen, G. Nossal, J.D. Watson
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that it had a groove in which both peptide and the variable T-cell receptor might
bind. X-ray crystallography also clarified the
interaction between an antibody and
its ligand, with the solution of the structure of an immune complex.
By 1989, therefore, the time was clearly ripe for a Cold Spring Harbor
Symposium focusing on the molecular, cellular, and structural aspects of
immunological recognition. The theme of the meeting centered on the interactions
among MHC molecules, peptides, and antigen receptors that trigger T-cell
activation, but sessions were devoted to the shaping of T-cell and B-cell
repertoires by these events and their consequences for lymphocyte activation,
tolerance, and autoimmune responses.
The final program included 114 speakers and 446 participants. Every available
seat in Grace Auditorium was occupied throughout the week, and the aisles were
filled. The meeting opened with splendid presentations by Leroy Hood, Philippa
Marrack, Don Wiley, Emil Unanue, and Hugh McDevitt, whose talks highlighted
the themes of the coming week. Then came 14 sessions of great intensity and an
elegant and wide-ranging summary by Jonathan Howard.
The meeting was supported in part by the National Cancer Institute and
National Institute of Allergy and Infectious Diseases; the National Science
Foundation; the U.S. Department of Energy, and the Lucille P. Markey Charitable
Trust.
PROGRAM
Opening Remarks
J. D. Watson
T-cell Development
Chairman: S. Tonegawa, Massachusetts Institute of Technology
B-cell Development
Chairman: T. Honjo, Kyoto University
Interactions between T-cell Receptors, Antigen, and MHC Molecules. I
Chairman: B. Benacerraf, Dana-Farber Cancer Institute
Self-recognition by B Cells and Antibodies
Chairman: F Melchers, Basel Institute for Immunology
Lymphocyte Activation. I
Chairman: R. Klausner, National Institutes of Health
Recognition by Antibodies
Chairman: D. Davies, National Institutes of Health
Antigen Processing
Chairman: H. Eisen, Massachusetts Institute of Technology
Histocompatibility Antigens
Chairman: W. Bodmer, Imperial Cancer Research Fund Laboratories
Tolerance in T Cells
Chairman: J. Miller, Walter and Eliza Hall Institute of Medical Research
Interactions between T-cell Receptors, Antigen, and MHC Molecules. II
Chairman: R. Zinkernagel, University of Zurich
Lymphocyte Activation. II
Chairman: N. Mitchison, University College
Selection of T-cell Receptors
Chairman: P Kourilsky, Institut Pasteur
Interactions between T-cell Receptors, Antigen, and MHC Molecules. III
Chairman: M. Gefter, Massachusetts Institute of Technology
Summary: J. Howard, AFRC, Institute of Animal Physiology
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MEETINGS
Genome Mapping and Sequencing
April 26-April 30, 1989
ARRANGED BY
Charles Cantor, Columbia University College of Physicians & Surgeons
Maynard Olson, Washington University School of Medicine
Richard Roberts, Cold Spring Harbor Laboratory
252 participants
This year's meeting on Genome Mapping and Sequencing was the second in
what is likely to be a continuing series. The meeting emphasized current
techniques in use for genome mapping and sequencing and highlighted some of
the systems in which great progress is being made. The importance of small
technical breakthroughs was exemplified by studies of telomeres. In 1988, a single
presentation, included at the last minute, described the cloning of a stretch of
DNA that hybridizes to all human telomeres. At this year's meeting, a whole
session needed to be devoted to telomeres. Among the many ongoing mapping
endeavors, several groups reported good progress in the hunt for specific human
disease genes, including the much sought after cystic fibrosis gene. On the
technical front, spectacular progress was announced in the use of confocal
microscopy to map genes directly onto chromosomes. The final session of the
meeting was devoted to computation and served to illustrate the important role
that computer science will play within genome research.
PROGRAM
Genome Organization
Chairman: V. McKusick, Johns Hopkins University
Telomeres
Chairman: C. Cantor, Columbia University College of Physicians & Surgeons
Polymorphism
Chairman: W. Bodmer, ICRE London
Mapping Techniques. I
Chairman: M. Olson, Washington University School of Medicine
Mapping Techniques, II
Chairman: S. Brenner, MRC Laboratory, Cambridge
Mapping Experience
Chairman: D. Cohen, CEPH, Paris
Sequencing
Chairman: E. Soeda, Riken Institute
Computation
Chairman: D. Lipman, National Library of Medicine
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Regulation of Liver Gene Expression
May 7-May 11, 1989
ARRANGED BY
Gerald Crabtree, Stanford University
George Fey, Research Institute of Scripps Clinic
Shirley Tilghman, Princeton University
265 participants
The second meeting of this series was
attended by more than 250 participants,
including speakers presenting exemplary work from
other areas of gene
regulation, such as Drosophila and yeast. The focus
of the meeting was on
mechanisms of gene regulation. Highlights included the
characterization and
cloning of hepatocyte nuclear factor 1 (HNF1), a key factor determining
hepatocyte-specific transcription of albumin, fibrinogen,
and other liver marker
genes. With the description of the cloning of
CBP and DBP and the purification of
HNF3 and HNF4, other factors determining liver-specific
transcription, significant
progress was reported toward the solution of a
key problem in this field: How can
interactions among factors that each may not be restricted to one cell type
generate cell-type-specific transcription? Novel types of
control elements in the far-
upstream region of the albumin gene were discovered that allowed the expression
of this gene in hepatic cells only when the cells were cultured in special media
and on a collagen matrix. This result demonstrates the existence of control
mechanisms that signal the contact of cells with the extracellular matrix to the
nucleus and activate the expression of specific genes. Along with bone marrow
cells, the liver has emerged as the target of choice for the correction of gene
defects. Several examples were presented for phenotypic corrections of defects in
genes that are primarily expressed in the liver. These included correction of the
M. Hattori, S. Humphries, G. Fey
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spf mutation by expression of a correct human gene in transgenic mutant mice
and the correction of a hereditary deficiency of LDL receptors in Watanabe
rabbits. In this case, the correct wild-type gene was introduced with retroviral
vectors into cultured Watanabe rabbit hepatocytes. Attempts to reintroduce
corrected cells into animals were described, including injection into the portal vein
and homing in the liver, as well as growth of hepatic cells on cytodex beads and
reimplantation of these grafts at extrahepatic sites. Important progress was
described in improving long-term acceptance of liver cell allografts in rats.
Recent work was presented on myo D, a master gene capable of converting
fibroblasts to muscle cells, and on the search for corresponding genes determin-
ing the hepatic phenotype by somatic cell genetics. Another highlight of the
meeting was the announcement of the purification and cloning of HGF, a novel
hepatocyte growth factor. Important progress was reported in the identification of
characteristic markers for hepatic precursor cells, mature hepatocytes, and biliary
epithelial cells. With the help of these markers, it was possible to follow the
differentiation from embryonal progenitor cells in culture to both hepatocytes and
biliary epithelial cells, and to study the influence of growth- and differentiation-
promoting agents on this process.
The liver is increasingly appreciated as an excellent experimental system for the
study of gene regulation. It offers the logistic feasibility of analyzing both the
transcriptional machinery at the biochemical level and a number of unique biologi-
cal processes involving gene regulation, such as regeneration and hepatocellular
carcinogenesis. The participants thanked the host laboratory and its meetings staff
for their excellent work and expressed their hopes that this series of meetings will
be continued at Cold Spring Harbor.
PROGRAM
Transcription. I
Chairman: G. Crabtree, Stanford University
Hormonal Modulation of Gene Expression
Chairman: G. Schutz, German Cancer Research Center
Transcription. II
Chairman: M. Yaniv, Institut Pasteur
Regulation of Liver Acute-Phase Genes
Chairmen: H. Baumann, Roswell Park Memorial Institute
G. Fey, Scripps Clinic and Research Foundation
Developmental Regulation
Chairman: S. Tilghman, Princeton University
Somatic Cell Genetics
Chairman: K. Fournier, Fred Hutchinson Cancer Research Institute
Liver Genes and Disease
Chairman: S.L.C. Woo, Baylor College of Medicine
Growth Regulation and Regeneration of Liver Cells
Chairman: B. Knowles, The Wistar Institute
Requirement for Hepatic Differentiation in Cultured Cells
Chairman: H. Isom, Pennsylvania State University College of Medicine
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C. elegans
May 10-May 14, 1989
ARRANGED BY
Scott Emmons, Albert Einstein College of Medicine
Jonathan Hodgkin, MRC Laboratory of Molecular Biology
Judith Kimble, University of Wisconsin
James McGhee, University of Calgary
385 participants
Attendance at this year's C. elegans meeting was almost 30% higher than two
years ago, reflecting the continuing growth and excitement in the field. Much
research on C. elegans has focused on a description of the organism. This
information sets the stage for genetic and molecular analyses of many important
problems in biology.
Analysis of genes identified by mutations continues to be a central approach of
C. elegans research. Most of the genes governing the sex of the animal have
been identified, and molecular studies of their products are well under way. A
likely candidate for the X-chromosome-specific sequence whose dosage
determines sex has been identified. Genes have been described that are required
for specification of fates of early embryonic blastomeres, determination of position
and polarity within the body, control of programmed cell death, development of
the vulva in the hermaphrodite and copulatory structures in the male, timing of
events during development, and many other functions. From analysis of cloned
genes, it has plays in determination of
position and direction in the body. Other developmental control genes have
similarity to growth factors and homeobox genes of higher organisms. Powerful
Wine and cheese
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transformation methods are now available for analysis of gene function. Sequences
have been identified that direct expression of the myosin-heavy-chain gene to
specific muscle tissues. Future work will address the question of how expression of
key genes is regulated in the genetic program whose outcome is the nematode
worm.
PROGRAM
Sex Determination and Dosage Compensation
Chairman: V. Ambros, Harvard University
Cell Biology
Chairman: J. Thomas, University of Washington
Developmental Pathways and Control Genes
Chairman: A. Fire, Carnegie Institution of Washington
Cell Fate and Differentiation
Chairman: P Meneely, Fred Hutchinson Cancer Research Center
Nervous System
Chairman: D. Moerman, University of British Columbia
Genome Organization and Gene Expression
Chairman: J. Shaw, University of Minnesota
Embryogenesis and Positional Information
Chairman: E. Schierenberg, University of Cologne
RNA Processing
May 17-May 21, 1989
ARRANGED BY
Michael Green, Harvard University
Anita Hopper, Hershey Medical Center, Pennsylvania State University
Norman Pace, Indiana University
448 participants
RNA processing encompasses the cellular mechanisms that convert primary
transcripts into functional RNAs and degrade RNAs not destined for further use
by
the cell. The large attendance at the 1989 RNA Processing meeting
testifies to the
rapid growth of the field and to the recognition that RNA processing affects many
areas of cellular function. The five-day meeting included eight
sessions of short
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presentations, three poster sessions, and a concluding session of four review
lectures of broad interest. Diverse topics were discussed,
ranging in detail from
the atom to the organism level.
A recurring theme of the meeting was the analysis of the molecular structure
involved in RNA processing. For example, local RNA structure determines catalytic
activities and substrate sites; long-range folding of large RNAs aligns splicing sites
and can determine developmentally controlled, alternative splicing pathways. RNA
processing often requires the assembly of macromolecular complexes, commonly
composed of stable RNAs and discrete proteins. Increasing success was reported
in dissecting the constituents of such complexes, for instance those involved in
splicing or polyadenylation, and in reconstituting them in vitro. The involvement of
RNA processing in regulatory mechanisms in several systems was discussed. Sex
determination in Drosophila, for instance, is dependent in part on alternative
mRNA processing.
The range of cellular events that rely on RNA or RNA processing continues to
expand. Recently discovered examples discussed at the meeting included the
service of RNA as a template for telomere formation in ciliates and probably
humans, and "editing," the alteration of mRNA sequences that occurs in many
organisms by modification, excision, or addition of nucleotides. Particularly,
J. Dahlberg, J. Cuddihy, R. Krug
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extensive additions to and excisions from some mRNAs in trypanosome mitochon-
dria question the source of sequence information for the editing process. Putative
templates remain unidentified, however.
The annual RNA Processing meeting is an important forum for communications
of recent results and methods. The large size of the 1989 meeting, and the fact
that many applicants could not be accommodated, prompted suggestions for finer
focus of future meetings, for example, on splicing phenomena or catalytic RNAs.
However, the consensus of participants at the 1989 RNA Processing meeting
seemed to be that the eclectic coverage provided by the current format is of
overriding value in this rapidly advancing field.
The meeting was supported in part by the National Science Foundation and
the National Institutes of Health (National Institute of General Medical Sciences).
PROGRAM
Catalytic RNA
Chairman: J. Szostak, Massachusetts General Hospital
Splicing: Specificity, Regulation, and Pathways
Chairman: J. Beggs, University of Edinburgh
snRNPs: Formation and Function
Chairman: J. Steitz, Yale University
Splicing: Factors and Spliceosome Assembly
Chairman: J. Abelson, California Institute of Technology
3' ENDS, hnRNPs, and Export
Chairman: T. Platt, University of Rochester Medical Center
Stable RNAs
Chairman: J. Dahlberg, University of Wisconsin
Regulation and Turnover
Chairman: B. Baker, Stanford University
Special Topics Reviews
Chairman: W. Keller, Biocenter of the University of Basel
RNA Tumor Viruses
May 24-May 28, 1989
ARRANGED BY
Hung Fan, University of California, Irvine
Eric Hunter, University of Alabama, Birmingham
398 participants
The 1989 RNA Tumor Virus meeting considered retrovirus replication, structure,
and pathogenesis. In the last few years, the meeting has become an important
forum for basic research in human retroviruses-this year nearly half of the
presentations concerned HIV and related primate viruses, or HTLV. Some of the
highlights included discussion of recent advances in retrovirus replication. In
particular, progress in identifying several retrovirus receptors was described,
including molecular cloning of the ecotropic murine leukemia virus receptor.
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Reports on the mechanism of retroviral integration included descriptions of in vitro
integration systems and mechanistic studies on the integrase protein. Considerable
attention was focused on human retrovirus regulatory proteins, particularly tat, rev,
and tax, although important information was presented, the highlight was the
description of high-resolution structures of avian and human retrovirus proteases;
these will be important in structure-function studies and, potentially, in the design
of new anti-retrovirus drugs. Sessions on retrovirus pathogenesis included
discussions on the mechanisms of virus-induced tumorigenesis and immunodefi-
ciency. Several animal model systems for immunodeficiency were presented,
including feline, murine, and human viruses.
PROGRAM
Replication-Entry through Integration
Chairmen: H. Varmus, University of California, San Francisco
S. Goff, Columbia University
Transcription and Transcriptional Control
Chairmen: N. Hopkins, Massachusetts Institute of Technology
C. Rosen, Roche Institute of Molecular Biology
Replication-RNA Splicing through Virus Assembly
Chairmen: A.M. Skalka, Fox Chase Cancer Center
A. Rein, Frederick Cancer Research Facility
Nonstructural/Regulatory Genes
Chairmen: M. Martin, NIAID, National Institutes of Health
B. Cullen, Howard Hughes Medical Institute, Duke University
Oncogenesis
Chairmen: P. Jolicoer, Clinical Research Institute of Montreal
W. Hayward, Memorial Sloan Kettering-Cancer Center
Protein Structure and Function Endogenous Viruses and Evolution
Chairmen: V. Vogt, Cornell University
J. Coffin, Tufts University School of Medicine
Vectors and Gene Transfer
Chairmen: M. Linial, Fred Hutchison Cancer Research Center
S. Hughes, NCI Frederick Cancer Research Facility
Immunosuppression and Cytopathogenesis
Chairmen: H. Robinson, University of Massachusetts Medical Center
F. Lilly, Albert Einstein College of Medicine
J. Schultz, W. Wachsman, H. Fan
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Yeast Cell Biology
August 15-August 20, 1989
ARRANGED BY
Scott Emr, California Institute of Technology
Amar Klar, NCI-Frederick Cancer Research Facility
John Pringle, University of Michigan
Steve Reed, Scripps Clinic and Research Foundation
325 participants
Participants of the meeting on Yeast Cell Biology considered the many ways in
which the experimental tractability of yeasts is being exploited in investigations of
fundamental problems in eukaryotic cell biology. The utility of this approach
depends in part on the degree to which structures and functions are conserved
between yeasts and the larger eukaryotes, and the meeting provided further
evidence that such conservation runs very deep indeed. The meeting also
provided abundant illustrations of just how experimentally tractable yeasts have
become. Many papers gave dramatic evidence that the traditional barriers (real
and psychological) to application of conventional cell biological approaches (light
microscopy, electron microscopy, and cell fractionation/in vitro reconstitution) to
yeast have been overcome. At the same time, the genetic approaches for which
the yeasts have long been renowned have become even more diverse and
powerful as a result of conceptual and technical advances presented at the
meeting. These genetic approaches are of two general types, both of which were
much in evidence. In "forward genetics',' potentially novel features of the cell are
explored by isolating and analyzing mutants with interesting phenotypes:
Molecular genetic methods (including DNA sequencing and the use of fusion
proteins to elicit antibody production) are then used to explore the functions of the
gene products at the molecular level. This approach has brought many exciting
recent advances, such as the realization of the very wide range of functions in
which GTP-binding/hydrolyzing proteins are involved, the discovery of cyclin-like
molecules involved in G1 control of the cell cycle, and the discovery of an appar-
ently novel pathway of secretion. Equally potent is the approach of "reverse
genetics': in which molecular genetic methods are used first to clone the gene
encoding a putatively important protein and then to make mutations in that gene
to explore the role of the protein in vivo. This approach continues to produce
many surprises, such as the new result that mutants unable to acidify their
vacuoles are apparently healthy. In a more general way, the practice of reverse
genetics in yeast (and a few other suitable organisms) has greatly increased our
appreciation of the subtlety of cellular functions and of the degree of redundancy
and overlap in the functions of individual proteins.
In summary, use of the powerful amalgam of genetic and nongenetic
approaches that can be applied to yeast has produced exciting progress in
understanding virtually all parts of the yeast cell, from the cell wall to the
nucleolous and microtubule, as reported at the 1989 Yeast Cell Biology meeting.
There is no reason to think that the pace of discovery will slow between now and
the next such meeting in 1991 and every reason to think that the results obtained
will be of wide interest to cell biologists generally.
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PROGRAM
Nucleus and Plasma Membrane
Chairman: J. Woolford, Carnegie Mellon University
Cytoskeleton and Morphogenesis
Chairman: F. Solomon, Massachusetts Institute of Technology
Chromosome Structure, Function, and Segregation
Chairman: M. Grunstein, University of California, Los Angeles
Secretion and Protein Sorting. I
Chairman: R. Trimble, New York State Department of Health
Cell Cycle and Growth
Chairman: K. Tatchell, North Carolina State University
Secretion and Protein Sorting, II
Chairman: E. Jones, Carnegie Mellon University
Signal/Transduction/Cell Wall
Chairman: J. Thorner, University of California, Berkeley
Mating Type, Meiosis, and Sporulation
Chairman: B. Byers, University of Washington
Cell Cycle Control
Chairman: P Fantes, University of Edinburgh
Secretion/Endocytosis
Chairman: S. Michaelis, Johns Hopkins University School of Medicine
Peroxisomes and Mitochondria
Chairman: H. Ruis, Universitat Wien
Molecular Genetics of Bacteria and Phages
August 22-August 27, 1989
ARRANGED BY
Gary Gussin, University of Iowa
Lucia Rothman-Denes, University of Chicago
Andrew Wright, Tufts Medical School
315 participants
The 1989 meeting on Molecular Genetics of Bacteria and Phages was extremely
successful and attracted more than 300 people, including many young investiga-
tors and graduate students. There were 112 talks and 130 posters covering all
aspects of prokaryotic molecular genetics. Prior to each session, the chairperson
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gave a brief overview of the topics to be discussed; this proved a useful addition
to the previous format. Topics included DNA replication site-specific recombina-
tion, transcriptional activation, antitermination of transcription, and posttranscrip-
tional control by RNA degradation or by translational control. Mechanisms of
signal transduction, membrane assembly, and protein secretion were also
discussed.
W. Szybalski, H. Murialdo A. Wright, S. Busby
G. Mosig, N. Sternberg, A. Abe les
There has been considerable progress in a number of these areas during the
past year. Of particular note was the number of systems in which DNA bending or
looping plays a role in regulation. Several reports supported a ubiquitous role for
IHF as a regulator of gene expression, as an essential element in site-specific
recombination, and as a factor required for packaging of phage DNA. In each of
these cases, IHF facilitates the formation of unique DNA structures through its
ability to bend DNA. The most dramatic example of DNA loop formation involved
in regulation was that shown to occur in the deo operon of E. coli (Dandanell and
Hammer). The deoR repressor, containing eight identical subunits, binds to three
operator sites and forms single and double loops, the latter being consistent with
its high efficiency and cooperative behavior observed in vivo. These studies all
ilrustrate how sites at a distance interact with one another. Significant progress in
the understanding of structural elements that alter stability (Emory and Belasco;
Wagner et al.) and new methods of analysis (Mackie) and understanding of this
complex process seems within reach.
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Wine and cheese
Among the exciting results presented was the
demonstration by Ebright that a
DNA-binding protein, cap, could by simple chemical
modification of a cysteine
residue in the DNA-binding helix be converted into an endonuclease, with
unaltered DNA-binding affinity and specificity. It should now
be possible to design
other reagents of this type that will allow cleavage of DNA at specifically selected
sites. The report (Van Dyk et al.) that overproduction of the groES and groEL gene
products, major heat shock proteins, suppresses a wide range of temperature-
sensitive mutations in E. coli further strengthens the notion that these proteins play
a major role in protein folding. Overall the presentations were of very high quality
and the meeting stimulated intense interest and discussion.
PROGRAM
Replication/Repair
Recombination/Excision/Transposition
Chromosome Packaging
RNA Polymerase-Promoter Interactions
Transcription Termination/Antitermination
Posttranscriptional Regulation
Protein Secretion/Membrane Assembly/Signal Transduction
Transcriptional Regulation. I: Activation
Transcriptional Regulation. II
Thermal Regulation/Modern Genetics
Eukaryotic DNA Replication
August 30-September 3, 1989
ARRANGED BY
Thomas Kelly, Johns Hopkins University School of Medicine
Bruce Stillman, Cold Spring Harbor Laboratory
290 participants
This was the second meeting on Eukaryotic DNA Replication held at Cold Spring
Harbor; the first was held two years ago. The meeting focused on all aspects of
the subject, including two sessions on replication of virus DNA; two sessions on
the replication of cell chromosomal DNA, including yeast and mammalian cells; a
session on the replication of extrachromosomal elements and selective amplifica-
tion of DNA; one session on replication proteins; and one session on the control
of DNA replication. In addition, two large poster sessions were held. As with the
previous meeting, the 1989 meeting saw a large amount of high-quality science,
indicating that the field is strong and will be for some time to come. It has also
become clear that the field of DNA replication is branching out to include topics
on gene regulation, cell cycle control, genome amplification and organization, and
cell biology.
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PROGRAM
Replication Proteins
Chairman: P Burgers, Washington University School of Medicine
Virus DNA Replication. I
Chairman: C. Prives, Columbia University
Cell Chromosome Replication. I
Chairman: J. Huberman, Roswell Park Memorial Institute
Virus DNA Replication. II
Chairman: P van der Vliet, University of Utrecht
Extrachromosomal Replication
Chairman: G. Wahl, The Salk Institute
Control of Cell Cycle and S Phase
Chairman: D. Beach, Cold Spring Laboratory
Cell Chromosome Replication. II
Chairman: R. Laskey, University of Cambridge
1/4,st 1,1 I
E. Johnson, S. Berberich
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Regulation of Eukaryotic mRNA Transcription
September 6-September 10, 1989
ARRANGED BY
Winship Herr, Cold Spring Harbor Laboratory
Robert Tijan, University of California, Berkeley
Keith Yamamoto, University of California, San Francisco
427 participants
The 1989 Cancer Cells meeting, Regulation of Eukaryotic mRNA Transcription,
was attended by an international group of over 400 scientists sharing overlapping
interests in regulation of transcription in eukaryotic cells. The reports presented by
the participants spanned a broad spectrum of topics, including the biochemistry of
general transcription factors, structural studies, yeast genetics, and Drosophila
development. In the first session, several groups reported the molecular cloning of
P. Rigby, J. Alwine, T Kadesch
J. Witkowski, D. Baltimore
R. Treisman, K. Yamamoto, P Sigler
the gene encoding the yeast TATA box binding factor TFIID, a major breakthrough
in understanding the structure and function of basic initiation factors. The se-
quence of this gene revealed that it had also been isolated genetically, because
mutations in this gene affect the selection of transcription initiation sites in yeast.
Another basic transcription factor, the RNA-polymerase-II-associated protein
complex RAP 30/74, was shown to process DNA helicase activity, suggesting it
may be involved in establishing an open transcription initiation complex. Many
studies described the dissection of sequence-specific DNA-binding transcription
factors revealing in increasing detail the many structural motifs involved in both
DNA binding and transcriptional activation. An unexpected finding revealed that a
chromosomal translocation associated with a class of leukemias results in the
fusion of a transcription factor expressed in lymphoid cells to a novel homeodo-
main, thus probably conferring a new DNA-binding specificity. One session
focused on the influence of chromatin and DNA topology on regulation of
transcription, with one report describing how sequence-specific factors are already
bound to the promoter in vivo before transcription of the gene is activated; this
indicates that other levels of regulation (e.g., protein modification) are involved. In
the final session, reports on the analysis of homeodomain genes in Drosophila
revealed how regulation of transcription factor activity can have dramatic effects on
development. The meeting closed with a striking presentation in which individual
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transcription complexes were revealed within the nuclei of stained Drosophila
embryos. The success of the meeting was indicated by the large number of
scientists standing in the aisles or sitting on the stairs of Grace Auditorium during
the sessions.
The meeting was funded by the National Science Foundation and National
Institutes of Health.
PROGRAM
RNA Polymerase II and Basal Initiation Factors
Chairman: A.L. Greenleaf, Duke University Medical Center
Initiation Complexes and Post-Initiation Events
Chairman: C. Gross, University of Wisconsin
Tissue Selective Enhancer and Promoter Factors
Chairman: R. Roeder, Rockefeller University
Mechanisms of Transcription Regulation: Activation Domains and Protein/Protein
Interactions
Chairman: M. Ptashne, Harvard University
Regulation of Transcription Factor Activity
Chairman: D. Baltimore, Whitehead Institute and Massachusetts Institute of Technology
Structure and Function of Sequence-Specific DNA Binding Proteins
Chairman: P.B. Sigler, Yale University
The Influence of Template Topology, Nuclear Matrices, and Chromatin Structure on
Transcription
Chairman: J. Wang, Harvard University
Transcription of Developmentally Regulated Genes
Chairman: M. Levine, Columbia University
Translational Control
September 13-September 17, 1989
ARRANGED BY
Michael Mathews, Cold Spring Harbor Laboratory
Nahum Sonenberg, McGill University
313 participants
The first Translational Control meeting was held at Cold Spring Harbor two years
ago. That meeting engendered great enthusiasm among its participants, many
of
whom felt that it signaled a renaissance of research in protein synthesis.
Judging
from the increased attendance, the wealth of new information and the high caliber
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B. Hayes
R. Bablanian, W. Merrick
N. Gupta, A. Roy, U. Maitra
M. Grunberg-Manago, B. Safer
of the presentations made during this year's
meeting, these expectations have
been translated into fact. Molecular genetic approaches have allowed great strides
to be made in defining the mechanism of
translation initiation in yeast and in
higher eukaryotes. Major contributions to this knowledge have stemmed from the
cloning of the genes for many of the eukaryotic initiation factors. Advances have
been made in defining the cis-acting elements within prokaryotic and eukaryotic
mRNAs that function in translational control, and it has become clear that
secondary and tertiary structure elements are key components in translational
control mechanisms operating during the initiation and elongation phases and in
ribosome frame shifting. Regulatory factors that either suppress or enhance
translation have been characterized, and it is anticipated that many more such
trans-acting factors will be identified in the next few years. The control of transla-
tion during development and growth has attracted considerable attention: As more
genes involved in the regulation of development, growth, and differentiation are
cloned, it becomes increasingly apparent that many of them are translationally
controlled.
PROGRAM
mRNA 5' Untranslated Region
Chairman: H. Voorma, University of Utrecht
Initiation
Chairman: W. Merrick, Case Western Reserve University
Elongation and Termination
Chairman: A. Spirin, Academy of Science of the USSR
Prokaryotes
Chairman: M. Grunberg-Manago, Foundation Edmond de Rothschild
Phosphorylation of Initiation Factors
Chairman: R. Thatch, Washington University
Stability, Poly (A), and Other Tales
Chairman: D. Cleveland, Johns Hopkins Medical School
Growth, Development, and Heat Shock
Chairman: R. Jackson, University of Cambridge
Initiation Factor Genes and Their Regulation
Chairman: A. Wahba, University of Mississippi Medical Center
A
L. Slobin, A. Spirin
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Modern Approaches to New Vaccines
Including Prevention of AIDS
September 20-September 24, 1989
ARRANGED BY
Fred Brown, Wellcome Biotechnology Ltd.
Robert Chanock, NIAID, National Institutes of Health
Harold S. Ginsberg, Columbia University
Richard Lerner, Research Institute of Scripps Clinic
276 participants
The seventh annual meeting on Modern Approaches to New Vaccines offered an
opportunity for molecular biologists, microbiologists, and clinical investigators to
interact and broaden their perspective of immunoprophylaxis. Biomedical scientists
concerned with prevention of viral, bacterial, or parasitic diseases met to
exchange the latest information on (1) the molecular and immunological properties
of important human and animal pathogens; (2) the application of this knowledge
to the development of new vaccine strategies, and (3) the evaluation of the
resulting candidate vaccines for safety and efficacy in the laboratory or in clinical
trials.
Among the many exciting advances described were the induction of antibodies
that catalyze peptide cleavage at a specific site, the development of a combinato-
rial system for cloning and expressing the antibody repertoire of an animal in
E. coli, the demonstration of the role of HIV gag-specific cytotoxic T cells in
resistance to AIDS, and the first experimental evidence that immunization with an
inactivated simian immunodeficiency virus (SIV) induces effective resistance in
monkeys to subsequent SIV challenge. Equally notable were the first descriptions
of the sequence and genome organization of the feline immunodeficiency virus
(FIV), which now appears to be a promising experimental surrogate for human
AIDS. Evidence was also presented indicating that HIV-2 evolved in West Africa
following infection of humans by an SIV indigenous to sooty mangabey monkeys
(SlVsmm). Finally, the feasibility of using synthetic peptides as immunogens
received a significant boost from a study demonstrating that reactivity of a
synthetic peptide with a monoclonal antibody directed against it could be
increased several orders of magnitude by substitution of appropriate amino
acids at certain sites in the linear sequence.
The meeting was supported in part by NIAID and the Rockefeller Foundation.
PROGRAM
Immunology, Bacteriology and Parasitology
Chairman: R. Lerner, Research Institute of Scripps Clinic
AIDS and Bacteriology
Chairman: M.B.A. Oldstone, Research Institute of Scripps Clinic
Virology. I
Chairman: B. Murphy, NIAID, National Institutes of Health
Virology. II
Chairman: R. Chanock, NIAID, National Institutes of Health
AIDS and Immunology
Chairman: E. Norrby, Karolinska Institutet
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J. Treanor, B. Murphy
R. Lerner, H. Ginsberg
F. Schbdel, M. Popescu
R. Chanock
AIDS. I
Chairman: P.R. Johnson, Georgetown University
AIDS. II
Chairman: H. Ginsberg, Columbia University
College of Physicians & Surgeons
Virology and Parasitology
Chairman: E. Wimmer, State University of New York, Stony
Brook
Virology, Parasitology, and Bacteriology
Chairman: F. Brown, Wellcome Biotechnology Ltd.
Summary: PR. Johnson, Georgetown University
Hepatitis B Viruses
September 25-September 28, 1989
R. Burke, H. Schaller
M. Lai, J. Monjardino
W. Mason, A. Jilbert
ARRANGED BY
Patricia Marion, Stanford University Medical School
Heinz Schaller, University of Heidelberg
268 participants
At the meeting on the Molecular Biology of Hepatitis B Viruses, new information
was presented on the replication, transcriptional regulation, and gene product
synthesis of hepatitis B virus (HBV) and on the host response to this virus family,
including the viral association with hepatocellular carcinoma. The development of
more efficient systems to replicate the various hepadnaviruses via transfection of
viral DNA into cultured cell lines has resulted in significant progress in the genetic
analysis of all aspects of virus replication. Viral sequences important in encapsida-
tion of the viral RNA pregenome, in initiation of both minus- and plus-strand DNA
synthesis, and in circularization of viral DNA have been located. Regions of the X
gene essential for reverse transcriptase activity and RNase H activity were
described, as well as regions of the structural proteins that are important in
membrane insertion or in assembly and eventual secretion.
In other sessions, speakers described new studies of the cellular factors
interacting with specific sequences of the viral enhancer and presented recent
findings on the trans-activating functions of the X gene product. In the area of
pathology and immunology of the HBV family, T-cell response to envelope
antigens and the X gene product were detected, although response to nucleocap-
sid antigens appeared to be stronger. In a session on the role of hepadnaviruses
in liver cancer, factors contributing to the development and growth of liver
malignancy were described, along with an aberrant oncogene structure or
expression associated with tumors in one of the animal models, but not in HBV
infection, and a high rate of specific modification of a single chromosome in
human tumors. These studies support the conclusion that chronic HBV infection
may lead to hepatocellular carcinoma by more than one route.
Recent studies of the replication of hepatitis delta virus (HDV), dependent on
HBV for secretion and subsequent infection, were presented. Specific interactions
between the HDV-encoded protein and the RNA were described, along with the
possible roles of two variants of the HDV protein created by RNA editing.
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PROGRAM
Replication. I
Chairman: J. Summers, University of New Mexico School of Medicine
Replication. II
Chairman: H. Schaller, University of Heidelberg
Hepatocellular Carcinoma
Chairman: K. Koike, Cancer Institute, Tokyo
Hepatitis Delta Virus
Chairman: M. Lai, University of Southern California School of Medicine
Structural Proteins. I
Chairman: P. Marion, Stanford University Medical School
Structural Proteins. II
Chairman: W. Gerlich, Georg August University, Gottingen
Transcription
Chairman: W. Mason, Fox Chase Cancer Center
X Gene
Chairman: W.S. Robinson, Stanford University
Pathology/Immunology
Chairman: D. Ganem, University of California, San Francisco
Molecular Neurobiology of Drosophila
P Marion, R. Cheung, J. Cullen
K. Koike W. Robinson
October 4-October 8, 1969
ARRANGED BY
William Pak, Purdue University
Donald Ready, Purdue University
179 participants
Approximately 175 researchers representing essentially all Drosophila neurobiol-
ogy laboratories gathered for the third biennial meeting. For this meeting, 153
abstracts were contributed and three poster sessions were held, in addition to the
seven slide sessions. Lively discussions ranged from the molecular structure of ion
channels to mutational analysis of learning.
Considerable progress was reported on the neurogenic genes that regulate
CNS development. Biochemical analysis of one neurogenic gene product, Notch,
has borne out the predictions of protein structure and topology deduced from the
gene sequence and has revealed subtleties of cellular localization. Growing
evidence suggests that Notch may have a role in cell-cell adhesion.
A growing family of genes that direct neural patterning have been recognized
as myc-related transcription factors. A combinatorial network of interactions among
these gene products was the focus of much discussion. Several papers described
patterns of gene activity in the developing nervous system as revealed by
enhancer traps. A notable early success of this method is the identification of a
new gene of the steroid receptor superfamily that is required both in the early
embryonic nervous system and in the later development of the compound eye. G
proteins and phospholipase C second-messenger cascades figured prominently
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M. Seeger, I. Hariharan, G. Rubin
in discussions of phototransduction. Evidence was presented suggesting that
sensory receptor-specific phosphoprotein phosphatase plays a role in both visual
and olfactory reception.
Different forms of the Shaker potassium channel gene products are expressed
differentially in the CNS. The functional significance of these variant transcripts is
beginning to be sorted out by patch-clamp analysis of Xenopus oocytes express-
ing combinations of Shaker transcripts. Functional domains of the Shaker proteins
are being elucidated by measurements made on channels altered by site-directed
mutagenesis.
Discussions of genes important to behaviors were highlighted by the report that
the per gene transcript cycles in synchrony with the circadian rhythm. Antibodies
to the per protein showed staining in neurons, photoreceptors, and glial cells in
the fly head, and the intensity of staining varied with the circadian rhythm.
PROGRAM
Neurogenesis
Chairman: J. Campos-Ortega, Universitat zu Koln
Nervous System Development: myc-Related Proteins and Others
Chairman: J. Posakony, University of California, San Diego
Sensory System Development
Chairman: G.M. Rubin, University of California, Berkeley
Sensory Transduction
Chairman: C. Zuker, University of California, San Diego
Early Neuronal Differentiation and Eye Development
Chairman: S. Benzer, California Insitute of Technology
Ion Channels
Chairman: R. Aldrich, Stanford University School of Medicine
Behavior
Chairman: J. Hall, Brandeis University
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BANBURY CENTER
DIRECTOR'S REPORT
The Banbury Center continues to be used throughout almost the entire year, with
the exception of an all-too-brief respite during the winter! Seventeen meetings were
held here, in addition to four advanced lecture courses on neurobiology and one
on mapping human diseases. More than 500 people participated at these
meetings. The majority came from the United States, but many were visitors from
Europe and as far afield as Japan and Australia. Bea To liver and Ellie Sidorenko in
the Center's office and Katya Davey at Robertson House did a wonderful job
looking after all aspects of the meetings. These meetings seem to cover an
increasingly diverse range of topics, a continuing testimony to the power of
molecular biology and genetics.
Topics in Basic Research
Although it is increasingly difficult to maintain a distinction between "basic" and
"applied" research, in 1989, there were two meetings that perhaps qualify as basic
research. One meeting was called Molecular Clocks of Evolution. A considerable
amount of data has been produced using differences in DNA between different
species to measure the relatedness of species. Some of the data obtained using
DNA as a molecular clock have required radical revision of previously accepted
taxonomic relationships, and the purpose of our meeting was to examine whether
the assumptions underlying the use of molecular clocks are justified. It was intrigu-
ing to see data with time scales measured in millions of years rather than the
minutes or hours of conventional molecular biological data!
Evolution was also the underlying theme of the meeting Molecular Genetics of
Early Drosophila and Mouse Development. Homology between related genes of
Banbury Meeting House, rear view
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different species is a very powerful tool for studying gene function, as the
research on Drosophila homeo box genes and their mouse equivalents has
shown. In addition, new advances such as homologous recombination offer the
possibility of directly manipulating the genomes of organisms like the mouse,
which were previously restricted to classic breeding experiments. This meeting
brought together the world's leading scientists working on mouse and Drosophila
development with a view to determining whether there are common themes to
studies of the molecular development of these two very different organisms. As
Science reported (244: 652-654 [1989]), the two groups did find common
ground, and we hope that the meeting has stimulated continuing interactions in
this field.
Molecular Genetics and Human Inherited Diseases
Extraordinary advances continue to be made in the exploitation of recombinant
DNA techniques for studying human inherited diseases, as shown by four
meetings held here this year. One of the great hopes of molecular genetics is that
it will provide an understanding of the genetics of human cancer, a promise that
comes closer to fulfillment each year. Some of the most important recent advances
in cancer research concern anti-oncogenes or tumor suppressor genes and their
interactions with oncogenes. This was the topic of the Banbury meeting,
Recessive Oncogenes and Tumor Suppression, held in March. It would be
invidious to pick out individual contributions, for the whole meeting was
remarkably stimulating and encouraging. The field seems to be at one of those
rare and exciting moments in research when a series of apparently unconnected
observations and findings are about to be unified.
The gene for Duchenne muscular dystrophy (DMD) was the first gene responsi-
ble for a human inherited disease to be cloned without any prior knowledge of the
protein involved. Research on DMD has moved rapidly from analysis of DNA to
studies of the function of the protein, named dystrophin, in muscle, brain, and
other tissues. Dystrophin, a very exciting meeting in March, drew together
research workers from all over the world to discuss, and in some cases to attempt
to reconcile, the latest results. It is a remarkable comment on the rapid progress
made possible by recombinant DNA techniques that a session could be devoted
to discussing therapeutic strategies for affected boys.
A major question is whether the strategies used to clone the DMD and cystic
fibrosis genes are applicable to other disorders, and whether other, more rapid
and efficient methods can be devised. The meeting, Molecular Cytogenetics:
Bridging the Resolution Gap, examined new strategies for handling and analyzing
DNA intermediate in size between the DNAs studied by cytogenetics and by
cloning techniques. It seems that although one can optimize techniques and
strategies, a considerable element of luck is involved in finding a sought-after gene
in kilobases of DNA.
Although cloning is laborious and time-consuming, the successes with the
DMD and cystic fibrosis genes demonstrate that it is possible to clone the genes
for human diseases caused by single genes. Most common disorders, however,
while showing strong familial tendencies, do not have a simple pattern of
inheritance and probably result from interactions between the environment and
one or more of a number of genes. Alcoholism is a classic example of such a
complex disease, and the Molecular Genetics and Biology of Alcoholism meeting
reviewed the data on the inheritance of alcoholism and attempted to evaluate
future strategies. As in the meeting held last year on schizophrenia, very few firm
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conclusions could be reached, except that there is a genetic component in
alcoholism. It seems unlikely that a real effort can begin on cloning the genes
involved in alcoholism without many more studies of families, a project about to
begin under the auspices of the National Institute on Alcohol Abuse and
Alcoholism.
Neurobiology of Vision
For 2 weeks in the middle of the summer, the Conference Center comes to
resemble mission control as it is inundated by computers used for the Computa-
tional Neuroscience course. Advantage was taken of their presence to hold a
Banbury Center meeting on Computational of Visual Processing. The
meeting covered such topics as spatial sampling, object recognition, and scene
analysis and involved hands-on computer modeling as well as more usual
presentations and discussions. There is no doubt that this kind of integrated
workshop/lecture format contributed enormously to the success of the meeting.
HIV and AIDS
Two meetings on HIV and AIDS dealt with quite different aspects of the problem.
The November meeting, Control of HIV Gene Expression, was a follow-up to a
similar meeting held in February of 1988. There were some concerns that the gap
between the two meetings was too long, but in the event it seemed just right.
Research has continued to demonstrate the complexities of the HIV genome and
of the interactions between the regulatory systems of the virus and the host cell. It
is still proving to be a highly controversial field despite (or because of) the intense
research activities. It was a particular pleasure to welcome Harold Varmus, newly
anointed Nobel Laureate and longtime associate of Banbury Center, to the
meeting.
The Immunological Aspects of AIDS meeting provided an opportunity for
researchers to determine what progress has been made in this field and what
topics require special attention. The primary target of HIV is the immune system,
and it might be expected that by now there would be a clear understanding of
how the virus produces an immunodeficient state. Such an understanding may be
a prerequisite for designing efficient and safe vaccines. However, the difficulties of
working with complex cell-culture systems or with animals make progress in this
vital area of research frustratingly slow.
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Practical Applications of Basic Research
One strategy proposed for dealing with viral infections is to target viral proteins
that are of critical importance to the life cycle of the virus. The viral proteinases
that cleave polyprotein precursors into individual viral proteins are one group of
such proteins. A very exciting meeting, Viral Proteinases as Targets for
Chemotherapy, examined what has been done in this research area. This was one
of the largest meetings of 1989, a testimony to the potential importance of this
approach for controlling viral infections, including AIDS.
The Applications of Basic Research in Mammalian Development meeting
exemplified the Banbury Center's objective of bringing together diverse groups of
people. The topics at this meeting ranged from sex determination, through
cryopreservation of embryos and gene transfer in domestic animals, to preimplan-
tation diagnosis of human diseases!
Environmental Hazards
The Mutation Induction and Heritability in Mammalian Germ Cells meeting dealt
with such important topics as How do mutations arise in germ-line cells? Can
these mutations be repaired? How can they be detected? In particular, participants
reviewed the ways in which new technical developments such as polymerase
chain reaction can be used to get estimates of germ cell mutation rates.
Sloan Foundation Workshops for Congressional
Staff and Science Journalists
The workshop for Congressional staff dealt not with a research topic, but with an
issue of public policy, the question of scientific misconduct. The meeting was
entitled The Ethos of Scientific Research because it was intended to examine the
set of beliefs held by scientists that maintains the integrity of the way in which
research is done. There have been many other meetings on this topic, but we
believe that ours was unique. The participants included those directly involved with
the issue in Washington and a group of distinguished scientists. For the first time,
these two groups had the opportunity to interact directly with each other in an
informal setting. Whatever the outcome in terms of legislation, there is no doubt
that the two groups-scientists and staff-left the meeting with a clear apprecia-
tion, if not understanding, of the intense feelings that this issue generates on both
sides.
Applications of the New Molecular Genetics was the theme of the science
journalists' workshop in May. The meeting covered topics that were united in being
amenable to new analysis because of new experimental techniques like
homologous recombination for gene targeting in mice. For the first time, we made
use of the.facilities of the DNA Learning Center to give the journalists an opportu-
nity to experience a little of what they write about! This was a great success, and
similar laboratory experiments will be featured in the new series of workshops
supported by the Sloan Foundation.
The Baring Brothers-CSHL Meeting
For the second year, the London merchant bankers Baring Brothers and Cold
Spring Harbor Laboratory hosted a meeting for senior executives of companies
with strong links to biotechnology. As in previous years, the topic of the meeting
was chosen to involve fascinating research that has potential applications in
biotechnology. Stanley Cohen introduced Growth Factors in Development, a
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meeting intended to introduce participants to the research being done on growth
factors and morphogens and to point to the therapeutic potential of these biologi-
cally active substances. Once again, the practical experience in the laboratory at
the DNA Learning Center was a tremendous success. On this occasion, DNA
samples were analyzed for the sickle cell anemia mutation using polymerase chain
reaction, restriction enzyme digest, and gel electrophoresis.
Other Meetings
The Center has been made available on occasion to other groups. The Deans of
the Associated Medical Schools of New York, the Board of Trustees of Huntington
Hospital, and Cold Spring Harbor School District held meetings here. In view of
the Center's increasing interest in science policy and human genetics, we were
particularly pleased to be able to host a joint meeting of the National Institutes of
Health and the Department of Energy human genome initiatives at Banbury.
Funding
The Corporate Sponsor Program provided the funding for five of the Banbury
Center meetings in 1989 and, in so doing, provided the bedrock on which the
Center's meeting program is built. The five meetings were Applications of Basic
Research in Mammalian Development; Viral Proteinases as Targets for
Chemotherapy; Recessive Oncogenes; Molecular Cytogenetics; and The
Molecular Genetics of Early Drosophila and Mouse Development. The
importance of the contributions from the Laboratory's Corporate Sponsors cannot
be overemphasized, especially in a period of declining Federal support for
meetings.
Corporations and private foundations seem to be taking on this role increas-
ingly. The Alfred P Sloan Foundation has already undertaken to support the
Congressional Staff and Science Journalist's Workshops for a further 3 years,
NIH-DOE Human Genome Meeting
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beginning in 1990. The Sloan Foundation also helped to underwrite the costs of
the Molecular Clocks of Evolution meeting as part of the Foundation's continuing
interest in promoting research on molecular evolution. The Muscular Dystrophy
Association funded the meeting on Dystrophin, and the Christopher D. Smithers
Foundation gave very generously to support the meeting on the Molecular
Genetics and Biology of Alcoholism. The book of this meeting will reach a wider
audience than is usually the case because of the generosity of an anonymous
donor who has underwritten the production costs of the book. Given the Center's
interest in human molecular genetics, I hope to persuade other disease-specific
foundations to consider holding workshops here.
Partial support for three meetings was obtained from Federal sources. The
Environmental Protection Agency underwrote the costs of the Mutation Induction
and Heritability in Mammalian Germ Cells meeting, and the National Institute for
Allergy and Infectious Diseases supported the meetings on HIV and AIDS.
Banbury Center Publications
Two books published in 1989 deserve special mention. Polymerase Chain
Reaction, part of the Current Communications in Molecular Biology series, was
based on the meeting sponsored by Perkin-Elmer Cetus, and it seems set to
become a best seller as applications of PCR increase day by day. The second
important publication was Banbury Report 32: DNA Technology and Forensic
Science. This could not have come at a more opportune moment as controversy
continues unabated about the standards to be applied in this real-life application
of molecular genetics. The papers and especially the discussions in this book
should make a very valuable contribution to this debate.
Banbury Center Publicity
Publicity for Banbury Center meetings can be a two-edged sword. On the one
hand, it provides a means of informing people about what goes on at our
meetings, but, on the other hand, it may cause administrative difficulties given the
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restricted numbers that can attend meetings here. On balance, the advantages are
likely to outweigh the disadvantages, and journalists and writers attended some
meetings in 1989 either for background or to write reports. The report in Science
on The Molecular Genetics of Early Drosophila and Mouse Development
meeting was an excellent example of how we can achieve a wider audience for
the information presented at our meetings. The DNA Technology and Forensic
Science meeting also received wide publicity, as did the Congressional Workshop,
The Ethos of Scientific Research, although not all of the latter was favorable.
Looking Forward to 1990
The Center will continue to hold meetings on topics in five main areas: (1) basic
research and technical developments in molecular biology and genetics; (2)
advances in the applications of molecular genetics to human inherited disorders,
especially complex disorders like alcoholism; (3) environmental issues; (4) the
increasing impact of molecular biology and genetics on the public; and (5) issues
of scientific policy that are of special importance to the research scientist, e.g.,
animal experimentation and granting mechanisms. These latter topics will become
increasingly important as public oversight of what scientists do continues to
increase. We have to lead, and not simply respond, in matters where there is
legitimate public interest in our activities. The Center will continue to play a unique
role in furthering all aspects of research in molecular biology and encouraging
thoughtful and thought-provoking examination of its relationships with society.
Jan A. Witkowski
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MEETINGS
Sloan Foundation Congressional Workshop on the Ethos
of Scientific Research
January 26 - January 28
ARRANGED BY
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1
P. Woolf, Princeton University, New Jersey: Some character-
istics of publicly reported cases.
D. Rennie, Journal of the American Medical Association, Mill
Valley, California: The editor, the journal, and scientific
misconduct.
B. Mishkin, Hogan & Hartson, Washington, D.C.: Need for
institutional policies and procedures.
SESSION 2
D. Zuckerman, House Subcommittee on Human Resources
& Intergovernmental Relations, Washington, D.C.: Role of
Congress in helping prevent and investigate scientific
fraud.
B. Chafin, House Subcommittee on Oversight & Investiga-
tions, Washington, D.C.: Collapse of self-regulation in the
absence of oversight.
W. Stewart, National Institutes of Health, Bethesda,
Maryland: Keeping Congress out of science.
SESSION 3
H. Wortis, Tufts University, Boston, Massachusetts: Science
investigation.
D. Korn, Stanford University Medical School, California:
Institutional policy and process.
J. Newburgh, National Institutes of Health, Bethesda,
Maryland: Response and role of NIH.
C. Scheman, Association of American Universities, Washing-
ton, D.C.: Issues relating to the development of institu-
tional policies.
G. Booth, N. Zinder, H. Varmus
D. Zuckerman, D. Nathans
M. Mathews, M. Ptashne, R. Axel
Recessive Oncogenes and Tumor Suppression
March 29 - April 1
ARRANGED BY
W. Cavanee, Ludwig Institute for Cancer Research, Montreal, Canada
N. Hastie, Western General Hospital, Edinburgh, Scotland
E.J. Stanbridge, University of California, Irvine
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SESSION 1: Somatic Cell Genetics
Chairperson: E.J. Stanbridge, University of California, Irvine
H. Harris, University of Oxford, England: Role of differentia-
tion in the suppression of malignancy.
I. Herskowitz, University of California, San Francisco:
Response and resistance to negative growth factors in
yeast: Function and control of synthesis of peptide
receptors.
J.C. Barrett, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina: Tumor
suppressor genes as negative regulators of cell growth.
SESSION 2: Deletions and Cancer
C. Harris, National Cancer Institute, Bethesda, Maryland:
Tumor suppression studies of human lung cancer.
N. Bouck, Northwestern University, Chicago, Illinois:
Suppressor control of an inhibitor of angiogenesis.
H. Zarbl, Massachusetts Institute of Technology, Cambridge:
Genetic analysis of transformation effector and suppres-
sor genes.
B.E. Weissman, University of North Carolina, Chapel Hill:
Tumor suppressor genes in pediatric cancers.
Chairperson: N. Hastie, Western General Hospital, Edinburgh, Scotland
W.K. Cavenee, Ludwig Institute for Cancer Research,
Montreal, Canada: Loss of genetic information in cancer
predisposition and progression.
R.L. White, Howard Hughes Medical Institute, Salt Lake City,
Utah: High-resolution mapping of inherited tumor genes.
B. Vogelstein, John Hopkins Oncology Center, Baltimore,
SESSION 3: Retinoblastoma
Maryland: Genetic alterations in colorectal tumors.
N. Hastie, Western General Hospital, Edinburgh, Scotland:
Wilms' tumor locus at 11p13.
B.A.J. Ponder, Institute of Cancer Research, Surrey, England:
Genetics of multiple endocrine neoplasia type 2.
Chairperson: W.K. Cavenee, Ludwig Institute for Cancer Research, Montreal, Canada
M.F. Hansen, M.D. Anderson Cancer Center, University of
Texas, Houston: Molecular genetics of familial mixed
cancer.
W.-H. Lee, University of California at San
Molecular basis of tumor suppression by the retino-
blastoma gene.
B. Phillips, Hospital for Sick Children, Toronto, Canada:
Characterization of mutations in the retinoblastoma gene.
W. Benedict, The Woodlands, Texas: The retinoblastoma
gene and its product.
D. Livingston, Dana-Farber Cancer Institute, Cambridge,
Massachusetts: SV40 T antigen-RB interactions.
R.A. Weinberg, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: The retinoblastoma gene.
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SESSION 4: Other Candidate Tumor Suppressor Genes
Chairperson: R.A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
B.M. Mechler, Johannes Gutenberg University, Mainz,
Federal Republic of Germany: Molecular basis for tumor
suppression in Drosophila.
M. Noda, The Institute of Physical and Chemical Research,
lbaraki, Japan: Biological activities of the transformation
suppressor gene Krev-1 and its mutants.
R. Schaefer, University of Zurich, Switzerland: Molecular and
SESSION 5: Strategies for Cloning Tumor Suppressor Genes
Chairperson: R.L. White, Howard Hughes Medical Institute,
J.D. Minna, National Cancer Institute, Bethesda, Maryland:
Chromosomal deletion in lung cancer.
E. Stanbridge, University of California, Irvine: Strategies for
cloning human tumor suppressor genes.
L. Strong, M.D. Anderson Cancer Center, University of Texas,
functional analysis of tumor suppressor genes by
transfection.
L.A. Liotta, National Cancer Institute, Bethesda, Maryland:
Metastasis suppressor gene.
R. Sager, Dana-Farber Cancer Institute, Cambridge,
Massachusetts: The gro gene as putative cytokine and
tumor suppressor.
Salt Lake City, Utah
Houston: Molecular genetics of the Wilms' tumor locus.
A. Balmain, Beatson Institute for Cancer Research, Glasgow,
Scotland: Chromosomal changes during tumor
progression.
SESSION 6: Oncogenelbmor Suppressor Gene Interactions
Chairperson: M. Ptashne, Harvard University, Boston, Massachusetts
E. Harlow, Cold Spring Harbor Laboratory, New York: Protein
complexes between p105-RB and DNA tumor-virus-
transforming proteins.
A.J. Levine, Lewis Thomas Laboratory, Princeton University,
New Jersey: The p53 proto-oncogene can suppress E1A
plus ras-mediated transformation.
F. McCormick, Cetus Corporation, Emeryville, California:
Role of GAP in ras transformation.
Dystrophin
M.H. Wig ler, Cold Spring Harbor Laboratory, New York:
Signal processing along the ras pathway.
S. Aaronson, National Cancer Institute, Bethesda, Maryland:
Growth-factor-activated pathways in the neoplastic
process.
J. Massague, University of Massachusetts Medical School,
Worcester: Control of growth and phenotype by TGF-13.
April 2 - April 5
ARRANGED BY
L.M. Kunkel, The Children's Hospital, Boston, Massachusetts
R. Worton, Hospital for Sick Children, Toronto, Canada
SESSION 1: The Human Dystrophin Gene: Putting Together a Physical Map
Chairperson: L.M. Kunkel, The Children's Hospital, Boston, Massachusetts
G.-J.B. van Ommen, University of Leiden, The Netherlands:
Review of physical map.
K.E. Davies, John Radcliffe Hospital, Oxford, England:
Deletions in the central and 3'-end of the dystrophin
gene: Genotype and phenotype.
U. Francke, Yale University, New Haven, Connecticut:
Characterization of dystrophin deletions by cDNA studies
and long-range mapping.
R.J. Bartlett, Duke Unviersity Medical Center, Durham, North
Carolina; A. Burghes, Ohio State University, Columbus;
J.S. Chamberlain, Baylor College of Medicine, Houston,
Texas; M. Koenig, The Children's Hospital, Boston,
Massachusetts, and A. Speer, Akademie der Wissen-
schaften der German Democratic Republic: Filling out
the map.
SESSION 2: Transcriptional Regulation and Expression
Chairperson: R. Worton, Hospital for Sick Children, Toronto, Canada
U. Nudel, The Weizmann Institute of Science, Rehovot, Israel:
Expression and promoter studies in rodent myogenic cells.J.-C. Kaplan, Institut National de la Sante et de la Recherche
Medicale, Paris, France: Transcripts of the dystrophin gene.
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L. Rowland A. Engel, E. Bonilla
H. Klamut, Hospital for Sick Children, Toronto, Canada:
Human gene promoter and expression in myogenic cells.
H. Blau, Stanford University, California: Cell biology of
dystrophin.
SESSION 3: Dystrophin Structure and Function
Chairperson: E. Lazarides, California Institute of Technology,
E. Bonilla, Columbia University College of Physicians &
Surgeons, New York, New York: Localization of dystrophin
in specialized regions of the muscle fiber.
E. Zibrzycka-Gaarn, Hospital for Sick Children, Toronto,
Canada: Site-specific antibodies to dystrophin and
localization to membrane vesicles.
K. Arahata, National Institute of Neuroscience, Tokyo, Japan:
Immunohistochemical study of dystrophin in DMD and
BMD.
M. Cullen, Newcastle General Hospital, England: Ultrastruc-
tural localization of dystrophin in human muscle by gold
labeling.
SESSION 4: Cytoskeletal Proteins: Structure and Function
Chairperson: A.G. Engel, Mayo Clinic, Rochester, Minnesota
V. Bennett, Duke University Medical Center, Durham, North
Carolina: Proteins of the spectrin-based membrane
skeleton.
E. Lazarides, California Institute of Technology, Pasadena:
Control of assembly of the membrane skeleton.
D. Critchley, University of Leicester, England: Cytoskeletal
proteins linking actin to the membrane in cell matrix
junctions.
R. Brown, Massachusetts General Hospital, Boston: Studies
of DMD gene expression in vitro.
Pasadena
S. Watkins, Dana-Farber Cancer Institute, Cambridge,
Massachusetts: Light and immunoelectron microscopic
localization of dystrophin.
G.-J.B. van Ommen, University of Leiden, The Netherlands:
Dystrophin localization in embryonic, fetal, and adult
mouse.
K. Campbell, University of Iowa, Iowa City: Purification of
dystrophin from rabbit muscle membranes.
T.J. Byers, Harvard University, Cambridge, Massachusetts:
Relationship of dystrophin to a- and [3-spectrins.
M. Koenig, The Children's Hospital, Boston, Massachusetts:
Dystrophin structure and possible function.
S.
S.
SESSION 5: Mutational Spectrum and Clinical Correlates
Chairperson: K. Davies, John Radcliffe Hospital, Oxford, England
K. Fischbeck, University of Pennsylvania Hospital, Philadel-
phia: Clinical spectrum of defects in the dystrophin gene.
A. Burghes, Ohio State University, Columbus: Correlation of
genotype and phenotype at the 5' end of the gene.
R. Worton, Hospital for Sick Children, Toronto, Canada:
Deletions and duplications of exons in DMD and BMD:
More on the frame-shift idea.
M. Koenig, The Children's Hospital, Boston, Massachusetts:
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Georgatos, Rockefeller University, New York: Nuclear
lamina: Organization principles and anchorage functions.
Craig, Johns Hopkins University Medical School,
Baltimore, Maryland: Muscle costameres: Transmem-
brane linkage between extracellular matrix, sarcolemma,
and myofiber bundles.
The frame-shift hypothesis: Correlation of mutation type
with phenotype.
J.S. Chamberlain, Baylor College of Medicine, Houston,
Texas: PCR technology for rapid deletion analysis.
M. Zatz, Universidade de Sao Paulo, Brazil: DNA and
dystrophin studies in Brazilian families.
E. Hoffman, The Children's Hospital, Boston, Massachusetts:
Dystrophin quality and quantity in DMD and BMD.
SESSION 6: Animal Models and Disease
Chairperson: M. Cullen, Newcastle General Hospital, England,
Massachusetts
G. Karpati, Montreal Neurological Institute and Hospital,
Quebec, Canada: Dystrophin expression in mosaic
muscle fibers of carrier mdx females and transplanted
mdx males.
T.A. Partridge, Charing Cross & Westminister Medical
School, London, England: Relationship between morphol-
ogy and content of introduced dystrophin in muscle of
the mdx mouse.
SESSION 7: What Does the Future Hold?
and L.M. Kunkel, The Children's Hospital, Boston,
J.L. Mandel, Institute of Biological Chemistry, Strasbourg,
France: Dystrophin gene and protein in chicken.
B.J. Cooper, Cornell University, Ithaca, New York: Expression
of dystrophin in the grmd dog.
R. Bartlett, Duke University Medical Center, Durham, North
Carolina: Studies of the golden retriever muscular
dystrophy.
Chairperson: D. Wood, Muscular Dystrophy Association, New York, New York
T.A. Partridge, Charing Cross Hospital, London, England:
Future of myoblast transplantation: The minimum require-
ment before consideration of clinical trials.
L.M. Kunkel, The Children's Hospital, Boston,
Massachusetts: Speculation on the function of dystrophin
and approaches to correction of the defect.
D. Wood, Muscular Dystrophy Association, New York, New
York: Where do we go from here? What is MDAs current
response to the 'big' question-how soon will we have a
cure?
Viral Proteinases as Targets for Chemotherapy
April 16 - April 19
ARRANGED BY
E. Wimmer, State University of New York, Stony Brook
S. Oroszlan, NCI-Frederick Cancer Research Facility, Maryland
H.-G. Krausslich, State University of New York, Stony Brook
SESSION 1
Chairpersons: J.H. Strauss, California Institute of Technolog
St. Louis, Missouri
E. Wimmer, State University of New York, Stony Brook:
Polyprotein processing in viral replication.
B.L. Semler, University of California at Irvine: Molecular
genetics of picornavirus protein processing.
P V Pallai, Boehringer Ingelheim Pharmaceuticals,
Ridgefield, Connecticut: Peptide cleavage by purified 3C.
y, Pasadena, and M.J. Schlesinger, Washington University,
E. Wimmer, State University of New York: Poliovirus
proteinase 2A.
A.C. Palmenberg, University of Wisconsin, Madison:
Cleavage specificity of the EMC 3C proteinase.
J. Wel link, Agricultural University, Wageningen, The
Netherlands: Processing of the CPMV polyproteins.
SESSION 2
Chairpersons: A.C. Palmenberg, University of Wisconsin, Madison, and B.L. Semler, University of California at Irvine
J. Strauss, California Institute of Technology, Pasadena: cis-
Acting structural and nonstructural proteinases encoded
by sindbis virus.
J. Weber, Centre Hospitalier Universitaire, Sherbrooke,
Canada: Adenovirus proteinase: Properties of a
recombinant enzyme expressed in E. coli.
M. Johnston, National Institute of Allergy and Infectious
Diseases, Bethesda, Maryland: AIDS drug discovery and
development: Present and future.
W. Dougherty, Oregon State University, Corvallis: Molecular
genetic analysis of a plant virus proteinase and its
conserved cleavage site.
R.J. Fletterick, University of California, San Francisco: X-ray
crystallography of trypsin variants.
J.F. Bazan, University of California, San Francisco: Viral
branches of the trypsin-like proteinase family.
M.J. Schlesinger, Washington University, St. Louis, Missouri:
A second sindbis virus autoproteinase: In vitro process-
ing of the viral nonstructural polyprotein.
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SESSION 3
Chairpersons: K. von der Helm, University of Munich, Federal Republic of Germany, and S. Oroszlan, NCI-Frederick
Cancer Research Facility, Maryland
S. Oroszlan, NCI-Frederick Cancer Research Facility,
Maryland: Retroviral polyprotein processing: An overview.
Y. Yoshinaka, Otsuka Pharmaceutical Co. Ltd., Tokushima,
Japan: Retroviral proteinase as an aspartic proteinase.
R.B. Luftig, Louisiana State University Medical Center, New
Orleans: Bacterial expression and activity of the Mo-MLV
proteinase.
M. Hatanaka, Kyoto University, Japan: HTLV-I proteinase.
M. Roberts, NCI-Frederick Cancer Research Facility,
Maryland: Lentiviral proteinases.
C. Debouck, Smith Kline & French Laboratories, King of
Prussia, Pennsylvania: Expression and structure-function
characterization of the HIV-1 proteinase and its gag-pol
substrate.
SESSION 4
M. Graves, Hoffmann-La Roche Inc., Nutley, New Jersey:
Characterization of HIV-1 proteinase.
K. von der Helm, University of Munich, Federal Republic of
Germany: Action and inhibition of the HIV proteinase.
H.-G. Krausslich, State University of New York, Stony Brook:
Processing of HIV polyproteins by bacterially expressed
HIV-1 proteinase.
R.I. Swanstrom, University of North Carolina, Chapel Hill:
Genetic analysis of the HIV proteinase.
J.M. Louis, National Cancer Institute, NIH, Bethesda,
Maryland: Studies with wild-type and mutant HIV-1
proteinase expressed in E. coli.
Chairperson: R.J. Fletterick, University of California, San Francisco
M.N.G. James, University of Alberta, Edmonton, Canada:
Crystallographic studies of AMV proteinase.
A. Wlodawer, NCI-Frederick Cancer Research Facility,
Maryland: Refined structure of a proteinase from RSV.
M. Navia, Merck, Sharp & Dohme Research Laboratories,
Rahway, New Jersey: Three dimensional structure of the
aspartyl-proteinase from HIV-1.
S. Foundling, E.I. du Pont de Nemours & Co., Wilmington,
Delware: Crystallographic analysis of AMV proteinase.
J. Erickson, Abbott Laboratories, Abbott Park, Illinois:
SESSION 5
Structural relationships between viral and eukaryotic
aspartic proteinases and the implications for retroviral
drug design.
R.S. DesJarlais, University of California, San Francisco:
Inhibitor design from known structures.
S. Oroszlan, NCI- Frederick Cancer Research Facility,
Maryland, and R.B. Luftig, Louisiana State University
Medical Center, New Orleans: Synthetic nonpeptide
inhibitors.
Chairperson: E. Wimmer, State University of New York, Stony Brook
C.S. Craik, University of California, San Francisco:
Expression and characterization of HIV-1 and HIV-2
proteinases.
S.B.H. Kent, California Institute of Technology, Pasadena: A
synthetic approach to the molecular biology of retroviral
proteinases: Structure-function studies of the HIV-1 and
HIV-2 enzymes and their substrates.
B.M. Dunn, University of Florida, Gainesville: Kinetic studies
on viral proteinases utilizing synthetic peptide substrates.
J. Leis, Case Western Reserve University, Cleveland, Ohio,
and A.M. Skalka, Fox Chase Cancer Center, Philadelphia,
Pennsylvania: Biochemical analysis of the ASLV
proteinase.
236
C. Carter, State University of New York, Stony Brook:
Substrate specificity determinants of the HIV-1 proteinase.
P.L. Darke, Merck, Sharp & Dohme Research Laboratories,
West Point, Pennsylvania: HIV-1 proteinase: Substrates,
inhibitors, and subunit interactions.
P Strop, Institute of Organic Chemistry and Biochemistry,
Prague, Czechoslovakia: Specificity and inhibition studies
on MAV proteinase.
M.T. Skoog, Boehringer Ingelheim Corporation, Ridgefield,
Connecticut: Substrate specificity of HIV proteinase.
B.D. Korant, E.I. du Pont de Nemours & Co., Wilmington,
Delware: Potential use of proteinase inhibitors as antiviral
agents.
Molecular Genetics of Early Drosophila and Mouse Development
April 20 - April 23
ARRANGED BY
M. Cappechi, University of Utah, Salt Lake City
SESSION 1
W. Bender; Harvard Medical School, Boston, Massachusetts:
Segmental regulation of the bithorax complex of
Drosophila.
W. McGinnis, Yale University, New Haven, Connecticut: A
homeo domain switch changes the regulatory function of
the deformed protein in Drosophila embryos.
SESSION 2
M. Levine, Columbia University, New York, New York: Spatial
regulation of homeo box gene expression in Drosophila.
M. Capecchi, University of Utah, Salt Lake City: Creating
mice with specific mutations by gene targeting.
A. Joyner, Mt. Sinai Hospital Research Institute, Toronto,
M.P. Scott, University of Colorado, Boulder: Genes that
control pattern formation during development.
M. Krasnow, Stanford University Medical Center, California:
Transcriptional regulation by homeotic gene products in
cultured Drosophila cells and in vitro.
Canada: Molecular genetic approaches to the analysis of
mammalian development.
P Gruss, Max Planck Institute of Biophysical Chemistry,
Gottingen, Federal Republic of Germany: Precision
mutagenesis by homologous recombination.
SESSION 3
E. Robertson, Columbia University, New York, New York:
Developmental potential of embryonic stem cells.
E.F. Wagner, Research Institute of Molecular Pathology,
Vienna, Austria: In situ analysis of c-fos expression in
transgenic mice.
R. Beddington, ICRF Developmental Biology Unit, Oxford,
England: Using lacZ as an in situ cell marker to analyze
tissue lineages in the midgestation mouse embryo.
F.H. Rudd le, Yale University, New Haven, Connecticut:
Mammalian Antennapedia class homeo box genes:
Organization, expression, and evolution.
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SESSION 4
B. Hogan, Vanderbilt University Medical School, Nashville,
Tennessee: Developmental expression of the murine vgr-1
gene: A new member of the TGF-13 multigene family.
Gruss, Max Planck Institute of Biophysical Chemistry,
Gottingen, Federal Republic of Germany: The hox-1.1
promoter directs expression to a specific region of the
embryo in transgenic mice.
G. Martin, University of California, San Francisco: New
approaches to identifying genes that control early
mammalian embryogenesis.
SESSION 5
A.R McMahon, Roche Institute of Molecular Biology, Nutley,
New Jersey: int-1 and pattern regulation.
R. Nusse, Netherlands Cancer Institute, Amsterdam: int-1
D. Duboule, European Molecular Biology Laboratory,
Heidelberg, Federal Republic of Germany: The organiza-
tion of the murine hox gene family resembles that of
Drosophila homeotic genes.
R. Krumlauf, National Institute for Medical Research,
London, England: The murine and Drosophila homeo
box clusters are derived from a common ancestor based
on similarities in structure and expression.
and int-4, two genes active in mouse mammary
tumorigenesis and in normal embryogenesis.
Sloan Foundation Journalists' Workshop on Applications
of the New Molecular Genetics
May 7 - May 9
ARRANGED BY
J.A. Witkowski, Banbury Center
Cold Spring Harbor Laboratory, New York
SESSION 1
C. Cepko, Harvard University, Boston, Massachusetts:
Studies of cell lineages in developing animals using
retroviruses as markers.
N. I. First, University of Wisconsin, Madison: Applications of
new methods of embryo manipulation in animal
husbandry.
M. Capecchi, University of Utah, Salt Lake City:
Homologous recombination and gene targeting.
SESSION 2
D. Mick los and M. Bloom, DNA Learning Center Cold
Spring Harbor Laboratory, New York: Laboratory
experiment and Smithsonian Search for Life exhibit.
SESSION 3
M. Martin, National Institute of Allergy and Infectious
Diseases, Bethesda, Maryland: Transgenic mice and
other animal models for the study of AIDS pathogenesis.
G.A. Evans, The Salk Institute, La Jolla, California: Cell
ablation studies for developmental studies.
A.N. Rowan, Tufts University Veterinary School, North
Grafton, Massachusetts: Ethical issues of the new
genetics.
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J. Palca, J.A. Witkowski, R. Cooke
D. Barnes, C. Joyce, M. Martin
Computational Models of Visual Processing
Workshop on Computational Neuroscience
June 26 - June 30
ARRANGED BY
J.A. Movshon and M. Landy, New York University, New York
SESSION 1: Sampling and the Retina
A.J. Ahumada, Jr., NASA Ames Research Center, Moffett
Field, California: Learning receptor position.
LT Maloney, New York University, New York: Retinal
sampling and early vision.
SESSION 2: Central Visual Neurons
P Lennie, University of Rochester, New York: Construction of
chromatically opponent receptive fields.
M.J. Hawken, New York University, New York: Spatial
organization of receptive fields in primate V1.
SESSION 3: Encoding
A.B. Watson, NASA Ames Research Center, Moffett Field,
California: Modeling visual neurons.
D.J. Heeger, Massachusetts Institute of Technology,
SESSION 4: Channels
D.G. Pelli, Syracuse University, New York: On the nature of
the noise that limits visual detection.
J. Nachmias, University of Pennsylvania, Philadelphia:
SESSION 5: Motion and Transparency
E.H. Adelson, Massachusetts Institute of Technology,
Cambridge: Analysis of orientation and motion.
N. Grzywacz, Whitaker College, Massachusetts Institute of
Technology, Cambridge: Does the visual cortex really
SESSION 6: Texture
N. Graham, Columbia University, New York, New York: Low-
level visual processes in texture segregation.
C. Chubb, New York University, New York: Expanding the
class of distinct textures with identical local average
energy spectra.
SESSION 7: Three-dimensional Structure
J.P. Frisby, University of Sheffield, England: PMF89, switcher,
and needles: A medley of AIVRU's stereo algorithms.
A.J. Parker, University Laboratory of Physiology, Oxford,
England: Stereo, surfaces, and shape.
SESSION 8: Surface Properties
M. D'Zmura, University of California, Irvine: Constraints on
the recovery of surface reflectance.
D.R. Williams, University of Rochester, New York:
Photoreceptor sampling and image motion.
D.C. Hood, Columbia University, New York, New York:
Models of the human rod receptor and the ERG.
R. Shapley, New York University, New York: Linear and
nonlinear contributions to direction selectivity of simple
cells in cat area 17.
Cambridge: Nonlinear model of cat striate cortex.
D.J. Field, University of Cambridge, England: Redundancy of
natural scenes and its relation to visual coding.
Ruminations on subthreshold summation.
H.R. Wilson, University of Chicago, Illinois: Spatial
mechanisms and visual pattern discrimination.
worry about the aperture problem?
D. Kersten, Brown University, Providence, Rhode Island:
Transparency: Psychophysics and computation.
J.R. Bergen, David Sarnoff Research Center, Princeton, New
Jersey: Energy measures, gain controls, and texture
perception.
H. Bulthoff, Brown University, Providence, Rhode Island:
Integration of depth modules.
S. Ullman, Massachusetts Institute of Technology,
Cambridge: 3D object recognition.
D. Brainard, Stanford University,
California: Predicting the
illuminant's effect on color appearance.
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Molecular Genetics and Biology of Alcoholism
October 10 - October 13
ARRANGED BY
H. Beg leiter, State University of New York Health Science Center, Brooklyn
C.R. Cloninger, Washington University School of Medicine, St. Louis, Missouri
SESSION 1: Genetic Studies I
Chairperson: J. Sambrook, University of Texas Medical Center,
A. Chakravarti, University of Pittsburgh, Pennsylvania:
Sampling design issues for segregation and linkage
studies in alcoholism.
J.S. Searles, University of Pennsylvania, Philadelphia:
Methodological limitations of genetic models of
alcoholism: Critique of extant research and suggestions
for future directions.
C.R. Cloninger, Washington University School of Medicine,
SESSION 2: Genetic Studies II
Dallas
St. Louis, Missouri: Clinical and genetic heterogeneity in
alcoholism.
R.E. Tarter, University of Pittsburgh, Pennsylvania: Vulnerabil-
ity to alcoholism: From individual differences to different
individuals.
T. Reich, Jewish Hospital of St. Louis, Missouri: Familial
transmission of alcoholism and related disorders.
Chairperson: P.M. Conneally, Indiana University Medical Center, Indianapolis
A.C. Heath, Washington University, St. Louis, Missouri:
Contributions of twin family studies to understanding the
inheritance of alcoholism.
N.G. Martin, Queensland Institute of Medical Research,
Herston, Australia: Twin studies of alcohol metabolism
and sensitivity.
R.J. Cadoret, University of Iowa, Iowa City: Use of the
adoption paradigm to delineate the role of genes,
environment, and their interaction in genesis of
alcoholism.
C.C.H. Cook, Middlesex Hospital Medical School, London,
England: Candidate genes and favored loci for
alcoholism.
D. Goldman, National Institute on Alcohol Abuse and
Alcoholism, Bethesda, Maryland: Candidate loci for
alcoholism: Cloning and analysis of ethanol metabolic
genes and tryptophan hydroxylase.
T.-K. Li, Indiana University School of Medicine, Indianapolis:
Animal models in the study of genetics and biology of
alcoholism.
240
SESSION 3: Putative Markers I
Chairperson: E. Gordis, National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland
H. Beg leiter, State University of New York Health Science
Center, Brooklyn: Neurophysiologic markers in sons of
alcoholic fathers: Data and criteria.
M. Schukit, University of California, San Diego: Challenges
of children of alcoholics with alcohol or diazepam.
B. Tabakoff, National Institute on Alcohol Abuse and
Alcoholism, Bethesda, Maryland: Neurochemical and
peripheral markers in alcoholism.
SESSION 4: Putative Markers II
D.P. Agarwal, Institute of Human Genetics, Hamburg,
Federal Republic of Germany: Human aldehyde
dehydrogenases: Genetic implications for alcohol
sensitivity, alcohol drinking habits, and alcoholism.
T.J. Peters, King's College School of Medicine, London,
England: Alcohol-acetaldehyde flush reactions in
Caucasians: Identification of biochemical defects and
genetic aspects.
Chairperson: R.S. Sparkes, University of California, Los Angeles, Health Science Center
E.P Noble, Neuropsychiatric Institute, University of California,
Los Angeles: Alcoholic fathers and their sons:
electrophysiologic, neurophysiologic, personality and
family correlates.
P Propping, Institute of Human Genetics, University of Bonn,
Federal Republic of Germany: Alcohol effect on the EEG:
Are there possibilities for applications of molecular
genetics?
SESSION 5: General Discussion
V. Hesselbrock, University of Connecticut, Farmington:
Social/behavioral factors that may attenuate/potentiate
genetic effects.
E.M. Wijsman, University of Washington, Seattle: Linkage
analysis of alcoholism: Problems and solutions.
J. Ott, Columbia University, New York, New York: Genetic
linkage analysis under uncertain disease definition.
Chairperson: A. Chakravarti, University of Pittsburgh, Pennsylvania
PR. Billings, Harvard Medical School, Boston,
Massachusetts: Genetics and behavioral disorders: What
will be the consequences of identifying a major gene in
alcoholism?
E. Gordis, National Institute on Alcohol Abuse and
Alcoholism, Rockville, Maryland: National Institute on
Alcohol Abuse and Alcoholism and research on the
genetics of alcoholism.
Applications of Basic Research in Mammalian Development
October 15 - October 18
ARRANGED BY
R.A. Pedersen, University of California, San Francisco
A. McLaren, MRC Mammalian Development Unit, University College London, England
N.L. First, University of Wisconsin, Madison
Keynote Address
N.L. First, University of Wisconsin, Madison: Application of
gamete and embryo biotechnology to animal production.
SESSION 1: Sex Determination
A. McLaren, MRC Mammalian Development Unit, University
College London, England: Sex determination in mice.
PS. Burgoyne, MRC Mammalian Development Unit,
SESSION 2: Gametogenesis
A.R. Bel lye, Columbia University College of Physicians &
Surgeons, New York, New York: The thecins, a novel
class of proteins associated with the sperm perinuclear
matrix,
University College London, England: Mammalian Y
chromosome function in early embryos and male
gametogenesis.
C. Racowsky, Arizona State University,
Tempe: Regulation of
meiotic maturation in hamster oocytes.
J. Eppig, The Jackson Laboratory, Bar
Harbor, Maine:
Growth and development of oocytes in vitro.
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SESSION 3: In Vitro Production of Embryos
P.M. Wassarman, Roche Institute of Molecular Biology,
Nutley, New Jersey: Fertilization in mammals.
SESSION 4: Cryopreservation of Germ Cells and Embryos
W.F. Rall, American Type Culture Collection, Rockville,
Maryland: New approaches to the cryopreservation of
mammalian embryos by vitrification.
SESSION 5: Embryo Multiplication
R.S. Prather, University of Missouri, Columbia: Cloning by
nuclear transfer in laboratory and domestic animal
embryos.
SESSION 6: Early Embryo Survival
D.G. Whittingham, MRC Experimental Embryology and
Teratology Unit, St. George's Hospital Medical School,
London, England: Genetic evaluation of embryos.
H.J. Leese, Department of Biology, University of York,
England: Assessment of embryo metabolism.
SESSION 7: Early Embryo Development
R.A. Pedersen, University of California, San Francisco:
Origin and growth of the extraembryonic cell lineages in
normal and parthenogenetic mouse embryos.
S. Heyner, Albert Einstein Medical Center, Philadelphia,
Pennsylvania: The insulin family of peptides: Expression
and role in development.
SESSION 8: Gene Transfer in Laboratory and Domestic Species
K.M. Ebert, Tufts University School of Veterinary Medicine,
North Grafton, Massachusetts: Present status of
transgenic livestock.
C. Spadafora, University of Rome, Italy: Sperm as vectors for
producing transgenic mice.
SESSION 9: Sex Identification in Agriculture and Human Genetics
K.L. White, Louisiana State University, Baton Rouge: Identifi-
cation of the sex of preimplantation mammalian embryos.
A.H. Handyside, Royal Postgraduate Medical School,
Hammersmith Hospital, London, England: Preimplantation
diagnosis of human inherited disease.
A. Bellve,
N. First,
R. Pedersen
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J.J. Parrish, University of Wisconsin, Madison: In vitro
fertilization of laboratory and domestic species.
J. Van Blerkom, University of Colorado, Boulder:
Consequences of cryopreservation in oocytes and
embryos.
V.E. Papaioannou, Tufts University School of Medicine,
Boston, Massachusetts: Developmental regulation of half
embryos.
J. Butler, University of Idaho, Moscow: Metabolism during
preimplantation development in farm animals.
R. Wales, School of Veterinary Studies, Murdoch University,
Western Australia: Energy metabolism during develop-
ment and differentiation of sheep embryos.
J.D. Biggers, Harvard Medical School, Boston,
Massachusetts: Regulation of pH in early mammalian
embryos.
D. Albertini, Tufts University School of Medicine: Role of
cvtoskeleton in early embryo development.
J. Kopchick, Ohio University, Athens: Mutagenesis of the
bovine growth hormone gene: Structure/function studies
employing transgenic mice.
Molecular Cytogenetics: Bridging the Resolution Gap
October 30 - November 2
ARRANGED BY
F.S. Collins, University of Michigan Medical School, Ann Arbor
D.H. Ledbetter, Baylor College of Medicine, Houston, Texas
H.F. Willard, Stanford University School of Medicine, California
M. Burmeister, K. Davies T. Hassold, H. Cooke
SESSION 1: Bridging Technologies
Chairperson: F.S. Collins, University of Michigan Medical School, Ann Arbor
M. Burmeister, University of California, San Francisco: Fine
structure genetic analysis of human chromosomes by
using radiation hybrid mapping.
D.C. Ward, Yale University School of Medicine, New Haven,
Connecticut: High-resolution gene mapping by in situ
hybridization.
B.J. Trask, Lawrence Livermore National Laboratory, Califor-
nia: Genomic distance estimated from the proximity of
fluorescence in situ hybridization sites in interphase
nuclei.
SESSION 2: Chromosome Structure
Chairperson: H.F. Willard, Stanford University School of M
H. Cooke, MRC Human Genetics Unit, Western General
Hospital, Edinburgh, Scotland: Human telomeres.
L. Clarke, University of California, Santa Barbara: Structure-
function analysis of centromeric DNA in fission yeast.
H.F. Willard, Stanford University School of Medicine, Califor-
nia: Molecular studies of X-inactivation.
B. Horsthemke, University of Essen, Federal Republic of
Germany: Microdissection and molecular analysis of
human chromosome regions involved in contiguous gene
syndromes.
K.E. Davies, John Radcliffe Hospital, Oxford, England:
Physical mapping and microdissection in the fragile X
region.
A.P. Monaco, Imperial Cancer Research Fund Laboratories,
London, England: Human genome linking with cosmids
and yeast artificial chromosomes.
edicine, California
S.D.M. Brown, St. Mary's Hospital Medical School, London,
England: Long-range genetic and physical mapping of
mouse chromosomes.
P Goodfellow, Lincoln's Inn Fields, London, England:
Structure of the pseudoautosomal boundary.
SESSION 3: Reverse Genetic Cloning Strategies
Chairperson: B.S. Emanuel, Children's Hospital of Philadelphia, Pennsylvania
F.S. Collins, University of Michigan Medical School, Ann
Arbor: Lessons from the cystic fibrosis gene search.
B.S. Emanuel, Children's Hospital of Philadelphia, Pennsylva-
nia: Molecular and cytogenetic studies of 22q11.
S.F. Warren, Emory University School of Medicine, Atlanta,
Georgia: Isolation of human Xq28 within a somatic cell
hybrid by fragile site-directed rearrangement: Application
to saturational cloning and genome analysis.
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SESSION 4: Contiguous Gene Syndromes
Chairperson: D.H. Ledbetter, Baylor College of Medicine, Houston, Texas
enetic disease by map position:U. Francke, Howard Hughes Medical Institute, Stanford
University, California: Contiguous gene syndrome in the
Xp21 region.
A. Ballabio, Baylor College of Medicine, Houston, Texas:
Contiguous gene syndromes in the distal short arm of
the human X chromosome.
R.L. Nussbaum, University of Pennsylvania, Philadelphia:
Identifying human g
Application of X-linked ophthalmological disease.
G.A. Bruns, The Children's Hospital, Boston, Massachusetts:
Organization of the WAGR region.
D.H. Ledbetter, Baylor College of Medicine, Houston, Texas:
Molecular dissection of the Miller-Dieker lissenopholy
syndrome.
SESSION 5: Origin and Mechanism of Chromosome Abnormalities
Chairperson: T. Hassold, Emory University Hospital, Atlanta, Georgia
T. Hassold, Emory University Hospital, Atlanta, Georgia:
Parental origin effects: imprinting and the parental origin
of chromosome abnormality.
R.D. Nicholls, University of Florida College of Medicine,
Gainesville: Prader-Willi and Angelman syndromes: Are
both parental contributions to chromosome 15q11q13
necessary for normal human development?
W. Reik, Institute of Animal Physiology and Genetics
Research, Cambridge, England: Role of DNA methylation
Control of HIV Gene Expression
in mammalian genome imprinting.
A. Chakravarti, University of Pittsburgh, Pennsylvania:
Analysis of nondisjunction in Down's syndrome and
ovarian teratoma.
C. Sapienza, Ludwig Institute for Cancer Research,
Montreal, Canada: Genetics of genome imprinting.
J.G. Hall, University of British Columbia, Vancouver, Canada:
Genomic imprinting: Relevance for human diseases.
November 7 - November 10
ARRANGED BY
B.R. Cullen, Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina
R. Franza, Cold Spring Harbor Laboratory, New York
F. Wong-Staal, National Cancer Institute, Bethesda, Maryland
SESSION 1: HIV Rev Function
Chairperson: B.R. Cullen, Howard Hughes Medical Institute
C.A. Rosen, Roche Institute of Molecular Biology, Nutley,
New Jersey: Regulation of HIV gene expression by rev.
G.N. Pavlakis, NCI-Frederick Cancer Research Facility, Mary-
G. Pavlakis
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Duke University Medical Center, Durham, North Carolina
land: Transcriptional organization and regulation of HIV-1
expression.
J. Rusche, Repligen Corporation, Cambridge, Mas-
sachusetts: Biochemical characterization of HIV-1 rev in-
teraction with the RRE.
M. Emerman, Fred Hutchinson Cancer Center, Seattle,
Washington: Regulation of HIV envelope gene expres-
sion/mechanism of rev gene action.
M. Hatanaka, Kyoto University, Japan: Nucleolar targeting
signals in HIV.
SESSION 2: HIV-1 tat Function
Chairperson: F. Wong-Staal, National Cancer Institute,
Bethesda, Maryland
B.M. Peter lin, Howard Hughes Medical Institute, University of
California, San Francisco: Activation and trans-activation
of HIV.
A.P. Rice, Cold Spring Harbor Laboratory, New York: tat
regulation of HIV-1 LTR-directed gene expression.
A. Frankel, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: Biochemistry, activity, and in-
hibition of the tat protein from HIV.
K.T. Jeang, National Institutes of Health, Rockville, Maryland:
Activation of the HTLV-1 and HIV-1 L7R by viral and cellu-
lar factors.
A.J. Kingsman and S.M. Kingsman, University of Oxford, En-
gland: Activation of the HIV LTR by tat in Xenopus
oocytes.
SESSION 3: Other HIV Gene Products
N. Sonenberg, McGill University, Montreal, Canada: Func-
tion of the tar sequence in posttranscriptional control of
HIV-1 gene expression.
M. Green, St. Louis University School of Medicine, Missouri:
Functional tat protein domains and inhibition of viral
gene.
Chairperson: M.A. Martin, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland
W. Haseltine, Dana-Farber Cancer Institute, Cambridge, Mas
sachusetts: HIV-1 vpr gene function.
M. Rosenberg, Smith Kline & French Laboratories, King of
Prussia, Pennsylvania: Role of HIV-1 proteinases.
L. Ratner, Washington University, St. Louis, Missouri: HIV
regulation by nef.
SESSION 4: Cellular Factors in HIV-1 Gene Regulation
Chairperson: R. Franza,
Cold Spring Harbor Laboratory, New York
A.S. Fauci, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda,
Maryland: Effects of lymphokines on HIV-1 gene
expression.
G.J. Nabel, Howard Hughes Medical Institute, University of
Michigan Medical Center, Ann Arbor: kB binding
proteins: Heterogeneity and mechanisms of activation.
R. Gaynor, University of California, Los Angeles, School of
Medicine: Transcriptional regulation of HIV.
A. Rabson, National Institute of Allergy and Infectious
Diseases, Bethesda, Maryland: Role of LTR regulatory
sequences in HIV replication.
M. Feinberg, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: Mutational analysis of LTR
function in HIV replication.
E. Verdin, Free University of Brussels, Belgium: Identification
of an inducible intragenic enhancer in HIV-1.
I. Chen, University of California, Los Angeles, School of
Medicine: HTLV gene regulation.
SESSION 5: HTLV and Animal Lentiviruses
Chairperson: M. Yoshida, Cancer Institute, Tokyo, Japan
W.C. Greene, Howard Hughes Medical Institute, Duke
University Medical Center, Durham, North Carolina:
Mechanism of HTLV-I rex action.
J. Hauber, Sandoz Research Institute, Vienna, Austria:
Functional analysis of the HTLV-1 rex gene regulation.
J.E. Clements, John Hopkins University School of Medicine,
Baltimore, Maryland: Regulation of gene expression of
visna virus by tat and cellular factors involves AP-1
recognition sequences.
D. Derse, National Cancer Institute, Frederick, Maryland:
EIAV tat is structurally and functionally related to HIV and
SIV tat proteins but lacks a methionine initiation codon.
S. Venkatesan, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Rockville, Mary-
land: Functional studies of HIV-1 nef and rev regulatory
proteins.
W. Haseltine, H. Varmus
A. Fauci, F Wong-Staal
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Mutation Induction and Heritability in Mammalian Germ Cells
November 12 - November 15
ARRANGED BY
J.W. Allen, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina
M.J. Moses, Duke University Medical Center, Durham, North Carolina
L.B. Russell, Oak Ridge National Laboratory, Tennessee
SESSION 1: Germ-line Properties Affecting Mutation Induction
Chairperson: M.A. Handel, University of Tennessee, Knoxville
L.D. Russell, Southern Illinois University, Carbondale:
Structural evidence for entry of substances into the
seminiferous tubule.
I.B. Fritz, University of Toronto, Canada: Cell-to-cell interac-
tions in the seminiferous tubule.
D.G. De Rooij, University of Utrecht, The Netherlands:
Relation between the proliferative activity of
spermatogonial stem cells and their sensitivity to irradia-
tion and adriamycin and to translocation induction.
M.A. Handel, University of Tennessee, Knoxville: Heritable
SESSION 2: Aberrant Chromosome Structure/Behavior
Chairperson: M.J. Moses, Duke University Medical Center,
I.-D. Adler, GSF-Institut fuer Saeugetiergenetik, Neuherberg,
Federal Republic of Germany: Clastogenic effects of
acrylamide in different germ cell stages.
M.J. Moses, Duke University Medical Center, Durham,
Carolina: The synaptonemal complex as an indicator of
chromosome damage.
J.W. Allen, U.S. Environmental Protection Agency, Research
Triangle Park, North Carolina: Mutagen effects on the
synaptonemal complex.
and Recovery
mutations in the analysis of spermatogenesis.
N.B. Hecht, Tufts University, Medford, Massachusetts:
Regulation of postmeiotic genes.
G. Sega, Oak Ridge National Laboratory, Tennessee:
Molecular targets, DNA breakage, DNA repair: Their
roles in mutation induction in mammalian germ cells.
A. Wyrobek, Lawrence Livermore National Laboratory,
California: Detection of specific locus mutation in human
sperm.
Durham, North Carolina
M.E. Dresser, Oklahoma Medical Research Foundation,
Oklahoma City: Structure-function relationships in meiotic
chromosome behavior: An experimental approach.
Livermore Laboratory,
California: Human sperm cytogenetics and the one-cell
zygote.
M.T. Davisson, The Jackson Laboratory, Bar Harbor, Maine:
Chromosome aberrations associated mutations: Effect on
mapping new mutants.
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SESSION 3: Variables Affecting the Rate and Nature of Mutations
Chairperson: L.B. Russell, Oak Ridge National Laboratory,
B.M. Cattanach, MRC Radiobiology Unit, Didcot, England:
Factors affecting the recovery of mutations from mouse
spermatogonial stem cells following X-irradiation.
J. Favor, GSF-Institut fuer Saeugetiergenetik, Neuherberg,
Federal Republic of Germany: Mutagenic action of ENU
in germ cells of the mouse as interpreted from specific
locus mutation results.
S.E. Lewis, Research Triangle Institute, Research Triangle
Park, North Carolina: Electrophoretically detected mosaic
mutants in the mouse.
J. Peters, MRC Radiobiology.Unit, Didcot, England:
Tennessee
Comparison of electrophoretic and specific locus
mutation responses and analysis of glucose phosphate
isomerase mutants in the mouse.
J.D. McDonald, McArdle Laboratory for Cancer Research,
University of Wisconsin, Madison: Investigation of inborn
errors of phenylalanine metabolism by efficient mutagene-
sis of the mouse germ line.
L.B. Russell, Oak Ridge National Laboratory, Tennessee:
Relation of germ-cell stages to nature of induced
mutations.
SESSION 4: Nonmutational Genetic Effects on Early Development
Chairperson: M.F. Lyon, MRC Radiobiology Unit, Didcot, England
D. Solter, The Wistar Institute of Anatomy and Biology,
Philadelphia, Pennsylvania: Genomic imprinting and
mammalian development.
L.M. Wiley, University of California, Davis: A chimera embryo
assay reveals a decrease in embryonic cellular prolifera-
tion induced by sperm from X-irradiated mice.
W.M. Generoso, Oak Ridge National Laboratory, Tennessee:
Developmental anomalies: Mutational consequences of
zygote exposure.
0. Smithies, University of North Carolina, Chapel Hill:
Manipulation of the mouse genome by homologous
recombination.
SESSION 5: Utilization of DNA Techniques in the Detection of Germ-line Mutations
Chairperson: H. Mohrenweiser, Lawrence Livermore National Laboratory, California
H. Mohrenweiser, Lawrence Livermore National Laboratory,
California: Detection of insertion, deletion, and rearrange-
ment mutations in the genome.
B.W. Kovacs, University of Southern California School of
Medicine, Los Angeles: Quantitation and characterization
of human germinal mutations at hypervariable loci.
N. Arnheim, University of Southern California, Los Angeles:
Analysis of DNA sequences in individual gametes.
R. Woychik, Oak Ridge National Laboratory, Tennessee:
Insertional mutagenesis in transgenic mice.
SESSION 6: Genetic Risk Estimation
Chairperson: W. Russell, Oak Ridge National Laboratory, Tennessee
W. Russell, Oak Ridge National Laboratory, Tennessee:
Problems and possibilities in genetic risk estimation.
V.L. Dellarco, U.S. Environmental Protection Agency,
Washington, D.C.: Quantitative genetic risk assessment:
Induction of heritable translocations by ethylene oxide as
an example.
M.C. Cimino, U.S. Environmental Protection Agency,
Washington, D.C.: Use of germ cell mutagenicity data at
the U.S. Environmental Protection Agency.
Molecular Clocks of Evolution
November 28 - December 1
J.B. Bishop, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina:
Mammalian heritable effects research in the National
Toxicology Program.
P.B. Selby, Oak Ridge National Laboratory, Tennessee:
Importance of the direct method of genetic risk
estimation and ways to improve it.
B.A. Bridges, MRC Cell Mutation Unit, University of Sussex,
Brighton, England: Meeting summary.
ARRANGED BY
D.J. Melnick, Columbia University, New York, New York
M. Goodman, Wayne State University School of Medicine, Detroit,
Michigan
R.J. Britten, California Institute of Technology, Corona del Mar
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SESSION 1: Paleontological Calibration of Critical Taxonomic Branch Points with Particular Reference to Molecular Data
Chairperson: P.G. Gingereich, University of Michigan, Ann Arbor
L.L. Jacobs, Southern Methodist University, Dallas, Texas:
Geological dating and molecular clocks.
E.C. Olson, University of California, Los Angeles: Calibrations
of ancient vertebrate origins.
J. Lake, University of California, Los Angeles: Origin of the
multicellular animals.
E.S. Vrba, Yale University, New Haven, Connecticut: Using
molecular and morphological evolutionary rates to study
evolutionary processes in a group of mammals.
E. Mayr, Museum of Comparative Zoology, Harvard
University, Cambridge, Massachusetts: General
discussion.
SESSION 2: Specific Applications of Molecular Clocks
Chairperson: R.E. Pollack, Columbia University, New York, New York
I Gojobori, National Institute of Genetics, Mishima, Japan:
Molecular evolutionary clocks of viral genes.
W.-H. Li, University of Texas, Houston: Molecular clocks and
mammalian phylogeny.
R. Cann, University of Hawaii, Honolulu: Human mtDNA,
SESSION 3: Rate Variation within and between Genomes
Chairperson: W.M. Brown, University of Michigan, Ann Arbor
J.R. Powell, Yale University, New Haven, Connecticut:
Intragenomic heterogeneity in rates of DNA evolution in
Drosophila; a note on DNA clocks in higher primates.
R.J. Britten, California Institute of Technology, Corona del
Mar: Differences in rate of evolution between regions of
the Drosophila melanogaster genome.
TI. Bonner, National Institute of Mental Health, Bethesda,
calibrating evolutionary rates, new technology for
detecting natural selection.
V. Sarich, University of California, Berkeley: General
discussion.
Maryland: Evidence for unequal rates of DNA evolution
in primates.
T. Ohta, National Institute of Genetics, Mishima, Japan:
Nearly neutral mutations and the molecular clock.
T.H. Jukes, University of California, Berkeley: General
discussion.
SESSION 4: The Effects of Selection on Rates of Molecular Evolution
Chairperson: M. Goodman, Wayne State University School of Medicine, Detroit, Michigan
W.M. Fitch, University of Southern California, Los Angeles:
When do clocks go wrong? How often? How badly?
M. Goodman, Wayne State University School of Medicine,
Detroit, Michigan: Darwinian evolution and the accelera-
tion/deceleration pattern in rates of mutation and fixation.
M. Riley, University of Massachusetts, Amherst: Effects of
natural selection on nucleotide polymorphism.
M. Nei, University of Texas Health Science Center, Houston:
Effects of positive and negative Darwinian selection on
molecular clocks: Data from the MHC and immunoglobu-
lin families.
E. Zuckerkandl, Linus Pau ling Institute of Science and
Medicine, Palo Alto, California: General discussion.
E. Olson, F. Ayala, H. Carson
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R. Pollack, E. Mayr
SESSION 5: Molecular Consequences of Behavior Demography, and Biogeography
Chairperson: R.L. Honeycutt, Texas A & M University, College Station
H.L. Carson, University of Hawaii, Honolulu: Hybridization of
species may confound the molecular clock.
R. De Salle, Yale University, New Haven, Connecticut:
Hawaiian Drosophila: Biogeography and molecular
clocks.
Immunological Aspects of AIDS
D.J. Melnick, Columbia University, New York, New York:
Rapid rates of molecular change as a consequence of
behavior and biogeography.
F.J. Ayala, University of California, Irvine: General discussion.
December 4 - December 7
ARRANGED BY
M. Oldstone, Scripps Clinic and Research Foundation, La Jolla, California
S. Putney, Repligen Corporation, Cambridge, Massachusetts
SESSION 1: HIV Genomic Variability
Chairperson: B.H. Hahn, University of Alabama at Birmingham: Determinants of pathogenicity in naturally occurring strains
of HIV-2.
S. Wain-Hobson, Institut Pasteur, Paris, France: Genetic vari-
ation of HIV-1 in vitro.
C.-Y. Ou, Center for Infectious Diseases, Centers for Disease
Control, Atlanta, Georgia: HIV evolution and transmission
in infected persons.
G. Myers, HIV Sequence Database, Los Alamos, New Mex-
ico: HIV protein pattern analysis.
S. Putney, Repligen Corporation, Cambridge, Massachu-
setts: Variation of the neutralizing determinants of HIV-1.
SESSION 2: HIV-Cell Interactions
Chairperson: R.A. Weiss, Chester Beatty Laboratories, London, England: HIV neutralization and interaction with receptors.
Y. Riviere, Institut Pasteur, Paris, France: Study of the pri-
mary cellular immune response to HIV-1, using recom-
binant vaccinia viruses.
M. Oldstone, Scripps Clinic and Research Foundation, La
Jolla, California: Anatomy of CTL vaccine.
A.S. Fauci, National Institute of Allergy and Infectious Dis-
eases, National Institutes of Health, Bethesda, Maryland:
Cytokine modulation of HIV expression.
E.G. Engelman, Stanford University School of Medicine,
California: Mechanisms responsible for CD4+ T -lym-
phocyte dysfunction and depletion in HIV-injected
patients.
M.A. Martin, National Institute of Allergy and Infectious Dis-
eases, National Institutes of Health, Bethesda, Maryland:
Structural and functional relations of the HIV envelope
gene.
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D.E. Mosier, Medical Biology Institute, La Jolla, California: J.M. Coffin, Tufts University
School of Medicine, Boston,
Consequences of HIV infection of hu-PBL-SCID mice.
Massachusetts: Genetic variation in retroviruses.
SESSION 3: HIV-Immune System Interactions: Antibody
Chairperson: J.J. Skehel, National Institute for Medical Research, London, England
P.L. Nara, NCI-Frederick Cancer Research Facility, Mary-
land: HIV-1 neutralization: A humoral paradox.
J. Salk, The Salk Institute for Biological Studies, San Diego,
California: Strategies for the control of HIV infection
and/or disease using an envelope-depleted inactivated
HIV immunogen.
R. De Mars, University of Wisconsin, Madison: A human
mutant cell - gene transfer system for studying immune
responses to HIV proteins.
D.D. Ho, University of California, Los Angeles, School of
Medicine: Quantitation of HIV-1 in the blood of infected
persons.
R.S. Fujinami, University of California, San Diego, La Jolla:
Common determinant between HIV gp41 and human
astrocytes.
SESSION 4: HIV-Immune System Interactions: CTL
Chairperson: M. Oldstone, Scripps Clinic and Research Foundation, La Jolla, California
B.D. Walker, Massachusetts General Hospital, Boston: Spec-
ificity of HIV-1-reactive CTLs.
F. Gotch, Institute of Molecular Medicine, John Radcliffe
Hospital, Oxford, England: Are HIV-specific CTLs termi-
nally differentiated in HIV-seropositive patients?
S. Koenig, National Institutes of Health, Bethesda, Maryland:
Cell-mediated immunity in HIV-seropositive individuals.
J.A. Berzofsky, National Cancer Institute, NIH, Bethesda,
Maryland: Viral sequence variation and MHC polymor-
phism in immune control of virus and viral escape.
J.L. Whitton, Research Institute of Scripps Clinic, La Jolla,
California: Virus sequence requirements for induction of
cytotoxic and lymphocytes and for CTL-mediated an-
tiviral immunity.
J. Chiller, Eli Lilly and Company, Indianapolis, Indiana:
General discussion.
SESSION 5: Viral Pathogenesis: Lessons from Animal Models
Chairperson: 0. Narayan, Johns Hopkins University School of Medicine,
A humoral paradox.
N.L. Letvin, Harvard Medical School, Southborough, Mas-
sachusetts: The CD8+ lymphocyte response in SIV-
infected rhesus monkeys.
Baltimore, Maryland: HIV-1 neutralization:
J.N. Coffin, Tufts University School of Medicine, Boston,
Massachusetts: Genetic variation in retroviruses.
J. Salk, S. Putney
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1989 PUBLICATIONS
Molecular Cloning: A Laboratory Manual (2nd edition)
J. Sambrook, E.F. Fritsch, and T. Maniatis
Molecular Biology of Signal Transduction
Symposia on Quantitative Biology 53
Drosophila: A Laboratory Handbook and Manual
M. Ashburner
Molecular Diagnostics of Human Cancer (Cancer Cells 7)
M. Furth and M. Greaves (eds.)
Vaccines 89
R. Lerner, H. Ginsberg, R. Chanock, and F Brown (eds.)
DNA Technology and Forensic Science (Banbury Report 32)
J. Ballantyne, G. Sensabaugh, and J. Witkowski (eds.)
Current Communications in Molecular Biology Series
Polymerase Chain Reaction
H. Erlich, R. Gibbs, and H. Kazazian, Jr. (eds.)
Recessive Oncogenes and Tumor Suppression
W. Cavenee, N. Hastie, and E. Stanbridge (eds.)
Viral Proteinases as Targets for Chemotherapy
H.-G. Krausslich, S. Oroszlan, and E. Wimmer (eds.)
Cytoskeletal Proteins in Tumor Diagnosis
M. Osborn and K. Weber (eds.)
Therapeutic Peptides and Proteins: Formulation, Delivery, and Targeting
D. Marshak and D. Liu (eds.)
Development and Application of Molecular Markers to Problems in Plant Genetics
T. Helentjaris and B. Burr (eds.)
Perspectives on the Molecular Biology and Immunology of the Pancreatic JY Cell
D. Hanahan, H. McDevitt, and G. Cahill, Jr. (eds.)
Molecular Genetics of Early Drosophila and Mouse Development
M. Capecchi (ed.)
Journals
Genes & Development (Volume 3, numbers 1-12B)
Cancer Cells: A Monthly Review (Volume 1, numbers 1-4)
Other
CSHL Annual Report, 1988
Abstract/program books for 14 CSHL meetings
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COLD SPRING HARBOR LABORATORY PRESS
This Report marks the emergence in 1989 of Cold Spring Harbor Laboratory
Press as a distinct operating unit of the Laboratory. Like the Banbury and DNA
Learning Centers, the Press has its own staff and operating budget. It combines
the acquisition and development of new publishing projects with the work of the
long-established Publications (book editorial and production) Department headed
by Nancy Ford; the Fulfillment and Marketing Departments headed by Charlaine
Apsel; and the new Journal Department headed by Judy Cuddihy. Thirty-three
staff members are currently employed by the Press, located in the Carnegie
Building, Urey Cottage, the Grace Auditorium Bookstore, and our warehouse in
Cold Spring Harbor village. Because of the size and dispersed nature of the
operation, communication between departments has to be good, in the interests
of efficiency.
The mission of CSHL Press is threefold: to provide revenue for the Laboratory
from monographs, journals, and other media; to extend the Laboratory's
educational activities by publishing the proceedings of its meetings and technical
manuals from its courses; and to produce Laboratory materials such as this
Annual Report and the meetings abstract/program books.
The "Bible of Molecular Biology": A New Testament
1989 proved to be an outstanding year. Among the most notable events, pride of
place must go to the publication in November of the second edition of Molecular
Cloning: A Laboratory Manual. "Eagerly awaited" has become a publisher's cliché,
but it was never more appropriate than in this case. After four years of labor, Joe
Sambrook, Ed Fritsch, and Tom Maniatis, with associate author, Nina Irwin, and
the assistance of over 60 scientific advisors, produced a manual that is
comprehensive, clear, authoritative, and as easy to use as any three-volume work
can be. This enterprise would not have been possible without the extraordinary
dedication of managing editor, Nancy Ford, and her assistants, Chris Nolan and
Michelle Ferguson. The publication of the first edition of Molecular Cloning, in
1982, put recombinant DNA technology within the grasp of scientists in every
biomedical discipline. It also alerted other publishers to the importance of
technical manuals in molecular biology. The subsequent seven years produced
many competing books, but the clamor of 25,000 advance orders for the second
edition and the sale of a further 10,000 copies within three months of publication
have shown us once again that a reputation for quality and reliability is a most
precious asset.
Strong Sales and Significant Influence
The success of Molecular Cloning did not obscure the impact made this year by
another of our laboratory manuals, Antibodies, by Ed Harlow, a senior scientist at
Cold Spring Harbor Laboratory, and David Lane of the Imperial Cancer Research
Fund Laboratories, UK. Published late in 1988, the book's sales climbed rapidly
past 10,000 copies in 1989 and collected a sheaf of admiring reviews.
These
noted, among other virtues, the exceptional clarity of the writing
about immunol-
ogy, a discipline notorious for the obscurity of its jargon. Antibodies is a unique
book and has attracted international interest. A French edition is in
preparation,
and we have hopes of a version in Japanese.
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A total of 14 books were published this year. Nine originated in meetings at the
Banbury Center and two of these are particularly notable. The Polymerase Chain
Reaction, in our rapidly published Current Communications series, summarizes a
wide range of investigators' experiences with a technique for DNA amplification
that is only three years old. Its literature is sparse, but its practical applications
seem almost limitless. The book has therefore been much in demand, selling over
2000 copies. Influence, however, does not always need large sales. With more
modest circulation, Banbury Report 32, containing contributions from lawyers as
well as scientists, has contributed significantly to the debate on the use of DNA
technology in forensic analysis, a subject now frequently found on the nation's
news pages. The innovative meetings at Banbury under Jan Witkowski's direction
suggest interesting publishing opportunities, and we continue to explore the best
ways of conveying to a wide audience a sense of having been there.
In the last days of the year, we received from the printer the first copies of a
magisterial work by Michael Ashburner. Drosophila: A Laboratory Handbook and
Manual distills into two volumes, 1700 pages long, an exceptional scholar's
knowledge of the tiny fruitfly from which so much knowledge of gene function has
come. These beautifully designed books will be classics.
The hallmark of CSHL Press publications continues to be an obsessive
concern for accuracy and quality. It is a pleasure to acknowledge the work of the
book editorial and production staff, who aim for the same high standards on every
project, whether it is a handsome monograph, an inexpensive paperback, the
meetings abstract books (14 in 1989), or the Laboratory's Annual Report. Particular
mention should be made of the important leadership given to the department by
Annette Kirk and Dorothy Brown while Nancy Ford was wholly committed to work
on Molecular Cloning. Lee Martin was a valuable addition to the Production staff
in 1989. We also sought extra assistance from advanced technology, with the
purchase of an optical scanner capable of reading manuscript pages straight into
computer files for editing. Our in-house microcomputer-based typesetting system
was applied for the first time to a large book, Vaccines 89, with satisfactory results
and savings of both time and money. More books will be typeset in this way next
year.
Continued Growth in Quality of Genes & Development
For Genes & Development, its third year of publication was one of continuous
growth: 538 manuscripts were offered for publication, a 38% increase over the
previous year, and 196 were published in 13 issues. A growing proportion of
papers submitted are now judged outstanding, rather than simply worthy of
publication, and as a result, the quality of issues has never been higher. This was
reflected in 1989 by the frequent selection of papers published in the journal for
editorial comment by other publications.
Much credit for this increase in quality lies with the editors who select the
papers to be published and the referees they consult. Reviewers are the
gatekeepers for any primary journal, and our thanks go to the editorial board
members and several hundred referees who unstintingly gave their time and
expertise to ensure that Genes & Development will continue to grow into a journal
of the highest quality.
Its rising reputation was reflected in a gratifying 30% increase in subscriptions.
The journal now has subscribers in 35 countries, and as the year ended, the level
of new as well as renewed subscriptions promised more circulation growth in
1990.
When a new journal is launched, high costs are incurred from the outset, while
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revenues accrue slowly. The investment required to reach break-even point can be
daunting, and careful cost control is imperative. To help defray the journal's
expenses, the decision was taken to levy a charge of $20 per page on papers
published in the journal in 1990. This assistance, with an increase in the other
sources of revenue, should bring to an end in 1990 the period of investment in
Genes & Development required from the Press and its co-owner, the Genetical
Society of Great Britain.
In January, Terri Grodzicker of the Laboratory's scientific staff became the
journal's U.S. editor, and she was able to combine successfully the growing
demands of the job with her duties as Assistant Director for Academic Affairs. Her
experience and enthusiasm have been invaluable. Toward the end of the year
Grahame Bulfield, the journal's European editor, announced his intention to step
down because of newly assumed responsibilities as Director of his institute.
Grahame was a founding editor of Genes & Development, and we are grateful for
all he did for the journal in its first three years. He will be succeeded in 1990 by
Nicholas Hastie, a senior scientist at the MRC Human Genetics Institute in
Edinburgh. Nick is highly respected as a scientist with imagination, energy, and
wide-ranging interests. These are ideal qualifications in an editor, and we look
forward to Nick's joining the editorial team. The journal department was also
strengthened by the addition of Michele Cleary, who brought both publishing and
laboratory experience to the role of editorial assistant.
A Second Journal Is Launched
The evolution of our Journal Department continued in 1989, when months of
preparation resulted in the September launch of the Press's second journal,
Cancer Cells: A Monthly Review. This subscription-based magazine of cancer
research replaced the once-yearly books published in the Cancer Cells
The field it covers is large and diverse, bringing together scientists of many
disciplines and a variety of medical specialists. Some scientists investigate cell
function at a molecular level and others pursue findings with therapy or diagnosis
in mind, whereas physicians try rationally to apply the emerging tests and
treatments. Cancer Cells' ambitious aim is to interest and educate them all.
With the help of Judy Cuddihy and the enthusiastic members of the Journal
Department, the editor, Paula Kiberstis, put together four monthly issues in 1989
containing invited short reviews, features, and commentaries that were informative
and occasionally provocative. These were delivered in an attractive, contemporary
design, between the notable covers that have become a feature of both our
journals. The subscription response to the substantial initial promotion campaign
mounted by our Marketing Department was highly satisfactory. These are early
days, but Cancer Cells has made a most promising start.
Striking Publicity and Overwhelming Orders
Our marketing activities in 1989 remained centered upon direct mail. Brochures,
leaflets, and a three-times-yearly newsletter, the Notebook, giving advance informa-
tion about our publications, were sent to many thousands of potential customers
worldwide. A complete catalog was circulated in the fall, and display advertise-
ments were placed in selected, large-circulation journals as appropriate.
Comments received from the scientific community suggest that our publicity was
more noticeable this year. Much of the credit belongs to the eye-catching
brochures, catalogs, and advertisements designed by new staff member
Jim
Suddaby. With another 1989 recruit, Lisa Sweeney, Jim also produced each issue
of the Notebook using desktop publishing techniques devised in-house.
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Our marketing activities also include the sale of publications at the larger
scientific conferences. Organized by Penny Sheppard, these appearances at
meetings attended by as many as 15,000 delegates provide valuable contacts with
current and prospective authors and reassurance that, in our core markets, we are
more than a match in sales for the large commercial houses. In 1989, we attended
eight American meetings, a larger number than usual, in fields as diverse as
human genetics, neuroscience, and microbiology. In addition, CSHL Press
exhibited for the first time at a European scientific meeting, the International
Immunology Congress in West Berlin, and at the Frankfurt Book Fair, where useful
discussions with a number of booksellers led to changes in sales policy that will
benefit both our customers and ourselves.
Charlaine Apsel combined the direction of these marketing activities with a
substantial hands-on role as head of the Fulfillment Department. The work of this
department proceeded steadily for much of the year, buoyed by the strong sales
of the new titles and the back list. But after publication of Molecular Cloning and
our catalog, orders arrived in unprecedented numbers by phone, FAX, and mail,
often several hundreds each day. Despite these pressures, the Customer Service
staff remained efficient and good-humored. Jackie Matura was a welcome and
timely addition to their ranks in mid-year.
The many thousands of advance orders for the manual were fulfilled within
three weeks of its publication. The Warehouse Manager, Guy Keyes, and those
who assisted him deserve congratulations, not just for this exceptional effort but
for maintaining an efficient dispatch service throughout the year.
The increase in our active titles this year and the need to keep adequate
copies of several best-selling titles in stock have swamped our warehouse. Rented
trailers are being used as an expedient, but our need for more storage space will
become critical in 1990 with the expected publication of at least 15 books. These
will include the next four titles in our prestigious monograph series, the next
edition of the serial compendium Genetic Maps in a completely revised format,
and several new technical manuals. We also anticipate the start of an important
new book series, Genome Analysis, edited by Kay Davies of Oxford University
and Shirley Tilghman of Princeton University. For her invaluable help in the
development of these and other new projects, I am extremely grateful to my
assistant, P.J. Harlow.
What Lies Ahead?
For many science publishers, the late 1980s have not been the best of times.
Anxiety about traditional products and markets has been fueled by declining
library budgets, falling R&D in Western industries, and the quickening growth of
electronic systems for copying, storing, and distributing information. Mergers and
acquisitions are creating a limited number of commercial giants with diverse
publishing interests, strong enough, it is hoped, to exploit the changes to come.
CSHL Press is the antithesis of that trend, a small independent house specializing
in certain areas of biology. Yet we have certain key advantages: proximity to a
world-class research center, the respect earned by the excellence of our past and
present publications, an experienced and professional staff close to the scientific
community, and active support for prudent expansion from James Watson,
Morgan Browne, and the Laboratory's Executive Committee. Our aim is to grow
without compromising our reputation for quality. If that can be accomplished,
there will still be a special place for CSHL Press, whatever the shape of science
publishing in the decade to come. John R. Inglis
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DNA LEARNING CENTER
David A. Mick los, Director
Mark V. Bloom, Assistant Director
In 1944, the eminent physicist Erwin Schrodinger published a small book entitled
What is Life? The Physical Aspects of the Living Cell, in which he mused on
cracking the molecular "code-script" that governs the inheritance and expression of
life functions. SchrOdinger, whose wave equation helped describe the structure of
the atom, stood in awe of the self-replicating ability of living things. He even went
so far as to suggest that the essence of the mystery of life might entail new
physical principles: "From all we have learnt about the structure of living matter, we
must be prepared to find it working in a manner that cannot be reduced to the
ordinary laws of physics:'
Schrodinger's book influenced a generation of scientists to quest after the
molecular "code-script" of life, including such pioneers of molecular biology as Max
w III it 11101111 = 114
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Delbruck, Francis Crick, and James Watson. No new laws of physics were
uncovered in cracking the genetic code. The fact that all molecules are
constructed according to the same physical chemical rules made it possible for
Watson and Crick to deduce the structure of the DNA molecule. With a deeper
understanding of the physical principles of DNA structure and function has come
the ability to treat DNA as "merely" a molecule with predictable biochemical
properties.
During the last 15 years, treating DNA as an ordinary molecule has led to the
extraordinary ability to dissect any of the 100,000 human genes that compose the
human chromosomes-the human genome. The dissection of the molecular
pathway through which hereditary information flows between DNA, RNA, and
protein molecules has added rich detail to our understanding of how human life
develops and changes-from fertilized egg to adulthood. It has also enabled
scientists to isolate and map to their chromosomal positions the genes responsible
for a number of genetic illnesses, including muscular dystrophy and cystic fibrosis.
The Human Genome Project
The inauguration of the Human Genome Project in 1988 marked the beginning of
a national commitment to apply DNA technology toward understanding human
health and development. Its goal is to determine the sequence of the estimated
three billion bits of molecular information-the arrangement of nucleotide rungs of
the DNA ladder-that constitute the entire code-script of human life.
Possession of an increasingly complete set of hereditary information will bring
numerous benefits to humankind. By pushing back the threshold of early disease
detection, DNA diagnosis will increase therapy options and play a positive role in
personal health management. Understanding the molecular basis of disease
should lead to therapies that treat the cause, rather than the symptoms, of illness.
Similar techniques are now used to produce DNA fingerprints, which are gaining
Glasnost- DNA style! In December a group of high school students, visiting from Moscow, came
to the Learning Center for an introduction to DNA experimentation. Assistant Director Mark Bloom
helps Soviet students with their experiment.
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acceptance as the most definitive evidence of identity in rape, murder, and
paternity cases.
The day is not far off when a battery of DNA diagnoses will likely be part of a
routine visit to the family doctor, providing an extraordinarily detailed picture of an
individual's own genetic frailties. DNA fingerprints will join fingerprints and thumb-
prints kept on file by law enforcement agencies. In 1989, Genetic Therapy, Inc.,
was formed as the first company to explore methods to replace and repair
defective genes.
The Social Imperative
Since the explosion of information made possible by the invention of the printing
press, a democracy has needed to be a society of literates. Similarly, the explosive
growth of DNA-based technology demands a society of DNA literates. It is clear
that the science of DNA will increasingly generate important public policy issues. If
we indeed believe in the Madisonian concept of an informed citizenry that partici-
pates in public decision making, then DNA literacy can no longer be considered
an esoteric pursuit.
Unfortunately, all indicators point to the fact that DNA science is moving so fast
that the gulf between technological advance and public understanding is wider
than ever before in the history of science. For example, a 1986 National Science
Foundation study found that 57% of Americans claim to have little or no
understanding of DNA. This state of public ignorance threatens the nation's ability
to make informed policy decisions about issues generated by the new biology.
To a great extent, public education will determine whether such information
realizes its compassionate potential for personal health management or is feared
as a sort of science fiction fortune telling. Clearly, society cannot afford another
era of abuse of genetics, such as was incurred during the Nazi quest for racial
purity. Public involvement is key to the development of guidelines governing
access to this genetic information to ensure protection of individual privacy rights.
As applications of DNA science leave the laboratories, trained personnel from
nearly every segment of society must interface with this new technology. Young
people entering the medical, agricultural, manufacturing, and even legal pro-
fessions will be expected to have a basic command of DNA science. There is
growing concern within the scientific community that a predicted shortage of
American-born biologists during the next several decades could severely diminish
our leadership in health-related research and development.
The Problems of Science Education
We are in the infancy of a scientific and social revolution of monumental
proportions. Even so, the exciting prospects and problematic aspects of human
genetics remain, for most young people, in the realm of science fiction. Thus, the
excitement of the Human Genome Project offers an important opportunity to
substantially reorganize science and health education to include new emphasis on
human genetics. Failure to do so means failure to examine many of the most
exciting topics science has to offer, failure to present socially and personally
relevant issues, and, in the final analysis, failure to fulfill teaching's
most important
function-to prepare citizens capable of informed votes on policy issues.
We live in an age when young people are buffeted by all manner of
distrac-
tions that keep them from pondering the biological mystery of life.
Students
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DNA experiments are offered to members of the Long Island Biological Association on a regular
basis. Mark Bloom helps LIBA members interpret their DNA gel.
socialized to be fascinated by money, and what it can buy, have little time for
physics or metaphysics. However, in working directly with DNA, the molecule of
life, we may have the last decent chance to interest young people in careers in
biological research.
The restructuring of biology curricula must not be aimed merely at the
academically gifted, but must be geared to the abilities of all young people. In the
1990s, a basic understanding of human genetics must be considered as important
as a basic understanding of hygiene and nutrition. "Retooling Biology Education
for the Gene Age',' a study conducted by the DNA Learning Center of 252 high
school biology teachers from 10 states confirmed this opinion; they rated genetics
along with ecology as the biology topics "most important in preparing students for
adult life:'
Our experience with over 1000 advanced high school teachers in 24 states
suggests that DNA literacy is only trickling through formal channels of science
communication. Curriculum setters at the state and even national levels have done
little to square teaching syllabuses with the reality of modern biology. Biology
curricula have evolved over the years by simply cramming in more and more facts.
So, at best, human genetics still must compete with frog biology for mention in the
classroom.
High school biology teachers are hamstrung by overambitious and outdated
syllabuses. Survey data show that the vast majority spend most of their class time
lecturing from textbooks. Yet the textbooks they teach from are typically five to ten
years out of date and fail to account for the biology that appears in the news
almost daily. Fewer and fewer biology students are given the opportunity for any
sort of meaningful laboratory experience, let alone
"advanced" experiments with
DNA. It is a sad fact that biology education has changed little from the days of
our grandparents. Hands-on laboratories are the exception; rote memorization is
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the norm. Thus, at a time when scientists are embarking upon the most ambitious
project in the history of biology, students are required to memorize terms and
definitions of observational biology, a historical science of little relevance to society.
DNA Science: A First Course in Recombinant DNA Technology
Molecular biology is generally construed as the culminating experience of the
biology major's academic career. We believe that lab-teaching in molecular biology
should be an initiating experience-introduced in general survey courses and
comprehensively instituted in advanced high school and beginning college level
courses. Through its Postgraduate Training Program and laboratory manual
Molecular Cloning, Cold Spring Harbor Laboratory has played a key role in
educating research biologists in molecular biological techniques. The DNA
Learning Center extends this training to high school and college teachers through
the DNA Science Workshop program.
The laboratory exercises developed for the workshop will be formally published
as DNA Science: A First Course in Recombinant DNA Technology by David
Mick los and Greg Freyer. A joint publication of Cold Spring Harbor Laboratory
Press and Carolina Biological Supply Company, the lab/text is the first specifically
written at the advanced high school and freshman college levels. In addition to
ten field-tested protocols, extensive notes give the novice teacher access to
technical subtleties that are the distillation of our teaching experience and research
collaborations with over 1100 educators across 24 states.
A separate text, written in a semi-journalistic style, builds upon basic biological
principles presented in a general survey course. Classical genetics and DNA
structure are reviewed in a historical chapter that traces the development of
molecular biology. An initial technique chapter explains the theory behind
methods actually used in the laboratory. The last four chapters discuss topics of
current interest that illustrate the use of recombinant DNA in basic and applied
research, drawing examples directly from prominent research journals, including
Cell, Science, and Nature.
Starting Early
A basic introduction to human genetics should, in fact, begin in elementary
and
middle school. These teachers, who interface with a cross section of
Americas
youth, constitute a major conduit through which scientific literacy can flow to
society. As a content area, human genetics at once builds upon
the traditional
health emphasis of elementary and middle-school science and offers an
entrée to
pure science. Genetics emphasizes science as a problem-solving
venture involving
the collecting, sharing, and analyzing of data. It is also consistent
with the across-
curriculum approach that incorporates science, math, and social studies
and
emphasizes the evaluation of science and its practical applications.
Children start their lives as natural scientists. Survey data
tell us that the
majority of elementary school students are enthusiastic about science;
however,
student interest decreases dramatically through the middle
and high school years.
Making best use of this window of opportunity during the elementary
years may
have two important effects. First, it can inculcate basic tenets
of scientific literacy
that are essential for all children as they grow into adulthood.
Second, it may light
an academic spark for science that will survive into
the college years.
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The Challenge to Informal Science Education
Although the nation's schools are the logical place to begin building a DNA literate
public, these formal channels of science education do not appear to be moving
quickly to integrate human genetics into curricula at the precollege and even
beginning college levels. This challenges agents of informal science education to
move quickly to fill the void in public education and play an active role in
preparing teachers to integrate human genetics at all levels. In this way, museums
and science centers can help bootstrap biology teaching into the gene age.
In 1985, Cold Spring Harbor Laboratory instituted enrichment activities for
precollege teachers and students under the title of the DNA Literacy Program.
Key was the development and testing of entry-level experiments in molecular
genetics. Although these laboratories were once viewed as somewhat esoteric,
there is now growing conviction that they are essential to a general biology
education. This sentiment has been legitimized by the Educational Testing Service,
which recommended the teaching of DNA manipulation laboratories in the
1989-1990 Advanced Placement (AP) Biology syllabus. These laboratories will
become compulsory for AP students in 1993-1994. Similar laboratories are
included in the 1989 edition of a widely used text published by the Biological
Science Curriculum Study.
As national curriculum setters, the Educational Testing Service and Biological
Science Curriculum Study have, in effect, mandated DNA laboratory teaching at
the high school level. Our experience in 24 states and Canada indicates that even
the elite cadre of AP and honors teachers do not have the hands-on experience
needed to introduce these laboratories with confidence. Thus, science centers can
play a critical role in updating teachers on molecular genetic techniques, with
which most have had no formal training. However, training activities are likely to
affect only the upper echelon of most motivated teachers. Science centers must
therefore take responsibility for the students of less-motivated teachers, who do
little laboratory teaching of any sort.
The DNA Learning Center initiated a laboratory field trip program in spring of
1988, following completion of the 8'02000 Laboratory. The program was an
immediate success; every laboratory space has been continuously booked since
that time, with a standing waiting list of 30 schools. Two laboratories are currently
offered:
Bacterial Transformation: This experiment illustrates the direct link between an
organism's genetic complement (genotype) and its observable characteristics
(phenotype). Students introduce a new gene into the bacterium Escherichia coli,
giving it the ability to grow in the presence of the antibiotic ampicillin. Teachers
take culture plates back to their schools for incubation and discussion of results.
DNA Restriction Analysis: This experiment demonstrates that DNA can be
precisely manipulated and that it behaves as predicted by the structure discovered
by Watson and Crick in 1953. Students use restriction enzymes to cut purified
DNA, and the resulting fragments are separated according to size using gel
electrophoresis. Students take home Polaroid snapshots of their results.
Our experience with rural schools in Alabama and public schools in New York
City indicates that DNA laboratories need not be confined to gifted high school
students. Laboratories are perhaps even more important to the nongifted student,
for whom involvement of several senses increases chances for internalization of the
biological concepts. These students may possess greater manual dexterity, and
achieve better results, than their academically gifted peers. Success with
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laboratory manipulation may provide a handle with which the nongifted student
can pull a theoretical concept into his or her realm of experience.
In spring 1989, we conducted a learning experiment that supports our
contention that there is no intrinsic reason why young people should not be given
the opportunity to try their hands at DNA manipulation labs. Eighteen gifted fifth
and sixth graders from local school districts were invited into the Bio2000
Laboratory for a Saturday laboratory program, "Fun with DNA." During two
introductory sessions, the youngsters observed and categorized Drosophila
DNA Learning Center Director David Micklos looks over experiments performed by elementary
school students.
mutations, analyzed inheritance of kernel characteristics in corn, used classmates'
trait data for a ministudy on population genetics, constructed models of DNA
molecules, and learned to handle sophisticated micropipets. In the final session,
the students successfully performed the DNA restriction analysis described above.
We found that the students' grasp of concepts was comparable to, or better
than, that of many of the high school students we have taught. Working with these
eager and inquisitive young scientists was at once invigorating and saddening.
Invigorating because it showed us the full measure of childhood thirst for
understanding of the natural world. Saddening, because we can only wonder in
how precious few of these young people the spark of science will be kept alive
through the remainder of their precollege schooling.
In an era when fewer teachers have the time or equipment to offer meaningful
laboratory experiences, the laboratory field trip program is a model for a cost-
effective means to provide pooled laboratory resources to a local region. Since
its
opening, the Bio2000 Laboratory has served 2000 students (105 classes) from
March to December 1988 and 3800 students (183 classes) in all of 1989. A DNA
teaching lab like ours can be equipped for $10,000-20,000, and a field trip
program can be operated at a cost of $30,000-50,000 per year (exclusive of
utilities and facility overhead). By making routine the performance of several
laboratory experiences, museums, regional science centers, vocational
technology
centers, and "magnet" schools can at once take up the slack in laboratory
teaching and help to train teachers for independent instruction.
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Vector DNA Science Workshops
The silver Vector vans that crisscross the country during the summer to give in-
service training to high school and college instructors have become the identifying
emblem of the DNA Literacy Program. Through summer 1990, the Vector staff will
have instructed nearly 1400 educators at 69 workshops across 28 states and
Canada. Allied programs in North Carolina and California will have independently
instructed an additional 621 teachers at 27 workshops. Recognizing the
educational value of this workshop experience, the State University of New York at
Stony Brook agreed to offer a credit option to DNA Science Workshop
participants nationwide. Teachers who complete both a workshop and follow-up
are eligible for three graduate credits from the Continuing Education Department.
A workshop has been held at the Stony Brook campus each summer since 1987,
sponsored by the University's Center for Biotechnology.
Our experience over the past four years has strengthened our conviction that
the DNA Science Workshop is equally valuable to college teaching faculty who
have little or no practical experience in molecular genetic analysis. Our first
workshop geared specifically to college teachers was held at Bethany College in
West Virginia in June 1989. This workshop was supported by a grant from the
National Science Foundation to Bethany College and was attended by faculty
members from a consortium of eight small colleges from West Virginia, Ohio, and
Pennsylvania. Positive feedback from this workshop reinforced our belief that the
information needs of college instructors are not far different from those of the high-
caliber AP teachers we have regularly encountered. We envision the Bethany
workshop as a model for a nationwide series of workshops patterned after our
successful high school program.
Colleges and universities provide infrastructures conducive to implementing
experiments introduced during the DNA Science Workshop. The entire course
can serve as the core of a sophomore-level molecular biology course, or individual
experiments can be integrated at various levels into the biology curricula, including
courses on general biology, cell biology, microbiology, genetics, and biochemistry.
Costs to equip and supply a DNA teaching laboratory are well within the means of
most college biology departments.
Educational Collaborations
The Curriculum Study has grown to include 24 Long Island school districts, which
receive numerous benefits, including lectures by scientists, reduced admission
fees to Learning Center programs, teacher in-service workshops, and equipment
purchase options. Curriculum Study teachers gain an insider's view of current
biological research and of the future of modern biology teaching. As the Curricu-
lum Study continues to grow, we strive to provide a support system for pioneer
teachers on Long Island, who are retooling biology education for the next century.
Through our collaboration with the Josiah Macy, Jr, Foundation, we have
extended our teacher-training and student programs to Macy-sponsored schools in
inner-city New York and New Haven, Connecticut, as well as in rural Alabama and
Arizona. In summer 1989, minority/rural students and teacher chaperones
representing each of the Macy-sponsored programs convened for a 2-week
workshop at the DNA Learning Center. The first week of the workshop provided a
microteaching experience, where students and their instructors learned DNA
manipulation techniques in preparation for implementing specialized laboratory
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courses at their home schools. During the second week, the students sampled
some New York culture, including the Metropolitan Museum, Bronx Zoo,
Broadway, the New York Mets, and a whale watch off Montauk Point.
A related collaboration is with the Macy BioPrep program at the University of
Alabama, at Tuscaloosa, where a DNA Science Workshop has been held each
year since 1987. With our assistance, the BioPrep staff has outfitted their own
Vector van, which carries DNA restriction and bacterial transformation experiments
to schools in rural Alabama. Since spring of 1988, the mobile laboratory has
visited 62 schools where BioPrep teachers have instructed 2000 students.
The 1986 workshop held at the University of California at Davis prompted the
creation of a state-supported instructional program. A mentor/teacher program was
established at San Francisco State University to give high school teachers training
in recombinant DNA techniques and access to working researchers who serve as
their mentors. Our workshop is taught at three locations in California, and they
have also "cloned" our Vector van approach to teaching. A minivan supplied by
Genentech, Inc.-named Helix I-carries equipment to participating schools,
where teachers and 600 students have performed DNA experiments.
A 1987 workshop, conducted in cooperation with the North Carolina Biotech-
nology Center, provided the initial impetus for what has become the nation's most
extensive state-supported program in molecular biology education. Lead teachers,
selected from throughout North Carolina, were trained at the 1987 workshop and
then returned to their regions to assist local scientists in conducting eight local
workshops in summer 1988 that reached an additional 172 teachers. By the end
of 1989, the number of teachers trained increased to 325.
The program also makes available, on a rotating basis, eight
equipment sets to
help teachers begin to implement DNA laboratories. By the end of the 1989-1990
school year, 100 schools, representing two thirds of the school districts
in the state,
will have used an equipment set. One small measure of the
program's success is
the case of Celeste Posey, a senior at the North Carolina School of Science
and
Mathematics, who, working under the mentorship of a teacher trained at
the 1987
workshop, took fifth place in the 1989 Westinghouse Talent Search.
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Students from New York, Con-
necticut, Alabama, and Ari-
zona participated in a two-
week workshop sponsored
by the Joshia Macy, Jr.
Foundation.
Another ongoing collaboration is with the Institute for Genetics Education at the
University of Wisconsin-Madison, where the DNA Science Workshop is one of
several modules devoted to the study of genetics and its ethical implications.
Reception of the workshop in 1988 was so enthusiastic that it has been incorpo-
rated as a standard part of the Institute's summer program.
As the year ended, we began a collaboration with the Howard Hughes Medical
Institute. Respected as the largest nongovernment contributor to medical research,
Hughes is now aiding the effort to revitalize science education. So, we were
pleased when the Vice President of Hughes, Joseph Perpich, asked us to help
establish a DNA science program in their home area of Montgomery County,
Maryland. During the next year, we will be working with Hughes to train
Montgomery County educators in laboratory-based DNA science teaching.
The Evaluation Program
As of fall 1989, we have personally instructed nearly 1100 high school and college
instructors in DNA science workshops. The majority have completed both a pre-
survey at the beginning of the workshop and a post-survey at the end of their
week-long training. In fall 1988, we began a mail survey to follow up on 252
teachers who had completed the workshop prior to 1988. The response of our
"alumni" was overwhelming; 90% returned completed surveys.
We have just completed a preliminary analysis of the survey data. The findings
document a number of behavioral changes that resulted from workshop participa-
tion and suggest ways to promote innovation in the science classroom.
Seven in ten teachers had presented new topics on molecular biology and
attempted at least one new laboratory during the school year following the
workshop. Three in ten had implemented laboratories on DNA transformation
(36%) and DNA restriction analysis (28%).
Many participants carried on networking activities to educate other teaching
professionals about molecular biology, including presentations (36%), lab
demonstrations (24%), presentations at professional meetings (11%), and training
workshops (11%).
A majority of workshop participants (54%) attempted to secure funds or
equipment with which to implement new laboratories. Seven in ten of those who
tried were successful, reporting a total of $189,000 in monetary support and
$88,000 in equipment/reagent donations.
The highly innovative science teacher feels more respected in the community
and has more positive attitudes about his/her students' parents and school
administration. This finding emphasizes that the more innovative teacher is not a
"lone wolf': but feels connected within a social system.
This silent background of positive attitudes about students, school system, and
community allows the innovator to overcome infrastructure constraints to laboratory
teaching-insufficient time, space, and equipment. The innovative teacher makes
greater use of all information sources, except television, and incorporates into
his/her teaching more information from primary sources-education and scientific
journals.
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We will have a complete set of data on 1988 participants later this fall. These
new data will give us an opportunity to test a predictive model of innovative
behavior. We will see if a discriminant function developed from the 1987 data set
can identify innovators among the 1988 cohort.
Materials Development
In September, we completed a $24,500 renovation of our downstairs space to
create a small prep and research laboratory. Supported by a grant from the
Banbury Fund, the renovation gives us much needed private space to adapt
research techniques to the needs of educators. The prep lab is fitted with two
small autoclaves that free us from endless trips to the Laboratory to sterilize
reagents and agar plates.
Basement area before and after renovation into a research lab.
We are developing a second set of laboratory exercises that articulate with and
build upon those introduced during the DNA Science Workshop. These
experiments will be published in a second edition of our DNA Science lab/text
planned for publication in 1991. Envisioned as the basis for a second-level course,
the new protocols will introduce three powerful techniques of molecular
biology-
Southern hybridization, DNA sequencing, and polymerase chain
reaction. Our
approach is to collaborate with a corporate partner that has
specific expertise in
the technology and work with them to optimize research-grade kits.
In spring 1989, we began a collaboration with United States
Biochemical
Corporation (USB) and Perkin-Elmer Cetus to develop polymerase
chain reaction
(PCR) for educational purposes. Of great interest is a kit that
allows students to
amplify a segment of their own DNA. We regard this as an
ideal "entry-level"
experience in DNA manipulation, combining the involvement
of an individually
performed experiment with the economy of an instructor
demonstration. Although
les are run together in
students prepare their own sample of DNA, student same
separate lanes of an agarose gel. Thus, one or at most
two gels would be
necessary for an entire class.
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James D. Watson
United States Biochemical, with expertise in PCR, DNA sequencing, and
nonisotopic detection systems, is an ideal corporate partner to assist in the
development of these second-level experiments. Furthermore, USB has expressed
interest in helping us to develop instructional materials that make use of video and
interactive computer software. This multimedia approach will complement
laboratory-based instruction exceeding the capabilities of either used alone.
Exhibit Development
A world-class museum program was established with the installation of The
Search for Life: Genetic Technology in the 20th Century, on loan from the
National Museum of American History of the Smithsonian Institution. The exhibit
chronicles the study of heredity from Darwin to DNA and confronts the visitor with
the promise and concern of genetic technology. Since its opening in September
1988, over 15,000 visitors have toured The Search For Life.
We now face the challenge of designing and executing new exhibits, revolving
around the Human Genome Project, that must be readied to replace the Smithso-
nian exhibit. The establishment of Exploring the Human Genome.exhibit at the
DNA Learning Center will mark one of the first major efforts to spark public
imagination about this important endeavor. Cold Spring Harbor Laboratory is an
especially fitting host for such an exhibit. The Laboratory's director, James Watson,
was the codiscoverer of the structure of DNA and is associate director of the
National Institutes of Health in charge of the Human Genome Project.
As a small institution, we can never hope to attract audiences the size of those
that visit the Smithsonian or the Museum of Natural History. Therefore, we intend
to extend our educational reach by "franchising" or leasing exhibits to other
science museums. Several factors should encourage franchising:
Cold Spring Harbor Laboratory has an established reputation in molecular
genetics, and the DNA Learning Center is the world's only museum dedicated to
biotechnology education. Few museums have a staff of molecular biology
interpreters or such access to expert assistance.
The cost of lease or franchise will be far less than it would be to develop an
exhibit from scratch.
Modular design will enable exhibit components to be configured for almost any
display area.
Exhibit elements will incorporate the latest audiovisual and computer technol-
ogy. Interactive features will encourage use of a number of senses to stimulate
interest and understanding.
DNA Detective: Variability in Human Molecular Genetics
The DNA Detective/DNA Diagnosis exhibit and the DNA manipulation laboratories
are the first elements of a coordinated interpretive program on the Human
Genome Project that captures the importance and excitement of human molecular
genetics. Each case module consists of three backlit visual displays that highlight
an actual case study involving DNA fingerprinting. Using a montage of
photographs and newspaper reports, the first display presents the facts of the
case and sets the stage for the DNA fingerprint data. The second display is
composed of tempered glass panels with the stylized DNA fingerprints of individu-
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als involved in the case. The observer slides the panels to juxtapose fingerprints-
a match results in an obvious color and pattern change of the overlapping "bar
codes:' The third display describes the resolution of the case.
Dr. and Mrs. Richard J. Roberts at opening of the DNA Detective exhibit.
The serialization of cases and the ease of exchanging materials between one or
more modules makes it cost-effective to create a rotating "gallery" of DNA
fingerprint cases. The Technology Center of Silicon Valley in San Jose, California
plans to install a unit for its opening in 1990, and several other museums have
expressed interest. The initial cases illustrate various applications of DNA
fingerprinting and, whenever possible, historical precedents in law, medicine, and
society:
Ghana Immigration (1985). This case from Britain was the first to introduce DNA
fingerprinting in a court of law. The data were used to prove the maternity of an
English woman and her child, who wished to emigrate from Ghana. Original case
materials were provided by Alec Jeffreys, University of Leicester.
Murder at Rodman Dam (1988). DNA fingerprints were used to help convict the
suspect in a double murder/rape case. This was the first case involving
DNA
fingerprint evidence in which the death penalty was handed down. Original case
materials were provided by Cellmark Diagnostics and the Florida State
Attorney's
Office.
Thoroughly Bred? (1989). In this case, the paternity of a thoroughbred race
horse
was in doubt. DNA fingerprints showed that the foal was
not sired by a famous
race horse, but by his less illustrious son. Original case
materials were provided by
Lifecodes Corporation.
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Corporate executives attending the Baring Brothers conference used a sophisticated new tech-
nique called polymerase chain reaction to perform a DNA diagnosis for sickle cell anemia.
Staff
The expanding programs of the DNA Learning Center (DNALC) are a testament to
the dedication and hard work of the staff. Education manager, John LeGuyader,
continues to shoulder most of the daily teaching responsibilities in the Bio2000
Laboratory. John's research and teaching experience enabled him to quickly
assume the role of senior instructor for the DNA Science Workshop program. His
organizational skills are now being put to effective use managing our Curriculum
study and Macy-school collaborations.
In January 1989, Susan Lauter (formerly Susan Zehl) left the Laboratory's Public
Affairs Department to join our permanent staff as designer. While a member of the
Public Affairs Department, Sue played an important part in the development of the
DNA Literacy Program. She has already launched us into the age of computer-
aided design, using our Sun computer and plotter to generate exhibit concepts
and artwork for our textbook, DNA Science: A First Course in Recombinant DNA
Technology. Sue's first exhibit design, DNA Detective, is currently on display at the
DNALC.
Anne Zollo has the unenviable task of overseeing the smooth running of the
DNALC. Her many responsibilities include scheduling laboratory and exhibit visits,
juggling travel schedules, and managing the bookstore. Perhaps most important,
Anne has adapted well to the occasionally frenetic pace of activity-without losing
her composure.
The teaching load was lightened by the arrival of part-time volunteer Kelly
Flynn. She is a perfect addition to our teaching staff-with a degree in biology
from Cornell University and experience in the laboratory of Amar Klar, a former
CSHL staff scientist. Kelly has also made an important contribution to the summer
workshop program, so we are very pleased that she will be helping us again this
summer.
Carrie Abel began part-time work at the DNALC in June 1989, assisting Sue
with artwork for the textbook. Carrie has an art degree from Syracuse University
and currently teaches at C.W. Post. Her artistic and organizational talents have
proven essential to the timely completion of the project.
Interns, ranging in age from high school sophomores to graduate students,
provide critical assistance to our teaching staff. Deserving special mention is John
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Kruper, who completed his doctorate in science education at the University of
Illinois at Chicago, in October 1989. Currently a postdoctoral fellow at the
University of Chicago, John has had primary responsibility for our evaluation
program, which tracks the many hundreds of teachers who have participated in
DNA Science Workshops over the years.
Chai Chen (aka "Sol':), presently a senior at Rensselaer Polytechnic Institute,
joined us for the summer 1989 Vector tour. Sol quickly adapted to life on the road
as a DNA gypsy and kept the workshops running smoothly. Lab aide Steve
Malloy, a senior at Cold Spring Harbor High School, has been joined by Steven
Friedenberg and Jeff Hwang, both sophomores at Half Hollow Hills East High
School. Their efforts are essential to the smooth functioning of the Bio2000
Laboratory.
Sandy Ordway, who together with Anne Meier helped coordinate our volunteer
program, is now a part-time DNALC staff member. Sandy continues to help with
museum visitation while providing much needed assistance with our evaluation
program. Working together, the staff are helping the DNALC continue to grow,
striving to reach its potential as an "exploratorium" of DNA.
PUBLICATIONS
Mick los, D. and J. Kruper. 1989. Retooling biology education for the gene age: Preliminary
results of a nationwide study of innovative teaching behavior among high school science
teachers. Cold Spring Harbor Laboratory, New York.
Mick los, D. and M. Bloom. 1989. DNA restriction analysis. Carol. Tips 53.
Mick los, D. and G. Freyer, eds. 1990. DNA Science: A First Course in Recombinant DNA
Technology. Cold Spring Harbor Laboratory Press, New York. (In press.)
Mick los, D. and G. Freyer 1989. A laboratory introduction to DNA restriction analysis,
Biotechnology Education 1: 16.
Vector Workshop Sites 1985-89
ALABAMA University of Alabama, Tuscaloosa
ARIZONA Tuba City High School
CALIFORNIA University of California, Davis
CONNECTICUT Choate Rosemary Hall, Wallingford
FLORIDA University of Florida, Gainesville
GEORGIA Fernbank, Inc., Atlanta
ILLINOIS Argonne National Laboratory, Chicago
Wheaton College"'
INDIANA Butler University, Indianapolis
IOWA Drake University, Des Moines
Murray State University
MANITOBA Red River Community College,
Winnipeg
MARYLAND Annapolis Senior High School
McDonogh School, Baltimore
MASSACHUSETTS Beverly High School
Dover-Sherborn High School
Randolph High School, Boston
Winsor School, Boston
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1987, 1988, 1989
1988
1986
1987
1989
1989
1986, 1987
1988
1987
1987
1988
1989
1989
1988
1986
1989
1988
1987
MICHIGAN
MISSOURI
NEW HAMPSHIRE
NEW YORK
NORTH CAROLINA
OHIO
PENNSYLVANIA
SOUTH CAROLINA
TEXAS
VERMONT
VIRGINIA
WASHINGTON
WEST VIRGINIA
WISCONSIN
Michigan State University, East Lansing*
Troy High School
Washington University, St. Louis
St. Paul's School, Concord
Albany High School
Bronx High School of Science
Cold Spring Harbor High School
DNA Learning Center
Huntington High School
Irvington High School
State University, Purchase
State University, Stony Brook
Wheatley School, Old Westbury
North Carolina School of Science, Durham
Cleveland Clinic
Ohio State University, Wooster*
Duquesne University, Pittsburgh
Germantown Academy, Philadelphia
Gwenyde Mercy College, King of Prussia*
Medical University of South Carolina,
Charleston
University of South Carolina, Columbia
University of Houston*
Champlain Valley Union High School
Jefferson School of Science, Alexandria
Department of Public Health, Seattle*
Bethany College
Marquette University, Milwaukee
University of Wisconsin, Madison
* Two -day workshop, all others five days.
Curriculum Study Membership 1989-90
Cold Spring Harbor Central School District*
Commack Union Free School District
East Williston Union Free School District*
Great Neck Public Schools*
Oyster Bay-East Norwich Central School District*
Half Hollow Hills Central School District
Harborfields Central School District
Herricks Union Free School District*
Huntington Union Free School District
Island Trees Union Free School District
Jericho Union Free School District*
Lawrence Public Schools
1989
1989
1989
1986, 1987
1987
1987
1985, 1987
1988, (3), 1989
1986
1986
1989
1987, 1988, 1989
1985
1987
1987
1989
1988
1988
1988
1988
1988
1989
1989
1987
1988
1989
1986, 1987
1988, 1989
Lindenhurst Public Schools
Locust Valley Central School District
Manhasset Public Schools
Northport-East Northport Union Free School District*
North Shore Central School District
Plainedge Public Schools
Plainview-Old Bethpage Central School District
Port Washington Union Free School District
Port ledge School
Sachem Central School District at Holbrook
South Huntington Union Free School District
Syosset Central School District*
* Founding members
EDUCATIOrrACTIVITI

Postgraduate Courses
The summer program of Postgraduate Courses at Cold Spring Harbor Laboratory
is aimed at meeting the special need for training in interdisciplinary subjects that
are either so new or so specialized that they are not adequately treated by
universities. Our aim is to provide intensive study in the most recent developments
and techniques in these subjects and to prepare students to enter directly into
research in a particular area. To ensure up-to-date coverage of current research
work, we bring together a workshop staff from many laboratories around the world
and supplement this staff with a series of seminar speakers.
Cloning and Analysis of Large DNA Molecules
April 9-April 22
INSTRUCTORS
Burke, David, Ph.D., Princeton University, New Jersey
Gemmill, Robert, Ph.D., Southwest Biomedical Center, Scottsdale, Arizona
Sternberg, Nat, Ph.D., E.I. du Pont de Nemours & Company, Wilmington, Delaware
ASSISTANTS
Pau lien, Sylvie, Ph.D., Southwest Biomedical Center Scottsdale, Arizona
Ruether, James, M.S., E.I. du Pont de Nemours & Company, Wilmington, Delaware
This course covered the theory and practice of manipulating and cloning high
molecular weight DNA. Lectures and laboratory work dealt with the use of
bacteriophage P1 and yeast artificial chromosome (YAC) cloning systems, the
isolation and manipulation of high molecular weight DNA from mammalian cells
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for cloning (including the size-selection of 200-300 kb DNA fragments), and the
analysis of high molecular weight DNA by pulse field gel (PFG) separation
techniques. P1 and YAC recombinant DNA molecules were produced, introduced
into cells (E. coli and yeast, respectively), and reisolated after appropriate clone
selection and colony screening procedures. Comparison of DNA separation
capabilities was made between the five major PFG techniques commonly in use.
All aspects of Southern blot analysis of DNA were covered including sample
digestion with restriction enzymes, separation on pulse field gels, Southern
transfer, hybridization, and interpretation of results. Students gained hands-on
experience through participation in ongoing efforts to prepare physical maps of
portions of human chromosomes 3 and 12. Lectures by outside speakers on
topics of current interest supplemented the laboratory work.
PARTICIPANTS
Ando, Asako, Ph.D., Tokai University, Japan
Bruns, Gail, Ph.D., Children's Hospital, Boston,
Massachusetts
Drabkin, Harry, M.D., University of Colorado, Boulder
Ganal, Martin, Ph.D., Cornell University, Ithaca, New York
Goedert, Michel, Ph.D., MRC Laboratory, Cambridge,
England
Henson, Victoria, Ph.D., Jackson Laboratory, Woods Hole,
Massachusetts
Kagan, Jacob, Ph.D., Temple University, Philadelphia,
Pennsylvania
SEMINARS
Hieter, P., Johns Hopkins Medical School. Yeast methods for
cloning and manipulating large DNA.
McClelland, M., University of Chicago. Cutting
chromosomes.
Livak, K., E.I. du Pont Experimental Station. Novel DNA
mapping technologies.
Garza, D., Washington University School of Medicine.
Mapping the Drosophila genome with yeast artificial
chromosomes.
Lafuse, Willliam, Ph.D., Ohio State University, Columbus
Petit, Christine, Ph.D., Institut Pasteur, Paris, France
Todd, Sean, B.S., University of Texas, Austin
Francis, David, B.A., University of California, Davis
Lamb, Allen, Ph.D., University of North Carolina, Chapel Hill
Marks, M. David, Ph.D., University of Nebraska, Lincoln
Scherer Stephen, B.S., Hospital for Sick Children, Toronto,
Canada
Stern, Marc-Henri, M.S., NCI-Naval Medical Oncology,
Bethesda, Maryland
Wicking, Carol, M.S., St. Mary's Hospital, London, England
Allshire, R., Cold Spring Harbor Laboratory. Introduction of
S. pombe chromosomes into mouse cells and analysis of
human telomeres.
Murray, A., University of California. Chromosome behavior in
Saccharomyces cerevisiae.
Carle, G., INSERM, Universite de Nice. Field inversion gel
electrophoresis.
Protein Purification and Characterization
April 9-April 22
INSTRUCTORS
Marshak, Dan, Ph.D., Cold Spring Harbor Laboratory, New York
Se lk, Linda, Ph.D., California Institute of Technology, Pasadena
Smith, John, Ph.D., Massachusetts General Hospital, Boston
ASSISTANTS
Clawson, Leigh, Ph.D., California Institute of Technology, Pasadena
Chang, Yie-Hwa, Ph.D., Massachusetts General Hospital, Boston
This course was intended for scientists who are not familiar with techniques of
protein isolation and characterization. Students learned the major techniques in
protein purification by actually performing four separate isolations including: (i) a
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regulatory protein from muscle tissue; (ii) a fusion protein from E. coli; (iii) a DNA-
binding protein from nuclei of tissue culture cells; and (iv) a chemically synthesized
peptide. A variety of chromatographic, electrophoretic, and bulk fractionation
techniques were employed including: ion exchange, gel filtration, hydrophobic
interaction, affinity-based adsorption, and immunoaffinity chromatography;
polyacrylamide gel and two-dimensional gel electrophoresis and electroblotting;
precipitation by salt and pH; and HPLC analysis. Methods of protein characteriza-
tion were discussed including amino acid analysis, protein sequencing, and mass
spectrometry. Emphasis was placed on methods of protein purification rather than
automated instrumental analysis. Guest lecturers discussed protein structure,
modifications of proteins, and methodologies for protein purification. Applications
of protein biochemistry to various areas of research in molecular biology were
discussed.
PARTICIPANTS
Baumann, Gotz, Ph.D., Sandoz, Ltd, Basel, Switzerland
D'Urso, Gennaro, B.A., Fred Hutchinson Cancer Center,
Seattle, Washington
Das, Gokul, Ph.D., Cold Spring Harbor Laboratory, New York
Holz, George, Ph.D., Tufts University, Medford,
Massachusetts
Jarrell, Kevin, Ph.D., Harvard University, Cambridge,
Massachusetts
Kleinberger, Tamar, Ph.D., Tel Aviv University, Israel
Leibowitz, Jacob, Ph.D., University of Alabama, Tuscaloosa
Loh, Johnson, B.S., Yale University, New Haven, Connecticut
Lossky, Marie, Ph.D., Brandeis University, Waltham,
Massachusetts
SEMINARS
Aebersold, R., University of British Columbia. Electro-blotting
of proteins.
Hunkapillar, M., Applied Biosystems, Inc. Protein
sequencing.
Kadonaga, J., University of California, San Diego. DNA
binding proteins.
Kent, S., California Institute of Technology. Peptide synthesis.
Pace, N., Texas A&M University. Physical measurements of
proteins.
Ludwig, Steven, Ph.D., University of Georgia, Athens
Myers, Jeff, B.A., University of Pennsylvania, Philadelphia
Ogunjobi, 0., Ph.D., University of Edinburgh, Scotland
Shepherd, Gordon, B.A., Massachusetts General Hospital,
Boston
Slepecky, Norma, Ph.D., Syracuse University, New York
Sowden, Mark, B.S., University of Oxford, England
Swenson, Katherine, Ph.D., Harvard Medical School, Boston,
Massachusetts
Weinrich, Scott, Ph.D., University of California, San Francisco
Paterson, Y, University of Pennsylvania. Antigenic sites on
proteins.
Robbins, P, Massachusetts Institute of Technology.
Glycoproteins.
Rose, G., University of Pennsylvania, Hershey Medical
Center. Protein folding.
Wilson, K., Applied Biosystems, Inc. Chromatography of
proteins-HPLC and capillary electrophoresis.
Wold, F., University of Texas, Houston. Posttranslational
modifications.
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Molecular Embryology of the Mouse
June 9-June 29
INSTRUCTORS
Lovel-Badge, Robin, Ph.D., NIMR, London, England
McMahon, Andy, Ph.D., Roche Institute of Molecular Biology, Nutley, New Jersey
CO-INSTRUCTORS
Cooke, Lesley, M.Sc., ICRF, Oxford, England
Mann, Jeff, Ph.D., Roche Institute of Molecular Biology, Nutley, New Jersey
This course is designed for molecular biologists, biochemists, and cell biologists
interested in applying their expertise to the study of mouse embryonic develop-
ment. Lecture and laboratory components of the course emphasized both the
practical aspects of working with mouse embryos and the conceptual basis of
current embryonic research. The following procedures and their potential applica-
tions were described: isolation and culture of germ cells and pre-implantation and
post-implantation embryos, embryo transfer, establishment and genetic manipula-
tion of embryo-derived stem cell lines, germ layer separation, chimera formation,
nuclear transplantation, microinjection of DNA into eggs, retroviral infection of
embryos, microinjection of cell lineage tracers, in situ hybridization and
immunohistochemistry. Guest lecturers discussed current research in the field.
PARTICIPANTS
Bodine, David M., Ph.D., National Institutes of Health,
Bethesda, Maryland
Capon, Daniel, Ph.D., Genentech, Inc., South San Francisco,
California
Christofori, Gerhard, Ph.D., University of Basel, Switzerland
Cossu, Giulio, M.D., University of Rome, Italy
Dandolo, Luisa, Ph.D., Institut Pasteur, Paris, France
Doglio, Luisa, Ph.D., University of Chicago, Illinois
Donoviel, Dorit, B.A., University of Washington, Seattle
ffrench-Constant, Charles, Ph.D., Cambridge University,
England
Gardiner, Edith, Ph.D., Yale University, New Haven,
Connecticut
Lawler, Jack, Ph.D., Brigham and Women's Hospital, Boston,
Massachusetts
Marth, Jamey, Ph.D., University of British Columbia,
Vancouver
Nose, Toshiaki, Ph.D., Mitsubishi-Kasei Institute, Tokyo, Japan
Quaranta, Vita, M.D., Research Institute of Scripps Clinic, La
Jolla, California
Vassar, Robert, B.A., University of Chicago, Illinois
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SEMINARS
McMahon, A., Roche Institute of Molecular Biology.
Preimplantation development.
Waelsch, S., Albert Einstein College of Medicine. Mouse
genetics-an historical perspective.
Beddington, R., ICRF Developmental Biology. Postimplanta-
tion development and cell lineages.
McLaren, A., MRC Mammalian Development Unit. Germ
cells.
Hogan, B., Vanderbilt University Medical Center. Extraem-
bryonic membranes and molecules.
Wasserman, P, Roche Institute of Molecular Biology.
Fertilization.
Mann, J., Roche Institute of Molecular Biology.
Parthenogenesis.
McLaren, A., MRC Mammalian Development Unit. Sex
determination I.
Lovell-Badge, R., National Institutes for Medical Research.
Sex determination II.
Robertson, L., Columbia University. Manipulation of es cells.
Lovell-Badge, R., National Instututes for Medical Research.
Teratocarcinomas.
Solter, D., Wistar Institute. Imprinting.
Rossant, J., Mount Sinai Hospital, Toronto. Trophoblast in
development.
. Gene targeting.
Jaenisch, R., Whitehead Institute. Mouse models of human
disease.
Advanced Bacterial Genetics
Hastie, N., MRC, Western General Hospital. Approaches to
reverse genetics.
Krumlauf, R., NIMR, London. Homeobox genes and mouse
development.
Rinchik, G., Mammalian Genetics and Development Section.
Genetic resources.
Papaioannou, G., Tufts University. Chimaeras in
development.
Cebra-Thomas, J., Princeton University. T-complex.
McMahon, A., Roche Institute of Molecular Biology. Gene
expression in development.
Costantini, F, Columbia University. Gene expression in
transgenic mice.
Strickland, S., State University of New York. Maternal RNA
and the mouse oocyte.
Stewart, C., Roche Institute of Molecular Biology. Growth
factors in development.
Cepko, C., Harvard Medical School. Cell lineage in the
nervous system.
Noden, D., Cornell University. Neural crest.
McKay, R., Massachusetts Institute of Technology. Early
neural tube development.
Williams, D., Children's Hospital, Boston. Hematopoietic stem
cells.
Curran, T., Roche Institute of Molecular Biology. Transcription
factors.
June 9-June 29
INSTRUCTORS
Berget, Peter, Ph.D., Carnegie Mellon University, Pittsburgh, Pennsylvania
Maurer, Russell, Ph.D., Case Western Reserve University, Cleveland, Ohio
Weinstock, George, Ph.D., University of Texas, Houston
ASSISTANTS
Jin, Xiaomei, B.S., University of Texas, Houston
Kean, Leslie, Ph.D., Case Western Reserve University, Cleveland, Ohio
Regan, Mary, B.S., Carnegie Mellon University, Pittsburgh, Pennsylvania
This laboratory course demonstrated genetic approaches that can be used to
analyze biological processes and their regulation, as well as detailed
structure/function relationships of genes. Techniques that were be covered
included: isolation, complementation, and mapping of mutations; use of transpos-
able genetic elements; construction of gene fusions; cloning of DNA; restriction
enzyme mapping; Southern blotting; macrorestriction mapping
of genomes by
pulse-field electrophoresis; and DNA sequencing. The course consisted
of a set of
experiments incorporating most of these techniques,
supplemented with lectures
and discussions. The aim was to develop in students the ability
to design a
successful genetic approach to any biological problem.
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PARTICIPANTS
Bramanti, Thomas, D.D.S., University of Texas, San Antonio
Farinha, Mark, B.S., Queen's University, Kingston, Ontario,
Canada
Fernandes, Prabhavathi, Ph.D., The Squibb Institute,
Princeton, New Jersey
Hannaert, Veronique, M.S., Institute of Cellular and
Molecular Pathology, Brussels, Belgium
Hughes, Carrie, Ph.D., University of Minnesota, Minneapolis
Ingham, Colin J., Ph.D., University of Wisconsin, Madison
Kaiser-Rogers, Kathleen, B.S., University of North Carolina,
Raleigh
SEMINARS
Kaplan, S., University of Texas Medical School. Photosyn-
thetic membrane biogenesis in Rhodobacter spaeroides.
Bassford, P, University of North Carolina. Genetic
approaches to studying protein export in E. coli.
Radman, M., Institut Jacques Monod. Mismatch repair
systems and the maintenance of genetic information.
Lamb, Andrew J., B.S., University of Aberdeen, Scotland
Maloney, Peter, Ph.D., Johns Hopkins University, Baltimore,
Maryland
Masure, H. Robert, Ph.D., University of Washington, Seattle
Rappa, Philip, B.S., Hunter College, New York, New York
Rouviere, Pierre, Ph.D., University of Utah, Salt Lake City
Sherman, Michael, Ph.D., Harvard Medical School, Boston,
Massachusetts
Songer, J. Glenn, Ph.D., University of Arizona, Tucson
Williams, Huw, Ph.D., University of Wales College of Cardiff
Ziegler, H. Kirk, Ph.D., Emory University, Atlanta, Georgia
Youngman, P, University of Pennsylvania. Use of transpo-
sons as tools for genetic manipulation in sporulating
gram positive bacteria.
Walker, G., Massachusetts Institute of Technology. Genetic
analysis of nodulation by Rhizobium.
Molecular Approaches to Ion Channel Function & Expression
June 9-June 29
INSTRUCTORS
White, Michael, Ph.D., University of Pennsylvania, Philadelphia
Snutch, Terry, Ph.D., University of British Columbia, Vancouver, Canada
Leonard, John, Ph.D., University of Illinois, Chicago
Goldin, Al, M.D., Ph.D., University of California, Irvine
Margiotta, Joseph, Ph.D., Mt. Sinai Medical Center, New York, New York
Dionne, Vince, Ph.D., University of California, San Diego
ASSISTANT
Gilbert, Mary, M.S., University of British Columbia, Vancouver, Canada
Application of the techniques of molecular biology to neurobiology has provided
novel approaches and a new level of sophistication in the examination of many
neurobiological problems. This intensive laboratory/lecture course is designed to
introduce students to the application of these techniques to the study of ion
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channels. Students concentrated initially on basic aspects of this approach, andthen proceeded to more integrated studies. The course dealt with the followingtopics: MRNA isolation and handling; preparation of in vitro transcripts for
expression and use as gybridization probes; Xenopus oocytes as an expression
system; characterization of newly expressed channels in oocytes using immu-
noprecipitation, voltage- and patch-clamping; design and implementation of
recording equipment; monitoring levels of and changes in channel expression
using Northern blot analysis. There were opportunities during the final week of the
course for students to undertake special projects of their own design using the
methods taught in the course.
PARTICIPANTS
Barr, Eliav, M.D., Johns Hopkins Hospital, Baltimore,
Maryland
Bennett, Eric S., B.S., University of Rochester, New York,
New York
Davies, Noel W., Ph.D., University of Leicester, England
Fiszman, Monica, Ph.D., National Institutes of Health,
Bethesda, Maryland
Garcia-Martinez, Esperanza, M.S., Universidad de Colima,
Mexico
SEMINARS
White, M., University of Pennsylvania. Biosynthesis in
assembly of the ACh receptor
Snutch, T, University of British Columbia. Cloning around
with channels.
Leonard, J., University of Illinois. Expression of NMDA
receptors in Xenopus oocytes.
Goldin, A., University of California. Structure-function studies
of the NA+ channel.
Haber, Roberta J., Ph.D., NCI, National Institutes of Health,
Bethesda, Maryland
Hsiung, Hansen, Ph.D., Lilly Corporate Center, Indianapolis,
Indiana
Izumo, Seigo, M.D., Children's Hospital, Boston,
Massachusetts
Jensen, Abigail, B.A., University of Wisconsin, Madison
MacDonald, John, Ph.D., University of Toronto, Canada
Beam, Kurt, Colorado State University. Developmental and
genetic regulation of Ca++ channels in muscle.
Enyeart, J., Ohio State University. Hormonal regulation of
Ca++ channels.
Dionne, V., University of California. Molecular studies of
GABA receptors.
Kinnamon, S., Colorado State University. How do we taste?
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Molecular Neurobiology of Human Disease
June 9-June 19
INSTRUCTORS
Black, Ira, Ph.D., Cornell University Medical Center, New York
Breakefield, Xandra, Ph.D., E.K. Shriver Center Waltham and Harvard Medical School,
Boston, Massachusetts
Gusella, James, Ph.D., Massachusetts General Hospital and Harvard Medical School,
Boston, Massachusetts
This intensive seminar course explored the molecular and cellular basis of
abnormal neural function. It focused on basic scientific studies that have provided
insight into the etiology and pathogenesis of neurologic and psychiatric diseases.
Emphasis was also placed on new techniques in neuroscience and molecular
genetics. Topics included: linkage analysis using DNA polymorphisms; strategies
for identifying and cloning defective neural genes; one genes in neural tumors;
gene therapy using viral vectors; creating animal models using embryonic stem
cells and transgenic animals; genetic defects in demyelination and lipidoses; viral
neurotropism; molecular events in development and degeneration; cellular events
in neural regeneration and brain grafting; neuroimmunology, ion channels in
epilepsy; and brain imaging.
PARTICIPANTS
Anderson, Mary Dilys, M.S., Yale University, New Haven,
Connecticut
Baez, Mel, Ph.D., Lilly Research Laboratories, Indianapolis,
Indiana
Barbany, Gisela, M.D., Karolinska Institute, Sweden
Bayney, Richard, Ph.D., Molecular Therapeutics, Inc., West
Haven, Conecticut
Bejjani, Bassem, M.D., E.K. Shriver Center Waltham,
Massachusetts
Cook, David, B.S., Yale University, New Haven, Connecticut
Davar, Gudarz, M.D., Massachusetts General Hospital,
Boston
Feldblum, Sophie, Ph.D., University of California, Los
Angeles
Gary, Todd, B.A., Vanderbilt University, Nashville, Tennessee
Janson, Lars, B.S., University of Uppsala, Sweden
Lee, Jung Kyo, Ph.D., Massachusetts General Hospital,
Boston
Perry, Sharon E., Ph.D., Vanderbilt University, Nashville,
Tennessee
SEMINARS
Gusella, J., Massachusetts General Hospital and Harvard
Medical School. Search for HD gene.
Hoffman, E., Boston Children's Hospital. Duchenne muscular
dystrophy gene and protein.
Racaniello, V., Columbia University College of Physicians &
Surgeons. Poliovirus.
Stevens, J., University of California School of Medicine.
Herpes latency in the nervous system.
Johnston, B., Columbia University College of Physicians &
Surgeons, New York. Lysosomal diseases.
Gravel, R., Toronto Hospital for Sick Children. Genetic
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Phelps, Creighton, Ph.D., National Institute on Aging,
National Institutes of Health, Bethesda, Maryland
Reiner, Orly, M.S., Weizmann Institute, Israel
Robertson, David, M.D., Yale Medical School, New Haven,
Connecticut
Sahin, Mustafa, B.S., Yale Medical School, New Haven,
Connecticut
Skinner Karen, Ph.D., National Institutes of Health,
Bethesda, Maryland
Straub, Richard, B.A., Cornell University, New York
Tobia, Annette, Ph.D., Squibb Corporation, Princeton, New
Jersey
Tombaugh, Geoffrey, B.A., Stanford University, California
Veruki, Margaret, B.S., University of Rochester New York
Watanabe, Takashi, M.D., University College of London,
England
Weiss, Joachim, M.D., Washington University, St. Louis,
Missouri
Zhou, Feng, Ph.D., Indiana University, Indianapolis
defects in lysosomal enzymes.
Selkoe, D., Brigham and Women's Hospital. Molecular
etiology of Alzheimer's disease.
Gusella, J. Massachusetts General Hospital and Harvard
Medical School. Familial Alzheimer's disease.
Wallace, D., Emory University. Mitochondrial inheritance.
Rappaport, J. National Institutes of Health. Structure and
function HIV I tat gene.
Ledbetter, D., Baylor College of Medicine. Chromosome
deletion causing lissencephaly in humans.
Herrup, K., E.K. Shriver Center. Neuron movement and
numbers in murine development.
Bernards, R., Massachusetts General Hospital. Molecular
biology of tumor progression and neuroblastoma.
Harlow, E., Cold Spring Harbor Laboratory. Oncoproteins.
Mallet, J., Centre National de la Recherche Scientifique.
Genes implicated in psychiatric illness.
Breakefield, X., E.K. Shriver Center. MAO deficiency state in
man.
Colman, D., Columbia University College of Physicians &
Surgeons. Biogenesis of myelin membrane.
Milner, R., Salk Institute. Genetic defects in myelin.
Young, A., University of Michigan. Neuropathogenesis of
HD.
Wexler, N., Columbia University. Molecular and human
aspects of HD.
Rossant, J., Mt. Sinai Hospital Research Institute. Creating
animal models using embryonic cells.
Sutcliffe, G., Research Institute, Scripps Clinic. New genetic
strategies for finding disease genes.
Gage, F, University of California School of Medicine. Brain
grafting.
Black, I., Cornell University Medical Center. Developmental
neuroplasticity.
Raichle, M., Washington University School of Medicine. Brain
imaging.
Aguayo, A., Montreal General Hospital. Regeneration in the
adult mammalian CNS.
Sanes, J., Washington University Medical Center. Cell
lineage in the CNS.
Rakic, P, Yale University School of Medicine. Altered neural
cell migration following environmental or genetic insults.
McNamara, J., Duke University Medical Center. Epilepsy.
Dingledine, R., University of North Carolina School of
Medicine. NMDA receptors.
Fields, H., University of California Medical School. Pain.
Genetic Approaches to Human Disease Using DNA Markers
June 21-June 25
INSTRUCTORS
Lander, Eric, Ph.D., Whitehead Institute and Harvard University, Cambridge, Massachusetts
Page, David, Ph.D., Whitehead Institute and Massachusetts Institute of Technology,
Cambridge
It has recently become feasible to map genes underlying some human diseases
and traits-even when the molecular basis is unknown-by studying individuals
from natural populations and using DNA markers (such as RFLPs). This intensive
lecture course explored the possibilities and difficulties of
applying these methods
to the study of various human diseases and traits, including simply-inherited
disorders (such as cystic fibrosis), complex disorders (such as heart disease
or
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psychiatric conditions), inherited and spontaneous cancers, and developmental
abnormalities (such as sex determination). Understanding such biological systems
requires an interplay among transmission genetics and cytogenetics in mammals,
human population genetics, and molecular biological techniques. Accordingly, the
course concentrated on ways to employ genetics to dissect complex biological
problems in natural populations.
PARTICIPANTS
Baron, Miron, M.D., New York State Psychiatric Institute, New
York
Bear, John, Ph.D., Memorial University of Newfoundland,
Canada
Blake, David, M.D., Columbia University, New York, New
York
Chen, Wei-Jane, M.D., Harvard School of Public Health,
Boston, Massachusetts
Chiang, Huey-Jenn, Ph.D., California Institute of Technology,
Pasadena
Crowe, Raymond, M.D., University of Iowa, Iowa City
De Vries, Niek, M.D., Academic Hospital, Holland
Fyer, Abby, M.D., Columbia University, New York, New York
SEMINARS
King, M.C., University of California. Genetic epidemiology
and breast cancer.
Burke, D., Princeton University. Analyzing and cloning large
DNA molecules.
Gilliam, C., Columbia University of Physicians & Surgeons.
Linkage analysis of neurological disorders.
Glaser, T., Massachusetts Institute of Technology. Wilm's
tumor and the genetics of recessive oncogenes.
Tanzi, R., Harvard University. The genetics of Alzheimer's
disease.
Giuffra, Luis, M.D., Yale University, New Haven, Connecticut
Gumerlock, Paul, Ph.D., University of California, Davis
Hogan, Kirk, M.D., University of Wisconsin, Madison
Janson, Lars, B.S., University of Uppsala, Sweden
Julian, Bruce, M.D., University of Alabama, Birmingham
Levinson, Douglas, M.D., Medical College of Pennsylvania,
Philadelphia
Mc Almon, Karen, M.D., University of California, San Diego
Perry, Sharon, Ph.D., Vanderbilt University, Nashville,
Tennessee
Raymond, Vincent, Ph.D., Centre de Recherche Laval
Robert-Giffard, Quebec, Canada
Straub, Richard, B.A., Cornell University, New York
Haines, J., Harvard University. Linkage analysis: Computer
methods.
Nussbaum, R., Pennsylvania State University. The curious
genetics of the Fragile X Syndrome.
Puck, J., Pennsylvania State University. X-linked immunodefi-
ciencies and the uses of somatic cell genetics.
Lincoln, S., Whitehead Institute. Constructing genetic linkage
maps.
286
Computational Neuroscience: Vision
July 2-July 15
INSTRUCTORS
Hildreth, Ellen, Ph.D., Massachusetts Institute of Technology, Cambridge
Movshon, J. Anthony, Ph.D., New York University, New York
ASSISTANTS
Geggenfunter, Karl, B.A., New York University, New York
Horswell, Ian, B.A., Massachusetts Institute of Technology, Cambridge
Poirson, Allen, B.A., Stanford University, California
Computational approaches to neuroscience have produced important advances in
our understanding of neural processing. Prominent successes have come in areas
where strong inputs from neurobiological, behavioral, and computational
approaches can interact. Through a combination of lectures and hands-on
experience with a computer laboratory, this course examined several areas,
including feature extraction, motion analysis, binocular stereopsis, color vision,
higher-level visual processing, visual neural networks, and oculomotor function.
The theme was that an understanding of the computational problems, the
constraints on solutions to these problems, and the range of possible solutions
can help guide research in neuroscience.
PARTICIPANTS
Basri, Ronen, B.S., Weizmann Institute, Israel
Beusmans, Jack M., M.S., University of California, Irvine
Chichilnisky, Eduardo, B.A., Stanford University, California
De Priest, Derryl, B.A., University of Rochester, New York
Elliott, David, B.S., Massachusetts Institute of Technology,
Cambridge
Freeman, William, M.S., Massachusetts Institute of Technol-
ogy, Cambridge
Galun, Merav, M.S., Hebrew University, Israel
Harris, Julie, B.S., University Laboratory of Physiology,
Oxford, England
He, Jijiang, M.S., University of Alabama, Birmingham
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Kiper, Daniel, M.A., New York University, New York
Knill, David, B.S., Brown University, Providence, Rhode
Island
Levitt, Jonathan, M.A., New York University, New York
Mansfield, John, B.S., University Laboratory of Physiology,
Oxford, England
O'Keefe, Lawrence, M.S., Florida State University, Tallahassee
Pol lick, Frank, M.S., University of California, Irvine
Rothwell, Bart, M.A., University of California, Los Angeles
Sha'ashua, Amnon, M.S., Weizmann Institute, Israel
SEMINARS
Frisby, J., University of Sheffield. Computational and
empirical studies of human stereo vision.
Sejnowski, T, Salk Institute. Neural network models of stereo
vision.
Adelson, E., Massachusetts Institute of Technology. Early
vision and the measurement of motion.
Newsome, W., Stanford University School of Medicine. Single
neurons and the perception of motion.
Wandell, B., Stanford University. Computational and empirical
studies of color vision.
Lee, H., Eastman Kodak Company. Lightness scales and
chromaticity convergence.
Bulthoff, H., Brown University. The psychophysics of cue
integration.
Hildreth, E., Massachusetts Institute of Technology. The
computational study of vision.
. C and HIPS.
. LISP and OBVIUS.
. Computational models of edge detection.
. Computational models of the recovery of 3-D
structure and motion.
Desimone, R., National Institute of Mental Health.
ATTENTION! Neural mechanisms in extrastriate visual
cortex.
Stoner, Gene, B.A., Salk Institute, San Diego, California
Stuck, Elizabeth, M.S., University of Minnesota, Minneapolis
Treue, Stefan, B.S., Massachusetts Institute of Technology,
Cambridge
Turk, Matthew, M.S., Massachusetts Institute of Technology,
Cambridge
Wuerger, Sofia, M.S., New York University, New York
Zabrodsky, Haggith, M.S., Hebrew University, Israel
Zhang, Jun, B.S., University of California, Berkeley
Lisberger, S., University of California School of Medicine.
Visual tracking.
Grimson, E., Massachusetts Institute of Technology.
Computational models of stereo vision.
. Models of object recognition.
Grzywacz, N., Massachusetts Institute of Technology. Single
neurons as complex processors: The example of visual
motion computations.
. Theories for how neurons interact to estimate the
visual velocity field.
Landy, M., New York University. Psychophysical observations
of early visual processing.
. Psychophysical observations of structure-from-
motion.
Morgan, M., University College London. The psychophysical
study of visual processing.
Mechanisms of feature analysis in human vision.
Movshon, J., New York University. Empirical studies of visual
processing.
C and HIPS.
. The physiology of early vision.
. Physiological studies of motion analysis.
. Physiological studies of binocular stereopsis.
Molecular Cloning of Eukaryotic Genes
July 3-July 23
INSTRUCTORS
Alt, Fred, Ph.D., Columbia University, New York, New York
Roberts, Tom, Ph.D., Dana Farber Cancer Institute, Boston, Massachusetts
Yancopolous, George, M.D., Ph.D., Regeneron Pharmaceuticals, Tarrytown, New York
ASSISTANTS
Morrow, Maureen, M.A., Columbia University, New York, New York
Wood, Ken, M.A., Dana Farber Cancer Institute, Boston, Massachusetts
Young, Fay, M.D., Columbia University, New York, New York
This laboratory and lecture course covered the principles of recombinant-DNA
technology and the application of these procedures to the study of eukaryotic
genes. The isolation, characterization, and expression of specific eukaryotic genes,
including strategies for isolating genes that encode rare mRNA sequences such
as subtractive hybridization, will be emphasized. Among the topics covered were:
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construction of cDNA libraries, construction of bacteriophage genomic DNA
libraries, rapid screening of DNA libraries with gene-specific hybridization probes,
purification and characterization of recombinant clones using restriction endo-
nuclease and blot hybridization analyses, PCR technology, and reintroduction and
expression of cloned genes in heterologous systems. Expression of cDNA clones
in bacteria and insect virus systems were taught. Guest lecturers discussed the
application of molecular cloning procedures to the study of specific eukaryotic
gene systems.
PARTICIPANTS
Abraham, Robert, Ph.D., Mayo Clinic, Rochester, Minnesota
Aggarwal, Aneel, Ph.D., Harvard University, Cambridge,
Massachusetts
Barrandon, Yann, M.D., Harvard Medical School, Boston,
Massachusetts
Cohen, Carl, Ph.D., St. Elizabeth's Hospital, Boston,
Massachusetts
Gifford, David, Ph.D., Massachusetts Institute of Technology,
Cambridge
Hall, Michael, Ph.D., Jules Stein Eye Institute, Los Angeles,
California
Jamnadass, Ramni, M.S., International Laboratory for
Research on Animal Diseases, Kenya, Africa
Rauch, Joyce, Ph.D., Montreal General Hospital, Canada
Reich, Eva-Pia, Ph.D., Yale University, New Haven,
Connecticut
Sarkar, Rita, Ph.D., Madras University, India
Schultz, Maggie, Ph.D., Hahnemann University, Philadelphia,
Pennsylvania
Slezynger, Thelma, Ph.D., Universidad Simon Bolivar,
Venezuela
Soyfer, Valery, Ph.D., Ohio State University, Columbus
Thomas, Patricia, Ph.D., Oklahoma Medical Research
Foundation, Oklahoma City
Thompson, Nancy, Ph.D., Rhode Island Hospital, Providence
Winchester, Robert, M.D., New York University School of
Medicine
SEMINARS
Alt, F, Columbia University. Myc family genes/B cell
differentiation.
Roberts, T., Dana Farber Cancer Institute. Signal
transduction.
McKnight, S., Carnegie Institute. DNA binding specificity
and genetic function of C/EBP.
Oste, C., Perkin-Elmer Cetus. Polymerase chain reaction
technology.
Hood, L., California Institute of Technology. Ig gene super-
family/New advances in biotechnololgy.
Yancopoulos, G., Regeneron Pharmaceuticals. Molecular
genetics of pre B-cell differentiation.
Schimke, R., Stanford University School of Medicine. Gene
amplification and related topics.
Rothstein, R., Columbia University. Gene cloning in yeast
systems.
Tucker P, University of Texas Southwestern. Regulated
expression of Ig genes.
Kiang, S.C., Mt. Sinai Medical School. IL-6 regulation of Ig
gene expression.
Cantor, C., Columbia University. Mapping the human
genome.
Smith, C., Columbia University. Functional elements of
chromosome structure.
Goff, S., Columbia University. Mutagenesis of retrovirus
genomes.
Harlow, E., Cold Spring Harbor Laboratory. EIA complexes
with the retinoblastoma protein.
Aruffo, A., Massachusetts General Hospital. Cloning cDNAs
encoding cell surface proteins by transient expression in
cos cells.
Kaufman, R., Genetics Institute. Cleavage of the P220
subunit of the cap-binding protein complex inhibits
mRNA accumulation, and not translation initiation in
intact cells.
Ca lame, K., Columbia University. Regulation of Ig gene
expression.
Kucherlapati, R., Albert Einstein College of Medicine. Gene
replacement in mammalian cells.
Mulligan, R., Whitehead Institute for Biomedical Research.
Retroviral vectors/Gene transfer into stem cells.
Jarvis, D., Texas A & M University. Baculovirus vectors.
Mandel, G., State University of New York, Stony Brook.
Electrophysiology to clone genes.
Herr W., Cold Spring Harbor Laboratory. Structure and
function of transcription factors.
DePinho, R., Albert Einstein College of Medicine. Transgenic
models for development.
Molecular and Developmental Biology of Plants
July 3-July 23
INSTRUCTORS
Maliga, Pal, Ph.D., Waksman Institute, Rutgers University, Piscataway, New Jersey
Gruissem, Wilhelm, Ph.D., University of California, Berkeley
Varner, Joseph, Ph.D., Washington University, St. Louis, Missouri
ASSISTANTS
Cosowsky, Laurey, M.S., Waksman Institute, Rutgers University, Piscataway, New Jersey
Hajdukiewitz, Peter, M.S., Waksman Institute, Rutgers University, Piscataway, New Jersey
Staub, Jeffrey, M.S., Waksman Institute, Rutgers University, Piscataway, New Jersey
This course provided an intensive overview of current topics and techniques in
plant biology, with emphasis on molecular and developmental biology and
genetics. It was designed for scientists with working knowledge of molecular
techniques who are either working with plant systems or wish to. The course
consisted of a rigorous lecture series, a hands-on laboratory, and informal
discussions. Different guest speakers provided both an in-depth discussion of their
work and an overview of their specialty. The laboratory covered established and
novel techniques in plant biology, including cell and tissue culture techniques,
gene transfer techniques, assays for transient gene expression, nucleic acid
manipulations, in vitro chloroplast transcription, footprint analysis, in situ detection
RNA and protein, genetics of Arabidopsis, genetics and cytogenetics of maize.
PARTICIPANTS
Avni, Adi, M.S., Weizmann Institute, Israel
Haider, Syed, M.S., University of Washington, Seattle
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Hershberger, Jane, Ph.D., Stanford University, California
Huttner, Eric, Ph.D., INRA, Versailles, France
Lai, Shoupeng, M.S., University of Maryland
Leyser, Otto line, B.A., University of Cambridge, England
Marrs, Kathleen, B.A., University of Illinois
Paje-Manalo, Leila, Ph.D., University of New Hampshire
Pereto, Juli, Ph.D., University of Pennsylvania, Philadelphia
Schena, Mark, Ph.D., University of California, San Francisco
Serrano, Elba, Ph.D., University of California Los Angeles
Medical School
Thomas, George, Ph.D., National Institutes of Health,
Bethesda, Maryland
Valles, Maria-Pilar, B.A., Centro de Investigacion, Barcelona,
Spain.
Van der Mark, Frits, Ph.D., Centre for Cytotechnology,
Netherlands
Vance, Nan, Ph.D., United States Dept. of Agriculture,
Corvallis, Oregon
Wang, Yi-Chang, Ph.D., Biotechnica International,
Cambridge, Massachusetts
SEMINARS
Sussex, I., Yale University. Plant development.
Varner, J., Washington University. Cell wall chemistry and
architecture.
Lamb, C., Salk Institute. Plant response to pathogens.
Fromm, M., Plant Gene Expression Center. Assays for
transient gene expression.
Gruissem, W., University of California. Plastid differentiation
during plant development.
Boynton, J., Duke University. Chlamydomonas organelle
genetics.
Miki, B., Plant Research Center. Microinjection.
Ahlquist, P, University of Wisconsin. Plant viruses.
Mottinger, J., University of Rhode Island. Maize cytogenetics.
Dooner, H., Advanced Genetic Sciences. Transposable
elements.
Zambryski, P, University of California. Agrobacterium biology
and applications.
Staskawicz, B., University of California. Plant host-pathogen
interaction.
Theologis, A., Plant Gene Expression Center. Hormonal
control of gene expression.
Quail, P, Plant Gene Expression Center. Phytochrome.
Maliga, P., Waksman Institute. Organelle genetics.
Messing, J., Waksman Institute. Regulation of gene
expression.
Chua, N.-H., Rockefeller University. Regulation of nuclear
gene expression.
Chory, J., Salk Institute. Transduction pathways.
Keegstra, K., University of Wisconsin. Protein targeting.
Free ling, M., University of California. Mutants to study plant
development.
Levings, C., North Carolina State University. Mitochondrial
genes, CMS.
Nasrallah, J., Cornell University. Self-incompatibility.
Meyerowitz, E., California Institute of Technology. Arabidop-
sis I.
Hoisington, D., University of Missouri. RFLP mapping.
Somerville, C., Michigan State. Arabidopsis II.
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Neurobiology of Drosophila
July 3-July 23
INSTRUCTORS
Bate, Michael, Ph.D., University of Cambridge, England
Campos-Ortega, Jose, Ph.D., University of Cologne, Federal Republic of Germany
Palka, John, Ph.D., University of Washington, Seattle
ASSISTANTS
Currie, Douglas, Ph.C., University of Cambridge, England
Dickinson, Michael, Ph.C., University of Washington, Seattle
This laboratory/lecture course provided an introduction to current research in
neuronal function and development in Drosophila. It was intended for researchers
at all levels who may want to use Drosophila as an experimental system for
studying neurobiology.
The course began with a crash course on Drosophila genetics and other
techniques which make Drosophila research distinctive, such as cytogenetics and
DNA transformation. The main emphasis, however, was on studies of the nervous
system.
The course covered basic electrophysiological techniques, as applied to
mutants with altered ion channels or sensory physiology. In the developmental
section, processes of neurogenesis including determination and pathway formation
were examined. The course familiarized students with various preparations,
including the embryonic nervous system, imaginal discs, and adult nervous
system. It also reviewed the different approaches being used in attempts to
unravel the molecular basis of neural development.
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PARTICIPANTS
Auld, Vanessa, B.S., University of Toronto, Canada
Campbell, Shelagh, M.S., University of Connecticut, Storrs
Chia, William, Ph.D., University of Bristol, England
Hovemann, Bernd, Ph.D., University of Heidelberg, Federal
Republic of Germany
Hummon, Margaret, Ph.D., Ohio University, Athens
Kimura, Hideo, Ph.D., The Salk Institute, San Diego,
California
SEMINARS
Aldrich, R., T. Schwarz, Stanford University, and J. Palka,
University of Washington. Physiology.
Ganetzky, B., University of Wisconsin. Genetics, emphasis
on "channel mutants."
Orr-Weaver, T., Whitehead Institute. P-element transformation.
Hartenstein, V., University of California. Embryogenesis.
Campos-Ortega, J., University of Cologne. Embryonic
neurogenesis.
Truman, J., University of Washington. Postembryonic
neurogenesis.
Kramer Helmut, Ph.D., University of California School of
Medicine, Los Angeles
Selleck, Scott, Ph.D., Washington University, St. Louis,
Missouri
Smith, Hazel, Ph.D., University of Warwick, England
Wolff, Tanya, B.S., Purdue University, West Lafayette, Indiana
Hartenstein, V, University of California, J. Palka, University of
Washington, and M. Bate, University of Cambridge.
Peripheral nervous system and muscle.
Goodman, C., University of California. Molecular aspects of
neural differentiation.
Ready, D., Purdue University, G. Rubin, University of Califor-
nia, and I.A. Meinertzhagen, Dalhousie University. Visual
system.
Heisenberg, M., California Institute of Technology, and C.P.
Kyriacou, University of Leicester. Brains and behavior.
Cellular and Molecular Biology of Learning and Memory
July 17-July 30
INSTRUCTORS
Byrne, John, Ph.D., University of Texas Medical School, Houston
Kandel, Eric, Ph.D., Columbia University College of Physicians & Surgeons, New York, New
York
Pearson, Keir, Ph.D., University of Alberta, Canada
Squire, Larry, Ph.D., University of California School of Medicine, San Diego
This lecture course provided an introduction to cell and molecular biological
approaches to learning and memory. Suited for graduate students in molecular
biology, neurobiology and psychology as well as research workers who are
interested in an introduction to this new field, the course covered topics ranging
from behavioral considerations of learning and memory to gene regulation
in the
nervous system. The lectures provided an intensive coverage of five
selected
areas: 1) an introduction to modern behavioral studies of learning and memory;
2)
the cell biology of neuronal plasticity and the regulation of gene expression
by
experience; 3) cellular and molecular mechanisms of simple forms
of learning and
memory in invertebrates and vertebrates; 4) cellular and molecular mechanisms
of
long-term potentiation; and 5) neural approaches to human learning
and its
abnormalities.
PARTICIPANTS
Adam, Geza, Ph.D., Hungarian Academy of Sciences,
Szeged, Hungary
Barbour Boris, B.S., University College of London, England
Barzilai, Ari, Ph.D., Columbia University, New York, New York
Blau, Susana, Ph.D., Nathan Kline Institute, Orangeburg,
New York
Haas, Kurt, B.S Albert Einstein College, Bronx, New
York
Gonczy, Pierre, B.S., Rockefeller University, New York, New
York
Hewes, Randall, B.A., University of Washington, Seattle
Hoch, Werner B.S., University of Heidelberg, Federal
Republic of Germany
Knowlton, Barbara, B.A., University of Southern California,
Los Angeles
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Kolb, Stephen, Ph.D., University of Texas, Austin
Kubo, Tai, Ph.D., Columbia University, New York, New York
Kuhl, Dietmar, Ph.D., Columbia University, New York, New
York
Martin, Donna, B.S., University of Michigan, Ann Arbor
Mestel, Rosemary, Ph.D., University of California Los
Angeles Medical Center
Nazif, Fidelma, B.S., University of Texas, Houston
SEMINARS
Kandel, E., Columbia University. Introduction to the cellular
study of learning.
Holland, R, Duke University. Introduction to learning theory.
Gould, J., Princeton University. Ethological approaches to
learning.
Byrne, J., University of Texas Medical School. Overview of
membranes and synaptic transmission.
Schulman, H., Stanford University. Overview of second
messenger systems and their role in learning.
Ganetzky, B., University of Wisconsin. Introduction to the
study of genes and behavior.
Brunet, J.-F., and P Pfaffinger, Columbia University. Cloning
of genes important to learning.
Curran, T, Roche Institute. Modulation of gene expression in
the vertebrate nervous system.
Adler, J., University of Wisconsin. Genes and the behavior of
bacteria.
Kenyon, C., University of California. Genes and the behavior
of C. elegans.
Kandel, E., Columbia University. Learning in Aplysia I.
Habituation.
. Learning in Aplysia II. Sensitization.
Byrne, J., University of Texas Medical School. Learning in
Aplysia III. Classical conditioning.
Pacheco, Mauro, Ph.D., University of Colima, Mexico
Raymond, Jennifer, B.A., University of Texas, Houston
Ruff, Naomi, B.S., NCI, National Institutes of Health,
Bethesda, Maryland
Shors, Tracey, Ph.D., University of Southern California, Los
Angeles
Suzuki, Wendy, B.A., The Salk Institute, San Diego, California
Takita, Masatoshi, M.S., Tokyo Institute of Technology, Japan
Quinn, C., Massachusetts Institute of Technology. Genetic
approaches to study associative learning in Drosophila.
Nicoll, R., University of California. Long-term potentiation I.
Long-term potentiation II.
Morris, R.G., University of Edinburgh. Role of the
Hippocampus and Hippocampal long-term potentiation in
learning.
Crow, T, University of Texas Medical School. Cellular
correlates of associative learning in Hermissenda.
Pearson, K., University of Alberta. Neuronal correlates of
motor learning.
Lisberger, S., University of California. Plasticity in the
vestibulo-occular reflex.
Thompson, R., University of Southern California. Cellular
locus and correlates of the classical conditioning of the
nictitating membrane response.
Greenough, W., University of Illinois. Morphological
correlates of learning and experience.
Squire, L., University of California. Memory in humans and
non-human primates.
Posner, M., Washington University. Neuropsychology of
cognition.
Price, D., Johns.Hopkins University. Alzheimer's diseases.
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Advanced Molecular Cloning and Expression
of Eukaryotic Genes
July 25-August 14
INSTRUCTORS
Botchan, Michael, Ph.D., University of California, Berkeley
Kingston, Robert, Ph.D., Harvard Medical School, Boston, Massachusetts
Myers, Richard, Ph.D., University of California, San Francisco
Rio, Donald, Ph.D Whitehead Institute, Cambridge, Massachusetts
ASSISTANTS
Misra, Sima, Ph.D., Whitehead Institute, Cambridge, Massachusetts
Robbins, Alan, Ph.D., E.I. du Pont de Nemours, Wilmington, Delaware
Taylor, Ian, Ph.D., Harvard Medical School, Boston, Massachusetts
This course focused on how to manipulate cloned eukaryotic genes to probe
questions on their structure, expression and function. As a model system, we
examined cis- and trans-acting components involved in the regulation of
eukaryotic gene expression. Students learned the theoretical and practical aspects
of constructing genomic and cDNA libraries. Expression libraries from various
organisms were screened with recognition site probes for specific DNA-binding
proteins. A variety of transfection techniques were used to introduce cloned DNA
molecules that have been manipulated in vitro into Drosophila and vertebrate
cells in culture. Mutants were generated by oligo-directed and random mutagene-
sis procedures and characterized by DNA sequencing. The expression pattern of
wildtype and mutant DNAs were analyzed by Si nuclease, RNase protection and
enzymatic assays. Techniques and theory for detecting and characterizing the
interaction between regulatory DNA sequences and trans-acting protein factors
were presented. Guest lecturers discussed present problems in eukaryotic
molecular biology as well as technical approaches to their solutions. Experience
with basic recombinant-DNA techniques was a prerequisite for admission to this
course.
PARTICIPANTS
Attie, Alan, Ph.D., University of Wisconsin, Madison
Behrens, Margarita, M.S., Institute de Investigaciones
Biomedicas, Madrid, Spain
Brisebois, Josee, M.S., McGill University, Montreal, Canada
Buchman, Timothy, Ph.D., Johns Hopkins Hospital,
Baltimore, Maryland
Chilton, Beverly, Ph.D., Texas Tech University, Lubbock
Cross, James, D.V.M., University of Missouri, Columbia
Korsgren, Catherine, B.A., St. Elizabeth's Hospital, Boston,
Massachusetts
Kronidou, Nafsika, B.A., Dartmouth College, Hanover, New
Hampshire
SEMINARS
Rio, D., Whitehead Institute. Regulation of Drosophila P
element transposition.
Myers, R., University of California. Molecular genetics of
Huntington disease.
Ptashne, M., Harvard University. Regulation of transcrip-
tion-A general view.
Louvi, Angeliki, B.S., University of Athens, Greece
Lu, Bing, M.S., Albert Einstein College, Bronx, New York
Macdonald, Mary, B.S., University of British Columbia,
Vancouver, Canada
Marshallsay, Christopher, B.S., Friedrich Miescher Institut,
Basel, Switzerland
Petch, Leslie, B.S., University of North Carolina, Chapel Hill
Sandrin, Mauro, Ph.D., University of Melbourne, Australia
Xu, Lin, M.S., Albert Einstein College, Bronx, New York
Yakobson, Bracha, M.S., Weizmann Institute, Israel
McKnight, S., Carnegie Institution. Clues from the structures
of transcription factors.
Guarente, L., Massachusetts Institute of Technology.
Eukaryotic transcription: A conserved process from yeast
to man.
Sharp, P, Massachusetts Institute of Technology.
Multi-factor
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transcription complexes.
Maniatis, T, Harvard University. Mechanisms of inducible
and tissue-specific gene expression.
Treisman, R., I.C.R.F, London. Induction of gene expression
following growth factor stimulation.
Courey, A., University of California. Transcriptional activation
by the glutamine-rich domains of human SP1.
Yeast Genetics
Herr, W., Cold Spring Harbor Laboratory. Structure and
function of eukaryotic transcription factors.
Kingston, R., Harvard Medical School. Transcriptional control
by heat in human cells.
Evans, R., Salk Institute. Molecular genetics of steroid and
thyroid hormone receptors.
July 25-August 14
INSTRUCTORS
Hieter, Phil, Ph.D., Johns Hopkins University, Baltimore, Maryland
Rose, Mark, Ph.D., Princeton University, New Jersey
Winston, Fred, Ph.D., Harvard Medical School, Boston, Massachusetts
ASSISTANTS
Chapman, Karen, B.A., Johns Hopkins University, Baltimore, Maryland
Hirschhorn, Joel, B.A., Harvard Medical School, Boston, Massachusetts
Meluh, Pamela, B.A., Princeton University, New Jersey
The major laboratory techniques used in the genetic analysis of yeast were
studied, including the isolation and characterization of mutants, tetrad analysis,
complementation, and mitotic recombination. Micromanipulation used in tetrad
analysis was carried out by all students. Molecular genetic techniques, including
yeast transformation, gene replacement, analysis of gene fusions, and elec-
trophoretic separation of chromosomes were applied to the analysis of yeast DNA.
Indirect immunofluorescence experiments were done to identify the nucleus,
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microtubules, and other cellular components. Lectures on fundamental aspects of
yeast genetics were presented along with seminars given by outside speakers on
topics of current interest.
PARTICIPANTS
Amberg, David, B.A., Dartmouth Medical School, Hanover,
New Hampshire
Arwood, Laura, Ph.D., North Carolina State University,
Raleigh
Austin, Judith, M.S., University of Wisconsin, Madison
Chakravarti, Debabrata, M.S., Albert Einstein College, Bronx,
New York
Chirico, William, Ph.D., Rockefeller University, New York,
New York
Hershey, John, Ph.D., University of California, Davis
Hilgen, Sharon, B.A., University of North Carolina, Chapel
Hill
Leberer, Ekkehard, Ph.D., University of Toronto, Canada
Moore, Claire, Ph.D., Tufts University, Medford,
Massachusetts
SEMINARS
Mitchell, A., Columbia University. Control of meiosis in yeast.
Carlson, M., Columbia University. Glucose repression in
yeast.
Wig ler, M., Cold Spring Harbor Laboratory. RAS control
pathways in yeast.
Guthrie, C., University of California School of Medicine.
snRNPs and splicing.
Broach, J., Princeton University. Plasmid persistance.
Herskowitz, I., University of California. A genetic hierarchy
responsible for yeast cell type.
Fetes, T., University of Chicago. Meiotic recombination in
yeast.
Hinnebusch, A., National Institutes of Health. Translational
control of transcriptional regulator.
Guarente, L., Massachusetts Institute of Technology.
Eukaryotic transcription: A conserved process from yeast
to man.
Sherman, F., University of Rochester. Post-translational
modification of cytochrome c.
Nakamura, Yoshikazu, Ph.D., University of Tokyo, Japan
Peltz, Stuart, Ph.D., University of Wisconsin, Madison
Prentice, Holly, M.S., Massachusetts General Hospital,
Boston
Rienhoff, Hugh, M.D., Fred Hutchinson Cancer Center,
Seattle
Rocco, James, B.S., Mt. Sinai School of Medicine, New York,
New York
Sinensky, Michael, Ph.D., Eleanor Roosevelt Institute, Denver,
Colorado
Schiavi, Susan, Ph.D., Harvard Medical School, Boston,
Massachusetts
Pringle, J., University of Michigan. Cellular morphogenesis
during the yeast cell cycle.
Fox, T., Cornell University. Translational control of yeast
mitochondrial genes and escape to the nucleus.
Novick, P., Yale University. Protein export in yeast.
Kurjan, J., Columbia. Cell-cell interaction involved in yeast
mating.
Hieter, P., Johns Hopkins Medical School. Chromosome
transmission fidelity in yeast.
Fink, G., Whitehead Institute. Molecular biology of cell fusion
in yeast.
Sternglanz, R., State University of New York. DNA
topoisomerases.
Rose, M., Princeton University. Genes affecting nuclear
fusion in yeast.
Winston, F, Harvard Medical School. Analysis of transcrip-
tion mutants in yeast.
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Molecular Probes of the Nervous System
July 25-August 14
INSTRUCTORS
Carlson, Steve, Ph.D., University of Washington, Seattle
Evans, Christopher, Ph.D., Stanford University, California
Levitt, Pat, Ph.D., Medical College of Pennsylvania, Philadelphia
ASSISTANT
Hal !den, Gunnel, Ph.D., University of California, Berkeley
This course was designed for scientists from various disciplines who are interested
in understanding the power and pitfalls of antibodies and nucleotide probes as
biochemical and anatomical reagents. A series of evening lectures addressed
basic and advanced immunology concepts and the use of molecular probes to
investigate current issues in neurobiology. The primary emphasis of the course
was to acquire practical laboratory experience through daily exercises using an
extensive number of techniques, including generation and characterization of
monoclonal antibodies to synthetic peptides and complex neural antigens,
immunocytochemistry, in situ hybridizaton, immunoassays (ELISA & RIA), affinity
chromatography and Western blotting. Approaches that combine the use of
molecular probes were highlighted by performing expression library screening and
exercises employing double labeling strategies. We also designed biological
assays in tissue culture to demonstrate functional relevance of specific molecules.
PARTICIPANTS
Antonelli, Marta, Ph.D., Universidad de Buenos Aires,
Argentina
Belting, Heinz-Georg, B.A., Yale University, New Haven,
Connecticut
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Brown, Abraham, Ph.D., Columbia University, New York,
New York
Buchner, Klaus, Ph.D., Freie Universitat, Berlin, Federal
Republic of Germany
Helms, Jill, D.D.S., University of Connecticut, Storrs
Krulewski, Thomas, M.S., Mt. Sinai School of Medicine, New
York, New York
McKeon, Tina, Ph.D., University of Vermont, Burlington
Rinaman, Linda, Ph.D., University of Pennsylvania,
Philadelphia
Savio, Tiziana, Ph.D., Universitat Zurich, Switzerland
SEMINARS
Fleischman, J., Washington University School of Medicine.
Igs and super family.
Kurt-Jones, Evelyn, Brigham Women's Hospital. T-cells.
. Interleukins.
Burrows, P, University of Alabama School of Medicine.
B cell differentiation.
Lagenaur, C., University of Pittsburgh School of Medicine.
Cell surface interactions in neural development.
Lee, V., Hospital of the University of Pennsylvania. Neurofila-
ment structure and regulation.
Chesselet, M.-F., Medical College of Pennsylvania. In-situ
hybridization histochemistry as a tool to study neurotrans-
mitter interactions in the basal ganglia.
Sharff, M., Albert Einstein College of Medicine. Somatic
mutations.
Buckley, K., Harvard Medical School. Synaptic vesicle
proteins.
Xiang, Chang, Ph.D., Lehigh University, Bethlehem,
Pennsylvania
Sretavan, David, Ph.D., Rockefeller University, New York,
New York
Wayne, Denise, Ph.D., Washington University Medical
School, St. Louis, Missouri
Hockfield, S., Yale University School of Medicine. The effect
of activity on the molecular anatomy of the developing
brain.
Alt, F., Columbia University College of Physicians &
Surgeons. Ig gene rearrangements.
Pintar, J., Columbia University College of Physicians &
Surgeons. Gene expression in development.
Dodd, J., Columbia University College of Physicians &
Surgeons. Axon pathfinding.
Evans, C., Stanford Medical School. Peptide processing and
expression.
Levitt, P., Medical College of Pennsylvania. Circuit formation
in CNS development.
Carlson, S., University of Washington. Proteoglycans as
synaptic components.
Molecular Neurobiology: Brain Development and Function
August 1-August 14
INSTRUCTORS
McKay, Ronald, Ph.D., Massachusetts Institute of Technology, Cambridge
Patrick, James, Ph.D., Baylor College of Medicine, Houston, Texas
Reichardt, Louis, Ph.D., University of California, San Francisco
Schwarz, Thomas, Ph.D., Stanford University, California
This lecture course presented both basic concepts and currently exciting
research
problems in molecular neurobiology. It focused on approaches and methods now
used to study the development and function of the nervous system. Topics
covered included gene expression, receptor structure and
function, ion channel
cloning, second messenger systems, learning, sensory
transduction, behavioral
genetics, neural induction, cell lineage, immortal cell lines, cell adhesion,
onco-
genes, neurite outgrowth. The course provided the
opportunity to discuss this
rapidly expanding research area with invited lecturers.
Students from a wide
variety of backgrounds (graduate students to faculty) were encouraged to apply.
PARTICIPANTS
Aldrich, Eric, B.A., George Washington University, Washing-
ton, D.C.
Allen, Kathryn, B.S., Institute of Neurology, London, England
Allsopp, Timothy, Ph.D., Max Planck Institut, Tubingen,
Federal Republic of Germany
Berman, Joshua, B.A., Mt. Sinai School of Medicine, New
York, New York
Delay, Rona, B.S., Colorado State University, Fort Collins
Eide, Anne-Lill, M.D., University of Oslo, Norway
Gregor, Paul, M.S., Weizmann Institute, Israel
Hart, Ian, B.S., University College, London, England
Hayashi, Motoharu, M.S., Kyoto University, Japan
Higashinakagawa, Toru, Ph.D., Mitsubishi Kasei Institute,
Tokyo, Japan
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Karlstrom, Rolf, B.S., University of Utah, Salt Lake City
Kessler, Daniel, B.S., Rockefeller University, New York, New
York
Leith, Erich, Ph.D., Worcester Foundation, Shrewsbury,
Massachusetts
Noda, Tetsuo, Ph.D., Whitehead Institute, Cambridge,
Massachusetts
Paganetti, Paolo, M.S., Brain Research Institute, Zurich,
Switzerland
Prendergast, George, Ph.D., New York University, New York
SEMINARS
Hayes, T, Massachusetts Institute of Technology. The
regulation of cell growth.
Myers, R., University of California. The molecular genetics of
Huntington's disease.
Stillman, B., Cold Spring Harbor Laboratory. DNA replication
in mammalian cells.
Bargmann, C., Massachusetts Institute of Technology.
Chemosensory neurons and chemotaxis in C. elegans.
Zipursky, L., University of California School of Medicine.
Genetic analysis of visual system development in
Drosophila.
McKay, R., Massachusetts Institute of Technology. Differentia-
tion pathways of mammalian CNS stem cells.
Bridgemen, P, Washington University School of Medicine.
Dynamics and structure of the nerve growth cone
cytoskeleton.
Scheller, R., Stanford University. The cellular and molecular
biology of neuropeptides.
Beach, D., Cold Spring Harbor Laboratory. Control of the
cell division cycle.
Bent ly, D., University of California. Axon outgrowth in insects.
Reichardt, L., University of California School of Medicine.
Factors regulating neurite outgrowth in mammals.
Pfeffer, S., Stanford University. Protein sorting and membrane
traffic in eukaryotic cells.
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Rubin, Michael, Ph.D., Rockefeller University, New York, New
York
Singer, Matthew, B.A., University of California, Berkeley
Skinner, Karen, Ph.D., National Institutes of Health,
Bethesda, Maryland
Smith, Paul, Ph.D., Institute of Neurology, London, England
Stoeckli, Kurt, M.S., Max Planck Institute, Martinsried,
Federal Republic of Germany
Weinstein, David, M.S., Columbia University College of
Physicians & Surgeons, New York, New York
lh le, J., St. Jude's Children's Research Hospital. The role of
hematopoetic growth factors in growth and differentiation.
Harlow, E., Cold Spring Harbor Laboratory. Interaction of
oncogenes with cellular control pathways.
Patrick, J., Baylor College of Medicine. Ligand-gated ion
channels.
Schwarz, T, Stanford University School of Medicine. A family
of K+ channels found by genetics.
Reed, R., Johns Hopkins School of Medicine. Sensory signal
transduction and models for neurogenesis.
Siegelbaum, S., Columbia University College of Physicians &
Surgeons. Molecular mechanisms regulating the
electrophysiological response of Aplysia.
Curran, T, Roche Institute. Transcription factors on the brain:
Fos, Jun and the AP-1 binding site.
Kennedy, Mary, California Institute of Technology. The
enzymology of Ca' regulated phosphorylation in the
brain.
Beer, E., University of California. Molecular genetics of
neural development in Drosophila.
Madison, D., Stanford University. Second messengers and
LTP in hippocampus.
Konishi, M., California Institute of Technology. Birdsong:
From behavior to molecules.
Molecular Cloning of Neural Genes
August 16-September 4
INSTRUCTORS
Eberwine, Jim, Ph.D., Stanford University, California
Evinger, Marian, Ph.D., Cornell University Medical Center, New York
Schachter, Beth, Ph.D., Mt. Sinai School of Medicine, New York, New York
ASSISTANTS
Inman, Irene, M.S., Stanford University, California
Sanchez, Mercedes, Ph.D., Mt. Sinai School of Medicine, New York, New York
This intensive laboratory/lecture course provided scientists with a basic knowledge
of the use of the techniques of molecular biology in examining questions of
neurobiological significance. Particular emphasis was placed on using and
discussing methods for circumventing the special problems posed in the study of
the nervous system; for example, examination of low abundance mRNAs in
extremely heterogeneous cell populations.
The laboratory work included mRNA quantitation methods (nuclease protection,
etc.), preparation of hybridization probes, library construction (lambda ZAP and
1ST procedure), plaque screening techniques (probe hybridization, antibody
interaction), DNA sequencing, PCR amplification, RNA amplification, and DNA
mediated gene transfer. A major portion of the course was devoted to in situ
hybridization and in situ transcription technologies. The lecture series, presented
by invited speakers, focused on emerging techniques and how they may be
applied to the study of the nervous system.
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PARTICIPANTS
Crews, Lynda, B.S., Emory University, Atlanta, Georgia
Finnell, Richard, Ph.D., Washington State University, Pullman
Fisher, Marilyn, Ph.D., University of Virginia, Charlottesville
Harsh, Griffith, M.D., University of California, San Francisco
Houenou, Lucien, Ph.D., Bowman Gray School of Medicine,
Winston-Salem, North Carolina
Howard, Marthe, Ph.D., Columbia University, New York, New
York
Leifer, Dana, M.D., Children's Hospital, Boston,
Massachusetts
MacKenzie, Robert, Ph.D., Abbott Laboratories, Abbott Park,
Illinois
Martuza, Robert, M.D., Massachusetts General Hospital,
Boston
SEMINARS
Goodman, R., Tufts University. Regulated expression of
neuropeptide genes.
Hahn, B., University of Colorado. Molecular cloning and the
definition of a gene product with brain-specific function.
Stevens, C., Yale University. Site-directed mutagenesis as a
tool for understanding channel gating.
Abood, M., Stanford University. Molecular analyses of opioid
systems.
Cepko, C., Harvard Medical School. Lineage analysis using
retrovirus vectors.
Hockfield, S., Yale University. The effects of activity on the
molecular anatomy of the developing brain.
Ciaranello, R., Stanford University. Molecular cloning of
neurotransmitter receptors.
Macromolecular Crystallography
Moran, Ofira, M.S., Sack ler School of Medicine, Israel
Sanders-Bush, Elaine, Ph.D., Vanderbilt University, Nashville,
Tennessee
Schlosshauer, Burkhard, Ph.D., Max Planck Institut,
Tubingen, Federal Republic of Germany
Trapido-Rosenthal, Henry, Ph.D., University of Florida,
Gainesville
Unsicker, Klaus, M.D., University of Marburg, Federal
Republic of Germany
Villarroel, Alvaro, M.S., State University of New York, Stony
Brook
Zaidi, Nikhat, Ph.D., University of Pittsburgh, Pennsylvania
Singer, R., University of Massachusetts Medical School.
Subcellular organization of nucleic acid sequences
revealed by high resolution in situ hybridization.
Jonassen, J., University of Massachusetts Medical School.
Endocrine regulation of pituitary hormone gene
expression.
Claudio, T, Yale University. Biogenesis and cell surface
distribution of acetylcholine receptor stably expressed in
cell lines.
Evans, C., Stanford University. Use of antibodies in
molecular cloning procedures.
Helfman, D., Cold Spring Harbor Laboratories. Regulation of
alternative splicing in the central nervous system.
Bailey, M., Milligen/Biosearch. Automated DNA synthesis.
October 11-October 24
INSTRUCTORS
Pflugrath, James, Ph.D., Cold Spring Harbor Laboratory, New York
McPherson, Alex, Ph.D., University of California, Riverside
Remington, S.J., Ph.D., University of Oregon, Eugene
Crystallography and X-ray diffraction yield a wealth of structural information
unobtainable through other methods. This intensive laboratory/computational
course focused on the major techniques used to determine the three-dimensional
structures of macromolecules. It was designed for scientists with a working
knowledge of protein structure and function, but who were new to macromolecular
crystallography. Topics that were covered included protein purification, crystalliza-
tion, crystal characterization, data collection (film and area detector methods), data
reduction, anomalous dispersion, phase determination, molecular replacement
and averaging, electron density interpretation, structure refinement, molecular
graphics, and molecular dynamics. Participants learned through extensive hands-
on experiments, informal discussions, and lectures on current applications of these
and related procedures given by outside speakers.
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PARTICIPANTS
Anderson, Dwight, Ph.D., University of Minnesota,
Minneapolis
Cerritelli, Susana, Ph.D., Brookhaven National Laboratory,
Upton, New York
Chang, Yie-Hwa, Ph.D., Massachusetts General Hospital,
Boston
Chaudhuri, Gautam, Ph.D., Chicago Medical School, Illinois
Cockle, Stephen A., Ph.D., Connaught Laboratories, Canada
Dewan, John, Ph.D., New York University, New York
Ganguli, Subrata, M.S., University of Illinois, Chicago
Gittis, Apostolos, Ph.D., Johns Hopkins University, Baltimore,
Maryland
Honegger, Annemarie, Ph.D., Rorer Biotechnology, King of
Prussia, Pennsylvania
Ilag, Leodevico, B.S., University of Tennessee, Memphis
Matthews, John, Ph.D., Naval Research Laboratory,
Washington, D.C.
Milligan, Daniel, B.A., University of California, Berkeley
Nanni, Raymond, Ph.D., Rutgers University, New Brunswick,
New Jersey
Sun, Wei-Hsiang, Ph.D., Massachusetts Institute of Technol-
ogy, Cambridge
Szabo, Linda, B.S., Eastman Kodak, Rochester, New York
Williams, Neal, B.S., University of Sydney, Australia
SEMINARS
McPherson, A., University of California. Protein purification.
Crystallization of macromolecules.
Carter, C., University of North Carolina. Experimental design
for efficient screening of crystal growth conditions.
Sweet, R., Brookhaven National Laboratory. Introduction to
crystallography.
X-ray sources and optics.
McPherson, A., University of California. Preliminary crystal
characterization.
Remington, S.J., University of Oregon. Data collection I.
Oscillation photography.
Pflugrath, J., Cold Spring Harbor Laboratory. Data collection
II. Area detector madness.
Remington, S.J., University of Oregon. MIR phase
refinement.
Jones, TA., University of Uppsala. Electron density
interpretation.
Remington, S.J., University of Oregon. Improving phases:
Solvent flatening, phase combination.
Saper, M.A., Harvard University. Molecular replacement.
Molecular averaging.
. Human histocompatibility antigen structure: A close
look of the peptide binding site.
Hendrickson, W.A., Columbia University. Application of
multiwavelength anomalous diffraction to direct
macromolecular structure determination.
Gronenborn, A., National Institutes of Health. Determination
of protein structure by 2D and 3D NMR.
Brunger, A., Yale University. Refinement and molecular
replacement with X-PLOR.
Tronrud, D., University of Oregon. Refinement with TNT.
Arnold, E., Rutgers University. Solution and analysis of the
human rhinovirus 14 structure: New insights into viral
structure-function relationships.
Molecular Genetics of Fission Yeast
October 24-November 6
INSTRUCTORS
David Beach, Ph.D., Cold Spring Harbor Laboratory, New
York
Peter Fantes, Ph.D., University of Edinburgh, Scotland
Jerry Hyams, Ph.D., University of College, London, England
Maureen McLeod, Ph.D., State University of New York, Brooklyn
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ASSISTANTS
Carolina Alpha, Ph.D., University College London, England
Emma Warbrick, M.A., University of Edinburgh, Scotland
The fission yeast (Schizosaccharomyces pombe) is increasingly being used as a
model organism for the study of basic aspects of cell biology. This course
introduced the student to all aspects of fission yeast biology, but with particular
emphasis on genetic manipulation (both classical and with recombinant DNA) and
the use of the organism for the study of cell biology. Topics covered included
chemical mutagenesis and mutant analysis, transformation and gene replacement
techniques, isolation of nuclei, preparation of nuclear DNA, plasmid recovery from
yeast into bacteria, cell cycle methods, cytology and immunocytochemical
techniques. In addition to hands-on experience, participants had the opportunity
to learn through informal group discussions and a lecture series designed to
complement the experimental section.
PARTICIPANTS
Allen, Jerry, B.S., University of Texas, Dallas
Cande, W. Zacheus, Ph.D., University of California, Berkeley
Damagnez, Veronique, B.A., C.N.R.S., Villejuif, France
Davey, John, Ph.D., University of Birmingham, England
DeCaprio, James, Ph.D., Dana Farber Cancer Institute,
Boston, Massachusetts
Dunphy, William, Ph.D., University of California, San Diego
Elble, Randolph, Ph.D., Cornell University, Ithaca, New York
Fikes, John, Ph.D., Massachusetts Institute of Technology,
Cambridge
SEMINARS
Fantes, P., University of Edinburgh. Introduction to fission
yeast.
Wise, J., University of Illinois. Roles of small ribonucleopro-
tein particles in RNA splicing and protein secretion.
Hyams, J., University College London. Fission yeast
cytology.
Gasser, S., ISREC, Lausanne. Genome organization and
nuclear structure in fission yeast.
McLeod, M., Downstate Medical School, Brooklyn.
Regulation of sexual differentiation in fission yeast.
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Gonda, David, Ph.D., Massachusetts Institute of Technology,
Cambridge
Hengst, Ludger, B.S., Max-Planck-Institut, Gottingen
Pichova, Alena, Ph.D., Czechoslovak Academy of Sciences
Pidoux, Alison, B.A., Imperial Cancer Research Fund,
London
Se linger, David, B.S., University of Illinois, Urbana
Subramani, Suresh, Ph.D., University of California, San
Diego
Thornton, Roy J., Ph.D., Massey University, New Zealand
Wang, Teresa, Ph.D., Stanford University, California
Wig ler, M., Cold Spring Harbor Laboratory. S. pombe as a
surrogate surrogate.
Young, P, Queens University, Ontario. Sodium transport in
fission yeast.
Beach, D., Cold Spring Harbor Laboratory. Cell cycle
control.
Clark, L., University of California, Santa Barbara.
Centromeres in fission yeast.
Klar, A., National Cancer Institute, Frederick. Regulation of
fission yeast mating-type interconversion.
Yanagida, M., Kyoto University. The nucleus and its division.
Seminars
Cold Spring Harbor Seminars were initiated to provide a semiformal avenue for
communication between the various research groups at the Laboratory. They are
particularly useful for research personnel who have joined the Laboratory during
the summer. The seminars also afford a necessary opportunity for the graduate
students and postgraduate staff to develop their skills in defending, organizing,
and presenting their research. In addition to those listed below, seminars were
given by many others involved in research at this laboratory.
1989
January
Larry Feig, Tufts University, Medford, Massachusetts:
Inhibition of the cellular ras pathway by a dominant
inhibitory ras mutant.
Peter Cornelius, East Carolina University, Greenville, North
Carolina: Regulation of lipoprotein lipase and glucose
transport in 3T3-L1 cells by tumor necrosis factor.
Michael Harrington, California Institute of Technology,
Pasadena, California: Characterizing disease-associated
proteins using two-dimensional gel electrophoresis and
amino acid sequence analysis-What are the current
challenges?
Jinez Morata, Universidad Autonima de Madrid, Spain:
Further explorations of the Bithorax complex of
Drosophila.
Mike Mulligan, Stanford University, California: Transcription,
initiation, and RNA processing in maize mitochondria.
Nina Federoff, Carnegie Institution of Washington, Baltimore,
Maryland: Developmental regulation of the maize control-
ling element Suppressor-Mutator.
Doug Engel, Northwestern University, Evanston, Illinois:
Erythroid cell gene regulation.
February
Drew Schwartz, Indiana University, Bloomington: Regulation
of Ac function-Gene-controlled demethylation of the
promoter region.
B.R. Brinkley, University of Alabama, Tuscaloosa:
Centromere structure and evolution-Repetitive microtu-
bule binding segments in the kinetochore of mammalian
chromosomes.
Sidney Strickland, State University of New York, Stony Brook:
Use of antisense and chimeric RNAs to study mRNA
recruitment in mouse oocytes.
Jeff Schell, Max-Planck Institut, Cologne, Federal Republic of
Germany: Genes involved in the control of plant
development.
Andreas Zimmer, University of Gottingen, Federal Republic
of Germany: New strategies in developmental biology-In
vivo mutagenesis as a tool to dissect mouse
development.
Diane M. Robins, Columbia University, New York, New York:
Regulation and evolution of an androgen-dependent
mouse gene.
Tom Cline, Princeton University, New Jersey: Molecular
genetics of the primary events in Drosophila sex
determination.
Masafumi Tanaka, Cold Spring Harbor Laboratory, New York:
Differential activation of transcription by ubiquitous and
cell-specific transcription factors Oct-1 and Oct-2.
March
Bill Clouston, Howard Florey Institute of Experimental
Physiology and Medicine, Melbourne, Australia: Tissue-
specific expression of an angiotensinogen minigene in
transgenic mice.
Vadim Nikiforov, Institute of Molecular Genetics, Moscow,
Union of Soviet Socialist Republics: Genetics of bacterial
RNA polymerase.
Hong Ma, California Institute of Technology, Pasadena,
California: The genes controlling flower development in
Arabidopsis.
Joe Gall, Carnegie Institution of Washington, Baltimore,
Maryland: Proteins associated with transcription units of
lampbrush chromosomes.
Phil C. Andrews, Purdue University, West Lafayette, Indiana:
Pancreatic prohormone processing.
Jim Rothman, Princeton University, New Jersey: Mechanism
of intracellular protein transport.
Jim Peacock, CSIRO-Div. of Plant Industry, Canberra,
Australia: Enhancer and promoter interactions in a plant
gene expression system.
Ron Morris, Rutgers University, New Jersey: Three genes
involved in mitosis in Aspergillus.
Jonathan Jones, John Innes Institute, Norwich, England:
Genetic properties of Ac in tobacco.
April
Barry Stripp, East Carolina University, Greenville, North
Carolina: Cloning, sequencing, and expression of New
Castle disease virus genes.
Terry Platt, University of Rochester New York: mRNA 3'-end
formation in E. coli and yeast.
Marc Van Montagu, Rijks Universiteit, Gent, Belgium:
Progress in plant genetic engineering.
Sandra Rempel, University of Calgary, Canada: Estrogen
regulation of c-myc proto-oncogene expression in prolifer-
ating chick oviduct.
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Walter Schaffner, University of Zurich, Switzerland: Oct
factors and lymphocyte-specific transcription.
Ruth Ann Nichols, Purdue University, West Lafayette,
Indiana: Characterization of a Drosophila homolog of the
vertebrate neuropeptide cholecystokinin.
Tom Peterson, Cold Spring Harbor Laboratory, New York:
Molecular analysis of the maize P locus and Ac
transposition.
Gunter Blobel, Rockefeller University, New York, New York:
Structure and function of the nuclear lamina and pore
complexes.
May
Rick Morimoto, Northwestern University, Evanston, Illinois:
Transcription and function of the human hsp70.
Judith Scheppler, Emory University, Atlanta, Georgia: Down
modulation of MHC class I antigens after HIV-1 infection.
Helen Blau, Stanford University, California: Plasticity of
differentiated cells.
Daniela Rhodes, Medical Research Council, Cambridge,
England: TFIIIA-Zinc fingers and DNA recognition.
Karl Riabowol, Cold Spring Harbor Laboratory, New York:
Mechanisms and specificity of FOS complex activation.
Erich Grotewold, Cold Spring Harbor Laboratory, New York:
Genes induced by protein synthesis inhibition in
Neurospora crassa.
Greg Dressler, Max-Planck Institute, Gottingen, Federal
Republic of Germany: Developmental expression of
murine Hox and Pax genes.
June
Tom Marr, Los Alamos National Laboratory, New Mexico:
Computational tools for physically mapping large
segments of DNA.
Huseyin Mehmet, ICRF, London, England: Expression of
c-myc.
Yung Yu, Medical Research Council, Cambridge, England:
Molecular genetics of the human serum protein,
complement component Ca.
Eric Richards, Cold Spring Harbor Laboratory, New York:
Characterization of telomeric and centromeric DNA
sequences from Arabidopsis.
Nahum Sonenberg, McGill University, Montreal, Canada:
5'-noncoding regions of eukaryotic mRNAs as effectors of
translation-Poliovirus and HIV-1.
Chin-Hwa Hu, Oregon State University, Corvallis: Strand
displacement and the molecular gymnastics in adenovi-
rus replication.
Jacek Skowronski, Cold Spring Harbor Laboratory, New
York: Latency and activation of the HIV-1 LTR in
transgenic mice.
July
Emma Lees, Imperial Cancer Research Fund, London,
England: Physical and functional properties of a
transcriptional regulator-The E2 protein from human
papillomavirus type 16.
Peter A. Peterson, Iowa State University, Ames: Characteriza-
tion of maize transposable elements.
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Nick Tonks, University of Washington, Seattle: Signal
transduction and protein tyrosine dephosphorylation.
Anthony Craig, Uppsala University, Sweden: Comparison of
mass spectrometric sequence information from peptides
using different ionization methods.
Michael Hubbard, University of Dundee, Scotland:
Phosphoprotein phosphatases and cellular regulation-
Reversible targeting of protein phosphatase 1 to
glycogen.
Peter Baciu, West Virginia University, Morgantown: Changes
in nuclear protein phosphorylation during granulocytic
differentiation of HL-60 cells.
Valery N. Soyfer, Ohibtate University, Columbus:
Lysenko-The crash of Soviet genetics in the age of Stalin
and Khruschev.
August
Catherine Thompson, The,,S0k Institute, La Jolla, California:
Structural and functional relationship of thyroid and
steroid hormone receptors,
September
Jackie Lees, ICRF, London, England: Functional analysis of
the mouse estrogen receptor.
Peter Star linger, University of Cologne, Federal Republic of
Germany: Experiments on the transposable element Ac
of Zea mays.
Christiane Zock, Institute of Genetics, University of Cologne,
Federal Republic of Germany: Mitigator sequence in the
major late promoter of Ad12.
Ulrich Wier, Princeton University, New Jersey: Activation of
AP1 transcription factor by E1A and cAMP.
Angus Wilson, Kings College, University of London,
England: Enhancement, replication, and silencing-Three
ways to control fl-globin gene activation.
October
Gil Morris, Cold Spring Haibor Laboratory, New York:
Regulation of PCNA expression.
Doug Melton, Harvard University, Boston, Massachusetts:
The role of peptide growth factors in cell determination
and patterning.
November
Lawrence A. Chasin, Columbia University, New York, New
York: Mutants at the dihydrofolate reductase locus
affecting DHFR RNA processing.
Scott C. Henderson, University of Western Ontario, Canada:
The architecture of arborescent nuclei-The silk gland
nuclear matrix.
Steve Bell, University of California, Berkeley: Species-specific
promoter recognition properties of the RNA polymerase I
transcription machinery.
Tim Tully, Brandeis University, Waltham, Massachusetts:
Memory formation in normal and mutant Drosophila.
December
Richard McIntosh, University of Colorado, Boulder: Microtu-
bule dynamics and chromosome movement.
Andrei Mirzabekov, Institute of Molecular Biology, Academy
of Sciences of USSR, Moscow: A new oligonucleotide
hybridization approach to sequencing DNA and
sequencing the arrangement of proteins along DNA.
Gerald Fink, Whitehead Institute, Cambridge, Massachusetts:
Genetic analysis of cell fusion in yeast-Protein kinases
strike again.
Jonas Salk, Salk Institute, San Diego, California: Strategies
for the control of HIV infection and/or disease using an
envelope depleted in activated HIV immunogen.
Ben Bowen, Pioneer Hi-Bred International, Johnston, Iowa:
The R gene as a novel visible marker for microprojectile
transformation of corn.
David Price, University of Iowa, Ames: Factors affecting
elongation by RNA polymerase II.
Mike Ruppert, Johns Hopkins Oncology Center, Baltimore,
Maryland: The Gli family of human zinc finger proteins.
Undergraduate Research
An important aspect of the summer program at the Laboratory is the participation
of college undergraduate students in active research projects under the supervi-
sion of full-time laboratory staff members. The program was initiated in 1959. Since
that year, 317 students have completed the course, and many have gone on to
creative careers in biological science.
The objectives of the program are to provide (1) a greater understanding of the
fundamental principles of biology, (2) an increased awareness of major problem
areas under investigation, (3) a better understanding of the physical and intellec-
tual tools for modern research and the pertinence of this information to future
training, and (4) a personal acquaintance with research, research workers, and
centers for study.
The following students, selected from over 100 applicants, took part in the
program, which was supported by the National Science Foundation, Burroughs
Wellcome Fund, Baring Bros., Miles Inc./Bayer AG, and Cold Spring Harbor
Laboratory.
Doug Adler, State University of New York, Binghamton
Research Advisor: Betty Moran
Cloning the retinoblastoma gene in baby rat kidney cells.
Lisa Bellavance, Drake University
Research Advisor: Loren Field
Organ dysgenesis in IV/-mice.
Ron Bose, University of Rhode Island
Research Advisor: Kim Arndt
Analysis of suppressors of sit4.
Ross Breckenridge, University of Cambridge
Research Advisor: Dan Marshak
Purification of He La p34 cdc2 using a novel assay.
Ivan Brockman, Cornell University
Research Advisor: Bruce Futcher
whi4 is a mutant of S. cerevisiae that may actually be
Whit -1.
Franco Carlotti, University of Cambridge
Research Advisor: Andy Rice
Properties of mutants within the cysteine-rich region of the
HIV tat protein.
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Nancy Fan, Harvard University
Research Advisor: Arne Stenlund
Synchronization of bovine papillomavirus transformed mouse
cells using centrifugal elutriation.
Ellen Gadbols, College of St. Catherine
Research Advisor: Bruce Stillman
Purification of a yeast protein equivalent to human RF-C.
Amy Kistler, University of Pennsylvania
Research Advisor: David He If man
Generation and purification of beta skeletal muscle
tropomyosin and two novel carboxy-terminal R tropomyo-
sin chimeras.
Karen Kopecek, Franklin and Marshall College
Research Advisor: Jeff Kuret
The feasibility of using direct expression cloning to
determine downstream components of signal transduc-
tion pathways.
James Lister, Pomona College
Research Advisor: Nouria Hernandez
Analysis of the A/T-rich region of the U6 snRNA promoter by
site-directed mutagenesis.
Steven Palmer, Wabash College
Research Advisor: Dafna Bar-Sagi
-
Isolation of the membrane,phospholipase AZ-gene from rat
brain cDNA in Xgt11.
Nives Pecina, University of Zagreb
Research Advisors: A. Krainer/G. Conway
Reconstitution of snRNPs.
Mika Slovak, Reed College
Research Advisor: David L. Spector
Effects of transcriptional inhibition upon the snRNP network.
Martin Stoddart, University of Cambridge
Research Advisor: Mike Mathews
Secondary structure determination of virus-associated RNAs
(VA R N As).
Karen Zito, Indiana University
Research Advisor: Winship Herr
Expression pattern of Oct-1 and Oct-2 in mice.
Nature Study Program
The Nature Study Program gives elementary and secondary school students the
opportunity to acquire a greater knowledge and understanding of their environ-
ment. Through a series of specialized field courses, students can engage in such
introductory programs as Nature Detectives, Seashore Life, and Pebble Pups, as
well as more advanced programs such as Marine Biology and Nature
Photography.
During the summer of 1989, a total of 480 students participated in the Nature
Study Program. Most classes were held outdoors, when weather permitted, or at
the Uplands Farm Nature Preserve, the headquarters of the Long Island Chapter
of the Nature Conservancy. The Laboratory has equipped and maintains
classrooms/laboratories as well as a darkroom at Uplands Farm. This facility is
used as a base for the students' exploration of the local environment. Field classes
are held on Laboratory grounds, St. John's Preserve, Fire Island National
Seashore, Caumsett State Park, the Cold Spring Harbor Fish Hatchery, and the
Muttontown Preserve, as well as other local preserves and sanctuaries. Students in
Marine Biology participated in a whale watch aboard the Finback II, operated by
the Okeanos Ocean Research Foundation Inc., Hampton Bays, New York.
The two-day Adventure Education class took students on a 22-mile bike hike to
Caumsett State Park and a 12-mile canoe trip on the Nissequoque River.
PROGRAM DIRECTOR
William M. Payoski, M.A., Adjunct Professor,
Nassau Community College
INSTRUCTORS
Maria Anfora, M.A., science teacher, West Babylon School District
Ruth Burgess, B.A., Cold Spring Harbor Nursery School
James Dunleavy, B.A., science teacher St. Anthony's High School
Cheryl Littman, B.A., science teacher, Northport School District
Linda Payoski, B.A., science teacher Uniondale High School
Marjorie Pizza, B.A., science teacher Glen Cove School District
COURSES
Nature Bugs
Nature Detectives
Advanced Nature Study
Introduction to Ecology
Frogs, Flippers, and Fins
Pebble Pups
Bird Study
Fresh Water Life
Seashore Life
Marine Biology
Nature Photography
Adventure Education
Astronomy
FINA
STATEMENT
FINANCIAL STATEMENT
BALANCE SHEET
year ended December 31, 1989
with comparative figures for year ended December 31, 1988
ASSETS
Operating Funds
Endowment &
Similar Funds
Land,
Building &
Equipment Funds
Total All FundsUnrestricted
RestrictedUndesignated Designated 1989 1988
Cash and cash equivalents $1,011,950 400,000 575,418 8,927,394 19,803,202 30,717,964 14,660,307
Marketable securities 91,252 - - 5,849,228 105,196 6,045,676 2,920,614
Accounts receivable:
Publications (less allowance for doubtful accounts
of $95,000 in 1989 and $24,000 in 1988) 1,884,531 - - - - 1,884,531 230,056
Other 195,572 - - 333,333 - 528,905 158,657
Grants receivable - - 2,024,479 - - 2,024,479 853,813
Accrued interest receivable - - - 153,978 153,978 232,526
Publications inventory 617,542 - - - - 617,542 602,807
Other assets, principally prepaid expenses 361,082 - - - 576,333 937,415 512,401
Contract deposit - - - - - - 161,143
Investment in employee residences - - - - 853,524 853,524 747,156
Land, buildings and equipment:
Land and improvements - - - - 3,248,451 3,248,451 2,579,440
Buildings - - - - 23,045,909 23,045,909 21,614,551
Furniture, fixtures and equipment - - - - 2,013,732 2,013,732 1,736,200
Laboratory equipment - - - - 4,752,761 4,752,761 4,550,493
Library books and periodicals - - - 365,630 365,630 365,630
- - - - 33,426,483 33,426,483 30,846,314
Less accumulated depreciation and amortization - - - - 11,172,671 11,172,671 9,774,795
Land, buildings and equipment, net - - - - 22,253,812 22,253,812 21,071,519
Construction in progress - - - - 7,222,851 7,222,851 2,774,090
Total assets $4,161,929 400,000 2,599,897 15,263,933 50,814,918 73,240,677 44,925,089
LIABILITIES AND FUND BALANCES
Operating Funds
Endowment &
Similar Funds
Land,
Building &
Equipment Funds
Total All FundsUnrestricted
RestrictedUndesignated Designated 1989 1988
Liabilities:
Accounts payable and accrued expenses $2,370,284 - - 632,696 3,002,980 1,842,148
Notes payable - - 1,063,857 1,063,857 670,000
Loan payable - - - 20,000,000 20,000,000 4,000,000
Deferred revenue 553,240 2,599,897 3,153,137 1,757,549
Total liabilities 2,923,524 - 2,599,897 - 21,696,553 27,219,974 8,269,697
Fund balances:
Unrestricted - undesignated 1,238,405 - - - - 1,238,405 4,355,654
Unrestricted-designated 400,000 - - - 400,000
Endowment and similar funds - 15,263,933 - 15,263,933 3,058,581
Land, buildings and equipment:
Expended - 17,424,570 17,424,570 15,734,248
Unexpended-Donor restricted - - - 10,843,739 10,843,739 7,958,695
Unexpended-Board authorized - - 850,056 850,056 5,548,214
Total fund balances 1,238,405 400,000 15,263,933 29,118,365 46,020,703 36,655,392
Total liabilities and fund balances $4,161,929 400,000 2,599,897 15,263,933 50,814,918 73,240,677 44,925,089
STATEMENT OF SUPPORT, REVENUE, AND EXPENSES
AND CHANGES IN FUND BALANCES
year ended December 31, 1989
with comparative figures for year ended December 31, 1988
Operating Funds
Endowment &
Similar Funds
Land,
Building &
Equipment Funds
Total All FundsUnrestricted
Undesignated Designated Restricted 1989 1988
Support and revenue:
Public support $876,134 - 3,618,335 5,549,775 1,914,925 11,959,169 10,921,519
Government grant awards - 9,412,256 - - 9,412,256 8,102,876
Indirect cost allowances 6,456,143 - - - 6,456,143 5,643,433
7,332,277 13,030,591 5,549,775 1,914,925 27,827,568 24,667,828
Other revenue:
Program fees 1,298,031 - - 1,298,031 956,795
Rental income 93,036 - - - - 93,036 89,658
Publications 4,449,690 - - - 4,449,690 1,640,491
Dining services 1,336,698 - - - 1,336,698 1,118,037
Rooms and apartments 774,769 - - - 774,769 544,753
Distribution from Robertson Funds 136,800 - 840,000 - - 976,800 930,000
Investment income 243,355 873,428 1,456,130 2,572,913 1,121,483
Miscellaneous 262,109 262,109 396,453
Total other revenue 8,594,488 - 840,000 873,428 1,456,130 11,764,046 6,797,670
Total support and revenue 15,926,765 13,870,591 6,423,203 3,371,055 39,591,614 31,465,498
Expenses
Program services:
Research 11,049,896 - - 11,049,896 9,138,957
Summer programs 846,398 2,011,855 - 2,858,253 2,421,858
Publications 3,934,216 - - - 3,934,216 1,719,187
Banbury Center conferences 131,100 285,581 - - 416,681 521,103
DNA Education Center programs 31,195 - 318,391 - '349,586 363,339
Total program services 4,942,909 13,665,723 - - 18,608,632 14,164,444
Supporting services:
Direct research support 495,853 - - - 495,853 485,915
Library 367,448 367,448 339,915
Operation and maintenance of plant 3,706,217 - - 3,706,217 3,259,354
General and administrative 3,067,652 54,439 - 3,122,091 2,890,857
Dining services 1,377,351 - 1,377,351 1,167,405
Interest - 1,149,302 1,149,302 339,055
Total supporting services 9,014,521 54,439 1,149,302 10,218,262 8,482,501
Depreciation - - 1,399,409 1,399,409 1,286,159
Total expenses 13,957,430 - 13,665,723 54,439 2,548,711 30,226,303 23,933,104
Excess of support and revenue over expenses
before designation $1,969,335 - 204,868 6,368,764 822,344 9,365,311 7,532,394
Designation:
Funds designated for neuroscience program (400,000) 400,000 - - - -
Excess of support and revenue over expenses
and designation 1,569,335 400,000 204,868 6,368,764 822,344 9,365,311 7,532,394
Other changes in fund balances:
Transfer to unexpended plant funds (4,353,951) - (70,000) 4,423,951 -
Capital expenditures - - (202,268) - 202,268
Transfer to restricted funds - 67,400 (67,400) -
Transfer to endowment funds (332,633) - - 5,903,988 (5,571,355) - -
Net increase (decrease) in fund balance (3,117,249) 400,000 - 12,205,352 (122,792) 9,365,311 7,532,394
Fund balance at beginning of year 4,355,654 - - 3,058,581 29,241,157 36,655,392 29,122,998
Fund balance at end of year $1,238,405 400,000 15,263,933 29,118,365 46,020,703 36,655,392
Copies of our complete, audited financial statements, certified by the independent auditing firm
of KPMG, Peat, Marwick & Co., are available upon request from the Comptroller, Cold Spring
Harbor Laboratory.
SOURCES OF REVENUE
YEAR ENDED DECEMBER 31, 1989
Federal Grants
and Contracts 38.6%
Endowments and
Similar Funds 4.7%
Auxiliary Activities 20.0%
Foundation and Private
Contributions and Grants 27.7%
Interest and Miscellaneous 5.0%
Corporate Contributions
and Grants 4.0%
COMPARATIVE OPERATING HISTORY
1985-1989
(Dollars in Thousands)
1985 1986 1987 1988 1989
Income:
Main Lab:
Grants and Contracts $9,071 9,439 10,409 10,799 13,062
Indirect Cost Reimbursement 4,406 4,533 4,779 5,707 6,412
Other 2,235 2,572 2,727 3,205 4,034
CSH Press 1,433 1,357 1,556 1,641 4,450
Banbury Center 724 963 982 976 1,012
DNA Learning Center - 349 660 622
Total income 17,869 18,864 20,802 22,988 29,592
Expenses:
Main Lab:
Grants & Contracts 9,071 9,439 10,409 10,799 13,062
Operation & maintenance of plant 2,284 2,442 2,791 3,010 3,412
General & Administrative 1,951 1,889 1,975 2,102 2,377
Other 2,076 2,124 2,633 3,049 3,165
CSH Press 1,030 1,060 1,311 1,719 3,934
Banbury Center 685 868 947 910 1,038
DNA Learning Center - - 260 590 635
Total expenses 17,097 17,822 20,326 22,179 27,623
Excess before depreciation and designation of funds 772 1,042 476 809 1,969
Depreciation (1,077) (1,093) (1,127) (1,286) (1,399)
Designation of funds (400)
Net operating excess (deficit) $(305) (51) (651) (477) 170
(1) The above amounts are presented on a combined basis for all funds for which Cold Spring Harbor prepares operating budgets.
(2) Funds designated to underwrite future direct and indirect expenses of the neuroscience program.
(2)
FINANCIAL SUPPOR
OF THE LABORAT

SOURCES OF SUPPORT
Cold Spring Harbor Laboratory is a nonprofit research and educational institution
chartered by the University of the State of New York. Less than half of its annual
support is derived from Federal grants and contracts. Contributions from the
private sector are tax exempt under the provisions of Section 501(c)(3) of the
Internal Revenue Code. In addition, the Laboratory has been designated a "public
charity" and, therefore, may receive funds resulting from the termination of "private"
foundations.
Over the years, the Laboratory has earned a reputation for innovative research
and high-level science education. By training young scientists in the latest
experimental techniques, it has helped spur the development of many research
fields, including tumor virology, cancer genes, gene regulation, movable genetic
elements, yeast genetics, and molecular neurobiology. This continual development
of new research programs and training courses requires substantial support from
private sources.
Because its endowment is small, because government support is highly
competitive and the uses of research grants are restricted, the Laboratory
depends on annual contributions from the private sector; foundations, corpora-
tions, and individuals for its central institutional needs.
The Second Century Campaign seeks to raise $44M in capital funds by
December 1991 for construction of new facilities, renovation of existing facilities,
and for staff and student endowment. This is the Laboratory's first public capital
campaign and it marks its Centennial.
METHODS OF CONTRIBUTING TO COLD SPRING HARBOR LABORATORY
Gifts o f money can be made directly to Cold Spring Harbor Laboratory.
Securities You can generally deduct the full amount of the gift on your income tax return,
and, of course, you need pay no capital gains tax on the stock's appreciation.
We recommend any of the following methods:
(1) Have your broker sell the stock and remit the proceeds to Cold Spring Harbor
Laboratory.
(2) Deliver the stock certificates to your broker with instructions to him to open an account
for Cold Spring Harbor Laboratory and hold the securities in that account pending
instructions from Cold Spring Harbor Laboratory.
(3) Send the unendorsed stock certificates directly to the Laboratory: Comptroller Cold
Spring Harbor Laboratory, Box 100, Cold Spring Harbor New York 11724. In a
separate
envelope send an executed stock power
Pooled Income Funds Combine gifts from a number of donors in a pool
for attractive
investment and tax purposes.
Appreciated real estate or personal property Sizable tax benefits can
result from such
Life
the Laboratory can use some in its program and can sell others.
de insurance and charitable remainder trusts can be
structured to suit the donor's
specific desires as to extent, timing, and tax needs.
Bequests Most wills probably need to be updated. Designating Cold
Spring Harbor Labo-
ratory as beneficiary ensures that a bequest will be utilized as
specified for continuing good.
Conversion of private foundation to "public" status on termination
This may be done
by creating a separate fund within Cold Spring Harbor
Laboratory whereby the assets of
the private foundation are accounted for as a separate
fund and used for the purposes
specified by the donor. Alternatively, the private
foundation can be established as a
"supporting organization of Cold Spring Harbor Laboratory."
For additional information, please contact the Director of
Development, Cold Spring Harbor
Laboratory, Box 100, Cold Spring Harbor, N.Y. 11724, or call
516-367-8840.
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GRANTS
January 1, 1989-December 31, 1989
COLD SPRING HARBOR LABORATORY
Grantor Program/Principal Investigator Duration of Grant Total Award
FEDERAL GRANTS
NATIONAL INSTITUTES OF HEALTH
Program Projects
Research Support
Equipment Support
Fellowships
Cancer Research Center, Dr. Mathews
Cancer Center Support, Dr. Roberts
PEBRA-HIV Grant, Dr. Herr
Oncogene Program Project, Dr. Wig ler
Dr. Arndt
Dr. Beach
Dr. Beach
Dr. Beach
Dr. L. Field
Dr. Franza
Dr. Frendeway
Dr. Futcher
Dr. Garrels
Dr. Gilman
Dr. Greider
Dr. Helfman
Dr. Hernandez
Drs. Klar/Futcher
Dr. Krainer
Dr. Kuret
Dr. Marr
Dr. Moran
Dr. Peterson
Dr. Pflugrath
Dr. Rice
Dr. Roberts
Dr. Roberts
Dr. Stillman
Dr. Wig ler
B.R.S.G. Award
Dr. Marshak
Dr. Roberts
Dr. Roberts
Dr. Ballester
Dr. Brill
Dr. J. Field
Dr. Kessler
Dr. Meyertons
Dr. Morris
Dr. Steinhelper
Dr. Stern
1/87-12/91
7/87-6/90
9/88-8/91
3/88-2/93
4/88-3/93
12/84-1/93
9/86-8/94
7/88-6/93
4/87-3/92
9/85-11/94
4/87-3/92
4/88-3/93
1/85-12/89
9/87-8/92
12/89-11/94
9/85-3/94
7/87-6/92
7/81-6/90
7/89-6/94
7/89-6/94
9/89-9/90
3/88-2/93
4/88-3/93
4/88-3/91
9/87-8/90
7/88-6/93
9/88-8/91
7/83-6/92
7/85-6/92
4/88-3/89
2/88-2/89
6/88-5/89
6/89-5/90
2/89-1/92
8/89-7/92
10/86-9/89
8/88-7/91
5/88-9/89
11/86-10/89
3/89-2/92
11/88-11/91
$16,787,416
5,346,907
3,672,816
4,869,923
1,288,964
1,481,482
2,125,179
1,488,740
568,521
1,497,483
775,814
1,115,434
2,028,833
608,291
1,130,019*
2,109,264
1,293,754
2,411,676
1,298,402*
1,312,808*
126,428*
547,214
704,475
573,503
528,037
1,598,876
446,241
1,869,678
8,426,929
121,971
189,000
27,331
36,300*
63,996*
46,667*
63,996
63,996
27,996
82,008
77,254*
63,996
* New Grants Awarded in 1989
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Grantor Program/Principal Investigator Duration of Grant Total Award
Training Support Institutional, Dr. Grodzicker 7/78-4/94 2,364,146
Course Support Advanced Bacterial Genetics, Dr. Grodzicker 5/80-4/93 559,540
Cancer Research Center Workshops,
Dr. Grodzicker
1/83-3/92 1,010,057
Neurobiology Short Term Training,
Dr. Hockfield
5/82-4/90 723,939
Meeting Support Cancer Cell 1989 4,000*
C. elegans 1987 & 1989 61,874
Eukaryotic DNA 1989 1,000*
Hepatitis B Virus 1989 3,000*
Liver Gene 1989 16,250*
RNA Processing 1988-1991 9,500
Symposium 1989 24,000*
NATIONAL SCIENCE FOUNDATION
Research Support Dr. Herr 6/88-5/91 240,000
Dr. Marshak 7/87-12/90 190,000
Dr. Martienssen 7/89-6/92 300,000*
Dr. Richards 7/89-6/92 285,000*
Dr. Roberts 1/83-5/90 640,000
Dr. Roberts 2/86-11/89 300,000
Dr. Roberts 8/87-1/90 43,106
Dr. Sundaresan 5/87-4/91 360,000
Dr. Zoller 8/88-7/89 92,000
Equipment Support Dr. Spector 3/87-2/89 95,000
Training Support Undergraduate Research Program, Dr. Herr 6/89-5/90 42,000*
Course Support Plant Molecular Biology 8/86-1/90 137,490
Molecular Genetics Courses Scholarships 5/89-4/90 25,730*
Dr. Grodzicker
Meeting Support Cancer Cell 1989 10,000*
C. elegans 1987-1989 22,819
Eukaryotic DNA Replication 1989 6,000*
Hepatitis B Virus 1989 5,000*
Symposium 1989 2,000*
RNA Processing Conference 4/88-3/91 30,000
DEPARTMENT OF ENERGY
Meeting Support Symposium 1989 10,000*
* New Grants Awarded in 1989
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Grantor Program/Principal Investigator Duration of Grant Total Award
NONFEDERAL GRANTS
Research Support
Aaron Diamond Foundation
American Cancer Society
Dr. Anderson
Dr. Bar-Sagi
12/88-11/91
7/89-6/91
200,000
194,000 *
Dr. Hanahan 7/87-6/89 160,000
Dr. Moran 1/88-12/90 90,500
Dr. Spector 7/87-6/91 363,000
Drs. Stillman, Gluzman,
Welch, Gilman, Institutional Award
7/82-6/90 300,000
Dr. Wig ler 4/89-3/90 10,000*
Dr. Wig ler, Professorship 1986-2012 1,333,333
Amersham International plc Dr. Harlow 11/86-10/91 799,635
Howard Hughes Medical Institute Neurobiology Support 1987-1990 1,000,000
Japan Health Science Foundation Dr. Roberts 12/89-2/90 20,000
J.N. Pew Jr. Charitable Trust Plant Group Support 4/87-4/90 260,000
LIBA Dr. Frendewey 4/88-3/89 25,000
Dr. Peterson 4/88-3/89 25,000
Muscular Dystrophy Association Dr. Helfman 7/86-6/89 94,500
Dr. Mathews 1/87-6/90 100,718
Mellam Family Foundation Dr. Franza 12/88-11/90 100,000
Monsanto Company Cooperative Research 10/84-9/89 2,089,200
New England Biolabs Dr. Roberts 1989 15,000*
Pfizer, Inc. Dr. Wig ler 1985-1990 500,000
Pioneer Hi-Bred International Inc. Cooperative Research 8/85-4/91
2,500,000
Rita Allen Foundation Dr. Herr 9/85-8/90
150,000
Dr. Hernandez 10/89-9/90
30,000"
Samuel Freeman Charitable Freeman Laboratory of Cancer Cell Biology 7/89-6/94
1,000,000*
Fellowships
American Cancer Society Dr. Conway
Dr. Ryan
10/88-9/91
7/88-6/90
3/89-8/89
63,000
90,000
11,500*
Dr. Chan 3/89-12/89 20,334*
Dr. Pittenger 7/89-6/92 112,200*
American Foundation for Dr. Laspia
AIDS Research 6/86-5/91 500,000
Bristol-Myers Company
Bioseeds International
Fellowship Support
Plant Fellowship Support
7/88-6/90
9/86-8/89
75,000
79,500
Cancer Research Institute Dr. Sturm 9/86-1/89 62,313
Dr. Efrat 3/87-2/90 69,000
Damon Runyon-Walter Dr. Michaeli 9/88-8/89 25,642
Winchell Cancer Fund Dr. D. Roberts 1/89-12/91 69,000 *
Dr. Melendy 9/89-8/90 1,082*
Government of Canada Dr. Tyers 7/87-6/90 100,000
Esther and Joseph A. Klingenstein Dr. Marshak
Fund, Inc. 7/87-6/89 51,000
Juvenile Diabetes Foundation Dr. Grant
International 7/89-6/92 76,140*
The Leukemia Society Dr. Das
of America 1987-1990 300,000
LIBA Four Fellowships a Year 9/86-8/89 105,000
Life Science Research Foundation Dr. Colicelli 9/89-8/92
105,000*
Dr. D. Roberts 12/88-11/90 30,000
Merck Sharp & Dohme Graduate Student
Support
Research Laboratories
New Grants Awarded in 1989
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Grantor Program/Principal Investigator Duration of Grant Total Award
Muscular Dystrophy Association Dr. Lees-Miller 7/88-6/89 51,000
Rita Allen Foundation Postdoctoral Support 1989 25,000*
Weizmann Institute of Science Dr. Gerst 9/89-8/91 57,000
Training Support
Baring Brothers & Co., Ltd. Undergraduate Research Program 1989 23,325*
Burroughs Wellcome Foundation Undergraduate Research Program 1987-1990 50,960
Grass Foundation Neurobiology Scholarship Support 1980-1989 151,670
Lucille P. Markey Charitable Trust Scholarship Support 1985-1989 220,000
Miles Research Center Undergraduate Research Program 1989 4,500*
Molecular Therapeutics
Robert H.P. Olney Undergraduate Research Program 1989 2,400*
Memorial Fund
Course Support
Alfred P. Sloan Fund Computational Neuroscience Course 1986-1989 140,000
Amersham International plc Advanced Molecular Cloning and 1989 1,000*
Expression of Eukaryotic Genes
Howard Hughes Medical Institute Neurobiology Courses 1987-1990 1,000,000
Meeting Support
Anheuser-Busch Companies, Inc. Yeast Cell Biology Conference 1989 500*
Beckman Instruments, Inc. Liver Gene Expression Conference 1989 500*
Bio-Rad Laboratories, Inc. Liver Gene Expression Conference 1989 500*
Chisso Corporation Liver Gene Expression Conference 1989 1,000"
Clontech Laboratories Inc. Liver Gene Expression Conference 1989 500*
Codon Liver Gene Expression Conference 1989 200*
ICN Biomedicals, Inc. Translational Control Conference 1989 20,000*
Life Technologies, Inc. Liver Gene Expression Conference 1989 300*
Lucille P. Markey Charitable Trust 54th Symposium: Immunological Recognition 1989 15,000*
March of Dimes Birth Liver Gene Expression Conference 1989 10,000*
Defects Foundation
Merck & Co., Inc. C. elegans Conference 1989 1,000*
Liver Gene Expression Conference 1989 500*
Nestle, S.A. Liver Gene Expression Conference 1989 1,000*
New England Biolabs, Inc. C. elegans Conference 1989 500*
Repligen Liver Gene Expression Conference 1989 250*
Rockefeller Foundation Vaccines Conference 1986-1990 45,000
Rhone-Poulenc, Inc. C. elegans Conference 1989 250*
The Salk Institute Biotechnology/ Liver Gene Expression Conference 1989 250*
Industrial Associates, Inc.
Stratagene Liver Gene Expression Conference 1989 500*
Syntex Research Liver Gene Expression Conference 1989 750*
United States Biochemical Liver Gene Expression Conference 1989 175*
Corporation
* New Grants Awarded in 1989
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DNA LEARNING CENTER
Grantor Program/Principal InvestigatOr- Duration of Grant Total Award
FEDERAL GRANTS
NATIONAL SCIENCE
FOUNDATION
NONFEDERAL GRANTS
The Banbury Fund
Dentsu Inc.
Harweb Foundation
J.M. Foundation
The Ester A. and Joseph
Klingenstein Fund, Inc.
Richard Lounsbery Foundation
Josiah Macy, Jr. Foundation
Teleflex Foundation
American Society for
Microbiology, Michigan Branch
Anne Arundel Public School,
Maryland
Bethany College, West Virginia
Biology Teachers' Organization,
Winnipeg, Canada
Board of Cooperative Education
Services, New York
Center for Biotechnology,
SUNY Stony Brook
Champlain Valley High School,
Vermont
Cooperating School District of
St. Louis Suburban Area, Inc.
Dover-Sherborn High School,
Maine
Nassau Community College
Project Share, Connecticut
University of Wisconsin
Commack School District
East Williston School District
Great Neck School District
Half Hollow Hills School District
Harborfields School District
Herricks School District
Huntington School District
Island Trees School District
Jericho School District
Lawrence School District
Locust Valley School District
Manhasset School District
Northport-East Northport School
District
North Shore School District
Oyster Bay-East Norwich
School District
Teacher Enhancement Program
Core Support
Core Support
Core Support
Core Support
Core Support
Core Support
Core Support
Core Support
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Vector Workshop
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
1987-90
1989
1989
1989
1989
1989
1989
1987-90
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
415,928
30,000
10,010
1,000
25,000
25,000
50,000
490,850
1,000
1,539
3,430
10,110
10,870
2,000
10,550
830
7,382
373
1,000
2,000
1,370
500
500
500
1,500
500
500
500
2,000
500
1,500
500
500
500
500
500
* New Grants Awarded in 1989
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Grantor Program/Principal Investigator Duration of Grant Total Award
Plainview-Old Bethpage Curriculum Study 1989 500
School District
Plainedge School District Curriculum Study 1989 2,000
Port ledge School District Curriculum Study 1989 500
Port Washington School District Curriculum Study 1989 500
Sachem School District Curriculum Study 1989 500
Syosset School District Curriculum Study 1989 500
Brunswick Appraisal Corp. The Search for Life Exhibit 1989 100
Shogren Industries Inc. The Search for Life Exhibit 1989 500
* New Grants Awarded in 1989
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BANBURY CENTER
Grantor Program/Principal Investigator Duration of Grant Total Award
FEDERAL GRANTS
U.S. Department of Agriculture
U.S. Department of Justice
Environmental Protection
Agency
OFFICE OF NAVAL
RESEARCH
NONFEDERAL SUPPORT
Alfred P. Sloan Foundation
Alfred P. Sloan Foundation
FMC Corporation
ICI Agrochemicals
ICPEMC
Lifecodes Corporation
Muscular Dystrophy Association
Pioneer Hi-Bred
International, Inc.
Plant Cell Research
Institute, Inc.
Ross Laboratories
R. Brinkley Smithers
Smithkline Beecham
Pharmaceuticals
Anonymous
RFLP's and the Molecular Biology of
Plants Conference
DNA Technology and Forensic
Science Conference
Mutation Induction and Heritability
in Mammalian Germ Cells
Computational Eye Movement Workshop
Journalists and Congressional Workshops
Molecular Clocks of Evolution
Electrophoresis of Large DNA Molecules
Recognition in Plant-Pathogen Interactions
Mutation Induction and Heritability
in Mammalian Germ Cells
DNA Technology and Forensic
Science Conference
Dystrophin Meeting
Recognition in Plant-Pathogen
Interactions
Recognition in Plant-Pathogen Interactions
Programmed Cell Death-Concepts
and Mechanisms
Molecular Genetics and Biology
of Alcoholism
Cloning the Antibody Repertoire
Molecular Genetics and Biology
of Alcoholism
9/88-8/89
10/88-9/89
1989
7/88-6/91
1990-1992
1989
1990
1989
1989
1988
1989
1989
1989
1989
1989
1990
1989
3,000
5,000
45,000"
62,125
150,000*
30,000*
5,000*
1,555"
5,000*
5,000*
19,885*
1,000*
1,500*
1, 000 *
50,000*
35,000 *
27,000*
* New Grants Awarded in 1989
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ANNUAL CONTRIBUTIONS
Unrestricted
Long Island Biological Association (LIBA)
The Long Island Biological Association is the oldest supporting organization for
Cold Spring Harbor Laboratory. Over the years a most unique and productive
partnership has developed wherein LIBA has become our "Friends of the
Laboratory" and accounts for the largest amount of unrestricted annual giving for
the Laboratory. (The detailed report of their activities appears later in this Annual
Report.)
Memorial Gifts
Anonymous
Dr and Mrs. Mortimer Arenstein
Ms. Regina Austin
Ms. Donna Bassin
Mr. and Mrs. Maurice Bauer
Mr. and Mrs. Harry Binder
Mrs. Dorothy E. Bird
Mr. and Mrs. Bruce R. Blovsky
Mr. and Mrs. George A. Butter
Mr. and Mrs. Robert Canaride
Ms. Sue D. Chase
Mr Lawrence M. Clum
Mr. and Mrs. Stewart D. Curley
Mr and Mrs. P James Delaney
Digital Equipment Corporation
Richard E. Doling, Esq.
Mr. and Mrs. John L. Englander
Mr. and Mrs. Bruce J. Einhorn
Ms. Marion Stern Enos
Mr. Bernard A. Feinberg
Mr. and Mrs. Norman Feinberg
Mr. Steven D. Felgran
Mr. and Mrs. Arthur Finer
Mr. and Mrs. Henry D. Fishel
Mr and Mrs. Samuel Frumkin
Mr. and Mrs. Hank Gaiss
Ms. Helena Gaviola
Dr. and Mrs. Richard L. Golden
Mr. and Mrs. Douglas G. Goldstein
Ms. Dorothy Gomberg
Mr. Robert A. Gorman
In memory of . . .
Cathy Susan Bird
George A. Humphrey, Sr.
Helen Leckerling
Jeanne Leckerling
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Mr and Mrs. Wallace Green
Mr. and Mrs. Leslie B. Greenberg
Gress Fabrics Inc.
Mr. and Mrs. Donald L. Hall
Mr. and Mrs. Peter Hardman
Dr. Charles Heilbrunn
Mr and Mrs. Arno Herzog
The Walter Hinrichsen Family
Mr. and Mrs. Edward L. Hott
Ms. Mary Lou Irvine
Mr and Mrs. Mort Jacobs
Mr and Mrs. Edward Kantner
Mr and Mrs. M. Kelly
Mr. and Mrs. Stanley Kivort
Mr and Mrs. Larry Kreditor
Mr and Mrs. Seith F Kreimer
Mr and Mrs. Jerome I. Kroll
Mr Howie Krooks
Mr and Mrs. Richard Leckerling
Mr. and Mrs. Sidney Leshin
Mr and Mrs. A. Leo Levin
Mr. and Mrs. David M. Levine
The Ruth H. Linn Family
Lions Club of Glen Cove
Ms. Sandra Lipman
Mr. and Mrs. Alan Lowenstern
Mr and Mrs. Harold Mack
Moses and Schreiber
Mr and Mrs. Kazukuni Miyagi
Mr. Charles W. Mooney, Jr.
Stephen J. Morse, Esq.
Gladys Montemarano
Joyce Montemarano
Irving Paeff
Robert L. Pieper
Joseph W. Muldoon, Esq.
Mr and Mrs. Glenn W. Mullen
Mr. and Mrs. Ken Nadel
Mr and Mrs. William J. Pecau
Mr and Mrs. Paul M. Peyser
The Irving Ratchick Family
Mr and Mrs. Stephen Rogowsky
Mr. and Mrs. Burton L. Rozner
Mr. Sheldon Sacks
Mr. Gregory Scandrett
Dr and Mrs. Charles F. Schiffer
Dr and Mrs. Philip Schneider
Mr. and Mrs. Jacob Schreiber
Mr and Mrs. Jack W. Schwartz
Ms. Linda Schwartz
Mr and Mrs. Gerald L. Shak
The Eva Shapiro Memorial
Foundation, Inc.
Mr. and Mrs. Bernard A. Sloane
Mr Theodore Steichen
Ms. Laurie Stern
Mr. Ralph W. Stern
Mr, and Mrs. Leonard E.
Stokes III
Mr. and Mrs. Paul Strauss
Dr and Mrs. Allan H. Toffler
Mr. and Mrs. Daniel Tyson
Union Carbide Corporation
Mr and Mrs. Steve Wormser
Mr and Mrs. Terry Arthur Zima
Beverly A. Raff
Mary Merritt Burke Ricker
Walter Sturm
Palmer B. Wald
Restricted
Corporate Sponsor Program
Cold Spring Harbor Laboratory is renowned throughout the scientific world as a
meeting place offering the most comprehensive series of conferences on
molecular biology available anywhere. In 1989, over 5500 scientists attended
meetings here, providing a unique opportunity for the exchange and discussion of
data. Access to these meetings is an important resource for the biotechnology
industry.
This meetings program would not be possible without the generosity of
members of the Corporate Sponsor Program who each contributed $17,500 to
help underwrite the costs of meetings in Grace Auditorium and to fund five
meetings at the Banbury Center. The Corporate Sponsor meetings at Banbury
Center cover topics in basic research as well as topics of special importance in
biotechnology. In 1989, these five Banbury Center meetings included Applications
of Basic Research in Mammalian Development; Viral Proteinases as Targets for
Chemotherapy; Recessive Oncogenes; Molecular Cytogenetics and The
Molecular Genetics of Early Drosophila and Mouse Development.
The benefits to the Sponsor companies were increased in 1989 to include the
waiver of all fees for eight representatives at Cold Spring Harbor Laboratory
meetings and the special Banbury Center conferences; gratis Cold Spring Harbor
Laboratory and Banbury Center publications including Genes & Development and
the new review journal, Cancer Cells; and acknowledgment in meeting abstracts
and publications.
Each year Federal funding for meetings becomes progressively more difficult to
find, and a greater burden falls on the corporate sector. The continuing success of
the Corporate Sponsor program shows that companies are prepared to assume
that burden to help promote the best in scientific research, and that the Program
is fulfilling an important role. 31 companies participated in the Program in 1989,
and the membership renewal rate continues to be 90%. Cold Spring Harbor
Laboratory is very pleased to acknowledge once again those companies that
make our meetings possible:
Alafi Capital Company
American Cyanamid Company
Amersham International plc
AMGen Inc.
Applied Biosystems, Inc.
Becton Dickinson and Company
Beecham Pharmaceuticals
Boehringer Mannheim Corporation
Ciba-Geigy Corporation/Ciba-Geigy Limited
Diagnostic Products Corporation
E.I. du Pont de Nemours & Company
Eastman Kodak Company
Genentech, Inc.
Genetics Institute
Glaxo Research Laboratories
Hoffmann-La Roche Inc.
Johnson & Johnson
Life Technologies, Inc.
Eli Lilly and Company
Millipore Corporation
Monsanto Company
Oncogene Science, Inc.
Pall Corporation
Perkin-Elmer Cetus Instruments
Pfizer Inc.
Pharmacia Inc.
Schering-Plough Corporation
Tambrands Inc.
The Upjohn Company
The Wellcome Research Laboratories,
Burroughs Wellcome Co.
Wyeth-Ayerst Research
Summary of Annual Contributions
Unrestricted Annual Contributions
CSHL Associates (1/1/89-12/31/89)
LIBA Members (1/1/89-12/31/89)
General
Memorials
Restricted Annual Contributions
DNA Learning Center
Dorcas Cummings Fund
Total Annual Contributions
Peter Orth Concert Sponsors
Mary Lenore Blair, Chairman
Jim and Carol Swiggett, Co-Chairmen
Drs. Harold & Shirley Andersen
Mr. Bruce K. Bernann
Mr and Mrs. G. Morgan Browne
Mr. and Mrs. Ward C. Campbell
Mrs. B.J. Darneille
Mr. and Mrs. Norris Darrell, Jr
Mr. and Mrs. Robert A. Gay
Mr. and Mrs. S. Gordon Hargraves
Mr. and Mrs. Charles R. Holocomb
$221,798
52,194
35,222
3,122
157,010
2,500
$312,336
$159,510
$471,846
Dr. and Mrs. Pavel Illner
Mr and Mrs. John F Johnston II
Mr. and Mrs. James J. Pirtle, Jr.
Mr. and Mrs. Bruce J. Rice
Mr. Paul Sheeline
Mr. Charles B. Updike
Mr. and Mrs. Robert P Walton
Dr and Mrs. James D. Watson
Middleton-White Imports, Ltd.
Nordberg Capital, Inc.
The Printery
SECOND CENTURY CAMPAIGN
January
Unrestricted Contributions
Anonymous 1
Anonymous 2
Anonymous 3
Mr. S. Reed Anthony
Mrs. Donald Arthur, Jr.
Mr. Edmund Bartlett
Mr and Mrs. Allen L. Boorstein
Mrs. Leonie T. Brigham
Bristol-Myers Squibb Foundation, Inc.
Mr. G. Morgan Browne
Mr and Mrs. Samuel Callaway
Mr and Mrs. Ward Campbell
Mr. Peter Cannell
Dr. Bayard Clarkson
Mr and Mrs. John Cleary
Mr and Mrs. Miner D. Crary, Jr
Mr. Robert L. Cummings
Mr and Mrs. Roderick H. Cushman
Mr. A. Neville Cutting
Mr and Mrs. George W. Cutting, Jr
Mr. Theodore N. Danforth
Mr and Mrs. Norris Darrell, Jr.
Mr and Mrs. de Clairville
Mr and Mrs. Donald Deming
Mr and Mrs. Joseph P. Downer
Mr. William Everdell
Mr and Mrs. Clarence Galston
Mr and Mrs. Robert B. Gardner, Jr
Mr and Mrs. H. Bentley Glass
Mr and Mrs. Edward Greenberg
Mr and Mrs. Henry U. Harris, Jr
Mr and Mrs. Sinclair Hatch
Mrs. Lita Annenberg Hazen
Mr and Mrs. Morris Karpen
Mr and Mrs. Albert Key
Mr and Mrs. Townsend J. Knight
Mr Abraham Krasnoff
1, 1986-December 31, 1989
$6,977,367
Mr and Mrs. George N. Lindsay
Mr. David L. Luke III
Mr. Robert R. Maxfield
Mr and Mrs. Edward McCann II
Mr and Mrs. William R. Miller
Mr O.B. Miller
Mr. Grinnell Morris
Dr and Mrs. Larry Nathanson
Mr and Mrs. Charles Noyes
Mr and Mrs. William H. Osborn, Jr
Dr. David D. Pall
Pall Corporation
Mr. William Parsons, Sr
Mrs. Francis T.P. Plimpton
Mrs. H. Irving Pratt
William and Maude Pritchard
Charitable Trust
Mr. Edward Pulling
Mr. James T. Pyle
Mrs. Curtis S. Read
Mr and Mrs. John R. Reese
Dr. Frederic Richards
Mr. J. Wright Rumbough
Mr and Mrs. Harvey E. Sampson
The Schiff Foundation
Mrs. Franz Schneider
Mr. H. Turner Slocum
Mrs. Alexander White Smith
Mr. George F. Sprague, Jr
Seth Sprague Educational and
Charitable Trust
The Stebbins Fund
Mrs. Robert Tilney, Jr
Dr. Jonathan Warner
Westvaco Corporation
Mr. Taggart Whipple
Mr. Robert Winthrop
Restricted Contributions
Endowment
Oliver and Lorraine Grace Director's Chair
Doubleday Professorship for Advance Cancer Research
Anonymous Professorship in Molecular Neuroscience
Libby Undergraduate Internship
Program
Howard Hughes Medical Institute
$29,873,806
$4,870,000
2,000,000
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Facilities Development
Cancer Biology
Neuroscience Center
The Achelis Foundation
Anonymous
The Arnold and Mabel Beckman Foundation
The Bodman Foundation
Booth Ferris Foundation
Dolan Family Foundation
The Samuel Freeman Charitable Trust
Howard Hughes Medical Institute
W.M. Keck Founation
The Esther A. and Joseph Klingenstein Fund, Inc.
The Kresge Foundation
Litchfield Charitable Trust
James S. McDonnell Foundation
The Pew Charitable Trusts
Fannie E. Rippel Foundation
Individual Contributors
Structural Biology
Lucille P. Markey Charitable Trust
Page Laboratory of Plant Genetics
Charles E. Culpeper Foundation
Ira W. De Camp Foundation
Morgan Guaranty Trust Company of New York
National Science Foundation
William and Maude Pritchard Charitable Trust
Individual Contributors
Guest Facilities
10 Guest Houses
Alumni Cabin Contributors
Dr. Herbert Boyer
Mr. David C. Clark
The Hyde-Watson Foundation
Mrs. George G. Montgomery, Jr.
New England Biological Laboratories
Dr. Mark Ptashne
Visiting Scientist Guest House
Russell and Janet Doubleday Fund
DNA Learning Center
Banbury Fund #1
Banbury Fund #2
The Brinkmann Foundation
New York State
23,003,806
Total Second Century Campaign
Contributions $36,851,173
SECOND CENTURY CAMPAIGN
Steering Committee
Oliver R. Grace, Co-Chairman
Mrs. Sinclair Hatch, Co-Chairman
George W. Cutting, Jr, Co-Chairman
Taggart Whipple, Co-Chairman
Townsend J. Knight, Co-Chairman
Leadership Gifts Committee
Oliver R. Grace, Chairman
G. Morgan Browne
Bayard Clarkson, M.D.
David L. Luke Ill
James D. Watson, Ph.D.
Taggart Whipple
Major Gifts Committee
Mrs. Sinclair Hatch, Chairman
Amayas Ames
Mrs. Harry A. Brooks
Robert L. Cummings
William Everdell
Mrs. Henry U. Harris, Jr.
Abraham Krasnoff
Laurie Landeau, V.M.D.
Mrs. George G. Montgomery, Jr.
Mrs. William Parsons, Jr.
H. Turner Slocum
Special Gifts Committee
George W. Cutting, Co-Chairman
William Miller Co-Chairman
Marjorie von Stade, Co-Chairman
Mrs. Edward Greenberg, Co-Chairman
Edmund Bartlett
David C. Clark
Arthur M. Crocker
Lawrence L. Davis
Mrs. Donald L. Deming
Joseph P Downer
COMMITTEES
John J. Evans
Charles J. Hubbard
Gordon Lamb
Edward Pulling
John R. Reese
J. Wright Rumbough, Jr.
Mrs. James F. Stebbins
Mrs. Stanley S. Trotman
Corporate Committee
David L. Luke Ill, Acting Chairman
G. Morgan Browne
Peter Cannell
Robert E. Cawthorn
Wililam R. Miller
David B. Pall, Ph.D.
Douglas Rogers
James D. Watson, Ph.D.
Henry Wendt
Sigi Ziering, Ph.D.
Foundation Gifts Committee
Taggart Whipple, Chairman
Mrs. C. Payson Colemann
Robert Ebert, Ph.D.
James W. Fordyce
John Klingenstein
Clarence F. Michalis
William E. Murray
Planned Gifts Committee
Townsend Knight, Chairman
Maureen Augusciak
John Cleary
William J. Kramer
William Parsons, Sr.
Colton Wagner
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Alumni Cabin Contributors
Dr. Robert Ach
Dr. Nicholas H. Acheson
Dr. Susan Bektesh
Dr. Minou Bina
Dr. Stephen H. Blose
Dr. Walter Bodemer
Dr. Fred J. Bollum
Dr. Alfred Bothwell
Dr. Herbert W. Boyer
Dr. Jeremy Brockes
Dr. John Carbon
Dr. Charles M. Cashel
Dr. James J. Champoux
Dr. Sruti Chattoraj
Dr. F. Daldal
Dr. Julian E. Davies
Dr. Jacquelin P Dudley
Dr. Patricia Earl
Dr. Raymond L. Erikson
Dr. David A. Foster
Dr. Michael W. Gray
Dr. Ronald Guggenheimer
Dr. Shiu-Lok Hu
Dr. Eric Hunter
Dr. Judith Jaehning
Dr. Yoshiaki Jto
Dr. Harumi Kasamatsu
Dr. Mary Welch-Keesey
Dr. Byungg-Dong Kim
Dr. Barbara B. Knowles
Dr. Hyam L. Leffert
Dr. Steven L. McKnight
Dr. Jeffrey H. Miller
Dr. Max P Oeschger
Dr. John A. Pollock
Dr. Joel L. Rosenbaum
Dr. Eli Shapiro
Dr. Kunitada Shimotohno
Dr. Yoshio Takagaki
Dr. Charles Van Beveren
Dr. George M. Weinstock
Dr. William S.M. Wold
Dr. Min-Liang Won
Mrs. Akiko Yamamoto
Dr. Kenji Yamamoto
Dr. Kenneth S. Zaret
Dr. David A. Zarling
BIOLOGICA
ASSOCIATION
Officers
George W. Cutting, Jr., Chairman
Mrs. Henry U. Harris, Vice-Chairman
James A. Eisenman, Treasurer
Mrs. John R Campbell, Secretary
G. Morgan Browne, Asst. Secretary/Treasurer
Directors
Mrs. Allen L. Boorstein
Mrs. Helen B. Chenery
John P Cleary
Arthur M. Crocker
Lawrence L. Davis
Mrs. Donald L. Deming
Joseph P Downer
Lester Dubnick, Ph.D.
Mrs. Duncan Elder
Mrs. Sinclair Hatch
Gordon E. Lamb
Edward F McCann
Mrs. Walter C. Meier
Arthur C. Merrill
Larry Nathanson, M.D.
John R. Reese
Douglas E. Rogers
Byam K. Stevens, Jr.
Mrs. Stanley S. Trotman, Jr.
Mrs. Philip R. von Stade
James D. Watson, Ph.D.
Mrs. Bradford Weekes Ill
Edward Pulling, Hon. Director
THE LONG ISLAND BIOLOGICAL ASSOCIATION (LIBA)
and Its Relation to the Cold Spring Harbor Laboratory
Biological research at Cold Spring Harbor began in 1890 when the Brooklyn
Institute of Arts and Sciences was looking for a place to set up a summer
laboratory as the headquarters of its Department of Zoology. Representatives of
the Institute were invited by Eugene S. Blackford, at that time the Fish
Commissioner of the State of New York, to inspect a site on Bungtown Road
across Northern Boulevard (25A) from the Fish Hatchery. The site was found to be
ideal, and so the original Laboratory was organized with Mr. Blackford as
president of the Board of Trustees. The land was leased from Mr. John D. Jones,
whose family since 1819 had operated various industries including shipbuilding,
coopering, and textile manufacture (later whaling, also) at the head of Cold Spring
Harbor. Bungtown Road, which runs through the Lab property, got its name from
the factory that specialized in making bungs-or stoppers-for barrels.
In 1892, the Laboratory's land was leased for a dollar a year from the Wawepex
Society, which Mr. Jones had organized as a corporation for holding real estate
and for investing funds for the propagation of fishes and for scientific research. In
1904 the Wawepex Society leased additional land to the Carnegie Institution of
Washington, which wanted to locate a Department of Experimental Evolution in the
Cold Spring Harbor area. Charles B. Davenport, who had been directing the
Laboratory since 1896, assumed the additional duties of director of the Carnegie
Institution's experimental station. Until 1934, Mr. Davenport lived in the large
Victorian house that still stands at the corner of Bungtown Road and 25A. Built in
1882 by John D. Jones, the house was renovated and repainted in its original
colors in 1979-80, when it was renamed Davenport House. Since 1934 it has
served as a dormitory for Laboratory scientists.
The Long Island Biological Association was established in 1924 when the
Brooklyn Institute decided to discontinue its research at Cold Spring Harbor and
offered its laboratory to two universities. Fortunately, a local group of interested
neighbors decided to assume responsibility for the Lab, and thus LIBA came into
being. For 38 years LIBA actually operated the Laboratory in conjunction with the
Carnegie Institution, but in 1962 it seemed advisable for the Laboratory to be
reorganized as an independent unit. Therefore, the property on which it now
stands was conveyed to it by LIBA, which, however, still retains reversionary
rights.
Today LIBA is one of twelve institutions participating in the support of the
Laboratory, each institution being represented on the Laboratory's Board of
Trustees.
LIBA has become an expanding group of "Friends of the
Laboratory" who help
support it through annual contributions.
A large part of the Laboratory's resources is obtained from governmental,
corporate, and foundation sources.as a result of grant applications
which are
submitted by the individual scientists. Years ago, 85% of the funding
came from
governmental agencies, but presently less than 50% comes
from these sources.
Therefore the scientists must rely on an assortment of foundations,
corporations,
Membership in LIBA requires a minimum annual contribution (tax
deductible) of $25 to the Cold Spring Harbor Laboratory.
Further information can be obtained from the Long
Island Biological Association, Box 100,
Cold Spring Harbor N.Y. 11724, or
by telephoning the Laboratory at (516) 367-8840.
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and individuals for an increasing share of their support. The researchers compete
for grants in their specific areas of study. If an award is made, a portion of the
award is returned to the Laboratory in the form of indirect costs for overhead. It is
important to remember that these grants are highly competitive, and even if a
grant is given an outstanding score by scientific peers, the funding may not be
available.
LIBA sponsors the Laboratory's Annual Giving Program, which is its largest
source of unrestricted annual gifts. These gifts enable the Laboratory to respond
quickly to urgent or unexpected needs. Also, primarily through LIBA Fellowships
and funds to start up new laboratories, LIBA helps ensure that the Cold Spring
Harbor Laboratory continues to attract the best and brightest young scientists.
The affairs of LIBA are handled by a board of 28 directors who are elected to
office by the membership at an annual meeting. LIBA members are invited to
bring their friends to lectures and open houses at the Laboratory.
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CHAIRMAN'S REPORT
As the study of biology here at Cold Spring Harbor Laboratory approaches its
centennial year, the Long Island Biological Association has completed its 65th and
perhaps most significant year in the support of basic research. At the close of its
fiscal year on September 30, 1989, membership reached 781, up 47% from 531 in
1988. Total contributions were $289,064 versus $261,525 in 1988. Included in our
membership were 135 Cold Spring Harbor Laboratory Associates (contributors of
$1,000 or more), up from 110 in 1988. This growth of support is of immense help
to the Laboratory by giving it the resources to attract the finest young scientists.
Additionally, this demonstration of broad-based advocacy is an important element
in attracting foundation and corporate grants.
LIBA's increased membership was due in large part to the efforts of LIBA
Director Mrs. Edward Greenberg. She conceived and planned a cocktail reception
at Airs lie, the home of Dr. and Mrs. James D. Watson, for members of the
community who were not LIBA members. It was a joyous occasion attended by
more than 400, and Jane and her committee of . .
Mrs. R. Richard Ablon
Mrs. Henry Babcock, Jr.
Mrs. Patricia Bell Thomson
Mrs. Robert L. Berger
Mrs. Vincent Carosella
Mrs. Gregory Coleman
Mrs. John Garver
Mrs. Gordon S. Hargraves
Mrs. George H. Howard III
Mrs. Nicholas lhasz
Mrs. Frederic B. Ingraham
Mrs. Lawrence J. Lippert
Mrs. David M. O'Neill
Mrs. Christopher Randolph
Mrs. Peter G. Schiff
Mrs. Steven Schwartzreich
Mrs. Bronson Trevor, Jr.
Mrs. Stanley Trotman, Jr.
Mrs. Bradford Weekes III
Mrs. Hugh J. Weidinger III
Mrs. Thomas Zoller
hosted 15 dinner parties for all attendees following the reception. Jim and Liz were
wonderful hosts and Jim Hope and his staff provided an outstanding selection of
hors d'oeuvres.
Dr. James D. Watson greets guests at the Airs lie Garden
Party for new LIBA members on June 10.
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Special thanks also go to Mr. and Mrs. James D. Mooney, Mr. and Mrs. Donald
L. Deming, and Mr. and Mrs. Joseph P. Downer, who also hosted receptions to
introduce members of their communities to the exciting research at Cold Spring
Harbor Laboratory.
In its continuing effort to increase the understanding of some aspects of
molecular biology amongst its membership, the Annual Meeting on January 15
included a panel consisting of Drs. James D. Watson, Ed Harlow, Winship Herr,
and Rich Roberts as well as Morgan Browne, the Lab's Administrative Director. The
discussion was moderated by John Reese and the panel fielded questions from
the membership about the Laboratory and its work.
Prior to this interesting discussion, Lawrence L. Davis, Chairman of the
Nominating Committee, thanked retiring directors Mrs. Donald Arthur, Mrs. George
N. Lindsay, Mr. William Payson, and Mr. Edward Pulling for their efforts on behalf
of the Laboratory. Mr. Pulling, who retired after 20 years as a LIBA director,
including 17 as its Chairman, was given special recognition by his election to
Honorary Director. Five new directors were elected. They were: Mrs. Helen B.
Chenery, Mr. John Cleary, Mrs. Donald Deming, Mrs. Edward Greenberg, and Mr.
Edward McCann.
The Ambassador of the Year Award was presented to Mrs. Sinclair Hatch for
her untiring efforts on behalf of the Laboratory. Wendy is a trustee of the
Laboratory, a director of LIBA, and serves on the Executive, Development, and
Finance & Investment Committees of the Lab, and also chairs the Major Gifts
Committee of the Second Century Campaign. Her energies go far beyond these
duties as she continually introduces new friends to the Lab and introduces staff
and visiting scientists to the community.
In February, the Cold Spring Harbor Laboratory Associates were treated to one
of the most interesting talks since the program's inception three years ago. John
Hicks, who heads the FBI's DNA Fingerprinting Division, which was officially
opened only a month before his talk, entertained us with stories of criminal investi-
gations that were aided by DNA fingerprinting. A light supper was served in
Blackford Hall following the program.
As in the past, the Associates were invited to hands-on laboratory workshops.
These events are designed to give members a better understanding of molecular
biology, DNA fingerprinting in particular, and the nature of the experimentation
carried on daily at the Laboratory.
Dr. Gustav Nossal addresses LIBA members at the Dorcas
Dr. Jan Witkowski instructs participants at a DNA workshop. Cummings Memorial Lecture in June.
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Again this year, the Dorcas Cummings Memorial Lecture was held during the
Laboratory's symposium. LIBA was indeed fortunate to have Dr. Gustav Nossal,
Director of the Eliza Hall Institute in Victoria, Australia, speak to the membership
and the distinguished attendees from around the world. As the subject of the
symposium was immunological recognition, his comments on some of the basic
elements of immunology were most interesting, and were delivered with great
humor.
Through the organizational efforts of Edward Pulling, more than 139 visiting
speakers and laboratory scientists attended 19 symposium dinner parties following
the lecture. This year's hosts were
Mrs. Donald Arthur
Mrs. Gilbert A. Ball
Mr. & Mrs. Loren Berry
Mr. & Mrs. G. Morgan Browne
Mr. & Mrs. John P Cleary
Mr. & Mrs. Miner Crary
Mr. & Mrs. Roderick H. Cushman
Mr. & Mrs. George W. Cutting
Mrs. Eugene DuBois
Mrs. Cary Fisher
Mr. & Mrs. Sinclair Hatch
Mrs. Ruth Bennett Jordan
Mrs. Carol Hill Lamb
Mr. & Mrs. Konrad Matthaei
Dr. & Mrs. Walter C. Meier
Dr. & Mrs. Larry Nathanson
Mr. & Mrs. Edward Post
Mr. & Mrs. Franz Schneider
Mr. & Mrs. James Stebbins
Mr. & Mrs. John Stevenson
Mayor & Mrs. Martin Travis
Mr. & Mrs. Philip von Stade
Mr. & Mrs. Robert Walton
Mr. & Mrs. Bradford Weekes III
These dinners are an annual highlight and are enjoyed by both the visiting
scientists and the members of the community.
Under the leadership of Dr. James D. Watson, science at Cold Spring Harbor
has flourished during the year. As one of its major educational functions is to host
symposia, meetings, and high-level courses in molecular biology, 1989 was a
spectacular success. At final count almost 5,600 visiting scientists participated.
Laboratory Highlights
By year's end, the number of staff scientists increased to 140. Some of the recent
developments include
Mike Wig ler was elected into the prestigious National Academy of Sciences.
While his scientific accomplishments are many, Mike is probably best known for
his co-isolation of the first human oncogene in 1981.
Ed Harlow and his team were the first to determine a physical link between a
viral oncogene and an anti-oncogene (a cancer -suppressing gene), thereby
providing a key piece of the cancer puzzle.
Through the generosity of LIBA members, LIBA Fellowships were awarded
to
Drs. Ashok Dubey, Anindya Dutta, Erich Grotewold, and Jeffrey Kazzaz.
Drs. Carol
Grader and Arne Stenlund were awarded New Investigator
Start-up Fund grants.
Mrs. Walter C. Meier and Mrs. Craig B. Ordway gave generously
of their time to
the DNA Learning Center as they most capably organized, recruited,
and directed
a corps of volunteers to staff the Smithsonian's Search for Life
exhibit this past
year. Our sincere thanks go to all those LIBA members who
staffed the exhibit.
The DNA Learning Center was dedicated in September
1988, the cornerstones
for the Beckman Neuroscience Laboratory and Dolan Hall were
laid in May 1989,
and six new heated cabins were dedicated in August 1989,
extending the course
and meeting season to seven months of the year.
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In addition to Genes and Development, the Lab now has a second journal.
The inaugural issue of Cancer Cells: A Monthly Review was sent out in
September.
The programs at the Banbury Center continued to draw together interested
professionals from around the country to discussions on such topics as diseases
and their possible problems of identification and treatment.
The most significant event of the year may have been the announcement in
February of the Second Century Campaign by the Laboratory Board of Trustees.
This capital campaign, the first in the Laboratory's history, is designed to meet the
Lab's needs and enable it to continue its remarkable track record as it embarks on
its second century.
The $44-million goal includes monies for the construction of the neuroscience
laboratory and teaching facility, the residence hall and 10 cabins for visiting
scientists, the refurbishing of McClintock Laboratory for cancer research, and the
establishment of a number of endowment funds to enable the Laboratory to attract
the very best young scientists. At the time of the announcement in April, more
than $27 million had been committed; as we go to press in November, nearly $31
million has been pledged.
The Future
The Laboratory begins its 100th year in 1990. Numerous centennial special events
are being planned. More and more, the Laboratory is receiving recognition as one
of the leading institutions for scientific research. Science Watch, a newsletter that
tracks trends and performance in basic research, proclaimed in its July 1989
headline "Cold Spring Harbor Packs Twice the Punch of Other Leading Indepen-
dent Labs': The article goes on to say, "The observation that Cold Spring Harbor
produces high-quality research will come as news to few. But what may surprise
many is that, over the past decade and a half, papers from CSH have carried
about twice the clout, measured by citations, as papers from several other premier
independent labs." The reputation of this remarkable institution, already very high
among scientists around the world, is growing among generous people who care
about the effectiveness of their gifts.
As the Laboratory embarks on its second century, it will make the important
transition from a summer to a year-round teaching institute specializing in DNA
science. This will require new facilities. More importantly, we must continue to
attract and retain exceptional scientists. Now is the proper time for us to reflect on
past success and to insure another hundred years of excellence.
George W. Cutting, Jr., Chairman
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Cold Spring Harbor Laboratory Associates*
October 1, 1988-September 30, 1989
Anonymous
Mr & Mrs. Bertram D. Aaron
Mr. Amyas Ames
Mrs. Donald Arthur, Jr.
Mrs. Marvin A. Asnes
Mr. Bruce E. Balding
Dr. John Bell-Thomson
Mr & Mrs. Allen L. Boorstein
Dr. David Botstein
Mrs. Leonie T. Brigham
Mrs. Harry A. Brooks
Mr & Mrs. G. Morgan Browne
Mr. & Mrs. John P Campbell
Mr & Mrs. Peter B. Cannell
Mr & Mrs. Vincent Carosella
Centerbrook Architects
Mr. & Mrs. Lionel Chaikin
Mr & Mrs. David C. Clark
Dr & Mrs. Bayard D. Clarkson
Mrs. Robert L. Clarkson, Jr
Mr James W. Cleary
Mr. & Mrs. John P Cleary
Mr & Mrs. Gregory S. Coleman
Mrs. John K. Colgate, Sr
Collaborative Research Inc.
Mr. Ronald M. Craigmyle, Jr
Mr & Mrs. Arthur M. Crocker
Mr. & Mrs. Robert L. Cummings
Mr & Mrs. Richard T. Cunniff
Mr & Mrs. Roderick H. Cushman
Mr. & Mrs. George W. Cutting, Jr
Ms. Lucy Cutting
Mr. Theodore N. Danforth
Mr. & Mrs. Norris Darrell, Jr.
Mrs. John L. Davenport
Michael Davidson Memorial &
Scholarship Fund
Mr. & Mrs. Donald L. Deming
Mr & Mrs. Joseph C. Dey
Mr. & Mrs. Charles F Dolan
Mr & Mrs. Joseph P Downer
Dr. & Mrs. Lester Dubnick
Mr. & Mrs. James A. Eisenman
Mr. & Mrs. Duncan Elder
Mr. & Mrs. William Everdell
Dr. Barry Michael Gaines
Mr. Robert B. Gardner, Jr
Mr. & Mrs. Charles S. Gay
Mr & Mrs. Robert A. Gay
Mr. & Mrs. Daniel W. Gerrity
Mr & Mrs. Joseph Gerrity
Mr. & Mrs. Thomas S.T. Gimbel
*Contributors of $1000.00 or more
Mr & Mrs. Allen Goldring
Mr David S. Gottesman
Mr & Mrs. Oliver R. Grace
Mr. & Mrs. Oliver R. Grace, Jr
Mr & Mrs. Edward Greenberg
Dr & Mrs. Peter M. Guida
Mr & Mrs. John W.B. Hadley
Rev. Linda Peyton Hancock
Mr & Mrs. Henry U. Harris, Jr.
Miss Maxine Harrison
Harweb Foundation
Mrs. Sinclair Hatch
Mr & Mrs. Horace Havemeyer, Jr.
Mr & Mrs. Thomas L. Higginson
Mr & Mrs. Charles J. Hubbard
Mr & Mrs. Waldo Hutchins III
Mr & Mrs. Nicholas L. lhasz
Mr & Mrs. John C. Jansing
Mr & Mrs. Francis S. Kinney
Mr & Mrs. John Klingenstein
Mr & Mrs. Townsend J. Knight
Dr Barbara B. Knowles
Mr & Mrs. Gordon Lamb
Dr. Laurie J. Landeau
Mr Orin Leach
Mr & Mrs. John H. Leib
Dr Robert V Lewis
Mr & Mrs. George N. Lindsay
Mr & Mrs. Robert V. Lindsay
Mrs. V.S. Littauer
Mr & Mrs. John H. Livingston
Mr Henry Luce III
Mr & Mrs. David L. Luke III
Ms. Martha Makanna
Mrs. John B. Marsh
Mr & Mrs. William H. Mathers
Mr. & Mrs. William L. Matheson
Mr & Mrs. Gerald M. Mayer, Jr
Mr & Mrs. Edward F McCann II
Miss Diana Mcllvaine
Dr & Mrs. Walter C. Meier
Mr Arthur C. Merrill
Mr & Mrs. Robert G. Merrill
Mr & Mrs. Clarence F Michalis
Mr & Mrs. William R. Miller
Miller-Richard, Inc.
Dr Peter Model
Mr & Mrs. George G. Montgomery, Jr
Mrs. F. Franklin Moon
Mr & Mrs. F Warren Moore
Mr & Mrs. Charles E. Murcott
Mr & Mrs. George Murnane, Jr
Mr & Mrs. Stephen V Murphy
Mr & Mrs. William J. Nammack
Dr & Mrs. Larry Nathanson
Mrs. John W. Nields
The Nordemann Foundation, Inc.
Mr & Mrs. Charles P Noyes
Mr. & Mrs. George D. O'Neill
Mr & Mrs. Arthur W. Page, Jr
Mr & Mrs. Walter H. Page
Dr & Mrs. David B. Pall
Mr & Mrs. Nicholas R. Parks
Mr. William Parsons, Jr
Charlotte Palmer Phillips Foundation, Inc.
Mr & Mrs. John A. Pieper
Mrs. Francis T.P. Plimpton
Mr & Mrs. Frank L. Polk, Jr
Mr & Mrs. Martin Pollak
Mr. & Mrs. F. Thomas Powers, Jr
Mrs. H. Irving Pratt
Mr & Mrs. Richardson Pratt, Jr
Mrs. Sherman Pratt
Mr Edward Pulling
Mrs. Seena H. Purdy
Mr William Rand
Mrs. Curtis S. Read
Mr & Mrs. John R. Reese
Mrs. Willis L.M. Reese
Mr & Mrs. Seymour Reich
Mr & Mrs. William S. Robertson
Mr Robert Sabin
Mrs. John Schiff
Mr & Mrs. Peter G. Schiff
Mr & Mrs. Franz Schneider
Mr & Mrs. Owen Smith
Mr & Mrs. Peter Solbert
Dr Davor Solter
Seth Sprague Educational & Charitable
Foundation
Mr & Mrs. James F Stebbins
Mr. & Mrs. Byam K. Stevens, Jr
Mr & Mrs. Richard M. Sykes
Mr & Mrs. David S. Taylor
Mr. & Mrs. Walter C. Teagle III
Estate of Emma Themm
Mrs. Robert W. Tilney, Jr.
Mr. & Mrs. Stanley S. Trotman
Mrs. Ernest T. Turner
Mrs. Mary Tweedy
Mr. & Mrs. Harold Van Richard
Mr & Mrs. Philip R. von Stade
Dr & Mrs. James D. Watson
Mr. & Mrs. Taggart Whipple
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Members**
October 1, 1988-September 30, 1989
Mr & Mrs. R. Richard Ablon
Mr & Mrs. Thomas H. Ackerman
Mr & Mrs. James F Adams
Mrs. Stirling S. Adams
Dr. & Mrs. Bruce M. Alberts
Mr & Mrs. Lee C. Alexander
Dr & Mrs. Ralph F. Alfenito
Mr. Robert G. Allen, Jr
Mr & Mrs. Robert L. Alpert
Mr & Mrs. Spencer Alpert
Dr & Mrs. Reese F. Alsop
Mr. & Mrs. Prescott Ammarell
Mrs. Hoyt Ammidon
Dr & Mrs. Carl W. Anderson
Mr Ronald C. Anderson
Mr. & Mrs. Evan Anhalt
Mr. & Mrs. Vincent Ansanelli, Jr.
Mr. & Mrs. Robert W. Anthony
Mr & Mrs. Silas Reed Anthony
Mr & Mrs. Martin S. Arbonies
Mr & Mrs. J.S. Armentrout, Jr
Mr. & Mrs. Richard Aurelio
Mrs. Robert W. Ayer
Dr. & Mrs. Alfred A. Azzoni
Mr & Mrs. Henry D. Babcock, Jr
Mrs. Richard F Babcock
Mr. & Mrs. Edward Backer
Mr & Mrs. Jens Bakke
Mr. & Mrs. Benjamin H. Balkind
Mrs. Gilbert A. Ball
Mr. & Mrs. Vincent C. Banker
Mrs. William N. Bannard
Mr. & Mrs. George Barclay
Dr. & Mrs. Henry H. Bard
Mr & Mrs. Richard Davis Barmon
Mrs. Dudley R. Barr
Mr & Mrs. Stephen A. Barre
Mr. Donald F Barrow
Mr. & Mrs. Edmund Bartlett
Mr & Mrs. Marshall Bartlett
Mr. & Mrs. Cliff Bates
Mr & Mrs. Pierre Beauchamp
Mr. & Mrs. Sherburn M. Becker
Mr. & Mrs. James Beckman
Mr David W. Beer
Mrs. Patricia Bell-Thomson
Mr & Mrs. Robert E. Benson
Dr & Mrs. Paul Berg
Mr. & Mrs. Robert Berger
Ms. Rosalind Berger
Dr. Barbara Bergman
Drs. Bruce & Susan Berlin
Mr Bruce K. Bernann
Mr & Mrs. Loren C. Berry
Mrs. Maureen G. Beuerlein
Mr. & Mrs. Nicholas Biddle, Jr
- Contributors of $25.00-999.00
344
Mr John C. Bierwirth
Mrs. William Binnian
Mrs. Dorothy E. Bird
Mr & Mrs. Cosmo D. Bitetti
Ms. Mary Lenore Blair
Mr Peter H. Blohm
Mr. & Mrs. Bruce R. Blovsky
Ms. Margery Blumenthal
Dr Russell K. Bomse
Mr. & Mrs. Elito J. Bongarzone
Dr Jonathan M. Borkum
Mr & Mrs. Murray Borson
Dr & Mrs. Hans E.R. Bosch
Dr Patricia Bossert
Mr & Mrs. James C. Bostwick
Dr Evelyn Botkin
Mrs. Shirley F. Bowring
Mr & Mrs. William Braden
Mr. Thomas A. Bradley, Jr
Mr & Mrs. Ralph Brandifino
Dr & Mrs. Lawrence H. Brickman
Mr. Lester E. Brion, Jr
Dr. & Mrs. Arik Brissenden
Dr & Mrs. Robert D. Broderick
Mr. & Mrs. Bert Brodsky
Mr F. Sedgwick Browne
Mr & Mrs. James T. Bryan, Jr
Mr & Mrs. Julian G. Buckley
Mr. Robert M. Bunnell
Ms. Mary Griggs Burke
Mr. & Mrs. John W. Busby
Dr Phyllis H. Cahn
Mr & Mrs. Thomas J. Calabrese
Mr & Mrs. Samuel R. Callaway
Mr & Mrs. Michael Cammarota
Mr & Mrs. David A. Campbell
& Mrs. Ward C. Campbell
Mr. & Mrs. Salvatore Campo
Mr & Mrs. Robert A. Carlson
Ms. Patricia K. Casentine
Ms. Mary Caslin
Mr. & Mrs. Jean Cattier
Mr & Mrs. Larry L. Chamberlin
Mr & Mrs. Gilbert W. Chapman, Jr
Mr & Mrs. Harry G. Charlston
Mr & Mrs. Paul J. Chase
Dr Lan Bo Chen
Dr. Eleanor Chernick
Mr & Mrs. Anwar Chitayat
Mr & Mrs. Jan S. Chock
Mr Donald C. Christ
Ms. Sue Ellen Christensen
Mr. Lawrence M. Clum
Mr. & Mrs. Albert J. Coffey
Mrs. C. Payson Coleman
Mr. & Mrs. Francis X. Coleman, Jr.
Mr & Mrs. John H. Coleman
Mr & Mrs. Emilio G. Collado
Mr. Bradley Collins
Mr & Mrs. Patrick Collins
Mr & Mrs. Kingsley Colton
Mrs. Ralph C. Colyer
Dr & Mrs. Joseph B. Conolly, Jr
Mr. & Mrs. Robert Cooper
Mrs. Howard Corning, Jr.
Mr & Mrs. Charles Craig
Mr & Mrs. Miner D. Crary, Jr
Mr & Mrs. Robert Cuddeback
Mr. Robert L. Cummings Ill
Mr & Mrs. Curtis Cushman
Dr & Mrs. Paul Cushman, Jr
Mr Theodorus VanWyck Cushny, Jr
Mr & Mrs. A. Neville Cutting
Mrs. Howard H. Dana
Mr. Theodore N. Danforth
Mr & Mrs. A. George Dartt
Mrs. Katya Davey
Dr Julian E. Davies
Dr & Mrs. Bernard D. Davis
Mr Lawrence L. Davis
Mr & Mrs. Daniel P Davison
Mrs. F. Trubee Davison
Mrs. Arthur H. Dean
Mr & Mrs. Raymond deClairville
Mr & Mrs. Louis D. DeLalio
Dr David T. Denhardt
Mr & Mrs. William R. Dens low, Jr
Mr & Mrs. Daniel C. De Roulet
Mrs. Douglas C. Despard, Jr
Ms. Carolyn C. Dilworth
Mr & Mrs. Richard Donsky
Mr & Mrs. Gerard T. Dooney
Mr & Mrs. Raymond C. Doop
Mr. E. Richard Droesch
Mrs. Eugene DuBois
Mr & Mrs. Charles Dubroff
Mr & Mrs. Leonard K. DuBrul
Dr & Mrs. John L. Duffy
Mr & Mrs. Anthony D. Duke, Jr
Mr & Mrs. Edgar P. Dunlaevy
Mr & Mrs. William T Dunn, Jr
Mr Don Durgin
Dr & Mrs. Gerard L. Eastman
Dr & Mrs. James D. Ebert
Mrs. Fred J. Eissler
Mr & Mrs. Ashton G. Eldredge
Mr Martin Elias
Mr & Mrs. Earl E. Ellis
Mr & Mrs. Stephen Ely
Dr Henry F Epstein
Mr & Mrs. Peter Esser
Mrs. James M. Estabrook
Mr. & Mrs. John J. Evans
Mrs. Raymond Z. Fahs
Mr. & Mrs. Harold L. Fates
Mr. John R. Fell
& Mrs. Colin C. Fenn
Mr. & Mrs. Peter L. Fetterolf
Mr & Mrs. Hans F. Fickenscher
Mr & Mrs. Douglas Findlay-Shirras
Mr. & Mrs. Noah Finkel
Mrs. Pearl S. Fisher
& Mrs. Dugald A. Fletcher
Dr. George W. Flint
Mr. & Mrs. Seth B. French, Jr.
Mr. & Mrs. Jack B. Friedman
Mr. Jack N. Friedman
Mr & Mrs. Robert B. Friedman
Mr. & Mrs. Guy Fritts
Dr C.R. Fuerst
Mr. Stephen D. Fuller
Mr. & Mrs. Victor Futter
Mr & Mrs. Hank Gaiss
Mr & Mrs. D. Kent Gale
Mr & Mrs. Clarence E. Galston
Mr & Mrs. John W. Galston
Mrs. James E. Gardner Jr.
Mr & Mrs. Murray B. Gardner
Mr & Mrs. John A. Garver
Mr & Mrs. John W. Gates
Mr & Mrs. E. Maxwell Geddes, Jr.
Mr Frederick G. Geissler
ME & Mrs. Martin Gellert
Ms. Lucille G. Gemson
Mr & Mrs. David A. George
Dr & Mrs. Stephen A. Gettinger
Mrs. Vera C. Gibbons
Mr & Mrs. Robert M. Gibney
Mr & Mrs. Gregory Gicas
Mr. Harry Giffords
Mr & Mrs. Stephen E. Gilhuley
Mr Robert Gilmor
Mr & Mrs. Robert Gilmor, Jr.
Mr & Mrs. Thomas ST. Gimbel
Dr Gail Girovard
Dr & Mrs. H. Bentley Glass
Mr & Mrs. Gerard Glavin
Mr & Mrs. Bernard J. Gloisten
Mr & Mrs. Edward R. Godfrey, Jr.
Dr G. Nigel Godson
Mr & Mrs. Whitney Goit II
Mr & Mrs. Lionel M. Goldberg
Dr & Mrs. Lewis Goldfinger
Mr & Mrs. Thomas Golon
Mr & Mrs. Kilbourn Gordon, Jr.
Mrs. Henry W. Grabowski
Ms. Deborah G. Grace
Mr & Mrs. William R. Grant
Mr & Mrs. Austen T. Gray
Mr Edward R. Greeff
Dr Maurice Green
Mr & Mrs. Alfred T. Gregory
Mr & Mrs. James M. Gresalfi
Dr. & Mrs. Raymond B. Griffiths
Dr. & Mrs. Donald S. Gromisch
Dr & Mrs. Michael Grosso
& Mrs. Frank Gundersen
Dr. Susan Gunduz
Mr. & Mrs. Irving Haber
Mr. & Mrs. Lawrence J. Hahn
Mr. & Mrs. Frank L. Hain
Mr. & Mrs. Donald L. Hall
Dr & Mrs. Seymour Halpern
Mr. & Mrs. Gordon Hargraves
Mr & Mrs. John F Harper
Dr. & Mrs. Alan Harris
Mr & Mrs. Gerald W. Hart
Dr & Mrs. Chester Hartenstein
Mr. & Mrs. Rolf D. Hartmann
Mr & Mrs. Stuart H. Hartmeyer
Mr. & Mrs. Thomas M. Hearn
Mr. & Mrs. Kenneth J. Heim
Mr. Huy ler C. Held
Mr Michael R. Held
Mr & Mrs. James E. Hellier
Mr. & Mrs. Donald J. Hendler
Mr. & Mrs. Robert V. Henning
Dr & Mrs. William Heroy
Dr & Mrs. Alfred D. Hershey
Ms. Valerie Hersig
Dr. Ira Herskowitz
Mr. & Mrs. Herman William Hertweck
Mr. & Mrs. Arno Herzog
Mrs. Charles L. Hewitt
Mr & Mrs. Charles A. Hickman
Mr. Albert P Hildebrandt
Mr. & Mrs. Lucien Hill
Hirschfeld Agency, Inc.
Mr & Mrs. Daniel Hittleman
Mrs. Albert L. Hoffman
Mr & Mrs. Charles R. Holcomb
Mr & Mrs. David R. Holmes
Dr & Mrs. Lawrence Horn
Mrs. George J. Hossfeld
Mr & Mrs. George J. Hossfeld, Jr
Mr. George H. Howard
Mr. & Mrs. George H. Howard III
Mrs. Katharine V.S. Howe
Mrs. Margaret Hamilton Howe
Mr & Mrs. Andrew Hulko
Mr & Mrs. Philip G. Hull
Mrs. John S. Humes
Mr. & Mrs. Robert Hutchings
Mr & Mrs. Warren C. Hutchins
Mr. & Mrs. Judson A.V. Hyatt
Mrs. David Ingraham
Mr & Mrs. Frederic B. Ingraham
Mr & Mrs. Fred A. Irwin
Mrs. Richard M. Jackson
Mr & Mrs. Valdemar F. Jacobsen
Mr & Mrs. Mitchell Jacobson
Mr. Irving D. Jakobson
Mr & Mrs. Willard M. Jaques
Mr & Mrs. Alfred A. Jarnow,
Jr.
Mr & Mrs. Robert D. Jay
Mrs. B. Brewster Jennings
Mr & Mrs. Marc W. Jensen
Mr. Hugh G. Johnson
Mrs. Laurence S. Johnson
Mr & Mrs. Richard Johnson, Jr.
Mr. William & Dr. Gail Jones
Mr. & Mrs. Richard Jordan
Mr & Mrs. John Juda, Jr
Mr Bill Ian Jurow
Mrs. Gilbert W. Kahn
Mr & Mrs. Edward Kammerer
Mr. & Mrs. Howard L. Kane
Mr Louis Kanter
Mr & Mrs. Kenneth Kaplan
Mr & Mrs. Morris I. Karpen
Mr. & Mrs. James Murray Kay, Jr
Dr. & Mrs. Francis C. Keil
Mr. Spencer Kellogg II
Mr Francis E. Kelly, Jr
Mr. & Mrs. J. Kevin Kenny
Mrs. Walter A. Kernan
Mrs. Louise M. King
Mrs. Lila W. Kirkland
Dr & Mrs. Alan Kisner
Mr & Mrs. Jeffrey A. Klein
Mr & Mrs. Walter R. Klein
Mr & Mrs. John Klingenstein
Mrs. Robert P Koenig
Mr & Mrs. Peter C. Kohler
Mr & Mrs. Michael L. Kolodner
Mrs. Jack Kolodny
Dr. Fred Kornblueh
Mr & Mrs. Bruce Andrew Korson
Mr & Mrs. Edward W. Kozlik
Ms. Kristina A. Kramer
Mr & Mrs. Paul Kramer
Mrs. Harold Kulla
Dr. Rakesh Kumar
Mr & Mrs. Mort Kunst ler
Mrs. Carol Hill Lamb
Mr & Mrs. Edward M. Lamont
Dr & Mrs. Ralph Landau
Mr. James Large, Jr.
Mr & Mrs. Charles L. Lassen
Mrs. Dwight Lawton, Jr.
Mrs. Leslie S. Learned
Mrs. Randall J. LeBoeuf, Jr
Mr & Mrs. Richard E. Leckerling
Mr. & Mrs. Henry C. Lee
Rev. & Mrs. T Carleton Lee
Mrs. Hudson B. Lemkau
Mr. & Mrs. Daniel Leon
Mr & Mrs. Thomas Leon
Mr & Mrs. Stephen M. Lessing
Dr. & Mrs. Monroe L. Levin
Dr. Robert Levin
Mr. James B. Lewis
Mrs. Elizabeth A. Lindsay
Mr George N. Lindsay, Jr
Dr & Mrs. Lawrence J. Lippert
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Mr. & Mrs. William Lister
Mr. & Mrs. Robert F Little
Mr. Angus C. Littlejohn
Mr. & Mrs. Candido V. Llovera
Mr. & Mrs. Alan J. Long
Mr. & Mrs. Donald Lopez
Mrs. Wladimir Z. Lotowycz
Mr & Mrs. Jerome D. Lucas
Mr. & Mrs. Sonny Lupinacci
Mrs. Phyllis G. Lynch
Mr. Richard H. MacDougall
Dr Cynthia J. MacKay
Mr & Mrs. John F. MacKay
Ms. Lisa R. MacKay
Mr & Mrs. Malcolm MacKay
Mr. Sayre MacLeod III
Dr & Mrs. James N. Macri
Mr & Mrs. Vincent J. Macri
Mrs. Henry R. Macy
Dr & Mrs. Vincent Madonia
Mr & Mrs. William E. Mahoney
Mr & Mrs. Victor Marco
Mrs. Lawrence M. Marks
Dr. Hanna Mar lens
Mr. & Mrs. John Maroney
Mr & Mrs. Joseph Marotta
Dr. Daniel R. Marshak
Mr. Leonard Marshall, Jr.
Mr. & Mrs. Milward W. Martin II
Mr & Mrs. William J. Martin, Jr
Mr & Mrs. Nicholas Massa
Mrs. Dorothea S. Mathews
Dr & Mrs. Fumio Matsumura
Mr & Mrs. Konrad H. Matthaei
Mr Charles T Matthews
Dr & Mrs. Joseph May
Dr. Marcia Kramer Mayer
Dr. Ernst Mayr
Mr & Mrs. Rocco Mazzotta
Dr & Mrs. Robert L. McCollom
Mr & Mrs. Victor C. McCuaig, Jr
Mr. & Mrs. James A. McCurdy II
Mr & Mrs. Peter J. McCusker
Mr. Richard C. McDaniel
Mr. Ian McDuffie
Mr & Mrs. Angus P McIntyre
Mr & Mrs. Randall P. McIntyre
Ms. Leila Laughlin McKnight
Mr & Mrs. Robert M. McLane
Mr & Mrs. John McLaughlin
Mr & Mrs. Frederic G. McMahon
ME & Mrs. Lawrence M. Mead, Jr
Mrs. Robert K. Meltzer
Ms. Adele Mendelsohn
Mr & Mrs. Arthur I. Mendolia
Mr & Mrs. Paul Meringoff
Mr. & Mrs. Robert G. Merrill
Ms. Francine M. Messina
Ms. Nancy Metz
Mrs. Frances Meurer
Mr & Mrs. Charles G. Meyer, Jr.
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Mr. & Mrs. George S. Meyer
Mr & Mrs. Richard W. Meyer
Mr & Mrs. Kennedy B. Middendorf
Mr & Mrs. Gerard Miller
Mr & Mrs. William H. Miller
Mrs. Newton Millham
Mr. & Mrs. M. Ronald Minge
Dr & Mrs. C. Mintzer
Mr. & Mrs. Keith M. Moffat
Mr. & Mrs. James D. Mooney, Jr.
Mr & Mrs. Richard K. Moore
Mr George Morgese
Mr & Mrs. Frank Mormando, Jr
Dorothy C. Morrell
Mr. & Mrs. Duncan C. Morrell
Mr Grinnell Morris
Mr & Mrs. Robert P Morse
Mr & Mrs. Charles Morton
Mrs. Frederick R. Moseley, Jr
Mount Holyoke Club
Mr & Mrs. Brent M. Mowery, Jr
Dr & Mrs. Peter Mudge
Mr & Mrs. Ronaldo Muir
Mr & Mrs. Glenn W. Mullen
Mr. & Mrs. Gardner M. Mundy
Dr & Mrs. John Paul Munteanu
Mr & Mrs. Francis W. Murray III
Mr & Mrs. T.C. Murray
Mr & Mrs. Rem V. Myers
Dr & Mrs. Hachiro Nakamura
Mr & Mrs. F Barry Nelson
Dr. Franklin Nelson
Mr & Mrs. John E. Nelson
Mr & Mrs. Vincent R. Nesi
Mr. & Mrs. Richard Neuendorffer
New York Community Trust
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